,Article,Date,Symbol,Time,Title,Url
0,"   By Sophie Sassard and Arno Schuetze | LONDON/FRANKFURT  LONDON/FRANKFURT Novartis AG NOVN.VX is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc's (MRK.N) over-the-counter products unit in a deal that could boost earnings at both companies.Healthcare bankers said an asset swap with Merck was the main focus for the Swiss drugmaker as it reviews its portfolio, although an outright sale of animal health or an exchange with other companies were still possible.One of the bankers said Novartis and Merck had been in talks for some time but asset swaps were hard to execute, due to the difficulty of comparing the relative attraction of different businesses.If the hoped-for swap with Merck does not work out, Novartis is likely to opt for a sale or swap with another leading animal health firm, such as Bayer (BAYGn.DE), Zoetis (ZTS.N), Sanofi (SASY.PA), Eli Lilly (LLY.N) or unlisted Boehringer Ingelheim.Bloomberg reported earlier that Novartis and Merck might each trade about $5 billion in assets under an eventual deal.Sources with knowledge of the matter had told Reuters last month that Novartis was ready to sell its animal health unit and had opened its books to Bayer and others for the business that could change hands for more than 3 billion euros ($4.1 billion). New chairman Joerg Reinhardt is casting a fresh eye over the Basel-based group following the departure of veteran chairman and one-time CEO Daniel Vasella, the architect of the merger of Ciba-Geigy and Sandoz that created Novartis in 1996.Reinhardt has defended the firm's diversified strategy, but has stressed Novartis will only hang on to businesses that are among world leaders. That has left uncertain the future of sub-scale operations like animal health and vaccines.PORTFOLIO FIT Novartis already agreed to sell its blood transfusion testing unit to Spain's Grifols (GRLS.MC) for $1.7 billion in November. Merck, meanwhile, has been saying for some time that its over-the-counter (OTC) consumer health business lacks scale and Bernstein analyst Tim Anderson said a swap could boost earnings per share at both companies by around 3 percent.Merck's OTC line-up would add products such as Claritin medicine for allergies, Coppertone sunblock and Dr Scholl's foot care, boosting Novartis's already strong consumer care portfolio.Analysts said Merck's products would fit well within the Novartis OTC business, since it is currently dominated by remedies for coughs, colds and pain. The Novartis animal health products include Sentinel and Prac-tic flea and tick treatments for dogs, as well as a range of other products for pets and farm animals, while its human vaccines operation mainly makes flu shots.Many drugmakers are currently shedding businesses, prompted by pricing pressures and increasing competition from generics that has forced a more rigorous approach to capital allocation. As part of that they are also showing a new willingness to consider whether other companies may be better owners for certain assets, thereby unlocking value for shareholders.Pfizer (PFE.N), for example, has already spun out its animal health operations into Zoetis and sold its infant nutrition business to Nestle NESN.VX.A Novartis spokeswoman told Reuters that the company does not comment on market rumor or speculation.Merck was not immediately available for comment outside regular U.S. business hours. ($1 = 0.7353 euros)(Additional reporting by Ben Hirschler in London and Sruthi Ramakrishnan in Bangalore; Editing by Supriya Kurane and Sophie Walker)",2014-01-09,MRK,"Thu Jan 9, 2014 | 9:24am EST",Novartis and Merck discuss earnings-boosting asset swap,http://www.reuters.com//article/us-novartis-merck-idUSBREA080RA20140109?type=companyNews
1,"  * Novartis may swap animal health, vaccines for Merck's OTC* Analysts see exchange boosting earnings for both firms* Swap preferred but trade sale also possible -bankers* Novartis, Merck may each trade $5 bln in assets -BloombergBy Sophie Sassard and Arno SchuetzeLONDON/FRANKFURT, Jan 9 Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck & Co Inc's  over-the-counter products unit in a deal that could boost earnings at both companies.Healthcare bankers said an asset swap with Merck was the main focus for the Swiss drugmaker as it reviews its portfolio, although an outright sale of animal health or an exchange with other companies were still possible.One of the bankers said Novartis and Merck had been in talks for some time but asset swaps were hard to execute, due to the difficulty of comparing the relative attraction of different businesses.If the hoped-for swap with Merck does not work out, Novartis is likely to opt for a sale or swap with another leading animal health firm, such as Bayer, Zoetis, Sanofi , Eli Lilly or unlisted Boehringer Ingelheim. Bloomberg reported earlier that Novartis and Merck might each trade about $5 billion in assets under an eventual deal.Sources with knowledge of the matter had told Reuters last month that Novartis was ready to sell its animal health unit and had opened its books to Bayer and others for the business that could change hands for more than 3 billion euros ($4.1 billion).New chairman Joerg Reinhardt is casting a fresh eye over the Basel-based group following the departure of veteran chairman and one-time CEO Daniel Vasella, the architect of the merger of Ciba-Geigy and Sandoz that created Novartis in 1996.Reinhardt has defended the firm's diversified strategy, but has stressed Novartis will only hang on to businesses that are among world leaders. That has left uncertain the future of sub-scale operations like animal health and vaccines. PORTFOLIO FIT Novartis already agreed to sell its blood transfusion testing unit to Spain's Grifols for $1.7 billion in November.Merck, meanwhile, has been saying for some time that its over-the-counter (OTC) consumer health business lacks scale and Bernstein analyst Tim Anderson said a swap could boost earnings per share at both companies by around 3 percent. Merck's OTC line-up would add products such as Claritin medicine for allergies, Coppertone sunblock and Dr Scholl's foot care, boosting Novartis's already strong consumer care portfolio.Analysts said Merck's products would fit well within the Novartis OTC business, since it is currently dominated by remedies for coughs, colds and pain.The Novartis animal health products include Sentinel and Prac-tic flea and tick treatments for dogs, as well as a range of other products for pets and farm animals, while its human vaccines operation mainly makes flu shots.Many drugmakers are currently shedding businesses, prompted by pricing pressures and increasing competition from generics that has forced a more rigorous approach to capital allocation. As part of that they are also showing a new willingness to consider whether other companies may be better owners for certain assets, thereby unlocking value for shareholders.Pfizer, for example, has already spun out its animal health operations into Zoetis and sold its infant nutrition business to Nestle.A Novartis spokeswoman told Reuters that the company does not comment on market rumour or speculation.Merck was not immediately available for comment outside regular U.S. business hours.",2014-01-09,MRK,"Thu Jan 9, 2014 | 9:20am EST",UPDATE 1-Novartis and Merck discuss earnings-boosting asset swap,http://www.reuters.com//article/novartis-merck-idUSL3N0KJ3B520140109?type=companyNews
2,"  Jan 8 Novartis AG is in talks with Merck & Co Inc to exchange its animal-health and human vaccines businesses for the drugmaker's over-the-counter health-products unit, Bloomberg reported, quoting people familiar with the matter.The two drugmakers may each trade about $5 billion in assets as part of the trade, the report said. ()The Swiss drugmaker was ready to sell its animal health subsidiary and opened its books to Bayer and other rivals for the business that could change hands for more than 3 billion euros ($4.1 billion), sources familiar with the matter had told Reuters last month. Drugmakers are shedding businesses and cutting costs due to overseas price controls and pressure on payments from insurers and the government. Pfizer Inc completed a spin off of its animal health products business in June. Novartis has not finalized a deal with Merck, and may choose another option, Bloomberg said. A Novartis spokeswoman told Reuters that the company does not comment on market rumor or speculation.Merck was not immediately available for comment outside regular U.S. business hours.",2014-01-09,MRK,"Wed Jan 8, 2014 | 9:48pm EST",Novartis in talks with Merck to exchange business units- Bloomberg,http://www.reuters.com//article/novartis-merck-idUSL3N0KJ0XL20140109?type=companyNews
3,"   By Toni Clarke  Shares of Merck & Co Inc (MRK.N) rose as much as 6.5 percent Monday after it filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma, putting the treatment on track to become the first in a new class of promising cancer drugs to reach the market.The application was filed earlier than investors had expected and ups the ante in a race between Merck and Bristol-Myers Squibb Co(BMY.N) for dominance of a class of drugs known as anti-PD-1 inhibitors that are expected to generate billions of dollars in peak sales.Merck's drug is designed to treat patients with advanced melanoma who have previously been treated with Bristol-Myers' melanoma drug Yervoy. The company is also testing the drug in other cancers, including lung and renal cancer.Bristol is testing its own PD-1 drug nivolumab in a variety of cancers, with lung cancer likely to be one of the first to move forward.""This is probably one of the most important classes of new drug,"" said Damien Conover, an analyst at Morningstar, who forecasts peak sales for Merck's drug, including multiple cancer indications, of $3 billion. He forecasts peak sales for Bristol's drug of $6 billion. The drugs are designed to restore the natural ability of the immune system to recognize and target cancer cells.While Bristol has more clinical trials and data to show for nivolumab, Merck's move in filing for MK-3475 early ""is a way to fight Bristol by getting out ahead of them,"" Conover said. Merck said it expects to complete its application in the first half of this year. Under a rolling application, completed portions of the package may be submitted and reviewed by the Food and Drug Administration on an ongoing basis.Jeffrey Holford, an analyst at Jefferies, said in a research note that the future of PD-1 development could focus on combination regimens. He said it is too early to decide on a winner in the PD-1 space, though he said Merck's drug ""does appear to have the best overall profile as a monotherapy.""Merck also benefited from other news on Monday. The company said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year. It previously said it was looking at options for separating the businesses but the company's statement reinforces the likelihood something will in fact occur.Separately, a preliminary review of Merck's experimental blood clot-preventing drug vorapaxar by the U.S. Food and Drug Administration found clinical trial data to be ""robustly positive"" and recommended the drug be approved in patients who have previously suffered a heart attack.Merck's shares rose 5.7 percent to $52.72 in afternoon trading on the New York Stock Exchange. Earlier in the day, they rose as high as $53.10.(Reporting by Toni Clarke in Washington; Editing by Bernadette Baum)",2014-01-13,MRK,"Mon Jan 13, 2014 | 2:01pm EST",Merck shares jump on early filing for skin cancer drug,http://www.reuters.com//article/us-merck-brief-idUSBREA0C13D20140113?type=companyNews
4,"  By Toni ClarkeJan 13 Shares of Merck & Co Inc rose as much as 6.5 percent Monday after it filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma, putting the treatment on track to become the first in a new class of promising cancer drugs to reach the market.The application was filed earlier than investors had expected and ups the ante in a race between Merck and Bristol-Myers Squibb Co for dominance of a class of drugs known as anti-PD-1 inhibitors that are expected to generate billions of dollars in peak sales.Merck's drug is designed to treat patients with advanced melanoma who have previously been treated with Bristol-Myers' melanoma drug Yervoy. The company is also testing the drug in other cancers, including lung and renal cancer.Bristol is testing its own PD-1 drug nivolumab in a variety of cancers, with lung cancer likely to be one of the first to move forward. ""This is probably one of the most important classes of new drug,"" said Damien Conover, an analyst at Morningstar, who forecasts peak sales for Merck's drug, including multiple cancer indications, of $3 billion. He forecasts peak sales for Bristol's drug of $6 billion.The drugs are designed to restore the natural ability of the immune system to recognize and target cancer cells. While Bristol has more clinical trials and data to show for nivolumab, Merck's move in filing for MK-3475 early ""is a way to fight Bristol by getting out ahead of them,"" Conover said.Merck said it expects to complete its application in the first half of this year. Under a rolling application, completed portions of the package may be submitted and reviewed by the Food and Drug Administration on an ongoing basis.Jeffrey Holford, an analyst at Jefferies, said in a research note that the future of PD-1 development could focus on combination regimens. He said it is too early to decide on a winner in the PD-1 space, though he said Merck's drug ""does appear to have the best overall profile as a monotherapy."" Merck also benefited from other news on Monday.The company said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year. It previously said it was looking at options for separating the businesses but the company's statement reinforces the likelihood something will in fact occur.Separately, a preliminary review of Merck's experimental blood clot-preventing drug vorapaxar by the U.S. Food and Drug Administration found clinical trial data to be ""robustly positive"" and recommended the drug be approved in patients who have previously suffered a heart attack.Merck's shares rose 5.7 percent to $52.72 in afternoon trading on the New York Stock Exchange. Earlier in the day, they rose as high as $53.10.",2014-01-13,MRK,"Mon Jan 13, 2014 | 1:54pm EST",UPDATE 2-Merck shares jump on early filing for skin cancer drug,http://www.reuters.com//article/merck-brief-idUSL3N0KN3QT20140113?type=companyNews
5,"  * Investors looking ahead to bellwether company earnings* Merck up after FDA review, strategic options plans* Lululemon, Sodastream, Express fall after outlooks* Indexes down: Dow 0.4 pct, S&P 0.4 pct, Nasdaq 0.3 pctBy Ryan VlastelicaNEW YORK, Jan 13 U.S. stocks fell on Monday as investors awaited an onslaught of corporate results to gauge how companies are faring amid mixed signs on economic growth.While some early reads on the season have been positive, market participants are looking for further justification that stocks are fairly valued with indexes near all-time highs.Following a jump of almost 30 percent last year, the S&P 500's forward price-to-earnings ratio is the highest in nearly seven years. While fourth-quarter earnings are seen rising 7.3 percent, according to Thomson Reuters data, the 9.8 ratio of negative to positive guidance is at a record. ""People are sitting on their hands, waiting for major results to figure out how strong this season may be,"" said Douglas DePietro, managing director at Evercore Partners in New York.DePietro was looking forward to results from JPMorgan Chase & Co and Wells Fargo & Co, both slated to report on Tuesday. General Electric Co, Goldman Sachs and Intel Corp are also reporting this week.Equity gains have largely come on accommodative monetary policies by the Federal Reserve, although not all economic indicators enjoyed a similar boost. The December payroll report, released on Friday, came in much lower than expected.The Dow Jones industrial average was down 67.72 points, or 0.41 percent, at 16,369.33. The Standard & Poor's 500 Index was down 7.55 points, or 0.41 percent, at 1,834.82. The Nasdaq Composite Index was down 12.93 points, or 0.31 percent, at 4,161.74. Losses were limited in the Dow and S&P by Merck & Co , which rose 2.9 percent to $51.33, after a preliminary U.S. Food and Drug Administration review said the company's experimental blood clot-preventing drug vorapaxar should be approved.The drugmaker also said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year.Equities have started 2014 on a lackluster note, dipping 0.7 percent year-to-date as market participants tried to gauge how quickly the Fed will wind down its stimulus. In merger news, Beam Inc agreed to be acquired by Suntory Holdings Ltd for $16 billion, including debt, while British engineering firm Amec provisionally agreed to buy Foster Wheeler in a cash and share deal that values the company at $3.13 billion. Shares of Beam jumped 24 percent to $83.16 while Foster Wheeler rose 1.3 percent to $31.86.""Merger and acquisition activity continues to be an underlying bullish sentiment for the market,"" said DePietro. ""It's one of the most positive things reflecting on the market.""On the downside, Scripps Networks Interactive Inc  fell 5.4 percent to $77.61 after the Wall Street Journal reported that the company had abandoned talks for a merger with Discovery Communications Inc last week. Discovery fell 1.7 percent to $82.62.Lululemon Athletica Inc, Express Inc and Sodastream International all fell after giving weak fourth-quarter outlooks. Lululemon sank 16 percent to $50.21 while Express slid 2.6 percent to $18.2 and Sodastream plunged 22 percent to $38.80.But Wendy's outlook was a bright spot, sending shares up 8.3 percent to $9.14 after the fast-food restaurant chain estimated adjusted quarterly earnings above analysts' expectations, as expenses fell due to franchising many company-owned outlets.",2014-01-13,MRK,"Mon Jan 13, 2014 | 1:12pm EST",US STOCKS-Wall St dips ahead of earnings flurry,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0KN1G020140113?type=companyNews
6,"  * Investors looking ahead to bellwether company earnings* Merck up after FDA review, strategic options plans* Suntory Holdings to acquire Beam for $83.50 per share* Lululemon, Sodastream, Express fall after outlooks* Indexes: Dow down 0.1 pct, S&P down 0.1 pct, Nasdaq flatBy Ryan VlastelicaNEW YORK, Jan 13 U.S. stocks dipped modestly on Monday as investors awaited an onslaught of corporate results to gauge how companies are faring amid mixed signs on economic growth.While early reads on the season have been strong, market participants are looking for further justification that stocks are fairly valued with indexes near all-time highs.Following a jump of almost 30 percent last year, the S&P 500 is above the mean forward price-to-earnings ratio and is at its highest level in nearly seven years. While earnings are seen rising 7.3 percent in the fourth quarter, according to Thomson Reuters data, the 9.8 ratio of negative guidance to positive outlooks is at a record. ""People are sitting on their hands, waiting for major results to figure out how strong this season may be,"" said Douglas DePietro, managing director at Evercore Partners in New York.DePietro was looking forward to results from JPMorgan Chase & Co and Wells Fargo & Co, both of which are slated to report on Tuesday. General Electric Co, Goldman Sachs and Intel Corp are also among the names reporting this week.Equity gains have largely come on accommodative monetary policies by the Federal Reserve, although not all economic indicators enjoyed a similar boost. The December payroll report, released on Friday, came in much lower than expected.The Dow Jones industrial average was down 25.30 points, or 0.15 percent, at 16,411.75. The Standard & Poor's 500 Index was down 1.93 points, or 0.10 percent, at 1,840.44. The Nasdaq Composite Index was up 1.73 points, or 0.04 percent, at 4,176.39. Losses were limited in the Dow and S&P by Merck & Co , which rose 2.9 percent to $51.33 after a preliminary review by the U.S. Food and Drug Administration said the company's experimental blood clot-preventing drug vorapaxar should be approved.In addition, the drugmaker said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year.Equities have started 2014 on a lackluster note, dipping 0.3 percent through the first seven trading sessions as market participants tried to gauge the pace of the winding down of market-friendly economic stimulus by the Federal Reserve.In merger news, Beam Inc agreed to be acquired by Suntory Holdings Limited for $16 billion, including debt, while British engineering firm Amec said it had provisionally agreed to buy Foster Wheeler in a cash and share deal that values the company at $3.13 billion. Shares of Beam jumped 24 percent to $83.16 while Foster rose 1.3 percent to $31.86.""Merger and acquisition activity continues to be an underlying bullish sentiment for the market,"" said DePietro. ""It's one of the most positive things reflecting on the market.""A string of companies tumbled after forecasting earnings.Lululemon Athletica Inc fell 16 percent to $50.07 after the yoga wear retailer cut its forecast for the fourth-quarter due to weak sales in January.Sodastream International slumped 21.2 percent to $39.30 after the home beverage system maker lowered its earnings outlook for 2013. Apparel retailer Express Inc  lost 3.2 percent to $18.41 after it lowered its fourth-quarter outlook.But Wendy's outlook was a bright spot, sending shares up 8.3 percent to $9.14 after the fast-food restaurant chain estimated adjusted quarterly earnings above analysts' expectations, as expenses fell due to franchising many company-owned outlets.",2014-01-13,MRK,"Mon Jan 13, 2014 | 11:53am EST",US STOCKS-Wall St down modestly on earnings caution; Merck gains,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0KN19K20140113?type=companyNews
7,"  * Suntory Holdings to acquire Beam for $83.50 per share* Lululemon, Sodastream, Express fall after outlooks* Merck climbs after prelim FDA review, strategic options plans* Indexes flatBy Chuck MikolajczakNEW YORK, Jan 13 U.S. stocks were flat in early trading Monday as gains in drugmaker Merck were offset by investor concern over valuations.Investor concern may be increasing as stocks have become expensive, with the S&P above the mean forward price-to-earnings ratio and at its highest level in nearly seven years. The benchmark S&P 500 surged almost 30 percent in 2013.According to Thomson Reuters data, fourth-quarter earnings are expected to grow 7.3 percent over the year-ago period. However, the 9.8 ratio of negative guidance to positive outlooks is currently the largest on record. ""It may be that people are speculating that is it is not going to be a very good season at this point,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois.""The last three earnings seasons, people have been questioning how much more earnings improvement can we get without revenue improvement, and it may be that is finally catching up with companies.""Gains in Merck, up 2.9 percent to $51.33, the biggest boost to both the Dow and S&P 500, helped limit declines. A preliminary review by the U.S. Food and Drug Administration said the company's experimental blood clot-preventing drug vorapaxar should be approved. In addition, the drugmaker said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year.Earnings are expected from 29 companies in the S&P 500 this week, including banks such as Morgan Stanley, Citigroup Inc, Goldman Sachs and JPMorgan Chase & Co. Results are also due from First Horizon National Corp , M&T Bank Corp, People's United Financial Inc  and Charles Schwab Corp.The Dow Jones industrial average rose 3.54 points or 0.02 percent, to 16,440.59, the S&P 500 lost 0.01 points or -0 percent, to 1,842.36 and the Nasdaq Composite  added 1.591 points or 0.04 percent, to 4,176.255.Equities have started 2014 on a lackluster note, dipping 0.3 percent through the first seven trading sessions as market participants try to gauge the pace of the winding down of market-friendly economic stimulus by the Federal Reserve. Beam Inc jumped 24.2 percent to $83.16 after the company agreed to be acquired by Suntory Holdings Limited for $16 billion, including debt, making the Japanese company the world's third-largest maker of distilled drinks.A string of companies tumbled after forecasting earnings.Lululemon Athletica Inc fell 16 percent to $50.07 after the yogawear retailer cut its forecast for the fourth-quarter due to weak sales in January.Sodastream International slumped 21.2 percent to $39.30 after the home beverage system maker after its 2013 outlook. Apparel retailer Express Inc  lost 3.2 percent to $18.41 after it lowered its fourth-quarter outlook.But Wendy's outlook was a bright spot, sending shares up 8.3 percent to $9.14 after the fast-food restaurant chain estimated adjusted quarterly earnings above analysts' expectations, as expenses fell due to franchising many company-owned outlets.British engineering firm Amec said it had provisionally agreed to buy Foster Wheeler in a cash and share deal that values the Swiss-based engineer at 1.9 billion pounds ($3.13 billion). Foster Wheeler shares added 1.3 percent to $31.86.",2014-01-13,MRK,"Mon Jan 13, 2014 | 10:12am EST",US STOCKS-Wall St flat on earnings caution; Merck climbs,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0KN10O20140113?type=companyNews
8,"   By Toni Clarke  Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved, based on ""robustly positive"" clinical trial results, according to a preliminary review of the data by the U.S. Food and Drug Administration.The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of outside medical experts who are expected to recommend whether it should be approved. The FDA usually follows the advice of its advisory panels.The drug, which would be sold under the brand name Zontivity, is designed to prevent heart-related deaths, cardiac arrests and strokes in patients who have had a recent heart attack. It would not be recommended for patients who have previously had a stroke because of an increased risk of bleeding in the brain.Results from a trial known as TRA 2P ""are sufficient to establish the effectiveness of vorapaxar for its proposed indication,"" the review found. The main safety concern with the drug is bleeding, the review found, though it noted that the rate of fatal bleeding was low in the population for whom the drug is proposed.The FDA did not recommend that the company establish a risk management program, nor did it recommend that the company conduct additional trials following approval. Vorapaxar works by preventing blood cells, known as platelets, from clumping together and forming clots in the arteries, which can lead to heart attacks. Other anti-platelets include aspirin and Plavix, which is made by Bristol-Myers Squibb Co. Merck's drug works in a different way, by inhibiting a receptor known as PAR-1.Each year about 525,000 Americans have heart attacks and about 190,000 have a second heart-related event, according to Merck. Standard therapy to prevent a second episode often includes treatment with aspirin and Plavix. Voraxapar would be given in addition to standard treatment. During clinical trials, safety monitors found that patients who had previously had a stroke were at higher risk of bleeding in the brain and were instructed to stop taking the drug. Merck then focused its analysis on patients who had had a heart attack but no stroke.Merck's shares rose 2.7 percent to $51.21 in early trading, helped also by news it had initiated its application to market a drug for patients with advanced melanoma.The company also said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action this year.(Reporting by Toni Clarke in Washington; Editing by Lisa Von Ahn and Bernadette Baum)",2014-01-13,MRK,"Mon Jan 13, 2014 | 9:57am EST",Merck's anti-blood clot drug should be approved: FDA review,http://www.reuters.com//article/us-merck-vorapaxar-idUSBREA0C0SZ20140113?type=companyNews
9,"  By Toni ClarkeJan 13 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved, based on ""robustly positive"" clinical trial results, according to a preliminary review of the data by the U.S. Food and Drug Administration.The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of outside medical experts who are expected to recommend whether it should be approved. The FDA usually follows the advice of its advisory panels.The drug, which would be sold under the brand name Zontivity, is designed to prevent heart-related deaths, cardiac arrests and strokes in patients who have had a recent heart attack. It would not be recommended for patients who have previously had a stroke because of an increased risk of bleeding in the brain. Results from a trial known as TRA 2P ""are sufficient to establish the effectiveness of vorapaxar for its proposed indication,"" the review found.The main safety concern with the drug is bleeding, the review found, though it noted that the rate of fatal bleeding was low in the population for whom the drug is proposed. The FDA did not recommend that the company establish a risk management program, nor did it recommend that the company conduct additional trials following approval.Vorapaxar works by preventing blood cells, known as platelets, from clumping together and forming clots in the arteries, which can lead to heart attacks. Other anti-platelets include aspirin and Plavix, which is made by Bristol-Myers Squibb Co. Merck's drug works in a different way, by inhibiting a receptor known as PAR-1. Each year about 525,000 Americans have heart attacks and about 190,000 have a second heart-related event, according to Merck. Standard therapy to prevent a second episode often includes treatment with aspirin and Plavix. Voraxapar would be given in addition to standard treatment.During clinical trials, safety monitors found that patients who had previously had a stroke were at higher risk of bleeding in the brain and were instructed to stop taking the drug. Merck then focused its analysis on patients who had had a heart attack but no stroke.Merck's shares rose 2.7 percent to $51.21 in early trading, helped also by news it had initiated its application to market a drug for patients with advanced melanoma.The company also said it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action this year.",2014-01-13,MRK,"Mon Jan 13, 2014 | 9:55am EST",UPDATE 2-Merck's anti-blood clot drug should be approved -U.S. FDA review,http://www.reuters.com//article/merck-vorapaxar-idUSL2N0KN0UN20140113?type=companyNews
10,"  Jan 13 Merck & Co said on Monday it is pursuing strategic options for its animal health and consumer businesses and expects to complete any action it takes this year.The company could ""determine the most value-creating option for each and could reach different decisions about the two businesses,"" Merck said in a statement ahead of a presentation at an investor conference later in the day. In November, Merck said it was looking at options for separating these businesses. Last week, Reuters and other outlets reported that bankers said Novartis AG was discussing swapping its animal health and human vaccines businesses for Merck's over-the-counter products unit.  Merck shares were trading at $49.96 before the bell, up from $49.86 at Friday's close.",2014-01-13,MRK,"Mon Jan 13, 2014 | 9:01am EST",Merck says consumer or animal health move possible in 2014,http://www.reuters.com//article/merck-mergers-idUSL2N0KN0VT20140113?type=companyNews
11,"  Jan 13 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved based on ""robustly positive"" clinical trial results, according to a preliminary review of the data by the U.S. Food and Drug Administration.The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of outside medical experts, who are expected to recommend whether it should be approved. The FDA usually follows the advice of its advisory panels.  The drug, which would be sold under the brand name Zontivity if approved, is designed to prevent heart-related deaths, heart attacks and strokes in patients who have had a recent heart attack but have not had a stroke. ",2014-01-13,MRK,"Mon Jan 13, 2014 | 8:35am EST",Merck's anti-blood clot drug should be approved -U.S. FDA staff,http://www.reuters.com//article/merck-vorapaxar-idUSL2N0KC0Y820140113?type=companyNews
12,"   By Ransdell Pierson | SAN FRANCISCO  SAN FRANCISCO Merck & Co's (MRK.N) researchers need to regain their confidence after an eight-year drought in developing important new medicines sapped employee morale, the company's recently hired research chief told Reuters.Employees of the second-largest U.S. drugmaker have been so badly shaken by rejected or failed drugs that their gloom has further undermined its legendary research, Merck Research Laboratories President Roger Perlmutter said in an interview during the annual JP Morgan Healthcare Conference late on Monday.""What's missing may be less the absence of a specific capability than it is a loss of esprit,"" said Perlmutter, who at age 60 replaced decade-long research chief Peter Kim in April. ""The various unfortunate occurrences caused people to lose the sense of joie de vivre. They lost the sense they could actually make a real difference.""At the same time, Perlmutter said he was optimistic that Merck's slump would soon end as important new products are approved.""Much of what I need to do is reinstill in the organization the sense of competence, of vigor, of thoroughness and the willingness to take real risks in order to achieve something great,"" he said.Perlmutter was no stranger to Merck when he came aboard last spring at the urging of Chief Executive Kenneth Frazier. He had overseen the company's basic research and preclinical development for four years before joining Amgen Inc (AMGN.O), the largest U.S. biotech company, in 2001 and heading its research until 2012. ""When I retired from Amgen, it was not my goal to take a job like this again; I'd done that,"" he said. ""And when Ken came to talk to me in the bucolic setting of Santa Barbara, with sailboats bobbing in the harbor, it was not my first thought that this is what I wanted to do.""But Perlmutter said his memory of the talent at Merck, including its respected chemists, drew him back to the New Jersey drugmaker, once dubbed ""The House that Research Built"" because of its emphasis on breakthrough medicines over the past half-century.The company developed the first statin, the first ACE inhibitor blood-pressure drug, the first measles vaccine. The first-in-class, best-in-class mindset was largely inspired by Roy Vagelos, a physician who was Merck's chief executive officer from 1985 to 1994. But the situation Perlmutter faced was sobering. Merck had introduced no important innovative medicines since 2006, when it won approvals for Gardasil, the first vaccine to prevent cervical cancer, and a new type of diabetes drug called Januvia.A trail of disappointments had ensued, including failed studies of cholesterol treatment Tredaptive and migraine drug telcagepant and ongoing regulatory delays for osteoporosis medicine odanacatib.""I had one of our very senior chemists express to me her concern that maybe she just isn't any good at this,"" Perlmutter said. ""She got to the point where she really doubted her own ability. And that level of self-doubt has an effect on people's performance."" Perlmutter said some promising developments with new drugs were beginning to lift morale, including a closely watched cancer treatment called MK-3475 that works by harnessing the immune system, highly potent new oral therapies for hepatitis C and an improved version of Gardasil.Shares of Merck jumped Monday after it announced it had applied for U.S. approval for MK-3475 in patients with advanced melanoma. The company is testing this PD-1 inhibitor against other cancers and is expected to combine the drug with its other experimental treatments for the disease.Merck also aims to license or buy more drugs from other companies. Perlmutter said research and development executives could now pursue deals and buy products on their own - tapping the company's chief financial officer only as a financial adviser - to speed up the process.""It's not an overnight thing, but people are developing a certain bounce to their step that was missing before,"" Perlmutter said, ""an actual sense they can achieve something.""(Reporting by Ransdell Pierson; Editing by Michele Gershberg and Lisa Von Ahn)",2014-01-14,MRK,"Tue Jan 14, 2014 | 11:46am EST","Merck needs a dose of joie de vivre, research chief says",http://www.reuters.com//article/us-merck-perlmutter-idUSBREA0D12C20140114?type=companyNews
13,"   By Toni Clarke  Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.The panel voted 10-1 in favor of the drug, which would, if approved, be sold under the brand name Zontivity. The FDA is not bound to follow the advice of its advisory panels but typically does so.Results from a trial known as TRA 2P were ""robust,"" panelists said, and justified approval for patients who had suffered a heart attack.They agreed with the company that the drug should not be used in patients with a history of stroke, since there was an increased risk of bleeding in the brain in this group of patients.""I think this drug addresses a real unmet medical need,"" said Dr. Philip Sager, consulting professor of medicine at Stanford University School of Medicine. The vote followed a positive analysis by reviewers for the FDA, whose report, published on Monday, also recommended the drug be approved.Vorapaxar works by preventing blood cells, or platelets, from clumping together and forming clots in the arteries, which can lead to heart attacks.Other anti-platelets include aspirin and Plavix, which is made by Bristol-Myers Squibb Co. Merck's drug works in a different way, by inhibiting a receptor known as PAR-1. The drug increased the overall risk of bleeding in clinical trials, though the risk in patients who had not had a stroke did not outweigh the drug's benefit, panelists said.Still, Dr. Sanjay Kaul, a cardiologist and professor at UCLA School of Medicine who voted in favor of approval, urged the FDA to ""do its due diligence"" around the bleeding risk. Each year about 190,000 Americans have a second heart-related event, according to Merck. Standard therapy to prevent a second episode often includes treatment with aspirin and Plavix. Vorapaxar would be given in addition to standard treatment.""The results of today's advisory committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack,"" Dr. Daniel Bloomfield, who leads Merck's cardiovascular research, said in a statement. ""We look forward to working with the FDA as it completes its review.""Merck has proposed that the drug's label urge caution when prescribing the drug for patients who weigh less than 60 kilograms (132 lbs) since the risk of bleeding in these patients appears to be higher than in heavier patients.Panelists could not reach a consensus recommendation on how lower-weight patients should be treated. Representatives from the FDA said they will continue to discuss the matter before making their final ruling.(Reporting by Toni Clarke in Washington; Editing by Nick Zieminski and Dan Grebler)",2014-01-15,MRK,"Wed Jan 15, 2014 | 5:31pm EST",FDA advisory panel backs Merck's blood clot-preventing drug,http://www.reuters.com//article/us-merck-vorapaxar-idUSBREA0E1KV20140115?type=companyNews
14,"  (Adds details, physician comment, background)By Toni ClarkeJan 15 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.The panel voted 10-1 in favor of the drug, which would, if approved, be sold under the brand name Zontivity. The FDA is not bound to follow the advice of its advisory panels but typically does so.Results from a trial known as TRA 2P were ""robust,"" panelists said, and justified approval for patients who had suffered a heart attack.They agreed with the company that the drug should not be used in patients with a history of stroke, since there was an increased risk of bleeding in the brain in this group of patients. ""I think this drug addresses a real unmet medical need,"" said Dr. Philip Sager, consulting professor of medicine at Stanford University School of Medicine.The vote followed a positive analysis by reviewers for the FDA, whose report, published on Monday, also recommended the drug be approved.Vorapaxar works by preventing blood cells, or platelets, from clumping together and forming clots in the arteries, which can lead to heart attacks. Other anti-platelets include aspirin and Plavix, which is made by Bristol-Myers Squibb Co. Merck's drug works in a different way, by inhibiting a receptor known as PAR-1.The drug increased the overall risk of bleeding in clinical trials, though the risk in patients who had not had a stroke did not outweigh the drug's benefit, panelists said.Still, Dr. Sanjay Kaul, a cardiologist and professor at UCLA School of Medicine who voted in favor of approval, urged the FDA to ""do its due diligence"" around the bleeding risk. Each year about 190,000 Americans have a second heart-related event, according to Merck. Standard therapy to prevent a second episode often includes treatment with aspirin and Plavix. Vorapaxar would be given in addition to standard treatment.""The results of today's advisory committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack,"" Dr. Daniel Bloomfield, who leads Merck's cardiovascular research, said in a statement. ""We look forward to working with the FDA as it completes its review.""Merck has proposed that the drug's label urge caution when prescribing the drug for patients who weigh less than 60 kilograms (132 lbs) since the risk of bleeding in these patients appears to be higher than in heavier patients.Panelists could not reach a consensus recommendation on how lower-weight patients should be treated. Representatives from the FDA said they will continue to discuss the matter before making their final ruling.(Reporting by Toni Clarke in Washington; Editing by Nick Zieminski and Dan Grebler)",2014-01-15,MRK,"Wed Jan 15, 2014 | 5:31pm EST",UPDATE 1-FDA advisory panel backs Merck's blood clot-preventing drug,http://www.reuters.com//article/merck-vorapaxar-idUSL2N0KP20420140115?type=companyNews
15,"  Jan 15 Merck & Co Inc's experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 10-1 in favor of the drug, which would, if approved, be sold under the brand name Zontivity. The FDA is not bound to follow the advice of its advisory panels but typically does so. The drug should not be recommended for patients who have previously had a stroke because of an increased risk of bleeding in the brain, the panel said.   (Reporting by Toni Clarke in Washington; Editing by Nick Zieminski)  ",2014-01-15,MRK,"Wed Jan 15, 2014 | 4:19pm EST",FDA advisory panel backs Merck's blood clot-preventing drug,http://www.reuters.com//article/merck-vorapaxar-idUSL2N0KP1VE20140115?type=companyNews
16,"  Jan 23 AZ Electronic Materials SA :  * Announcement of level of acceptances, extension of offer from Merck * Source text for Eikon:  * For more news, please click here   ",2014-01-23,MRK,"Thu Jan 23, 2014 | 2:37am EST",BRIEF-Hi-tech material firm AZ says Merck's offer extended to Feb. 5,http://www.reuters.com//article/azelectronicmaterials-brief-idUSWLB006TJ20140123?type=companyNews
17,"   By Bill Berkrot  No serious safety concerns were raised over Merck & Co's experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside medical experts who will discuss whether the drug merits approval.The Allergenic Products Advisory Committee will meet on Tuesday to review Ragwitek, a pill placed under the tongue that, if approved, would be an alternative to regular injections administered by doctors for ragweed pollen allergies.At the meeting, the panel will be asked to discuss whether available clinical trial data supports the safety and the efficacy of the product in persons 18 years of age and older and make recommendations to the U.S. Food and Drug Administration.The committee will also be asked to recommend to the agency whether any additional studies of the drug might be needed. The FDA documents appeared to favor the drug's safety, saying ""none of the adverse events categorized as serious by investigators or (Merck) are considered related to the study drug.""The document also said ""there were no deaths in any of the five clinical development trials of Ragwitek.""About 30 million people in the United States suffer allergies to ragweed pollen, the FDA said. Analysts see eventual Ragwitek sales of about $300 million. However, Morningstar analyst Damien Conover said sales could reach as much as $1 billion if enough allergy sufferers prefer the pill to injections.The pill, which is comprised of extracts from short ragweed pollen, would be taken daily beginning 12 weeks prior to the start of the ragweed pollen season and throughout the season. Merck filed its application seeking U.S. approval of Ragwitek last March. The drug, and another pill for grass pollen allergies called Grastek, are being developed along with Danish Drugmaker ALK Abello.In December, an FDA advisory committee unanimously recommended approval of Grastek.Merck shares were down 9 cents at $51.51 on the New York Stock Exchange, against the broader markets, which were down more than 1 percent.(Reporting by Bill Berkrot; Editing by Bernadette Baum)",2014-01-24,MRK,"Fri Jan 24, 2014 | 12:46pm EST",No serious side effects with Merck allergy pill: FDA documents,http://www.reuters.com//article/us-merck-allergy-idUSBREA0N1CQ20140124?type=companyNews
18,"   By Bill Berkrot  Jan 24 No serious safety concerns were raised over Merck & Co's experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside medical experts who will discuss whether the drug merits approval.The Allergenic Products Advisory Committee will meet on Tuesday to review Ragwitek, a pill placed under the tongue that, if approved, would be an alternative to regular injections administered by doctors for ragweed pollen allergies.At the meeting, the panel will be asked to discuss whether available clinical trial data supports the safety and the efficacy of the product in persons 18 years of age and older and make recommendations to the U.S. Food and Drug Administration.The committee will also be asked to recommend to the agency whether any additional studies of the drug might be needed. The FDA documents appeared to favor the drug's safety, saying ""none of the adverse events categorized as serious by investigators or (Merck) are considered related to the study drug.""The document also said ""there were no deaths in any of the five clinical development trials of Ragwitek."" About 30 million people in the United States suffer allergies to ragweed pollen, the FDA said.Analysts see eventual Ragwitek sales of about $300 million. However, Morningstar analyst Damien Conover said sales could reach as much as $1 billion if enough allergy sufferers prefer the pill to injections. The pill, which is comprised of extracts from short ragweed pollen, would be taken daily beginning 12 weeks prior to the start of the ragweed pollen season and throughout the season.Merck filed its application seeking U.S. approval of Ragwitek last March. The drug, and another pill for grass pollen allergies called Grastek, are being developed along with Danish Drugmaker ALK Abello.In December, an FDA advisory committee unanimously recommended approval of Grastek.Merck shares were down 9 cents at $51.51 on the New York Stock Exchange, against the broader markets, which were down more than 1 percent.",2014-01-24,MRK,"Fri Jan 24, 2014 | 12:38pm EST",No serious side effects with Merck allergy pill -FDA documents,http://www.reuters.com//article/merck-allergy-idUSL2N0KY15220140124?type=companyNews
19,"  Merck & Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy. It voted 8 to 0, with one abstention, that the data supported the drug's safety.About 30 million people in the United States suffer allergies to ragweed pollen, according to the FDA. Analysts see eventual Ragwitek sales of about $300 million. However, Morningstar analyst Damien Conover believes sales could reach as much as $1 billion if enough allergy sufferers prefer Ragwitek, a pill, to injections.The pill, which is comprised of extracts from short ragweed pollen, would be taken daily beginning 12 weeks prior to the start of the ragweed pollen season and throughout the season. Merck filed its application seeking U.S. approval of Ragwitek last March. The drug, and another pill for grass pollen allergies called Grastek, are being developed along with Danish Drugmaker ALK Abello. In December, an FDA advisory committee unanimously recommended approval of Grastek.(Reporting by Toni Clarke in Washington and Bill Berkrot in New York; Editing by Andre Grenon and David Gregorio)",2014-01-28,MRK,"Tue Jan 28, 2014 | 2:12pm EST","U.S. FDA panel: data support safety, efficacy of Merck allergy drug",http://www.reuters.com//article/us-merck-ragwitek-idUSBREA0R1K020140128?type=companyNews
20,"  Jan 28 Merck & Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy. It voted 8 to 0, with one abstention, that the data supported the drug's safety. About 30 million people in the United States suffer allergies to ragweed pollen, according to the FDA.Analysts see eventual Ragwitek sales of about $300 million. However, Morningstar analyst Damien Conover believes sales could reach as much as $1 billion if enough allergy sufferers prefer Ragwitek, a pill, to injections. The pill, which is comprised of extracts from short ragweed pollen, would be taken daily beginning 12 weeks prior to the start of the ragweed pollen season and throughout the season. Merck filed its application seeking U.S. approval of Ragwitek last March. The drug, and another pill for grass pollen allergies called Grastek, are being developed along with Danish Drugmaker ALK Abello.In December, an FDA advisory committee unanimously recommended approval of Grastek.",2014-01-28,MRK,"Tue Jan 28, 2014 | 2:11pm EST","UPDATE 1-U.S. FDA panel: data support safety, efficacy of Merck allergy drug",http://www.reuters.com//article/merck-ragwitek-idUSL2N0L21FV20140128?type=companyNews
21,"  Jan 28 Merck & Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy. It voted 8 to 0, with one abstention, that it supported the drug's safety.  Ragwitek is designed to treat allergic reaction to short ragweed pollen. ",2014-01-28,MRK,"Tue Jan 28, 2014 | 1:57pm EST","U.S. FDA panel: data support safety, efficacy of Merck allergy drug",http://www.reuters.com//article/merck-ragwitek-idUSL2N0L21DB20140128?type=companyNews
22,"   By Soyoung Kim and Olivia Oran | NEW YORK  NEW YORK Merck & Co Inc (MRK.N) has received approaches from large consumer companies interested in buying its consumer healthcare business, best known for Coppertone sunscreen and Claritin allergy medicine, according to people familiar with the matter.Merck's consumer healthcare business, which also includes Dr. Scholl's foot care and other consumer products, could be worth as much as $8 billion to $10 billion in a sale, or roughly four to five times the unit's annual revenue, some of the people said.Merck, the No. 2 U.S. drugmaker after Pfizer Inc (PFE.N), is considering alternatives for both its consumer and animal health businesses and has said it expects to complete the review in 2014.Among a range of options it has considered for the consumer unit, Merck discussed a potential asset swap with Novartis AG NOVN.VX, under which Merck would give up its consumer assets in return for the Swiss drugmaker's animal health and other units, Reuters and others previously reported.The probability of carrying out such a deal, however, is currently seen as low due to the complexity of valuing different businesses, prompting Merck to explore an outright sale of its consumer unit as well, people familiar with the matter said.Merck has been in conversations with several interested parties and is being advised by Morgan Stanley (MS.N) on the process, the people said, asking not to be named because the conversations are private. For its much larger animal health unit, the second-largest in the industry after Zoetis Inc (ZTS.N), Merck is evaluating the potential of spinning it off as a separate publicly traded company, people familiar with the matter said.Analysts and people familiar with the industry say big consumer companies such as Reckitt Benckiser Group (RB.L) and Procter & Gamble Co (PG.N) could be logical buyers for Merck's consumer healthcare business.Reckitt already owns over-the-counter medicines including Mucinex and Nurofen and the international rights for the Scholl foot care business. Its chief executive told Reuters in a September interview that Reckitt aimed to be a major player in consumer healthcare and has the firepower to do sizeable deals. Procter & Gamble Co (PG.N) also has a portfolio that includes a range of medicines and beauty products.Reckitt and P&G declined to comment.Johnson & Johnson (JNJ.N) is the biggest player in the $200 billion global consumer health industry, with about 4 percent of the market, followed by Bayer AG (BAYGn.DE) and GlaxoSmithKline Plc (GSK.L). Merck, however, is relatively small with around 1 percent of the market. Merck has said in the past that it views its consumer business as sub-scale.In considering options for the consumer and animal health businesses, Merck is following in the footsteps of other drugmakers such as Pfizer Inc (PFE.N), which created shareholder value by seperating non-core assets.Pfizer sold its infant-nutrition business to Nestle SA NESN.VX for $11.9 billion in 2012, and last year spun off its animal health unit as a separate publicly traded company called Zoetis.Many other drugmakers have been looking to shed businesses, prompted by pricing pressure and increasing competition that has forced a more rigorous approach to capital allocation. They have shown a new willingness to consider whether other companies may be better owners for certain assets.A Merck spokeswoman declined to comment on details of the strategic review. Morgan Stanley did not respond to requests for comment.(Reporting by Soyoung Kim and Olivia Oran, additional reporting by Arno Schuetze, Martinne Geller and Ben Hirschler; Editing by David Gregorio)",2014-01-31,MRK,"Fri Jan 31, 2014 | 2:06pm EST",Merck gets buyout interest for consumer health unit: sources,http://www.reuters.com//article/us-merck-unit-idUSBREA0U1L020140131?type=companyNews
23,"   By Soyoung Kim and Olivia Oran | NEW YORK  NEW YORK Jan 31 Merck & Co Inc has received approaches from large consumer companies interested in buying its consumer healthcare business, best known for Coppertone sunscreen and Claritin allergy medicine, according to people familiar with the matter.Merck's consumer healthcare business, which also includes Dr. Scholl's foot care and other consumer products, could be worth as much as $8 billion to $10 billion in a sale, or roughly four to five times the unit's annual revenue, some of the people said.Merck, the No. 2 U.S. drugmaker after Pfizer Inc, is considering alternatives for both its consumer and animal health businesses and has said it expects to complete the review in 2014.Among a range of options it has considered for the consumer unit, Merck discussed a potential asset swap with Novartis AG , under which Merck would give up its consumer assets in return for the Swiss drugmaker's animal health and other units, Reuters and others previously reported.The probability of carrying out such a deal, however, is currently seen as low due to the complexity of valuing different businesses, prompting Merck to explore an outright sale of its consumer unit as well, people familiar with the matter said.Merck has been in conversations with several interested parties and is being advised by Morgan Stanley on the process, the people said, asking not to be named because the conversations are private. For its much larger animal health unit, the second-largest in the industry after Zoetis Inc, Merck is evaluating the potential of spinning it off as a separate publicly traded company, people familiar with the matter said.Analysts and people familiar with the industry say big consumer companies such as Reckitt Benckiser Group and Procter & Gamble Co could be logical buyers for Merck's consumer healthcare business.Reckitt already owns over-the-counter medicines including Mucinex and Nurofen and the international rights for the Scholl foot care business. Its chief executive told Reuters in a September interview that Reckitt aimed to be a major player in consumer healthcare and has the firepower to do sizeable deals. Procter & Gamble Co also has a portfolio that includes a range of medicines and beauty products.Reckitt and P&G declined to comment.Johnson & Johnson is the biggest player in the $200 billion global consumer health industry, with about 4 percent of the market, followed by Bayer AG and GlaxoSmithKline Plc. Merck, however, is relatively small with around 1 percent of the market. Merck has said in the past that it views its consumer business as sub-scale.In considering options for the consumer and animal health businesses, Merck is following in the footsteps of other drugmakers such as Pfizer Inc, which created shareholder value by seperating non-core assets.Pfizer sold its infant-nutrition business to Nestle SA  for $11.9 billion in 2012, and last year spun off its animal health unit as a separate publicly traded company called Zoetis.Many other drugmakers have been looking to shed businesses, prompted by pricing pressure and increasing competition that has forced a more rigorous approach to capital allocation. They have shown a new willingness to consider whether other companies may be better owners for certain assets.A Merck spokeswoman declined to comment on details of the strategic review. Morgan Stanley did not respond to requests for comment.",2014-01-31,MRK,"Fri Jan 31, 2014 | 1:58pm EST",Merck gets buyout interest for consumer health unit -sources,http://www.reuters.com//article/merck-unit-idUSL2N0L50N520140131?type=companyNews
24,"   By Philip Blenkinsop | BRUSSELS  BRUSSELS Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself.The collaboration involves a new generation of drugs designed to activate the immune system. The first in the field - Bristol-Meyer Squibb's Yervoy - is targeting melanoma, the deadliest form of skin cancer.Rival Merck filed the first part of an application to market its own potential drug for advanced melanoma earlier this month, pushing up its share price. The firm is testing the same drug for lung and renal cancer.Ablynx, which already has a neurology partnership with the U.S. drugmaker dating back to 2012, said on Monday that it would be responsible for discovering antibody-derived proteins, known as nanobodies, to target ""immune checkpoint modulators"".The modulators regulate the body's immune response, but cancers can evade the immune system because tumor cells can be like the patient's own and can also interfere with the immune response.Ablynx believes its nanobodies - typically a 10th the size of an antibody, and able to penetrate further and be manipulated more than an antibody - could help activate the immune system to attack cancer cells. Under the terms of the deal, Ablynx will receive a payment of 20 million euros and up to 10.7 million euros in research funding during an initial three-year research term.The firm is eligible for payments on reaching development, regulatory and commercial milestones with a potential to accrue as much as 1.7 billion euros plus royalties.$35 BILLION MARKET  ""This is a very big new initiative,"" Chief Executive Edwin Moses told Reuters by telephone, adding that normally products would take 10 to 15 years to get to market.""What's a little bit different here is that because the potential of this therapeutic approach is so encouraging, you see the products beginning to get fast-track status from regulators ... you could see three, four, five years taken off that timeline, although you've got to wait and see.""Analysts estimate peak sales for Yervoy could be $6 billion, while the market for cancer immunotherapy could reach $35 billion a year in a decade. Ablynx shares rose as much as 6.9 percent and at 1220 GMT were up 6.2 percent at 7.69 euros, the strongest performers on a slightly weaker Euronext Brussels market.KBC Securities analyst Jan De Kerpel, with a ""buy"" rating on the stock, raised his price target to 13 euros from 12.5.""Altogether they get some 30 million euros. This is not just Merck trying something. That was the first deal in 2012,"" he said. ""The conclusion from that first project is that they are very pleased with how Ablynx works and they are now coming with a much bigger project.""Ablynx, loss-making since it listed its shares on the stock market in 2007, makes its revenues through development deals with large pharma groups such as Merck Serono, AbbVie and Boehringer Ingelheim.(Reporting By Philip Blenkinsop; Editing by Pravin Char)",2014-02-03,MRK,"Mon Feb 3, 2014 | 7:32am EST",Ablynx agrees Merck cancer deal worth up to 1.7 billion euros,http://www.reuters.com//article/us-ablynx-merck-idUSBREA1209K20140203?type=companyNews
25,"  * Ablynx initially to get 20 mln euros, plus 10.7 mln for research* Therapy designed to trigger body's own immune system* Ablynx shares gain up to 6.9 pct* Analysts says cancer immunotherapy market could hit $35 bln a yrBy Philip BlenkinsopBRUSSELS, Feb 3 Belgian biotech company Ablynx  has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself.The collaboration involves a new generation of drugs designed to activate the immune system. The first in the field - Bristol-Meyer Squibb's Yervoy - is targeting melanoma, the deadliest form of skin cancer.Rival Merck filed the first part of an application to market its own potential drug for advanced melanoma earlier this month, pushing up its share price. The firm is testing the same drug for lung and renal cancer. Ablynx, which already has a neurology partnership with the U.S. drugmaker dating back to 2012, said on Monday that it would be responsible for discovering antibody-derived proteins, known as nanobodies, to target ""immune checkpoint modulators"".The modulators regulate the body's immune response, but cancers can evade the immune system because tumour cells can be like the patient's own and can also interfere with the immune response.Ablynx believes its nanobodies - typically a 10th the size of an antibody, and able to penetrate further and be manipulated more than an antibody - could help activate the immune system to attack cancer cells.Under the terms of the deal, Ablynx will receive a payment of 20 million euros and up to 10.7 million euros in research funding during an initial three-year research term. The firm is eligible for payments on reaching development, regulatory and commercial milestones with a potential to accrue as much as 1.7 billion euros plus royalties.$35 BILLION MARKET  ""This is a very big new initiative,"" Chief Executive Edwin Moses told Reuters by telephone, adding that normally products would take 10 to 15 years to get to market.""What's a little bit different here is that because the potential of this therapeutic approach is so encouraging, you see the products beginning to get fast-track status from regulators ... you could see three, four, five years taken off that timeline, although you've got to wait and see.""Analysts estimate peak sales for Yervoy could be $6 billion, while the market for cancer immunotherapy could reach $35 billion a year in a decade.Ablynx shares rose as much as 6.9 percent and at 1220 GMT were up 6.2 percent at 7.69 euros, the strongest performers on a slightly weaker Euronext Brussels market.KBC Securities analyst Jan De Kerpel, with a ""buy"" rating on the stock, raised his price target to 13 euros from 12.5.""Altogether they get some 30 million euros. This is not just Merck trying something. That was the first deal in 2012,"" he said. ""The conclusion from that first project is that they are very pleased with how Ablynx works and they are now coming with a much bigger project.""Ablynx, loss-making since it listed its shares on the stock market in 2007, makes its revenues through development deals with large pharma groups such as Merck Serono, AbbVie  and Boehringer Ingelheim.",2014-02-03,MRK,"Mon Feb 3, 2014 | 7:28am EST",UPDATE 1-Ablynx agrees Merck cancer deal worth up to 1.7 bln euros,http://www.reuters.com//article/ablynx-merck-idUSL5N0L81E720140203?type=companyNews
26,"  * FTSE 100 down 0.3 percent* Lloyds falls; delays dividend prospect after mis-selling charge* Reckitt up on talk of move for Merck unitBy Tricia WrightLONDON, Feb 3 Britain's top shares inched lower on Monday, extending recent hefty falls, led down by Lloyds Banking Group.Lloyds fell 2.4 percent after it said it had set aside a further 1.8 billion pounds ($2.96 billion) in the fourth quarter to compensate customers mis-sold payment protection insurance (PPI), and dividend payouts were to come later than some in the market had anticipated.""Continued higher-than-expected PPI claims - now elongated to an extent than surprised me - and the resumption of dividend payments moved back later than expected has certainly taken the shine of the stock,"" said Jordan Hiscott, sales trader at Gekko Global Markets.However, he said the 100-day moving average, currently at 77.8, could act as support - noting that Gekko's client base is using Monday's weakness in the shares, now trading at 81.3 pence, as a buying opportunity. Consumer goods company Reckitt Benckiser, however, rose 1.9 percent, one of the biggest boosts to the FTSE 100, with traders citing speculation the maker of Nurofen pain relief tablets may make a move for Merck & Co's consumer healthcare (CH) business.""We believe the acquisition of Merck's OTC/CH assets would ... be very attractive to RB (Reckitt Benckiser),"" analysts at Bernstein wrote in a note.""We estimate this would push RB up from global #9 to #3 in CH and would result in RB becoming the global leader in Cough, Cold and Allergy."" The FTSE 100 was down 21.01 points, or 0.3 percent, at 6,489.43 points by 0924 GMT, having dropped 0.4 percent on Friday. It fell 3.5 percent in January, its biggest monthly decline since last June and its worst January since 2010.After an encouraging start to the year, which saw the UK benchmark post gains in the first two weeks, equity markets took a turn for the worse as unease about slowing Chinese growth and the withdrawal of U.S. monetary stimulus spread from emerging market currencies to the world's big stock markets.Alongside the emerging market worries, investor concern has focused on the current earnings season, and whether it will result in profits strong enough to justify lofty valuations after a bumper 2013.While Monday was quiet on the earnings front, there are plenty of releases later on in the week - from the likes of oil majors BG and BP, drugmakers AstraZeneca  and GlaxoSmithKline, and mobile phone group Vodafone . Vodafone is set to become one of the latest high profile victims of the chaos engulfing the emerging economies of Africa and Asia, readying itself for a big slide in its overseas revenues, weekend press reports said.""(Earnings have) been particularly ropey in the UK,"" Peel Hunt equity strategist Ian Williams said.""I think one or two investors have realised that valuations are at the top end of that recent range and you can't afford the number of disappointments on the trading front which we still appear to be getting,"" he said.The FTSE 100 is trading on a 12-month forward price/earnings ratio of 13.3 times, against its 10-year average of 11.9 times, Thomson Reuters Datastream shows.Of the 17 percent of European companies to have reported so far, 44 percent have missed profits expectations, while 46 percent have missed expectations on revenue, Thomson Reuters Starmine data shows.",2014-02-03,MRK,"Mon Feb 3, 2014 | 4:37am EST","FTSE inches lower, pulled down by Lloyds",http://www.reuters.com//article/markets-britain-stocks-idUSL5N0L814X20140203?type=companyNews
27,"  BRUSSELS Feb 3 Belgian biotech company Ablynx  has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.29 billion) to develop potential new treatments for cancer.The Belgian firm, which already has a neurology partnership with Merck dating back to Oct 2012, said on Monday that it would be charged with discovering antibody-derived proteins, known as nanobodies, to target 'immune checkpoint modulators'.The latter regulate the body's immune response, but cancers can evade the host immune system that response since tumour cells are the patient's own. Ablynx believes its tiny nanobodies could help activate the immune system to attack cancer cells. Under the terms of the deal, Ablynx will receive a payment of 20 million euros and up to 10.7 million euros in research funding during an initial three-year research term. Ablynx is eligible to receive payments on reaching certain development, regulatory and commercial milestones with a potential to accrue as much as 1.7 billion euros plus royalties. Merck will be responsible for the development, manufacture and commercialisation of any products resulting from the partnership.",2014-02-03,MRK,"Mon Feb 3, 2014 | 2:19am EST",Ablynx signs Merck deal worth up to 1.7 bln euros,http://www.reuters.com//article/ablynx-merck-idUSL5N0L80HV20140203?type=companyNews
28,"  BRUSSELS Feb 3 Ablynx NV :  * Announces worldwide cancer immunotherapy discovery collaboration and licensing agreement with Merck   * Collaboration, licensing agreement is focused on the discovery and development of several predefined nanobody candidates  * Co will receive an upfront payment of 20 mln euros; up to 10.7 mln euros in research funding during the initial three year  * Is eligible to receive development, regulatory and commercial milestone payments on achieved sales threshold  * Has ultimate potential to accrue as much as 1.7 bln euros plus tiered royalties   ",2014-02-03,MRK,"Mon Feb 3, 2014 | 1:28am EST","BRIEF-Ablynx, Merck sign cancer immunotherapy collaboration, licensing agreement",http://www.reuters.com//article/ablynx-results-idUSWEB00HJ520140203?type=companyNews
29,"   By Ransdell Pierson  Merck & Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but the company announced potentially lucrative new cancer-drug partnerships with rival U.S. drugmakers.For the full year, Merck expected to earn $3.35 to $3.53 per share, excluding special items. The average analyst estimate was $3.48 per share.""Overall, I view this guidance as 'good enough,' given fairly widespread Street concerns about a 'mega-miss,'"" ISI Group analyst Mark Schoenebaum said, adding that investors remain more focused on prospects for the company's array of experimental drugs.Separately on Wednesday, Merck said it plans to test its closely followed immuno-oncology drug MK-3475, in combination with medicines being developed by Pfizer Inc, Amgen Inc and Incyte Corp. Financial terms of the deals were not disclosed.Merck shares were up 0.3 percent in midday trading on the New York Stock Exchange, after rising as much as 3.1 percent earlier on Wednesday.Schoenebaum said investors were enthused about the planned new studies of MK-3475, a so-called PD-1 inhibitor that works by harnessing the immune system to find and destroy cancer cells.Industry analysts believe the medicine, if approved, could generate annual sales of $2 billion or more and greatly improve treatment of melanoma and potentially other cancers. They also believe such immuno-oncology drugs may have special promise if used in combination with each other. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter. That compared with $908 million, or 30 cents per share, in the year-earlier period.Excluding special items, Merck earned 88 cents per share. The average analyst forecast was 89 cents per share, according to Thomson Reuters I/B/E/S.Revenue fell 4 percent to $11.32 billion. Wall Street was expecting $11.36 billion. Merck shares rose 22 percent in 2013, underperforming a 27 percent average gain for other large U.S. and European drugmakers, amid waning sales of its Januvia diabetes medicines and uncertainty about its drug pipeline.The company is hoping that MK-3475 and other drugs will be approved and revive sales and earnings growth, following failures or setbacks over the past five years for its treatments for heart disease, osteoporosis and other diseases.Sales of Januvia, Merck's biggest product, fell 1 percent to $1.12 billion in the fourth quarter, while sales of a related combination medicine called Janumet rose 11 percent to $503 million. Double-digit sales gains were seen for arthritis treatment Remicade and HIV treatment Isentress.But sales of asthma drug, Singulair, now facing generics, tumbled 38 percent to $298 million. Sales of the company's animal health products, which usually prop up results, slipped 3 percent to $871 million in the quarter. They were hurt by the company's voluntary suspension of sales earlier in the year of Zilmax, a feed supplement that some critics have alleged caused dangerous weight gains in cattle.Merck said on Wednesday it will study MK-3475 in combination with Pfizer's approved kidney-cancer drug Inlyta, and separately test MK-3475 against various cancers in combination with a Pfizer immuno-oncology drug called PF-05082566 (PF-2566). The Pfizer drug targets a protein called the human 4-1BB receptor.Incyte and Merck will conduct an early-stage trial of MK-3475 in combination with Incyte's experimental INCB24360 - a so-called IDO inhibitor. They will be tested on patients with advanced lung cancer, and other advanced cancers.The Merck drug will be tested with Amgen's experimental medicine, called talimogene laherparepvec, in an early-stage study of patients with advanced melanoma. The drug, nicknamed ""T-VEC,"" is a virus that is injected directly into tumor tissue in hopes of stimulating the immune system to attack cancer cells.Shares of Incyte slipped 1.5 percent to $61.97, while Pfizer shares eased 1.3 percent to $30.78. Amgen shares were little changed.(Editing by Jeffrey Benkoe and Bernadette Baum)",2014-02-05,MRK,"Wed Feb 5, 2014 | 12:52pm EST","Merck results flag, but cancer-drug deals lift shares",http://www.reuters.com//article/us-merck-results-idUSBREA140SI20140205?type=companyNews
30,"  By Ransdell PiersonFeb 5 Merck & Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but the company announced potentially lucrative new cancer-drug partnerships with rival U.S. drugmakers.For the full year, Merck expected to earn $3.35 to $3.53 per share, excluding special items. The average analyst estimate was $3.48 per share.""Overall, I view this guidance as 'good enough,' given fairly widespread Street concerns about a 'mega-miss,'"" ISI Group analyst Mark Schoenebaum said, adding that investors remain more focused on prospects for the company's array of experimental drugs.Separately on Wednesday, Merck said it plans to test its closely followed immuno-oncology drug MK-3475, in combination with medicines being developed by Pfizer Inc, Amgen Inc  and Incyte Corp. Financial terms of the deals were not disclosed.Merck shares were up 0.3 percent in midday trading on the New York Stock Exchange, after rising as much as 3.1 percent earlier on Wednesday.Schoenebaum said investors were enthused about the planned new studies of MK-3475, a so-called PD-1 inhibitor that works by harnessing the immune system to find and destroy cancer cells. Industry analysts believe the medicine, if approved, could generate annual sales of $2 billion or more and greatly improve treatment of melanoma and potentially other cancers. They also believe such immuno-oncology drugs may have special promise if used in combination with each other.The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter. That compared with $908 million, or 30 cents per share, in the year-earlier period.Excluding special items, Merck earned 88 cents per share. The average analyst forecast was 89 cents per share, according to Thomson Reuters I/B/E/S. Revenue fell 4 percent to $11.32 billion. Wall Street was expecting $11.36 billion.Merck shares rose 22 percent in 2013, underperforming a 27 percent average gain for other large U.S. and European drugmakers, amid waning sales of its Januvia diabetes medicines and uncertainty about its drug pipeline.The company is hoping that MK-3475 and other drugs will be approved and revive sales and earnings growth, following failures or setbacks over the past five years for its treatments for heart disease, osteoporosis and other diseases.Sales of Januvia, Merck's biggest product, fell 1 percent to $1.12 billion in the fourth quarter, while sales of a related combination medicine called Janumet rose 11 percent to $503 million. Double-digit sales gains were seen for arthritis treatment Remicade and HIV treatment Isentress. But sales of asthma drug, Singulair, now facing generics, tumbled 38 percent to $298 million.Sales of the company's animal health products, which usually prop up results, slipped 3 percent to $871 million in the quarter. They were hurt by the company's voluntary suspension of sales earlier in the year of Zilmax, a feed supplement that some critics have alleged caused dangerous weight gains in cattle.Merck said on Wednesday it will study MK-3475 in combination with Pfizer's approved kidney-cancer drug Inlyta, and separately test MK-3475 against various cancers in combination with a Pfizer immuno-oncology drug called PF-05082566 (PF-2566). The Pfizer drug targets a protein called the human 4-1BB receptor.Incyte and Merck will conduct an early-stage trial of MK-3475 in combination with Incyte's experimental INCB24360 - a so-called IDO inhibitor. They will be tested on patients with advanced lung cancer, and other advanced cancers.The Merck drug will be tested with Amgen's experimental  medicine, called talimogene laherparepvec, in an early-stage study of patients with advanced melanoma. The drug, nicknamed ""T-VEC,"" is a virus that is injected directly into tumor tissue in hopes of stimulating the immune system to attack cancer cells.Shares of Incyte slipped 1.5 percent to $61.97, while Pfizer shares eased 1.3 percent to $30.78. Amgen shares were little changed.",2014-02-05,MRK,"Wed Feb 5, 2014 | 12:52pm EST","UPDATE 3-Merck results flag, but cancer-drug deals lift shares",http://www.reuters.com//article/merck-results-idUSL2N0LA0GS20140205?type=companyNews
31,"  * ADP report a tick below expectations, Dec. revised lower* Tableau Software soars after earnings, outlook* Merck shares up after results* Futures off: Dow 43 pts, S&P 8 pts, Nasdaq 12 ptsBy Rodrigo CamposNEW YORK, Feb 5 U.S. stocks were set to fall at the open on Wednesday after a slightly disappointing reading on the private labor market and ahead of data on the services sector. * The U.S. private sector created 175,000 jobs in January, slightly below the expectation of 180,000, while the data for December was revised lower to 227,000 from 238,000. December's data widely overshot a broader report from the Labor Department which showed just 74,000 jobs were created in December. The market-moving government report is due Friday.* U.S. data is being closely watched after a weak reading in the factory sector on Monday sent Wall Street into a tailspin and triggered a global equities selloff.* At 10 a.m. (1500 GMT) ISM will report its non-manufacturing PMI for January. Economists expect a slight acceleration in the pace of growth to a reading of 53.7 from 53 in December. * The limp data earlier in the week added to concerns about growth in China and over the outlook for some emerging market economies. A recent rout in emerging currencies spurred some central banks to act, pressuring bond and stock holdings and luring investors into assets perceived as relatively safe, like the yen, and U.S. and German government debt.* U.S. stocks rebounded on Tuesday, buoyed by encouraging earnings, as the market attempted to steady in the wake of its largest selloff in months on Monday.* S&P 500 e-mini futures fell 8 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures fell 43 points and Nasdaq 100 futures lost 12 points. * Merck shares rose 1.4 percent in premarket trading after the Dow component reported sales and profit that just missed analysts' estimates.* Shares of Tableau Software jumped 12 percent premarket after the data analysis software maker forecast better-than-expected revenue for this quarter and reported results that handily beat analysts' estimates.* Shares of Cognizant Technology Solutions fell 4.9 percent before the opening bell. The IT services provider forecast slower-than-expected revenue growth after fourth-quarter results that matched market estimates.* Designer clothing company Ralph Lauren Corp  reported a 10 percent rise in third-quarter profit, helped by higher sales at its own stores, sending its shares up 5.1 percent in premarket trading.* CVS Caremark Corp said Wednesday it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. Its shares fell 2.3 percent in premarket trading.",2014-02-05,MRK,"Wed Feb 5, 2014 | 8:47am EST",US STOCKS-Wall Street to fall after jobs data; services eyed,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LA0NO20140205?type=companyNews
32,"  Feb 5 Canada's main stock index looked set to reverse the previous session's gains on Wednesday even as upbeat euro zone economic data pointed to a gradual recovery in the currency bloc.TOP STORIES * The euro zone's private sector logged its busiest month in 2-1/2 years in January as buoyant manufacturing growth outshone a more modest expansion in services activity, surveys showed.* Time Warner Inc reported a better-than-expected 5 percent rise in quarterly revenue, helped by growth in its Warner Bros movie studio business and premium TV service Home Box Office.* Merck & Co Inc reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.* TMX Group Ltd reported a fourth-quarter profit that comfortably beat analysts' estimate as trading activity improved.* Intact Financial Corp reported a 40 percent drop in fourth-quarter profit, hurt mainly by severe winter weather, but raised its dividend.MARKET SNAPSHOT * Canada stock futures traded down 0.19 percent* U.S. stock futures , , were down around 0.03 percent and 0.28 percent * European shares, were mixedCOMMODITY PRICE MOVES * Thomson Reuters-Jefferies CRB Index : 288.3274; rose 0.44 percent* Gold futures : $1,261; rose 0.74 percent * U.S. crude : $97.73; rose 0.56 percent* Brent crude : $105.88; rose 0.09 percent* LME 3-month copper : $7,057; rose 0.23 percentCANADIAN STOCKS TO WATCH * Osisko Mining Corp : The company said on Tuesday a Quebec court has scheduled a hearing in early March to decide if its complaints against Goldcorp Inc, which has made a C$2.6 billion hostile bid for Osisko, have merit. ANALYSTS' RECOMMENDATIONS Following is a summary of research actions on Canadian companies reported by Reuters.* Suncor Energy Inc : Raymond James cuts target price to C$45 from C$46 on the company's mixed fourth-quarter results.* Surge Energy Inc : National Bank Financial resumes with outperform rating and price target of C$8.50 as the company continues to screen as one of the most sustainable models in the energy patch.* WestJet Airlines Ltd : Raymond James cuts target price to C$28 from C$31 as the company reported fourth-quarter results in line with expectations.ON THE CALENDAR * Major Canadian economic data includes building permits .* Major U.S. events and data includes ADP national employment and ISM non-manufacturing index.",2014-02-05,MRK,"Wed Feb 5, 2014 | 8:28am EST",CANADA STOCKS-TSX may open lower despite strong euro data,http://www.reuters.com//article/markets-canada-stocks-idUSL3N0LA3EY20140205?type=companyNews
33,"  (Corrects time of release of ADP data to 8:15 a.m. from 8:30 a.m.)* Tableau Software soars after results, outlook* Merck shares up after results* Futures off: Dow 7 pts, S&P 3 pts, Nasdaq 3 ptsNEW YORK, Feb 5 U.S. stock index futures fell slightly on Wednesday as traders awaited key data on the labor market and services sector.* U.S. data is being closely watched after a weak reading in the factory sector on Monday sent Wall Street into a tailspin and triggered a global equities selloff. * ADP will publish its January report on private job creation at 8:15 a.m. EST (1315 GMT). Economists surveyed by Reuters expect 180,000 jobs were created last month, down from 238,000 in December.* At 10:00 a.m. (1500 GMT) ISM will report its non-manufacturing PMI for January. Economists expect a slight acceleration in the pace of growth to a reading of 53.7 from 53 in December. * The limp data earlier in the week added to concerns about growth in China and over the outlook for some emerging market economies. A recent rout in emerging currencies spurred some central banks to act, pressuring bond and stock holdings and luring investors into assets perceived as relatively safe, like the yen, and U.S. and German government debt.* U.S. stocks rebounded on Tuesday, buoyed by encouraging earnings, as the market attempted to steady in the wake of its largest selloff in months on Monday.* S&P 500 e-mini futures fell 3 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures fell 7 points and Nasdaq 100 futures lost 3 points. * Merck shares rose 2.9 percent in premarket trading after the Dow component reported sales and profit that just missed analysts' estimates.* Shares of Tableau Software jumped 14 percent in premarket trading after the data analysis software maker forecast better-than-expected revenue for this quarter and reported results that handily beat analysts' estimates.* CVS Caremark Corp said on Wednesday it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. Its shares fell 1.7 percent in light premarket trading.(Reporting by Rodrigo Campos; Editing by Bernadette Baum)",2014-02-05,MRK,"Wed Feb 5, 2014 | 8:14am EST",CORRECTED-US STOCKS-Futures dip modestly ahead of private jobs data,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LA0I120140205?type=companyNews
34,"  Feb 5 Merck & Co Inc reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter. That compared with $908 million, or 30 cents per share, in the year-earlier period.  Company revenue fell 4 percent to $11.32 billion. Wall Street was expecting $11.36 billion, according to Thomson Reuters I/B/E/S. ",2014-02-05,MRK,"Wed Feb 5, 2014 | 7:13am EST",Merck 4th-quarter sales just miss Wall St estimate,http://www.reuters.com//article/merck-results-idUSL2N0LA04A20140205?type=companyNews
35,"  Feb 6 Merck & Co has agreed to pay $100 million to settle hundreds of lawsuits accusing the U.S. drugmaker of downplaying serious health risks associated with its NuvaRing contraceptive device, Bloomberg reported on Thursday, citing people familiar with the deal.The agreement, which would settle cases in federal and state courts, will be announced on Friday and pay about $58,000 per complaint, according to the report.Merck is facing more than 1,700 lawsuits accusing it of failing to adequately warn NuvaRing users or downplaying a potential increased risk of developing dangerous blood clots known as venous thromboembolism, according to a recent filing with the U.S. Securities and Exchange Commission. Plaintiffs are seeking damages for a range of injuries allegedly caused by the birth control device, including heart attack, stroke and sudden death.A judge presiding over federal cases, which have been consolidated in Missouri federal court, has scheduled a hearing on the matter for Friday morning. NuvaRing has been available to women in the United States since 2001. It is one of several contraceptive products that have been linked to an increased risk of developing blood clots that can cause strokes and heart attacks. Should the $100 million figure prove to be accurate, Merck would pay a fraction of what at least one company has paid in similar settlements. German drugmaker Bayer AG last year said it had so far paid nearly $1.6 billion to settle thousands of lawsuits involving accusations that its Yaz and Yazmin birth control pills caused blood clots that led to strokes and heart attacks.Merck spokeswoman Lainie Keller declined to comment on the Bloomberg report.",2014-02-06,MRK,"Thu Feb 6, 2014 | 6:10pm EST",Merck to settle NuvaRing lawsuits for $100 mln -media report,http://www.reuters.com//article/merck-settlement-idUSL2N0LB27M20140206?type=companyNews
36,"   By Ben Hirschler | LONDON  LONDON Feb 6 AstraZeneca is moving an experimental Alzheimer's drug into late-stage development, taking on U.S. rival Merck & Co which announced plans to start similar final-stage research in December.Britain's second-biggest drugmaker revealed its plan to move AZD3293 into the last phase of testing needed for registration as it announced full-year results on Thursday.Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.Such oral drugs are known as BACE inhibitors and are viewed as a promising new approach to fighting the memory-robbing condition. BACE inhibitor drugs have taken centre stage after an injectable class of medicines targeting beta-amyloid plaque failed or fell short in trials conducted by Pfizer and Eli Lilly.Not all experts accept that reducing beta-amyloid is the key to defeating Alzheimer's, however, and the safety of the new BACE drugs has also been a subject of concern after Lilly pulled the plug on its product due to liver toxicity.Mene Pangalos, AstraZeneca's head of innovative medicines and early development, told analysts there had been no signs of similar problems with his company's product. AZD3293 also had a clean profile in terms of potential heart problems, he added. ""We have a very potent molecule, not dissimilar to Merck's molecule,"" he added.AstraZeneca is integrating Phase II and Phase III trials for its drug, which Pangalos said could either lead to a second pivotal Phase III study or, if the data was strong enough, an immediate filing for regulatory approval. ISI analyst Mark Schoenebaum said Merck was probably some six months ahead of AstraZeneca in the BACE race, with the first Phase III data from the U.S. company's programme likely to emerge in around 2017.Dementia - of which Alzheimer's disease is the most common form - already affects 44 million people worldwide and this is set to reach 135 million by 2050, according to Alzheimer's Disease International, a non-profit campaign group.Unlike heart disease and cancer, no major advancements have been seen in Alzheimer's drug research since the first treatment was approved in 1993 by U.S. regulators.Current Alzheimer's drugs, including generic forms of Pfizer's Aricept (donepezil), can minimally and briefly help memory and ability to perform daily functions, but do not slow the disease.",2014-02-06,MRK,"Thu Feb 6, 2014 | 9:03am EST",AstraZeneca takes on Merck in Alzheimer's drug race,http://www.reuters.com//article/astrazeneca-earnings-alzheimers-idUSL5N0LB31520140206?type=companyNews
37,"  FRANKFURT Feb 6 Germany's Merck on Thursday extended the offer period for its planned $2.6 billion takeover of Britain's AZ Electronic Materials to Feb. 18. Merck - the world's largest maker of liquid crystals used in TVs, tablet and smartphone screens - said AZ Electronic shareholders representing 56.48 percent of share capital had accepted the 403.5 pence per share cash offer as of Feb. 5.  ",2014-02-06,MRK,"Thu Feb 6, 2014 | 4:05am EST",Merck extends offer for AZ Electronic takeover to Feb. 18,http://www.reuters.com//article/merck-az-extension-idUSWEB00HUU20140206?type=companyNews
38,"  Feb 6 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.* The Obama administration will narrow its controversial drone program in Pakistan to target a short list of high-level terrorists, and aim to end it during the prime minister's current term, senior U.S. officials have told their Pakistani counterparts. ()* Insurers are facing pressure from regulators and lawmakers about plans that offer limited choices of doctors and hospitals: a tactic the industry said is vital to keep down coverage prices in the new health law's marketplaces. ()* CVS Caremark Corp, United States' second-largest pharmacy chain, would stop selling all cigarettes and tobacco products nationwide by October, saying they have no place in a drugstore company that is trying to become more of a health-care provider. ()* Apple Inc is facing a claim for about $2 billion in damages from a German patent-holding company, IPCom GmbH, that alleges the U.S. technology giant infringed on a cellphone technology it owns, a German court said Wednesday. ()* Twitter Inc's fourth-quarter revenue surged, but so did concerns about the site's ability to grow and engage users. Costs continued to rise faster than revenue, and shares fell after hours. ()* Google Inc under a tentative deal with European Commission regulators agreed to tweak the way it presents search results in Europe to address concerns that it is abusing its dominance in online search to favor its own services at the expense of rivals. ()* Relations between Bill Gates and Steve Ballmer were strained at times as they worked with the board to find the third CEO in Microsoft Corp's history. The six-month search started with 100 candidates. () * Pandora Media Inc provided guidance for the first quarter and 2014 that missed Wall Street's consensus views, though the Internet-radio service continued to report strong revenue growth in its fourth quarter. ()* More than one in six men aged 25 years to 54 years don't have jobs. It is partly a symptom of a U.S. economy slow to recover from the worst recession in 75 years and also a chronic condition that shows how technology and globalization are transforming jobs faster than many workers can adapt. ()* Work to expand the Panama Canal has virtually halted, and the group in charge of construction said the project is on the ""brink of failure"" after talks to resolve $1.6 billion in cost overruns broke down. ()* Union Pacific and BNSF Railway allege inadequate repair work led to several derailments in cases that raise questions about whether repair shops or railroads are responsible for equipment safety. () * Government investigators looking into the cyber attacks on Neiman Marcus Group LLC and Target Corp  believe the malicious software used in the heists was specifically tailored to exploit vulnerabilities in each retailer's checkout systems. ()* Time Warner Inc broke out financial results for HBO for the first time on Wednesday, showing that the premium cable channel is generating far bigger profits than emerging rival Netflix Inc but HBO's revenue is growing at a much slower pace. ()* Ralph Lauren Corp reported a 9.7 percent climb in its third-quarter profit. The company whose upscale brands include Polo and Club Monaco has continued to post stronger sales in recent quarters as consumers in the luxury sector have proved to be more resilient after the recession. ()* The ranks of U.S. public companies grew last year for the first time since the go-go days of the Internet boom, getting a long-awaited boost from an expanding economy and renewed investor interest in U.S. stocks. () * The arrest of bitcoin advocate Charles Shrem is a blow to a currency that has been red-hot with users and some investors. But ""2014 will be like the Industrial Revolution for bitcoin,"" he says. ()* More lenders are introducing fees on checking accounts, just as consumers and business are pouring record amounts into the most basic of banking services. ()* Merck & Co unveiled an unusual plan to collaborate with three rivals, Pfizer Inc, Amgen Inc and Incyte Corp to study how Merck's immunotherapy cancer drug performs in combination with other treatments. ()* GlaxoSmithKline PLC managed to increase sales marginally last year despite problems in China, reversing two years of falling revenue for the U.K.'s largest drug maker. ()* The National Labor Relations Board on Wednesday revived a sweeping proposal to streamline and speed union-organizing elections at companies, positioning the agency for a fight with business groups, which stymied the original 2011 measure in court on a technicality. ()* Circassia, a company specializing in treating cat, grass and dust-mite allergies is planning to float an offering on the London Stock Exchange, a move that people familiar with the situation said is aimed at raising 175 million pounds ($285 million), which would rank as one of the biggest U.K. biotech listings ever. ()* Akamai Technologies Inc, whose fourth-quarter earnings rose 18 percent, benefited from increasing demand for content over the Internet with its network of servers and other equipment to expedite content delivery. ()* Yelp Inc said its fourth-quarter loss narrowed as revenue soared as the Internet company continued to attract more visitors and added local business accounts. ()",2014-02-06,MRK,"Thu Feb 6, 2014 | 1:26am EST",PRESS DIGEST - Wall Street Journal - Feb 6,http://www.reuters.com//article/press-digest-wsj-idUSL3N0LB18R20140206?type=companyNews
39,"   By Meredith Davis | CHICAGO  CHICAGO Merck Animal Health, a division of Merck & Co., entered into a 12-month research agreement with Utrecht University to develop a vaccine for Porcine Epidemic Diarrhea virus (PEDv), a deadly pig virus spreading across the U.S. farm belt, the company said.The highly contagious pig virus, which does not affect humans, has been seen in Europe and Asia, but was first discovered in the United States in April 2013 and has spread to 23 U.S. states and two Canadian provinces.""Vaccine development on PEDv has been hampered by the difficulty of growing the virus in cell culture and, until very recently, by the lack of tools for its genetic manipulation,"" Peter Rottier, a scientist at the Netherlands' Utrecht University said in a statement. PEDv, which causes diarrhea, vomiting and severe dehydration in hogs, is transmitted orally and through pig faeces. Strict biosecurity measures have been hog producers' first line of defense against the virus. Harrisvaccines, an Ames, Iowa based animal pharmaceutical company was one of the first U.S. companies to develop a vaccine to fight PEDv.While older pigs have a chance of survival, the virus kills 80 to 100 percent of piglets that contract it. There are no official figures on the number of U.S. pigs killed by the virus but industry analysts estimate millions of hogs have died and the virus could reduce the U.S. hog supplies by 2 to 4 percent. Vaccines have been used to fight PEDv in Asia and Europe but those vaccines are not approved for use in the United States due to concerns over their effectiveness, animal health officials said.(Reporting by Meredith Davis; Editing by David Gregorio)",2014-02-07,MRK,"Fri Feb 7, 2014 | 6:07pm EST","Merck, Utrecht University to research pig virus vaccine",http://www.reuters.com//article/us-usa-hogs-virus-idUSBREA161ZD20140207?type=companyNews
40,"   By Meredith Davis | CHICAGO  CHICAGO Feb 7 Merck Animal Health, a division of Merck & Co., entered into a 12-month research agreement with Utrecht University to develop a vaccine for Porcine Epidemic Diarrhea virus (PEDv), a deadly pig virus spreading across the U.S. farm belt, the company said.The highly contagious pig virus, which does not affect humans, has been seen in Europe and Asia, but was first discovered in the United States in April 2013 and has spread to 23 U.S. states and two Canadian provinces. ""Vaccine development on PEDv has been hampered by the difficulty of growing the virus in cell culture and, until very recently, by the lack of tools for its genetic manipulation,"" Peter Rottier, a scientist at the Netherlands' Utrecht University said in a statement.PEDv, which causes diarrhea, vomiting and severe dehydration in hogs, is transmitted orally and through pig faeces. Strict biosecurity measures have been hog producers' first line of defense against the virus. Harrisvaccines, an Ames, Iowa based animal pharmaceutical company was one of the first U.S. companies to develop a vaccine to fight PEDv. While older pigs have a chance of survival, the virus kills 80 to 100 percent of piglets that contract it. There are no official figures on the number of U.S. pigs killed by the virus but industry analysts estimate millions of hogs have died and the virus could reduce the U.S. hog supplies by 2 to 4 percent.Vaccines have been used to fight PEDv in Asia and Europe but those vaccines are not approved for use in the United States due to concerns over their effectiveness, animal health officials said.",2014-02-07,MRK,"Fri Feb 7, 2014 | 6:02pm EST","Merck, Utrecht University to research pig virus vaccine",http://www.reuters.com//article/usa-hogs-virus-idUSL2N0LC20D20140207?type=companyNews
41,"  Merck & Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.The product, which contains the hormones estrogen and progestin commonly found in birth control bills, is associated with an increased risk of developing blood clots that can cause heart attacks, strokes or sudden deaths. Available to women in the United States since 2001, NuvaRing is one of several contraceptive products linked to this higher risk.Merck, the second-biggest U.S. drugmaker, denied any fault under the agreement, which must be accepted by 95 percent of about 3,800 eligible patients involved in lawsuits pending in federal and state courts. A lawyer for the plaintiffs, Roger Denton of Schlichter, Bogard and Denton, said the settlement, reached after nearly a year of negotiations, is ""an outstanding result and in the best interests of all the women who have suffered an injury associated with the use of Nuvaring.""Under the settlement, Merck would pay a fraction of what at least one company has paid in a similar settlement. German drugmaker Bayer AG said last year it had paid nearly $1.6 billion to settle thousands of lawsuits involving accusations that its Yaz and Yazmin birth control pills caused blood clots that led to strokes and heart attacks. Merck shares were up 1 percent at $54.32 on the New York Stock Exchange, in line with a 1.2-percent advance in the ARCA Pharmaceutical Index of large U.S. and European drugmakers.(Reporting by Ransdell Pierson; Additional reporting by Jessica Dye; Editing by Jeffrey Benkoe and Bernadette Baum)",2014-02-07,MRK,"Fri Feb 7, 2014 | 11:53am EST",Merck to pay $100 million in NuvaRing contraceptive settlement,http://www.reuters.com//article/us-merck-nuvaring-idUSBREA1615F20140207?type=companyNews
42,"  Feb 7 Merck & Co said on Friday it will pay $100 million to resolve all U.S. product liability lawsuits alleging it downplayed serious health risks involving its NuvaRing intrauterine contraceptive device.The product, which contains the hormones estrogen and progestin commonly found in birth control bills, is associated with an increased risk of developing blood clots that can cause heart attacks, strokes or sudden deaths. Available to women in the United States since 2001, NuvaRing is one of several contraceptive products linked to this higher risk. Merck, the second-biggest U.S. drugmaker, denied any fault under the agreement, which must be accepted by 95 percent of about 3,800 eligible patients involved in lawsuits pending in federal and state courts.A lawyer for the plaintiffs, Roger Denton of Schlichter, Bogard and Denton, said the settlement, reached after nearly a year of negotiations, is ""an outstanding result and in the best interests of all the women who have suffered an injury associated with the use of Nuvaring."" Under the settlement, Merck would pay a fraction of what at least one company has paid in a similar settlement. German drugmaker Bayer AG said last year it had paid nearly $1.6 billion to settle thousands of lawsuits involving accusations that its Yaz and Yazmin birth control pills caused blood clots that led to strokes and heart attacks.Merck shares were up 1 percent at $54.32 on the New York Stock Exchange, in line with a 1.2-percent advance in the ARCA Pharmaceutical Index of large U.S. and European drugmakers.",2014-02-07,MRK,"Fri Feb 7, 2014 | 11:52am EST",UPDATE 2-Merck to pay $100 mln in NuvaRing contraceptive settlement,http://www.reuters.com//article/merck-nuvaring-idUSL2N0LC0WR20140207?type=companyNews
43,"  Feb 7 Merck & Co said on Friday it has agreed to pay $100 million to resolve all U.S. product liability lawsuits involving its NuvaRing contraceptive product. Merck, the second-biggest U.S. drugmaker, denied any fault under the agreement, which it said must be accepted by 95 percent of the approximately 3,800 eligible patients involved in lawsuits now pending in federal and state courts. The lawsuits allege Merck downplayed serious health risks associated with the product, including dangerous blood clots.  ",2014-02-07,MRK,"Fri Feb 7, 2014 | 10:05am EST",Merck to pay $100 mln in NuvaRing contraceptive settlement,http://www.reuters.com//article/merck-nuvaring-idUSL2N0LC0WH20140207?type=companyNews
44,"  U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product.Merck, which is working with Samsung Bioepis on the project, said on Monday its version of glargine - the generic name for Lantus - would soon enter late-stage Phase III studies in type 1 and type 2 diabetes.Until now, the only company with a copycat version of Lantus in late-stage clinical development has been Eli Lilly. ""The relevance of today's announcement to Sanofi is the potential for greater price erosion and market share loss from two 'generic' Lantus,"" analysts at Bernstein said in a research note.""We currently model 'generic' erosion of Lantus in our Sanofi model in the mid-2016 timeframe. This erosion could accelerate more quickly now that a second player is likely to enter in the 2016 timeframe."" In the case of the Lilly product, Sanofi sued triggering a 30-month stay of approval by the U.S. Food and Drug Administration. It could consider the same action with Merck. Lantus accounts for close to a fifth of Sanofi's total sales and over a third of its operating profit.(Reporting by Ben Hirschler; Editing by Anthony Barker)",2014-02-10,MRK,"Mon Feb 10, 2014 | 12:16pm EST",Merck joins race to copy Sanofi's diabetes drug Lantus,http://www.reuters.com//article/us-sanofi-merck-idUSBREA191FT20140210?type=companyNews
45,"  Feb 10 U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's  top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product.Merck, which is working with Samsung Bioepis on the project, said on Monday its version of glargine - the generic name for Lantus - would soon enter late-stage Phase III studies in type 1 and type 2 diabetes.Until now, the only company with a copycat version of Lantus in late-stage clinical development has been Eli Lilly. ""The relevance of today's announcement to Sanofi is the potential for greater price erosion and market share loss from two 'generic' Lantus,"" analysts at Bernstein said in a research note. ""We currently model 'generic' erosion of Lantus in our Sanofi model in the mid-2016 timeframe. This erosion could accelerate more quickly now that a second player is likely to enter in the 2016 timeframe."" In the case of the Lilly product, Sanofi sued triggering a 30-month stay of approval by the U.S. Food and Drug Administration. It could consider the same action with Merck.Lantus accounts for close to a fifth of Sanofi's total sales and over a third of its operating profit.",2014-02-10,MRK,"Mon Feb 10, 2014 | 11:41am EST",Merck joins race to copy Sanofi's diabetes drug Lantus,http://www.reuters.com//article/sanofi-merck-idUSL5N0LF33J20140210?type=companyNews
46,"   By Olivia Oran, Soyoung Kim and Anjuli Davies | NEW YORK/LONDON  NEW YORK/LONDON A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.Reckitt Benckiser Group PLC and Procter & Gamble Co are also among the parties that have held discussions with Merck about buying the unit, best known for Coppertone sunscreen and Claritin allergy medicine, the sources said this week.The Merck business, which also includes Dr. Scholl's foot care and other consumer products, could be worth $10 billion to $12 billion in a potential sale, the people said, asking not to be identified because the process is private.Despite the large size of a potential deal and the unit's various product lines, Merck is focused on selling the consumer health business in its entirety, not in parts, the people said.Merck, Bayer, Novartis, Reckitt and P&G all declined to comment.Merck is meeting with potential buyers after receiving preliminary offers a few weeks ago, and is expected to seek second-round offers in late March, the people said.Germany's Bayer already has a strong portfolio of consumer products including pain medication Aleve and antacid Alka-Seltzer, but is looking at deals to expand the business further. In 2012, Bayer lost a bidding war with Reckitt for Schiff Nutrition International Inc, which agreed to sell to the British consumer products group for $1.3 billion.Reckitt owns over-the-counter medicines including Mucinex and Nurofen and the international rights for the Scholl foot care business. Its chief executive told Reuters in September that Reckitt aimed to be a major player in consumer healthcare and has the firepower to do sizeable deals. Procter & Gamble also has a portfolio that includes a range of health products, including Vicks cold and flu treatment and Prilosec heartburn medication.Among a range of options it has considered for the consumer unit, Merck discussed a potential asset swap with Novartis AG under which Merck would give up its consumer assets in return for the Swiss drugmaker's animal health and other units, Reuters and others previously reported.The probability of carrying out such a deal, however, was seen as low due to the complexity of valuing different businesses, prompting Merck to explore an outright sale of its consumer unit as well, Reuters reported in January.Novartis remains interested, and could offer cash instead if an asset swap does not pan out, the people familiar with the matter said. Merck, the second-largest U.S. drugmaker after Pfizer Inc, is being advised by Morgan Stanley on the process, Reuters reported last month.FRAGMENTED INDUSTRY Johnson & Johnson is the biggest player in the $200 billion global consumer health industry, with about 4 percent of the market. Bayer, GlaxoSmithKline PLC, Novartis, Pfizer and Sanofi SA are the other major players, each with a market share of more than 2 percent.Merck, however, is relatively small with around 1 percent of the market, and has said in the past that it views its consumer business as sub-scale. Other large companies with consumer healthcare divisions, such as Johnson & Johnson and Sanofi, have competing products to Merck and are seen as unlikely buyers. Sanofi's Allegra allergy medication and Johnson and Johnson's Zyrtec may overlap with Merck's Claritin brand.GSK is not pursuing the Merck business either, given its current low appetite for deals and the poor fit between the firms' consumer health portfolios, according to one person familiar with the matter. Merck's Claritin allergy franchise would also overlap with GSK's Flonase nasal spray, the person added.A GSK spokesman declined to comment.In exploring alternatives for the consumer business, Merck is following in the footsteps of other drugmakers such as Pfizer, which created shareholder value by separating non-core assets.Pfizer sold its infant-nutrition business to Nestle SA for $11.9 billion in 2012, and last year spun off its animal health unit as a separate publicly traded company called Zoetis Inc.Many other drugmakers have been looking to shed businesses, prompted by pricing pressure and increasing competition that has forced a more rigorous approach to capital allocation. They have shown a new willingness to consider whether other companies may be better owners for certain assets.(Reporting by Olivia Oran and Soyoung Kim in New York and Anjuli Davies in London; additional reporting by Arno Schuetze in Frankfurt; Editing by Richard Chang)",2014-02-19,MRK,"Wed Feb 19, 2014 | 4:12pm EST","Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources",http://www.reuters.com//article/us-merck-bids-idUSBREA1I22T20140219?type=companyNews
47,"  Feb 20 The following corporate finance-related stories were reported by media:* A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.* Private equity firm Blackstone Group and Singapore sovereign wealth fund GIC are in advanced talks to acquire a minority stake in Kronos Inc that could value the resources management software firm at around $4.5 billion, two people familiar with the matter said on Wednesday.* France's EDF is seeking to sell 70 percent of Italian unit Edison's wind farm operations as it looks to bring on board a financial partner to help to fund expansion, three sources close to the matter said on Wednesday. * German diversified healthcare group Fresenius  is considering making a bid for the medical nutrition unit of France's Danone in what could be a 4 billion euro ($5.50 billion) deal, two people familiar with the matter told Reuters. * ITC, India's largest cigarette maker, is firming up plans to foray into non-carbonated beverages and dairy businesses next fiscal to establish itself as one of the largest food companies in the country, the Economic Times reported, citing a senior industry executive aware of the plans.()* Furiex Pharmaceuticals Inc, which is developing a drug for irritable bowel syndrome, has put itself up for sale, Bloomberg reported on Wednesday, citing people with knowledge of the matter.* The owners of Finland's Paroc are expected to launch a sale of the insulation material maker which could fetch more than 650 million euros ($894 million), three sources familiar with the matter said. * Repsol and Argentina are poised to sign a $5 billion compensation deal that will draw a line under a bitter legal dispute that has raged since Buenos Aires expropriated the Spanish energy group's assets in the country two years ago, the Financial Times reported, citing people familiar with the negotiations. ()* State-run Korea Electric Power Corp has appointed Barclays Plc to sell some of its offshore assets amid pressure from the nation's lawmakers to reduce debt, the Wall Street Journal reported, citing people familiar with the matter. ()For the Morning News Call-EMEA newsletter click on",2014-02-20,MRK,"Thu Feb 20, 2014 | 12:58am EST",UPDATE 1-Market Chatter-Corporate finance press digest,http://www.reuters.com//article/market-chatter-idUSL3N0LP1PX20140220?type=companyNews
48,"  Feb 20 The following corporate finance-related stories were reported by media:* A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.* France's EDF is seeking to sell 70 percent of Italian unit Edison's wind farm operations as it looks to bring on board a financial partner to help to fund expansion, three sources close to the matter said on Wednesday.* German diversified healthcare group Fresenius  is considering making a bid for the medical nutrition unit of France's Danone in what could be a 4 billion euro ($5.50 billion) deal, two people familiar with the matter told Reuters. * ITC, India's largest cigarette maker, is firming up plans to foray into non-carbonated beverages and dairy businesses next fiscal to establish itself as one of the largest food companies in the country, the Economic Times reported, citing a senior industry executive aware of the plans.()* Furiex Pharmaceuticals Inc, which is developing a drug for irritable bowel syndrome, has put itself up for sale, Bloomberg reported on Wednesday, citing people with knowledge of the matter. * The owners of Finland's Paroc are expected to launch a sale of the insulation material maker which could fetch more than 650 million euros ($894 million), three sources familiar with the matter said. * Repsol and Argentina are poised to sign a $5 billion compensation deal that will draw a line under a bitter legal dispute that has raged since Buenos Aires expropriated the Spanish energy group's assets in the country two years ago, the Financial Times reported, citing people familiar with the negotiations. ()* State-run Korea Electric Power Corp has appointed Barclays Plc to sell some of its offshore assets amid pressure from the nation's lawmakers to reduce debt, the Wall Street Journal reported, citing people familiar with the matter. ()For the Morning News Call-EMEA newsletter click on",2014-02-20,MRK,"Wed Feb 19, 2014 | 11:05pm EST",Market Chatter- Corporate finance press digest,http://www.reuters.com//article/market-chatter-idUSL3N0LP1GK20140220?type=companyNews
49,"   By Bill Berkrot | March 4  March 4 An immunotherapy pill to treat an allergy to house dust mites being tested by Merck & Co  significantly reduced common nasal symptoms, such as sneezing and stuffy nose, according to data from a midstage clinical trial, the company said on Tuesday.The drug, MK-8237, reduced nasal symptoms by 49 percent at the higher tested dose and 27 percent at the lower dose compared with a placebo after 24 weeks of treatment. The results, which were deemed to be statistically significant, were presented on Tuesday at the American Academy of Allergy, Asthma and Immunology (AAAAI) meeting in San Diego.MK-8237, a once-a-day tablet designed to dissolve under the tongue, is the third oral allergy immunotherapy treatment being developed by Merck. The U.S. drugmaker and its Danish allergy development partner ALK Abello are awaiting U.S. approval decisions likely this year for sublingual tablets that treat grass and ragweed allergies that would be alternatives to regular allergy shots at a doctor's office.Over time, the drugs train the immune system to stop reacting abnormally to exposure to allergens. The primary goal of the 124-patient study was a significant reduction at week 24 in average total nasal symptom score (TNSS) reported over the last four hours of a six-hour session in a special room where they were exposed to enough dust mites to set off allergic reactions. TNSS was comprised of itchy nose, blocked nose, runny nose and sneezing.A secondary goal combined TNSS results at 24 weeks with a measure of ocular symptoms, such as red, itchy or watery eyes. By that measure, the higher dose of the Merck drug reduced symptoms by 52 percent compared with placebo and by 29 percent for the lower dose. The reduction in eye symptoms alone was as high as 68 percent, Merck said. ""We had not expected to see such pronounced effects on both nasal and ocular symptoms with this product, so we are very encouraged by this data,"" Dr. Hendrik Nolte, clinical leader of Merck's allergy immunotherapy program who presented the data at the meeting, said in a telephone interview.No serious adverse side effects were reported by patients in the study. The most common side effects, deemed to be mild to moderate, included throat irritation, mouth edema and lip swelling.Merck said it is recruiting patients for a large, pivotal Phase III trial of the dust mite allergy treatment that it hopes to complete next year.",2014-03-04,MRK,"Tue Mar 4, 2014 | 5:30pm EST",Merck says dust mite allergy drug reduces symptoms in midstage study,http://www.reuters.com//article/merck-allergy-idUSL1N0M11X520140304?type=companyNews
50,"  March 5 A combination of oral drugs for hepatitis C developed by Merck & Co appeared to be well tolerated and highly effective in treating the liver disease in patients also infected with HIV, according to data from a midstage clinical trial presented on Wednesday.The Merck drugs, MK-5172 and MK-8742, which belong to promising new classes of anti-viral medicines, were tested over a 12-week course of treatment both with and without the older hepatitis C drug ribavirin in co-infected patients.After 12 weeks of treatment, all 29 patients who received the two Merck drugs and ribavirin had undetectable levels of the hepatitis C virus. Among those who got just the experimental Merck drugs, 26 of 29, or 90 percent, appeared to have the hepatitis C virus eliminated from their blood.If the virus remains undetectable 12 weeks after completion of treatment, those patients are considered cured. The available data from the ongoing study was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. More detailed results of the study dubbed C-Worthy are expected to be presented at a European medical meeting in April, Merck said.No co-infected patients discontinued treatment due to either an adverse side effect or study medication intolerance, Merck said. The most common side effects of fatigue and headache were no more prevalent in patients with hepatitis C and HIV infection than what had been observed in patients with hepatitis C alone. A new era in treatment for the serious liver disease has begun with several companies, including Gilead Sciences Inc , AbbVie and Bristol-Myers Squibb Co, developing all oral treatment regimens that have demonstrated cure rates well in excess of 90 percent with treatment durations of just 12 weeks or shorter. Current standard treatments take 24 to 48 weeks and include the injected drug interferon that causes miserable flu-like symptoms and cure about 75 percent of patients.Those also living with the virus that causes AIDS are an important patient population.About seven million people worldwide are co-infected with HIV and hepatitis C (HCV). Co-infected patients have a three times higher rate of progression to cirrhosis and a six times higher risk of liver decompression than those with HCV alone.",2014-03-05,MRK,"Wed Mar 5, 2014 | 5:56pm EST",Merck hepatitis C drugs work in HIV co-infected patients -study,http://www.reuters.com//article/merck-hepatitis-idUSL1N0M22FO20140305?type=companyNews
51,"  (In 2nd paragraph adds dropped word ""not"" to show that vaccine also shrank tumors not injected with the drug.)By Bill BerkrotMarch 14 An experimental Amgen Inc  cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.The vaccine shrank tumors that were directly injected with the drug and tumors around the body that were not injected, according to the data.The drug, talimogene laherparepvec, also known as T-vec, is an engineered virus designed to replicate inside the injected tumor, killing cancer cells there, as well as prime the immune system to attack other cancer cells around body.Dr. Robert Andtbacka, one of the study's lead investigators, in a telephone interview, called the results ""very encouraging.""Amgen last year released initial data from the 295-patient Phase III study showing that T-vec succeeded in demonstrating a significant tumor response that lasted at least six months. The latest data analyzed 4,000 tumor lesions to study the response to the drug in injected versus non-injected tumors. Of the directly injected tumors, 64 percent shrank by at least half, and 47 percent of those had a complete response, meaning the lesion had disappeared, researchers said.Of the uninjected lesions in the skin or lymph nodes, known as non-visceral tumor lesions, 34 percent shrank by at least half with a complete response seen in 21 percent of those.""We also want to see responses in distant lesions that are not injected such as in the liver, in the lung and other places,"" Andtbacka explained. Of those so-called visceral tumors on solid organs, 15 percent shrank by at least 50 percent, said Andtbacka, who presented the data at the Society of Surgical Oncology Cancer Symposium in Phoenix.""This indicates to us that we have activation of the immune system to fight these tumors at a distant site,"" Andtbacka said.""This is a new generation of oncolytic immunotherapy where you're seeing very robust responses in injected lesions but  also robust responses in non-injected lesions. This bodes well for the future for this product,"" added Andtbacka, an associate professor in the division of surgical oncology at the University of Utah School of Medicine. Amgen said it expects to have further data in the first half of this year showing whether T-vec ultimately helped patients in the study to live longer. The company has not yet said when it will apply for approval of the medicine.Andtbacka said he expects the future of the drug will involve its use in combination with other types of cancer immunotherapies, especially in treating patients with non injectable visceral tumors.Amgen is already testing T-vec in combination with Bristol-Myers Squibb's melanoma drug Yervoy and has agreed to study T-vec in combination with Merck & Co's  experimental immunotherapy from a highly promising class called PD-1 inhibitors.Melanoma is the most aggressive form of skin cancer. About 132,000 melanoma cases occur globally each year, according to World Health Organization.""We are extremely excited about the data and the potential for combinations with other treatments,"" said David Chang, Amgen's head of global oncology development.(Reporting by Bill Berkrot; Editing by Leslie Adler)",2014-03-14,MRK,"Fri Mar 14, 2014 | 5:19pm EDT",CORRECTED-Amgen vaccine triggers immune response in advanced melanoma -study,http://www.reuters.com//article/amgen-cancer-idUSL2N0MB1PD20140314?type=companyNews
52,"  Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.The two drugmakers said their decision, first reported by Bloomberg News, is based on uncertainty about whether insurance programs offered under the Affordable Care Act are governed by federal laws that ban kickbacks to businesses.To cap rising healthcare costs and give consumers more incentive to reduce spending, insurers in recent years have increased the out-of-pocket costs patients are expected to pay for medications. At the same time, most drugmakers offer patient assistance programs, or coupons, to people who might otherwise not be able to afford medications that have been prescribed by doctors. Merck, which makes drugs such as Januvia for diabetes, said it plans to revisit its decision once more information is available about implementation of the law governing the federal health program.Glaxo, maker of asthma medication Advair, said it is ""committed to helping patients access our medications."" Amgen Inc, which makes biotech drugs including arthritis medication Enbrel, said it continues to offer cost-sharing assistance to eligible patients. ""Under the new health insurance exchanges, it is not uncommon for patients to face coinsurance of 40 percent or more for their prescriptions,"" Amgen said in an emailed statement.(Reporting by Deena Beasley; Editing by Leslie Adler)",2014-03-26,MRK,"Wed Mar 26, 2014 | 6:27pm EDT","Merck, Glaxo end co-pay assistance for Obamacare plans",http://www.reuters.com//article/us-obamacare-pharmaceuticals-idUSBREA2P2B220140326?type=companyNews
53,"  March 26 Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.The two drugmakers said their decision, first reported by Bloomberg News, is based on uncertainty about whether insurance programs offered under the Affordable Care Act are governed by federal laws that ban kickbacks to businesses.To cap rising healthcare costs and give consumers more incentive to reduce spending, insurers in recent years have increased the out-of-pocket costs patients are expected to pay for medications. At the same time, most drugmakers offer patient assistance programs, or coupons, to people who might otherwise not be able to afford medications that have been prescribed by doctors. Merck, which makes drugs such as Januvia for diabetes, said it plans to revisit its decision once more information is available about implementation of the law governing the federal health program.Glaxo, maker of asthma medication Advair, said it is ""committed to helping patients access our medications."" Amgen Inc, which makes biotech drugs including arthritis medication Enbrel, said it continues to offer cost-sharing assistance to eligible patients. ""Under the new health insurance exchanges, it is not uncommon for patients to face coinsurance of 40 percent or more for their prescriptions,"" Amgen said in an emailed statement.(Reporting by Deena Beasley; Editing by Leslie Adler)",2014-03-26,MRK,"Wed Mar 26, 2014 | 6:26pm EDT","Merck, Glaxo end co-pay assistance for Obamacare plans",http://www.reuters.com//article/health-obamacare-pharmaceuticals-idUSL1N0MN25N20140326?type=companyNews
54,"  FRANKFURT, March 26 German liquid crystal maker Merck will propose a two-for-one share split in order to attract more private investors, it said on Wednesday.It would propose the share split to its shareholders at the annual general meeting on May 9, it added. The value of Merck shares have doubled over the past three years, trading well over 100 euros for one year now. Shares gained 1.5 percent to 122.75 euros ($170) around 1430 GMT nearly in line with the German blue chip index. ($1 = 0.7258 euros)  ($1 = 0.7258 Euros)   (Reporting by Kirsti Knolle; Editing by Marilyn Gerlach)",2014-03-26,MRK,"Wed Mar 26, 2014 | 10:41am EDT",Merck plans to propose two-for-one share split,http://www.reuters.com//article/merck-stocks-idUSWEB00KT220140326?type=companyNews
55,"   By Vrinda Manocha  Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck - struggling with slowing sales, delays in new drug approvals and failures of experimental drugs - said in October it would cut 8,500 jobs and chop annual operating costs by $2.5 billion.""The main thing for Davis to focus on is trying to make Merck's structure more flexible so that it can move more quickly to areas that have good returns,"" Morningstar analyst Damien Conover said.He said a key decision Davis would have to help make related to the company's plans for its animal healthcare and consumer business.Reuters reported in February that Merck was in discussions to sell its consumer healthcare business, as part a plan to narrow its focus to its pharmaceutical products with the best chance of winning regulatory approval.Davis, 47, was the CFO of Baxter for four years until May 2010. Since then, he has been running Baxter's medical products business and oversaw the integration of the medication delivery and renal businesses, along with manufacturing and research and development. ""(Davis) will be an asset to us in implementing a significantly streamlined, more flexible cost structure and operating model, while enabling us to focus on our highest-potential growth opportunities,"" Merck CEO Kenneth Frazier said in a statement on Thursday.Faced with patent expiries and competition from generics, Merck and its peers, including Pfizer Inc, AstraZeneca Plc and Teva Pharmaceutical Industries, have aimed to bolter growth by slashing jobs and costs.Merck is facing slowing sales growth for its biggest franchise, the diabetes drugs Januvia and Janumet which have combined annual sales of $6 billion. Sales of its asthma drug, Singulair, have plunged since its went off patent in 2012. A year back, Merck brought back one of its veterans to head research and development after setbacks to some of its most important experimental drugs.""We will be closely listening to any comments around further restructuring and divestitures with a new CFO coming in,"" JPMorgan analyst Chris Schott wrote in a note.Davis will take on his new role in Merck on April 23, replacing Peter Kellogg, the company's CFO since 2007. Kellogg, who was previously CFO at Biogen Idec Inc, will leave the company on May 16.""I don't think there was any negative sentiment towards the outgoing CFO,"" Morningstar's Conover told Reuters. ""He'd really done a good job with integrating Schering-Plough and a lot of the cost cutting plans initially.""Davis joined Baxter in 2004 after more than 14 years at Eli Lilly and Co. The news of his appointment comes on the same day that Baxter said it would spin off its biotechnology operations and focus on its core medical technology business.Merck's shares were down slightly at about $55.85 in afternoon trading on the New York Stock Exchange.(Editing by Rodney Joyce and Savio D'Souza)",2014-03-27,MRK,"Thu Mar 27, 2014 | 1:02pm EDT",Merck names Baxter exec as CFO,http://www.reuters.com//article/us-merck-co-cfo-idUSBREA2Q1LD20140327?type=companyNews
56,"  (Recasts to add background, analyst comment, shares)By Vrinda ManochaMarch 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck - struggling with slowing sales, delays in new drug approvals and failures of experimental drugs - said in October it would cut 8,500 jobs and chop annual operating costs by $2.5 billion.""The main thing for Davis to focus on is trying to make Merck's structure more flexible so that it can move more quickly to areas that have good returns,"" Morningstar analyst Damien Conover said.He said a key decision Davis would have to help make related to the company's plans for its animal healthcare and consumer business.Reuters reported in February that Merck was in discussions to sell its consumer healthcare business, as part a plan to narrow its focus to its pharmaceutical products with the best chance of winning regulatory approval. Davis, 47, was the CFO of Baxter for four years until May 2010. Since then, he has been running Baxter's medical products business and oversaw the integration of the medication delivery and renal businesses, along with manufacturing and research and development.""(Davis) will be an asset to us in implementing a significantly streamlined, more flexible cost structure and operating model, while enabling us to focus on our highest-potential growth opportunities,"" Merck CEO Kenneth Frazier said in a statement on Thursday.Faced with patent expiries and competition from generics, Merck and its peers, including Pfizer Inc, AstraZeneca Plc and Teva Pharmaceutical Industries, have aimed to bolter growth by slashing jobs and costs. Merck is facing slowing sales growth for its biggest franchise, the diabetes drugs Januvia and Janumet which have combined annual sales of $6 billion. Sales of its asthma drug, Singulair, have plunged since its went off patent in 2012.A year back, Merck brought back one of its veterans to head research and development after setbacks to some of its most important experimental drugs.""We will be closely listening to any comments around further restructuring and divestitures with a new CFO coming in,"" JPMorgan analyst Chris Schott wrote in a note. Davis will take on his new role in Merck on April 23, replacing Peter Kellogg, the company's CFO since 2007.Kellogg, who was previously CFO at Biogen Idec Inc, will leave the company on May 16.""I don't think there was any negative sentiment towards the outgoing CFO,"" Morningstar's Conover told Reuters. ""He'd really done a good job with integrating Schering-Plough and a lot of the cost cutting plans initially.""Davis joined Baxter in 2004 after more than 14 years at Eli Lilly and Co. The news of his appointment comes on the same day that Baxter said it would spin off its biotechnology operations and focus on its core medical technology business.Merck's shares were down slightly at about $55.85 in afternoon trading on the New York Stock Exchange.   (Editing by Rodney Joyce and Savio D'Souza)",2014-03-27,MRK,"Thu Mar 27, 2014 | 12:59pm EDT",UPDATE 2-Merck names Baxter exec as CFO,http://www.reuters.com//article/merck-co-cfo-idUSL4N0MO38320140327?type=companyNews
57,"  Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.The move come as Merck is struggling with slowing sales of its flagship drugs and failures or delays in new drug approvals, while Baxter is planning to split into two companies.Sales of Merck's diabetes drug, Januvia, have been slowing and sales of its asthma drug, Singulair, fell by a more than a third last quarter due to generic competition.The company cut 8,500 jobs in October and said it would cut annual operating costs by $2.5 billion. Davis ""will be an asset to us in implementing a significantly streamlined, more flexible cost structure and operating model, while enabling us to focus on our highest-potential growth opportunities,"" Merck CEO Kenneth Frazier said in a statement.Davis, 47, was CFO of Baxter for four years until May 2010. Since then he has been the corporate vice president and president of the company's medical products business. In his current role he oversaw the integration of the medication delivery and renal businesses, along with corporate manufacturing and research and development, Merck said. Davis joined Baxter in 2004 after more than 14 years at Eli Lilly and Co.Merck said Kellogg, 58 and its CFO since 2007, played a major role in the company's acquisition of rival Schering-Plough in 2009. He will leave the company on May 16.(Reporting By Vrinda Manocha in Bangalore; Editing by Rodney Joyce and Savio D'Souza)",2014-03-27,MRK,"Thu Mar 27, 2014 | 8:52am EDT",Merck appoints Baxter executive as CFO,http://www.reuters.com//article/us-merck-co-cfo-idUSBREA2Q0VO20140327?type=companyNews
58,"  (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)March 27 Merck & Co Inc said it appointed Robert Davis as chief financial officer, effective April 23, replacing Peter Kellogg. Davis, 47, is joining Merck from Baxter International Inc  where he oversaw the integration of the company's two major businesses, along with corporate manufacturing and R&D. Merck said Peter Kellogg, 58, the CFO since 2007, will leave the company on May 16. (Reporting By Vrinda Manocha in Bangalore; Editing by Rodney Joyce)",2014-03-27,MRK,"Thu Mar 27, 2014 | 8:45am EDT",CORRECTED-Merck appoints Baxter executive as CFO,http://www.reuters.com//article/merck-co-cfo-idUSL4N0MO37P20140327?type=companyNews
59,"  SEOUL, April 1 South Korea will allow certain levels of animal feed additive zilpaterol in beef from June, a government official said on Tuesday, opening the door to imports of some meat containing the growth enhancer and its domestic sale.Seoul had said in October that restrictions would be eased sometime in 2014, ending a zero tolerance policy on zilpaterol-based drugs such as Merck & Co's Zilmax.The feed additive has been under global scrutiny since a video emerged in the United States in August showing animals struggling to walk and with other signs of distress after taking a growth drug.South Korea suspended some U.S. beef imports for more than two months last year after traces of zilpaterol were found in two shipments. Son Seong-wan, a director in South Korea's food ministry, told Reuters that from June the government would allow 1 part per billion (ppb) of zilpaterol in beef muscle and 5 ppb in beef liver. He said that compared with levels of 2 ppb in beef muscle permitted in Canada and 12 ppb in beef liver in the United States.He added that 60 days of public hearings on the move had begun in February. Many Asian and European countries ban the import of zilpaterol-fed beef due to concerns about the side effects of additives.(Reporting by Meeyoung Cho; Editing by Joseph Radford)",2014-04-01,MRK,"Mon Mar 31, 2014 | 11:21pm EDT",S.Korea to allow sales of Merck's Zilmax from June,http://www.reuters.com//article/zilpaterol-korea-beef-idUSL4N0MT0O920140401?type=companyNews
60,"  * Drug is first such immunotherapy pill licensed in U.S.* Merck and partner ALK Abello expected to launch rival drug this year* Shares in Stallergenes rise 6 percent   (Adds detail, share price, analyst comment)CHICAGO/PARIS, April 2, France's Stallergenes  has received U.S. regulatory approval to sell the first immunotherapy pill against grass allergies in the world's biggest pharmaceutical market, sending its shares up 6 percent on Wednesday.Stallergenes has said it sees a potential U.S. market of nearly 3 million patients that will eventually be worth $1 billion in annual sales for these types of drugs. ""That's very positive news as the group is considerably expanding its market,"" Gilbert Dupont analysts wrote in a note.Oralair is a fast-dissolving tablet to be placed under the tongue that contains extracts from five types of grass pollen: sweet vernal, orchard, perennial rye, timothy and Kentucky bluegrass. It harnesses the immune system to alleviate allergies and is an alternative to current treatments that need to be injected. Merck and Danish partner ALK Abello are also expected to launch their rival therapy Grastek in the United States this year. In December, both drugs received strong recommendations from outside advisers to the U.S. Food and Drug Administration (FDA).Oralair was approved in the European Union in 2008 and is also sold in Canada, Australia and Russia for the treatment of grass pollen allergy. It generated revenue of 22.2 million euros ($30.5 million) in 2013, up 37 percent from 2012. Greer Laboratories, Stallergenes' U.S. partner, aims to begin selling Oralair within weeks of the FDA's go-ahead. But the peak season for Oralair prescriptions is between December and June, so U.S. revenue from the drug this year should be limited, Stallergenes' former chief executive said last month.The approval of Oralair triggers a first milestone payment of $10 million from Greer to Stallergenes. Overall, Stallergenes is due to receive milestone payments totaling up to $120 million, plus royalties and an undisclosed transfer price.Shares in Stallergenes were 6 percent higher at 61.49 euros at 0840 GMT, trading at more than twice their average daily volume and giving the company a market capitalisation of 843 million euros.  ($1 = 0.7271 Euros)   (Reporting by Susan Kelly in Chicago and Natalie Huet in Paris; Editing by Eric Walsh and James Regan)",2014-04-02,MRK,"Wed Apr 2, 2014 | 4:44am EDT",UPDATE 1-Stallergenes wins U.S. go-ahead for Oralair allergy pill,http://www.reuters.com//article/stallergenes-usa-idUSL1N0MU0FR20140402?type=companyNews
61,"   By P.J. Huffstutter and Tom Polansek | CHICAGO  CHICAGO Merck & Co Inc wants to feed its controversial feed additive Zilmax to 240,000 U.S. cattle to prove it is safe. But there is a problem: giant meat processors like Cargill Inc don't want to touch animals fed with the drug.Merck plans to conduct the biggest ever test of its kind in an effort to reintroduce the weight-adding drug into the United States and Canada after suspending sales last August. A test herd of this size is currently worth up to $500 million.Feedlot owners, however, are reluctant to participate in the study until they get a guarantee that slaughterhouses will be willing to buy the Zilmax-fed animals.Snags with the study, whose size was confirmed to Reuters by Merck, have not been previously reported.""I'd be happy to sign up, just as soon as Merck tells me who is going to pay me after they're done,"" said a feedlot owner in Texas. ""It's been a horrible time, with the drought. I can't afford to give away a steer, let alone hundreds.""Cargill Inc and Tyson Foods Inc, two of the world's largest beef processors, told Reuters their stance on Zilmax had not changed since last autumn, when they stopped accepting cattle fed the drug following reports it may cause lameness. Together the two companies control 37 percent of the daily U.S. beef processing capacity.Reuters reported in December that Tyson stopped taking Zilmax-fed livestock after more than two dozen animals that had been fed the drug arrived at one of its slaughterhouses with missing hooves.The beef processors said their ban would remain until Merck had scientifically proven that Zilmax was safe for animals. They also want certainty that key export markets in Asia and elsewhere will accept such beef products.Merck has said it is confident in the ""safety and performance"" of Zilmax. The U.S. Food and Drug Administration has deemed the drug safe for both animals and humans. A source with National Beef Packing Company said the company was not accepting Zilmax-fed cattle. JBS USA Holdings Inc, another major beef processor, did not return calls and emails for comment.Merck in December said the evaluations would start in the first quarter. But company spokeswoman Pamela Eisele declined to say this week where the 240,000 cattle would come from in the United States, whether the tests had started, or whether Merck had signed up any packing plants, ranchers or feedlots - which house and fatten up the cattle before they are slaughtered.Eisele said the company's current plan was to sign up at least 50 U.S. feedlots, out of more than 73,000 nationwide, to participate in field tests over several months. Merck hopes to enroll five to 15 feedlots for each slaughterhouse that agrees to process the cattle, she added.Anne Burkholder, who runs a 3,000-head feed yard in Cozad, Nebraska, is eager to hear results.""We need to have a large study, where we can really look at mobility and well-being issues we're seeing in the present,"" said Burkholder, who switched to another feed additive after Merck suspended Zilmax sales. She said she never had any problems with Zilmax.QUESTIONS ABOUT STUDY The attempt to launch a large-scale study underscores Merck's determination to put zilpaterol-based Zilmax, once the largest-selling growth drug for cattle, back on the lucrative agriculture drug market.The scale is unprecedented for a randomized, controlled study of cattle, and the logistics involved with tracking so many cattle ""boggle the mind,"" said Morgan Scott, an epidemiology professor at Kansas State University. Merck said it believed the field evaluations will ""support the results of previous studies and the safety of the product.""A principal investigator hired by Merck, who is an epidemiologist and veterinarian, will oversee the study and analyze data, Eisele said.Merck has declined to name the investigator, or any of the scientists or other academic experts involved in the study, but said it would release the results once the study was completed.Some livestock researchers have questioned why Merck has declined to say who is leading the research effort. Others have criticized the company for promoting the study's outcome before data are collected or analyzed.""It would suggest that they've already decided the results,"" Scott said.Christopher Reinhardt, a feedlot extension specialist at Kansas State University, said meat packers and feedlots will make certain results are objectively reported. Merck has ""a vested interest in the outcome but their partners don't, so there is sort of a check and balance in place,"" he said.Animal science experts said large-scale field studies - if done well - can offer valuable insight into drug interactions and impacts in the real world after the initial laboratory vetting required for federal regulatory approval.With Zilmax off the market since last August, rival pharmaceutical firms have grabbed market share. Many U.S. feedlots have switched to ractopamine-based Optaflexx, made by Merck rival Eli Lily & Co.'s Elanco Animal Health unit.(Reporting by P.J. Huffstutter and Tom Polansek. Editing by David Greising and Ross Colvin)",2014-04-04,MRK,"Fri Apr 4, 2014 | 1:44pm EDT","Exclusive: Merck wants to test Zilmax on 240,000 cattle but beef industry resists",http://www.reuters.com//article/us-zilmax-cattle-test-idUSBREA331H520140404?type=companyNews
62,"  * Senate Finance Committee Chairman Wyden calls for reform* Total of profits stashed abroad up 93 percent 2008-2013* GE tops list, followed by Microsoft, Pfizer, Merck, AppleBy Kevin Drawbaugh and Patrick Temple-WestWASHINGTON, April 8 Foreign profits held overseas by U.S. corporations to avoid taxes at home nearly doubled from 2008 to 2013 to top $2.1 trillion, said a private research firm's report, prompting a call for reform by the Senate's top tax law writer.""The new numbers ... certainly highlight what is one of the key challenges for tax reform. I do think there need to be some reforms in this area,"" Senate Finance Committee Chairman Ron Wyden told reporters on Tuesday on Capitol Hill.Under U.S. law, corporations do not have to pay income tax on most of their overseas profits until they are brought into the United States. These earnings can be held offshore for years if they are classified as indefinitely invested abroad. Research firm Audit Analytics said in a report issued last week that the total of such earnings was up 93 percent from 2008 to 2013, citing federal financial filings for companies listed in the Russell 1000 index of U.S. corporations.Conglomerate General Electric Co had the biggest pile of earnings stored abroad, at $110 billion, the firm said.Next were software maker Microsoft Corp, with $76.4 billion; drugmakers Pfizer Inc, with $69 billion, and Merck & Co Inc, with $57.1 billion; and high-tech group Apple Inc, with $54.4 billion, it said.In response, GE said in a statement: ""GE operates in more than 170 countries, and most of these overseas earnings have been reinvested in active business operations like manufacturing facilities and loans to non-U.S. customers."" Microsoft, Merck and Pfizer were not immediately available for comment. Apple did not respond to requests for comment.BAUCUS AND WYDEN  Congress has quarreled for years over the law that lets multinationals stash profits abroad tax-free. Some favor killing the law - known as offshore corporate income tax deferral - and some back a one-time tax holiday that would let companies bring foreign profits home, or ""repatriate"" them, at a low tax rate.Debate over offshore deferral flared again in November when Wyden's predecessor as finance committee chairman, former Democratic Senator Max Baucus, proposed doing both. Baucus resigned weeks later to become U.S. ambassador to China.Wyden in the past has called for repeal of offshore deferral, along with a repatriation holiday, among other changes to the tax code, which he last month called ""a rotten carcass that the special interests feast on.""No decisive action is likely for now, however, with Congress deadlocked over fiscal issues at least until after the November mid-term congressional elections, according to policy analysts.Next year lawmakers are likely to mount another push to overhaul the tax code, a politically difficult feat that has not been pulled off since 1986, when Republican President Ronald Reagan and a divided Congress managed to get it done.The top U.S. corporate income tax rate is 35 percent, though few multinationals pay anywhere near that thanks to tax-reducing loopholes written into the code in the past 28 years, including some that have enabled wider use of offshore deferral.   (Additional reporting by Lewis Krauskopf and Bill Berkrot in New York, Bill Rigby in Seattle, Edwin Chan in San Francisco; Editing by Howard Goller and Tom Brown)",2014-04-08,MRK,"Tue Apr 8, 2014 | 7:06pm EDT",Untaxed U.S. corporate profits held overseas top $2.1 trln -study,http://www.reuters.com//article/usa-tax-offshore-idUSL2N0N01FD20140408?type=companyNews
63,"   By Bill Berkrot  A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.Results of the study called C-Worthy were presented on Thursday at the annual meeting of the European Association for the Study of the Liver (EASL) in London. Researchers are due on Friday to present results of how the Merck pills fared in more difficult to treat patients, such as those who failed to be helped by prior treatments and those with more advanced liver disease.In the arm of the Phase II study presented on Thursday, 43 of 44 patients treated with 100 milligrams of MK-5172 and 50 mg of MK-8742 once a day for 12 weeks achieved sustained virologic response (SVR), which is considered cured. One patient relapsed, researchers said.Those who have no detectable levels of the hepatitis C virus in their blood 12 weeks after completing the 12 weeks of treatment are deemed to have achieved SVR.Current standard treatments take 24 or 48 weeks, cure about 75 percent of patients and involve miserable side effects that have led thousands of patients to put off treatment and wait for highly touted new drugs to become available. The study also included results of patients treated with the two Merck drugs plus the older drug ribavirin for both 12 weeks and eight weeks. But all eyes will be on the ribavirin-free results as several companies race to produce all-oral treatment regimens that include neither ribavirin nor interferon, which are both used in current treatments and cause flu-like symptoms, anemia and other side effects.Gilead Sciences Inc, AbbVie and Bristol-Myers Squibb Co are also developing a new generation of all-oral hepatitis C treatments that in previous trials have demonstrated cure rates in excess of 90 percent, while cutting treatment duration to 12 weeks with few side effects. Gilead, which later this year could have a one pill, once a day two-drug regimen approved in the United States, is widely perceived by Wall Street to be the best of the bunch with some analysts forecasting annual sales of $9 billion or more.Merck is a bit behind the other three companies in its development timeline, but could prove to be the one that gives Gilead a run for its money as it aims to also produce a one pill, once a day regimen. The AbbVie and Bristol-Myers programs involve more pills and more drugs, but equally impressive cure rates so far in clinical testing.""Merck has begun a Phase III trial in (previously untreated patients) using one pill, once per day. This should increase everyone's confidence that Merck really has a regimen competitive with Gilead's,"" ISI Group analyst Mark Schoenebaum said in a research note. The Merck anti-viral medicines, which hamper the virus' ability to replicate in different ways, were tested in patients who had the genotype 1 form of the virus - the most prevalent and considered the most difficult to treat.The most common side effects seen with the Merck drugs were fatigue, headache and nausea.An estimated 170 million people are believed to be infected with hepatitis C worldwide. If left untreated, the progressive disease can lead to cirrhosis, liver cancer or the need for a liver transplant.(Reporting by Bill Berkrot; Editing by Bernard Orr)",2014-04-10,MRK,"Thu Apr 10, 2014 | 1:17am EDT",Merck hepatitis C drugs shine in easier to treat patients: study,http://www.reuters.com//article/us-hepatitis-merck-idUSBREA390B120140410?type=companyNews
64,"   By Bill Berkrot | April 10  April 10 A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.Results of the study called C-Worthy were presented on Thursday at the annual meeting of the European Association for the Study of the Liver (EASL) in London. Researchers are due on Friday to present results of how the Merck pills fared in more difficult to treat patients, such has those who failed to be helped by prior treatments and those with more advanced liver disease.In the arm of the Phase II study presented on Thursday, 43 of 44 patients treated with 100 milligrams of MK-5172 and 50 mg of MK-8742 once a day for 12 weeks achieved sustained virologic response (SVR), which is considered cured. One patient relapsed, researchers said.Those who have no detectable levels of the hepatitis C virus in their blood 12 weeks after completing the 12 weeks of treatment are deemed to have achieved SVR. Current standard treatments take 24 or 48 weeks, cure about 75 percent of patients and involve miserable side effects that have led thousands of patients to put off treatment and wait for highly touted new drugs to become available.The study also included results of patients treated with the two Merck drugs plus the older drug ribavirin for both 12 weeks and eight weeks. But all eyes will be on the ribavirin-free results as several companies race to produce all-oral treatment regimens that include neither ribavirin nor interferon, which are both used in current treatments and cause flu-like symptoms, anemia and other side effects.Gilead Sciences Inc, AbbVie and Bristol-Myers Squibb Co are also developing a new generation of all-oral hepatitis C treatments that in previous trials have demonstrated cure rates in excess of 90 percent, while cutting treatment duration to 12 weeks with few side effects. Gilead, which later this year could have a one pill, once a day two-drug regimen approved in the United States, is widely perceived by Wall Street to be the best of the bunch with some analysts forecasting annual sales of $9 billion or more.Merck is a bit behind the other three companies in its development timeline, but could prove to be the one that gives Gilead a run for its money as it aims to also produce a one pill, once a day regimen. The AbbVie and Bristol-Myers programs involve more pills and more drugs, but equally impressive cure rates so far in clinical testing. ""Merck has begun a Phase III trial in (previously untreated patients) using one pill, once per day. This should increase everyone's confidence that Merck really has a regimen competitive with Gilead's,"" ISI Group analyst Mark Schoenebaum said in a research note.The Merck anti-viral medicines, which hamper the virus' ability to replicate in different ways, were tested in patients who had the genotype 1 form of the virus - the most prevalent and considered the most difficult to treat.The most common side effects seen with the Merck drugs were fatigue, headache and nausea.An estimated 170 million people are believed to be infected with hepatitis C worldwide. If left untreated, the progressive disease can lead to cirrhosis, liver cancer or the need for a liver transplant.   (Reporting by Bill Berkrot; Editing by Bernard Orr)",2014-04-10,MRK,"Thu Apr 10, 2014 | 1:00am EDT",Merck hepatitis C drugs shine in easier to treat patients -study,http://www.reuters.com//article/health-hepatitis-merck-idUSL2N0N12E220140410?type=companyNews
65,"  Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.The company, which developed the tablet with Denmark's ALK Abello, said it expects to launch the drug, approved for patients age 5 to 65, in the United States by late April.Immunotherapies work by boosting the body's immune system and making it less sensitive to allergens.Grastek contains extracts of the timothy grass allergen. The tablet is placed under the tongue and dissolves. An advisory committee to the FDA unanimously recommended approval of the drug in December. Panelists also called for post-approval studies to test the product's safety in children, citing side effects such as lip swelling, throat irritation and oral blistering.Earlier this month, the FDA approved Stallergenes' immunotherapy treatment for five types of grass pollen. The French company has said it sees a potential U.S. market of nearly 3 million patients that will eventually be worth $1 billion in annual sales for these types of drugs. Merck's pollen treatment received regulatory approval in Canada in February and has been available in Europe since 2006 under the name Grazax.Merck shares closed at $55.57 Monday on the New York Stock Exchange.(Reporting by Natalie Grover in Bangalore and Susan Kelly in Chicago; Editing by Savio D'Souza, Bernard Orr)",2014-04-14,MRK,"Mon Apr 14, 2014 | 7:59pm EDT",Merck's grass pollen allergy drug wins U.S. approval,http://www.reuters.com//article/us-merck-co-fda-grastek-idUSBREA3D1UD20140414?type=companyNews
66,"  April 14 Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.The company, which developed the tablet with Denmark's ALK Abello, said it expects to launch the drug, approved for patients age 5 to 65, in the United States by late April.Immunotherapies work by boosting the body's immune system and making it less sensitive to allergens.Grastek contains extracts of the timothy grass allergen. The tablet is placed under the tongue and dissolves. An advisory committee to the FDA unanimously recommended approval of the drug in December. Panelists also called for post-approval studies to test the product's safety in children, citing side effects such as lip swelling, throat irritation and oral blistering.Earlier this month, the FDA approved Stallergenes'  immunotherapy treatment for five types of grass pollen. The French company has said it sees a potential U.S. market of nearly 3 million patients that will eventually be worth $1 billion in annual sales for these types of drugs. Merck's pollen treatment received regulatory approval in Canada in February and has been available in Europe since 2006 under the name Grazax.Merck shares closed at $55.57 Monday on the New York Stock Exchange.(Reporting by Natalie Grover in Bangalore and Susan Kelly in Chicago; Editing by Savio D'Souza, Bernard Orr)",2014-04-14,MRK,"Mon Apr 14, 2014 | 7:57pm EDT",UPDATE 1-Merck's grass pollen allergy drug wins U.S. approval,http://www.reuters.com//article/merck-grastek-idUSL2N0N61RN20140414?type=companyNews
67,"  April 14 Merck & Co Inc said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy vaccine, Grastek, for patients aged 5 to 65.The company, which developed the tablet-based drug with Denmark's ALK Abello, said it expects to launch the treatment in the United States by late April. An advisory committee to the U.S. FDA had unanimously recommended the approval of the drug in December. The immunotherapy treatment, which got regulatory approval in Canada in February, has been available in Europe since 2006 under the name Grazax. Merck's stock closed at $55.57 on Monday on the New York Stock Exchange.   (Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)",2014-04-14,MRK,"Mon Apr 14, 2014 | 6:36pm EDT",Merck's grass pollen allergy vaccine wins U.S. approval,http://www.reuters.com//article/merck-co-fda-grastek-idUSL3N0N646A20140414?type=companyNews
68,"  The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek.The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis. (r.reuters.com/nyg68v)The approval for Ragwitek comes days after U.S. regulatory approval for Merck's grass pollen allergy drug Grastek. Merck's Grastek will compete with Stallergenes SA's immunotherapy treatment for five types of grass pollen, which was approved by the FDA earlier this month. (This story corrects fourth paragraph to say Grastek, not Ragwitek, will compete with Stallergenes' drug) (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)",2014-04-17,MRK,"Thu Apr 17, 2014 | 3:58pm EDT",Merck's ragweed pollen allergy drug gets U.S. approval,http://www.reuters.com//article/us-merck-ragwitek-fda-idUSBREA3G21D20140417?type=companyNews
69,"  (Corrects fourth paragraph to say Grastek, not Ragwitek, will compete with Stallergenes' drug)April 17 The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis. (r.reuters.com/nyg68v) The approval for Ragwitek comes days after U.S. regulatory approval for Merck's grass pollen allergy drug Grastek. Merck's Grastek will compete with Stallergenes SA's  immunotherapy treatment for five types of grass pollen, which was approved by the FDA earlier this month.   (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)",2014-04-17,MRK,"Thu Apr 17, 2014 | 3:57pm EDT",CORRECTED-Merck's ragweed pollen allergy drug gets U.S. approval,http://www.reuters.com//article/merck-ragwitek-fda-idUSL3N0N944E20140417?type=companyNews
70,"  (The following statement was released by the rating agency) CHICAGO, April 24 (Fitch) Fitch Ratings has affirmed Merck & Co.'s (Merck)  long-term ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating  Outlook remains Negative. In addition, Fitch has affirmed the company's  short-term ratings at 'F1'. A full list of rating actions follows at the end of  this release.  The ratings apply to approximately $24.6 billion in outstanding debt.  KEY RATING DRIVERS The Negative Outlook mainly reflects that leverage (total debt/EBITDA) has  remained above 1.5 times (x) since Merck's $5 billion, largely debt-funded share  repurchases in second-quarter of 2013. While leverage has declined to 1.65x from  its peak of 1.92x at June 30, 2013, it remains higher than what Fitch would  expect for an 'A+' credit rating for this issuer.  Fitch expects that Merck will continue to favor share repurchases over  deleveraging, acknowledging the possibility of further debt-funded stock  buybacks. Notably, the company has roughly $10.4 billion remaining on its  existing repurchase authorization. Sales at-risk to patent expiries have declined to roughly 20% of total firm  sales. Roughly one-third of those sales are generated by biologics, which tend  have significantly less market share erosion in the face of generic (biosimilar)  than do traditional small molecule drugs. Merck has made progress in building its late-stage pipeline. The company has  approximately 20 new molecular entities (NMEs) in phase 3 development or  registration. Merck initiated a restructuring program in October 2013, which Fitch expects  will be supportive to margins during the intermediate term. The company will  focus on costs in a number of areas including manufacturing, general  administration and research & development. Fitch believes the rumored sale of the company's consumer business would be  strategically sound, as it would increase the company's focus on its core  mission of developing and marketing innovative medicines. However, unless the  company were to use some of the proceeds to pay down debt, the incremental loss  of diversification and EBITDA would be incrementally negative for Merck's credit  rating. Fitch expects modest growth for Merck's Januvia/Janumet franchise, as the market  becomes increasingly crowded with new entrants. Although, the growth in the  number of diabetic patients and some share gains from older generic treatment  modalities should offset the competitive headwind. Fitch forecasts that Merck will generate $5.8 billion - $6.1 billion in FCF  during 2014 as improving margins offset soft revenue. Debt Financed Share Repurchases Fitch expects that Merck will continue with shareholder friendly actions during  the near term, some of which may be funded by debt. Merck purchased $5.3 billion  (net of issuances) of its common stock during 2013, compared to $1.3 billion  during 2012. The repurchases were executed under a $15 billion program  authorized in May 2013 and a previously authorized program. The company has  approximately $10.4 billion remaining under the May 2013 share repurchase  program. The repurchases were funded, in large part, with debt issuances. Patent Exposure Easing The company faces significant number of patent expiries during the next two  years. However, roughly only 20% of total firm sales are at risk. In addition,  Remicade and PEG-Intron, which account for about 6.2% of total firm, are  biologics and tend not to experience the rapid sales loss to generic competition  as do traditiona, one small molecule pharmaceuticals. Expanding Late Stage Pipeline Fitch expects Merck to continue to build its late-stage pipeline, despite the  company's intention to narrow its focus its focus on R&D projects. The company's  late stage pipeline is broad with new molecular entities (NMEs) to treat cancer,  bacterial and viral infections, diabetes, cardiovascular disease, central  nervous system disorders, osteoporosis, allergies and other maladies.  While the majority of these projects are internally developed, Merck has  partnered with other innovator firms to take advantage of technological  advancements that were discovered externally. The landscape for drug development  is expanding, particularly as more is learned about how genetics influence the  development, prevention and treatment of disease.  Cost Cutting Continues In October 2013, Merck initiated a new global restructuring program, in an  effort to sharpen its global commercial and research & development focus. The  company expects to reduce its total workforce by approximately 8,500 positions,  including those in sales, administration and research & development.  Merck will sell some real estate, move its corporate headquarters and continue  to work towards improving the efficiency of its manufacturing and supply  network. The restructuring program is expected to be substantially completed by  the end of 2015. Estimated pre-tax restructuring costs are approximately $2.5  billion - $3 billion, of which two-thirds will be cash-related. Consumer Business Possibly for Sale  Fitch believes the sale of Merck's consumer products business would be a net  negative for the company's credit profile, with the expectation that the  proceeds of the sales would not be used for debt reduction. While the consumer  business accounts for roughly 4% of total firm sales, Fitch estimates the  segment's contribution to the firm's total EBITDA is less than that. Regardless,  we believe the negative effects of a less diversified product portfolio and a  lower base of profitability will more than offset the benefits to the firm from  increasing its focus on its core competency of drug development and marketing in  the near term. More Competition for Januvia/Janumet Fitch expects that the growing number of diabetic patients and continued market  share gains from some older generic diabetes treatments will more than offset  the increasing number of competitors in the diabetes treatment market, resulting  in relatively soft sales growth for Januvia/Janumet, Merck's largest selling  franchise. Growth has slowed in recent years due to competition (DPP-4  inhibitors, SGLT2 inhibitors, GLP-1 agonists) entering the diabetes market. In  addition, concerns over the safety of these drugs(DPP-4 inhibitors) have been a  headwind to growth, although the FDA recently reaffirmed their safety regarding  pancreatitis and pancreatic cancer.  Solid Free Cash Flow Expected Fitch forecasts that Merck will continue to generate significantly positive free  cash flow generate, including expected 2014 FCF of $5.8 billion - $6.1 in FCF  during 2014. Improving margins driven by an improving sales mix and strong cost  control should more than offset the negative effect that expected soft top-line  growth will have on cash generation. Adequate Liquidity Fitch looks for Merck to maintain adequate liquidity through strong FCF  generation and ample access to the credit markets. FCF for the LTM ending Dec.  31, 2013 was $8.35 billion. At the end of the period, Merck had approximately  $17.5 billion in cash plus short-term investments and full availability on its  $4 billion revolver, maturing in May 2017.  At Dec. 31, 2013, Merck had roughly $24.6 billion in debt outstanding, with $4.7  billion maturing in 2014, $2 billion in 2015, $2.3 billion in 2016 and $1  billion in 2017. Fitch expects near- to mid-term maturities will be satisfied  primarily through refinancing in the public debt markets. RATING SENSITIVITIES Fitch would consider revising the Rating Outlook to Stable if Merck pursued a  capital deployment strategy that maintained gross debt leverage below 1.5X  during the long term, including managing through operational stress such as  patent expiries and clearly taking a more conservative approach to its use of  debt. In addition, the company must demonstrate long-term positive sales growth  through demand for core drug products and uptake of new medicines.  Rating pressure would stem from total debt leverage remaining above 1.5x in the  intermediate term. The high leverage would likely be driven by incremental  borrowing to fund acquisitions or share repurchases. Leverage pressure could  also result from operational weakness due to an inability to achieve in  achieving cost containment targets or generating sales growth despite is  improving patent risk profile and expanding late-stage pipeline. In addition,  Fitch anticipatates that FCF would be constrained in this scenario. RATING ACTIONS Fitch has affirmed the follow ratings for Merck:   --Long-term Issuer Default Rating (IDR) at 'A+';  --Senior unsecured debt rating at 'A+'; --Bank loan rating at 'A+'; --Short-term IDR at 'F1'; --Commercial paper rating at 'F1'. The Rating Outlook on the long-term ratings remains Negative. Contact: Primary Analyst Bob Kirby, CFA Director +1-312-368-3147  Fitch Ratings, Inc. 70 West Madison Street Chicago, IL 60602 Secondary Analyst Michael Zbinovec Senior Director +1-312-368-3164 Committee Chairperson Michael Weaver Managing Director +1-312-368-3156 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research: --'Corporate Rating Methodology' (Aug. 12, 2013); --'Rating Pharmaceutical Companies - Sector Credit Factors' (Aug. 9, 2012). Applicable Criteria and Related Research:  Corporate Rating Methodology: Including Short-Term Ratings and Parent and  Subsidiary Linkage here Rating Pharmaceutical Companies  here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-04-24,MRK,"Thu Apr 24, 2014 | 2:11pm EDT",Fitch Affirms Merck & Co.'s Long-term IDR at 'A+'; Outlook Remains Negative,http://www.reuters.com//article/fitch-affirms-merck-cos-long-term-idr-at-idUSFit69795920140424?type=companyNews
71,"   By Anjuli Davies, Olivia Oran and Soyoung Kim | LONDON/NEW YORK  LONDON/NEW YORK Merck & Co Inc is in the final stages of selling its consumer healthcare unit for close to $14 billion, with Bayer AG and Reckitt Benckiser Group Plc among final contenders to clinch a deal as soon as next week, people familiar with the matter said.Germany's Bayer and British consumer products giant Reckitt have emerged as frontrunners to win the auction after each offering roughly $13.5 billion for the Merck consumer unit, best known for Coppertone sunscreen and Claritin allergy medicine, the sources said.Both bidders are very keen to buy the asset and the price tag could go higher in the final days, one person added. All the people asked not to be named because the matter is not public.Representatives for U.S. drugmaker Merck, as well as Bayer and Reckitt, declined to comment.The sale would be the latest in a wave of healthcare deals in recent days, including Zimmer Holdings Inc's $13.35 billion acquisition of orthopaedics rival Biomet Inc and the agreement between Novartis AG and GlaxoSmithKline Plc to trade more than $20 billion worth of assets, with Eli Lilly and Co buying Novartis' animal health business for $5.4 billion.At the same time, Valeant Pharmaceuticals International Inc and Bill Ackman are locked in a $47 billion battle for Allergan Inc; Mylan Inc is seeking to buy Sweden's Meda AB for around $9 billion including debt; and there is talk of a $100 billion bid for AstraZeneca Plc from Pfizer Inc. RECORD HEALTHCARE M&A The deal surge has driven healthcare M&A volumes to $153.3 billion so far this year, the highest year-to-date level since Thomson Reuters has started tracking data. Pharmaceutical deals have accounted for 71 percent of overall healthcare deals.The Merck auction also drew interest from several other healthcare and consumer giants including Procter & Gamble Co, Boehringer Ingelheim, Novartis and Sanofi SA, people familiar with the matter have said. The impending sale underscores drugmakers' efforts to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition.Reckitt owns over-the-counter medicines including Mucinex and Nurofen and the international rights for the Scholl foot care business. Its chief executive told Reuters in September that Reckitt aimed to be a major player in consumer healthcare and had the firepower to do sizeable deals.Germany's Bayer already has a strong portfolio of consumer products including pain medication Aleve and antacid Alka-Seltzer, but is looking at deals to expand the business further. In 2012, Bayer lost a bidding war with Reckitt for Schiff Nutrition International Inc, which agreed to sell to the British consumer products group for $1.3 billion. Over-the-counter health products are attractive to companies like Reckitt and Bayer because they tap into consumer and demographic trends such as aging populations, ballooning healthcare costs and more interest in wellness.They also enjoy brand loyalty, fat margins and strong growth - and because of that they don't come cheap.Merck is looking to sell its consumer unit as it is not a leader in the space and holds only around 1 percent of the market. In exploring alternatives for the consumer business, Merck is following in the footsteps of other drugmakers such as Pfizer, which has created shareholder value by separating non-core business units.Pfizer sold its infant-nutrition business to Nestle SA for $11.9 billion in 2012 and last year spun off its animal health unit as a separate publicly traded company called Zoetis Inc.(Additional reporting by Martinne Geller and Ben Hirschler; Editing by Mark Trevelyan)",2014-04-26,MRK,"Sat Apr 26, 2014 | 3:21pm EDT",Exclusive: Merck in final talks to sell consumer unit for near $14 billion - sources,http://www.reuters.com//article/us-merck-co-sale-idUSBREA3P0I220140426?type=companyNews
72,"  (Adds Cosco Group, Allergan, Comcast and others; updates Alstom and Merck & Co)April 28 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid battle for Britain's AstraZeneca Plc after having two bids rejected, as deal-making grips the healthcare industry. AstraZeneca urged its shareholders to take no action over the approach and said it remained confident in its independent strategy.** Britain's Reckitt Benckiser Group confirmed on Monday that it was in talks to buy Merck & Co Inc's  consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals. Germany's Bayer AG is also vying to buy the unit, which could fetch about $13.5 billion.** German drugmaker Bayer AG is exploring the sale of its $10 billion plastics unit to focus on growing its health business, Bloomberg reported citing people with knowledge of the matter.** Comcast Corp on Monday agreed to a three-way deal with Charter Communications Inc as part of Comcast's efforts to win regulatory approvals for its proposed $45 billion purchase of Time Warner Cable Inc. Under the deal, Charter would pay Comcast $7.3 billion for 1.4 million subscribers.** France said it would defend jobs and its national interest as it met suitors eyeing a breakup of engineering group Alstom on Monday and suggested it preferred Germany's Siemens over U.S. giant General Electric.** Grupo Oi SA, Brazil's biggest fixed-line telephone carrier, on Monday got closer to its planned merger with Portugal Telecom SGPS SA as investors were willing to place more than enough bids in a share offering expected to be worth at least 8 billion reais ($3.6 billion), sources told Reuters.** Buyout firm Cinven is investing in Norwegian software company Visma AS in a deal that values Visma at around 2.5 billion euros ($3.46 billion) including debt.** Energy Transfer Partners LP, owner of gasoline retailer Sunoco Inc, said it would buy Susser Holdings Corp  in a deal valued at $1.8 billion to create a standalone retailing business.** Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion, including milestone payments to access Furiex's promising treatment for irritable bowel syndrome.** Alibaba Group Holding Ltd IPO-ALIB.N and a private equity firm co-founded by its executive chairman Jack Ma have agreed to buy a $1.22 billion stake in Youku Tudou Inc, as China's ecommerce giant intensifies its focus on online video business.** Australian food firm Goodman Fielder has rejected a $1.2 billion takeover bid from Wilmar International Ltd and a Hong Kong-listed investment management firm as too low, but expectations are high that the parties will keep talking. ** Japan's Orix Corp has agreed to buy Hartford Financial Services Group's Japanese unit for $895 million as part of efforts to expand its life insurance business in the world's third-largest economy.** Private equity group Arle Capital said on Monday that it had agreed to acquire Innovia Group, a British maker of materials to be used in England's new five and ten pound notes, for an enterprise value of 498 million euros ($689 million).** Viom Networks Ltd, an Indian phone tower operator majority owned by the Tata group, is looking to raise funds either through a stake sale or an overseas listing that could raise up to $350 million, sources with direct knowledge of the matter said.** Wal-Mart Stores Inc paid about $234 million in debt related to the purchase of a stake in its Indian joint venture with Bharti Enterprises, which the U.S. retailer ended in October last year, according to its 2014 annual report.** British defense contractor Ultra Electronics Holdings Plc  said it would acquire Forensic Technology WAI Inc, a maker of crime-scene investigation equipment, for C$94 million ($85.2 million) to expand in the security sector.** Denmark's Spar Nord Bank said on Monday it would take over retail customers from Basisbank with a business volume of 300 million Danish crowns ($55.6 million). ** Egypt's Citadel Capital said on Sunday that it was selling its majority stake in the Sudanese Egyptian Bank to the Islamic Solidarity bank of Sudan for $22 million.** French oil major Total SA has put its liquefied petroleum gas unit Totalgaz up for sale and has received around 10 expressions of interest from potential buyers, daily Les Echos reported on Monday.** Newmont Mining Corp has terminated merger talks with Barrick Gold Corp , Barrick said on Monday.** Mineral sands group Sierra Rutile Ltd said it was no longer in takeover talks with interested parties.** Malaysian state asset manager Permodalan Nasional Bhd is considering a proposal to merge four of its portfolio companies to form Southeast Asia's second largest property firm by assets, a source with direct knowledge of the matter said. ** Swedish drugmaker Meda has rejected an improved takeover offer from U.S. generics firm Mylan, saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.** London-listed oil and gas explorer Ophir Energy  said on Monday it was no longer interested in making a takeover offer for rival Premier Oil after a proposal was rejected by the Premier Oil board.** Russia's Alliance Group, which owns the Khabarovsk oil refinery in Russia's Far East, has agreed to merge its assets with a company controlled by Eduard Khudainatov, a former senior executive at Rosneft, an Alliance spokesman said on Monday.** Italian broadcaster Mediaset confirmed it had received expressions of interest from foreign players for its pay-TV business - though it gave no names - as media speculation grows a tie-up could be on the horizon.** Mining veteran and former Xstrata head Mick Davis has offered to buy BHP Billiton's thermal coal division, which could form the core of his X2 Resources, the Sunday Times said.** Germany's Siemens will sell a majority stake in its VAI Metals Technologies unit to Japan's Mitsubishi Heavy Industries, an Austrian newspaper reported on Saturday citing industry experts.** Austria's electricity provider Verbund has offered to sell its stake in troubled Italian energy group Sorgenia as part of a debt restructuring plan with creditor banks, a spokeswoman for the state-owned utility said on Monday. Verbund, which holds 46 percent of Sorgenia, wrote a letter to the banks recently offering its 46 percent stake by way of contribution to the debt restructuring, the spokeswoman said.** American Realty Capital Properties Inc is in talks to buy NorthStar Realty Finance Corp, according to people familiar with the matter, in a deal that would combine a major property owner with a real estate financing company.** Steria said it expected Sopra to file its all-share offer for the French IT services group in May, with the result of the tender likely to come in July.** Maker of Botox Allergan Inc, facing an unsolicited bid from Valeant Pharmaceuticals International Inc , is preparing to approach Shire Plc again with a potential takeover offer after being rebuffed in recent months, people familiar with the matter said on Monday.** China's Cosco Group and five other investors have expressed interest in a majority stake in Piraeus port , the largest in the country, Greece's privatization agency HRADF said on Monday.   ($1 = 0.72 Euros)  ($1 = 1.10 Canadian dollars)  ($1 = 5.39 Danish crowns)  ($1 = 2.22 Brazilian real)   (Compiled by Avik Das and Ankit Ajmera in Bangalore)",2014-04-28,MRK,"Mon Apr 28, 2014 | 4:07pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0NK2UN20140428?type=companyNews
73,"  LONDON Britain's Reckitt Benckiser Group Plc (RB.L) confirmed on Monday it was in talks to buy Merck & Co's (MRK.N) consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.The consumer products group over the weekend emerged as a front runner in the auction for the unit, best known for Coppertone sunscreen and Claritin allergy medicine, sources told Reuters on Saturday. Germany's Bayer AG (BAYGn.DE) is also vying to buy the unit, which could fetch about $13.5 billion.""RB confirms that it is in discussions with Merck regarding an offer for its consumer health business,"" the company said on Monday. ""We understand that we are part of a competitive process."" Bayer Chief Executive Marijn Dekkers indicated on Monday that the company still aims to be the world leader in over-the-counter medicines. While acquiring Merck's consumer health business would go a long way toward achieving that goal, he did not tip his hand on the Merck bidding process after Bayer announced its first-quarter results.Dekkers, on a conference call with analysts, said in order to become world No. 1 in OTC the company needed not only significant organic growth but also ""bolt-on acquisitions."" Reuters reported on Saturday that Merck was in the final stages of selling the consumer business for close to $14 billion and that the price could go higher in the final days of bidding. Reckitt owns over-the-counter medicines, including Mucinex and Nurofen and the international rights for the Scholl foot care business. Germany's Bayer has a strong portfolio of consumer products, including pain medication Aleve and antacid Alka-Seltzer.(Reporting by Paul Sandle in London; additional reporting by Marilyn Gerlach in Frankfurt and Bill Berkrot in New York; editing by Kate Holton and Matthew Lewis)",2014-04-28,MRK,"Mon Apr 28, 2014 | 1:46pm EDT",Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com//article/us-reckittbenckisergp-idUSBREA3R11520140428?type=companyNews
74,"  (Adds comments by Bayer CEO, company background)LONDON, April 28 Britain's Reckitt Benckiser Group Plc confirmed on Monday it was in talks to buy Merck & Co's consumer health business, the latest asset up for grabs in a wave of recent  pharmaceutical deals.The consumer products group over the weekend emerged as a front runner in the auction for the unit, best known for Coppertone sunscreen and Claritin allergy medicine, sources told Reuters on Saturday. Germany's Bayer AG  is also vying to buy the unit, which could fetch about $13.5 billion. ""RB confirms that it is in discussions with Merck regarding an offer for its consumer health business,"" the company said on Monday. ""We understand that we are part of a competitive process.""Bayer Chief Executive Marijn Dekkers indicated on Monday that the company still aims to be the world leader in over-the-counter medicines. While acquiring Merck's consumer health business would go a long way toward achieving that goal, he did not tip his hand on the Merck bidding process after Bayer announced its first-quarter results. Dekkers, on a conference call with analysts, said in order to become world No. 1 in OTC the company needed not only significant organic growth but also ""bolt-on acquisitions."" Reuters reported on Saturday that Merck was in the final stages of selling the consumer business for close to $14 billion and that the price could go higher in the final days of bidding.Reckitt owns over-the-counter medicines, including Mucinex and Nurofen and the international rights for the Scholl foot care business. Germany's Bayer has a strong portfolio of consumer products, including pain medication Aleve and antacid Alka-Seltzer.    (Reporting by Paul Sandle in London; additional reporting by Marilyn Gerlach in Frankfurt and Bill Berkrot in New York; editing by Kate Holton and Matthew Lewis)",2014-04-28,MRK,"Mon Apr 28, 2014 | 1:44pm EDT",UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com//article/reckitt-benc-grp-merckco-idUSL6N0NK5FU20140428?type=companyNews
75,"  (Repeats to fix story format)LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals. The consumer products group emerged as a front runner in the auction for the unit, best known for Coppertone sunscreen and Claritin allergy medicine, at the weekend, according to Reuters. Germany's Bayer AG is also vying to buy the unit, which could fetch about $13.5 billion.  ""RB confirms that it is in discussions with Merck regarding an offer for its consumer health business,"" the company said on Monday. ""We understand that we are part of a competitive process.""   (Reporting by Paul Sandle; editing by Kate Holton)",2014-04-28,MRK,"Mon Apr 28, 2014 | 12:46pm EDT",RPT-Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com//article/reckitt-benc-grp-merck-co-idUSL6N0NK5DE20140428?type=companyNews
76,"  LONDON, April 28 Britain's Reckitt Benckiser Group confirmed on Monday it was in talks to buy Merck & Co Inc's consumer health business, the latest asset up for grabs in a wave of pharmaceutical deals.The consumer products group emerged as a front runner in the auction for the unit, best known for Coppertone sunscreen and Claritin allergy medicine, at the weekend, according to Reuters. Germany's Bayer AG is also vying to buy the unit, which could fetch about $13.5 billion.  ""RB confirms that it is in discussions with Merck regarding an offer for its consumer health business,"" the company said on Monday. ""We understand that we are part of a competitive process.""   (Reporting by Paul Sandle; editing by Kate Holton) ",2014-04-28,MRK,"Mon Apr 28, 2014 | 12:26pm EDT",Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com//article/reckitt-benc-grp-merck-co-idUSASM0006FU20140428?type=companyNews
77,"   By Caroline Valetkevitch | NEW YORK  NEW YORK U.S. stocks rose on Tuesday, boosted by upbeat results from companies including Merck & Co and a rebound in Facebook and other high-growth shares.Merck & Co (MRK.N)'s shares climbed 3.6 percent to $58.72, giving the S&P 500 its biggest lift, after it reported stronger-than-expected earnings.Further deal activity on the healthcare front also lifted the market. Britain's Reckitt Benckiser Group Plc (RB.L) confirmed talks to buy Merck's consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.""Investors are viewing (that activity) as a signal for positive conditions in which businesses are willing and able to offer substantial sums of cash and/or stocks,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.Also supportive: most S&P 500 companies are beating earnings forecasts, albeit on lowered expectations, he said.Earnings estimates have rebounded, however, as more companies have reported results. First-quarter profit growth for S&P 500 companies is seen at 3.7 percent, based on actual results and estimates for companies yet to report, compared with a forecast for 2.1 percent growth at the beginning of the month, Thomson Reuters data showed. The Dow Jones industrial average .DJI rose 86.63 points or 0.53 percent, to 16,535.37, the S&P 500 .SPX gained 8.9 points or 0.48 percent, to 1,878.33 and the Nasdaq Composite .IXIC added 29.142 points or 0.72 percent, to 4,103.543.Shares of Facebook (FB.O), up 3.6 percent at $58.15, led the way higher on the Nasdaq, a day after selling off along with a host of other momentum names.Shares of Twitter (TWTR.N) jumped 4.6 percent to $42.62 ahead of its results after the bell, when it reported 255 million monthly active users, up from the previous quarter but not enough to satisfy investors. The stock was down 10.2 percent in after-hours trading. Also after the bell, shares of eBay (EBAY.O) fell 3.8 percent to $52.45 as its second-quarter forecast fell short of estimates.During the regular session, Sprint Corp (S.N) shares jumped 11.3 percent to $8.27. The No. 3 U.S. mobile provider reported an increase in quarterly revenue, as expected, due to a new billing plan that lowered wireless expenses.On the down side, Coach Inc (COH.N) reported a sharp drop in North American sales and the stock slumped 9.3 percent to $45.71. Archer Daniels Midland Co (ADM.N) finished down 2.6 percent at $43.23 after its first-quarter profit and sales missed Wall Street estimates.About 6.3 billion shares changed hands on U.S. exchanges, below the 6.6 billion average this month, according to data from BATS Global Markets.The Fed's two-day policy meeting began on Tuesday, with the central bank expected to again scale back its monthly bond purchase program. Investors will also be eager to get any guidance on when it might raise interest rates.Data suggested the economy continued to gain momentum after the winter lull. U.S. consumer confidence dipped in April but remained near a six-year high, while home prices rose in February.(Editing by Bernadette Baum and Nick Zieminski)",2014-04-29,MRK,"Tue Apr 29, 2014 | 4:55pm EDT","Wall Street ends up on earnings, rebound in high-growth shares",http://www.reuters.com//article/us-markets-stocks-idUSBREA360QI20140429?type=companyNews
78,"  * Merck quarterly profit tops estimate but revenue misses* Twitter to report earnings after market close* More U.S. companies beating earnings expectations* Indexes up: Dow 0.5 pct, S&P 0.5 pct, Nasdaq 0.7 pct   (Updates with eBay down after the bell)By Caroline ValetkevitchNEW YORK, April 29 U.S. stocks rose on Tuesday, boosted by upbeat results from companies including Merck & Co and a rebound in Facebook and other high-growth shares.Merck & Co 's shares climbed 3.6 percent to $58.72, giving the S&P 500 its biggest lift, after it reported stronger-than-expected earnings.Further deal activity on the healthcare front also lifted the market. Britain's Reckitt Benckiser Group Plc  confirmed talks to buy Merck's consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals. ""Investors are viewing (that activity) as a signal for positive conditions in which businesses are willing and able to offer substantial sums of cash and/or stocks,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.Also supportive: most S&P 500 companies are beating earnings forecasts, albeit on lowered expectations, he said.Earnings estimates have rebounded, however, as more companies have reported results. First-quarter profit growth for S&P 500 companies is seen at 3.7 percent, based on actual results and estimates for companies yet to report, compared with a forecast for 2.1 percent growth at the beginning of the month, Thomson Reuters data showed. The Dow Jones industrial average rose 86.63 points or 0.53 percent, to 16,535.37, the S&P 500 gained 8.9 points or 0.48 percent, to 1,878.33 and the Nasdaq Composite  added 29.142 points or 0.72 percent, to 4,103.543.Shares of Facebook, up 3.6 percent at $58.15, led the way higher on the Nasdaq, a day after selling off along with a host of other momentum names.Shares of Twitter jumped 4.6 percent to $42.62 ahead of its results after the bell, when it reported 255 million monthly active users, up from the previous quarter but not enough to satisfy investors. The stock was down 10.2 percent in after-hours trading.Also after the bell, shares of eBay fell 3.8 percent to $52.45 as its second-quarter forecast fell short of estimates. During the regular session, Sprint Corp shares jumped 11.3 percent to $8.27. The No. 3 U.S. mobile provider reported an increase in quarterly revenue, as expected, due to a new billing plan that lowered wireless expenses.On the down side, Coach Inc reported a sharp drop in North American sales and the stock slumped 9.3 percent to $45.71.Archer Daniels Midland Co finished down 2.6 percent at $43.23 after its first-quarter profit and sales missed Wall Street estimates.About 6.3 billion shares changed hands on U.S. exchanges, below the 6.6 billion average this month, according to data from BATS Global Markets.The Fed's two-day policy meeting began on Tuesday, with the central bank expected to again scale back its monthly bond purchase program. Investors will also be eager to get any guidance on when it might raise interest rates.Data suggested the economy continued to gain momentum after the winter lull. U.S. consumer confidence dipped in April but remained near a six-year high, while home prices rose in February.    (Editing by Bernadette Baum and Nick Zieminski)",2014-04-29,MRK,"Tue Apr 29, 2014 | 4:53pm EDT","US STOCKS-Wall St ends up on earnings, rebound in high-growth shares",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NL24R20140429?type=companyNews
79,"   By Arno Schuetze and Olivia Oran | FRANKFURT/NEW YORK  FRANKFURT/NEW YORK Bayer AG (BAYGn.DE) is offering to swap its animal health assets for Merck & Co Inc's (MRK.N) consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business.As part of its bid, Bayer has offered to pay the remainder of the acquisition price in cash, these people said, who asked not to be named because the matter is not public.Bayer and Britain's Reckitt Benckiser Group (RB.L) are among the final contenders for the Merck unit, best known for Coppertone sunscreen and Claritin allergy medicine, Reuters reported last weekend.Bayer's animal health business had net sales of 1.3 billion euros ($1.8 billion) in 2013, according to the company's website. Representatives for Bayer declined to comment and Merck did not respond to requests for comment. Bayer's asset swap offer is yet another evidence of drugmakers' efforts to exit weaker businesses and focus resources on areas of strength.Last week, Novartis and GlaxoSmithKline Plc (GLAX.NS) agreed to trade more than $20 billion worth of assets, with Eli Lilly and Co (LLY.N) buying Novartis' animal health business for $5.4 billion. However, asset swaps are often complicated and hard to value and there is no guarantee Bayer's offer will prevail over cash offers from rival suitors, people familiar with the matter said.Merck's auction has also drawn interest from several other healthcare and consumer giants including Boehringer Ingelheim, Sanofi SA (SASY.PA), Procter & Gamble Co (PG.N) and Novartis AG NOVN.VX, Reuters previously reported. A sale of Merck's consumer business could approach $14 billion with an outcome expected this week, sources said last week.Reckitt confirmed on Monday it was in talks to buy the Merck unit. Bayer's Chief Executive Marijn Dekkers said on Monday during a conference call with analysts that OTC ""is an important business for us.""Reckitt owns over-the-counter medicines, including Mucinex and Nurofen and the international rights for the Scholl foot care business. Germany's Bayer has a strong portfolio of consumer products, including pain medication Aleve and antacid Alka-Seltzer.(Reporting by Arno Scheutze in Frankfurt and Olivia Oran in New York,; additional reporting by Soyoung Kim in New York and Sophie Sassard in London; Editing by Leslie Adler and Phil Berlowitz)",2014-04-29,MRK,"Tue Apr 29, 2014 | 4:40pm EDT","Bayer offers animal health assets, cash for Merck's OTC unit -sources",http://www.reuters.com//article/us-merck-co-bayer-idUSBREA3S12B20140429?type=companyNews
80,"  (Adds background on Merck auction)By Arno Schuetze and Olivia OranFRANKFURT/NEW YORK, April 29 Bayer AG  is offering to swap its animal health assets for Merck & Co Inc's consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business.As part of its bid, Bayer has offered to pay the remainder of the acquisition price in cash, these people said, who asked not to be named because the matter is not public.Bayer and Britain's Reckitt Benckiser Group are among the final contenders for the Merck unit, best known for Coppertone sunscreen and Claritin allergy medicine, Reuters reported last weekend. Bayer's animal health business had net sales of 1.3 billion euros ($1.8 billion) in 2013, according to the company's website. Representatives for Bayer declined to comment and Merck did not respond to requests for comment.Bayer's asset swap offer is yet another evidence of drugmakers' efforts to exit weaker businesses and focus resources on areas of strength. Last week, Novartis and GlaxoSmithKline Plc agreed to trade more than $20 billion worth of assets, with Eli Lilly and Co buying Novartis' animal health business for $5.4 billion.However, asset swaps are often complicated and hard to value and there is no guarantee Bayer's offer will prevail over cash offers from rival suitors, people familiar with the matter said. Merck's auction has also drawn interest from several other healthcare and consumer giants including Boehringer Ingelheim, Sanofi SA, Procter & Gamble Co and Novartis AG , Reuters previously reported.A sale of Merck's consumer business could approach $14 billion with an outcome expected this week, sources said last week.Reckitt confirmed on Monday it was in talks to buy the Merck unit. Bayer's Chief Executive Marijn Dekkers said on Monday during a conference call with analysts that OTC ""is an important business for us.""Reckitt owns over-the-counter medicines, including Mucinex and Nurofen and the international rights for the Scholl foot care business. Germany's Bayer has a strong portfolio of consumer products, including pain medication Aleve and antacid Alka-Seltzer.   (Reporting by Arno Scheutze in Frankfurt and Olivia Oran in New York,; additional reporting by Soyoung Kim in New York and Sophie Sassard in London; Editing by Leslie Adler and Phil Berlowitz)",2014-04-29,MRK,"Tue Apr 29, 2014 | 4:39pm EDT","UPDATE 1-Bayer offers animal health assets, cash for Merck's OTC unit -sources",http://www.reuters.com//article/merck-co-bayer-idUSL2N0NL1ZW20140429?type=companyNews
81,"  * Merck quarterly profit tops estimate but revenue misses* Twitter to report earnings after market close* More U.S. companies beating earnings expectations* Indexes up: Dow 0.5 pct, S&P 0.5 pct, Nasdaq 0.7 pct   (Updates to close)By Caroline ValetkevitchNEW YORK, April 29 U.S. stocks rose on Tuesday, boosted by upbeat results from companies including Merck & Co and a rebound in Facebook and other high-growth shares.Merck & Co 's shares climbed 3.6 percent to $58.72, giving the S&P 500 its biggest lift, after it reported stronger-than-expected earnings. Further deal activity on the healthcare front also lifted the market, with Britain's Reckitt Benckiser Group Plc  confirming talks to buy Merck's consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.""Investors are viewing (that activity) as a signal for positive conditions in which businesses are willing and able to offer substantial sums of cash and/or stocks,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.Also supportive: the majority of S&P 500 companies are beating earnings forecasts, albeit on lowered expectations, he said.Earnings estimates have rebounded, however, as more companies have reported results. First-quarter profit growth for S&P 500 companies is seen at 3.7 percent, based on actual results and estimates for companies yet to report, compared with a forecast for 2.1 percent growth at the beginning of the month, Thomson Reuters data showed. The Dow Jones industrial average rose 86.63 points or 0.53 percent, to 16,535.37, the S&P 500 gained 8.9 points or 0.48 percent, to 1,878.33 and the Nasdaq Composite  added 29.142 points or 0.72 percent, to 4,103.543.Shares of Facebook, up 3.6 percent at $58.15, led the way higher on the Nasdaq, a day after selling off along with a host of other momentum names.Shares of Twitter jumped 4.6 percent to $42.62 ahead of its results after the bell, when it reported 255 million monthly active users, up from the previous quarter but not enough to satisfy investors. The stock was last down 8.6 percent. During the regular session, Sprint Corp shares jumped 11.3 percent to $8.27. The No. 3 U.S. mobile provider reported an increase in quarterly revenue, as expected, due to a new billing plan that lowered wireless expenses.On the down side, Coach Inc reported a sharp drop in North American sales and the stock slumped 9.3 percent to $45.71.Archer Daniels Midland Co finished down 2.6 percent at $43.23 after its first-quarter profit and sales missed Wall Street estimates.About 6.3 billion shares changed hands on U.S. exchanges, below the 6.6 billion average this month, according to data from BATS Global Markets.The Fed's two-day policy meeting began on Tuesday, with the central bank expected to again scale back its monthly bond purchase program. Investors will also be eager to get any guidance on when it might raise interest rates.Data suggested the economy continued to gain momentum after the winter lull. U.S. consumer confidence dipped in April but remained near a six-year high, while home prices rose in February.    (Additional reporting by Angela Moon; Editing by Bernadette Baum and Nick Zieminski)",2014-04-29,MRK,"Tue Apr 29, 2014 | 4:31pm EDT","US STOCKS-Wall St ends up on earnings, rebound in high-growth shares",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NL20T20140429?type=companyNews
82,"   By Arno Schuetze and Olivia Oran | FRANKFURT/NEW YORK, April 29  FRANKFURT/NEW YORK, April 29 Bayer AG  is offering to swap its animal health assets with Merck & Co Inc's consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg up in the $14 billion auction of the Merck business. As part of its bid, Bayer has offered to pay the remainder of the acquisition price in cash, these people said, who asked not to be named because the matter is not public. Bayer and Britain's Reckitt Benckiser Group are among the final contenders for the Merck unit, best known for Coppertone sunscreen and Claritin allergy medicine, Reuters reported last weekend. Bayer's animal health business had net sales of 1.3 billion euros ($1.8 billion) in 2013, according to the company's website. Representatives for Bayer and Merck did not respond to requests for comment.   (Reporting by Arno Scheutze in Frankfurt and Olivia Oran in New York; additional reporting by Soyoung Kim in New York and Sophie Sassard in London; Editing by Leslie Adler)",2014-04-29,MRK,"Tue Apr 29, 2014 | 4:01pm EDT","Bayer offers animal health assets, cash for Merck's OTC unit -sources",http://www.reuters.com//article/merck-co-bayer-idUSL2N0NL1WI20140429?type=companyNews
83,"  Merck & Co Inc (MRK.N) reported better-than-expected quarterly earnings, helped by sharply lower research spending and asset sales, but revenue came in slightly below expectations.The No. 2 U.S. drugmaker, whose shares rose 3 percent, said on Tuesday it earned $1.70 billion, or 57 cents per share, in the first quarter. That compared with $1.59 billion, or 52 cents, in the year-earlier period.Excluding special items, Merck earned 88 cents per share, well above the average analyst estimate of 79 cents compiled by Thomson Reuters I/B/E/S.Merck's global revenue fell 4 percent to $10.26 billion, hurt by generic competition for its Singulair treatment for allergy and asthma. Wall Street expected $10.44 billion. Merck said it slashed its research spending by 20 percent in the quarter to $1.5 billion, as it scrapped work on experimental medicines no longer part of its main research focus or deemed to have limited commercial potential.Marketing and administrative expenses fell 8.5 percent to $2.73 billion, also bolstering results. ""Although the revenues were lighter than expected, Merck continues to impress with prudent expense management, particularly in research and development,"" said BMO Capital Markets analyst Alex Arfaei.Arfaei said it remains to be seen, however, how the cuts will ultimately affect the pace of drug development. Merck is expected to soon announce the sale of its consumer healthcare products unit. Its sales fell 4 percent to $546 million in the quarter, hurt by a shortened allergy season in North America.Merck reaffirmed it expects earnings this year of $3.35 to $3.53 per share, excluding special items.(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe and Chizu Nomiyama)",2014-04-29,MRK,"Tue Apr 29, 2014 | 2:44pm EDT","Merck first-quarter profit tops estimate, but revenue misses",http://www.reuters.com//article/us-merck-results-idUSBREA3S0DY20140429?type=companyNews
84,"  (Adds analyst comment, details on lower costs, shares)April 29 Merck & Co Inc reported better-than-expected quarterly earnings, helped by sharply lower research spending and asset sales, but revenue came in slightly below expectations.The No. 2 U.S. drugmaker, whose shares rose 3 percent, said on Tuesday it earned $1.70 billion, or 57 cents per share, in the first quarter. That compared with $1.59 billion, or 52 cents, in the year-earlier period.Excluding special items, Merck earned 88 cents per share, well above the average analyst estimate of 79 cents compiled by Thomson Reuters I/B/E/S. Merck's global revenue fell 4 percent to $10.26 billion, hurt by generic competition for its Singulair treatment for allergy and asthma. Wall Street expected $10.44 billion.Merck said it slashed its research spending by 20 percent in the quarter to $1.5 billion, as it scrapped work on experimental medicines no longer part of its main research focus or deemed to have limited commercial potential. Marketing and administrative expenses fell 8.5 percent to $2.73 billion, also bolstering results.""Although the revenues were lighter than expected, Merck continues to impress with prudent expense management, particularly in research and development,"" said BMO Capital Markets analyst Alex Arfaei. Arfaei said it remains to be seen, however, how the cuts will ultimately affect the pace of drug development.Merck is expected to soon announce the sale of its consumer healthcare products unit. Its sales fell 4 percent to $546 million in the quarter, hurt by a shortened allergy season in North America.Merck reaffirmed it expects earnings this year of $3.35 to $3.53 per share, excluding special items.   (Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe and Chizu Nomiyama)",2014-04-29,MRK,"Tue Apr 29, 2014 | 2:38pm EDT","UPDATE 2-Merck 1st-quarter profit tops estimate, but revenue misses",http://www.reuters.com//article/merck-results-idUSL2N0NL0F620140429?type=companyNews
85,"  * Merck quarterly profit tops estimate but revenue misses* Twitter to report earnings after market close* More U.S. companies beating earnings expectations* Indexes up: Dow 0.6 pct, S&P 0.5 pct, Nasdaq 0.7 pct   (Updates to afternoon, changes byline)By Caroline ValetkevitchNEW YORK, April 29 U.S. stocks rose on Tuesday, helped by upbeat results from companies including Merck & Co and Sprint, as well as more deal activity on the healthcare front. Merck & Co 's shares jumped 2.9 percent to $58.35, giving the S&P 500 its biggest lift, after it reported stronger-than-expected results.Also, Britain's Reckitt Benckiser Group Plc confirmed talks to buy Merck's consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.""We've gone through a fair chunk of earnings and market participants kind of get the story at this juncture. On balance, with expectations having been lowered, earnings beats are coming in around 70 percent and most of the forward-looking statements have generally been pretty decent,"" said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia, which manages about $63 billion in assets. First-quarter profit growth for S&P 500 companies is seen at 3.7 percent, based on actual results and estimates for companies yet to report, compared with a forecast for 2.1 percent growth at the beginning of the month, Thomson Reuters data showed.The Dow Jones industrial average rose 91.86 points or 0.56 percent, to 16,540.6, the S&P 500 gained 8.35 points or 0.45 percent, to 1,877.78 and the Nasdaq Composite  added 28.264 points or 0.69 percent, to 4,102.665.Sprint Corp shares jumped 10.2 percent to $8.19 after the No. 3 U.S. mobile provider reported an increase in quarterly revenue, as expected, due to a new billing plan that lowered wireless expenses. On the down side, Coach Inc reported a sharp drop in North American sales and the stock slumped 8.5 percent to $46.15.Archer Daniels Midland Co were last down 3 percent at $43.03 after its first-quarter profit and sales missed Wall Street estimates.The Fed's two-day policy meeting began on Tuesday, with the central bank expected to again scale back its monthly bond purchase program. Investors will also be eager to get any guidance on when it might raise interest rates.Data suggested the economy continued to gain momentum after the winter lull. U.S. consumer confidence dipped in April but remained near a six-year high, while home prices rose in February.Shares of Twitter, up 3.8 percent at $42.26, is due to report after the market close.     (Additional reporting by Angela Moon; Editing by Bernadette Baum and Nick Zieminski)",2014-04-29,MRK,"Tue Apr 29, 2014 | 1:56pm EDT","US STOCKS-Wall St gains with upbeat earnings, more deal activity",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NL1IC20140429?type=companyNews
86,"   By Soyoung Kim, Olivia Oran and Sophie Sassard | NEW YORK/LONDON  NEW YORK/LONDON Merck & Co Inc (MRK.N) is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas.Merck, which is also in the process of selling its $14 billion consumer healthcare unit, is working with an investment bank on the potential sale of the off-patent drugs, which could draw interest from generic drugmakers, the people said.Merck's off-patent drugs are called ""diversified brands"" and many are sold in emerging markets. The sale processes underscore efforts by large drugmakers to shed smaller divisions they view as non-core so they can better focus on their mainstay products. They have shown new willingness to consider large asset swaps with rivals to exit weaker businesses and bolster core areas where they are already top players.Sanofi SA (SASY.PA), being advised by Evercore Partners Inc (EVR.N), is also in the market with its aging drug portfolio, which could fetch between $7 billion and $8 billion, Reuters reported on Tuesday. Representatives for Merck declined to comment. The sources asked not to be named because the matter is not public.Both Merck and Sanofi have an extensive line-up of older products that could be carved out, following similar moves now under way at Pfizer Inc (PFE.N) and GlaxoSmithKline Plc (GSK.L) to place older products in separate divisions. Pfizer announced last year it planned to separate its business into three units - innovative pharmaceuticals; vaccines, oncology and consumer health; and established products. The U.S. group has not ruled out a full breakup.GSK is starting down a similar path, and CEO Andrew Witty said on Wednesday that he would consider single products or broader divestiture of its established drugs.(Reporting by Soyoung Kim, Olivia Oran in New York and Sophie Sassard in London, Additional reporting by Ransdell Pierson, Editing by Prudence Crowther and Ken Wills)",2014-04-30,MRK,"Wed Apr 30, 2014 | 6:50pm EDT",Exclusive: Merck explores $15 billion-plus drug portfolio sale,http://www.reuters.com//article/us-merck-sale-exclusive-idUSBREA3T10M20140430?type=companyNews
87,"  (Adds Shell, Vale, Etihad Etisalat, America Movil and others; updates Exelon Corp)April 30 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Bayer AG is offering to swap its animal health assets for Merck & Co Inc's consumer healthcare business, people familiar with the matter said on Tuesday, in a move that could give the German drugmaker a leg-up in the $14 billion auction of the Merck business.** Exelon Corp said it would buy Pepco Holdings Inc  for $6.83 billion, helping it overtake Duke Energy Corp  as the biggest power distribution company in the United States.** Sanofi SA is looking to sell a portfolio of older drugs that could fetch $7 billion-$8 billion, according to people familiar with the matter, yet another example of drugmakers trying to shed non-core assets and focus on high-growth areas.** Australian mining firm Padbury Mining Ltd's $6.5 billion deal to fund a new iron ore port and rail development on the resource-rich western coast has fallen through, the company said on Wednesday.** French Economy Minister Arnaud Montebourg said on Wednesday that his government would examine a request from Alstom SA unions to raise the state's shareholding in the company, which is the subject of takeover talks.Separately, the head of General Electric said that talks with the French government on its offer for Alstom's  energy assets had been ""productive"" and he expressed confidence that the deal would go through despite a potential rival offer from Germany's Siemens.** Swiss private bank J. Safra Sarasin has agreed to buy Morgan Stanley's Swiss private banking unit, beefing up its business with the wealthy in the Middle East and Latin America.** China Petrochemical Corp (Sinopec Group) said on Wednesday that it and state-owned power group China Huadian Corp have agreed to take a combined 15 percent stake in a liquefied natural gas project controlled by Malaysian state oil firm Petronas in Canada.** Iran has terminated China National Petroleum Corp's  contract to develop the Azadegan oilfield after the Chinese energy giant ignored repeated appeals to work on it, Iranian news agency Shana said on Wednesday.** India's Jindal Steel and Power Ltd and JSW Steel Ltd are in competing talks to buy parts of insolvent Italian steelmaker Lucchini, sources with direct knowledge of the matter said.** German auto parts and tire maker Continental AG  plans to buy the remainder of Emitec, a supplier of emissions technology, from GKN Plc.** Linux operating system vendor Red Hat Inc said it would buy privately held storage systems provider Inktank Ceph Enterprise for $175 million to expand in the fast growing market for software-defined storage.** An Indian court has temporarily halted generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of rival Ranbaxy Laboratories Ltd until it decides on a petition for a probe into alleged insider trading. ** Mapletree Group, owned by Singapore's state investor Temasek Holdings Pte Ltd, plans to partner with U.S-based Oakwood Worldwide in forming a joint venture in the serviced apartment business.** Etihad Airways has signaled that it was ready to continue talks on a potential investment in Italy's troubled Alitalia but it refuses to budge on tough conditions on debt restructuring and job cuts, a source close to the talks said on Wednesday.** Israeli geothermal energy producer Ormat Industries  said its U.S. subsidiary is examining the possibility of raising money by bringing in equity partners for a small number of assets in the United States.** The banking foundation that is top shareholder in Banca Carige is awaiting clearance from Italy's Treasury to cut its stake to 19 percent from 43.4 percent at present, the chairman of the not-for-profit entity said on Wednesday.** Volkswagen AG is edging closer toward taking full control of its Swedish truck division Scania, after its buyout offer won broad support from shareholders and fell just short of an acceptance threshold.** Hastings Funds Management and China Merchants Group have won a state government auction for a 98-year lease on Australia's Port of Newcastle, the world's biggest coal export terminal, paying a higher-than-expected A$1.75 billion ($1.62 billion). ** Indonesia's PT Perusahaan Gas Negara Tbk said it will buy liquefied natural gas from BP Plc's Tangguh plant for its two floating storage facilities to meet rising demand in Southeast Asia's biggest economy.** A consortium of RRJ Capital and Temasek Holdings have agreed to invest 1.3 billion euros ($1.80 billion) in ING Groep's European and Japanese insurance and investment management unit ahead of its planned IPO, the Dutch financial services firm said in a statement on Wednesday.** Africa-focused oil and gas explorer Tullow Oil  has sold majority stakes in two UK North Sea gas assets to Faroe Petroleum Plc for $75.6 million and said it was looking for buyers of other North Sea assets.** The biggest investor in Salini Impregilo will reduce its stake in the Italian builder to around 75 percent from 90 percent by the end of the summer, Chief Financial Officer Massimo Ferrari said on Wednesday.** Israeli mobile operator Pelephone signed a deal with Sweden's Ericsson to supply equipment and build a fourth-generation (4G) network, its parent company said on Wednesday.** Croatia's state power board Hrvatska Elektroprivreda (HEP) said on Wednesday that it had received qualified bids for the construction of a 500-megawatt thermal power plant on the northern Adriatic, but declined to offer details until the bids were assessed.** Royal Dutch Shell Plc's proposed LNG Canada liquefied natural gas export plant in British Columbia tiptoed closer to reality on Wednesday, with the company signing a formalized partnership agreement with its three Asian partners, nudging the project into the next stage of development. Shell also boosted its stake in the project to 50 percent from 40 percent. ** Guinea's President Alpha Conde said on Wednesday he hoped Brazilian miner Vale would bid to reclaim two iron ore permits, because the company had not been involved in the alleged corruption that led to their cancellation.** Saudi Arabia's Etihad Etisalat (Mobily) is in talks to acquire 20 percent of Etihad Atheeb Telecommunications  through a rights issue by the loss-making telecom operator, according to a bourse statement on Wednesday.** India's Piramal Enterprises Ltd has agreed to buy a 9.99 percent stake in Shriram City Union Finance Ltd  valued at about $130 million, its latest investment in a firm linked to the Chennai-based Shriram group.** Latin America's biggest phone company America Movil  expects regulators to approve its deal to take control of Telekom Austria within two months, it said on Wednesday.** Charter Communications, which lost out to Comcast Corp in a bid to acquire Time Warner Cable Inc , has withdrawn its slate of nominees to Time Warner Cable's board. As part of a deal with Comcast announced on Monday to swap customers, Charter had withdrawn its slate, a Charter spokesman said on Wednesday.** Grupo Argos, a Colombian holding company, is looking to invest in the energy sector elsewhere in Latin America later this year, its chief executive said on Wednesday.** Lithuanian state-owned companies said they had asked the competition authority for approval to buy stakes in the Baltic state's gas and power utilities from Germany's E.ON .** Reckitt Benckiser Group said on Wednesday it was no longer in active talks with Merck & Co about buying its consumer health business, leaving Germany's Bayer  as the leading contender for the $14 billion business.** Lloyds Banking Group has reached an agreement to sell $500 million of shipping loans from its remaining ship finance portfolio as the British bank cuts sector exposure, finance and banking sources familiar with the matter said on Wednesday.** China's commerce ministry has approved with conditions German liquid crystal maker Merck KGaA's planned $2.6 billion takeover of UK-listed AZ Electronic Materials.** Energizer Holdings Inc said it planned to separate into two publicly traded companies, one for batteries and other household products and the other for personal care brands such as Schick razors and Stayfree female hygiene products.** The three brothers who own Fratelli Rossetti would consider selling part of the Italian luxury shoemaker to fund future expansion, while keeping the business founded by their father firmly under family control.** ArcelorMittal SA, the world's largest steelmaker, and Bekaert Group on Wednesday agreed to swap their stakes in their Brazil, Costa Rica and Ecuador ventures, part of a broader plan to extend a four-decade partnership in fast-growing markets, an executive said.   ($1 = 0.59 British pounds)  ($1 = 1.08 Australian dollars)  ($1 = 0.72 euros)   (Compiled by Avik Das and Ankit Ajmera in Bangalore)",2014-04-30,MRK,"Wed Apr 30, 2014 | 4:07pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0NM3J320140430?type=companyNews
88,"   By Martinne Geller | LONDON  LONDON Reckitt Benckiser Group (RB.L) said on Wednesday it was no longer in active talks with Merck & Co (MRK.N) about buying its consumer health business, leaving Germany's Bayer (BAYGn.DE) as a leading contender for the $14 billion business.Bayer has offered to swap its animal health assets for the Merck consumer business that includes Coppertone sunscreen and pay the remainder of the price in cash, Reuters reported on Tuesday, citing people familiar with the matter.That swap may have given Bayer a leg up, since Reckitt, known for paying top dollar for attractive assets, backed down.""We are a highly disciplined acquirer with strict return metrics, which we will not break,"" said Reckitt Benckiser Chief Executive Rakesh Kapoor in an emailed statement.""The consumer health market remains highly fragmented and we will continue to evaluate opportunities that fit both our strategic and financial criteria."" Merck has not made a final decision on any sale and there is no guarantee that Bayer will emerge as the winner, people familiar with the matter said on Wednesday.The auction also drew interest from other healthcare and consumer giants including Boehringer Ingelheim, Sanofi SA (SASY.PA), Procter & Gamble Co (PG.N) and Novartis AG NOVN.VX, Reuters previously reported. The consumer health sector has seen a wave of deals as it benefits from ageing populations in the West and rising incomes in emerging markets.Last week, Prestige Brands Holdings (PBH.N) agreed to pay $750 million for the maker of e.p.t home pregnancy tests and Sucrets cough lozenges, while Reckitt last month agreed to buy the global rights for the K-Y intimate lubricant brand from Johnson & Johnson (JNJ.N).Merck and Bayer declined to comment. Bayer has a diverse portfolio that includes over-the-counter remedies such as Aleve and Alka-Seltzer and an animal health business with annual sales of 1.3 billion euros ($1.8 billion).In 2012, Bayer lost out to Reckitt in the battle for Schiff Nutrition, after Reckitt offered $1.3 billion for entry into the U.S. vitamin and supplements market.Reckitt, which also makes Mucinex and Nurofen medicines, said on Monday that it was in talks to buy Merck's consumer business, the latest asset up for grabs in a string of healthcare deals.(Reporting by Martinne Geller in London; Additional reporting by Frank Siebelt in Frankfurt; Editing by Keiron Henderson and Robin Pomeroy)",2014-04-30,MRK,"Wed Apr 30, 2014 | 3:55pm EDT",Reckitt Benckiser says no longer in talks with Merck,http://www.reuters.com//article/us-reckitt-benc-grp-merck-co-idUSBREA3T0S220140430?type=companyNews
89,"  * Germany's Bayer now seen as a leading contender* No final decision made by Merck   (Adds background, context, byline, bullet points)By Martinne GellerLONDON, April 30 Reckitt Benckiser Group  said on Wednesday it was no longer in active talks with Merck & Co about buying its consumer health business, leaving Germany's Bayer as a leading contender for the $14 billion business.Bayer has offered to swap its animal health assets for the Merck consumer business that includes Coppertone sunscreen and pay the remainder of the price in cash, Reuters reported on Tuesday, citing people familiar with the matter.That swap may have given Bayer a leg up, since Reckitt, known for paying top dollar for attractive assets, backed down. ""We are a highly disciplined acquirer with strict return metrics, which we will not break,"" said Reckitt Benckiser Chief Executive Rakesh Kapoor in an emailed statement.""The consumer health market remains highly fragmented and we will continue to evaluate opportunities that fit both our strategic and financial criteria.""Merck has not made a final decision on any sale and there is no guarantee that Bayer will emerge as the winner, people familiar with the matter said on Wednesday. The auction also drew interest from other healthcare and consumer giants including Boehringer Ingelheim, Sanofi SA , Procter & Gamble Co and Novartis AG, Reuters previously reported.The consumer health sector has seen a wave of deals as it benefits from ageing populations in the West and rising incomes in emerging markets. Last week, Prestige Brands Holdings agreed to pay $750 million for the maker of e.p.t home pregnancy tests and Sucrets cough lozenges, while Reckitt last month agreed to buy the global rights for the K-Y intimate lubricant brand from Johnson & Johnson.Merck and Bayer declined to comment.Bayer has a diverse portfolio that includes over-the-counter remedies such as Aleve and Alka-Seltzer and an animal health business with annual sales of 1.3 billion euros ($1.8 billion).In 2012, Bayer lost out to Reckitt in the battle for Schiff Nutrition, after Reckitt offered $1.3 billion for entry into the U.S. vitamin and supplements market.Reckitt, which also makes Mucinex and Nurofen medicines, said on Monday that it was in talks to buy Merck's consumer business, the latest asset up for grabs in a string of healthcare deals.   (Reporting by Martinne Geller in London; Additional reporting by Frank Siebelt in Frankfurt; Editing by Keiron Henderson and Robin Pomeroy)",2014-04-30,MRK,"Wed Apr 30, 2014 | 3:48pm EDT",UPDATE 2-Reckitt Benckiser says no longer in talks with Merck,http://www.reuters.com//article/reckitt-benc-grp-merck-co-idUSL6N0NM6GE20140430?type=companyNews
90,"  LONDON, April 30 Reckitt Benckiser Group  is no longer in active talks with Merck & Co about buying its consumer health business, the company said on Wednesday.""We are a highly disciplined acquirer with strict return metrics, which we will not break,"" said Reckitt Benckiser Chief Executive Rakesh Kapoor in an emailed statement. ""The consumer health market remains highly fragmented and we will continue to evaluate opportunities that fit both our strategic and financial criteria.""  (Reporting by Martinne Geller in London; editing by Keiron Henderson)",2014-04-30,MRK,"Wed Apr 30, 2014 | 1:11pm EDT",Reckitt Benckiser says no longer in talks with Merck,http://www.reuters.com//article/reckitt-benc-grp-merck-co-idUSL6N0NM6DV20140430?type=companyNews
91,"  EQUITIESNEW YORK - U.S. stocks rose on Tuesday, boosted by upbeat results from companies including Merck & Co and a rebound in Facebook and other high-growth shares.Merck & Co's shares climbed 3.6 percent to $58.72, giving the S&P 500 its biggest lift, after it reported stronger-than-expected earnings.Further deal activity on the healthcare front also lifted the market. Britain's Reckitt Benckiser Group Plc RB.L confirmed talks to buy Merck's consumer health business, the latest asset up for grabs in a wave of recent pharmaceutical deals.For a full report, double click on- - - - LONDON - Britain's blue chip shares hit a 7-1/2 week closing high on Tuesday, bolstered by upbeat corporate earnings reports from oil major BP and wealth manager St. James's Place.BP, up 2.9 percent, contributed most points to the UK benchmark index as it raised its quarterly dividend and said more share buybacks were on the cards. St. James's Place , which said it got off to a strong start in 2014, advanced 2 percent.For a full report, double click on- - - - TOKYO - Japanese shares rose on Wednesday, supported by some upbeat domestic earnings guidance and gains in Wall Street shares, with investors looking to the Bank of Japan's ongoing policy meeting.While few market players think the BOJ will ease its policy on Wednesday, many of them expect stimulus later in the year. They will be scrutinising the BOJ's economic report and Governor Haruhiko Kuroda's news conference for any hint on the timing..For a full report, double click on- - - - HONG KONG - Hang Seng Index set to open up 0.1 percent. For a full report, double click on- - - - FOREIGN EXCHANGE SYDNEY - The euro nursed broad losses early on Wednesday, having been put under pressure by soft German inflation numbers while the yen stayed on the defensive ahead of a policy decision by the Bank of Japan.A key measure of German inflation came in at a lower-than-expected 1.1 percent on the year, raising the risk that the euro area reading will also undershoot expectations later in the day.For a full report, double click on- - - -  TREASURIES NEW YORK - U.S. Treasury prices tumbled for a second straight session on Tuesday, pressured by a brighter U.S. economic outlook, with the Federal Reserve expected to continue reducing its bond purchases and investors bracing for a strong jobs report later this week.With the world's largest economy seemingly on a stable recovery path, the Fed, which began its two-day meeting on Tuesday, is expected to carry on tapering its asset-buying, a negative scenario for Treasuries. The Fed is also unlikely to alter its forward guidance on interest ratesFor a full report, double click on- - - - COMMODITIES GOLD  SINGAPORE - Gold was little changed on Wednesday as investors awaited cues from the U.S. Federal Reserve's policy statement and key economic data, even as political tensions in Ukraine provided some safe-haven support.Spot gold was steady at $1,295.20 an ounce by 0024 GMT, after closing flat in the previous session.For a full report, double click on- - - - BASE METALS SYDNEY - London copper inched higher on Wednesday but remained below recent eight-week peaks, underpinned by tight credit conditions in top consumer China and as volumes fade ahead of a string of economic data and a series of holidays this week.Three-month copper on the London Metal Exchange CMCU3 had edged up 0.2 percent to $6,722.25 a tonne by 0106 GMT, paring small losses from the previous session.For a full report, double click on- - - - OIL NEW YORK - Oil prices rose on Tuesday as traders refocused on geopolitical risks from an outbreak of violence in Libya to Russia's intervention in Ukraine.On Monday, oil posted its biggest daily decline in a month, when Libya lifted a force majeure from the eastern Zueitina oil port, raising prospects for rising shipments.For a full report, double click on    (Compiled by Abhishek Vishnoi)",2014-04-30,MRK,"Tue Apr 29, 2014 | 11:00pm EDT",India Morning Call-Global Markets,http://www.reuters.com//article/morningcall-india-idUSL3N0NM0SU20140430?type=companyNews
92,"  (Corrects errorneous word in fourth paragraph)By Sophie Sassard and Soyoung KimLONDON/NEW YORK May 1 German drugmaker Bayer AG  is nearing an agreement to buy Merck & Co Inc's  consumer healthcare unit, people familiar with the matter said, in a deal that could value the business at around $14 billion. Reckitt Benckiser Group, one of the final contenders in the auction, said on Wednesday it was no longer in active talks to buy the Merck business, leaving Bayer in the pole position to win the asset, which is best known for Coppertone sunscreen and Claritin allergy medicine.Bayer and Merck are hammering out final terms of an agreement and could announce the transaction in the next several days, the people said, asking not to be named because the matter is not public. Representatives for Bayer and Merck declined to comment. Reuters first reported last week that Bayer and Reckitt had  emerged as frontrunners in the auction with each offering roughly $13.5 billion, a price that could come close to $14 billion when the deal is finalized. Bloomberg News reported on Thursday that Bayer entered exclusive talks with Merck.Bayer has also edged out other rival bidders in the auction, including Procter & Gamble Co, Boehringer Ingelheim, Novartis AG  and Sanofi SA, people familiar with the matter said.   (Reporting by Sophie Sassard in London and Soyoung Kim in New York; Editing by Steve Orlofsky)",2014-05-01,MRK,"Thu May 1, 2014 | 4:18pm EDT",REFILE-Bayer nears deal to buy Merck consumer unit -sources,http://www.reuters.com//article/merck-consumer-idUSL2N0NJ0D720140501?type=companyNews
93,"   By Sophie Sassard and Soyoung Kim | LONDON/NEW YORK  LONDON/NEW YORK German drugmaker Bayer AG (BAYGn.DE) is nearing an agreement to buy Merck & Co Inc's (MRK.N) consumer healthcare unit, people familiar with the matter said, in a deal that could value the business at around $14 billion.Reckitt Benckiser Group (RB.L), one of the final contenders in the auction, said on Wednesday it was no longer in active talks to buy the Merck business, leaving Bayer in the pole position to win the asset, which is best known for Coppertone sunscreen and Claritin allergy medicine. Bayer and Merck are hammering out final terms of an agreement and could announce the transaction in the next several days, the people said, asking not to be named because the matter is not public. Representatives for Bayer and Merck declined to comment.Reuters first reported last week that Bayer and Reckitt had emerged as forerunners in the auction with each offering roughly $13.5 billion, a price that could come close to $14 billion when the deal is finalized.. Bloomberg News reported on Thursday that Bayer entered exclusive talks with Merck. Bayer has also edged out other rival bidders in the auction, including Procter & Gamble Co (PG.N), Boehringer Ingelheim, Novartis AG NOVN.VX and Sanofi SA (SASY.PA), people familiar with the matter said.(Reporting by Sophie Sassard in London and Soyoung Kim in New York; Editing by Steve Orlofsky)",2014-05-01,MRK,"Thu May 1, 2014 | 3:26pm EDT",Bayer nears deal to buy Merck consumer unit: sources,http://www.reuters.com//article/us-merck-consumer-idUSBREA400SO20140501?type=companyNews
94,"  (Adds futures, news)LONDON May 1 Britain's FTSE 100 index is seen opening 5 points higher, or 0.07 percent, according to financial bookmakers. Futures for the index are up 0.2 percent by 0639 GMT.* The UK blue chip index closed 0.2 percent higher at 6,780.03 points in the previous session after hitting an intraday peak of 6,794.88, the highest level since early March.* Trading volumes are likely to be thin as other stock markets in Europe are closed for the May Day holiday.* LLOYDS BANKING GROUP - The bank reported a 22 percent increase in first-quarter pretax profit and said it continued to expect to apply for permission in the second half of the year to restart dividend payments.* BG - Britain's third-biggest oil and gas company reported a 6 percent fall in first-quarter operating profit as it struggled with lower output and continued troubles at its Egyptian liquefied natural gas (LNG) plant.* ROLLS-ROYCE - The company said it was on track to report flat revenue and profit in 2014, in line with an earlier forecast, and said that a one-off charge in its marine unit meant that its performance would be weighted to the second half.* BSKYB - British pay-TV operator BSkyB added 74,000 net new TV customers in the third quarter, more than double the growth it recorded last year, as it shrugged off the competition from BT. * SCHRODERS - The British fund manager said assets under management rose to a record 268 billion pounds ($452.53 billion) in the first quarter of 2014 after it took in new money across a range of products.* WEIR GROUP - The British engineer said it remained on track for a return to growth this year as demand for oil and gas equipment and services outstripped sluggish mining orders in the first quarter.* British house prices rose much faster than expected last month to record their biggest annual rise since the start of the financial crisis, data from mortgage lender Nationwide showed on Thursday. * SMITH & NEPHEW - Europe's largest maker of artificial joints posted a 5 percent drop in underlying trading profit.* The Dow Jones industrial average closed at its first record high of 2014 on Wednesday after the U.S. Federal Reserve gave an upbeat view of the economy's prospects as it announced another cut to its massive bond-buying programme.* The Fed said in a statement it would reduce its monthly bond purchases to $45 billion from $55 billion, as expected. That will keep it on track to end the programme as soon as October.* RECKITT BENCKISER - The company is no longer in active talks with Merck & Co about buying its consumer health business, it said on Wednesday. * London copper slipped to a seven-session low on Thursday after China's manufacturing sector showed a slight improvement in April but missed forecasts, while prices were set to drift with top consumer China on a two-day break.* Brent crude eased down towards $108 a barrel, not far above its lowest in more than two weeks, as a potential rise in Libya's oil supply and record-high inventories in the United States weighed on prices.TODAY'S UK PAPERS > Financial Times> Other business headlines               Multimedia versions of Reuters Top News are now available for:  * 3000 Xtra    : visit topnews.session.rservices.com  * BridgeStation: view story .134  For more information on Top News visit  topnews.reuters.com   (Reporting by Atul Prakash, editing by Tricia Wright)",2014-05-01,MRK,"Thu May 1, 2014 | 2:42am EDT",UPDATE 1-UK Stocks-Factors to watch on May 1,http://www.reuters.com//article/markets-britain-factors-idUSL6N0NN0ZU20140501?type=companyNews
95,"  LONDON May 1 Britain's FTSE 100 index is seen opening 5 points higher, or 0.07 percent, according to financial bookmakers.* The UK blue chip index closed 0.2 percent higher at 6,780.03 points in the previous session after hitting an intraday peak of 6,794.88, the highest level since early March.* Trading volumes are likely to be thin as other stock markets in Europe are closed for the May Day holiday.* The Dow Jones industrial average closed at its first record high of 2014 on Wednesday after the U.S. Federal Reserve gave an upbeat view of the economy's prospects as it announced another cut to its massive bond-buying programme.* The Fed said in a statement it would reduce its monthly bond purchases to $45 billion from $55 billion, as expected. That will keep it on track to end the programme as soon as October.* RECKITT BENCKISER - The company is no longer in active talks with Merck & Co about buying its consumer health business, it said on Wednesday.* London copper slipped to a seven-session low on Thursday after China's manufacturing sector showed a slight improvement in April but missed forecasts, while prices were set to drift with top consumer China on a two-day break.* Brent crude eased down towards $108 a barrel, not far above its lowest in more than two weeks, as a potential rise in Libya's oil supply and record-high inventories in the United States weighed on prices. * UK CORPORATE DIARY: BG GROUP PLC                         Q1 BRITISH SKY BROADCASTING GROUP PLC   Q3  LLOYDS BANKING GROUP PLC             Q1 TRADE ROLLS-ROYCE HOLDINGS PLC             TRADING SCHRODERS PLC                        Q1 TRADE SHIRE PLC                            Q1  SMITH & NEPHEW PLC                   Q1 SYNTHOMER PLC                        TRADING WEIR GROUP PLC                       Q1 TRADE TODAY'S UK PAPERS > Financial Times> Other business headlines               Multimedia versions of Reuters Top News are now available for:  * 3000 Xtra    : visit topnews.session.rservices.com  * BridgeStation: view story .134  For more information on Top News visit  topnews.reuters.com   (Reporting by Atul Prakash, editing by Tricia Wright)",2014-05-01,MRK,"Thu May 1, 2014 | 2:01am EDT",UK Stocks-Factors to watch on May 1,http://www.reuters.com//article/markets-britain-factors-idUSL6N0NN0VG20140501?type=companyNews
96,"  Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug as it failed to improve survival rates without the cancer worsening, sending Endocyte's shares tumbling as much as 63 percent.Vintafolide, Endocyte's lead drug, was recommended for conditional approval in Europe in March but Friday's trial failure could cast a shadow on the approval.""Now, with this development, we think the chances of formal approval are slim to none,"" Christopher Raymond, analyst at Robert W. Baird, wrote in a note.The drug is the only ovarian cancer treatment in advanced trials for Merck, which is considered one of the forerunners in cancer drug research along with Roche.The European conditional approval, based on initial data, is given to drugs when they treat serious conditions with no other treatment options. The approval recommendation on March 21 had nearly doubled Endocyte's share price.The halted trial was testing vintafolide in ovarian cancer patients who had received prior treatment.The drug failed to improve progression-free survival rates, and an independent safety committee reviewing the trial recommended that it be halted. However, the committee did not identify any safety concerns for patients enrolled in the trial, the companies said in separate statements on Friday.The companies said they had notified study investigators to suspend screening and dosing participants in the trial.""We are reviewing and validating the data in collaboration with Merck in order to gain a better understanding of the interim trial results and make our formal decision regarding the execution of the trial,"" Endocyte Chief Executive Ron Ellis said in the statement. Patients on the late-stage trial either received the drug in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), or a combination of PLD plus a placebo.Baird's Raymond said that Friday's news can also raise questions on Endocyte's entire technology platform.The company's technology works by binding anti-cancer agents to certain receptors on cancer cells, thereby improving their efficacy. Apart from vintafolide, which is also being tested in lung and breast cancers, Endocyte is developing two more cancer drugs  based on the same technology.Endocyte and Merck signed a $1 billion partnership for the drug, also called Vynfinit, in April 2012.Endocyte's shares were down 62 percent at $6.66 in late morning trading on the Nasdaq. Merck was down about 2 percent at $58.49. (Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)",2014-05-02,MRK,"Fri May 2, 2014 | 12:20pm EDT","Endocyte's ovarian cancer drug fails trial, shares sink",http://www.reuters.com//article/us-merck-co-endocyte-idUSKBN0DI15F20140502?type=companyNews
97,"  * Safety committee recommends a halt to trial* Trial failure casts doubt on European approval* Endocyte shares fall as much as 63 pct   (Adds analyst comments, background; updates stock movement)May 2 Merck & Co Inc and Endocyte Inc  said they had stopped a late-stage trial of their experimental ovarian cancer drug as it failed to improve survival rates without the cancer worsening, sending Endocyte's shares tumbling as much as 63 percent.Vintafolide, Endocyte's lead drug, was recommended for conditional approval in Europe in March but Friday's trial failure could cast a shadow on the approval.""Now, with this development, we think the chances of formal approval are slim to none,"" Christopher Raymond, analyst at Robert W. Baird, wrote in a note.The drug is the only ovarian cancer treatment in advanced trials for Merck, which is considered one of the forerunners in cancer drug research along with Roche. The European conditional approval, based on initial data, is given to drugs when they treat serious conditions with no other treatment options. The approval recommendation on March 21 had nearly doubled Endocyte's share price.The halted trial was testing vintafolide in ovarian cancer patients who had received prior treatment.The drug failed to improve progression-free survival rates, and an independent safety committee reviewing the trial recommended that it be halted. However, the committee did not identify any safety concerns for patients enrolled in the trial, the companies said in separate statements on Friday.The companies said they had notified study investigators to suspend screening and dosing participants in the trial.""We are reviewing and validating the data in collaboration with Merck in order to gain a better understanding of the interim trial results and make our formal decision regarding the execution of the trial,"" Endocyte Chief Executive Ron Ellis said in the statement. Patients on the late-stage trial either received the drug in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), or a combination of PLD plus a placebo.Baird's Raymond said that Friday's news can also raise questions on Endocyte's entire technology platform.The company's technology works by binding anti-cancer agents to certain receptors on cancer cells, thereby improving their efficacy.Apart from vintafolide, which is also being tested in lung and breast cancers, Endocyte is developing two more cancer drugs  based on the same technology.Endocyte and Merck signed a $1 billion partnership for the drug, also called Vynfinit, in April 2012.Endocyte's shares were down 62 percent at $6.66 in late morning trading on the Nasdaq. Merck was down about 2 percent at $58.49.   (Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)",2014-05-02,MRK,"Fri May 2, 2014 | 11:52am EDT","UPDATE 2-Endocyte's ovarian cancer drug fails trial, shares sink",http://www.reuters.com//article/merck-co-endocyte-idUSL3N0NO3LR20140502?type=companyNews
98,"  Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo. An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.     (Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)",2014-05-02,MRK,"Fri May 2, 2014 | 8:35am EDT",Merck and Endocyte's ovarian cancer drug fails in trial,http://www.reuters.com//article/us-merck-co-endocyte-idUSKBN0DI0T520140502?type=companyNews
99,"  May 2 Merck & Co Inc and Endocyte Inc  said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo.  An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.     (Reporting by Esha Dey in Bangalore; Editing by Maju Samuel) ",2014-05-02,MRK,"Fri May 2, 2014 | 8:33am EDT",Merck and Endocyte's ovarian cancer drug fails in trial,http://www.reuters.com//article/merck-co-endocyte-idUSL3N0NO3HH20140502?type=companyNews
100,"  (For more Reuters DEALTALKS, double click on )By Ransdell PiersonNEW YORK May 4 Leading global pharmaceutical companies have started to view their vast portfolios of older, established prescription drugs as vehicles for raising large sums of cash to fuel development of new medicines with far higher profit margins.France's Sanofi and U.S. drugmakers Merck & Co  and Abbott Laboratories are exploring selling off their mature drugs that have lost patent protection, Reuters reported this week, citing people familiar with the plans. Officials at the three companies declined to comment.The divestments could bring in more than $7 billion for Sanofi, north of $15 billion for Merck and over $5 billion for Abbott, the sources said, giving them considerable firepower to develop, or buy, promising experimental medicines.Such a shift would also remove a source of pricing pressure, since many of the older medicines are sold in emerging markets, where governments are increasingly demanding lower prices.""It makes sense to sell your low-growth assets that drag down profit margins and to redeploy that cash to higher-value innovative biotech assets,"" said John Boris, an analyst with SunTrust Robinson Humphrey.The trickier part, according to some people familiar with the processes, is finding a buyer, particularly if many of these assets reach the market around the same time. Suitors could include generic or specialty drugmakers looking to widen their product line, or private equity firms content to milk the cash flow from the aging products without having to worry about the expense of drug development.The Merck products in particular could attract the interest of Valeant Pharmaceuticals, which derives a quarter of its revenue from branded generics sold in emerging markets, said Alex Arfaei, an analyst with BMO Capital Markets. Valeant's Chief Executive Michael Pearson has said he favors established products over pumping cash into risky research and development projects.Once companies divest their mature drugs, good-selling patent-protected drugs can have a bigger impact on financial results, said Len Yaffe, portfolio manager of the healthcare fund at StockDoc Partners in San Francisco.Patent protection for a new drug is generally 20 years from the time the patent was approved, but it can then take a medicine 10 or more years to be developed and reach the market, giving a limited window for exclusivity.""From a smaller revenue base, it's easier to grow revenue and earnings faster,"" Yaffe said, especially as new drugs are approved and make contributions. CASH COWS LOSE APPEAL The interest in unloading these older assets represents a shift for Big Pharma, which has relied on them as cash generators to cushion steep revenue declines from more recent drug patent expiries. Almost all are sold outside the United States, where governments are increasingly demanding lower prices.""That makes them less profitable and attractive,"" said Morningstar analyst Debbie Wang. ""It's gotten tougher in the past two or three years.""The divestments would also feed into a larger shakeout of the pharma industry, whose major players are in the midst of a series of asset sales and swaps to better focus on the types of medicines that will bring them the most growth. That logic has fueled Pfizer Inc's $106 billion unsolicited takeover bid for AstraZeneca and a $20 billion swap between Novartis and GlaxoSmithKline.Merck drugs likely to be sold include blood pressure treatments Cozaar and Hyzaar, with combined sales of $1 billion last year; cholesterol fighter Zocor, with sales of $301 million, and hair growth drug Propecia, with sales of $283 million. Sales of Abbott's aging drugs, which it calls ""established pharmaceuticals,"" fell 3 percent last year to $4.97 billion, irking many investors.When GSK reported quarterly financial results on Wednesday, it announced separate results for its established products division. Pfizer on Monday is expected to do the same, as a possible prelude to eventually divesting its mature drugs.GSK last September sold two blood clot medicines that are branded generics, Arixtra and Fraxiparine, and a related factory, to South Africa's Aspen Pharmacare for $1.1 billion, as part of its strategy to focus on growth products.""You should not be surprised if we were able to transact a disposal of some of that established product portfolio in the next year or two,"" Chief Executive Andrew Witty told reporters last week. ""That is not part of our future.""Pfizer, which recently spun off its animal health and infant formula businesses, is considering whether to divest its own established products unit, which includes hundreds of off-patent drugs and ones that will soon lose patent protection.Some analysts say an AstraZeneca purchase would allow Pfizer to combine the mature drugs divisions of both for a more significant sale or spin-off.But Pfizer has said it would not be able to divest the unit until 2017, following a review of its financial performance. It is one of the company's three main businesses, and with revenue of $9.46 billion last year, it generated 18 percent of total Pfizer sales.There are clear risks for Merck, Sanofi and others, however, in concentrating their bets so much more heavily on the success of new medicines""Being more focused cuts both ways: your successes are magnified, but if you have failures, you feel them more when you have a less-diverse business,"" said Edward Jones analyst Judson Clark.   (Reporting by Ransdell Pierson,; additional reporting by Ben Hirschler in London and Bill Berkrot, Soyoung Kim and Olivia Oran in New York; Editing by Martin Howell)",2014-05-04,MRK,"Sun May 4, 2014 | 8:00am EDT",DEALTALK-Big Pharma stands to profit by cleaning out its medicine chests,http://www.reuters.com//article/pharmaceuticals-sales-idUSL2N0NO02R20140504?type=companyNews
101,"   By Ransdell Pierson and Bill Berkrot  Merck & Co (MRK.N) Chief Executive Kenneth Frazier said he does not expect a wave of giant mergers in the drug industry despite a spate of recent activity, adding that Merck will seek out promising medicines rather than lower taxes in any future deals.""I don't see an arms race"" in the industry ""although different companies are sizing up their own (drug) portfolios and growth prospects and some feel they will be enhanced through combinations,"" Frazier said in a telephone interview after a company meeting with investors in Boston.Earlier on Tuesday Merck announced the sale of its own array of consumer care products to Germany's Bayer AG (BAYGn.DE) for $14.2 billion.Sale of the products, including brands such as Coppertone sunscreen, MiraLAX laxative and Claritin allergy pills, will allow Merck to focus on its more-lucrative prescription drugs business.Frazier is no stranger to mega-mergers, having been head of Merck's pharmaceuticals operations when the company paid $41 billion in 2009 to buy U.S. rival Schering-Plough Corp. He became CEO of Merck in 2011. The industry's merger pace had fallen off until recent weeks, when a series of large deals and takeover attempts emerged, highlighted by Pfizer Inc's (PFE.N) now-$106 billion unsolicited bid for British drugmaker AstraZeneca Plc (AZN.L).Pfizer aims to buy AstraZeneca and domicile the combined company in the United Kingdom to take advantage of lower corporate tax rates, a growing trend called tax inversions.Frazier said his company was not interested in such financial engineering. ""Tax inversions clearly have value, but what motivates us is to bring medically important products to patients,"" he said. Adam Schechter, Merck's head of global human health who oversaw the integration of Schering-Plough, does not expect Merck to enter into another major acquisition in the foreseeable future, although that may be wishful thinking on his part.""It takes a lot of effort and energy to try to pull two big companies together. Having done it once, it's not something you look forward to doing ever again,"" he said. ""We realize that we have to pay attention to things that are going on around us and take notice. We would be interested in looking at bolt-ons,"" he said, referring to smaller acquisitions.Asked about reports that Merck was considering selling its portfolio of older branded drugs no longer under patent protection, Schechter said those so-called diversified products were vital to Merck's growth in emerging markets, where there tends to be a preference for known brands over generics.""It's also a part of manufacturing and how we have our facilities organized, so it's not easy to think of a way just to pull that out,"" he said.Merck believes developing markets, with their burgeoning middle classes, will continue to be an important growth driver for the number two U.S. drugmaker, he said.(Reporting by Ransdell Pierson; Editing by Ken Wills)",2014-05-06,MRK,"Tue May 6, 2014 | 5:58pm EDT",Merck executives say not tempted by merger mania,http://www.reuters.com//article/us-merck-mergers-idUSBREA450ZE20140506?type=companyNews
102,"  (Adds Ardian, Liberty Interactive, Casa Saba, AstraZeneca, Alitalia, B/E Aerospace, Commerzbank, BMW, Wendel, Albania, updates Bayer)May 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:** Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry.** Endurance Specialty Holdings Ltd is considering increasing its offer to acquire rival reinsurer Aspen Insurance Holdings Ltd to around $50 per share, or roughly $3.26 billion, people familiar with the matter said.** John Malone's Liberty Interactive Corp filed with regulators to spin off its stake in travel website TripAdvisor Inc and ownership of online retailer BuySeasons into a separate company valued at about $3 billion.** French investment group Wendel on Tuesday said it planned to sell a 4.3 percent stake in Saint-Gobain , Europe's biggest supplier of construction materials, for about 1 billion euros ($1.39 billion), through an accelerated bookbuilding process.** Private equity firm Warburg Pincus LLC is exploring a sale of New Breed Logistics Inc in a deal that could value the supply chain management company at more than $1 billion, according to people familiar with the matter.** Mexican company Grupo Casa Saba said on Tuesday it had agreed the sale of its pharmacy retail business to European retailer Alliance Boots for 8.3 billion Mexican pesos ($638.07 million).** Investment manager Pamplona Capital Management is to buy UK train leasing company Beacon Rail for around $450 million from a subsidiary of Japan's Mitsubishi UFJ Financial Group .** Bezeq Israel Telecom subsidiary Walla Communications agreed to sell its classified ads website Yad2 to Axel Springer Digital Classifieds for 788 million shekels ($228 million) in cash.** Chinese internet service provider Tencent Holdings  plans to acquire an 11.3 percent stake in digital mapping service provider Navinfo Co Ltd for 1.17 billion yuan ($187.3 million), Navinfo said late on Monday. ** U.S. group Lexmark International said on Tuesday it had made a 1.2 billion crown ($183 million) cash bid for Sweden's Readsoft that was unanimously recommended by the software company's board.** French President Francois Hollande said General Electric's bid for Alstom's energy business was not acceptable as it stands and that the government's aim was to get better offers.** German auto parts and tire maker Continental  would be able to shoulder another multi-billion euro acquisition in the next 18 months, finance chief Wolfgang Schaefer told Reuters.** German sportswear company Adidas is considering offers for its struggling Rockport shoe brand, its chief executive said on Tuesday. ** Corinthian Colleges Inc said it would explore strategic alternatives as student enrollments decline and the company faces potential legal action from U.S. regulators.** German utility MVV Energie and French group Semardel have formed a joint venture to manage energy-from-waste plants, eyeing a wave of contract renewals in France due in coming years.** Bouygues Telecom and Vivendi's SFR unit are both ready to make offers for French virtual mobile network operator Virgin Mobile, Les Echos newspaper reported on Tuesday.** Malaysian state asset manager Permodalan Nasional Bhd is considering a proposal to merge four of its portfolio companies to form Southeast Asia's second largest property firm by assets, a source with direct knowledge of the matter said.** One of Brazil's biggest sugar and ethanol groups Sao Martinho SA said on Monday that it signed a deal to acquire control of sugar and ethanol mill Santa Cruz SA from Luiz Ometto Partcipacoes SA and other stake holders.** European private equity firm Ardian is selling its 22 percent stake in French caterer Newrest to Newrest's management, Ardian said on Tuesday.** AstraZeneca Plc laid out its defence against Pfizer Inc's $106-billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop. ** Gulf carrier Etihad has restarted talks to take a stake in Alitalia but would invest in the loss-making Italian airline only if its strict conditions are met, a source close to the matter said on Tuesday.** European planemaker Airbus is not interested in the potential sale of all or part of seating supplier and parts distributor B/E Aerospace, two people familiar with the matter said.Also, B/E Aerospace, which made a surprise announcement of reviewing strategic alternatives on Sunday, is actively engaging in early stage conversations with potential buyers but is not in advanced talks with any company, according to people familiar with the matter.** Commerzbank AG has attracted five final bids for a multi-billion-euro portfolio of Spanish property loans, being sold as it takes advantage of a recovery in the country's real estate market to help clean up its finances, sources said.** BMW said on Tuesday legal barriers prevented the German luxury auto maker from raising its stake in a Chinese joint venture company, even as rival Daimler appeared to have found a loophole to soften strict ownership rules.** A fund run by billionaire investor John Paulson has acquired minority stakes in a bank and a water company in Greece, adding to evidence the country was attracting international investors back after a deep six-year slump.** Albania plans to auction off 13 oil exploration blocks, including one offshore, to oil majors and other foreign companies after a significant discovery has attracted strong interest, a government minister said.** Financial markets post-trade services providers the Depository Trust & Clearing Corporation (DTCC) and Euroclear have proposed a joint venture that will simplify the settlement of trades and ease access to collateral, the two companies said on Tuesday.** Two members of the board of Mexico's national oil company Pemex said on Tuesday the company has yet to make a decision about whether or not to sell its 9.3 percent stake in Spain's Repsol.($1 = 3.46 Israeli shekels)  ($1 = 6.55 Swedish crowns)  ($1 = 6.25 Chinese yuan)  ($1 = 0.7177 Euros)   (Compiled by Avik Das and Ankit Ajmera in Bangalore)",2014-05-06,MRK,"Tue May 6, 2014 | 3:48pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0NS1Z420140506?type=companyNews
103,"  (The following statement was released by the rating agency) NEW YORK, May 06 (Fitch) The sale of Merck's consumer products business will  increase the company's focus on its core mission of developing and marketing  innovative medicines, according to Fitch Ratings. German-based Bayer AG Tuesday  said it planned to buy Merck's consumer health unit for $14.2 billion. The transaction is consistent with Fitch's expectation that a number of major  pharmaceutical companies will continue to consider divestitures of businesses  that are not core to a business model focused on biomedical innovation. This is  particularly relevant to firms such as Merck who have strengthened product  pipelines that are expected to support long-term growth. The consumer business only accounts for approximately 4% of Merck's total sales,  and Fitch estimates the segment's EBITDA margin is less than that of the  pharmaceutical business and the total firm. Nevertheless, the incremental loss  of diversification and EBITDA would be marginally negative for Merck's credit  profile. We view the $14.2 billion cash sale as incrementally negative for the  company's credit profile, with the expectation that the proceeds of the sales  would not be used for debt reduction, but rather to fund payments to  shareholders and business development activities, including acquisitions. While the transaction will significantly increase liquidity, the relatively  modest estimated loss of EBITDA will further stress gross debt leverage of  1.65x, which is currently high for the company's current 'A+' credit rating.  Fitch looks for Merck to maintain adequate liquidity through strong FCF  generation and ample access to the credit markets. FCF for the LTM ending Dec.  31, 2013, was $8.35 billion. At the end of the period, Merck had approximately  $17.5 billion in cash plus short-term investments and full availability on its  $4 billion revolver maturing in May 2017.  At Dec. 31, 2013, Merck had roughly $24.6 billion in debt outstanding, with $4.7  billion maturing in 2014, $2 billion in 2015, $2.3 billion in 2016 and $1  billion in 2017. Fitch expects near- to midterm maturities will be satisfied  primarily through refinancing in the public debt markets. Fitch rates Merck 'A+' with a Negative Rating Outlook, and a downgrade of the  ratings could stem from total debt leverage remaining above 1.5x in the  intermediate term. The high leverage could be driven by incremental borrowing to  fund acquisitions or share repurchases; although incremental liquidity provided  by the cash proceeds from the sale of the consumer health business mitigates  this concern in the near term. Leverage pressure could also result from  operational weakness due to an inability to achieve cost-containment targets or  by generating sales growth despite an improving patent risk profile and an  expanding late-stage pipeline.  Contact:  Robert Kirby, CFA Director Corporates +1 312 368-3147 Fitch Ratings, Inc. 70 W. Madison  Chicago, IL  Megan Neuburger Senior Director U.S. Corporates +1 212 908-0501   Kellie Geressy-Nilsen Senior Director Fitch Wire +1 212 908-9123 33 Whitehall St. New York, NY  Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. The above article originally appeared as a post on the Fitch Wire credit market  commentary page. The original article can be accessed at www.fitchratings.com.  All opinions expressed are those of Fitch Ratings. ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-05-06,MRK,"Tue May 6, 2014 | 2:45pm EDT",Fitch: Merck Consumer Business Sale Improves Its Core Focus,http://www.reuters.com//article/fitch-merck-consumer-business-sale-impro-idUSFit69955920140506?type=companyNews
104,"   By Ludwig Burger | FRANKFURT  FRANKFURT Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry.""This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business,"" Bayer's chief executive, Marijn Dekkers,  said in a statement on Tuesday.Merck, which is selling non-prescription brands such as the MiraLAX laxative and Afrin cold remedy, said it expects after-tax proceeds of between $8 billion and $9 billion from the sale, which is expected to close in the second half of 2014.[ID:nBw7dblqda]The transaction, the largest in the German healthcare industry since Bayer bought rival Schering for 17 billion euros ($24 billion) in 2006, will make Bayer the world's second-biggest consumer healthcare company, as it seeks to make better use of its distribution network and sales force.""We can take these products and market them more forcefully than Merck has been able to do so far,"" Dekkers said in a conference call with analysts.    Bayer, the inventor of aspirin and maker of Bepanthen skin care products and Canesten antifungal creams, has repeatedly said it wants to take the top spot in the rankings.Drug makers have embarked on a major reshuffling of their business portfolios. Novartis and GlaxoSmithKline (GSK) last month agreed to trade more than $20 billion worth of assets, while AstraZeneca is fighting off a $106 billion takeover approach from Pfizer.Meanwhile companies including France's Sanofi, Merck & Co and Abbott are looking at selling off mature drugs that have lost patent protection.OTC drugs units carry far lower margins than prescription drugs businesses but many drug majors regard them as attractive complements due to the stable stream of cash they can generate. They akso require less spending on research and development and can be less exposed to the loss of patent protection where consumers remain loyal to a brand even when cheap copies become available. But Reckitt Benckiser Group, one of the final contenders in Merck's auction, said on April 30 it was no longer in active talks to buy the Merck business, leaving Bayer in pole position.Bayer also edged out other rival bidders, including Procter & Gamble Co, Boehringer Ingelheim, Novartis and Sanofi , people familiar with the matter have said. J&J commands about 4 percent of the consumer health market - worth nearly $200 billion at the retail level.Merck & Co has around 1 percent with brands including Dr Scholl foot care, Coppertone sunscreen and Claritin allergy medicine.    The fragmented OTC industry is consolidating fast. Novartis and GSK will form a joint venture in consumer healthcare as part of their agreement last month.That deal is set to elevate the combined group, with $9.5 billion in sales, to the top of the global consumer health ranking, overtaking Johnson & Johnson and Bayer.But Bayer said the Merck deal will put it back on the second rung, with $7.4 billion in combined sales. J&J's consumer unit has $14.7 billion but market observers exclude many of its products, such as Listerine mouth wash, from their analysis of the OTC market.With Bayer paying 6.5 times 2013 revenue and 21 times earnings before interest, taxes, depreciation and amortisation (EBITDA), analysts at Deutsche Bank said the price tag may seem ""eye-watering"" at first sight.""The deal works both strategically and financially, and creates value (albeit to a modest degree),"" the analysts said, adding it reduces volatility in the Bayer business and provides a predictable cash flow.Bayer's enlarged consumer care unit will account for about 13 percent of group sales, up from 10 percent now.Bayer's shares closed 0.9 percent lower at 99.07 euros, while the STOXX Europe 600 health care index slipped 0.4 percent. Reuters first reported last month that Bayer and Reckitt had  emerged as frontrunners in the auction with each initially offering roughly $13.5 billion. In addition, Bayer agreed to sell to Merck some rights to its Adempas drug against high blood pressure in the lung and other experimental cardiovascular drugs, saying it needed a marketing partner.As part of that alliance, Merck will pay up to $2.1 billion, including $1.1 billion in milestone payments contingent on development achievements.Bayer said it plans to finance the OTC acquisition with a bridge loan facility provided by Bank of America Merrill Lynch, BNP Paribas and Mizuho, which will be syndicated to a larger group of banks. It added no asset sales were needed to preserve its credit rating of ""A-"". (Additional reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila and Greg Mahlich)",2014-05-06,MRK,"Tue May 6, 2014 | 1:48pm EDT",Bayer wins Merck & Co's $14 bln consumer unit auction,http://www.reuters.com//article/us-merck-co-bayer-idUSKBN0DM0O120140506?type=companyNews
105,"   By Ludwig Burger | FRANKFURT  FRANKFURT Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry.""This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business,"" Bayer's chief executive, Marijn Dekkers, said in a statement on Tuesday.Merck, which is selling non-prescription brands such as the MiraLAX laxative and Afrin cold remedy, said it expects after-tax proceeds of between $8 billion and $9 billion from the sale, which is expected to close in the second half of 2014.The transaction, the largest in the German healthcare industry since Bayer bought rival Schering for 17 billion euros ($24 billion) in 2006, will make Bayer the world's second-biggest consumer healthcare company, as it seeks to make better use of its distribution network and sales force.""We can take these products and market them more forcefully than Merck has been able to do so far,"" Dekkers said in a conference call with analysts.Bayer, the inventor of aspirin and maker of Bepanthen skin care products and Canesten antifungal creams, has repeatedly said it wants to take the top spot in the rankings.Drug makers have embarked on a major reshuffling of their business portfolios. Novartis and GlaxoSmithKline (GSK) last month agreed to trade more than $20 billion worth of assets, while AstraZeneca is fighting off a $106 billion takeover approach from Pfizer.Meanwhile companies including France's Sanofi, Merck & Co and Abbott are looking at selling off mature drugs that have lost patent protection.OTC drugs units carry far lower margins than prescription drugs businesses but many drug majors regard them as attractive complements due to the stable stream of cash they can generate.They akso require less spending on research and development and can be less exposed to the loss of patent protection where consumers remain loyal to a brand even when cheap copies become available. But Reckitt Benckiser Group, one of the final contenders in Merck's auction, said on April 30 it was no longer in active talks to buy the Merck business, leaving Bayer in pole position.Bayer also edged out other rival bidders, including Procter & Gamble Co, Boehringer Ingelheim, Novartis and Sanofi , people familiar with the matter have said.J&J commands about 4 percent of the consumer health market - worth nearly $200 billion at the retail level.Merck & Co has around 1 percent with brands including Dr Scholl foot care, Coppertone sunscreen and Claritin allergy medicine.The fragmented OTC industry is consolidating fast. Novartis and GSK will form a joint venture in consumer healthcare as part of their agreement last month. That deal is set to elevate the combined group, with $9.5 billion in sales, to the top of the global consumer health ranking, overtaking Johnson & Johnson and Bayer.But Bayer said the Merck deal will put it back on the second rung, with $7.4 billion in combined sales.J&J's consumer unit has $14.7 billion but market observers exclude many of its products, such as Listerine mouth wash, from their analysis of the OTC market.With Bayer paying 6.5 times 2013 revenue and 21 times earnings before interest, taxes, depreciation and amortization (EBITDA), analysts at Deutsche Bank said the price tag may seem ""eye-watering"" at first sight.""The deal works both strategically and financially, and creates value (albeit to a modest degree),"" the analysts said, adding it reduces volatility in the Bayer business and provides a predictable cash flow. Bayer's enlarged consumer care unit will account for about 13 percent of group sales, up from 10 percent now.Bayer's shares closed 0.9 percent lower at 99.07 euros, while the STOXX Europe 600 health care index slipped 0.4 percent.Reuters first reported last month that Bayer and Reckitt hademerged as frontrunners in the auction with each initially offering roughly $13.5 billion.In addition, Bayer agreed to sell to Merck some rights to its Adempas drug against high blood pressure in the lung and other experimental cardiovascular drugs, saying it needed a marketing partner.As part of that alliance, Merck will pay up to $2.1 billion, including $1.1 billion in milestone payments contingent on development achievements.Bayer said it plans to finance the OTC acquisition with a bridge loan facility provided by Bank of America Merrill Lynch, BNP Paribas and Mizuho, which will be syndicated to a larger group of banks.It added no asset sales were needed to preserve its credit rating of ""A-"".(Additional reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila and Greg Mahlich)",2014-05-06,MRK,"Tue May 6, 2014 | 1:10pm EDT",Bayer wins Merck & Co's $14 billion consumer unit auction,http://www.reuters.com//article/us-merck-co-bayer-idUSBREA450BL20140506?type=companyNews
106,"  * Bayer to become OTC drug market's second biggest operator* Merck expects after-tax proceeds of between $8-$9 bln* Largest German healthcare deal since Schering takeover* Bayer sells some rights to lung drug for up to $2.1 bln   (Adds details on industry ranking, shares, comment by analyst)By Ludwig BurgerFRANKFURT, May 6 Germany's Bayer AG  has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare industry.""This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business,"" Bayer's chief executive, Marijn Dekkers,  said in a statement on Tuesday.Merck, which is selling non-prescription brands such as the MiraLAX laxative and Afrin cold remedy, said it expects after-tax proceeds of between $8 billion and $9 billion from the sale, which is expected to close in the second half of 2014.The transaction, the largest in the German healthcare industry since Bayer bought rival Schering for 17 billion euros ($24 billion) in 2006, will make Bayer the world's second-biggest consumer healthcare company, as it seeks to make better use of its distribution network and sales force.""We can take these products and market them more forcefully than Merck has been able to do so far,"" Dekkers said in a conference call with analysts.Bayer, the inventor of aspirin and maker of Bepanthen skin care products and Canesten antifungal creams, has repeatedly said it wants to take the top spot in the rankings. Drug makers have embarked on a major reshuffling of their business portfolios. Novartis and GlaxoSmithKline (GSK) last month agreed to trade more than $20 billion worth of assets, while AstraZeneca is fighting off a $106 billion takeover approach from Pfizer.Meanwhile companies including France's Sanofi, Merck & Co and Abbott are looking at selling off mature drugs that have lost patent protection.OTC drugs units carry far lower margins than prescription drugs businesses but many drug majors regard them as attractive complements due to the stable stream of cash they can generate.They akso require less spending on research and development and can be less exposed to the loss of patent protection where consumers remain loyal to a brand even when cheap copies become available.But Reckitt Benckiser Group, one of the final contenders in Merck's auction, said on April 30 it was no longer in active talks to buy the Merck business, leaving Bayer in pole position.Bayer also edged out other rival bidders, including Procter & Gamble Co, Boehringer Ingelheim, Novartis and Sanofi , people familiar with the matter have said. J&J commands about 4 percent of the consumer health market - worth nearly $200 billion at the retail level.Merck & Co has around 1 percent with brands including Dr Scholl foot care, Coppertone sunscreen and Claritin allergy medicine.The fragmented OTC industry is consolidating fast. Novartis and GSK will form a joint venture in consumer healthcare as part of their agreement last month.That deal is set to elevate the combined group, with $9.5 billion in sales, to the top of the global consumer health ranking, overtaking Johnson & Johnson and Bayer.But Bayer said the Merck deal will put it back on the second rung, with $7.4 billion in combined sales. J&J's consumer unit has $14.7 billion but market observers exclude many of its products, such as Listerine mouth wash, from their analysis of the OTC market.With Bayer paying 6.5 times 2013 revenue and 21 times earnings before interest, taxes, depreciation and amortisation (EBITDA), analysts at Deutsche Bank said the price tag may seem ""eye-watering"" at first sight.""The deal works both strategically and financially, and creates value (albeit to a modest degree),"" the analysts said, adding it reduces volatility in the Bayer business and provides a predictable cash flow.Bayer's enlarged consumer care unit will account for about 13 percent of group sales, up from 10 percent now.Bayer's shares closed 0.9 percent lower at 99.07 euros, while the STOXX Europe 600 health care index slipped 0.4 percent.Reuters first reported last month that Bayer and Reckitt had  emerged as frontrunners in the auction with each initially offering roughly $13.5 billion.In addition, Bayer agreed to sell to Merck some rights to its Adempas drug against high blood pressure in the lung and other experimental cardiovascular drugs, saying it needed a marketing partner.As part of that alliance, Merck will pay up to $2.1 billion, including $1.1 billion in milestone payments contingent on development achievements.Bayer said it plans to finance the OTC acquisition with a bridge loan facility provided by Bank of America Merrill Lynch , BNP Paribas and Mizuho, which will be syndicated to a larger group of banks.It added no asset sales were needed to preserve its credit rating of ""A-"".  ($1=0.7177 euros)   (Additional reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila and Greg Mahlich)",2014-05-06,MRK,"Tue May 6, 2014 | 1:09pm EDT",UPDATE 3-Bayer wins Merck & Co's $14 bln consumer unit auction,http://www.reuters.com//article/merck-co-bayer-idUSL3N0NS25F20140506?type=companyNews
107,"  May 6 Merck & Co Inc :  * CEO says would be interested in buying animal health brands if they are""right products at the right price""  * Research chief says benefits of experimental odanacatib osteoporosis drug outweigh potential risks  * Says mk-3475 melanoma drug has potential against 30 tumor types  * Says global cancer sales now $76 billion, could grow to $120 billon by 2020  * Says still committed to anacetrapib drug to raise ""good"" hdl cholesterol, and to bace inhibitor drug for alzheimer's disease  * CEO says company's animal health business has global scale, unlike its consumer healthcare business being sold to Bayer",2014-05-06,MRK,"Tue May 6, 2014 | 12:56pm EDT",BRIEF-Merck CEO says would be interested in buying animal health brands at right price,http://www.reuters.com//article/merck-brief-idUSWEN00D8220140506?type=companyNews
108,"   By Ransdell Pierson  Merck & Co said on Tuesday it plans to seek marketing approvals this year for an osteoporosis drug and a product to reverse the effects of anesthesia that have long been delayed by safety concerns.The No. 2 U.S. drugmaker will seek approval in the second half of the year for odanacatib, its experimental treatment for osteoporosis in postmenopausal women, and will seek approval in 2014 for sugammadex, meant to reverse the effects of muscle relaxants after surgery.Merck shares were down 2 percent at $57.50 in morning trading on the New York Stock Exchange.The company is counting on odanacatib, sugammadex and other experimental drugs, including promising treatments for hepatitis C and cancer, to boost its earnings growth following generic competition for its Singulair asthma treatment and other brands.But Merck research chief, Roger Perlmutter, in a company meeting with investors in Boston to review research projects, said a numerically higher incidence of stroke and atrial fibrillation - a type of irregular heartbeat most common in the elderly - was seen in patients taking odanacatib than those taking placebos in studies. Perlmutter also said a type of skin thickening and itching called morphea was seen in 0.2 percent of patients taking odanacatib. He said 0.1 percent of patients had fractures in the shaft of the femur, or thigh bone, a greater incidence than seen in the placebo group.ISI Group analyst Mark Schoenebaum said the half-day Merck research meeting had been relatively uneventful, except for news that Merck would seek approval this year for odanacatib. ""That's an upside surprise,"" he said in a research note. ""But the news was tempered perhaps by their disclosure that there was a numerical imbalance in atrial fibrillation and stroke"" and there were skin issues.Analysts at Cowen and Co have predicted that odanacatib, if approved, could reap Merck annual sales of $1 billion by 2020. Odanacatib works through a new mechanism of action, by blocking a protein called cathespin K, and would compete with widely used older drugs called bisphosphonates that include Merck's own Fosamax.Bisphosphonates, leading treatments for osteoporosis, have raised concern because of rare cases of disintegration of jaw bone as well as femur fractures. Merck said the jaw condition had not been seen with odanacatib. Merck last year said it was delaying its application for odanacatib because it needed additional data from a clinical trial.As for sugammadex, the FDA declined to approve the injectable product in 2008, citing concerns about its possible association with allergic reactions and bleeding. Sugammadex has already been approved in more than 50 countries, where it is sold under the brand name Bridion. It generated worldwide sales of $73 million in the first quarter. But analysts believe the medicine, if approved in the United States, could generate annual sales of $500 million or more. Earlier on Tuesday, Merck said it would sell its consumer healthcare business for $14.2 billion to Germany's Bayer AG, adding to a string of major cross-border deals in the healthcare industry.Merck's consumer brands include Dr Scholl foot care, Coppertone sunscreen and its Claritin allergy medicine. They were acquired from Merck's 2009 purchase of U.S. drugmaker Schering-Plough.In addition, Bayer agreed to sell to Merck some rights to its Adempas drug against high blood pressure in the lung, and other experimental cardiovascular drugs, saying it needed a marketing partner.As part of that alliance, Merck will pay up to $2.1 billion, including $1.1 billion in milestone payments contingent on development achievements.Merck said it is selling off the consumer products to increase its focus on developing more-lucrative prescription drugs. (Editing by Bernadette Baum)",2014-05-06,MRK,"Tue May 6, 2014 | 11:27am EDT","Merck to seek approval of osteoporosis drug, cites safety risks",http://www.reuters.com//article/us-merck-research-idUSKBN0DM14K20140506?type=companyNews
109,"   By Ransdell Pierson  May 6 Merck & Co said on Tuesday it plans to seek marketing approvals this year for an osteoporosis drug and a product to reverse the effects of anesthesia that have long been delayed by safety concerns.The No. 2 U.S. drugmaker will seek approval in the second half of the year for odanacatib, its experimental treatment for osteoporosis in postmenopausal women, and will seek approval in 2014 for sugammadex, meant to reverse the effects of muscle relaxants after surgery.Merck shares were down 2 percent at $57.50 in morning trading on the New York Stock Exchange.The company is counting on odanacatib, sugammadex and other experimental drugs, including promising treatments for hepatitis C and cancer, to boost its earnings growth following generic competition for its Singulair asthma treatment and other brands.But Merck research chief, Roger Perlmutter, in a company meeting with investors in Boston to review research projects, said a numerically higher incidence of stroke and atrial fibrillation - a type of irregular heartbeat most common in the elderly - was seen in patients taking odanacatib than those taking placebos in studies.Perlmutter also said a type of skin thickening and itching called morphea was seen in 0.2 percent of patients taking odanacatib. He said 0.1 percent of patients had fractures in the shaft of the femur, or thigh bone, a greater incidence than seen in the placebo group. ISI Group analyst Mark Schoenebaum said the half-day Merck research meeting had been relatively uneventful, except for news that Merck would seek approval this year for odanacatib.""That's an upside surprise,"" he said in a research note. ""But the news was tempered perhaps by their disclosure that there was a numerical imbalance in atrial fibrillation and stroke"" and there were skin issues.Analysts at Cowen and Co have predicted that odanacatib, if approved, could reap Merck annual sales of $1 billion by 2020.Odanacatib works through a new mechanism of action, by blocking a protein called cathespin K, and would compete with widely used older drugs called bisphosphonates that include Merck's own Fosamax. Bisphosphonates, leading treatments for osteoporosis, have raised concern because of rare cases of disintegration of jaw bone as well as femur fractures. Merck said the jaw condition had not been seen with odanacatib.Merck last year said it was delaying its application for odanacatib because it needed additional data from a clinical trial.As for sugammadex, the FDA declined to approve the injectable product in 2008, citing concerns about its possible association with allergic reactions and bleeding. Sugammadex has already been approved in more than 50 countries, where it is sold under the brand name Bridion. It generated worldwide sales of $73 million in the first quarter. But analysts believe the medicine, if approved in the United States, could generate annual sales of $500 million or more.Earlier on Tuesday, Merck said it would sell its consumer healthcare business for $14.2 billion to Germany's Bayer AG , adding to a string of major cross-border deals in the healthcare industry.Merck's consumer brands include Dr Scholl foot care, Coppertone sunscreen and its Claritin allergy medicine. They were acquired from Merck's 2009 purchase of U.S. drugmaker Schering-Plough.In addition, Bayer agreed to sell to Merck some rights to its Adempas drug against high blood pressure in the lung, and other experimental cardiovascular drugs, saying it needed a marketing partner.As part of that alliance, Merck will pay up to $2.1 billion, including $1.1 billion in milestone payments contingent on development achievements.Merck said it is selling off the consumer products to increase its focus on developing more-lucrative prescription drugs.   (Editing by Bernadette Baum)",2014-05-06,MRK,"Tue May 6, 2014 | 11:19am EDT","Merck to seek approval of osteoporosis drug, cites safety risks",http://www.reuters.com//article/merck-research-idUSL2N0NS0U520140506?type=companyNews
110,"  FRANKFURT Bayer said it was looking for opportunities to expand its in animal health unit, even after it agreed to buy Merck & Co's non-prescription drugs business for $14.2 billion.""We have a good animal health business and we would like to get bigger and stronger,"" Chief Executive Marijn Dekkers told analysts in a conference call on Tuesday. ""There are things happening in the animal health market that we are closely observing."" Novartis last month sold its animal health unit to Eli Lilly for $5.4 billion. Sources have said that Bayer had been among the suitors for the unit. (Reporting by Ludwig Burger)",2014-05-06,MRK,"Tue May 6, 2014 | 8:31am EDT",Bayer says looking for opportunities to grow animal health unit,http://www.reuters.com//article/us-merckco-bayer-animal-health-idUSBREA450GS20140506?type=companyNews
111,"  * AstraZeneca forecasts show variables in drug modelling* $45 bln sales prediction widely seen as over-optimisticBy Ben HirschlerLONDON, May 7 Ten-year sales forecasts from AstraZeneca - a central plank of its defence against a $106 billion bid approach from Pfizer - underscore how valuing drugs is an art as well as a science.While imponderables exist in any corporate valuation, pharmaceuticals are especially tricky, given the hazards of drug development and the long timelines of an industry where it typically takes 10 to 15 years to bring a new product to market.AstraZeneca's prediction of sales above $45 billion by 2023 was widely seen as over-optimistic by industry analysts who have a more conservative view on many of the myriad factors that feed into modelling future drug sales.One thing is certain: most experimental drugs fail.The average new drug has just a 6 percent chance of making it to market when it enters initial Phase I testing in humans, according to Thomson Reuters CMR International, which specialises in measuring pharmaceutical R&D performance.This rises to 69 percent by the time a new medicine reaches final Phase III clinical trials, and 90 percent once it is submitted for regulatory approval.""There will be things in our pipeline that won't work - that's par for the course,"" Briggs Morrison, AstraZeneca's global head of medicines development, said on Wednesday.Nonetheless, Morrison, who worked for Pfizer until 2012, believes his colleagues at AstraZeneca have honed the art of predicting future sales by blending the factors behind a new drug's commercial success. The first pass involves evaluating the technical aspects of whether a medicine actually works, followed by judging whether wary regulators are likely to give it a green light, and then finally assessing its likely market share and pricing.Given the many variables and the risk of over-promising and under-delivering, most drug companies prefer not to make long-term sales forecasts in normal times.But these are not normal times for AstraZeneca, and it hopes that by sharing key parts of its internal Long Range Plan, prepared for the board each year, it can prove it is worth a lot more than the 50 pounds per share offered by Pfizer. MOLECULAR ROULETTE For investors, pharmaceutical investment remains to a large degree a game of molecular roulette.Skimming through a 44-slide presentation on the new forecasts this week, AstraZeneca Chief Executive Pascal Soriot acknowledged the uncertainties but argued his group had one of the most compelling and visible pipelines in the industry.He compared his forecasts to those made by Genentech before it was acquired by Roche in 2009. In that case, the numbers were achieved, but the sales did not all come from the expected products.Overall, AstraZeneca believes its drug pipeline has a 36 percent chance of success, with potential peak annual sales of $63 billion translating to $23 billion on a risk-adjusted basis. But the success rate varies hugely from product to product.Alzheimer's drug AZD3293, which is about to enter Phase III testing and could in theory have annual sales of $5 billion, has a mere 9 percent probability of success, while the Phase III inhaled lung drug PT003 has a better than two-thirds chance.Competitors, too, can skew prospects. AstraZeneca's benralizumab for severe asthma, for example, faces a rival biotech drug from GlaxoSmithKline, and clinical trials for both will ultimately determine if it is a hit or a miss.Pricing is another major uncertainty, especially in specialty medicines where prices have gone through the roof in recent years, sparking a backlash in areas like hepatitis C.Morrison said AstraZeneca's forecasts assumed more pricing pressure over time, but he acknowledged there was a risk.""It's a problem - let's be candid,"" he said. ""You need creative ways of pricing that society will feel offer fair value.""That is relevant in the hot field of cancer medicine, where AstraZeneca is chasing Bristol-Myers Squibb, Merck & Co  and Roche in the emerging field of immuno-oncology, which involves using drugs to boost the body's immune system.AstraZeneca said it broadly agreed with forecasts that immuno-oncology could be a $28-35 billion a year market - but those numbers assume no dislocation in the current market that prices some cancer drugs at more than $100,000 per patient.Overall, AstraZeneca expects the pipeline to make up a third of sales by 2023, with the balance coming from existing drugs, where market expectations are more solid but still far from certain.The company's 2023 forecast for sales of $3.5 billion of heart drug Brilinta, for example, is far higher than the $1.3 billion consensus forecast for 2018 sales - a big gap that leaves many analysts scratching their heads.   (Editing by Will Waterman)",2014-05-07,MRK,"Wed May 7, 2014 | 11:54am EDT","In AstraZeneca fight, valuing drugs as much art as science",http://www.reuters.com//article/astrazeneca-pfizer-valuation-idUSL6N0NT3E820140507?type=companyNews
112,"  U.S. health regulators on Thursday approved a blood clot preventer developed by Merck & Co for use by patients who have had a heart attack or who suffer from blockages in the arteries of the legs.The drug, vorapaxar, was approved to reduce the risk of heart attacks, stroke, cardiovascular death and the need for procedures to improve blood flow to the heart, the Food and Drug Administration said.Merck will sell the new medicine under the brand name Zontivity.The approval follows a recommendation for its use by an FDA advisory panel that voted 10-1 in favor of the drug in January. The approval had been delayed over safety concerns due to serious and sometimes fatal bleeding in patients who were given the drug in clinical trials.Zontivity is not approved for use in patients who have suffered a stroke, as those patients were found to be at particularly high risk of dangerous bleeding. ""In patients who have had a heart attack or who have peripheral arterial disease, this drug will lower the risk of heart attack, stroke, and cardiovascular death,"" Ellis Unger, director of the Office of Drug Evaluation I in the FDA's Center for Drug Evaluation and Research, said in a statement.Zontivity works by preventing platelets in the blood from clumping together and forming clots in the arteries, which can lead to heart attacks and strokes. Each year about 190,000 Americans have a second heart-related event, according to Merck. Zontivity is expected to be used in addition to standard therapy given to prevent a second heart attack - typically aspirin and the clot preventer Plavix. (Reporting by Bill Berkrot; Editing by Mohammad Zargham)",2014-05-08,MRK,"Thu May 8, 2014 | 6:29pm EDT",U.S. FDA approves Merck blood clot preventer,http://www.reuters.com//article/us-merck-fda-idUSKBN0DO1OF20140508?type=companyNews
113,"  May 8 U.S. health regulators on Thursday approved a blood clot preventer developed by Merck & Co  for use by patients who have had a heart attack or who suffer from blockages in the arteries of the legs.The drug, vorapaxar, was approved to reduce the risk of heart attacks, stroke, cardiovascular death and the need for procedures to improve blood flow to the heart, the Food and Drug Administration said.Merck will sell the new medicine under the brand name Zontivity.The approval follows a recommendation for its use by an FDA advisory panel that voted 10-1 in favor of the drug in January. The approval had been delayed over safety concerns due to serious and sometimes fatal bleeding in patients who were given the drug in clinical trials. Zontivity is not approved for use in patients who have suffered a stroke, as those patients were found to be at particularly high risk of dangerous bleeding.""In patients who have had a heart attack or who have peripheral arterial disease, this drug will lower the risk of heart attack, stroke, and cardiovascular death,"" Ellis Unger, director of the Office of Drug Evaluation I in the FDA's Center for Drug Evaluation and Research, said in a statement. Zontivity works by preventing platelets in the blood from clumping together and forming clots in the arteries, which can lead to heart attacks and strokes.Each year about 190,000 Americans have a second heart-related event, according to Merck. Zontivity is expected to be used in addition to standard therapy given to prevent a second heart attack - typically aspirin and the clot preventer Plavix.   (Reporting by Bill Berkrot; Editing by Mohammad Zargham)",2014-05-08,MRK,"Thu May 8, 2014 | 6:25pm EDT",U.S. FDA approves Merck blood clot preventer,http://www.reuters.com//article/merck-fda-idUSL2N0NU2II20140508?type=companyNews
114,"  FRANKFURT May 8 German chemicals and pharmaceuticals company Merck on Thursday said it would seek to delist AZ Electronic Materials, after securing control over 97.85 percent of the company. Merck, the world's largest maker of liquid crystals used in TVs and tablet and smartphone screens, agreed in December to buy AZ for $2.6 billion to expand its range of specialist chemicals for hi-tech gadgets.    (Reporting by Frank Siebelt, writing by Edward Taylor; editing by Jane Baird)  ",2014-05-08,MRK,"Thu May 8, 2014 | 2:12pm EDT",Merck KGaA to delist AZ Electronic Materials,http://www.reuters.com//article/merck-az-electronic-mt-delisting-idUSL6N0NU6AZ20140508?type=companyNews
115,"  (Repeats Wednesday story with no changes)* AstraZeneca forecasts show variables in drug modelling* $45 bln sales prediction widely seen as over-optimisticBy Ben HirschlerLONDON, May 7 Ten-year sales forecasts from AstraZeneca - a central plank of its defence against a $106 billion bid approach from Pfizer - underscore how valuing drugs is an art as well as a science.While imponderables exist in any corporate valuation, pharmaceuticals are especially tricky, given the hazards of drug development and the long timelines of an industry where it typically takes 10 to 15 years to bring a new product to market.AstraZeneca's prediction of sales above $45 billion by 2023 was widely seen as over-optimistic by industry analysts who have a more conservative view on many of the myriad factors that feed into modelling future drug sales.One thing is certain: most experimental drugs fail.The average new drug has just a 6 percent chance of making it to market when it enters initial Phase I testing in humans, according to Thomson Reuters CMR International, which specialises in measuring pharmaceutical R&D performance.This rises to 69 percent by the time a new medicine reaches final Phase III clinical trials, and 90 percent once it is submitted for regulatory approval.""There will be things in our pipeline that won't work - that's par for the course,"" Briggs Morrison, AstraZeneca's global head of medicines development, said on Wednesday. Nonetheless, Morrison, who worked for Pfizer until 2012, believes his colleagues at AstraZeneca have honed the art of predicting future sales by blending the factors behind a new drug's commercial success.The first pass involves evaluating the technical aspects of whether a medicine actually works, followed by judging whether wary regulators are likely to give it a green light, and then finally assessing its likely market share and pricing.Given the many variables and the risk of over-promising and under-delivering, most drug companies prefer not to make long-term sales forecasts in normal times.But these are not normal times for AstraZeneca, and it hopes that by sharing key parts of its internal Long Range Plan, prepared for the board each year, it can prove it is worth a lot more than the 50 pounds per share offered by Pfizer. MOLECULAR ROULETTE For investors, pharmaceutical investment remains to a large degree a game of molecular roulette.Skimming through a 44-slide presentation on the new forecasts this week, AstraZeneca Chief Executive Pascal Soriot acknowledged the uncertainties but argued his group had one of the most compelling and visible pipelines in the industry.He compared his forecasts to those made by Genentech before it was acquired by Roche in 2009. In that case, the numbers were achieved, but the sales did not all come from the expected products.Overall, AstraZeneca believes its drug pipeline has a 36 percent chance of success, with potential peak annual sales of $63 billion translating to $23 billion on a risk-adjusted basis. But the success rate varies hugely from product to product.Alzheimer's drug AZD3293, which is about to enter Phase III testing and could in theory have annual sales of $5 billion, has a mere 9 percent probability of success, while the Phase III inhaled lung drug PT003 has a better than two-thirds chance.Competitors, too, can skew prospects. AstraZeneca's benralizumab for severe asthma, for example, faces a rival biotech drug from GlaxoSmithKline, and clinical trials for both will ultimately determine if it is a hit or a miss.Pricing is another major uncertainty, especially in specialty medicines where prices have gone through the roof in recent years, sparking a backlash in areas like hepatitis C.Morrison said AstraZeneca's forecasts assumed more pricing pressure over time, but he acknowledged there was a risk.""It's a problem - let's be candid,"" he said. ""You need creative ways of pricing that society will feel offer fair value.""That is relevant in the hot field of cancer medicine, where AstraZeneca is chasing Bristol-Myers Squibb, Merck & Co  and Roche in the emerging field of immuno-oncology, which involves using drugs to boost the body's immune system.AstraZeneca said it broadly agreed with forecasts that immuno-oncology could be a $28-35 billion a year market - but those numbers assume no dislocation in the current market that prices some cancer drugs at more than $100,000 per patient.Overall, AstraZeneca expects the pipeline to make up a third of sales by 2023, with the balance coming from existing drugs, where market expectations are more solid but still far from certain.The company's 2023 forecast for sales of $3.5 billion of heart drug Brilinta, for example, is far higher than the $1.3 billion consensus forecast for 2018 sales - a big gap that leaves many analysts scratching their heads.   (Editing by Will Waterman)",2014-05-08,MRK,"Thu May 8, 2014 | 1:30am EDT","RPT-In AstraZeneca fight, valuing drugs as much art as science",http://www.reuters.com//article/astrazeneca-pfizer-valuation-idUSL6N0NT61K20140508?type=companyNews
116,"   By Bill Berkrot  When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight. The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating  excitement among researchers and investors. At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades. Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.Brief summaries, or abstracts, of thousands of studies to be presented at the ASCO meeting were released on Wednesday. ""This area should represent a major advance in cancer therapy and patient survivability,"" said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. ""Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies."" The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers anti PD-1 drug nivolumab.Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years.Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy.In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose. Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab.MOST LIKELY TO BENEFIT  As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.Namouni said Bristol would focus on PD-L1 positive patients only in a large Phase III lung cancer trial of previously untreated subjects. Its Phase III studies of those who had received prior treatments will include PD-L1 negative patients.   (Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)",2014-05-14,MRK,"Wed May 14, 2014 | 6:14pm EDT","Bristol, Merck, Roche immune therapies are cancer meeting focus",http://www.reuters.com//article/us-health-cancer-immunotherapy-idUSKBN0DU20C20140514?type=companyNews
117,"  (Adds more information on Bristol-Myers Phase III plan in final paragraph)By Bill BerkrotMay 14 When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating  excitement among researchers and investors.At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades.Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.Brief summaries, or abstracts, of thousands of studies to be presented at the ASCO meeting were released on Wednesday. ""This area should represent a major advance in cancer therapy and patient survivability,"" said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. ""Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies.""The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers  anti PD-1 drug nivolumab.Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years. Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy.In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose.Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab. MOST LIKELY TO BENEFIT As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.Namouni said Bristol would focus on PD-L1 positive patients only in a large Phase III lung cancer trial of previously untreated subjects. Its Phase III studies of those who had received prior treatments will include PD-L1 negative patients.    (Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)",2014-05-14,MRK,"Wed May 14, 2014 | 5:54pm EDT","UPDATE 1-Bristol, Merck, Roche immune therapies are cancer meeting focus",http://www.reuters.com//article/health-cancer-immunotherapy-idUSL1N0O024O20140514?type=companyNews
118,"   By Bill Berkrot  May 14 When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck & Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.The drugs, known as anti-PD-1 or anti-PDL1 therapies, are biotech medicines that work by blocking a tumor's ability to camouflage itself, thereby allowing T cells in the immune system to recognize and attack the cancer.They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating  excitement among researchers and investors.At the American Society of Clinical Oncology meeting in Chicago beginning May 30, researchers will for the first time present data on Roche's anti-PDL1 drug in advanced bladder cancer for which there have been few advances in decades.Merck will have no less than 16 studies involving its highly touted anti PD-1 drug, MK-3475, including a first look at the drug as an initial lung cancer treatment. Early data released on Wednesday showed 36 percent of 45 patients had an initial immune response to the treatment. Merck will also provide results from the first trial of the drug in head and neck cancer.Brief summaries, or abstracts, of hundreds of studies to be presented at the ASCO meeting were released on Wednesday. ""This area should represent a major advance in cancer therapy and patient survivability,"" said Len Yaffe, portfolio manager for the healthcare fund StockDoc Partners. ""Wall Street is increasingly recognizing the multibillion-dollar potential for cancer immunotherapies.""The potential for lasting effects of these drugs will be on display in a pair of studies involving the Bristol-Myers  anti PD-1 drug nivolumab.Researchers will present follow-up data from a 107-patient nivolumab study in metastatic melanoma showing that 41 percent were still alive after three years, an apparent leveling off from the 48 percent survival rate after two years.Three-year survival with advanced melanoma was virtually unheard of prior to the advent of cancer immunotherapy. In a trial of patients whose advanced kidney cancer had progressed following prior treatments, the mean overall survival was 25.5 months for the 2 milligram nivolumab dose.Past kidney cancer studies of drugs currently in use have demonstrated a mean survival of about 14 months, said Fouad Namouni, Bristol's head of global development for nivolumab. MOST LIKELY TO BENEFIT As drugmakers face greater scrutiny over how they price new therapies - with immuno-oncology expected to be among the most expensive - several studies will aim to identify which patients are most likely to benefit from the new treatments.Researchers can now perform a test to determine the degree to which the PD-L1 protein is expressed on the surface of cancer cells. On a 0 to 3 scale, a score of 0 or 1 is considered PD-L1 negative, while 2 or 3 is deemed PD-L1 positive.If early data is confirmed in larger trials, this class of immunotherapies could become standalone treatments for some patients, while PD-L1 negative patients may require combination or alternative therapies, according to some researchers.In a small, Phase I study of Bristol's nivolumab in previously untreated patients with advanced lung cancer, five out of 10 PD-L1 positive patients saw their tumors shrink by at least 30 percent. No such responses were seen among 7 PD-L1 negative patients. Roche also saw half of the 20 PD-L1 positive patients in its bladder cancer trial respond to its drug.Namouni said Bristol would focus on PD-L1 positive patients in planning its large Phase III trials.   (Reporting by Bill Berkrot; Editing by Michele Gershberg and Andre Grenon)",2014-05-14,MRK,"Wed May 14, 2014 | 5:00pm EDT","Bristol, Merck, Roche immune therapies are cancer meeting darlings",http://www.reuters.com//article/health-cancer-immunotherapy-idUSL1N0NZ1K320140514?type=companyNews
119,"  BRUSSELS May 14 Belgian biotech group Ablynx  said its cash reserves increased in the first quarter after an upfront payment from Merck & Co as part of a research deal for immune oncology.The group, which develops a series of experimental drugs based on the nanobodies found in llamas, repeated it expected to use 30 to 35 million euros ($41.1-$48.0 mln) of these reserves in 2014 as it continued to invest in the development and clinical trials of its medicines. Ablynx said that its cash reserves grew by 2.8 million euros in the first quarter to 203 million.  The group increased its first quarter revenues by 115 percent from the same period last year to 11.2 million euros, with its net loss shrinking to 2.8 million euros from 6.7 million in the first quarter of 2013. ($1 = 0.7296 Euros) ($1 = 0.7296 Euros)   (Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)",2014-05-14,MRK,"Wed May 14, 2014 | 2:00am EDT",Belgium's Ablynx increases cash position after Merck payment,http://www.reuters.com//article/ablynx-results-idUSL6N0O012620140514?type=companyNews
120,"  * All-cash deal priced at $415 mln* Bayer unit had $120 mln of sales in 2013* Unit makes catheters to remove clots from arteries and veins* Deal follows Bayer purchase of Merck's OTC drugs business   (Adds detail, background)FRANKFURT, May 15 U.S. medical devices company Boston Scientific on Thursday agreed to buy Bayer AG's  vascular catheter business for $415 million to widen its range of devices to treat clogged blood vessels. Boston Scientific said the business, called Bayer Interventional, will help it expand its portfolio of devices for cardiology, radiology and peripheral vascular procedures.""This transaction will enable us to reach more effectively the more than 27 million patients worldwide who suffer from the debilitating effects of peripheral vascular disease,"" it said, referring to the obstruction of large blood vessels, typically in arms or legs. The all-cash deal is expected to close in the second half of 2014.Bayer's HealthCare unit last week trumped rival bidders for Merck & Co's consumer care business in a $14.2 billion deal. The German group has previously said it would seek growth in the areas of life science and molecular sciences.""With this sale, our Medical Care division can concentrate on innovation and growth in radiology and diabetes care, where we already have a strong presence,"" Olivier Brandicourt, CEO of Bayer HealthCare, said in a statement.The catheter business, which achieved sales of about $120 million last year, will become part of Boston Scientific's existing Peripheral Interventions business, the U.S. company said.   (Reporting by Ludwig Burger and Edward Taylor; Editing by David Goodman)",2014-05-15,MRK,"Thu May 15, 2014 | 8:32am EDT",UPDATE 1-Boston Scientific buys Bayer's vascular catheter business,http://www.reuters.com//article/bayer-boston-scient-idUSL6N0O142V20140515?type=companyNews
121,"  (Adds background on Cialis, Viagra, regulatory issues)NEW YORK May 28 Sanofi and Eli Lilly and Co on Wednesday said they would ask health regulators for permission to sell Cialis, the world's top-selling anti-impotence drug, without a prescription.Currently available by prescription only, the tablet was first approved by the European Medicines Agency in 2002 and then by the U.S. Food and Drug Administration in 2003.It is one of Lilly's biggest products, having generated almost $2.2 billion in worldwide sales last year. The drug is also approved to treat enlarged prostate glands.Under the terms of the agreement, Sanofi is buying the exclusive rights to apply for approval of Cialis tablets over the counter in the United States, Europe, Canada and Australia. Terms of the licensing agreement were not disclosed. The tablet would be sold by Sanofi's consumer healthcare unit, which had sales last year of $4.1 billion from a wide array of non-prescription brands, including vitamins and treatments for allergies, coughs, colds and the flu.It remains to be seen, however, whether regulators will allow Cialis to be sold without a prescription, in view of possible side effects. Like rival anti-impotence drugs, such as Pfizer Inc's Viagra, Cialis can cause a dangerous fall in blood pressure if taken with nitrates, a class of heart drugs that include nitroglycerin. The U.S. Food and Drug Administration, in weighing whether to allow prescription drugs to be sold over the counter, weighs whether patients are able to understand complex aspects of their disease, or exactly when to take the drug to ensure safe use.The FDA in 2008, for instance, rejected Merck & Co's  bid to sell its Mevacor cholesterol-lowering drug without a prescription, after an independent panel of medical experts expressed concern that patients might take it instead of more-effective newer medicines. Cialis will face competition from cheaper generics in the United States in 2017, the same year that Teva Pharmaceuticals Industries is expected to begin selling generic prescription forms of Viagra under an agreement reached with Pfizer last year.Viagra, the first drug to treat impotence, was approved by U.S. regulators in 1998. It has annual sales of about $1.5 billion.(Reporting by Ransdell Pierson; Editing by Nick Zieminski)",2014-05-28,MRK,"Wed May 28, 2014 | 4:07pm EDT","UPDATE 1-Sanofi, Lilly pursue Cialis over-the-counter approval",http://www.reuters.com//article/sanofi-lilly-cialis-idUSL1N0OE1P920140528?type=companyNews
122,"   By Deena Beasley  A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday.Merck filed in January for U.S. Food and Drug approval of MK3475, now known as pembrolizumab, as a treatment for melanoma, the deadliest form of skin cancer. But the drug's biggest sales opportunity is expected to be in treating lung cancer, which causes the most cancer deaths in the United States each year.The drug is part of an emerging class of medications that work by blocking a protein called PD-1, or Programmed Death receptor, used by cancer cells to evade the body's immune system.Morningstar has estimated that Merck's peak annual sales of pembrolizumab could reach $6 billion.A Phase I study in 411 patients with melanoma that had spread to other parts of the body found that 69 percent were alive after a year of treatment. At 18 months, researchers estimated that overall survival was 62 percent, with some patients on the drug for more than two years. The findings were presented at the American Society of Clinical Oncology meeting in Chicago.Patients with metastatic melanoma often have high levels of PD-L1 protein in their tumors. When PD-L1 attaches to its receptor PD-1 on immune cells, tumors are able to hide from the immune system; drugs that target either PD-L1 or PD-1 inhibit this interaction.More than half the patients in the melanoma trial had previously been treated with ipilimumab, which is sold by Bristol-Myers Squibb Co under the brand name Yervoy. It is part of a class known as CTLA-4 blockers that work by unleashing a different part of the immune system. Overall, 34 percent of patients had tumor shrinkage after treatment with Merck's drug, including 40 percent not treated with ipilimumab and 28 percent whose cancer worsened despite ipilimumab. The most common immune-related adverse events included thyroid problems. Four percent of patients stopped treatment due to side effects.""In general, this is probably the safest drug I have ever used in metastatic melanoma patients,"" said Dr Antoni Ribas, professor of hematology-oncology at the University of California, Los Angeles and the study's lead investigator. A separate arm of the trial - 45 previously untreated patients with advanced non-small cell lung cancer who tested positive for PD-L1 - showed by one measurement that 47 percent had tumor shrinkage. A different measurement showed that 26 percent of those patients responded to the drug.Two different methods were used because standard measures can underestimate the impact of drugs that work by targeting the immune system, said Dr Alise Reicin, Merck vice president oncology.She estimated that around 70 percent of advanced non small-cell lung cancer patients have tumors that express PD-L1.Merck said the median duration of response had not been reached in the lung cancer trial, with some patients continuing on the drug for at least a year. Results for a trial segment involving 217 patients with advanced non-small cell lung cancer who had previously been treated with other drugs were slated for presentation at the ASCO meeting on Tuesday.Dr Reicin declined to comment on when Merck would file for regulatory approval of pembrolizumab as a treatment for lung cancer. The company did say it plans to launch in September a Phase III study comparing the drug to chemotherapy in previously-untreated patients with PD-L1 positive, advanced NSCLC.Merck on Sunday presented data from a small number of patients with advanced head and neck cancer who were treated with pembrolizumab. Of the patients deemed to be high expressers of PD-L1, 45 percent experienced tumor shrinkage, compared with 11 percent for the overall group.The FDA is slated to decide by late October whether to approve pembrolizumab for patients with advanced melanoma previously treated with ipilimumab.Merck is studying pembrolizumab across more than 30 types of cancers, as a stand-alone treatment and in combination with other drugs.Drugs targeting either PD-1 or PD-L1 are also under development at companies including Roche AG, AstraZeneca Plc and Bristol-Myers.",2014-06-02,MRK,"Mon Jun 2, 2014 | 7:34am EDT","Merck immune system-booster effective in skin, lung cancer",http://www.reuters.com//article/us-health-cancer-merck-co-idUSKBN0ED12120140602?type=companyNews
123,"   By Deena Beasley | June 2  June 2 A highly anticipated new immunotherapy from Merck & Co Inc proved effective in patients with advanced melanoma as well as some with lung cancer or head and neck cancer, according to early-stage studies presented on Monday.Merck filed in January for U.S. Food and Drug approval of MK3475, now known as pembrolizumab, as a treatment for melanoma, the deadliest form of skin cancer. But the drug's biggest sales opportunity is expected to be in treating lung cancer, which causes the most cancer deaths in the United States each year.The drug is part of an emerging class of medications that work by blocking a protein called PD-1, or Programmed Death receptor, used by cancer cells to evade the body's immune system.Morningstar has estimated that Merck's peak annual sales of pembrolizumab could reach $6 billion.A Phase I study in 411 patients with melanoma that had spread to other parts of the body found that 69 percent were alive after a year of treatment. At 18 months, researchers estimated that overall survival was 62 percent, with some patients on the drug for more than two years. The findings were presented at the American Society of Clinical Oncology meeting in Chicago.Patients with metastatic melanoma often have high levels of PD-L1 protein in their tumors. When PD-L1 attaches to its receptor PD-1 on immune cells, tumors are able to hide from the immune system; drugs that target either PD-L1 or PD-1 inhibit this interaction.More than half the patients in the melanoma trial had previously been treated with ipilimumab, which is sold by Bristol-Myers Squibb Co under the brand name Yervoy. It is part of a class known as CTLA-4 blockers that work by unleashing a different part of the immune system. Overall, 34 percent of patients had tumor shrinkage after treatment with Merck's drug, including 40 percent not treated with ipilimumab and 28 percent whose cancer worsened despite ipilimumab.The most common immune-related adverse events included thyroid problems. Four percent of patients stopped treatment due to side effects.""In general, this is probably the safest drug I have ever used in metastatic melanoma patients,"" said Dr Antoni Ribas, professor of hematology-oncology at the University of California, Los Angeles and the study's lead investigator. A separate arm of the trial - 45 previously untreated patients with advanced non-small cell lung cancer who tested positive for PD-L1 - showed by one measurement that 47 percent had tumor shrinkage. A different measurement showed that 26 percent of those patients responded to the drug.Two different methods were used because standard measures can underestimate the impact of drugs that work by targeting the immune system, said Dr Alise Reicin, Merck vice president oncology.She estimated that around 70 percent of advanced non small-cell lung cancer patients have tumors that express PD-L1.Merck said the median duration of response had not been reached in the lung cancer trial, with some patients continuing on the drug for at least a year. Results for a trial segment involving 217 patients with advanced non-small cell lung cancer who had previously been treated with other drugs were slated for presentation at the ASCO meeting on Tuesday.Dr Reicin declined to comment on when Merck would file for regulatory approval of pembrolizumab as a treatment for lung cancer. The company did say it plans to launch in September a Phase III study comparing the drug to chemotherapy in previously-untreated patients with PD-L1 positive, advanced NSCLC.Merck on Sunday presented data from a small number of patients with advanced head and neck cancer who were treated with pembrolizumab. Of the patients deemed to be high expressers of PD-L1, 45 percent experienced tumor shrinkage, compared with 11 percent for the overall group.The FDA is slated to decide by late October whether to approve pembrolizumab for patients with advanced melanoma previously treated with ipilimumab.Merck is studying pembrolizumab across more than 30 types of cancers, as a stand-alone treatment and in combination with other drugs.Drugs targeting either PD-1 or PD-L1 are also under development at companies including Roche AG, AstraZeneca Plc and Bristol-Myers.",2014-06-02,MRK,"Mon Jun 2, 2014 | 7:30am EDT","Merck immune system-booster effective in skin, lung cancer",http://www.reuters.com//article/health-cancer-merck-co-idUSL1N0OI0P020140602?type=companyNews
124,"  Swiss drugmaker Novartis AG said it has appointed Bruno Strigini, one of Merck & Co Inc's top executives, to head its oncology unit.Novartis said Strigini, who served as the president of Merck's European and Canadian operations, was appointed with immediate effect. (link.reuters.com/tyk79v)Strigini takes over from Alessandro Riva, who headed Novartis' Oncology Development and Medical Affairs division on an interim basis after the departure of Herve Hoppenot earlier in the year. Novartis in April bought London-based GSK's oncology products for $14.5 billion plus another $1.5 billion that depends on the results of a trial in melanoma in a deal that strengthened the company's No. 2 global position in cancer. Cancer is a particular focus for some drugmakers as novel medicines show promise by boosting the body's immune system. Drugmakers are seen stocking up their oncology pipelines as they bet that combinations of drugs will become the future of cancer care.   (Reporting by Aashika Jain in Bangalore; Editing by Eric Walsh)",2014-06-02,MRK,"Sun Jun 1, 2014 | 9:00pm EDT",Novartis appoints Merck executive as oncology chief,http://www.reuters.com//article/us-novartis-appointment-merck-co-idUSKBN0ED00F20140602?type=companyNews
125,"  June 2 Swiss drugmaker Novartis AG  said it has appointed Bruno Strigini, one of Merck & Co Inc's  top executives, to head its oncology unit.Novartis said Strigini, who served as the president of Merck's European and Canadian operations, was appointed with immediate effect. (link.reuters.com/tyk79v) Strigini takes over from Alessandro Riva, who headed Novartis' Oncology Development and Medical Affairs division on an interim basis after the departure of Herve Hoppenot earlier in the year. Novartis in April bought London-based GSK's oncology products for $14.5 billion plus another $1.5 billion that depends on the results of a trial in melanoma in a deal that strengthened the company's No. 2 global position in cancer. Cancer is a particular focus for some drugmakers as novel medicines show promise by boosting the body's immune system. Drugmakers are seen stocking up their oncology pipelines as they bet that combinations of drugs will become the future of cancer care.    (Reporting by Aashika Jain in Bangalore; Editing by Eric Walsh)",2014-06-02,MRK,"Sun Jun 1, 2014 | 8:16pm EDT",Novartis appoints Merck executive as oncology chief,http://www.reuters.com//article/novartis-appointment-merckco-idUSL3N0OJ00U20140602?type=companyNews
126,"   By Ransdell Pierson  An infectious disease expert and former head dealmaker at Merck & Co is racing against his ex-employer and other drugmakers to develop a treatment for a germ that ravages the colon and kills as many as 14,000 Americans each year.Roger Pomerantz on Monday became chief executive officer of privately held Seres Health, whose lead product has proven highly effective against the c. difficile bacteria in early-stage clinical trials. The condition occurs in patients who have been treated with broad-spectrum antibiotics that kill off ""friendly"" bacteria in the gut, allowing c. difficile to take root and prosper there. It causes colitis, including serious diarrhea and fever that can recur and are not well-controlled by current treatments. The infections, which are most dangerous for the elderly and others with weakened immune systems, typically occur in hospitals, nursing homes and doctor's offices, but are becoming more common in the community at large.Some industry analysts have said effective treatments against c. difficile could have blockbuster sales potential.   The Seres oral capsule, called SER 109, in early clinical trials quickly eliminated symptoms in more than 90 percent of patients, Pomerantz said in a telephone interview. All patients previously had multiple recurrences of c. difficile after standard antibiotic treatments such as vancomycin and metronidazole.Rather than killing c. difficile, SER 109, which contains spores from bacteria initially harvested from human stool, restores balance to the microbiome, where millions of types of bacteria interact in the colon, Pomerantz said.""There's no ick factor,"" he said. ""There's no stool in our capsules, just (bacterial) spores"" that have been replicated countless times on laboratory dishes, refined and purified. Mid-stage trials of SER 109 involve about 40 patients and are being conducted at numerous centers, including the Mayo Clinic and Massachusetts General Hospital. They should be completed in the next six weeks, after which Seres aims to conduct late-stage studies, Pomerantz said. ""We have multiple large pharmaceutical companies interested in our company,"" Pomerantz said, but he would not comment about any possible licensing plans. Merck's injectable treatment, called MK-3415A, is a combination of two monoclonal antibodies that do not target c. difficile itself but instead block toxins produced by the germ. It is now in late-stage studies.  Pomerantz, who once headed infectious disease research for Johnson & Johnson, joined Merck in 2010 in a similar capacity. Soon afterward he took charge of business development, overseeing licensing deals and acquisitions.But he left Merck last summer after an executive reshuffling and in November became chairman of Cambridge, Massachusetts-based Seres, a role he retains.Pomerantz said SER 109 and other Seres products also could treat diabetes, obesity and metabolic syndrome, diseases the microbiome is believed to affect. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2014-06-06,MRK,"Fri Jun 6, 2014 | 12:45pm EDT",Former Merck dealmaker takes aim at colon germ,http://www.reuters.com//article/us-pomerantz-merck-seres-idUSKBN0EH1Z320140606?type=companyNews
127,"  * Merck to buy Idenix; Analog to purchase Hittite* Apple attracts heavy trading following stock split* International Game Technology shares fly after Reuters report* CBOE Volatility Index up, day after hitting lowest since Feb '07* Dow up 0.1 pct; S&P 500 up 0.1 pct; Nasdaq up 0.3 pct   (Updates to close)By Caroline ValetkevitchNEW YORK, June 9 The Dow and S&P 500 ended at record highs again on Monday as more deal news raised enthusiasm for stocks, though Wall Street's fear gauge advanced. It was a fourth straight record closing high for the S&P 500 and a third for the Dow. The gains, though, have been moderate in most recent sessions and volume lighter than average.The CBOE Volatility Index rebounded after falling on Friday to its lowest level since February 2007. Wall Street's ""fear gauge"" rose 3.9 percent to end at 11.15. The VIX remains at nearly half of its historical average, which some analysts worry is a signal that the market is not fully accounting for issues that could derail the rally.Monday's merger activity prompted investors to buy some stocks. Merck & Co said it has agreed to buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion.""Every Monday virtually there seem to be new deals,"" said Bruce Zaro, chief technical strategist at Delta Global Asset Management in Boston. ""It shows how lush corporate balance sheets are, and that's certainly fueling the market's advance."" The Dow Jones industrial average rose 18.82 points or 0.11 percent, to 16,943.10. The S&P 500 gained 1.83 points or 0.09 percent, to 1,951.27. The Nasdaq Composite  added 14.84 points or 0.34 percent, to 4,336.24.The Dow set an intraday record high at 16,970.17, while the S&P 500 touched an all-time intraday high at 1,955.55.In other deal news, Analog Devices Inc said it would buy Hittite Microwave Corp in a deal valued at $2 billion. Tyson Foods Inc prevailed over Pilgrim's Pride Corp  in a bidding war over Hillshire Brands Co, offering to buy the maker of Jimmy Dean sausages for $8.55 billion, including debt.Shares of Idenix, which has three drugs in development to treat hepatitis C, soared 229 percent to $23.79 on heavy volume. In contrast, Gilead Sciences the maker of the market-leading hepatitis C treatment, Sovaldi, fell 4.1 percent to $79. Gilead was the biggest drag on the Nasdaq and the S&P 500.Hittite shot up 28.6 percent to $77.90. Hillshire rose 5.3 percent to $62.06. Merck, a Dow component, edged up 0.2 percent to $57.94. Analog gained 5 percent to $55.31. Tyson slid 6.5 percent to $37.50.Late in the session, International Game Technology  shares surged after Reuters reported the slot machine maker is working with Morgan Stanley to explore a sale. The stock jumped 14.4 percent to end at $14.31. It was the S&P 500's top percentage gainer.Apple Inc was the Nasdaq's most-active stock, rising 1.6 percent to $93.70 in heavy volume in the tech titan's first trading session after a seven-for-one stock split.With just 5.4 billion shares changing hands on U.S. exchanges, Monday's volume is below the 5.75 billion average for the last month, according to data from BATS Global Markets.   (Editing by Jan Paschal)",2014-06-09,MRK,"Mon Jun 9, 2014 | 4:58pm EDT","US STOCKS-Dow, S&P 500 extend string of record closes; VIX up",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0OQ1QV20140609?type=companyNews
128,"  * Merck to buy Idenix; Analog to purchase Hittite* Apple sees heavy trading following stock split* CBOE Volatility Index up, day after hitting lowest since Feb '07* Dow up 0.1 pct; S&P 500 down 0.01 pct; Nasdaq up 0.2 pct   (Updates to late afternoon)By Caroline ValetkevitchNEW YORK, June 9 U.S. stocks were nearly flat on Monday after the Dow and S&P 500 hit intraday record highs again on more deal news, while Wall Street's fear gauge rebounded.The CBOE Volatility index gained 6.3 percent to 11.41 after falling on Friday to its lowest level since February 2007. The VIX remains at nearly half of its historical average, which some analysts worry is a signal that the market is not fully accounting for issues that could derail the rally. The S&P 500 and Dow have repeatedly hit record highs in recent sessions. If the S&P 500 ends Monday's session higher, it will mark its 11th rise of the past 13 sessions, and its seventh record close of the past eight trading days.There's ""still skepticism about this rally, so consequently, we're not in an overbought position here,"" said Bucky Hellwig, senior vice president of BB&T Wealth Management in Birmingham, Alabama.Merger activity gave investors a reason to buy some stocks on Monday. Merck & Co said it has agreed to buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion. Analog Devices Inc said it would buy Hittite Microwave Corp in a deal valued at $2 billion. Tyson Foods Inc prevailed over Pilgrim's Pride Corp  in a bidding war over Hillshire Brands Co, offering to buy the maker of Jimmy Dean sausages for $8.55 billion, including debt.Shares of Idenix, which has three drugs in development to treat hepatitis C, more than tripled, soaring 231.2 percent to $23.95 on heavy volume. In contrast, Gilead Sciences  the maker of the market-leading hepatitis C treatment, Sovaldi, fell 4.1 percent to $79.04. Gilead was the biggest negative influence on the S&P 500 and Nasdaq.Hittite jumped 28.6 percent to $77.89. Hillshire rose 5.4 percent to $62.10. Merck, a Dow component, dipped 0.02 percent to $57.84. Analog gained 5 percent to $55.34. Tyson slid 5.6 percent to $37.89. The Dow Jones industrial average rose 8.38 points or 0.05 percent, to 16,932.66. The S&P 500 slipped 0.15 point or 0.01 percent, to 1,949.29. The Nasdaq Composite  added 6.74 points or 0.16 percent, to 4,328.14.Earlier, the Dow set an intraday record high at 16,970.17, while the S&P 500 touched an all-time intraday high at 1,955.55.Apple Inc was the Nasdaq's most active name, rising 1.5 percent to $93.58 in heavy volume in the tech titan's first trading session after a seven-for-one stock split.On Friday, Nikkei news service reported that Apple was preparing to sell its first wearable device in October, aiming to produce 3 million to 5 million smartwatches a month in its initial run.Family Dollar Stores Inc jumped 13.6 percent to $68.75 as the S&P 500's biggest percentage gainer after hedge fund billionaire Carl Icahn disclosed late on Friday a 9.39 percent stake, making him the discount retailer's largest shareholder. Dollar General Corp rose 7.9 percent to $62.56.(Additional reporting by Ryan Vlastelica; Editing by Jan Paschal)",2014-06-09,MRK,"Mon Jun 9, 2014 | 2:59pm EDT",US STOCKS-Wall St near flat after hitting new highs; VIX gains,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0OQ1EC20140609?type=companyNews
129,"  * Merck to buy Idenix; Analog to purchase Hittite* Apple sees heavy trading following stock split* CBOE Volatility Index up, day after hitting lowest since Feb '07* Dow up 0.1 pct; S&P 500 up 0.1 pct; Nasdaq up 0.3 pct   (Updates to mid-afternoon, changes byline)By Caroline ValetkevitchNEW YORK, June 9 U.S. stocks edged higher on Monday, pushing the Dow and S&P 500 to intraday record highs again after a series of deals, though Wall Street's fear gauge also bounced back. If the S&P 500 ends higher on Monday, that will mark its 11th rise of the past 13 sessions, and its seventh record close of the past eight trading days.The CBOE Volatility index rose 5.8 percent to 11.35 following its drop on Friday to its lowest level since February 2007. The VIX remains at nearly half of its historical average, which some analysts worry is a signal that the market is not fully accounting for issues that could derail the rally.A flurry of merger activity gave investors a reason to buy some stocks on Monday. Merck & Co said it has agreed to buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion. Analog Devices Inc said it would buy Hittite Microwave Corp in a deal valued at $2 billion. Tyson Foods Inc prevailed over Pilgrim's Pride Corp  in a bidding war over Hillshire Brands Co, offering to buy the maker of Jimmy Dean sausages for $8.55 billion, including debt.Shares of Idenix more than tripled, surging 231.4 percent to $23.96 on heavy volume, while Hittite shot up 28.7 percent to $77.92. Hillshire rose 5.2 percent to $61.98. Merck, a Dow component, was flat at $57.85. Analog gained 5.1 percent to $55.40. Tyson slid 5.2 percent to $38.03.The Dow Jones industrial average rose 10.61 points or 0.06 percent, to 16,934.89. The S&P 500 gained 1.31 points or 0.07 percent, to 1,950.75. The Nasdaq Composite  added 11.96 points or 0.28 percent, to 4,333.36. Earlier, the Dow set an intraday record high at 16,970.17, while the S&P 500 touched an all-time intraday high at 1,955.55.Apple Inc was the Nasdaq's most active name, rising 1.6 percent to $93.73 in heavy volume in the tech titan's first trading session after a seven-for-one stock split.On Friday, the Nikkei news service reported that Apple was preparing to sell its first wearable device in October, aiming to produce 3 million to 5 million smartwatches a month in its initial run.Family Dollar Stores Inc jumped 13.6 percent to $68.75 as the S&P 500's biggest percentage gainer after hedge fund billionaire Carl Icahn disclosed late on Friday a 9.39 percent stake in the company, making him the discount retailer's largest shareholder. Dollar General Corp climbed 9 percent to $63.23.(Additional reporting by Ryan Vlastelica; Editing by Jan Paschal)",2014-06-09,MRK,"Mon Jun 9, 2014 | 2:15pm EDT","US STOCKS-Wall St slightly extends gains, lifted by deals",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0OQ19620140609?type=companyNews
130,"   By Ransdell Pierson  Merck & Co Inc MRK.N said Monday it would buy Idenix Pharmaceuticals Inc IDIX.O for $3.85 billion and plans to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C.Merck said it would pay $24.50 per share, more than three times Idenix's Friday closing price of $7.23.The payoff for Merck could come from a triple therapy that may cure patients with all genotypes, or strains, of the hepatitis C virus in as little as four to six weeks, its research chief, Roger Perlmutter, said in an interview.""An ideal therapy means something that works in every hepatitis C-infected patient, irrespective of which genotype,"" Perlmutter said. ""Our goal is to cure everyone quickly using an oral regimen.""The deal comes as drugmakers aim to better compete with Gilead Sciences Inc's GILD.O Sovaldi, an $84,000 treatment approved in December that generated an unprecedented $2.3 billion in sales in the first few months on the market.The cost of Sovaldi, which cures well in excess of 90 percent of patients in as little as 8 weeks of treatment, has drawn sharp criticism from insurers and government officials. (Full Story)Idenix has three drugs in development to treat hepatitis C, most notably a pill in early-stage trials called IDX21437. Like Sovaldi, it is a nucleotide inhibitor - or ""nuc"" - that blocks a protein needed by the hepatitis C virus to replicate.Merck hopes to combine IDX21437 with its two high-profile experimental oral treatments, a protease inhibitor called MK-5172 and a so-called NS5A inhibitor called MK-8742 that together received a ""breakthrough therapy"" designation from the U.S. Food and Drug Administration. (Full Story) In a recent mid-stage trial, Merck's two-drug combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C.The Idenix drug in earlier studies has shown effectiveness against all six main genotypes of hepatitis C, without raising serious safety concerns that have dogged other drugs in its class. Bristol Myers paid $2.5 billion for Inhibitex to get its nuc, but scrapped the drug in 2012 after serious side effects were seen in trials.Hepatitis C drugs have a history of being expensive, largely because some 170 million people worldwide have the often-fatal liver disease and have not had good treatment options.Bristol paid a 163 percent premium for Inhibitex. Gilead acquired Sovaldi by agreeing in 2011 to pay $11 billion in cash for biotech company Pharmasset, an 89 percent premium for a company with no marketed products. Perlmutter said Merck hopes the triple combination will cure patients in 4 to 6 weeks, substantially more quickly than current treatments and those in clinical trials.LARGER MARKET OPPORTUNITY Leerink Partners analyst Seamus Fernandez said IDX21437 has not shown any of the skeletal or cardiac toxicity signals that were seen with Bristol's failed drug. Moreover, he said safety of the Idenix drug, at least from preclinical studies, looks very similar to Sovaldi. ""Merck's presentation supports a much larger and longer market opportunity in hepatitis C"" than expected, justifying the price of the deal, Baird Equity Research analyst Brian Skorney said in a research note.Merck and Cambridge, Massachusetts-based Idenix said they expected the transaction to close in the third quarter.Idenix said in March it was involved in a patent dispute with Gilead related to its hepatitis C treatment in Oslo, Norway. (Full Story)Credit Suisse acted as the financial adviser to Merck, while Hughes Hubbard & Reed LLP was its legal adviser.Centerview Partners was Idenix's financial adviser and Sullivan & Cromwell acted as its legal adviser.Idenix's shares soared 232 percent to $24.03 on Monday. Shares of Achillion Pharmaceuticals ACHN.O, another maker of hepatitis C drugs, jumped 42 percent. Merck's shares were down slightly. (Additional reporting by Natalie Grover in Bangalore and Bill Berkrot in New York; Editing by Maju Samuel, Kirti Pandey and Nick Zieminski)",2014-06-09,MRK,"Mon Jun 9, 2014 | 1:00pm EDT",Merck & Co to buy Idenix to boost hepatitis C drugs portfolio,http://www.reuters.com//article/us-merck-co-idenix-pharma-idUSKBN0EK0Z720140609?type=companyNews
131,"  (Adds comments from Merck research chief, analysts, details on drugs)By Ransdell PiersonJune 9 Merck & Co Inc said Monday it would buy Idenix Pharmaceuticals Inc for $3.85 billion and plans to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C.Merck said it would pay $24.50 per share, more than three times Idenix's Friday closing price of $7.23.The payoff for Merck could come from a triple therapy that may cure patients with all genotypes, or strains, of the hepatitis C virus in as little as four to six weeks, its research chief, Roger Perlmutter, said in an interview.""An ideal therapy means something that works in every hepatitis C-infected patient, irrespective of which genotype,"" Perlmutter said. ""Our goal is to cure everyone quickly using an oral regimen.""The deal comes as drugmakers aim to better compete with Gilead Sciences Inc's Sovaldi, an $84,000 treatment approved in December that generated an unprecedented $2.3 billion in sales in the first few months on the market.The cost of Sovaldi, which cures well in excess of 90 percent of patients in as little as 8 weeks of treatment, has drawn sharp criticism from insurers and government officials.Idenix has three drugs in development to treat hepatitis C, most notably a pill in early-stage trials called IDX21437. Like Sovaldi, it is a nucleotide inhibitor - or ""nuc"" - that blocks a protein needed by the hepatitis C virus to replicate. Merck hopes to combine IDX21437 with its two high-profile experimental oral treatments, a protease inhibitor called MK-5172 and a so-called NS5A inhibitor called MK-8742 that together received a ""breakthrough therapy"" designation from the U.S. Food and Drug Administration.In a recent mid-stage trial, Merck's two-drug combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C.The Idenix drug in earlier studies has shown effectiveness against all six main genotypes of hepatitis C, without raising serious safety concerns that have dogged other drugs in its class. Bristol Myers paid $2.5 billion for Inhibitex to get its nuc, but scrapped the drug in 2012 after serious side effects were seen in trials.Hepatitis C drugs have a history of being expensive, largely because some 170 million people worldwide have the often-fatal liver disease and have not had good treatment options. Bristol paid a 163 percent premium for Inhibitex. Gilead acquired Sovaldi by agreeing in 2011 to pay $11 billion in cash for biotech company Pharmasset, an 89 percent premium for a company with no marketed products.Perlmutter said Merck hopes the triple combination will cure patients in 4 to 6 weeks, substantially more quickly than current treatments and those in clinical trials.LARGER MARKET OPPORTUNITY  Leerink Partners analyst Seamus Fernandez said IDX21437 has not shown any of the skeletal or cardiac toxicity signals that were seen with Bristol's failed drug. Moreover, he said safety of the Idenix drug, at least from preclinical studies, looks very similar to Sovaldi.""Merck's presentation supports a much larger and longer market opportunity in hepatitis C"" than expected, justifying the price of the deal, Baird Equity Research analyst Brian Skorney said in a research note.Merck and Cambridge, Massachusetts-based Idenix said they expected the transaction to close in the third quarter.Idenix said in March it was involved in a patent dispute with Gilead related to its hepatitis C treatment in Oslo, Norway.Credit Suisse acted as the financial adviser to Merck, while Hughes Hubbard & Reed LLP was its legal adviser.Centerview Partners was Idenix's financial adviser and Sullivan & Cromwell acted as its legal adviser.Idenix's shares soared 232 percent to $24.03 on Monday. Shares of Achillion Pharmaceuticals, another maker of hepatitis C drugs, jumped 42 percent. Merck's shares were down slightly.(Additional reporting by Natalie Grover in Bangalore and Bill Berkrot in New York; Editing by Maju Samuel, Kirti Pandey and Nick Zieminski)",2014-06-09,MRK,"Mon Jun 9, 2014 | 12:51pm EDT",UPDATE 3-Merck to buy Idenix to boost hepatitis C drugs portfolio,http://www.reuters.com//article/merck-co-idenix-pharma-idUSL4N0OQ2Y320140609?type=companyNews
132,"  * Merck to buy Idenix, Analog to buy Hittite* Apple sees heavy trading following stock split* CBOE Volatility index near lowest since Feb '07* Dow, S&P 500 and Nasdaq all up 0.1 pct   (Updates to open)By Ryan VlastelicaNEW YORK, June 9 U.S. stocks advanced on Monday, boosted by a number of major acquisition deals, though gains were slight with key indexes continuing to hover around records. If the S&P 500 ends higher on Monday, that will mark its 11th rise of the past 13 sessions, and its seventh record close of the past eight trading days. While Wall Street's upward trend looks intact, traders may need new catalysts to bid the market up further lest the momentum runs out of steam.Market participants will continue to watch the CBOE Volatility index, which rose 3.5 percent. On Friday, the ""fear index"" fell to its lowest level since February 2007. It remains nearly half of its historical average, which some analysts worry is a signal that the market is not fully accounting for issues that could derail the rally.""I don't think you can argue that the market is stretched. There's room for the economy to grow, and while the VIX may suggest some complacency, I don't see the kind of euphoria that would indicate over-optimism about stocks,"" said Rex Macey, who helps oversee $20 billion in assets as chief investment officer at Wilmington Trust in Atlanta, Georgia. ""I would be careful about pulling back on stocks too soon."" Merck & Co agreed to buy Idenix Pharmaceuticals Inc  in a deal valued at about $3.85 billion, while Analog Devices Inc said it would buy Hittite Microwave Corp  in a deal valued at $2 billion.Separately, Tyson Foods Inc prevailed over Pilgrim's Pride Corp in a bidding war over Hillshire Brands Co , offering to buy the company for $8.55 billion including debt. Shares of Idenix more than tripled, jumping 231 percent to $23.95 on heavy volume, while Hittite gained 28 percent to $77.75; Hillshire rose 4.8 percent to $61.76. Merck dipped 0.8 percent to $57.40 while Analog was up 6.1 percent at $55.93 and Tyson fell 2.6 percent to $39.08.The Dow Jones industrial average rose 9.96 points, or 0.06 percent, to 16,934.24, the S&P 500 gained 1.69 points, or 0.09 percent, to 1,951.13 and the Nasdaq Composite  added 6.14 points, or 0.14 percent, to 4,327.54.Apple Inc was the Nasdaq's most active name, rising 0.2 percent to $92.40 in heavy volume in the tech titan's first session after a seven-for-one stock split. Separately, the Nikkei on Friday reported that Apple was preparing to sell its first wearable device in October, aiming to produce 3 million to 5 million smartwatches a month in its initial run.Family Dollar Stores Inc jumped 16 percent to $70.25 as the S&P's biggest percentage gainer after hedge fund billionaire Carl Icahn late Friday reported a 9.39 percent stake in the company, making him the discount retailer's largest shareholder. Dollar General Corp surged 11 percent to $64.23.(Editing by Bernadette Baum)",2014-06-09,MRK,"Mon Jun 9, 2014 | 10:17am EDT","US STOCKS-Wall St edges up, lifted by mergers, acquisitions",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0OQ0OM20140609?type=companyNews
133,"  * Merck to buy Idenix, Analog to buy Hittite* Apple may see heavy action following stock split* CBOE Volatility index at lowest level since Feb '07* Futures down: Dow 10 pts, S&P 2.4 pts, Nasdaq 4 pts   (Adds Family Dollar news)By Ryan VlastelicaNEW YORK, June 9 U.S. stock index futures pointed to modest losses at the open on Monday, as a rash of corporate deals weren't enough reason for investors to keep buying following a rally that has taken major indexes to repeated record highs. * The S&P 500 has risen in 10 of the past 12 sessions, ending at records six times in the past seven trading days. On Friday, the benchmark index was lifted by the May payroll report, which pointed to improving economic conditions, though it was slightly weaker than expected. While Wall Street's upward trend looks intact, traders may need new catalysts to maintain its momentum.* Merck & Co agreed to buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion, while Analog Devices Inc said it would buy Hittite Microwave Corp in a deal valued at $2 billion. * Shares of Idenix more than tripled, jumping 237 percent to $24.34 on heavy premarket volume. Merck dipped 0.8 percent to $57.40. Hittite popped 29 percent to $78.12.* Market participants will continue to watch the CBOE Volatility index, which fell Friday to its lowest level since February 2007. The ""fear index"" is almost half of its historical average, which some analysts worry is a signal that the market is not fully accounting for issues that could derail the rally.* Apple Inc may see heavy action on Monday, the first session after a seven-for-one stock split. The tech titan fell 0.4 percent to $91.89 before the bell. The Nikkei on Friday reported that Apple was preparing to sell its first wearable device this October, aiming to produce 3 million to 5 million smartwatches a month in its initial run. * S&P 500 futures fell 2.4 points and were slightly below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures fell 10 points and Nasdaq 100 futures fell 4 points.* About 68,000 S&P 500 e-mini contracts traded hands as of 8:30 a.m. EDT (1230 GMT), indicating another day of light trading, which could make the market susceptible to big swings.* Family Dollar Stores Inc jumped 12.5 percent to $68.10 in heavy premarket trading after hedge fund billionaire Carl Icahn late Friday reported a 9.39 percent stake in the company, making him the discount retailer's largest shareholder.* Tyson Foods Inc said it reached a ""unilaterally binding offer"" to buy Hillshire Brands Co for $8.55 billion, including debt, beating out Pilgrim's Pride Corp . Hillshire rose 4.9 percent to $61.83 before the bell.   (Editing by Bernadette Baum)",2014-06-09,MRK,"Mon Jun 9, 2014 | 8:43am EDT",US STOCKS-Futures point to dip at the open despite deals,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0OQ0GO20140609?type=companyNews
134,  June 9 Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.Merck will pay $24.50 per share in cash - more than three times Idenix's Friday closing price.  The companies said they expect the transaction to close in the third quarter.    (Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel) ,2014-06-09,MRK,"Mon Jun 9, 2014 | 7:47am EDT",Merck to buy Idenix for about $3.85 billion,http://www.reuters.com//article/merck-co-idenix-pharma-idUSL4N0OQ2WL20140609?type=companyNews
135,"  (Fixes Rex Macey's job title and firm's name, which both changed recently, to chief allocation officer at Wilmington Trust Investment Advisors from chief investment officer at Wilmington Trust, in this U.S. stock report published June 9)* Merck to buy Idenix, Analog to buy Hittite* Apple sees heavy trading following stock split* CBOE Volatility index near lowest since Feb '07* Dow, S&P 500 and Nasdaq all up 0.1 pctBy Ryan Vlastelica NEW YORK, June 9 U.S. stocks advanced on Monday, boosted by a number of major acquisition deals, though gains were slight with key indexes continuing to hover around records.If the S&P 500 ends higher on Monday, that will mark its 11th rise of the past 13 sessions, and its seventh record close of the past eight trading days. While Wall Street's upward trend looks intact, traders may need new catalysts to bid the market up further lest the momentum runs out of steam.Market participants will continue to watch the CBOE Volatility index, which rose 3.5 percent. On Friday, the ""fear index"" fell to its lowest level since February 2007. It remains nearly half of its historical average, which some analysts worry is a signal that the market is not fully accounting for issues that could derail the rally. ""I don't think you can argue that the market is stretched. There's room for the economy to grow, and while the VIX may suggest some complacency, I don't see the kind of euphoria that would indicate over-optimism about stocks,"" said Rex Macey, chief allocation officer at Wilmington Trust Investment Advisors in Atlanta, Georgia. ""I would be careful about pulling back on stocks too soon.""Merck & Co agreed to buy Idenix Pharmaceuticals Inc  in a deal valued at about $3.85 billion, while Analog Devices Inc said it would buy Hittite Microwave Corp  in a deal valued at $2 billion.Separately, Tyson Foods Inc prevailed over Pilgrim's Pride Corp in a bidding war over Hillshire Brands Co , offering to buy the company for $8.55 billion including debt. Shares of Idenix more than tripled, jumping 231 percent to $23.95 on heavy volume, while Hittite gained 28 percent to $77.75; Hillshire rose 4.8 percent to $61.76. Merck dipped 0.8 percent to $57.40 while Analog was up 6.1 percent at $55.93 and Tyson fell 2.6 percent to $39.08.The Dow Jones industrial average rose 9.96 points, or 0.06 percent, to 16,934.24, the S&P 500 gained 1.69 points, or 0.09 percent, to 1,951.13 and the Nasdaq Composite  added 6.14 points, or 0.14 percent, to 4,327.54.Apple Inc was the Nasdaq's most active name, rising 0.2 percent to $92.40 in heavy volume in the tech titan's first session after a seven-for-one stock split. Separately, the Nikkei on Friday reported that Apple was preparing to sell its first wearable device in October, aiming to produce 3 million to 5 million smartwatches a month in its initial run.Family Dollar Stores Inc jumped 16 percent to $70.25 as the S&P's biggest percentage gainer after hedge fund billionaire Carl Icahn late Friday reported a 9.39 percent stake in the company, making him the discount retailer's largest shareholder. Dollar General Corp surged 11 percent to $64.23.(Editing by Bernadette Baum)",2014-06-10,MRK,"Tue Jun 10, 2014 | 12:39pm EDT","CORRECTED-US STOCKS-Wall St edges up, lifted by mergers, acquisitions",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0OQ0OM20140610?type=companyNews
136,"  Merck & Co Inc's (MRK.N) research chief Roger Perlmutter said the No. 2 U.S. drugmaker would consider big acquisitions of biotech companies for their medicines, rather than to obtain their drug-development technologies.Perlmutter, speaking on Thursday to analysts and investors at the annual Goldman Sachs healthcare conference being held near Los Angeles, said Merck continues to have an appetite for deals following its planned $3.85 billion purchase of Idenix Pharmaceuticals Inc IDIX.O.Merck earlier this week announced its agreement to buy Idenix, and  plans to combine the two companies' most promising oral drugs for hepatitis C to produce a faster, more effective cure for the often-fatal liver infection affecting 170 million people worldwide.Perlmutter on Thursday said Merck has been a pioneer in development of hepatitis C drugs, including injectable interferon medicines that had been the backbone of therapy but which are now being sidelined in favor of more effective and better-tolerated drugs. He said newer Merck drugs, including a hoped-for triple therapy using an experimental Idenix treatment called IDX21437, will make Merck a top hepatitis C competitor in years to come.""The best (drug) regimen that has a fair cost proposition will take a substantial part of the market and that's where I want to be,"" he said. Perlmutter could not immediately be reached by Reuters for further comment, including what he meant by ""fair cost proposition.""The company's shares were little change at $58.30 in afternoon trading on the New York Stock Exchange.  (Reporting by Ransdell Pierson; Editing by Bernard Orr)",2014-06-12,MRK,"Thu Jun 12, 2014 | 3:05pm EDT",Merck open to more biotech deals: research chief,http://www.reuters.com//article/us-merck-perlmutter-idUSKBN0EN26O20140612?type=companyNews
137,"  June 12 Merck & Co Inc :  * Research chief, speaking at Goldman Sachs healthcare conference, says Merck would be open to big acquisition for biotechproducts, not for technology platform  * Research chief says company aims to capture ""substantial"" part of hepatitis c  market by selling best drugs at ""fair cost proposition"" ",2014-06-12,MRK,"Thu Jun 12, 2014 | 11:38am EDT",BRIEF-Merck research chief says company aims for big share of hepatitis C market,http://www.reuters.com//article/merck-brief-idUSWEN00DGJ20140612?type=companyNews
138,"   By Andrew Longstreth | NEW YORK  NEW YORK Within the next two weeks, the U.S. Supreme Courtis expected to rule in a major case that could make it much harder for shareholders to band together against public companies in securities fraud class actions. If the court rules in favor of Halliburton (HAL.N) and against a group of shareholders, then the oilfield services company won't be the only business to gain. A handful of other major companies would also likely reap immediate benefit.Those companies, including drug makers Merck & Co Inc (MRK.N) and Pfizer Inc (PFE.N), banks HSBC Holdings Plc (HSBA.L) and Regions Financial Corp (RF.N), and casino company Las Vegas Sands Corp (LVS.N), are defendants in shareholder lawsuits that have been granted class action status. A decision setting a higher bar for class actions would not end the lawsuits, but it would allow these defendants to file briefs demanding that shareholders have to again seek court approval for the status - and this time under a new, tougher standard. If they fail to get that approval, the cases would effectively end.In 2013, settlements were reached in 67 cases totaling $4.8 billion, according to Cornerstone Research. A ruling in the oil company's favor in Halliburton v. Erica P. John Fund could save other businesses facing pending class actions hundreds of millions of dollars collectively. Around 200 shareholder class actions are filed every year alleging that misleading statements and material omissions made by companies and their executives caused a stocks share price to drop. Nearly 400 shareholder securities class actions are  pending in various stages of litigation, according to data gathered by the Stanford Law School Securities Class Action Clearinghouse.But only a relatively small number of the pending cases have been granted class action status. In each instance, a judge must determine at a certification hearing whether the status is appropriate. One consideration is whether the people in the class have common issues or merely related ones. To be a class, they must have common issues.'FRAUD ON THE MARKET' Class certification is a critical stage in shareholder class actions because it puts pressure on defendants to settle by increasing the liability they face. Generally, the larger the class size, the more damages a company faces and the more that plaintiffs' lawyers can make. Law firms can receive as much as a third of the settlement in attorneys' fees.In the case before the Supreme Court, Halliburton is seeking to overturn a 1988 decision, Basic v. Levinson, which adopted the fraud on the market theory. Under the theory, a defendant's material misrepresentation that affects the price of publicly traded securities is presumed to have been relied on by a purchaser who suffered a loss.That theory assumes public information about a company is known to the market and plaintiffs do not have to show that they relied on a specific misrepresentation, only that they purchased shares before the truth came out.In the case against Halliburton, shareholders alleged it understated asbestos liabilities while overstating both  revenues in its engineering and construction business and the benefits of its merger with Dresser Industries. The court has several options, including leaving intact Basic v. Levinson to maintain the status quo. At the other extreme, it could overturn Basic v. Levinson - and so doom securities class actions by requiring plaintiffs to show they relied on misinformation when they purchased securities. A third option would be to find a middle ground that would require plaintiffs to show that the misrepresentation had a significant effect on the stock price but that would not overturn Basic. During oral arguments, some of the justices appeared to signal that the middle option would be their preference. The middle option would still be a win for the defendant corporations by creating more hurdles for shareholders to clear before being allowed to sue as a group.Merck is facing one of the largest pending shareholder cases that already has class action status. The lawsuit, filed in 2005, alleges that the company made misleading statements about its painkiller drug Vioxx, which the company withdrew from the market in 2004 over concerns that it increased the risk of heart attacks and strokes. The plaintiffs alleged that after Merck disclosed the problems with Vioxx, its market capitalization shrunk by billions of dollars.In January 2013, U.S. District Judge Stanley Chesler of New Jersey certified a class of individuals and entities who purchased Merck securities from May 21, 1999, to Sept. 29, 2004. HALT IN THE PROCEEDINGS Foreshadowing the potential impact of the Halliburton decision, a lawyer for Merck in November asked a federal judge in New Jersey to put a halt to proceedings in the case pending the outcome of the Supreme Court decision in Halliburton. The lawyer said the plaintiffs case rested squarely on the fraud on the market theory and that part of the case would likely have to be re-litigated following the Halliburton decision. The court denied the request. Merck and an attorney for the plaintiffs had no comment on the potential impact of Halliburton on the case.HSBC could also benefit from the Supreme Courts ruling. The bank is appealing a $2.46 billion judgment against one of the companys units, formerly known as Household International Inc. The plaintiffs alleged that Household was engaged in systemic predatory lending and that it misrepresented the credit quality of its loan portfolio.The judgment, entered by a federal judge in Chicago last year, was the largest ever following a securities fraud class action trial, according to the plaintiffs law firm.On appeal to the 7th U.S. Circuit Court of Appeals, lawyers for HSBC are seeking an order vacating the judgment and sending the case back to the district court. In a brief filed in February, HSBC said that if the Supreme Court jettisons Basics presumption of reliance on a misrepresentation, a class status review ""will be beyond question.Pfizer is facing a trial later this year over allegations made by shareholders that it fraudulently misrepresented the safety of its Celebrex and Bextra pain-relieving drugs. The lawsuit covers investors who bought Pfizer stock between Oct. 31, 2000, and Oct. 19, 2005, a period in which the company's share price fell by roughly half and its market value tumbled by well over $100 billion.Pfizer and the plaintiffs agreed to delay the trial until after the Halliburton decision. In a letter to the court, Pfizer said it believed that after the Halliburton decision, it may be necessary to revisit class certification or other pre-trial motion practice.",2014-06-12,MRK,"Thu Jun 12, 2014 | 11:35am EDT","Merck, Pfizer, HSBC could be big winners from shareholder case",http://www.reuters.com//article/us-usa-court-halliburton-analysis-idUSKBN0EN10620140612?type=companyNews
139,"   By Alasdair Reilly | LONDON  LONDON Bayer (BAYGn.DE) has signed a $14.2 billion acquisition loan backing its purchase of U.S.-based Merck's (MRK.N) consumer care business, the lead banks said in a statement on Wednesday.The loan was underwritten on an equal basis by mandated lead arrangers and bookrunners Bank of America Merrill Lynch, BNP Paribas and Mizuho Bank and saw strong support from Bayer's core relationship banks with 23 banks joining in syndication.Mandated led arrangers were BBVA, Santander, Bank of Tokyo-Mitsubishi UFJ, Barclays, Citigroup, Commerzbank, Credit Agricole CIB, Credit Suisse, Deutsche Bank, Goldman Sachs, HSBC, JP Morgan, RBS, Societe Generale, SMBC and Unicredit. Lead arrangers were ANZ, Bank of New York Mellon, BayernLB, ING, Intesa SanPaolo, Helaba and SEB. The financing comprises a $12.2 billion bridge to capital markets facility and a $2 billion medium-term facility. The one-year bridge loan pays 25 basis points (bps) over Libor, while the four-year facility pays 50 bps, as previously reported. The bridge loan is expected to be taken out in the capital markets through a combination of senior and hybrid corporate bonds.The financing is Bayer's largest loan financing since its 16.5 billion euro ($22.35 billion) acquisition of domestic rival Schering in 2006, which was funded with a 7 billion euro syndicated loan and a 7 billion euro bridge loan via Citigroup and Credit Suisse. Bayer is rated A- by Standard & Poor's, A3 by Moody's and A by Fitch. (Editing by Christopher Mangham)",2014-06-18,MRK,"Wed Jun 18, 2014 | 6:36am EDT",Bayer signs $14.2 billion acquisition loan,http://www.reuters.com//article/us-loans-bayer-idUSKBN0ET14920140618?type=companyNews
140,"   By Alasdair Reilly | LONDON, June 18  LONDON, June 18 Bayer has signed a $14.2 billion acquisition loan backing its purchase of US-based Merck's consumer care business, the lead banks said in a statement on Wednesday.The loan was underwritten on an equal basis by mandated lead arrangers and bookrunners Bank of America Merrill Lynch, BNP Paribas and Mizuho Bank and saw strong support from Bayer's core relationship banks with 23 banks joining in syndication.Mandated led arrangers were BBVA, Santander, Bank of Tokyo-Mitsubishi UFJ, Barclays, Citigroup, Commerzbank, Credit Agricole CIB, Credit Suisse, Deutsche Bank, Goldman Sachs, HSBC, JP Morgan, RBS, Societe Generale, SMBC and Unicredit. Lead arrangers were ANZ, Bank of New York Mellon, BayernLB, ING, Intesa SanPaolo, Helaba and SEB. The financing comprises a $12.2 billion bridge to capital markets facility and a $2 billion medium-term facility. The one-year bridge loan pays 25 basis points (bps) over Libor, while the four-year facility pays 50 bps, as previously reported. (ID:nRLP49395a)The bridge loan is expected to be taken out in the capital markets through a combination of senior and hybrid corporate bonds. The financing is Bayer's largest loan financing since its 16.5 billion euro ($22.35 billion) acquisition of domestic rival Schering in 2006, which was funded with a 7 billion euro syndicated loan and a 7 billion euro bridge loan via Citigroup and Credit Suisse.Bayer is rated A- by Standard & Poor's, A3 by Moody's and A by Fitch. ($1 = 0.7383 Euros)   (Editing by Christopher Mangham)",2014-06-18,MRK,"Wed Jun 18, 2014 | 6:29am EDT",RLPC-Bayer signs $14.2 bln acquisition loan,http://www.reuters.com//article/loans-bayer-idUSL6N0OZ09J20140618?type=companyNews
141,"  Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children.The company said it plans to file for marketing approval for Emend in the U.S. for the new pediatric formulation in the second half of 2014.Merck said 51 percent of patients getting Emend showed no vomiting, no retching and no use of rescue medication for nausea and vomiting 25 to 120 hours following the beginning of chemotherapy, compared to 26 percent of those on a placebo. More than 70 percent of cancer patients undergoing chemotherapy suffer from nausea and vomiting that may result in a delay or discontinuation of treatment.  Prolonged nausea and vomiting can also lead to weight loss, dehydration and malnutrition. Emend is already approved for treating chemotherapy-induced nausea and vomiting in adults and had global sales of $507 million in 2013.Tesaro Inc's experimental drug Rolapitant, if approved, will compete with Emend.  (Reporting by Shailesh Kuber and Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty and Joyjeet Das)",2014-06-30,MRK,"Mon Jun 30, 2014 | 9:42am EDT",Merck nausea drug works in children in late-stage trial,http://www.reuters.com//article/us-merck-co-study-idUSKBN0F516S20140630?type=companyNews
142,"  (Adds details, background, share movement)June 30 Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children.The company said it plans to file for marketing approval for Emend in the U.S. for the new pediatric formulation in the second half of 2014. Merck said 51 percent of patients getting Emend showed no vomiting, no retching and no use of rescue medication for nausea and vomiting 25 to 120 hours following the beginning of chemotherapy, compared to 26 percent of those on a placebo.More than 70 percent of cancer patients undergoing chemotherapy suffer from nausea and vomiting that may result in a delay or discontinuation of treatment. Prolonged nausea and vomiting can also lead to weight loss, dehydration and malnutrition. Emend is already approved for treating chemotherapy-induced nausea and vomiting in adults and had global sales of $507 million in 2013.Tesaro Inc's experimental drug Rolapitant, if approved, will compete with Emend.   (Reporting by Shailesh Kuber and Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty and Joyjeet Das)",2014-06-30,MRK,"Mon Jun 30, 2014 | 9:23am EDT",UPDATE 1-Merck nausea drug works in children in late-stage trial,http://www.reuters.com//article/merck-co-study-idUSL4N0PB32Z20140630?type=companyNews
143,"  June 30 Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children.The company said 51 percent of patients getting Emend showed no vomiting, no retching and no use of rescue medication for nausea and vomiting 25 to 120 hours following the beginning of chemotherapy, compared to 26 percent of those on a placebo.  The drug is already approved for treating chemotherapy-induced nausea and vomiting in adults.   (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty) ",2014-06-30,MRK,"Mon Jun 30, 2014 | 8:22am EDT",Merck nausea drug works in children in late-stage trial,http://www.reuters.com//article/merck-co-study-idUSL4N0PB31Z20140630?type=companyNews
144,"  * Coppertone, Dr. Scholl's draw interest after $14 bln deal* Bayer says to hold on to non-drug consumer brands   (Adds U.S. antitrust approval for Merck deal)By Ludwig Burger and Arno SchuetzeFRANKFURT, July 1 German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone brands it bagged as part of a $14 billion buy from U.S. Merck, despite overtures from companies keen to grab them, widening its healthcare line to include consumer goods.Just weeks after clinching the deal to buy Merck 's non-prescription drugs business, Bayer - best known as a life sciences company which makes cancer drugs - is being courted by rivals keen to acquire the foot care and sunscreen brands, several people with knowledge of the approaches told Reuters.But when asked about the expressions of interest for Dr. Scholl's and Coppertone - each worth more than $1 billion - Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter & Gamble Co and Novartis .""We intend to keep the portfolio acquired from Merck & Co. as a core business,"" Bayer said in a written statement.The German company, which makes contraceptives as well as prescription drugs against cancer, heart disease and multiple sclerosis, said when it bought the Merck business that its aim was to become global leader in over-the-counter (OTC) medicines. On Tuesday, Bayer said that the U.S. Federal Trade Commission had approved the Merck deal, which was the largest in the German healthcare sector since Bayer bought rival Schering for 17 billion euros ($24 billion) in 2006. Antitrust clearance in some other markets remains outstanding.But with Bayer's existing OTC medicines business listing products like aspirin and Canesten antifungal creams, some are questioning the logic of it wanting to keep everyday products like sunscreen.""They aren't really part of the core business and don't have much to do with medicines in the strict sense,"" said Warburg Research analyst Ulrich Huwald.Offloading Dr. Scholl's foot care and Coppertone, which account for 27 percent of the Merck bundle's combined annual sales, would allow Bayer to focus on Merck's core healthcare products such as allergy remedy Claritin and MiraLAX laxative, analysts say, and give it the resources to make the most of those brands. Repeated comments by chief executive Marijn Dekkers in the past that Bayer - the inventor of aspirin - is mainly about life sciences and molecular research, seem to have given hope to consumer goods companies that he might yet have wanted to part with brands that have little to do with healthcare.Reckitt Benckiser, which owns the Scholl foot care brand outside the United States, as well as Beiersdorf and L'Oreal were seen as potential acquirers. Officials at the three companies declined to comment.GOING FOR SHELF SPACE?  There are however sound reasons for Bayer to retain Coppertone and Dr. Scholl's despite the products being so different to much of its other business: Big U.S. drug store chains such as Walgreen Co and CVS Caremark  prefer dealing with suppliers that can fill large amounts of shelf space and the two big consumer brands would add to Bayer's bargaining power.Bayer has also said that the Merck deal, which is expected to close in the second half of the year, should allow it to make better use of its distribution network and sales force and give it more clout when dealing with retailers.There may however be another reason Bayer is reluctant to sell. Having bought Merck's unit for more than twice the core earnings multiple at which Johnson & Johnson, the world's largest consumer care company, is trading, any spin-off sales might reveal it to have overpaid.One source said Coppertone and Dr. Scholl's, with $275 million and $309 million in 2013 sales, respectively, could be worth as much as $4 billion between them, reflecting the sales multiple of about 6.5 that Bayer paid for the entire Merck consumer bundle.But another person said that Dr. Scholl's was more likely to fetch $1 billion to $1.5 billion, and Coppertone about $1 billion, because personal care products change hands for lower multiples than the medicines included in last month's deal.Selling on some consumer brands for a lower earnings multiple than what was agreed for the entire Merck portfolio would exposed the high price paid for the remaining OTC drugs - and might not go down well with Bayer investors.""Shareholders would start to do the maths,"" the source said.   (Additional reporting by Anjuli Davis and Ben Hirschler in London; Editing by Sophie Walker and Pravin Char)",2014-07-01,MRK,"Tue Jul 1, 2014 | 11:28am EDT",UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands,http://www.reuters.com//article/bayer-brands-idUSL6N0PC4N120140701?type=companyNews
145,"  (Corrects fourth paragraph to read ""portfolio acquired from Merck"", not ""portfolio acquired by Merck"")* Coppertone, Dr. Scholl's draw interest after $14 bln deal* Bayer says to hold on to non-drug consumer brandsBy Ludwig Burger and Arno SchuetzeFRANKFURT, July 1 German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone brands it bagged as part of a $14 billion buy from U.S. Merck, despite overtures from companies keen to grab them, widening its healthcare line to include consumer goods.Just weeks after clinching the deal to buy Merck 's non-prescription drugs business, Bayer - best known as a life sciences company which makes cancer drugs - is being courted by rivals keen to acquire the foot care and sunscreen brands, several people with knowledge of the approaches told Reuters.But when asked about the expressions of interest for Dr. Scholl's and Coppertone - each worth more than $1 billion - Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter & Gamble Co and Novartis .""We intend to keep the portfolio acquired from Merck & Co. as a core business,"" Bayer said in a written statement.The German company, which makes contraceptives as well as prescription drugs against cancer, heart disease and multiple sclerosis, said when it bought the Merck business that its aim was to become global leader in over-the-counter (OTC) medicines. The deal was the largest in the German healthcare sector since Bayer bought rival Schering for 17 billion euros ($24 billion) in 2006.But with Bayer's existing OTC medicines business listing products like aspirin and Canesten antifungal creams, some are questioning the logic of it wanting to keep everyday products like sunscreen.""They aren't really part of the core business and don't have much to do with medicines in the strict sense,"" said Warburg Research analyst Ulrich Huwald.Offloading Dr. Scholl's foot care and Coppertone, which account for 27 percent of the Merck bundle's combined annual sales, would allow Bayer to focus on Merck's core healthcare products such as allergy remedy Claritin and MiraLAX laxative, analysts say, and give it the resources to make the most of those brands. Repeated comments by chief executive Marijn Dekkers in the past that Bayer - the inventor of aspirin - is mainly about life sciences and molecular research, seem to have given hope to consumer goods companies that he might yet have wanted to part with brands that have little to do with healthcare.Reckitt Benckiser, which owns the Scholl foot care brand outside the United States, as well as Beiersdorf and L'Oreal were seen as potential acquirers. Officials at the three companies declined to comment.GOING FOR SHELF SPACE?  There are however sound reasons for Bayer to retain Coppertone and Dr. Scholl's despite the products being so different to much of its other business: Big U.S. drug store chains such as Walgreen Co and CVS Caremark  prefer dealing with suppliers that can fill large amounts of shelf space and the two big consumer brands would add to Bayer's bargaining power.Bayer has also said that the Merck deal, which is expected to close in the second half of the year, should allow it to make better use of its distribution network and sales force and give it more clout when dealing with retailers.There may however be another reason Bayer is reluctant to sell. Having bought Merck's unit for more than twice the core earnings multiple at which Johnson & Johnson, the world's largest consumer care company, is trading, any spin-off sales might reveal it to have overpaid.One source said Coppertone and Dr. Scholl's, with $275 million and $309 million in 2013 sales, respectively, could be worth as much as $4 billion between them, reflecting the sales multiple of about 6.5 that Bayer paid for the entire Merck consumer bundle.But another person said that Dr. Scholl's was more likely to fetch $1 billion to $1.5 billion, and Coppertone about $1 billion, because personal care products change hands for lower multiples than the medicines included in last month's deal.Selling on some consumer brands for a lower earnings multiple than what was agreed for the entire Merck portfolio would exposed the high price paid for the remaining OTC drugs - and might not go down well with Bayer investors.""Shareholders would start to do the maths,"" the source said.   (Additional reporting by Anjuli Davis and Ben Hirschler in London; Editing by Sophie Walker)",2014-07-01,MRK,"Tue Jul 1, 2014 | 9:50am EDT",CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands,http://www.reuters.com//article/bayer-brands-idUSL6N0PC2LQ20140701?type=companyNews
146,"  (Adds background on Sovaldi, rival drugs)By Ransdell PiersonJuly 11 Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough  treatment for hepatitis C, citing the expense to federal healthcare programs.""Given the impact Sovaldi's cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug,"" the lawmakers said in a release. ""It is unclear how Gilead set the price for Sovaldi.""Sovaldi's cost can soar to $168,000 in patients that need longer treatment periods, not including the costs of other drugs used with it, the senators said. Gilead acquired Sovaldi (sufosbuvir) in 2012 by paying more than $11 billion for Pharmasset Inc. The deal began to bear fruit after Sovaldi produced stellar results in late-stage clinical trials and was approved by U.S. regulators late last year.The nucleotide analog inhibitor, or ""nuke,"" blocks a protein needed by the hepatitis C virus to replicate. Other companies, including Merck & Co, are developing their own nukes and other new types of hepatitis C treatments. The criticism from the two senators follows complaints from private healthcare insurers about the price of the most potent new treatment for the dangerous liver disease, which affects more than 3 million Americans.Gilead's pill, which cures patients more quickly than older drugs, and with fewer side effects, captured $2.3 billion in sales during its first full quarter on the market, a record for the drug industry. The drugmaker has defended the price, saying Sovaldi reduces overall treatment costs for hepatitis C by lowering the number of required healthcare visits and sidestepping the need for other medicines that treat side effects of older therapies.Wyden, an Oregon Democrat, and committee member Chuck Grassley, a Republican from Iowa, said in a letter to Gilead Chief Executive Officer John Martin that Sovaldi's price could also dramatically increase the cost of caring for an estimated 1.8 million prisoners infected with the hepatitis C virus.The senators said Pharmasset, before being acquired by Gilead, had expected to profitably sell the drug in the United States for $36,000, according to Securities and Exchange Commission documents.   (Reporting by Ransdell Pierson in New York; Editing by Lisa Von Ahn)",2014-07-11,MRK,"Fri Jul 11, 2014 | 11:15am EDT",UPDATE 1-U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug,http://www.reuters.com//article/gilead-sciences-sovaldi-senators-idUSL2N0PM0UB20140711?type=companyNews
147,"  FRANKFURT, July 26 Merck will start offering non-prescription drugs in China as part of a push to double revenues in the region to 1 billion euros ($1.3 billion) by 2018, Chief Executive Karl-Ludwig Kley told German weekly Wirtschaftswoche. Merck will focus on treatments related to diabetes, thyroid issues and heart problems, and supply medication made at a new factory in Nantong which is due to start production in 2017, Wirtschaftswoche said.    ($1 = 0.7447 Euros)   (Reporting by Edward Taylor; Editing by Ruth Pitchford)  ",2014-07-26,MRK,"Sat Jul 26, 2014 | 7:35am EDT",Merck aims to hike revenues in China to 1 bln eur by 2018,http://www.reuters.com//article/merck-china-wirtschaftswoche-idUSL6N0Q10AR20140726?type=companyNews
148,"   By Ransdell Pierson | NEW YORK  NEW YORK Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.The largest U.S. drugmaker, whose laboratories have not come up with any big-selling new medicines for a decade, is expected to report significantly lower second-quarter revenue.While many industry watchers expect Pfizer to re-engage with Britain's AstraZeneca in coming months, some say the U.S. drugmaker should consider targets more focused on biotechnology, a strategy that has paid off for Merck & Co and Bristol-Myers Squibb Co. Although Pfizer is conducting trials ofpromising products - including breast cancer drug palbociclib and vaccines against meningitis and staph aureus - it needs far more drugs to generate meaningful sales growth, said Ori Hershkovitz, analyst with the Tel Aviv-based Sphera Fund, which holds Pfizer shares.""Pfizer is in a very desperate spot, having seen most of its pipeline disappoint and facing multiple patent expirations,"" he said. ""It needs growth; it needs to buy a pipeline."" Pfizer on May 26 officially abandoned its six-month quest for AstraZeneca after its final $118 billion offer was spurned. Investors still see a rationale for the deal, which would allow Pfizer to enjoy lower corporate tax rates as a UK-based company and a promising pipeline of new cancer treatments. Under British takeover law, AstraZeneca could reach out to Pfizer in August and Pfizer could make renewed overtures to its smaller rival in November.""I definitely think Pfizer will come back for Astra at a somewhat higher bid,"" Hershkovitz said. But he recommended Pfizer consider smaller targets whose treatments might broaden  its existing research priorities, such as Belgium's UCB SA and Switzerland's Actelion Ltd. UCB, which makes treatments for epilepsy, rheumatoid arthritis and Parkinson's disease, has annual sales of $5 billion, and a market value of $17 billion. Actelion sells lucrative drugs for orphan diseases, rare and often life-threatening conditions that command high prices. It has annual sales of $2 billion and a market capitalization of $15 billion.  Leerink Swann analyst Jason Gerberry has said it might make sense for Pfizer to buy Dublin-based generic drugmaker Actavis, which itself just bought U.S. specialty drugmaker Forest Laboratories for $25 billion.Disappointment with Pfizer is reflected in its stock price, which has fallen 1.4 percent this year, against a 11 percent gain for the ARCA Pharmaceutical Index of large U.S. and European drugmakers. Over the past two years, its shares have risen 27 percent, versus a 44 percent jump for the drug sector.A fresh wave of patent expirations on Pfizer's top drugs is approaching. Its Celebrex painkiller faces generics in the United States late this year, while impotence treatment Viagra goes generic in 2017. The company's biggest product, Lyrica for nerve pain, loses U.S. patent protection by 2018. The three drugs have combined annual sales of almost $9 billion, and account for almost 20 percent of Pfizer's total revenue.  Biotechs with drugs already on the market and which also  have exciting technologies should be on Pfizer's wish list, said Navid Malik, analyst with London-based Cenkos Securities. He cited companies such as Celgene Inc and Vertex Pharmaceuticals Inc.Roger Pomerantz, who headed business development at Merck from 2010 until last summer, said the potential of Merck's immuno-oncology drugs - medicines which train the immune system to recognize cancer cells - was not recognized even within the company for several years after it acquired them.""It's who you have on the inside helping you understand the science"" that counts, he said. (Reporting by Ransdell Pierson; Editing by Michele Gershberg and Lisa Shumaker)",2014-07-28,MRK,"Mon Jul 28, 2014 | 1:36am EDT",Pfizer's need for deal looms larger with earnings report,http://www.reuters.com//article/us-pfizer-strategy-idUSKBN0FX0AR20140728?type=companyNews
149,"  * UPS shares fall after outlook, weighing on transports* Windstream rallies; set to spin off assets into REIT* Merck up as results beat expectations, but Pfizer slips* Indexes: Dow flat, S&P off 0.1 pct, Nasdaq up 0.2 pct   (Updates to close; adds Twitter and American Express results)By Ryan VlastelicaNEW YORK, July 29 U.S. stocks fell on Tuesday, dropping in a broad selloff as a weak outlook from courier company UPS weighed on sentiment and pressured transportation stocks.Although a rally in telecom stocks helped to limit the broader market's decline, the S&P 500 ended below its 14-day moving average for a second straight day. Nine of the 10 primary S&P 500 sectors fell on the day.United Parcel Service shares fell 3.7 percent to $98.86 after the world's biggest courier company slashed its earnings forecast for the year due to spending to boost capacity. It also reported second-quarter earnings that were below expectations. Rival shipping company FedEx Corp was down 1.6 percent at $147.14. The Dow Jones Transportation index, which is often viewed as a proxy for business activity, fell 1.4 percent. It is about 3 percent away from the record closing high hit last week.UPS is the latest bellwether name whose results have disappointed investors, following Amazon.com Inc and Boeing Co last week. Nonetheless, this earnings season has largely been a positive for equities.With more than half the S&P 500 having reported already, almost 70 percent have topped earnings expectations, according to Thomson Reuters data, well above the long-term average of 63 percent. More than 63 percent have topped revenue forecasts, above the long-term average of 61 percent.""If we started to see more negative outlooks, that would be a reason to pause, but so far this earnings season speaks to the health of corporate America and suggests markets still have room to run,"" said David Lebovitz, global market strategist at J.P. Morgan Funds in New York. Telecom stocks were the only sector of the market to rise on Tuesday, adding 2.2 percent after Windstream Holdings  filed to spin off assets into a tax-efficient publicly traded real estate investment trust. The stock jumped 12.3 percent to $11.83 in its busiest trading day on record. Frontier Communications added 14.3 percent to $6.79.After the market closed, Twitter Inc jumped 14.5 percent to $44.20 in extended trading after the social networking company reported second-quarter results, which included revenue that more than doubled. The shares had closed up 1.7 percent in regular NYSE trade ahead of the results.Dow component American Express Co also reported after the market closed; its shares were little changed after the bell.The Dow Jones industrial average fell 70.16 points, or 0.41 percent, to 16,912.43, the S&P 500 lost 8.93 points, or 0.45 percent, to 1,969.98, and the Nasdaq Composite  dropped 2.21 points, or 0.05 percent, to 4,442.70. The Nasdaq's decline was tempered by biotechnology shares, with the Nasdaq Biotech index up 1.1 percent.Dow components Pfizer and Merck, the No. 1 and No. 2 U.S. drug companies, respectively, reported better-than-expected results. Merck's new drugs offset declining sales of those facing generic competition. Pfizer was helped by growing sales of its cancer medicines. Merck rose 1.1 percent at $58.58 while Pfizer shed 1.2 percent to $29.73.Corning Inc dropped 9.3 percent to $20 after reporting earnings that came in below estimates as demand fell for its Gorilla Glass, which is used in iPhones and Galaxy devices.Economic data had little impact on the direction of equities.U.S. consumer confidence jumped in July to a high not seen since October 2007, but single-family home prices fell 0.3 percent in May on a seasonally adjusted basis, falling short of expectations.President Barack Obama said the United States was imposing new sanctions on Russia in the energy, arms and finance sectors, following similar moves by the European Union in reaction to Moscow's support for rebels in eastern Ukraine.About 57 percent of stocks traded on the New York Stock Exchange closed lower on the day while about 47 percent of Nasdaq-listed shares ended in negative territory. About 5.59 billion shares traded on all U.S. platforms, according to BATS exchange data, compared with the month-to-date average of 5.54 billion.   (Editing by Meredith Mazzilli; Editing by Leslie Adler)",2014-07-29,MRK,"Tue Jul 29, 2014 | 4:28pm EDT",US STOCKS-Wall Street ends down; Twitter rallies after-hours,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0Q42D520140729?type=companyNews
150,"  * UPS shares fall after outlook, weighs on transports* Windstream rallies; set to spin off assets into REIT* Merck up as results beat expectations, but Pfizer slips* Indexes: Dow flat, S&P off 0.1 pct, Nasdaq up 0.2 pct   (Updates to afternoon trading)By Ryan VlastelicaNEW YORK, July 29 U.S. stocks mostly fell on Tuesday as a weak outlook from UPS weighed on sentiment and pressured transportation stocks, though other corporate results capped losses in equities. United Parcel Service shares fell 3.1 percent to $99.47 after the world's biggest courier company slashed its earnings forecast for the year due to spending to boost capacity. It also reported earnings that were below expectations.Rival shipping company FedEx Corp was down 0.8 percent at $148.36. The Dow Jones Transportation index, which is often viewed as a proxy for business activity, fell 0.7 percent. It is about 2.3 percent away from a record closing high hit last week.UPS is the latest bellwether name to disappoint in its results, following Amazon.com Inc and Boeing Co  last week. Nonetheless, this earnings season has largely been a positive for equities. With more than half the S&P 500 having reported, almost 70 percent have topped earnings expectations, according to Thomson Reuters data, well above the long-term average of 63 percent. More than 63 percent have topped revenue forecasts, above the long-term average of 61 percent. ""If we started to see more negative outlooks, that would be a reason to pause, but so far this earnings season speaks to the health of corporate America and suggests markets still have room to run,"" said David Lebovitz, global market strategist at J.P. Morgan Funds in New York.Telecom stocks were by far the strongest of the day, up 2.7 percent after Windstream Holdings filed to spin off assets into a tax-efficient publicly-traded real estate investment trust. The stock jumped 12.8 percent to $11.88 in its busiest trading day on record. Frontier Communications added 11.1 percent to $6.60.The Dow Jones industrial average fell 28.61 points or 0.17 percent, to 16,953.98, the S&P 500 lost 4.13 points or 0.21 percent, to 1,974.78 and the Nasdaq Composite  added 4.78 points or 0.11 percent, to 4,449.69. The Nasdaq was boosted by biotechnology shares, with the Nasdaq Biotech index up 1.4 percent.Dow components Merck and Pfizer reported better-than-expected results. Merck's new drugs offset declining sales of ones facing generic competition and Pfizer was helped by growing sales of its cancer medicines. Merck rose 1.7 percent at $58.95 while Pfizer shed 0.9 percent to $29.83.Corning Inc dropped 9.8 percent to $19.90 after reporting earnings that came in below estimates.U.S. consumer confidence jumped in July to a high not seen since October 2007 but single-family home prices fell 0.3 percent in May on a seasonally-adjusted basis, falling short of expectations.The Federal Reserve began a two-day meeting on monetary policy. The Fed could make subtle yet telling changes to its policy statement due Wednesday, as it plans how and when to eventually raise interest rates.    (Editing by Meredith Mazzilli)",2014-07-29,MRK,"Tue Jul 29, 2014 | 2:50pm EDT","US STOCKS-Wall St edges lower on UPS outlook, telecom shares rally",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0Q41XR20140729?type=companyNews
151,"  * Windstream rallies; set to spin off assets into REIT* Merck rises as results beat expectations, but Pfizer slips* Herbalife shares tumble after it cuts sales outlook* Indexes: Dow flat, S&P off 0.1 pct, Nasdaq up 0.2 pct   (Updates prices, changes comment, adds Corning)By Rodrigo CamposNEW YORK, July 29 U.S. stocks were little changed on Tuesday after a rally in the telecommunications sector lost steam and a lower earnings forecast from UPS weighed on sentiment.Windstream Holdings jumped 12.8 percent to $11.88 in its busiest trading day on record after the company filed to spin off assets into a tax-efficient publicly-traded real estate investment trust. The strategy triggered bets on long-term advantages for peers but the initial gains reversed in late morning trade. The S&P telecoms sector index rose 2.8 percent after earlier gaining as much as 5.5 percent.""Winstream was unbelievably good at keeping this close to the vest and everybody was surprised,"" said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh. However, she said, ""the rethinking of the larger telecoms becoming REITs took the wind off of the market.""Telecom stocks were still higher on bets they could also be looking for ways to reduce taxes. AT&T was up 3.3 percent to $36.83, Verizon gained 1.6 percent to $52.40, CenturyLink was up 4.3 percent to $39.33 and Frontier Communications added 11.1 percent to $6.60.Weighing on the S&P 500, shares of UPS fell 3.4 percent to $99.14 after the world's biggest courier company slashed its earnings forecast for the year due to spending to boost capacity. The S&P industrial sector fell 0.6 percent. Corning shares dropped 9.8 percent to $19.90 after second-quarter core earnings came in below analysts' estimates.Dow components Merck and Pfizer reported better-than-expected results. Merck's new drugs offset declining sales of ones facing generic competition and Pfizer was helped by growing sales of its cancer medicines.Merck shares were up 1.7 percent at $58.95 while Pfizer shed 0.4 percent to $29.97. The Dow Jones industrial average fell less than a point to 16,981.89, the S&P 500 lost 1.84 points or 0.09 percent, to 1,977.07 and the Nasdaq Composite added 7.86 points or 0.18 percent, to 4,452.77.U.S. consumer confidence jumped in July to a high not seen since October 2007 but single-family home prices fell 0.3 percent in May on a seasonally-adjusted basis, falling short of expectations.The Federal Reserve began a two-day meeting on monetary policy. The Fed could make subtle yet telling changes to its policy statement due Wednesday, as it plans how and when to eventually raise interest rates.Shares of health insurer Aetna fell 3.6 percent to $81.74, even as it reported a higher second-quarter profit helped by last year's acquisition of Medicare and Medicaid provider Coventry Health Care.Herbalife cut its sales outlook for the year after raising it three months earlier, following billionaire investor Bill Ackman's latest round of accusations against the company last week. Shares of the weight-loss and nutrition products company slid 11 percent to $60.07.    (Editing by Bernadette Baum and Nick Zieminski)",2014-07-29,MRK,"Tue Jul 29, 2014 | 12:25pm EDT",US STOCKS-Wall St flat as telecom gains offset by earnings,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0Q41G020140729?type=companyNews
152,"  (Corrects paragraph 11 to show UPS is on Dow transportation index, not Dow industrials)* Windstream rallies; set to spin off assets into REIT* Pfizer, Merck rise as results beat expectations* Herbalife shares tumble after it cuts sales outlook* Indexes up: Dow 0.34 pct, S&P 0.24 pct, Nasdaq 0.55 pctBy Rodrigo CamposNEW YORK, July 29 U.S. stocks rose Tuesday on news about a spinoff in the telecommunications sphere that sent most stocks in the sector soaring and on better-than-expected results from Pfizer and Merck. Windstream Holdings jumped 18.2 percent to $12.45 in its most brisk trading on record after the company filed to spin off assets into a tax-efficient publicly-traded real estate investment trust.The strategy triggered bets on long-term advantages for peers and the S&P telecoms sector index rose 3.9 percent with AT&T up 4 percent to $37.09, Verizon  up 2.4 percent at $52.82, CenturyLink up 9.2 percent to $41.18 and Frontier Communications up 18.2 percent to $7.02.The Windstream spinoff's long reach boosted shares in other network owners and operators, with Comcast and Time Warner Cable up more than 2 percent each, lifting the S&P consumer discretionary sector 0.6 percent. ""The market to some degree has been locked into a range and struggling to find leadership of late, so the movement in telecoms is important in that regard,"" said Gordon Charlop, a managing director at Rosenblatt Securities in New York.Dow components Merck and Pfizer reported better-than-expected quarterly results. Merck's new drugs offset declining sales of ones facing generic competition and Pfizer was helped by growing sales of its cancer medicines.   Merck shares were up 1.5 percent at $58.85 and Pfizer added 0.4 percent to $30.22.The Dow Jones industrial average rose 58.51 points or 0.34 percent, to 17,041.1, the S&P 500 gained 4.66 points or 0.24 percent, to 1,983.57 and the Nasdaq Composite  added 24.35 points or 0.55 percent, to 4,469.26. U.S. consumer confidence jumped in July to a high not seen since October 2007 but single-family home prices fell 0.3 percent in May on a seasonally adjusted basis, falling short of expectations.""The data has been unremarkable, there's nothing in there to cause the market to deviate from its current trajectory,"" said Charlop. ""Unless we have earnings surprises I don't see anything that will derail the move to the upside.""The Federal Reserve began a two-day meeting on monetary policy. The Fed could make subtle yet telling changes to its policy statement due Wednesday, as it plans how and when to eventually raise interest rates.Weighing on the Dow Jones Transportation Average, shares of UPS fell 3.3 percent to $99.32 after the world's biggest courier company slashed its earnings forecast for the year due to spending to boost capacity.  The index was down 0.8 percent.Shares of health insurer Aetna fell 2.7 percent to $82.54, even as it reported a higher second-quarter profit helped by last year's acquisition of Medicare and Medicaid provider Coventry Health Care.Herbalife cut its sales outlook for the year after raising it three months earlier, following billionaire investor Bill Ackman's latest round of accusations against the company last week. Shares of the weight-loss and nutrition products company slid 11.9 percent to $59.44.    (Editing by Bernadette Baum)",2014-07-29,MRK,"Tue Jul 29, 2014 | 11:16am EDT","CORRECTED-US STOCKS-Wall St gains, telecoms sector lifted by Windstream",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0Q417M20140729?type=companyNews
153,"   By Ransdell Pierson  Merck & Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.  Merck, the No. 2 U.S. drugmaker, has been busy with deal-making in recent months, including an agreement to sell its consumer care business to Germanys Bayer AG for $14.2 billion. In June, it agreed to buy Idenix Pharmaceuticals Inc for $3.85 billion and hopes to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C.Chief Executive Kenneth Frazier, in a conference call with analysts on Tuesday, said Merck was not interested in major acquisitions, but instead favors smaller ""bolt-on"" deals like the Idenix transaction.Merck is counting on its experimental drugs, including an immuno-oncology drug called pembrolizumab, to help drive revenue and earnings growth in coming years, Frazier said.The company plans to launch pembrolizumab by late October for treatment of melanoma and is testing the drug for cancers of the lung, head and neck and bladder. It plans to introduce insomnia drug Suvorexant, long been delayed by safety concerns, by late 2014 or 2015, if it is approved by regulators.""Merck will likely have another flattish year in 2014 in terms of financial performance but then growth should return more consistently thereafter,"" helped by new drugs, Sanford Bernstein analyst Tim Anderson said in a research note. Merck shares were up 1.3 percent at $58.72.The company earned $2.03 billion, or 68 cents per share, in the second quarter. That compares with $906 million, or 30 cents per share, in the year-earlier period, when it took charges for acquisitions and restructuring.Excluding special items, Merck earned 85 cents per share, topping the average 81 cent forecast of analysts surveyed by Thomson Reuters I/B/E/S. U.S. rival Pfizer Inc on Tuesday also reported better-than-expected quarterly results.Merck said it expects full-year earnings of $3.43 to $3.53 per share, tightening its earlier forecast of $3.35 to $3.53. The new outlook included expected dilution of up to 9 cents per share from the Bayer and Idenix deals.Global revenue slipped 1 percent to $10.93 billion, but exceeded expectations of $10.6 billion.     Sales of consumer care brands, such as its Miralax laxative and Afrin cold remedy, jumped 19 percent to $583 million. Sales of prescription drugs slipped 2 percent to $9.1 billion, hurt by a 21 percent drop for its Nasonex nasal allergy treatment due to generic competition.    Sales of HIV treatment Isentress rose 10 percent to $453 million, while Remicade arthritis drug sales increased 15 percent to $607 million.Combined sales of Merck's biggest drugs, diabetes treatments Januvia and Janumet, rose 2 percent to $1.58 billion. Their growth has slowed this year with competition from newer drugs. (Editing by Michele Gershberg, Bernadette Baum and Jeffrey Benkoe)",2014-07-29,MRK,"Tue Jul 29, 2014 | 10:37am EDT",Merck quarterly profit beats estimates; shares gain,http://www.reuters.com//article/us-merck-results-idUSKBN0FY10320140729?type=companyNews
154,"  (Adds comments from CEO, analysts, details on drug pipeline)By Ransdell PiersonJuly 29 Merck & Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.Merck, the No. 2 U.S. drugmaker, has been busy with deal-making in recent months, including an agreement to sell its consumer care business to Germany's Bayer AG for $14.2 billion. In June, it agreed to buy Idenix Pharmaceuticals Inc for $3.85 billion and hopes to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C.Chief Executive Kenneth Frazier, in a conference call with analysts on Tuesday, said Merck was not interested in major acquisitions, but instead favors smaller ""bolt-on"" deals like the Idenix transaction.Merck is counting on its experimental drugs, including an immuno-oncology drug called pembrolizumab, to help drive revenue and earnings growth in coming years, Frazier said.The company plans to launch pembrolizumab by late October for treatment of melanoma and is testing the drug for cancers of the lung, head and neck and bladder. It plans to introduce insomnia drug Suvorexant, long been delayed by safety concerns, by late 2014 or 2015, if it is approved by regulators. ""Merck will likely have another flattish year in 2014 in terms of financial performance but then growth should return more consistently thereafter,"" helped by new drugs, Sanford Bernstein analyst Tim Anderson said in a research note.Merck shares were up 1.3 percent at $58.72.The company earned $2.03 billion, or 68 cents per share, in the second quarter. That compares with $906 million, or 30 cents per share, in the year-earlier period, when it took charges for acquisitions and restructuring. Excluding special items, Merck earned 85 cents per share, topping the average 81 cent forecast of analysts surveyed by Thomson Reuters I/B/E/S.U.S. rival Pfizer Inc on Tuesday also reported better-than-expected quarterly results. Merck said it expects full-year earnings of $3.43 to $3.53 per share, tightening its earlier forecast of $3.35 to $3.53. The new outlook included expected dilution of up to 9 cents per share from the Bayer and Idenix deals.Global revenue slipped 1 percent to $10.93 billion, but exceeded expectations of $10.6 billion.Sales of consumer care brands, such as its Miralax laxative and Afrin cold remedy, jumped 19 percent to $583 million. Sales of prescription drugs slipped 2 percent to $9.1 billion, hurt by a 21 percent drop for its Nasonex nasal allergy treatment due to generic competition.Sales of HIV treatment Isentress rose 10 percent to $453 million, while Remicade arthritis drug sales increased 15 percent to $607 million.Combined sales of Merck's biggest drugs, diabetes treatments Januvia and Janumet, rose 2 percent to $1.58 billion. Their growth has slowed this year with competition from newer drugs.    (Editing by Michele Gershberg, Bernadette Baum and Jeffrey Benkoe)",2014-07-29,MRK,"Tue Jul 29, 2014 | 10:34am EDT",UPDATE 3-Merck quarterly profit beats estimates; shares gain,http://www.reuters.com//article/merck-results-idUSL2N0Q40IS20140729?type=companyNews
155,"   By Rodrigo Campos | NEW YORK  NEW YORK U.S. stocks were set to rise slightly at the open on Tuesday following better-than-expected results from companies such as Pfizer and Merck and ahead of data on consumer sentiment.Merck (MRK.N) reported better-than-expected quarterly results as new drugs offset declining sales of ones facing generic competition. Pfizer's (PFE.N) higher-than-expected second-quarter earnings were helped by growing sales of its cancer medicines. Merck was up 1 percent in premarket, while Pfizer gained 0.6 percent.Shares of UPS (UPS.N) fell 3 percent premarket after the world's biggest courier company slashed its earnings forecast for the year as it spent to boost capacity. Single-family home prices fell 0.3 percent in May on a seasonally adjusted basis, falling short of expectations calling for a 0.2 percent gain. The Conference Board's consumer sentiment for July is due at 10:00 a.m. EDT. Later on Tuesday, the Federal Reserve begins a two-day meeting on monetary policy. The Fed could make subtle yet telling changes to its policy statement due Wednesday, as it plans how and when to eventually raise interest rates. S&P 500 e-mini futures were up 3 points and fair value - a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract - indicated a slightly higher open. Dow Jones industrial average e-mini futures rose 40 points and Nasdaq 100 e-mini futures added 7 points.Shares of Windstream Holdings (WIN.O) jumped 31 percent in premarket trading after the company filed to spin off assets into a publicly-traded real estate investment trust. Shares of health insurer Aetna (AET.N) fell 2.6 percent before the opening bell, even as it reported a higher second-quarter profit, helped by last year's acquisition of Medicare and Medicaid provider Coventry Health Care. Spirit Airlines (SAVE.O) rose 2.6 percent in light premarket trading after the low-cost U.S. carrier reported a 54 percent rise in second-quarter profit.  Costco (COST.O) shares rose 2.2 percent premarket after Goldman Sachs added the stock to its conviction buy list.Herbalife (HLF.N) cut its sales outlook for the year after raising it three months earlier, following billionaire investor Bill Ackman's latest round of accusations against the company last week. Shares of the weight-loss and nutrition products company slid 12 percent in premarket trading.  (Editing by Bernadette Baum)",2014-07-29,MRK,"Tue Jul 29, 2014 | 9:19am EDT","Wall Street to rise on earnings, data weighs",http://www.reuters.com//article/us-markets-stocks-idUSKBN0FY13L20140729?type=companyNews
156,"  * Windstream rallies; set to spin off assets into REIT* Pfizer, Merck rise as results beat expectations* Herbalife shares tumble after it cuts sales outlook* Futures up: Dow 40 pts, S&P 3 pts, Nasdaq 7 pts   (Updates prices, adds data)By Rodrigo CamposNEW YORK, July 29 U.S. stocks were set to rise slightly at the open on Tuesday following better-than-expected results from companies such as Pfizer and Merck and ahead of data on consumer sentiment. * Merck reported better-than-expected quarterly results as new drugs offset declining sales of ones facing generic competition. Pfizer's higher-than-expected second-quarter earnings were helped by growing sales of its cancer medicines.  Merck was up 1 percent in premarket, while Pfizer gained 0.6 percent.* Shares of UPS fell 3 percent premarket after the world's biggest courier company slashed its earnings forecast for the year as it spent to boost capacity.* Single-family home prices fell 0.3 percent in May on a seasonally adjusted basis, falling short of expectations calling for a 0.2 percent gain. The Conference Board's consumer sentiment for July is due at 10:00 a.m. EDT (1400 GMT). * Later on Tuesday, the Federal Reserve begins a two-day meeting on monetary policy. The Fed could make subtle yet telling changes to its policy statement due Wednesday, as it plans how and when to eventually raise interest rates.* S&P 500 e-mini futures were up 3 points and fair value - a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract - indicated a slightly higher open. Dow Jones industrial average e-mini futures rose 40 points and Nasdaq 100 e-mini futures added 7 points. * Shares of Windstream Holdings jumped 31 percent in premarket trading after the company filed to spin off assets into a publicly-traded real estate investment trust.* Shares of health insurer Aetna fell 2.6 percent before the opening bell, even as it reported a higher second-quarter profit, helped by last year's acquisition of Medicare and Medicaid provider Coventry Health Care.* Spirit Airlines rose 2.6 percent in light premarket trading after the low-cost U.S. carrier reported a 54 percent rise in second-quarter profit.* Costco shares rose 2.2 percent premarket after Goldman Sachs added the stock to its conviction buy list.* Herbalife cut its sales outlook for the year after raising it three months earlier, following billionaire investor Bill Ackman's latest round of accusations against the company last week. Shares of the weight-loss and nutrition products company slid 12 percent in premarket trading.    (Editing by Bernadette Baum)",2014-07-29,MRK,"Tue Jul 29, 2014 | 9:16am EDT","US STOCKS-Wall St to rise on earnings, data weighs",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0Q40UF20140729?type=companyNews
157,"  * Pfizer, Merck rise as results beat expectations* Herbalife shares tumble after it cuts sales outlook* Futures up: Dow 33 pts, S&P 3 pts, Nasdaq 7 ptsNEW YORK, July 29 U.S. stock index futures edged higher on Tuesday following better-than-expected results from companies such as Pfizer and Merck and ahead of data on home prices and consumer sentiment.* Merck reported better-than-expected quarterly results as new drugs offset declining sales of ones facing generic competition. Pfizer's higher-than-expected second-quarter earnings were helped by growing sales of its cancer medicines. * The economic calendar for Tuesday includes S&P/Case-Shiller home price index for May at 9:00 a.m. EDT (1300 GMT) and the Conference Board's consumer sentiment for July an hour later.* Later on Tuesday, the Federal Reserve begins a two-day meeting on monetary policy. The Fed could make subtle yet telling changes to its policy statement due Wednesday, as it plans how and when to eventually raise interest rates. * S&P 500 e-mini futures were up 3 points and fair value - a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract - indicated a slightly higher open. Dow Jones industrial average e-mini futures rose 33 points and Nasdaq 100 e-mini futures added 7 points. * Shares of health insurer Aetna rose after it reported a higher second-quarter profit, helped by last year's acquisition of Medicare and Medicaid provider Coventry Health Care.* Spirit Airlines rose 2.6 percent in light premarket trading after the low-cost U.S. carrier reported a 54 percent rise in second-quarter profit.* Costco shares rose 2.2 percent premarket after Goldman Sachs added the stock to its conviction buy list.* Herbalife cut its sales outlook for the year after raising it three months earlier, following billionaire investor Bill Ackman's latest round of accusations against the company last week. Shares of the weight-loss and nutrition products company slid 11.4 percent in premarket trading.    (Reporting by Rodrigo Campos; Editing by Bernadette Baum)",2014-07-29,MRK,"Tue Jul 29, 2014 | 7:51am EDT","US STOCKS-Futures rise on earnings, data on tap",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0Q40JY20140729?type=companyNews
158,"  July 29 Merck & Co reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.The No. 2 U.S. drugmaker on Tuesday said it earned $2.03 billion, or 68 cents per share, in the second quarter. That compared with $906 million, or 30 cents per share, in the year-earlier period, when Merck took charges for acquisitions and restructuring. Excluding special items, Merck earned 85 cents per share. Analysts, on average, were expecting 81 cents per share, according to Thomson Reuters I/B/E/S.  (Reporting by Ransdell Pierson)",2014-07-29,MRK,"Tue Jul 29, 2014 | 7:10am EDT","Merck beats forecasts, as newer drugs offset generics",http://www.reuters.com//article/merck-results-idUSL2N0Q30S920140729?type=companyNews
159,"   By Toni Clarke | WASHINGTON  WASHINGTON The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.The drug, to be called Belsomra, is the first in a new class of sedatives that block chemicals in the brain called orexins that help keep people awake.Belsomra, known generically as suvorexant, has the potential to cause next-day sleepiness and impaired driving. As a result, the FDA said, no more than one pill should be taken per night and the dose should not exceed 20 milligrams.The FDA had asked Merck to study the next-day driving performance of people who took the drug amid concerns the sedative could lead to next-day drowsiness.The test showed impaired driving in patients who took 20 milligrams of the drug. Patients therefore ""should be cautioned against next-day driving or activities requiring full mental alertness,"" the FDA said in a statement.Even those who take a lower dose should be made aware of the potential for next-day driving impairment because individuals may respond differently to any given drug, the agency said. The FDA approved the drug in 5, 10, 15 and 20 milligram doses.Merck said it expects the drug to be available in late 2014 or early 2015, once the Drug Enforcement Administration has made its final decision on the scheduling of the drug.The FDA recommended that Belsomra be listed as a controlled substance because it can be addictive and has the potential to be abused. The DEA has proposed that the drug be given a Schedule IV designation. Schedule 1 drugs have the greatest potential for abuse while Schedule V drugs have the least potential.Merck's shares rose 1.4 percent on the New York Stock Exchange on Wednesday to close at $57.85.Merck had originally proposed that non-elderly adults start on 20 milligrams and increase to 40 milligrams if needed. It recommended that elderly patients start by taking 15 milligrams and increase to 30 if necessary. FDA officials said at an advisory committee meeting in May 2013 that there was little evidence to show the drug was more effective at higher doses and considerable evidence to show it was less safe.""Using the lowest effective dose can reduce the risk of side effects, such as next-morning drowsiness,"" said Dr. Ellis Unger, an official in the FDA's drugs division.Merck said on Wednesday that the recommended dose of Belsomra is 10 milligrams within 30 minutes of going to bed, with at least seven hours before a patient needs to wake up. The drug is designed for people who have difficulty getting to sleep and staying asleep. (Reporting by Toni Clarke; Editing by Sandra Maler, Mohammad Zargham and Lisa Shumaker)",2014-08-13,MRK,"Wed Aug 13, 2014 | 5:28pm EDT",U.S. FDA approves Merck insomnia drug,http://www.reuters.com//article/us-merck-insomnia-idUSKBN0GD1WN20140813?type=companyNews
160,"  (Updates with company comment)By Toni ClarkeWASHINGTON Aug 13 The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.The drug, to be called Belsomra, is the first in a new class of sedatives that block chemicals in the brain called orexins that help keep people awake.Belsomra, known generically as suvorexant, has the potential to cause next-day sleepiness and impaired driving. As a result, the FDA said, no more than one pill should be taken per night and the dose should not exceed 20 milligrams.The FDA had asked Merck to study the next-day driving performance of people who took the drug amid concerns the sedative could lead to next-day drowsiness.The test showed impaired driving in patients who took 20 milligrams of the drug. Patients therefore ""should be cautioned against next-day driving or activities requiring full mental alertness,"" the FDA said in a statement. Even those who take a lower dose should be made aware of the potential for next-day driving impairment because individuals may respond differently to any given drug, the agency said.The FDA approved the drug in 5, 10, 15 and 20 milligram doses.Merck said it expects the drug to be available in late 2014 or early 2015, once the Drug Enforcement Administration has made its final decision on the scheduling of the drug. The FDA recommended that Belsomra be listed as a controlled substance because it can be addictive and has the potential to be abused. The DEA has proposed that the drug be given a Schedule IV designation.Schedule 1 drugs have the greatest potential for abuse while Schedule V drugs have the least potential.Merck's shares rose 1.4 percent on the New York Stock Exchange on Wednesday to close at $57.85. Merck had originally proposed that non-elderly adults start on 20 milligrams and increase to 40 milligrams if needed. It recommended that elderly patients start by taking 15 milligrams and increase to 30 if necessary.FDA officials said at an advisory committee meeting in May 2013 that there was little evidence to show the drug was more effective at higher doses and considerable evidence to show it was less safe.""Using the lowest effective dose can reduce the risk of side effects, such as next-morning drowsiness,"" said Dr. Ellis Unger, an official in the FDA's drugs division.Merck said on Wednesday that the recommended dose of Belsomra is 10 milligrams within 30 minutes of going to bed, with at least seven hours before a patient needs to wake up. The drug is designed for people who have difficulty getting to sleep and staying asleep.(Reporting by Toni Clarke; Editing by Sandra Maler, Mohammad Zargham and Lisa Shumaker)",2014-08-13,MRK,"Wed Aug 13, 2014 | 5:27pm EDT",UPDATE 2-U.S. FDA approves Merck insomnia drug,http://www.reuters.com//article/merck-insomnia-idUSL2N0QJ2BB20140813?type=companyNews
161,"  WASHINGTON Aug 13 The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co..The drug, to be called Belsomra, is the first in a new class of sedatives that block chemicals in the brain called orexins that help keep people awake. Belsomra, known generically as suvorexant, has the potential to cause next-day sleepiness and impaired driving.  The FDA approved the drug in four different strengths, with 20 milligrams being the maximum.    (Reporting by Toni Clarke; Editing by Sandra Maler)",2014-08-13,MRK,"Wed Aug 13, 2014 | 3:46pm EDT",U.S. FDA approves Merck insomnia drug,http://www.reuters.com//article/merck-insomnia-idUSL2N0QJ2A120140813?type=companyNews
162,"   By Deena Beasley | LOS ANGELES  LOS ANGELES U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.If approved by the Food and Drug Administration, the drug would be the first in a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.Companies including Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc are racing to develop similar treatments for a variety of cancers. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.The FDA is slated to decide on New Jersey-based Merck's application no later than October 28, but sources said the agency could give its approval within coming weeks. The sources, who spoke on condition of anonymity because they were not authorized to discuss the FDA's plans, also acknowledged that the early approval was not guaranteed.A spokeswoman for the FDA said the agency cannot discuss the status of applications.Merck is first seeking to sell its PD-1 drug for patients whose skin cancer does not respond to treatment with Yervoy, a Bristol-Myers immunotherapy that targets a different part of the immune system.Studies have shown that pembrolizumab shrinks tumors in about a third of patients with late-stage melanoma, a disease that kills around 10,000 Americans each year.""My hope is that over the next five to 10 years, we will be curing over half of melanoma patients,"" said Dr Steven O'Day, director of the Los Angeles Skin Cancer Institute.Dr Antoni Ribas, professor of hematology-oncology at the University of California, Los Angeles, and a pembrolizumab trial lead investigator, said having the drug on the market will be ""a big deal"" for patients who currently have few options. ""If we have pembro approved, it makes a big difference. About a third of those patients will have a chance of a durable, long-lasting response,"" he said.Merck and its rivals are also studying PD-1 drugs as a treatment for several types of cancer. Lung cancer, which kills nearly 160,000 Americans annually, is seen as the biggest sales opportunity for the new class of treatments.Most current oncology treatments seek to kill cancer cells directly whereas immuno-oncology drugs unleash the body's own ability to recognize and destroy cancer cells, which medical  researchers say could have broader reach.A potential risk is that stimulating the immune system could cause side effects ranging from mild rash to more serious liver problems or colitis. FIRST IN LUNG CANCER    Bristol hopes to be first to the market with an immunotherapy for lung cancer. It is studying its experimental PD-1 drug, nivolumab, both as a stand-alone therapy and in combination with Yervoy, also known as ipilimumab, which inhibits a protein called CTLA-4. ""We believe a combination of immuno-oncology agents represents the best chance for patients to achieve long-term survival,"" said Michael Giordano, head of development, oncology and immunology, at Bristol.He said Bristol is submitting lung cancer data to the FDA on a rolling basis and expects to complete its application by year-end, which ""certainly gives us confidence that we are in the lead, potentially first in lung cancer."" Merck is not studying pembrolizumab in combination with its own experimental drugs, but does have studies underway with  drugs from Amgen and others. Merck is also conducting a study of the PD-1 drug in combination with its older melanoma drug Sylatron.""In oncology, combinations typically provide superior  benefit,"" Roger Perlmutter, head of research at Merck, said in a June interview. ""But picking them is tricky. We first need to understand it as monotherapy.""Perlmutter could not be reached for comment regarding pembrolizumab's approval timeline.Roche, granted FDA ""breakthrough therapy"" designation in June for its experimental drug MPDL3280A as a treatment for bladder cancer, is conducting a range of trials in various types of cancer, including combination treatment studies.""We have a broad pipeline of targeted therapies,"" said Sandra Horning, chief medical officer at Roche's Genentech unit.(This version of the story corrects paragraph 17 to remove reference to Novartis as a research partner) (Reporting By Deena Beasley; Editing by Michele Gershberg and Diane Craft)",2014-08-25,MRK,"Mon Aug 25, 2014 | 6:14pm EDT",Exclusive: U.S. approval of Merck cancer immunotherapy expected soon,http://www.reuters.com//article/us-merck-cancer-fda-idUSKBN0GP0VU20140825?type=companyNews
163,"   By Ransdell Pierson  Aug 25 Advaxis Inc on Monday said it will test an experimental immuno-oncology drug in combination with a high-profile immunotherapy from Merck & Co Inc as a treatment for patients with advanced prostate cancer.The tiny U.S. biotechnology company, in its second cancer collaboration with a large drugmaker in the past month, said it would evaluate the use of its ADXS-PSA as a standalone treatment and also study it in combination with Merck's pembrolizumab in the Phase I/Phase II trial.Merck's drug is a member of an exciting new class of medicines called ""PD-1 inhibitors"" that work by blocking the PD-1 protein, thereby taking the brakes off immune system cells and prodding them to attack tumors.The Advaxis drug consists of a modified form of the Listeria bacterium fused to a protein called PSA that is shed by prostate tumors. It is meant to spur creation of immune system soldiers, called T-cells, that are primed to recognize and kill prostate cancer cells.By using different approaches, the drugmakers hope the two drugs have a better chance of knocking down the prostate cancer than either could achieve on its own.""If the combination of drugs shows an added effect, the companies would likely continue their collaboration,"" perhaps under a licensing deal, said Daniel O'Connor, chief executive officer of Advaxis. Prostate cancer is the most common  cancer among men, other than skin cancer.  One man in six will get prostate cancer during his lifetime, and about  3 percent of men die from the disease, according to Advaxis.O'Connor, in an interview, said his company will bear most costs of the study, which is slated to begin in early 2015 and probably be conducted by a contract research organization. Merck will provide the pembrolizumab, an injectable monoclonal antibody, to be used in the trial.PD-1 inhibitors and other immuno-oncology drugs have already shown promise against other types of cancer, including melanoma, but have not yet been tested to any great extent against prostate cancer, according to David Mauro, executive director of oncology at Merck. ""We think this combination gives us the opportunity to do early exploration in prostate cancer and bring immuno-oncology into this space,"" Mauro said in an interview.Merck previously announced collaborations with several other drugmakers on combined uses of pembrolizumab with their medicines, including British drugmaker GlaxoSmithKline, Pfizer Inc, Amgen Inc and Incyte Corp.Advaxis last month announced a collaboration with British drugmaker AstraZeneca to test immunotherapy drugs from both companies in combination. Under that deal, AstraZeneca's drug MEDI4736 will be evaluated in a Phase I/II clinical study together with the U.S. company's cancer vaccine ADXS-HPV. The AstraZeneca drug blocks PD-L1, a protein similar to PD-1.The combination will be tested in patients with cervical cancer and head and neck cancer, tumors that are closely linked to infection with the human papillomavirus.(Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-08-25,MRK,"Mon Aug 25, 2014 | 7:00am EDT","RPT-Advaxis, Merck to test immune therapies against prostate cancer",http://www.reuters.com//article/advaxis-merck-co-cancer-idUSL2N0QS2EE20140825?type=companyNews
164,"   By Ransdell Pierson  Aug 25 Advaxis Inc on Monday said it will test an experimental immuno-oncology drug in combination with a high-profile immunotherapy from Merck & Co Inc as a treatment for patients with advanced prostate cancer.The tiny U.S. biotechnology company, in its second cancer collaboration with a large drugmaker in the past month, said it would evaluate the use of its ADXS-PSA as a standalone treatment and also study it in combination with Merck's pembrolizumab in the Phase I/Phase II trial.Merck's drug is a member of an exciting new class of medicines called ""PD-1 inhibitors"" that work by blocking the PD-1 protein, thereby taking the brakes off immune system cells and prodding them to attack tumors.The Advaxis drug consists of a modified form of the Listeria bacterium fused to a protein called PSA that is shed by prostate tumors. It is meant to spur creation of immune system soldiers, called T-cells, that are primed to recognize and kill prostate cancer cells.By using different approaches, the drugmakers hope the two drugs have a better chance of knocking down the prostate cancer than either could achieve on its own.""If the combination of drugs shows an added effect, the companies would likely continue their collaboration,"" perhaps under a licensing deal, said Daniel O'Connor, chief executive officer of Advaxis. Prostate cancer is the most common  cancer among men, other than skin cancer.  One man in six will get prostate cancer during his lifetime, and about  3 percent of men die from the disease, according to Advaxis.O'Connor, in an interview, said his company will bear most costs of the study, which is slated to begin in early 2015 and probably be conducted by a contract research organization. Merck will provide the pembrolizumab, an injectable monoclonal antibody, to be used in the trial.PD-1 inhibitors and other immuno-oncology drugs have already shown promise against other types of cancer, including melanoma, but have not yet been tested to any great extent against prostate cancer, according to David Mauro, executive director of oncology at Merck. ""We think this combination gives us the opportunity to do early exploration in prostate cancer and bring immuno-oncology into this space,"" Mauro said in an interview.Merck previously announced collaborations with several other drugmakers on combined uses of pembrolizumab with their medicines, including British drugmaker GlaxoSmithKline, Pfizer Inc, Amgen Inc and Incyte Corp.Advaxis last month announced a collaboration with British drugmaker AstraZeneca to test immunotherapy drugs from both companies in combination. Under that deal, AstraZeneca's drug MEDI4736 will be evaluated in a Phase I/II clinical study together with the U.S. company's cancer vaccine ADXS-HPV. The AstraZeneca drug blocks PD-L1, a protein similar to PD-1.The combination will be tested in patients with cervical cancer and head and neck cancer, tumors that are closely linked to infection with the human papillomavirus.(Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-08-25,MRK,"Mon Aug 25, 2014 | 12:01am EDT","Advaxis, Merck to test immune therapies against prostate cancer",http://www.reuters.com//article/advaxis-merck-co-cancer-idUSL2N0QS27G20140825?type=companyNews
165,"   By Ransdell Pierson  Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer. Financial terms of the deal were not disclosed.Xalkori, which has annual sales of $400 million and is also known by its chemical name, crizotinib, was approved in 2011 for lung cancer patients who have a specific mutation in the so-called ALK gene, as determined by an approved diagnostic test.The mutation occurs in a small percentage of patients with non small cell lung cancer, the most common form of lung cancer. It makes them good candidates for treatment with Xalkori, a targeted drug that can help shrink or slow tumor growth for these patients.    Pembrolizumab works by removing the brakes from the immune system, allowing it to detect and destroy cancer cells. The differing mechanisms of action from combination therapy are meant to deliver a one-two punch to cancer cells.The Merck drug, called a PD-1 inhibitor, is expected to be approved within months in the United States and to become a blockbuster treatment for melanoma, and possibly later for lung cancer and other types of cancer, depending on results of ongoing clinical trials. Merck, Bristol-Myers Squibb, Swiss drugmaker Roche and AstraZeneca Plc are leading the charge in developing PD-1 inhibitors or similar immunotherapies. Some industry analysts believe the medicines will capture combined annual sales of up to $30 billion by 2025. Merck and Pfizer previously said they would collaborate in combination trials of pembrolizumab both with Pfizer's approved Inlyta (axitinib) treatment for kidney cancer, and with an experimental drug called PF-2566 that Pfizer is evaluating in numerous cancer types. PF-2566 stimulates activity of 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation. ""For Pfizer, these collaborations help secure their drugs in a market that is going under a paradigm shift"" toward immunotherapies, said Morningstar analyst Damien Conover. ""I see it more of a defensive move to make sure Pfizer's drugs are being used in the anti-PD-1 space, instead of being bypassed.""Merck is not studying pembrolizumab in combination with its own experimental drugs, but has other combination studies planned or underway with a growing number of drugmakers, including Amgen. Merck is also conducting a study of its PD-1 inhibitor in combination with its own older melanoma drug, Sylatron.Shares of Pfizer and Merck were both up about 0.6 percent in morning trading on the New York Stock Exchange. (Editing by Bernadette Baum and Dan Grebler)",2014-08-26,MRK,"Tue Aug 26, 2014 | 12:36pm EDT",Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com//article/us-pfizer-merck-cancer-idUSKBN0GQ16N20140826?type=companyNews
166,"  (Repeats to widen subscription.)By Ransdell PiersonAug 26 Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's  experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer. Financial terms of the deal were not disclosed.Xalkori, which has annual sales of $400 million and is also known by its chemical name, crizotinib, was approved in 2011 for lung cancer patients who have a specific mutation in the so-called ALK gene, as determined by an approved diagnostic test.The mutation occurs in a small percentage of patients with non small cell lung cancer, the most common form of lung cancer. It makes them good candidates for treatment with Xalkori, a targeted drug that can help shrink or slow tumor growth for these patients. Pembrolizumab works by removing the brakes from the immune system, allowing it to detect and destroy cancer cells.The differing mechanisms of action from combination therapy are meant to deliver a one-two punch to cancer cells.The Merck drug, called a PD-1 inhibitor, is expected to be approved within months in the United States and to become a blockbuster treatment for melanoma, and possibly later for lung cancer and other types of cancer, depending on results of ongoing clinical trials. Merck, Bristol-Myers Squibb, Swiss drugmaker Roche  and AstraZeneca Plc are leading the charge in developing PD-1 inhibitors or similar immunotherapies. Some industry analysts believe the medicines will capture combined annual sales of up to $30 billion by 2025.Merck and Pfizer previously said they would collaborate in combination trials of pembrolizumab both with Pfizer's approved Inlyta (axitinib) treatment for kidney cancer, and with an experimental drug called PF-2566 that Pfizer is evaluating in numerous cancer types. PF-2566 stimulates activity of 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation. ""For Pfizer, these collaborations help secure their drugs in a market that is going under a paradigm shift"" toward immunotherapies, said Morningstar analyst Damien Conover. ""I see it more of a defensive move to make sure Pfizer's drugs are being used in the anti-PD-1 space, instead of being bypassed.""Merck is not studying pembrolizumab in combination with its own experimental drugs, but has other combination studies planned or underway with a growing number of drugmakers, including Amgen.Merck is also conducting a study of its PD-1 inhibitor in combination with its own older melanoma drug, Sylatron.Shares of Pfizer and Merck were both up about 0.6 percent in morning trading on the New York Stock Exchange.(Editing by Bernadette Baum and Dan Grebler)",2014-08-26,MRK,"Tue Aug 26, 2014 | 12:27pm EDT",RPT-UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com//article/pfizer-merck-cancer-idUSL1N0QW1DT20140826?type=companyNews
167,"  (Adds analyst comment, details on rival PD-1 inhibitors)By Ransdell PiersonAug 26 Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's  experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer. Financial terms of the deal were not disclosed.Xalkori, which has annual sales of $400 million and is also known by its chemical name, crizotinib, was approved in 2011 for lung cancer patients who have a specific mutation in the so-called ALK gene, as determined by an approved diagnostic test.The mutation occurs in a small percentage of patients with non small cell lung cancer, the most common form of lung cancer. It makes them good candidates for treatment with Xalkori, a targeted drug that can help shrink or slow tumor growth for these patients. Pembrolizumab works by removing the brakes from the immune system, allowing it to detect and destroy cancer cells.The differing mechanisms of action from combination therapy are meant to deliver a one-two punch to cancer cells.The Merck drug, called a PD-1 inhibitor, is expected to be approved within months in the United States and to become a blockbuster treatment for melanoma, and possibly later for lung cancer and other types of cancer, depending on results of ongoing clinical trials. Merck, Bristol-Myers Squibb, Swiss drugmaker Roche  and AstraZeneca Plc are leading the charge in developing PD-1 inhibitors or similar immunotherapies. Some industry analysts believe the medicines will capture combined annual sales of up to $30 billion by 2025.Merck and Pfizer previously said they would collaborate in combination trials of pembrolizumab both with Pfizer's approved Inlyta (axitinib) treatment for kidney cancer, and with an experimental drug called PF-2566 that Pfizer is evaluating in numerous cancer types. PF-2566 stimulates activity of 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation. ""For Pfizer, these collaborations help secure their drugs in a market that is going under a paradigm shift"" toward immunotherapies, said Morningstar analyst Damien Conover. ""I see it more of a defensive move to make sure Pfizer's drugs are being used in the anti-PD-1 space, instead of being bypassed.""Merck is not studying pembrolizumab in combination with its own experimental drugs, but has other combination studies planned or underway with a growing number of drugmakers, including Amgen.Merck is also conducting a study of its PD-1 inhibitor in combination with its own older melanoma drug, Sylatron.Shares of Pfizer and Merck were both up about 0.6 percent in morning trading on the New York Stock Exchange.(Editing by Bernadette Baum and Dan Grebler)",2014-08-26,MRK,"Tue Aug 26, 2014 | 10:52am EDT",UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com//article/pfizer-merck-cancer-idUSL1N0QW0QB20140826?type=companyNews
168,"  Aug 26 Pfizer Inc on Tuesday said it will test its Xalkori lung cancer drug with Merck & Co's  experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.Xalkori, which has annual sales of $400 million and is also known by its chemical name crizotinib, was approved in 2011 for lung cancer patients who have a specific mutation in the so-called ALK gene, as determined by an approved diagnostic test.The mutation only occurs in a small percentage of patients with non small cell lung cancer, the most common form of lung cancer, but makes them good candidates for treatment with Xalkori.Pembrolizumab, by contrast, works by removing the brakes from the immune system, allowing it to detect and destroy cancer cells. The differing mechanisms of action from combination therapy are meant to deliver a one-two punch to cancer cells. The Merck drug, called a PD-1 inhibitor, is expected to be approved within months in the United States and to become a blockbuster treatment for melanoma, and possibly later for lung cancer and other types of cancer, depending on results of ongoing clinical trials.Merck is not studying pembrolizumab in combination with its own experimental drugs, but does have studies underway with other drugmakers, including Amgen. Merck is also conducting a study of the PD-1 drug in combination with its older melanoma drug Sylatron.(Reporting by Ransdell Pierson; Editing by Bernadette Baum)",2014-08-26,MRK,"Tue Aug 26, 2014 | 9:07am EDT",Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com//article/pfizer-merck-cancer-idUSL1N0QW0ND20140826?type=companyNews
169,"  * Decision expected since last October* Review requested by Merck subsidiary* Levels scientifically safe - ministry official   (Adds quotes and details)By Meeyoung ChoSEOUL, Sept 2 South Korea has lifted a ban on the use of animal feed additive zilpaterol in beef, opening the door to imports containing the growth enhancer as well as domestic sales of the product.Seoul said last October that it intended to ease its zero-tolerance policy on zilpaterol-based drugs, such as Merck & Co Inc's Zilmax, after a risk assessment fould it could be permitted at certain levels. Many European countries as well as China ban the import of zilpaterol-fed beef due to concerns about side effects of the  additive, which is used to aid growth in the weeks before animals are slaughtered.South Korea last year suspended some U.S. beef imports for more than two months after traces of zilpaterol were found in two shipments. An official at South Korea's food ministry confirmed on Tuesday that imports of beef muscle with 1 part per billion (ppb) of zilpaterol, 5 ppb in beef liver and 10 ppb in beef kidney had been approved as of late last month.""The approved levels are scientifically safe even if consumers have them for the rest of their lives,"" the official told Reuters by phone. ""The decision has come after asking farmers via months of public notices.""He noted the approved levels were lower than in other countries, such as the United States, which permits 12 ppb of zilpaterol in beef liver. South Korea delayed the decision to lift the ban for a month earlier this year after a request from China. The reason for the request was not known, the ministry official said on Tuesday.South Korea is a major importer of beef from Australia, the United States and New Zealand.Zilmax was approved by the U.S. Food and Drug Administration in 2006. South Korea's assessment of its ban was carried out at the request of Merck's subsidiary MSD Animal Health Korea.(Reporting by Meeyoung Cho; Editing by Richard Pullin)",2014-09-02,MRK,"Tue Sep 2, 2014 | 3:23am EDT",UPDATE 1-S.Korea lifts ban on beef with feed additive -food ministry,http://www.reuters.com//article/beef-southkorea-idUSL3N0R31T520140902?type=companyNews
170,"   By Deena Beasley  U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.The decision marks the first U.S. approval for a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.For Tom Stutz, a 74-year-old retired lawyer living in Southern California, the Merck drug has meant a new lease on life. ""I was really ready to mail it in,"" before entering a pembrolizumab trial in April 2012 after melanoma had spread to his lungs, liver and back, he said.Stutz, who still receives an infusion of the drug every three weeks, said he has ""gone from not being able to turn over in bed, to being able to play tennis three days a week, and ride a bike 25 miles a day.""He said side effects amounted to some itching.""This is not a drug that attacks the cancer directly. It enables the immune system to do the job that it is capable of doing,"" said Dr. Louis Weiner, director of the Lombardi Comprehensive Cancer Center at Georgetown University. ""This is the first beachhead that's been taken. It's going to be all out assault on many different types of cancer.""Merck and others, including Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc, are racing to develop PD-1 pathway drugs as treatments for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025. Melanoma, the deadliest form of skin cancer, kills around 10,000 Americans each year, according to the National Cancer Institute.The FDA said clinical trials of Keytruda showed that it shrank tumors in around 24 percent of patients with advanced melanoma whose disease worsened after prior treatment.The agency had designated the drug a ""breakthrough therapy,"" and approved it nearly two months ahead of an Oct. 28 decision deadline. Reuters reported exclusively last week that the approval was likely to come far earlier than the deadline [L1N0R52D3]. Keytruda is the sixth new melanoma drug approved by the FDA since 2011.""This is a patient population with few options ... We are highly encouraged by the response rate and the duration of response,"" said Dr Rick Pazdur, director of the Office of Hematology and Oncology in the FDA's drug evaluation center. ""The true benefit of these drugs may be in patients who do not have metastatic disease, but are at risk of recurrence.""Merck said one of its first priorities was to see whether the drug is effective in patients with earlier-stage cancer.Keytruda will be priced at about $12,500 per month, which ""is consistent with other innovative oncology medicines,"" Merck said. For patients with advanced melanoma, the median duration of treatment has been 6.2 months. Common side effects of Keytruda seen during clinical trials included fatigue, cough, nausea, itchy skin, rash and diarrhea. Because it stimulates the immune system, Keytruda has the potential for severe immune-mediated side effects, including liver problems and colitis.Merck is studying the drug in more than 30 different types of tumors, said Roger Perlmutter, head of research at the pharmaceutical company. Merck expects to present data from studies in lung, bladder and gastric cancers at a European medical meeting later this month.Perlmutter said Merck's next FDA filing for Keytruda will depend on which trials ""yield the most powerful results.""Bristol expects to complete by the end of this year a ""rolling"" submission for FDA approval of its drug, Opdivo, or nivolumab, for certain patients with late-stage lung cancer. The company also plans to file an FDA application by the end of this month for use of the drug, which is approved in Japan, for patients with advanced melanoma. (Reporting By Deena Beasley; Editing by Bernard Orr, Diane Craft and Ken Wills)",2014-09-04,MRK,"Thu Sep 4, 2014 | 6:43pm EDT",U.S. approves Merck immune-stimulating drug for melanoma,http://www.reuters.com//article/us-merck-melanoma-fda-idUSKBN0GZ2GQ20140904?type=companyNews
171,"  (Adds comments from patient, Merck, FDA, Georgetown)By Deena BeasleySept 4 U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.The decision marks the first U.S. approval for a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.For Tom Stutz, a 74-year-old retired lawyer living in Southern California, the Merck drug has meant a new lease on life. ""I was really ready to mail it in,"" before entering a pembrolizumab trial in April 2012 after melanoma had spread to his lungs, liver and back, he said.Stutz, who still receives an infusion of the drug every three weeks, said he has ""gone from not being able to turn over in bed, to being able to play tennis three days a week, and ride a bike 25 miles a day.""He said side effects amounted to some itching. ""This is not a drug that attacks the cancer directly. It enables the immune system to do the job that it is capable of doing,"" said Dr. Louis Weiner, director of the Lombardi Comprehensive Cancer Center at Georgetown University. ""This is the first beachhead that's been taken. It's going to be all out assault on many different types of cancer.""Merck and others, including Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc, are racing to develop PD-1 pathway drugs as treatments for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.Melanoma, the deadliest form of skin cancer, kills around 10,000 Americans each year, according to the National Cancer Institute.The FDA said clinical trials of Keytruda showed that it shrank tumors in around 24 percent of patients with advanced melanoma whose disease worsened after prior treatment. The agency had designated the drug a ""breakthrough therapy,"" and approved it nearly two months ahead of an Oct. 28 decision deadline. Reuters reported exclusively last week that the approval was likely to come far earlier than the deadline .Keytruda is the sixth new melanoma drug approved by the FDA since 2011.""This is a patient population with few options ... We are highly encouraged by the response rate and the duration of response,"" said Dr Rick Pazdur, director of the Office of Hematology and Oncology in the FDA's drug evaluation center. ""The true benefit of these drugs may be in patients who do not have metastatic disease, but are at risk of recurrence."" Merck said one of its first priorities was to see whether the drug is effective in patients with earlier-stage cancer.Keytruda will be priced at about $12,500 per month, which ""is consistent with other innovative oncology medicines,"" Merck said. For patients with advanced melanoma, the median duration of treatment has been 6.2 months.Common side effects of Keytruda seen during clinical trials included fatigue, cough, nausea, itchy skin, rash and diarrhea. Because it stimulates the immune system, Keytruda has the potential for severe immune-mediated side effects, including liver problems and colitis.Merck is studying the drug in more than 30 different types of tumors, said Roger Perlmutter, head of research at the pharmaceutical company. Merck expects to present data from studies in lung, bladder and gastric cancers at a European medical meeting later this month.Perlmutter said Merck's next FDA filing for Keytruda will depend on which trials ""yield the most powerful results.""Bristol expects to complete by the end of this year a ""rolling"" submission for FDA approval of its drug, Opdivo, or nivolumab, for certain patients with late-stage lung cancer. The company also plans to file an FDA application by the end of this month for use of the drug, which is approved in Japan, for patients with advanced melanoma.   (Reporting By Deena Beasley; Editing by Bernard Orr, Diane Craft and Ken Wills)",2014-09-04,MRK,"Thu Sep 4, 2014 | 6:33pm EDT",UPDATE 2-U.S. approves Merck immune-stimulating drug for melanoma,http://www.reuters.com//article/merck-co-melanoma-fda-idUSL1N0R52D320140904?type=companyNews
172,"  Sept 4 U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.The drug is the first in a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells. Melanoma, the deadliest form of skin cancer, is diagnosed in around 76,000 Americans each year and around 10,000 will die from the disease annually, according to the National Cancer Institute. The FDA said in a statement that clinical trials of Keytruda showed that it shrank tumors in around 24 percent of patients with advanced melanoma whose disease worsened after prior treatment. The agency had designated Keytruda as a ""breakthrough therapy,"" and approved the drug nearly two months ahead of an  Oct. 28 decision deadline.   (Reporting By Deena Beasley; Editing by Bernard Orr)",2014-09-04,MRK,"Thu Sep 4, 2014 | 2:56pm EDT",U.S. FDA approves Merck immune-stimulating drug for melanoma,http://www.reuters.com//article/merck-melanoma-fda-idUSL1N0R529020140904?type=companyNews
173,"  Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.Immunotherapy is a mechanism that uses the body's own immune system to eliminate cancer cells.In its lawsuit filed in the U.S. District Court of Delaware, Bristol-Myers said Merck was planning to exploit its invention with a later-developed treatment, pembrolizumab, violating the company's May 20 patent. U.S. regulators on Thursday approved the use pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.Bristol-Myers is using its patented technology to develop its own drug, nivolumab, which is being tested in different areas of cancer including melanoma. The company also plans to file an application with the U.S. Food and Drug Administration by the end of this month for use of the drug, which is approved in Japan, for patients with advanced melanoma.Other pharmaceutical companies including Roche Holding AG and Novartis AG are also in the process of developing similar drugs.According to the American Cancer Society, about 76,100 new melanomas will be diagnosed this year. The disease is the most dangerous kind of skin cancer and can originate in any part of the body that contains pigment-containing cells. Both Bristol-Myers and Merck could not be reached for a comment outside regular working hours.The case is Bristol-Myers Squibb Co and Ono Pharmaceutical co ltd v. Merck & Co Inc, U.S. District Court, for the district of Delaware, Wilmington No. 14-CV-01131  (Reporting by Amrutha Penumudi in Bangalore; Editing by Lisa Shumaker)",2014-09-06,MRK,"Fri Sep 5, 2014 | 9:46pm EDT",Bristol-Myers sues Merck over U.S. immunotherapy patent,http://www.reuters.com//article/us-bristol-myers-merck-co-lawsuit-idUSKBN0H102X20140906?type=companyNews
174,"  Sept 5 Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.Immunotherapy is a mechanism that uses the body's own immune system to eliminate cancer cells.In its lawsuit filed in the U.S. District Court of Delaware, Bristol-Myers said Merck was planning to exploit its invention with a later-developed treatment, pembrolizumab, violating the company's May 20 patent.U.S. regulators on Thursday approved the use pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.Bristol-Myers is using its patented technology to develop its own drug, nivolumab, which is being tested in different areas of cancer including melanoma. The company also plans to file an application with the U.S. Food and Drug Administration by the end of this month for use of the drug, which is approved in Japan, for patients with advanced melanoma.Other pharmaceutical companies including Roche Holding AG  and Novartis AG are also in the process of developing similar drugs. According to the American Cancer Society, about 76,100 new melanomas will be diagnosed this year. The disease is the most dangerous kind of skin cancer and can originate in any part of the body that contains pigment-containing cells.Both Bristol-Myers and Merck could not be reached for a comment outside regular working hours. The case is Bristol-Myers Squibb Co and Ono Pharmaceutical co ltd v. Merck & Co Inc, U.S. District Court, for the district of Delaware, Wilmington No. 14-CV-01131(Reporting by Amrutha Penumudi in Bangalore; Editing by Lisa Shumaker)",2014-09-06,MRK,"Fri Sep 5, 2014 | 9:25pm EDT",Bristol-Myers sues Merck over U.S. immunotherapy patent,http://www.reuters.com//article/bristol-myers-merck-co-lawsuit-idUSL1N0R703L20140906?type=companyNews
175,"  Sept 9 Merck & Co Inc :  * Merck CEO, at Morgan Stanley Global Healthcare Conference, says tax inversion deals would not fit its corporate strategy  * CEO says tax inversion benefit would require overly large transaction  * CEO says changes needed to make U.S. tax rate more competitive, but may notoccur until after 2016 elections  * CEO says advantages from tax inversion deals would not be ""durable"" because of likely changes in coming years to U.S. tax policy  * CEO says new big deals would be disruptive, although prior Schering Plough  acquisition made sense",2014-09-09,MRK,"Tue Sep 9, 2014 | 8:38am EDT",BRIEF-Merck CEO says tax inversion deals would not fit its corporate strategy,http://www.reuters.com//article/merck-brief-idUSWEN00DYE20140909?type=companyNews
176,"   By Ransdell Pierson  Merck & Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments. The once-weekly pill, deemed a potential blockbuster product by some industry analysts, significantly reduced risk of fractures of the hip and spine, and of non-vertebral fractures, compared with placebo, Merck said on Monday.The trial, called LOFT, involved almost 17,000 women, 65 years or older, who had been diagnosed with the bone-thinning disease that primarily affects postmenopausal women.Although the overall rate of side effects was similar in the two patient groups, those taking odanacatib had slightly higher incidence of death and atrial fibrillation, a type of irregular heartbeat that can cause stroke.There were similar numbers of cardiovascular events in both patient groups, although a numerically higher incidence of strokes in the odanacatib group was not deemed statistically significant.Five patients taking odanacatib developed atypical fractures of the thigh-bone, compared with none in the placebo group. Similar rare femur fractures have been among the most worrisome side effects of the leading class of treatments, called bisphosphonates, which include Merck's own Fosamax and generic forms of it sold by others.Keith Kaufman, a senior Merck research official, said all patients who developed the thigh fractures had encountered some form of trauma and had severe osteoporosis. By contrast, he said many such fractures associated with bisphosphonates have been ""spontaneous.""    Kaufman noted that certain skin lesions occurred more often in patients taking odanacatib, than those in the placebo group, but said the condition went away or moderated after treatment was stopped. ""The safety profile (of odanacatib) has some red flags"" which could create concern among regulators, BMO Capital Markets analyst Alex Arfaei said in a research note. Even so, he said odanacatib's benefits appear to outweigh its risks.Arfaei predicted the drug will be approved by early 2016 and have sales of $536 million in 2020.In a late-stage trial whose results were described in 2012, odanacatib demonstrated effectiveness in preventing fractures, boosting Wall Street hopes that the new type of osteoporosis treatment would be approved and eventually generate annual sales of up to $2 billion.  Merck initially planned to seek marketing approval in the first half of 2013. But the company early last year said it would delay its filing until 2014 because of certain ""safety issues"" that needed to be resolved in an ongoing extension of the LOFT study.Kaufman said the marketing application has now been delayed again, until 2015, ""to collect additional long-term data"" on the relative benefit and risk of odanacatib.Odanacatib works by blocking cathepsin K, an enzyme involved in the body's natural process of resorbing bone.Merck shares closed down 3 cents at $59.52 Monday on the New York Stock Exchange. (Reporting by Ransdell Pierson; Editing by Meredith Mazzilli, Bernard Orr)",2014-09-15,MRK,"Mon Sep 15, 2014 | 4:59pm EDT","Merck osteoporosis drug passes trial, but side effects hover",http://www.reuters.com//article/us-merck-osteoporosis-idUSKBN0HA1Y820140915?type=companyNews
177,"  (Adds Merck comment, details on side effects, effectiveness)By Ransdell PiersonSept 15 Merck & Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.The once-weekly pill, deemed a potential blockbuster product by some industry analysts, significantly reduced risk of fractures of the hip and spine, and of non-vertebral fractures, compared with placebo, Merck said on Monday.The trial, called LOFT, involved almost 17,000 women, 65 years or older, who had been diagnosed with the bone-thinning disease that primarily affects postmenopausal women.Although the overall rate of side effects was similar in the two patient groups, those taking odanacatib had slightly higher incidence of death and atrial fibrillation, a type of irregular heartbeat that can cause stroke.There were similar numbers of cardiovascular events in both patient groups, although a numerically higher incidence of strokes in the odanacatib group was not deemed statistically significant. Five patients taking odanacatib developed atypical fractures of the thigh-bone, compared with none in the placebo group.Similar rare femur fractures have been among the most worrisome side effects of the leading class of treatments, called bisphosphonates, which include Merck's own Fosamax and generic forms of it sold by others.Keith Kaufman, a senior Merck research official, said all patients who developed the thigh fractures had encountered some form of trauma and had severe osteoporosis. By contrast, he said many such fractures associated with bisphosphonates have been ""spontaneous."" Kaufman noted that certain skin lesions occurred more often in patients taking odanacatib, than those in the placebo group, but said the condition went away or moderated after treatment was stopped.""The safety profile (of odanacatib) has some red flags"" which could create concern among regulators, BMO Capital Markets analyst Alex Arfaei said in a research note. Even so, he said odanacatib's benefits appear to outweigh its risks.Arfaei predicted the drug will be approved by early 2016 and have sales of $536 million in 2020. In a late-stage trial whose results were described in 2012, odanacatib demonstrated effectiveness in preventing fractures, boosting Wall Street hopes that the new type of osteoporosis treatment would be approved and eventually generate annual sales of up to $2 billion.Merck initially planned to seek marketing approval in the first half of 2013. But the company early last year said it would delay its filing until 2014 because of certain ""safety issues"" that needed to be resolved in an ongoing extension of the LOFT study.Kaufman said the marketing application has now been delayed again, until 2015, ""to collect additional long-term data"" on the relative benefit and risk of odanacatib.Odanacatib works by blocking cathepsin K, an enzyme involved in the body's natural process of resorbing bone.Merck shares closed down 3 cents at $59.52 Monday on the New York Stock Exchange.   (Reporting by Ransdell Pierson; Editing by Meredith Mazzilli, Bernard Orr)",2014-09-15,MRK,"Mon Sep 15, 2014 | 4:51pm EDT","UPDATE 2-Merck osteoporosis drug passes trial, but side effects hover",http://www.reuters.com//article/merck-osteoporosis-idUSL1N0RG1NN20140915?type=companyNews
178,"  Sept 15 Merck & Co on Monday said it expects next year to seek U.S. approval for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary effectiveness goals in a late-stage trial.The drug significantly reduced risk of fractures of the hip and spine, and of non-vertebral fractures, compared with placebo, Merck said in a release. Overall risk of side effects was similar in the two patient groups, although certain skin lesions and atypical fractures of the thigh bone occurred more often in patients taking the Merck drug, than those in the placebo group, Merck said. There were similar numbers of heart attacks and strokes in both patient groups, although a numerically higher incidence of strokes in the odanacatib group was not deemed statistically significant. (Reporting by Ransdell Pierson; Editing by Meredith Mazzilli)",2014-09-15,MRK,"Mon Sep 15, 2014 | 1:56pm EDT",Merck says osteoporosis drug achieves goal in large trial,http://www.reuters.com//article/merck-osteoporosis-idUSL1N0RG1M020140915?type=companyNews
179,"  (Adds Trian Fund Management, Verizon, Endesa, TIM, Allianz, Sulzer, Perutnina Ptuj, Espirito Santo Financial Group, Falabella, UniCredit, Abertis, IAC/Interactive Corp, Hess Corporation, Merck & Co, PZU and Mediobanca)Sept 17 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Activist investor Nelson Peltz's Trian Fund Management LP urged DuPont to break itself up, saying that efforts already underway at the industrial conglomerate to shed some of its businesses were not enough to fix what it called the company's ""underperformance.""** Verizon Communications Inc is open to divesting its network's assets including its cell towers, the company's chief financial officer told investors at a conference in Los Angeles.** The board of Spanish electricity firm Endesa SA  approved the sale of its Latin American assets to Italian parent group Enel SpA for 8.25 billion euros ($10.7 billion), the firm said in a statement.** Brazilian wireless carrier TIM said in a securities filing that Telecom Italia had denied any negotiations following a Bloomberg report of a potential deal to counter Spanish rival Telefonica SA in Latin America's largest market.** German insurer Allianz SE will overhaul and may sell parts of its U.S. property and casualty business Fireman's Fund after struggling for years to bring underwriting losses under control, the company said.** A group of bondholders of insolvent Espirito Santo Financial Group requested a court injunction against the sale of Portuguese insurer Tranquilidade by the successor of Banco Espirito Santo.** Chile-based retailer Falabella SACI said on Wednesday it had bought leading Peruvian home improvement chain Maestro Peru SA for about $490 million as it seeks to increase its presence in Peru's fast-growing economy.** UniCredit SpA, Italy's biggest bank by assets, is expected to pick a partner for exclusive talks to buy a stake of up to 50 percent in its asset management division Pioneer towards the end of September, two sources familiar with the matter said.** Spanish infrastructure group Abertis said it had agreed to sell its 33.33 percent stake in Mexico's Aeropuertos Mexicanos del Pacifico for $222 million to Promotora Aeronautica del Pacifico. ** An Israeli financial news website reported that New York-based media and Internet company IAC/Interactive Corp  has offered to buy Israel-based Perion Network Ltd , but a source with knowledge of the matter later said the report was untrue.** Hess Corp and Venezuela's state-run PDVSA have found an interested buyer for their 350,000 barrel per day Hovensa refinery in the Virgin Islands, sources close to the deal told Reuters, confirming a local news report.** Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.** Eastern Europe's largest insurer, Poland's PZU, has agreed to spin off part of its Lithuanian business to assuage competition concerns and pave the way for its purchase of Lithuanian rival Lietuvos Draudimas.** Italian top investment bank Mediobanca plans to sell the entire stakes it owns in publisher RCS Mediagroup  and telecoms group Telecom Italia by June 2015, a source close to the board said. ** Slovenian poultry producer Perutnina Ptuj is exploring options including a sale that might value the company at as much as 140 million euros ($181.44 million), sources familiar with the matter said.** Sulzer AG said was in talks over a potential tie-up with U.S.-based compressor and turbine maker Dresser-Rand .** Endo International Plc  made an unsolicited offer to buy Auxilium Pharmaceuticals Inc  for about $2.2 billion, which analysts said could complicate Auxilium's buyout of Canadian eye drug maker QLT Inc  .** Auxilium Pharmaceuticals Inc said it would not withdraw its offer to buy Canadian eye drug maker QLT Inc  and adopted a poison pill, a day after receiving an unsolicited buyout offer from Endo International Plc.** New York-based media and Internet company IAC/Interactive Corp has offered to buy Israel-based Perion Network , an Israeli financial news website said. Israel's Calcalist, quoting unnamed market sources, said IAC has offered more than $500 million for Perion.** Wilhelmsen Maritime Services, a unit of Norway's Wilh. Wilhelmsen Holding, is seeking a partner for two of its business lines and may eventually sell them, the company said. ** Maersk Drilling, a unit of A.P. Moller-Maersk , said it had sold its Venezuelan drilling barge activities. Maersk Drilling made a similar announcement on Tuesday but later said the statement had been uploaded erroneously.** The management of pay-TV provider Sky Deutschland  has advised minority investors not to accept an offer from BSkyB, a token gesture given that BSkyB's terms are little more than a formality required after its purchase of a controlling stake in the broadcaster.** A German magazine report said hedge funds were considering purchasing stake in sportwearmaker Adidas . The hedge funds include Third Point, run by Daniel Loeb; Knight Vinke, run by Eric Knight; and TCI, run by Chris Hohn, said Germany's manager magazin, citing unnamed sources.""We don't have a shareholding and it's not something we're following,"" Eric Knight told Reuters.** Czech energy and industry holding group EPH is interested in buying Polish cargo firm CTL Logistics, Czech daily newspaper E15 reported, citing an unnamed source.**  Kuwait Food Co (Americana) asked for its shares to be suspended on the Kuwaiti bourse after its main shareholder said it was reviewing its portfolio, including its stake in the firm.** Canada's Ontario Teachers' Pension Plan will get complete control of Bristol Airport, UK's ninth busiest airport, by buying out co-shareholder Australian asset manager Macquarie Group Ltd.** The board of directors of Brazilian telecommunications firm Grupo Oi SA authorized management to begin looking for a buyer for its 75 percent stake in Africatel Holdings BV, according to a securities filing.** Dubai lender Mashreq has no interest in purchasing assets of Standard Chartered in the United Arab Emirates, but is open to acquisitions in Egypt and Turkey, its chief executive told Reuters.** France's government has contacted banks about the possibility of privatising or selling a stake in state-controlled lottery and betting monopoly Francaise des Jeux (FDJ), Le Monde newspaper reported.($1 = 0.7712 euro)  ($1 =2.8580 Peruvian sols)   (Compiled by Anet Josline Pinto and Anya George Tharakan in Bangalore)",2014-09-17,MRK,"Wed Sep 17, 2014 | 4:01pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0RI2YN20140917?type=companyNews
180,"  Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.Under the agreement, Sun Pharma will acquire the worldwide rights to the drug, tildrakizumab, for all possible indications.The drug is currently in late-stage trials for use in chronic plaque psoriasis, an inflammatory skin disease. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including manufacturing and marketing the approved product, the companies said. Merck's shares were down about 1 percent at $59.41 on the New York Stock Exchange on Wednesday. Sun Pharmaceutical's shares closed at 792.40 rupees on the National Stock Exchange of India.  (Reporting By Samantha Kareen Nair; Editing by Simon Jennings)",2014-09-17,MRK,"Wed Sep 17, 2014 | 12:21pm EDT",Merck licenses experimental psoriasis drug to India's Sun Pharma,http://www.reuters.com//article/us-merck-co-psoriasis-idUSKBN0HC1JG20140917?type=companyNews
181,"  Sept 17 Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.Under the agreement, Sun Pharma will acquire the worldwide rights to the drug, tildrakizumab, for all possible indications. The drug is currently in late-stage trials for use in chronic plaque psoriasis, an inflammatory skin disease. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including manufacturing and marketing the approved product, the companies said. Merck's shares were down about 1 percent at $59.41 on the New York Stock Exchange on Wednesday. Sun Pharmaceutical's shares closed at 792.40 rupees on the National Stock Exchange of India.   (Reporting By Samantha Kareen Nair; Editing by Simon Jennings)",2014-09-17,MRK,"Wed Sep 17, 2014 | 10:12am EDT",Merck licenses experimental psoriasis drug to India's Sun Pharma,http://www.reuters.com//article/merck-co-psoriasis-idUSL3N0RI4AG20140917?type=companyNews
182,"   By Ludwig Burger | FRANKFURT  FRANKFURT Drugs and chemicals maker Merck KGaA (MRCG.DE) agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp SIAL.O for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history.The deal helps Merck, 70 percent controlled by the descendants of its 17th century founder, to focus more on supplying drugmakers and academic institutions with chemicals and services, seen as offering a steadier income stream than drug development.""With this acquisition we have the opportunity to turn one of our most reliable businesses into a core earnings contributor,"" said finance chief Marcus Kuhnert.Merck, which has been hit by several drug development failures, said it was happy for its own pharmaceuticals business to remain a medium-sized entity.The deal was approved by Sigma-Aldrich's management but still needs acceptance from more than 50 percent of the target's shareholders. Merck said it will acquire Sigma-Aldrich shares for $140 apiece, a 36 percent premium over the one-month average closing price and a 37 percent more than the latest closing price of $102.37 on Friday, Sept. 19.St Louis, Missouri-based Sigma had 2013 sales of $2.7 billion and provides big pharma groups including Pfizer Inc (PFE.N) and Novartis AG NOVN.VS with lab substances such as cell culture substrates. It also makes chemicals for the technology sector and food testing products.The combined lab supplies business would gain more exposure in North America and Asia, taking on global players such as Thermo Fisher Scientific Inc (TMO.N). The deal would immediately top-up adjusted earnings per share. RECORD PACE The move comes as healthcare companies strike deals at a record pace, with year-to-date activity in the sector topping $380 billion, well over double the year-ago level, according to Thomson Reuters data.It represents the second major transatlantic deal for a German company in the space of a few hours, after Siemens AG (SIEGn.DE) agreed to buy oilfield equipment maker Dresser-Rand Group Inc DRC.N for $7.6 billion. Shares in Merck, which initially turned negative on the news, closed 4.3 percent higher at 72.63 euros, against a 0.2 percent lower European chemicals index .SX4P.Merck expects the tie-up, funded from about 2 billion euros in cash reserves and the issue of new debt, to yield annual synergy benefits of 260 million euros ($334 million) within three years after closing, by measures such as streamlining manufacturing, administration and research. It said it was too early to say if any jobs would be cut. The deal would more than double the lab equipment unit's adjusted core earnings, even without such synergy gains; including them, the increase would be 139 percent, based on proforma 2013 results.""The fact that (the Merck family) are not taking a big step further into pharma shows that continuous returns on their investment over time are certainly important to the family,"" said analyst Ulrich Huwald at brokerage Warburg.At about 6 billion euros in annual sales, Merck's pharmaceuticals unit is well outside the global top 20, having suffered a series of drug development setbacks such as with an experimental cancer vaccine known as tecemotide, or Stimuvax, which did not come to market due to poor study results. WAY FORWARD   The group said on Monday that alliances, not major takeovers, would be the way forward for the unit. ""The pharmaceuticals business (will) remain a good and solid mid-sized player"", Kley said.Merck had earlier this year signaled that big pharma assets were on its radar and some analysts took a positive view on the fact it had steered clear of such moves. Citi analyst Andrew Baum said in a note the acquisition came at a steep premium of about 30 times Sigma's expected 2015 earnings per share, but argued the deal was better than buying a biotech or pharmaceutical asset given what he said was Merck's ""long-standing poor track record in pharmaceutical R&D"". Merck, the largest maker of liquid crystals for TV and computer screens, made lab supplies a major pillar of its business when it purchased U.S. group Millipore for $6 billion in 2010. Combining with Sigma would make it one of the global market's top three, the group said.Merck's biggest deal before this one was the takeover of Swiss biotech company Serono for 10.3 billion euros.Initial bridge loans to finance the deal will be replaced by about 4 billion euros in bank loans and 7 billion euros in bonds. Merck said strong combined cash flows would allow for rapid deleveraging.Guggenheim Securities and JP Morgan advised Merck on the deal, together with law firm Skadden, while Morgan Stanley acted as financial adviser to Sigma-Aldrich, with Sidley Austin as legal adviser.   (Additional reporting by Maria Sheahan and Ben Hirschler; Editing by Keith Weir and David Holmes)",2014-09-22,MRK,"Mon Sep 22, 2014 | 12:56pm EDT",Germany's Merck to buy Sigma-Aldrich for $17 billion to boost lab supplies operation,http://www.reuters.com//article/us-merck-sigma-aldrich-idUSKCN0HH1CK20140922?type=companyNews
183,"   By Ben Hirschler | MADRID  MADRID Merck & Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas  in the United States, also has potential in stomach cancer, new research shows.Early clinical trial results reported on Sunday mean that gastric, or stomach cancer can be added to a growing list of tumor types where so-called immunotherapy may have an important role to play.Keytruda belongs to a drug class designed to help the body's own immune system fend off cancer by blocking a protein known as Programed Death receptor (PD-1), or a related target PD-L1, used by tumors to evade disease-fighting cells.On Sept. 4 it became the first drug of this type to win U.S. approval, although rivals including Bristol-Myers Squibb, Roche and AstraZeneca are working on similar products.While developed first for melanoma, these medicines are also showing promise in a range of other tumor types, including kidney, lung, bladder, and head and neck cancer. In a small Phase I study involving 39 patients with PD-L1 positive, advanced stomach cancer, a total of 12 people - or 31 percent - saw their tumors shrink after being given Keytruda, Kei Muro of Japan's Aichi Cancer Center Hospital told the European Society of Medical Oncology annual congress.Importantly, overall response rates were similar in Asian patients -- a population with a high rate of stomach cancer -- and non-Asian patients, Muro said.The Phase I clinical trial is continuing but at the time of analysis the duration of responses in individual patients ranged from more than eight weeks to more than 20 weeks.  Merck said it planned to start a larger Phase II study in the first quarter of 2015 on the back of the encouraging data.Common adverse side effects included thyroid problems and fatigue, while serious grade 3-5 adverse events occurred in three patients. There was one treatment-related death.Immunotherapy is dominating the meeting of oncologists in Madrid as excitement builds about an approach that promises to push many cancer patients into remission by unleashing the power of their own immune systems to fight tumors. Further data on Merck's drug as a treatment for bladder cancer is also due to be released on Monday in Madrid. Some analysts believe the new immunotherapy drug class could generate more than $30 billion in annual sales worldwide by 2025 - a figure that reflects both the wide range of patients who could benefit and the high price of the medicines.The U.S. price for Keytruda is around $12,500 per month in melanoma patients, for whom the median duration of treatment has been 6.2 months. (Reporting by Ben Hirschler; Editing by Greg Mahlich)",2014-09-28,MRK,"Sun Sep 28, 2014 | 3:51am EDT",Merck drug extends immune system fight to stomach cancer,http://www.reuters.com//article/us-health-cancer-merck-idUSKCN0HN07J20140928?type=companyNews
184,"  * Keytruda shrinks tumours in small gastric cancer study* Evidence of immunotherapy's expanding role in cancer* Merck plans to start Phase II study in first quarter 2015By Ben HirschlerMADRID, Sept 28 Merck & Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas  in the United States, also has potential in stomach cancer, new research shows.Early clinical trial results reported on Sunday mean that gastric, or stomach cancer can be added to a growing list of tumour types where so-called immunotherapy may have an important role to play.Keytruda belongs to a drug class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1, used by tumours to evade disease-fighting cells. On Sept. 4 it became the first drug of this type to win U.S. approval, although rivals including Bristol-Myers Squibb , Roche and AstraZeneca are working on similar products.While developed first for melanoma, these medicines are also showing promise in a range of other tumour types, including kidney, lung, bladder, and head and neck cancer.In a small Phase I study involving 39 patients with PD-L1 positive, advanced stomach cancer, a total of 12 people - or 31 percent - saw their tumours shrink after being given Keytruda, Kei Muro of Japan's Aichi Cancer Center Hospital told the European Society of Medical Oncology annual congress. Importantly, overall response rates were similar in Asian patients -- a population with a high rate of stomach cancer -- and non-Asian patients, Muro said.The Phase I clinical trial is continuing but at the time of analysis the duration of responses in individual patients ranged from more than eight weeks to more than 20 weeks.Merck said it planned to start a larger Phase II study in the first quarter of 2015 on the back of the encouraging data. Common adverse side effects included thyroid problems and fatigue, while serious grade 3-5 adverse events occurred in three patients. There was one treatment-related death.Immunotherapy is dominating the meeting of oncologists in Madrid as excitement builds about an approach that promises to push many cancer patients into remission by unleashing the power of their own immune systems to fight tumours.Further data on Merck's drug as a treatment for bladder cancer is also due to be released on Monday in Madrid.Some analysts believe the new immunotherapy drug class could generate more than $30 billion in annual sales worldwide by 2025 - a figure that reflects both the wide range of patients who could benefit and the high price of the medicines.The U.S. price for Keytruda is around $12,500 per month in melanoma patients, for whom the median duration of treatment has been 6.2 months.   (Reporting by Ben Hirschler; Editing by Greg Mahlich)",2014-09-28,MRK,"Sun Sep 28, 2014 | 3:15am EDT",Merck drug extends immune system fight to stomach cancer,http://www.reuters.com//article/health-cancer-merck-idUSL6N0RS04820140928?type=companyNews
185,"  MADRID Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year.Keytruda is the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, but it also has potential in a range of other cancers. Bladder cancer is seen as a disease that is likely to be amenable to such drugs, which are designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1.Roche has a similar experimental drug that is currently in the lead in addressing the specific indication of bladder cancer.  In Merck's study involving 29 people with PD-L1 positive, advanced bladder cancer, seven patients -- or 24 percent -- saw their tumors shrink after being given Keytruda, Elizabeth Plimack of Philadelphia's Fox Chase Cancer Center told the European Society of Medical Oncology on Monday. Based on this data, Merck said it would initiate a pivotal Phase III study this year to further explore the use of Keytruda in advanced bladder cancer.Promising results using Keytruda in stomach cancer were also reported on Sunday.  (Reporting by Ben Hirschler; Editing by Crispian Balmer)",2014-09-29,MRK,"Mon Sep 29, 2014 | 5:19am EDT",Merck immunotherapy drug shows promise in bladder cancer,http://www.reuters.com//article/us-health-cancer-merck-idUSKCN0HO0QO20140929?type=companyNews
186,"  MADRID, Sept 29 Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year.Keytruda is the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, but it also has potential in a range of other cancers.Bladder cancer is seen as a disease that is likely to be amenable to such drugs, which are designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1. Roche has a similar experimental drug that is currently in the lead in addressing the specific indication of bladder cancer. In Merck's study involving 29 people with PD-L1 positive, advanced bladder cancer, seven patients -- or 24 percent -- saw their tumours shrink after being given Keytruda, Elizabeth Plimack of Philadelphia's Fox Chase Cancer Center told the European Society of Medical Oncology on Monday. Based on this data, Merck said it would initiate a pivotal Phase III study this year to further explore the use of Keytruda in advanced bladder cancer.Promising results using Keytruda in stomach cancer were also reported on Sunday.    (Reporting by Ben Hirschler; Editing by Crispian Balmer)",2014-09-29,MRK,"Mon Sep 29, 2014 | 5:00am EDT",Merck immunotherapy drug shows promise in bladder cancer,http://www.reuters.com//article/health-cancer-merck-idUSL6N0RT0N420140929?type=companyNews
187,"  (Adds share move, analyst forecast)By Bill BerkrotOct 1 An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's  Zetia in a midstage clinical trial, Esperion said on Wednesday.Esperion shares rose more than 40 percent in after-hours trade.In a 12-week study involving 348 patients with high LDL cholesterol, the Esperion drug, ETC-1002, led to an average 30 percent reduction in levels of the ""bad"" cholesterol for those who received a 180 milligram dose and a 27 percent reduction with a 120 mg dose, according to initial results.Both were deemed to be statistically significant differences compared with reductions in patients taking Zetia, known chemically as ezetimibe, Esperion said. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer Inc's Lipitor, now available as generic atorvastatin, and AstraZeneca Plc's Crestor. The reductions were roughly half of the LDL-lowering magnitude seen with new injectable biotech cholesterol drugs, called PCSK9 inhibitors, likely to be approved next year.The Esperion drug, when combined with 10 mg of Zetia, led to LDL reductions of 48 percent for the high dose of ETC-1002 and 43 percent with the lower dose.""These are very encouraging results. It basically shows efficacy, and it shows that it can be added to ezetimibe to get more efficacy,"" Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine in Houston and one of the study's investigators, said in a telephone interview. ""Statins are going to stay first-line drugs,"" he said. ""There's lots of people who have a hard time taking a high dose of statin or taking a statin at all.""Esperion is also conducting trials combining its drug with various statins.If approved, the Esperion drug is almost surely going to be less expensive than the more effective biologics, making it a potential option that physicians could reach for before putting patients on the injectables, Ballantyne said. JMP Securities analyst Jason Butler has forecast annual peak sales in excess of $1 billion for the medicine.ETC-1002 also led to significantly greater reductions than Zetia in C-reactive protein, a marker of inflammation associated with heart disease, the company said.ETC-1002 is the first in a new class of drugs called ACL inhibitors that work by reducing cholesterol synthesis in the liver and increasing expression of LDL receptors that remove cholesterol from the blood.The most common side effects were common cold symptoms and upper respiratory tract infections. The rates of muscle-related adverse side effects seen with ETC-1002 patients, including those with statin intolerance, were similar to rates for Zetia, Esperion said.Esperion shares rose to $35 in extended trading from a Nasdaq close at $24.42.    (Reporting by Bill Berkrot; Editing by Andre Grenon and Leslie Adler)",2014-10-01,MRK,"Wed Oct 1, 2014 | 4:47pm EDT",UPDATE 1-Esperion drug succeeds in lowering LDL cholesterol -study,http://www.reuters.com//article/esperion-cholesterol-idUSL2N0RW2RJ20141001?type=companyNews
188,"   By Bill Berkrot  Oct 1 A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc  lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.In the 12-week study involving 348 patients with high LDL cholesterol the Esperion drug, ETC-1002, led to an average 30 percent reduction in levels of the ""bad"" cholesterol for those who received a 180 milligram dose and a 27 percent reduction with a 120 mg dose, according to initial results.Both were deemed to be statistically significant differences compared with reductions experienced by patients taking Zetia, known chemically as ezetimibe, the company said.The LDL reductions seen with the once daily ETC-1002 pill were somewhat less than can be achieved by the more powerful statins, such as Pfizer Inc's Lipitor, now available as generic atorvastatin, and AstraZeneca Plc's Crestor. It was roughly half of the LDL lowering magnitude seen with new injectable biotech cholesterol drugs, called PCSK9 inhibitors, likely to be approved next year. The Esperion drug, when combined with 10 mg of Zetia, led to LDL reductions of 48 percent for the high dose of ETC-1002 and 43 percent with the lower dose.""These are very encouraging results. It basically shows efficacy, and it shows that it can be added to ezetimibe to get more efficacy,"" Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine in Houston and one of the study's investigators, said in a telephone interview. ""Statins are going to stay first line drugs,"" he said. ""There's lots of people who a have hard time taking a high dose of statin or taking a statin at all.""If approved, the Esperion drug is almost surely going to be less expensive than the more effective biologics, making it a potential option that physicians could reach for before putting patients on the injectables, Ballantyne said. Esperion is also conducting trials combining its drug with various statins.ETC-1002 also led to significantly greater reductions than Zetia in C-reactive protein, a marker of inflammation associated with heart disease, the company said.ETC-1002 is the first in a new class of drugs called ACL inhibitors that work by reducing cholesterol synthesis in the liver and increasing expression of LDL receptors that remove cholesterol from the blood.The most common side effects were common cold symptoms and upper respiratory tract infections. The rates of muscle-related adverse side effects seen with ETC-1002 patients, including those with statin intolerance, were similar to rates for Zetia, Esperion said.   (Reporting by Bill Berkrot. Editing by Andre Grenon)",2014-10-01,MRK,"Wed Oct 1, 2014 | 4:05pm EDT",Esperion drug succeeds in lowering LDL cholesterol -study,http://www.reuters.com//article/esperion-cholesterol-idUSL2N0RV34B20141001?type=companyNews
189,"   By Mike Gambale  NEW YORK, Oct 1 (IFR) - Bayer launched a US$7bn six-tranche acquisition bond financing for Merck's consumer care business Wednesday at levels 10bp-25bp inside of initial price thoughts, leads on the trade said.The US$850m three-year fixed-rate tranche was launched at Treasuries plus 55bp, versus guidance of 60bp area and initial price thoughts of 80bp; the US$2bn five-year at T+80bp versus 85bp guidance and 90bp IPTs; the US$1.5bn seven-year at T+ 90bp versus 95bp guidance and IPTs of 105bp; the US$1.75bn 10-year at T+110bp versus guidance of 115bp and IPTs of 125bp. Bayer (A3/A-) also launched a US$500m two-year floating-rate note at Libor plus 25bp versus 30bp area guidance and IPTs of 37.5bp, and a US$400m three-year FRN at Libor plus 28bp. Plans for a five-year FRN were dropped. Joint bookrunners Bank of America Merrill Lynch, Deutsche Bank, Goldman Sachs and JP Morgan are expected to price the deal, issued by Bayer US Finance, later on Wednesday.For more detail, click on    (Reporting by Mike Gambale; Writing by Natalie Harrison; Editing by Marc Carnegie)",2014-10-01,MRK,"Wed Oct 1, 2014 | 1:32pm EDT",Bayer launches US$7bn six-tranche acquisition bond,http://www.reuters.com//article/bayer-bonds-launch-idUSL2N0RW1TR20141001?type=companyNews
190,  BERLIN Oct 1 Bayer Ag * Completes takeover of merck & co otc drug unit  Further company coverage:  ,2014-10-01,MRK,"Wed Oct 1, 2014 | 11:31am EDT",BRIEF-Bayer completes takeover of Merck & Co OTC drug unit,http://www.reuters.com//article/bayer-merck-co-ma-idUSFWN0RV02P20141001?type=companyNews
191,"  BERLIN Oct 1 Bayer Ag* Says bayer closes acquisition of consumer care business of merck & co., inc., united states, for usd 14.2 billion  * Says to receive up to usd 2.1 billion from strategic pharma collaboration   Further company coverage: ",2014-10-01,MRK,"Wed Oct 1, 2014 | 11:29am EDT",BRIEF-Bayer closes buy of Merck & Co consumer care business,http://www.reuters.com//article/bayer-merck-co-ma-idUSFWN0RV02Q20141001?type=companyNews
192,"  (The following statement was released by the rating agency) CHICAGO, October 06 (Fitch) Fitch Ratings has assigned an 'A+' rating Merck &  Co.'s (Merck) Euro denominated senior unsecured notes offering. Merck intends to  use all or a substantial portion of the net proceeds from the offering to  refinance existing debt. The Rating Outlook is Negative and applies to approximately $23.1 billion in  outstanding debt. A full list of Merck's ratings follows near the end of this  release. KEY RATING DRIVERS --The Negative Outlook mainly reflects that leverage (total debt/EBITDA) has  remained above 1.5 times (x) since Merck's $5 billion, largely debt-funded share  repurchases in second-quarter 2013 (2Q'13). While leverage has declined to 1.52x  from its peak of 1.92x at June 30, 2013, the Oct. 1, 2014 sale of its consumer  business to Bayer will modestly weigh on EBITDA and leverage.  --Fitch expects that Merck will continue to favor share repurchases over  deleveraging, acknowledging the possibility of further debt-funded stock  buybacks. Notably, the company has roughly $7 billion remaining on its existing  repurchase authorization. --Sales at-risk to patent expiries have declined to roughly 20% of total firm  sales. Roughly one-third of those sales are generated by biologics, which tend  to have significantly less market share erosion in the face of generic  (biosimilar) than do traditional small molecule drugs. --Merck has made progress in building its late-stage pipeline. The company has  approximately 20 new molecular entities (NMEs) in phase 3 development or  registration. --Merck initiated a restructuring program in October 2013, which Fitch expects  will be supportive to margins during the intermediate term. Merck will focus on  costs in a number of areas including manufacturing, general administration and  research & development. --Fitch believes the sale of Merck's consumer business was strategically sound,  as it increasec the company's focus on its core mission of developing and  marketing innovative medicines. However, the sale incrementall decreases the  diversification of the company's business model. --Fitch expects modest growth for Merck's Januvia/Janumet franchise, as the  market becomes increasingly crowded with new entrants. Although, the growth in  the number of diabetic patients and some share gains from older generic  treatment modalities should offset the competitive headwinds. --Fitch forecasts that Merck will generate $5.8 billion - $6.1 billion in FCF  during 2014 as improving margins offset soft revenue. Debt Financed Share Repurchases Fitch expects that Merck will continue with shareholder friendly actions during  the near term, some of which may be funded by debt. Merck purchased $2.3 billion  (net of issuances) of its common stock during the first six months of 2014. The  repurchases were executed under a $15 billion program authorized in May 2013 and  a previously authorized program. Merck has approximately $7 billion remaining  under the May 2013 share repurchase program.  Patent Exposure Easing Merck faces significant number of patent expiries during the next two years.  However, roughly only 20% of total firm sales are at risk. In addition, Remicade  and PEG-Intron (accounting for about 6.2% of total firm) are biologics and tend  not to experience the rapid sales loss to generic competition as do traditiona,  one small molecule pharmaceuticals. Expanding Late Stage Pipeline Fitch expects Merck to continue to build its late-stage pipeline, despite the  company's intention to narrow its focus its focus on R&D projects. Merck's late  stage pipeline is broad with new molecular entities (NMEs) to treat cancer,  bacterial and viral infections, diabetes, cardiovascular disease, central  nervous system disorders, osteoporosis, allergies and other maladies. The  September 2014 FDA approval of Keytruda was a significant milestone in Merck's  development of cancer treatments. While the majority of these projects are internally developed, Merck has  partnered with other innovator firms to take advantage of technological  advancements that were discovered externally. The landscape for drug development  is expanding, particularly as more is learned about how genetics influence the  development, prevention and treatment of disease.  Cost Cutting Continues In October 2013, Merck initiated a new global restructuring program, in an  effort to sharpen its global commercial and research & development focus. Merck  is working on reducing costs in the areas of sales, administration and research  & development. Merck continues to work towards improving the efficiency of its  manufacturing and supply network. The restructuring program is expected to be  substantially completed by the end of 2015. Estimated pre-tax restructuring  costs are approximately $2.5 billion - $3 billion, of which two-thirds will be  cash-related. Consumer Business Sale  Fitch believes the sale of Merck's consumer products business is a modest  negative for its credit profile, with the expectation that the proceeds of the  sales would not be used for debt reduction. While the consumer business  accounted for roughly 4% of total firm sales, Fitch estimates the segment's  contribution to Merck's total EBITDA is less than that. Regardless, Fitch  believes the negative effects of an incrementally less diversified product  portfolio and a lower base of profitability will more than offset the benefits  to the firm from increasing its focus on its core competency of drug development  and marketing in the near term. More Competition for Januvia/Janumet Fitch expects that the growing number of diabetic patients and continued market  share gains from some older generic diabetes treatments will more than offset  the increasing number of competitors in the diabetes treatment market. This will  result in relatively soft sales growth for Januvia/Janumet, Merck's largest  selling franchise. Growth has slowed in recent years due to competition (DPP-4  inhibitors, SGLT2 inhibitors, GLP-1 agonists) entering the diabetes market. In  addition, concerns over the safety of these drugs(DPP-4 inhibitors) have been a  headwind to growth. However, the FDA recently reaffirmed their safety regarding  pancreatitis and pancreatic cancer.  Solid Free Cash Flow Expected Fitch forecasts that Merck will continue to generate significantly positive free  cash flow generate, including expected 2014 FCF of $5.8 billion - $6.1 in FCF  during 2014. Improving margins driven by an improving sales mix and strong cost  control should more than offset the negative effect that expected soft top-line  growth will have on cash generation. Adequate Liquidity Fitch looks for Merck to maintain adequate liquidity through strong FCF  generation and ample access to the credit markets. FCF for the LTM ending June  30, 2014 was $5.1 billion. At the end of the period, Merck had approximately  $13.4 billion in cash plus short-term investments and full availability on its  $4 billion revolver, maturing in May 2017.  At June 30, 2014, Merck had roughly $24.1 billion in debt outstanding. Fitch  expects near- to mid-term maturities will be satisfied primarily through  refinancing in the public debt markets. RATING SENSITIVITIES Fitch would consider revising the Rating Outlook to Stable if Merck pursued a  capital deployment strategy that maintained gross debt leverage below 1.5X  during the long term, including managing through operational stress such as  patent expiries and clearly taking a more conservative approach to its use of  debt. In addition, Merck must demonstrate long-term positive sales growth  through demand for core drug products and uptake of new medicines.  Rating pressure would stem from total debt leverage remaining above 1.5x in the  intermediate term. The high leverage would likely be driven by incremental  borrowing to fund acquisitions or share repurchases. Leverage pressure could  also result from operational weakness due to an inability to achieve in  achieving cost containment targets or generating sales growth despite is  improving patent risk profile and expanding late-stage pipeline. In addition,  Fitch anticipatates that FCF would be constrained in this scenario. Fitch currently rates Merck as follows:   --Long-term IDR 'A+';  --Senior unsecured debt rating 'A+'; --Bank loan rating 'A+'; --Short-term IDR 'F1'; --Commercial paper rating 'F1'. The Rating Outlook on the long-term ratings is Negative. Contact: Primary Analyst Bob Kirby, CFA Director +1-312-368-3147  Fitch Ratings, Inc., 70 West Madison Street, Chicago, IL 60602 Secondary Analyst Michael Zbinovec Senior Director +1-312-368-3164 Committee Chairperson Michael Weaver Managing Director +1-312-368-3156 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research: --'Corporate Rating Methodology' (May 28, 2014); --'Rating Pharmaceutical Companies - Sector Credit Factors' (Aug. 9, 2012). Applicable Criteria and Related Research:  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage here Rating Pharmaceutical Companies  here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-10-06,MRK,"Mon Oct 6, 2014 | 2:10pm EDT",Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative,http://www.reuters.com//article/fitch-rates-mercks-eur-debt-offering-a-o-idUSFit78182020141006?type=companyNews
193,"  Oct 6(Reuters) -Following are terms and conditionsof a multi tranche deal priced on Monday.Borrower                Merck & Co., Inc.* * * * Tranche 1Issue Amount            1.0 billion euroMaturity Date           October 15, 2021Coupon                  1.125 pctIssue price             99.873Spread                  42 basis pointsUnderlying govt bond    Over midswapsISIN                    XS1028941976 * * * * Tranche 2Issue Amount            500 million euroMaturity Date           October 15, 2034Coupon                  2.5 pctIssue price             98.839 Spread                  82 basis pointsUnderlying govt bond    over midswapsISIN                    XS1028941893 * * * * Tranche 3Issue Amount            1.0 billion euroMaturity Date           October 15, 2026Coupon                  1.875 pctIssue price             99.236 Spread                  62 basis pointsUnderlying govt bond    Over midswapsISIN                    XS1028941117 * * * * Common termsPayment Date            October 15,2014Lead Manager(s)         JP Morgan, Deutsche Bank AG, BNP Paribas, BAML, RBS, BBVA,Santander, HSBC, Lebenthal, Societe Generale,Standard Chartered Bank Ratings                 A2(Moody's) & AA  (S&P),Listing                 NYSEDenoms (K)              100-1Governing Law           New YorkFull fees               UndisclosedSecurity details and RIC, when available, will beonCustomers can right-click on the code forperformance analysis of this new issueFor ratings information, double click onFor all bonds data, double click onFor Top international bonds newsFor news about this issuer, double click on the issuer RIC,where assigned, and hit the newskey (F9 on Reuters terminals)",2014-10-06,MRK,"Mon Oct 6, 2014 | 1:36pm EDT",New Issue- Merck & Co prices multi tranche deal,http://www.reuters.com//article/idUSL3N0S13D120141006?type=companyNews
194,"   By Sophie Sassard and Ben Hirschler | LONDON  LONDON Oct 14 GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.Potential bidders include private equity firm KKR, India's Lupin and Denmark's Lundbeck, all of which are interested in acquiring rights to products in certain regions.Britain's biggest drug maker is looking to divest the mature products in a bid to improve its growth profile and wants to dispose of off-patent drugs marketed in North America and western Europe.The medicines on the block, known as established products, are expected to have combined 2014 sales of around 1 billion pounds ($1.6 billion), although their sales are declining due to competition from cheap generic drugs.The sources said GSK was looking for a multiple of more than two times sales, suggesting a price of at least $3.2 billion.GSK, which is being advised by Lazard, aims to find buyers by the end of the year and is keen to maximise returns for shareholders, whether that means selling the products as a single unit or splitting them up by region, they added.Danish pharmaceutical company Lundbeck is reviewing a bid for products marketed in North America as it seeks to expand there, two of the sources said. KKR has teamed up with private Netherlands-based gastrointestinal specialist Norgine in a bid to acquire some of GSK's drugs sold in Europe, said the same people.Indian generics firm Lupin is also expected to participate in the second round of the auction and would be interested in products in the United States, said the sources.Other private equity funds with an interest in healthcare are also looking at some specific products. Some bidders might still emerge with an interest in the entire portfolio, although this scenario is seen as less likely.Acquiring GSK's older drugs would be more complicated for private equity funds than other drug manufacturers as GSK is not planning to sell the factories, which means the funds would need to outsource manufacturing and distribution operations. GSK, Lundbeck, KKR and Norgine all declined to comment.Lupin, meanwhile, has said for some months it wants to enhance its U.S. branded generics business and a company official previously confirmed to Reuters it was looking for deals, while declining comment on specific targets.SIGNIFICANT INTEREST  GSK Chief Executive Andrew Witty said in July that there had been significant interest from both mid-sized pharmaceutical companies and buyout specialists in the assets now on the block.The GSK brands up for sale include antidepressant Paxil, migraine treatment Imitrex, Zantac for stomach acid and Zofran for nausea. The company intends to retain the rights to such products in emerging markets, where they are still growing.Ditching mature products sold in Western markets makes long-term sense, since sales are declining. However, these items remain very profitable, so a sale may dilute earnings per share, which could further strain GSK's already stretched dividend cover.Sales of all GSK's established products - including those being retained - totalled 1.51 billion pounds in the first half of 2014, down 18 percent on a year earlier.GSK's decision to carve out some of its mature drug portfolio is part of a wider industry trend, with Mylan  agreeing in July to buy Abbott Laboratories' branded specialty and generics business in non-U.S. developed markets.Other companies including Sanofi and Merck & Co  are also looking at similar divestments.(1 US dollar = 0.6277 British pound)   (Additional reporting by Freya Berry and Anjuli Davies in London; editing by Susan Thomas)",2014-10-14,MRK,"Tue Oct 14, 2014 | 12:55pm EDT",Geographic split likely for GSK mature drugs sale -sources,http://www.reuters.com//article/gsk-ma-mature-drugs-idUSL6N0S93D820141014?type=companyNews
195,"   By Daniel Wiessner  A subsidiary of Merck & Co has agreed to pay U.S. states $31 million to settle claims that it overcharged their Medicaid programs for an antidepressant it had sold at a discount to pharmacy companies, attorney generals from three states said on  Wednesday.The officials from Idaho, New York and Florida said Organon USA Inc offered the drug, Remeron, to nursing home pharmacies at a discount to encourage its use over competitors. At the same time, the company reported the full cost of the drug when seeking reimbursements from state Medicaid programs, the states claimed.New Jersey-based Organon, which did not admit any wrongdoing, also was accused of improperly promoting use of the drug by children and teens.  The agreement, which includes Washington, D.C., and every state besides Arizona, settled whistleblower lawsuits filed in 2007 in federal courts in Massachusetts and Texas. Under the deal, New York will receive about $2.5 million, Idaho about $53,000, and Florida $483,000, the states' attorney generals said in separate statements. Preserving the integrity of our Medicaid program and weeding out those who seek to defraud it is a top priority for my office, New York Attorney General Eric Schneiderman said. A spokeswoman for Merck said the company was ""pleased to put this matter behind us."" Organon, originally based in the Netherlands, was acquired in 2007 by Schering-Plough Corp, which later merged with Merck.  (Reporting by Daniel Wiessner; Editing by Ted Botha and David Gregorio)",2014-10-15,MRK,"Wed Oct 15, 2014 | 4:08pm EDT",Merck unit to pay $31 million to settle fraud claims by U.S. states,http://www.reuters.com//article/us-pharmaceuticals-remeron-idUSKCN0I42IO20141015?type=companyNews
196,"   By Daniel Wiessner  Oct 15, A subsidiary of Merck & Co has agreed to pay U.S. states $31 million to settle claims that it overcharged their Medicaid programs for an antidepressant it had sold at a discount to pharmacy companies, attorney generals from three states said on  Wednesday.The officials from Idaho, New York and Florida said Organon USA Inc offered the drug, Remeron, to nursing home pharmacies at a discount to encourage its use over competitors. At the same time, the company reported the full cost of the drug when seeking reimbursements from state Medicaid programs, the states claimed. New Jersey-based Organon, which did not admit any wrongdoing, also was accused of improperly promoting use of the drug by children and teens. The agreement, which includes Washington, D.C., and every state besides Arizona, settled whistleblower lawsuits filed in 2007 in federal courts in Massachusetts and Texas. Under the deal, New York will receive about $2.5 million, Idaho about $53,000, and Florida $483,000, the states' attorney generals said in separate statements. ""Preserving the integrity of our Medicaid program and weeding out those who seek to defraud it is a top priority for my office,"" New York Attorney General Eric Schneiderman said.A spokeswoman for Merck said the company was ""pleased to put this matter behind us."" Organon, originally based in the Netherlands, was acquired in 2007 by Schering-Plough Corp, which later merged with Merck.   (Reporting by Daniel Wiessner; Editing by Ted Botha and David Gregorio)",2014-10-15,MRK,"Wed Oct 15, 2014 | 4:04pm EDT",Merck unit to pay $31 mln to settle fraud claims by U.S. states,http://www.reuters.com//article/pharmaceuticals-remeron-idUSL2N0SA22920141015?type=companyNews
197,"  LONDON Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumors to another cancer type.Early clinical results with Roche's drug, known as MPDL3280A, in so-called triple negative breast cancer (TNBC) will be revealed at the Dec. 9-13 San Antonio Breast Cancer Symposium, the firm said after announcing third-quarter results.TNBC does not respond to either of two kinds of hormonal therapy or drugs that target HER2 receptors, such as Roche's own Herceptin.Merck later confirmed that it, too, would present data on TNBC with its competitor drug Keytruda at the same breast cancer meeting.Both drugs belong to a class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1, used by tumors to evade disease-fighting cells. Developed first for melanoma, these medicines are also showing promise in a range of other tumor types. Roche's MPDL3280A, which is not yet approved for any type of cancer, is already being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers. Merck's Keytruda became the first in the new wave of immune-boosting medicines to be approved for treating melanoma in the United States last month and is also being tested in a range of other tumor types.Some analysts believe the new immunotherapy drug class could generate more than $30 billion (18.66 billion pounds) in annual sales for the industry as a whole by 2025, reflecting both the wide range of patients who could benefit and the high cost of the medicines. The two other main rivals in the space are Bristol-Myers Squibb and AstraZeneca.  (Reporting by Ben Hirschler in LONDON; editing by Keiron Henderson and Susan Thomas)",2014-10-17,MRK,"Fri Oct 17, 2014 | 2:59am EDT","Roche, Merck extend immunotherapy fight to breast cancer",http://www.reuters.com//article/us-roche-results-cancer-idUSKCN0I60HA20141017?type=companyNews
198,"  LONDON Swiss drugmaker Roche and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumours to another cancer type.Early clinical results with Roche's drug, known as MPDL3280A, in so-called triple negative breast cancer (TNBC) will be revealed at the Dec. 9-13 San Antonio Breast Cancer Symposium, the firm said after announcing third-quarter results.TNBC does not respond to either of two kinds of hormonal therapy or drugs that target HER2 receptors, such as Roche's own Herceptin.Merck later confirmed that it, too, would present data on TNBC with its competitor drug Keytruda at the same breast cancer meeting.Both drugs belong to a class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1, used by tumours to evade disease-fighting cells. Developed first for melanoma, these medicines are also showing promise in a range of other tumour types. Roche's MPDL3280A, which is not yet approved for any type of cancer, is already being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers. Merck's Keytruda became the first in the new wave of immune-boosting medicines to be approved for treating melanoma in the United States last month and is also being tested in a range of other tumour types.Some analysts believe the new immunotherapy drug class could generate more than $30 billion (18.66 billion pounds) in annual sales for the industry as a whole by 2025, reflecting both the wide range of patients who could benefit and the high cost of the medicines. The two other main rivals in the space are Bristol-Myers Squibb and AstraZeneca.  (Reporting by Ben Hirschler in LONDON; editing by Keiron Henderson and Susan Thomas)",2014-10-17,MRK,"Fri Oct 17, 2014 | 2:45am EDT","Roche, Merck extend immunotherapy fight to breast cancer",http://www.reuters.com//article/uk-roche-results-cancer-idUSKCN0I51ZM20141017?type=companyNews
199,"  (Adds Merck also presenting breast cancer data in December)LONDON Oct 17 Swiss drugmaker Roche  and U.S. group Merck & Co are to present data on their rival immunotherapy drugs in breast cancer in December, extending the novel approach to fighting tumours to another cancer type.Early clinical results with Roche's drug, known as MPDL3280A, in so-called triple negative breast cancer (TNBC) will be revealed at the Dec. 9-13 San Antonio Breast Cancer Symposium, the firm said after announcing third-quarter results.TNBC does not respond to either of two kinds of hormonal therapy or drugs that target HER2 receptors, such as Roche's own Herceptin. Merck later confirmed that it, too, would present data on TNBC with its competitor drug Keytruda at the same breast cancer meeting.Both drugs belong to a class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1, used by tumours to evade disease-fighting cells. Developed first for melanoma, these medicines are also showing promise in a range of other tumour types.Roche's MPDL3280A, which is not yet approved for any type of cancer, is already being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers. Merck's Keytruda became the first in the new wave of immune-boosting medicines to be approved for treating melanoma in the United States last month and is also being tested in a range of other tumour types.Some analysts believe the new immunotherapy drug class could generate more than $30 billion in annual sales for the industry as a whole by 2025, reflecting both the wide range of patients who could benefit and the high cost of the medicines.The two other main rivals in the space are Bristol-Myers Squibb and AstraZeneca.    (Reporting by Ben Hirschler in LONDON; editing by Keiron Henderson and Susan Thomas)",2014-10-17,MRK,"Fri Oct 17, 2014 | 2:41am EDT","UPDATE 1-Roche, Merck extend immunotherapy fight to breast cancer",http://www.reuters.com//article/roche-results-cancer-idUSL6N0SC0IR20141017?type=companyNews
200,"   By Joseph Ax | NEW YORK  NEW YORK A former Bank of New York Mellon Corp (BK.N) employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc (MRK.N) employee about potential pharmaceutical mergers.Federal prosecutors in New York said David Post, 41, a product manager at the bank, received nonpublic information from a former Rutgers Business School classmate about three companies: Idenix Pharmaceuticals, Ardea BioSciences and ViroPharma Inc [VIRO.UL].Prosecutors did not name the classmate, but on Oct. 14 they charged Zachary Zwerko, a former senior finance analyst with Merck, with passing inside tips about the same three stocks to a Rutgers classmate who worked at a bank.The connection was confirmed when the U.S. Securities and Exchange Commission on Friday amended a parallel civil complaint against Zwerko to include Post as a defendant.Ron Gruendl, a spokesman for Bank of New York Mellon, said Post's conduct was not connected to his work at the bank. ""We have cooperated fully with law enforcement and regulatory agencies,"" he said. ""He is no longer employed here.""According to criminal and civil court filings, Zwerko passed information to Post about Merck's acquisition of Idenix as well as Ardea and ViroPharma, which Zwerko learned were potential acquisition targets. Post then traded on the information and split the profits with Zwerko, authorities said.AstraZeneca PLC (AZN.L) announced a bid for Ardea in April 2012, while Shire PLC (SHP.L) announced a takeover of ViroPharma in November 2013. ""Post and Zwerko tried to keep law enforcement authorities in the dark by using prepaid cell phones and a dummy e-mail account to communicate inside information, and Post doled out the kickbacks inside his own home,"" Sanjay Wadhwa, senior associate director of the SEC's New York regional office, said in a statement.At a court hearing before U.S. District Judge Alvin Hellerstein, a tearful Post admitted he executed a series of trades between 2012 and 2014 based on the tips. He entered a guilty plea to one count of conspiracy and three counts of securities fraud as part of a cooperation agreement with the Manhattan U.S. Attorney's office.Assistant U.S. Attorney Jessica Masella said in court that Post is believed to have earned more than $700,000 in illicit profits.Post, a resident of Livingston, New Jersey, is scheduled to be sentenced in January and faces up to 20 years in prison on each securities fraud count and up to 5 years on the conspiracy charge, although a maximum sentence is unlikely. (Reporting by Joseph Ax; Editing by Richard Chang)",2014-10-24,MRK,"Fri Oct 24, 2014 | 4:46pm EDT",Ex-Bank of New York Mellon employee pleads guilty to insider trading,http://www.reuters.com//article/us-insidertrading-bank-of-ny-melln-idUSKCN0ID21620141024?type=companyNews
201,"  (Adds details of case, statement from SEC official)By Joseph AxNEW YORK Oct 24 A former Bank of New York Mellon Corp employee on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc  employee about potential pharmaceutical mergers.Federal prosecutors in New York said David Post, 41, a product manager at the bank, received nonpublic information from a former Rutgers Business School classmate about three companies: Idenix Pharmaceuticals, Ardea BioSciences and ViroPharma Inc.Prosecutors did not name the classmate, but on Oct. 14 they charged Zachary Zwerko, a former senior finance analyst with Merck, with passing inside tips about the same three stocks to a Rutgers classmate who worked at a bank.The connection was confirmed when the U.S. Securities and Exchange Commission on Friday amended a parallel civil complaint against Zwerko to include Post as a defendant. Ron Gruendl, a spokesman for Bank of New York Mellon, said Post's conduct was not connected to his work at the bank.""We have cooperated fully with law enforcement and regulatory agencies,"" he said. ""He is no longer employed here."" According to criminal and civil court filings, Zwerko passed information to Post about Merck's acquisition of Idenix as well as Ardea and ViroPharma, which Zwerko learned were potential acquisition targets. Post then traded on the information and split the profits with Zwerko, authorities said.AstraZeneca PLC announced a bid for Ardea in April 2012, while Shire PLC announced a takeover of ViroPharma in November 2013.""Post and Zwerko tried to keep law enforcement authorities in the dark by using prepaid cell phones and a dummy e-mail account to communicate inside information, and Post doled out the kickbacks inside his own home,"" Sanjay Wadhwa, senior associate director of the SEC's New York regional office, said in a statement. At a court hearing before U.S. District Judge Alvin Hellerstein, a tearful Post admitted he executed a series of trades between 2012 and 2014 based on the tips.He entered a guilty plea to one count of conspiracy and three counts of securities fraud as part of a cooperation agreement with the Manhattan U.S. Attorney's office.Assistant U.S. Attorney Jessica Masella said in court that Post is believed to have earned more than $700,000 in illicit profits.Post, a resident of Livingston, New Jersey, is scheduled to be sentenced in January and faces up to 20 years in prison on each securities fraud count and up to 5 years on the conspiracy charge, although a maximum sentence is unlikely.   (Reporting by Joseph Ax; Editing by Richard Chang)",2014-10-24,MRK,"Fri Oct 24, 2014 | 4:42pm EDT",UPDATE 1-Ex-Bank of New York Mellon employee pleads guilty to insider trading,http://www.reuters.com//article/insidertrading-bank-of-ny-melln-idUSL2N0SJ2NQ20141024?type=companyNews
202,"   By Joseph Ax | NEW YORK  NEW YORK Oct 24 A former Bank of New York Mellon Corp trader on Friday pleaded guilty to insider trading based on tips from a former Merck & Co Inc  employee about potential pharmaceutical mergers.Federal prosecutors in New York said David Post, 41, a product manager at the bank, received nonpublic information from a former Rutgers Business School classmate about three companies: Idenix Pharmaceuticals, Ardea BioSciences and ViroPharma Inc.Prosecutors did not name the classmate, but on Oct. 14 they charged Zachary Zwerko, a former senior finance analyst with Merck, with passing inside tips about the same three stocks to a Rutgers classmate who worked at a bank.The connection was confirmed when the U.S. Securities and Exchange Commission on Friday amended a parallel civil complaint against Zwerko to include Post as a defendant. According to criminal and civil court filings, Zwerko passed information to Post about Merck's acquisition of Idenix as well as Ardea and ViroPharma, which Zwerko learned were potential acquisition targets.AstraZeneca PLC announced a bid for Ardea in April 2012, while Shire PLC announced a takeover of ViroPharma in November 2013. At a court hearing before U.S. District Judge Alvin Hellerstein, a tearful Post admitted he executed a series of trades between 2012 and 2014 based on the tips.He entered a guilty plea to one count of conspiracy and three counts of securities fraud as part of a cooperation agreement with the Manhattan U.S. Attorney's office. Assistant U.S. Attorney Jessica Masella said in court that Post is believed to have earned more than $700,000 in illicit profits.Ron Gruendl, a spokesman for Bank of New York Mellon, said Post's conduct was not connected to his work at the bank.""We have cooperated fully with law enforcement and regulatory agencies,"" he said. ""He is no longer employed here.""Post, a resident of Livingston, New Jersey, is scheduled to be sentenced in January and faces up to 20 years in prison on each securities fraud count and up to 5 years on the conspiracy charge, although a maximum sentence is unlikely.   (Reporting by Joseph Ax; Editing by Richard Chang)",2014-10-24,MRK,"Fri Oct 24, 2014 | 1:40pm EDT",Ex-Bank of New York Mellon trader pleads guilty to insider trading,http://www.reuters.com//article/insidertrading-bank-of-ny-melln-idUSL2N0SJ1S620141024?type=companyNews
203,"   By Caroline Valetkevitch | NEW YORK  NEW YORK U.S. stocks ended near flat on Monday, pausing after the S&P 500's biggest weekly gain since January 2013, while energy shares fell with another decline in oil prices.Among the day's biggest positives, shares of Gilead Sciences (GILD.O) rose 1.7 percent to $112.59, a day ahead of its scheduled earnings release. Micron Technology (MU.O) shares jumped 4 percent to $32.30 and was the largest percentage gainer on both the S&P 500 and Nasdaq 100 after it announced a $1 billion stock repurchase.But energy shares were by far the day's biggest drag, with the S&P 500 energy index .SPNY falling 2 percent. U.S. crude oil CLc1 briefly traded below $80 a barrel after Goldman Sachs slashed its crude price forecasts, citing abundant supply and lackluster demand.The S&P 500 ended the day down slightly after closing out its best week since early January 2013, a sharp recovery from the market's recent selloff. The index is now up 5.3 percent from its Oct. 15 low.""After almost a 10 percent correction on the S&P, the bulls showed up and sent the prices right back up. Now... we're on track for closing in the upper half of the range for the month, which is a bullish sign,"" said Adam Sarhan, chief executive of Sarhan Capital in New York.Accommodative central bank policies globally should keep ""an underlying bid for stocks,"" he said. The Dow Jones industrial average .DJI rose 12.53 points, or 0.07 percent, to 16,817.94, the S&P 500 .SPX lost 2.95 points, or 0.15 percent, to 1,961.63 and the Nasdaq Composite .IXIC added 2.22 points, or 0.05 percent, to 4,485.93.  The majority of companies are beating earnings expectations. With results in from 213 of the S&P 500 companies, 71.4 percent beat analysts' forecasts, which would be highest percentage since the third quarter of 2011, Thomson Reuters data showed. U.S.-traded shares of Brazilian companies tumbled after President Dilma Rousseff won reelection, defeating market favorite Aecio Neves by a slim margin.  Petrobras ADRs (PBR.N) slumped 13.7 percent to $11.16 and Vale (VALE.N) lost 5.2 percent to $10.58. A Brazilian exchange-traded fund (EWZ.P) dropped 5.4 percent. After the bell, shares of Twitter (TWTR.N) dropped 9.6 percent to $43.88 after it reported quarterly revenue that surpassed expectations but forecast fourth-quarter sales that may miss targets. On the S&P 500, the largest decliner was Nabors Industries (NBR.N), down 6.7 percent to $17.48. On the Nasdaq, the largest decliner was Tesla Motors (TSLA.O), down 5.8 percent at $221.67. Declining NYSE issues outnumbered advancers 1,737 to 1,308, for a 1.33-to-1 ratio on the downside; on the Nasdaq, 1,424 issues fell and 1,235 advanced for a 1.15-to-1 ratio.The benchmark S&P 500 index posted 53 new 52-week highs and one new low; the Nasdaq Composite recorded 45 new highs and 62 new lows.About 6.1 billion shares changed hands on U.S. exchanges, below the 8 billion average this month, according to data from BATS Global Markets.  (Additional reporting by Rodrigo Campos; Editing by Bernadette Baum, Meredith Mazzilli and Nick Zieminski)",2014-10-27,MRK,"Mon Oct 27, 2014 | 4:40pm EDT",Wall St. flat after last week's big gain; energy weighs,http://www.reuters.com//article/us-markets-stocks-idUSKBN0IG13Z20141027?type=companyNews
204,"   By Ransdell Pierson  Cost cuts enabled Merck & Co to beat third-quarter earnings forecasts but disappointing sales of its Gardasil cervical cancer vaccine and other big products sent its shares about 2 percent lower.Merck said on Monday it earned $895 million, or 31 cents per share, in the quarter. That compared with $1.12 billion, or 38 cents per share, in the year-earlier period. Excluding special items, Merck earned 90 cents per share, topping the average analyst forecast of 88 cents per share, according to Thomson Reuters I/B/E/S.Company sales fell 4 percent to $10.56 billion, below Wall Street expectations of $10.67 billion. Gardasil sales fell 11 percent to $590 million due to lower purchases by U.S. government programs. Sales of arthritis treatment Remicade rose 5 percent to $604 million, a marked slowdown from the 17 percent growth seen in the prior quarter, with competition in Europe from cheaper ""biosimilar"" versions of the medicine. And sales of HIV treatment Isentress fell 3 percent to $412 million, due to increasing competition and reduced purchases by wholesalers.""The foundation with the core franchises is weakening,"" BMO Capital Markets analyst Alex Arfaei said, as Merck pushes ahead with development of promising new treatments for cancer.    Sanford Bernstein analyst Tim Anderson said company expenses were 6 percent below his expectations, helping to offset the revenue shortfall.Merck shares fell 1.8 percent to $56.55 on the New York Stock Exchange in late afternoon trading.    Early this month, Merck sold its consumer care business to Germany's Bayer AG for $14.2 billion.Some analysts have called for Merck to sell off other businesses, including older drugs that have lost U.S. patent protection that are sold in emerging markets. But company Chief Executive Kenneth Frazier said they generate cash that can be invested in experimental drugs, and would not be divested without careful consideration.""We will continue to evaluate opportunities as appropriate,"" he said on a conference call, referring to potential divestitures.Merck said the U.S. Food and Drug Administration had designated its Keytruda immuno-oncology drug as a potential ""breakthrough therapy"" for advanced non-small-cell lung cancer, the most common form of lung cancer.  The ""breakthrough"" designation, given by the FDA to medicines deemed likely to demonstrate ""substantial improvement"" over existing drugs, assures fast track review by the agency.Keytruda, approved last month for advanced melanoma, belongs to a new class of drugs that unleash the immune system to fight cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1. Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc are also developing such drugs, and analysts say they could generate more than $30 billion in annual sales by 2025.Merck narrowed its full-year 2014 profit forecast to between $3.46 and $3.50 per share, from its earlier view of $3.43 to $3.53 per share. (Reporting by Ransdell Pierson; Editing by Bernadette Baum, Alden Bentley and Richard Chang)",2014-10-27,MRK,"Mon Oct 27, 2014 | 3:26pm EDT",Weak Merck sales overshadow third-quarter cost cuts,http://www.reuters.com//article/us-merck-co-results-idUSKBN0IG12620141027?type=companyNews
205,"  (Adds analyst comment, details on product sales, shares)By Ransdell PiersonOct 27 Cost cuts enabled Merck & Co to beat third-quarter earnings forecasts but disappointing sales of its Gardasil cervical cancer vaccine and other big products sent its shares about 2 percent lower.Merck said on Monday it earned $895 million, or 31 cents per share, in the quarter. That compared with $1.12 billion, or 38 cents per share, in the year-earlier period.Excluding special items, Merck earned 90 cents per share, topping the average analyst forecast of 88 cents per share, according to Thomson Reuters I/B/E/S.Company sales fell 4 percent to $10.56 billion, below Wall Street expectations of $10.67 billion. Gardasil sales fell 11 percent to $590 million due to lower purchases by U.S. government programs.Sales of arthritis treatment Remicade rose 5 percent to $604 million, a marked slowdown from the 17 percent growth seen in the prior quarter, with competition in Europe from cheaper ""biosimilar"" versions of the medicine. And sales of HIV treatment Isentress fell 3 percent to $412 million, due to increasing competition and reduced purchases by wholesalers. ""The foundation with the core franchises is weakening,"" BMO Capital Markets analyst Alex Arfaei said, as Merck pushes ahead with development of promising new treatments for cancer.Sanford Bernstein analyst Tim Anderson said company expenses were 6 percent below his expectations, helping to offset the revenue shortfall.Merck shares fell 1.8 percent to $56.55 on the New York Stock Exchange in late afternoon trading. Early this month, Merck sold its consumer care business to Germany's Bayer AG for $14.2 billion.Some analysts have called for Merck to sell off other businesses, including older drugs that have lost U.S. patent protection that are sold in emerging markets.But company Chief Executive Kenneth Frazier said they generate cash that can be invested in experimental drugs, and would not be divested without careful consideration. ""We will continue to evaluate opportunities as appropriate,"" he said on a conference call, referring to potential divestitures.Merck said the U.S. Food and Drug Administration had designated its Keytruda immuno-oncology drug as a potential ""breakthrough therapy"" for advanced non-small-cell lung cancer, the most common form of lung cancer.The ""breakthrough"" designation, given by the FDA to medicines deemed likely to demonstrate ""substantial improvement"" over existing drugs, assures fast track review by the agency.Keytruda, approved last month for advanced melanoma, belongs to a new class of drugs that unleash the immune system to fight cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1.Bristol-Myers Squibb, Roche Holding AG and AstraZeneca Plc are also developing such drugs, and analysts say they could generate more than $30 billion in annual sales by 2025.Merck narrowed its full-year 2014 profit forecast to between $3.46 and $3.50 per share, from its earlier view of $3.43 to $3.53 per share.   (Reporting by Ransdell Pierson; Editing by Bernadette Baum, Alden Bentley and Richard Chang)",2014-10-27,MRK,"Mon Oct 27, 2014 | 3:24pm EDT",UPDATE 3-Weak Merck sales overshadow Q3 cost cuts,http://www.reuters.com//article/merck-co-results-idUSL1N0SM0NP20141027?type=companyNews
206,"  Oct 27 Merck & Co reported lower than expected third quarter revenue, hurt by sharply lower sales of its Gardasil vaccine against cervical cancer, but cost cuts enabled the company to beat earnings forecasts.The No. 2 U.S. drugmaker on Monday said it earned $895 million, or 31 cents per share, in the third quarter. That compared with $1.12 billion, or 38 cents per share, in the year-earlier period.  Excluding special items, Merck earned 90 cents per share. Analysts, on average, expected 88 cents per share, according to Thomson Reuters I/B/E/S.   (Reporting by Ransdell Pierson Editing by W Simon) ",2014-10-27,MRK,"Mon Oct 27, 2014 | 7:18am EDT","Merck beats Q3 forecast, cost cuts offset Gardasil decline",http://www.reuters.com//article/merck-co-results-idUSL2N0SJ22Y20141027?type=companyNews
207,"  * Q3 adj EBITDA 2.01 bln euros vs poll avg 1.96 bln* Beat driven by crop chemicals, Xarelto sales* Raises FY profit aim on effects of fx, Merck OTC* Shares gain 3.5 percent   (Adds details on drug sales, analyst comment, shares)FRANKFURT, Oct 30 Germany's largest drugmaker Bayer said underlying core earnings advanced by 1.4 percent, slightly surpassing expectations, on strong sales of pesticides and stroke prevention pill Xarelto.Bayer said on Thursday its third-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at 2.01 billion euros ($2.53 billion), edging past the average estimate of 1.96 billion euros in a Reuters poll. Adjusted core earnings at the CropScience unit rose by more than a quarter to 278 million euros, shored up by growth in recently launched products, in particular fungicides and herbicides.Bayer now aims to raise group EBITDA before special items by a mid-single-digit percentage, taking into account the acquisition of Merck & Co. Inc.'s consumer health business it wrapped up on Oct. 1 as well as more favourable currency effects. It had previously forecast a low to medium single-digit percentage gain.The euro was up slightly against the U.S. dollar on average over the third quarter but the European currency has lost about 8 percent against the dollar over the last six months, bolstering the euro-value of overseas revenues.Bayer, the inventor of Aspirin and maker of Yasmin birth-control pills, said pharmaceuticals sales rose by a currency- and portfolio-adjusted 10.3 percent to 3.04 billion euros, boosted by a better-than-expected 70 percent gain of sales in anti-clotting drug Xarelto, mainly used to prevent strokes in the elderly. ""Healthcare performance was okay, but the beat was really driven by CropScience, an area where we had concerns,"" analysts at brokerage Berenberg said in a note.The shares gained 3.5 percent at 0830 GMT, outperforming a 1 percent gain in the STOXX Europe 600 Health Care index.Bayer shares have advanced 7.6 percent over the past three months, outperforming the 2.3 percent gain in the European sector benchmark, as investors welcomed the company's plan to split off and separately list its plastics division.($1 = 0.7940 Euros)   (Reporting by Ludwig Burger; Editing by Kirsti Knolle and Maria Sheahan)",2014-10-30,MRK,"Thu Oct 30, 2014 | 4:49am EDT",UPDATE 1-Bayer Q3 adj profit gains slightly on strong crop chemicals,http://www.reuters.com//article/bayer-results-idUSL5N0SP1BB20141030?type=companyNews
208,"   By P.J. Huffstutter  Merck & Co. is taking steps to resume sales of its controversial cattle feed additive Zilmax by changing the way the drug is administered, hoping to recapture some market share in the beef industry, where the U.S. herd has the fewest animals in more than 60 years.The U.S. Food and Drug Administration has approved adjustments to the drug's label that would allow veterinarians and feedlot operators to use a lower dose and alternative method of feeding the drug to beef cattle, Merck said Wednesday. The new ""component feeding"" option would allow Zilmax, which can add up to 30 pounds of marketable meat to a 1,300-pound steer, to be fed in one smaller daily ration, rather than continually throughout the day, Merck nutritionist Dr. David Yates told Reuters. ""We began working on this component feeding (label change) several years ago,"" Yates said. The decision to do so was prompted by cattle producers, he said, looking for more ""efficiency and convenience at a feedyard.""In August 2013, Merck suspended sales of Zilmax in the United States and Canada amid concerns about animals showing signs of distress after use of the weight-gain product. A study published in March suggested that the number of U.S. cattle deaths that may be linked to Zilmax was much higher than the figures reported by the drug company to the federal government.U.S. regulators approved the label change on Friday, Yates said. The label still allows the drug to be fed continually to cattle.Merck, which said Zilmax is safe if properly used, also recently filed a proposed label update in Canada. When Zilmax was pulled off the market, many U.S. feedlot operators switched to ractopamine-based Optaflexx, made by Merck rival Eli Lily & Co.'s Elanco Animal Health unit. Elanco's patent on ractopamine has expired, and Zoetis Inc's generic products are eating into Elanco's dominance. Zoetis said on Tuesday that sales of livestock products grew 12 percent in the company's third-quarter, compared to the year-ago period.If Zilmax becomes available to U.S. feedlots again, it could appeal to U.S. livestock industry scrambling for tonnage. Beta-agonist drugs like Zilmax can produce extra meat from a U.S. cattle herd fallen to its lowest point in 63 years.  Cargill Inc [CARG.UL] and Tyson Foods Inc, two of the world's largest beef processors, have refused to accept Zilmax-feed cattle since last year, following reports it may cause lameness in animals. The companies could not immediately be reached for comment on Merck's new dosage plan.Merck also said Wednesday it has rolled out a mandatory training program for Zilmax feeding. The company plans field tests of the new ""component feeding"" program.Merck shares were up 0.2 percent at $59.47 in midday trading. (Additional reporting by Natalie Grover in Bangalore; Editing by David Gregorio)",2014-11-05,MRK,"Wed Nov 5, 2014 | 2:09pm EST",Merck takes steps to return Zilmax to U.S. cattle market,http://www.reuters.com//article/us-merck-co-fda-idUSKBN0IP1VI20141105?type=companyNews
209,"  (New throughout, adds details, interview, adds  byline)By P.J. HuffstutterNov 5 Merck & Co. is taking steps to resume sales of its controversial cattle feed additive Zilmax by changing the way the drug is administered, hoping to recapture some market share in the beef industry, where the U.S. herd has the fewest animals in more than 60 years.The U.S. Food and Drug Administration has approved adjustments to the drug's label that would allow veterinarians and feedlot operators to use a lower dose and alternative method of feeding the drug to beef cattle, Merck said Wednesday.The new ""component feeding"" option would allow Zilmax, which can add up to 30 pounds of marketable meat to a 1,300-pound steer, to be fed in one smaller daily ration, rather than continually throughout the day, Merck nutritionist Dr. David Yates told Reuters.""We began working on this component feeding (label change) several years ago,"" Yates said. The decision to do so was prompted by cattle producers, he said, looking for more ""efficiency and convenience at a feedyard."" In August 2013, Merck suspended sales of Zilmax in the United States and Canada amid concerns about animals showing signs of distress after use of the weight-gain product.A study published in March suggested that the number of U.S. cattle deaths that may be linked to Zilmax was much higher than the figures reported by the drug company to the federal government.U.S. regulators approved the label change on Friday, Yates said. The label still allows the drug to be fed continually to cattle. Merck, which said Zilmax is safe if properly used, also recently filed a proposed label update in Canada.When Zilmax was pulled off the market, many U.S. feedlot operators switched to ractopamine-based Optaflexx, made by Merck rival Eli Lily & Co.'s Elanco Animal Health unit. Elanco's patent on ractopamine has expired, and Zoetis Inc's  generic products are eating into Elanco's dominance. Zoetis said on Tuesday that sales of livestock products grew 12 percent in the company's third-quarter, compared to the year-ago period.If Zilmax becomes available to U.S. feedlots again, it could appeal to U.S. livestock industry scrambling for tonnage. Beta-agonist drugs like Zilmax can produce extra meat from a U.S. cattle herd fallen to its lowest point in 63 years.Cargill Inc and Tyson Foods Inc, two of the world's largest beef processors, have refused to accept Zilmax-feed cattle since last year, following reports it may cause lameness in animals. The companies could not immediately be reached for comment on Merck's new dosage plan.Merck also said Wednesday it has rolled out a mandatory training program for Zilmax feeding. The company plans field tests of the new ""component feeding"" program.Merck shares were up 0.2 percent at $59.47 in midday trading.   (Additional reporting by Natalie Grover in Bangalore; Editing by David Gregorio)",2014-11-05,MRK,"Wed Nov 5, 2014 | 2:06pm EST",UPDATE 1-Merck takes steps to return Zilmax to U.S. cattle market,http://www.reuters.com//article/merck-co-fda-idUSL4N0SV76820141105?type=companyNews
210,"   By Ransdell Pierson  Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs. ""The company has determined that the Zetia and Vytorin intangible assets are not impaired,"" the No. 2 U.S. drugmaker said on Monday in a regulatory filing, noting its assessment was based on having seen ""unblinded"" data from the huge study.Merck's statement suggests that the study, meant to determine whether Zetia can prevent heart attacks, strokes and deaths, proved favorable to its $2.5 billion-a-year drug. A related Merck drug, Vytorin, pairs Zetia with Merck's statin Zocor (simvastatin), and has annual sales of $1.5 billion.Pam Eisele, a Merck spokeswoman, said the company had no further comment on the trial results, or their likely financial impact on Zetia and Vytorin.   Merck almost a decade ago began the study, called IMPROVE-IT, to determine whether adding Zetia to simvastatin is better at preventing heart attacks, deaths and strokes than simvastatin alone.Trial results are slated to be unveiled on Nov. 17 in Chicago, at the annual scientific sessions of the American Heart Association. Merck earlier this year warned that it might have to write down the value of Zetia and Vytorin if the study did not prove Zetia provided an incremental benefit to patients.Zetia, which prevents absorption of ""bad"" LDL cholesterol in the intestines, was approved by U.S. regulators in 2002 based on its ability to lower cholesterol 25 percent beyond reductions seen with simvastatin alone. Statins work by reducing the liver's production of cholesterol, and can cut LDL levels by 50 percent or more. No previous studies have ever proven conclusively whether Zetia or Vytorin actually improve patient outcomes.Despite longstanding doubts about Zetia's effectiveness, many doctors have prescribed it and Vytorin on the assumption that Zetia's demonstrated ability to further lower cholesterol will lead to better patient outcomes.  Shares of Merck were down 1 percent in afternoon trading on the New York Stock Exchange.      (Reporting by Ransdell Pierson in New York; Editing by Lisa Shumaker)",2014-11-10,MRK,"Mon Nov 10, 2014 | 3:34pm EST","Merck expects no writedowns for Zetia, Vytorin cholesterol drugs",http://www.reuters.com//article/us-merck-zetia-idUSKCN0IU26J20141110?type=companyNews
211,"   By Ransdell Pierson  Nov 10 Merck & Co on Monday said long-awaited data from an 18,000-patient trial suggest the company will not have to write down the value of its blockbuster Zetia and Vytorin cholesterol drugs.""The company has determined that the Zetia and Vytorin intangible assets are not impaired,"" the No. 2 U.S. drugmaker said on Monday in a regulatory filing, noting its assessment was based on having seen ""unblinded"" data from the huge study.Merck's statement suggests that the study, meant to determine whether Zetia can prevent heart attacks, strokes and deaths, proved favorable to its $2.5 billion-a-year drug. A related Merck drug, Vytorin, pairs Zetia with Merck's statin Zocor (simvastatin), and has annual sales of $1.5 billion.Pam Eisele, a Merck spokeswoman, said the company had no further comment on the trial results, or their likely financial impact on Zetia and Vytorin. Merck almost a decade ago began the study, called IMPROVE-IT, to determine whether adding Zetia to simvastatin is better at preventing heart attacks, deaths and strokes than simvastatin alone.Trial results are slated to be unveiled on Nov. 17 in Chicago, at the annual scientific sessions of the American Heart Association. Merck earlier this year warned that it might have to write down the value of Zetia and Vytorin if the study did not prove Zetia provided an incremental benefit to patients. Zetia, which prevents absorption of ""bad"" LDL cholesterol in the intestines, was approved by U.S. regulators in 2002 based on its ability to lower cholesterol 25 percent beyond reductions seen with simvastatin alone. Statins work by reducing the liver's production of cholesterol, and can cut LDL levels by 50 percent or more.No previous studies have ever proven conclusively whether Zetia or Vytorin actually improve patient outcomes. Despite longstanding doubts about Zetia's effectiveness, many doctors have prescribed it and Vytorin on the assumption that Zetia's demonstrated ability to further lower cholesterol will lead to better patient outcomes.Shares of Merck were down 1 percent in afternoon trading on the New York Stock Exchange.(Reporting by Ransdell Pierson in New York; Editing by Lisa Shumaker)",2014-11-10,MRK,"Mon Nov 10, 2014 | 3:32pm EST","Merck expects no writedowns for Zetia, Vytorin cholesterol drugs",http://www.reuters.com//article/merck-zetia-idUSL2N0T01XD20141110?type=companyNews
212,"  Nov 10 A former Bank of America banker who advises clients in the healthcare sector has joined Credit Suisse, according to an internal memo.Sumit Khedekar, who previously worked at the Swiss bank for ten years earlier in his career, will rejoin in January 2015.A Credit Suisse spokesman on Monday confirmed the contents of the memo. Khedekar has worked with clients in the large pharma, specialty pharma and biotech sectors, which have seen a record amount of mergers and acquisitions this year.Healthcare dealmaking has topped $352.6 billion so far this year, more than double levels seen at the same time last year, according to Thomson Reuters data. The Credit Suisse healthcare group has worked on notable transactions this year including Merck & Co Inc's  acquisition of biotech company Idenix and Zimmer Holdings Inc's  pending acquisition of medical device company Biomet. (Reporting by Olivia Oran; Editing by Diane Craft)",2014-11-10,MRK,"Mon Nov 10, 2014 | 3:02pm EST",MOVES-Former Bank of America healthcare banker joins Credit Suisse,http://www.reuters.com//article/khedekar-moves-idUSL2N0T01U120141110?type=companyNews
213,"  * Gilead climbs after Merck's hepatitis C drug trial results* Dow transportation average hits new high* Cable companies fall after Obama net neutrality statement* Indexes up: Dow 0.2 pct, S&P 0.2 pct, Nasdaq 0.2 pct   (Updates to early afternoon)By Caroline ValetkevitchNEW YORK, Nov 10 U.S. stocks edged higher in afternoon trading on Monday, lifting the Dow and S&P 500 to intraday highs after the indexes advanced for a third straight week, helped by railroad shares. The Dow Jones transportation average was up 1 percent, also hitting another intraday record high, led by gains in railroad shares including Union Pacific, which was up 1.9 percent and among the top gainers on the S&P 500.Results late Friday from Berkshire Hathaway   showed profit from the BNSF railroad rose about 5 percent. Berkshire Class B shares were up 0.7 percent at $144.59, also among the top gainers in the S&P 500.Oil prices extended recent losses, with U.S. crude oil prices falling below $78 a barrel, helping shares of some consumer companies. Wal-Mart, due to report results on Thursday, climbed 1.5 percent.""It's been a very sharp rally off a very sharp correction, no reason it shouldn't go higher but all it takes is one very determined seller to start a cascade of selling,"" said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.The Dow Jones industrial average rose 27.1 points, or 0.15 percent, to 17,601.03, the S&P 500 gained 4.53 points, or 0.22 percent, to 2,036.45 and the Nasdaq Composite  added 10.68 points, or 0.23 percent, to 4,643.21. The bulk of U.S. third-quarter earnings are in, though a handful of high-profile retailers have yet to report.The Dow has gained 7.3 percent while the S&P 500  has risen 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011.Gilead Sciences rose 0.8 percent after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 0.6 percent at $59.Shares of cable providers fell after U.S. President Barack Obama said the Federal Communications Commission should reclassify broadband to regulate it more like a public utility. Comcast lost 3.5 percent.Advancing issues outnumbered declining ones on the NYSE by 1,630 to 1,379, for a 1.18-to-1 ratio on the upside; on the Nasdaq, 1,492 issues rose and 1,130 fell for a 1.32-to-1 ratio favoring advancers.   (Additional reporting by Chuck Mikolajczak; Editing by Bernadette Baum and Nick Zieminski)",2014-11-10,MRK,"Mon Nov 10, 2014 | 1:30pm EST",US STOCKS-Wall Street climbs to new highs; transports rally,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T01LZ20141110?type=companyNews
214,"  * Gilead climbs after Merck's hepatitis C drug trial results* McDonald's sales fall in October* Cable companies fall after Obama net neutrality statement* Indexes up: Dow 0.16 pct, S&P 0.25 pct, Nasdaq 0.3 pct   (Updates to midday)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks rose modestly on Monday, as an absence of major market catalysts gave investors little reason to make big bets after the Dow and S&P 500 advanced for a third straight week to record highs. Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's and network equipment maker Cisco Systems.""Sort of a reluctant rally on the day,"" said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.""It's been a very sharp rally off a very sharp correction, no reason it shouldn't go higher but all it takes is one very determined seller to start a cascade of selling."" McDonald's Corp rose 0.3 percent to $95.41 after its worldwide sales at restaurants open at least 13 months fell 0.5 percent in October but still beat expectations.Gilead Sciences rose 1.7 percent to $108.27 after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 1.1 percent to $58.69. Thomson Reuters data showed that of 448 companies in the S&P 500 to report earnings, 74.6 percent beat expectations, above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 10 percent over the year-ago period.The Dow has gained 7.3 percent while the S&P 500  has risen 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011.The Dow Jones industrial average rose 27.67 points, or 0.16 percent, to 17,601.6, the S&P 500 gained 5.08 points, or 0.25 percent, to 2,037 and the Nasdaq Composite  added 13.93 points, or 0.3 percent, to 4,646.47.Shares in cable providers fell after U.S. President Barack Obama said the Federal Communications Commission should reclassify broadband to regulate it more like a public utility. Comcast lost 3.5 percent to $53.21, Time Warner  fell 3.9 percent to $138.06, and Cablevision  shed 2 percent to $18.55.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue as housing demand strengthened. Its shares rose 3.9 percent to $33.47.       (Editing by Bernadette Baum and Nick Zieminski)",2014-11-10,MRK,"Mon Nov 10, 2014 | 11:58am EST",US STOCKS-Wall Street climbs modestly after three-week run,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T01AD20141110?type=companyNews
215,"  * Gilead climbs after Merck's hepatitis C drug trial results* McDonald's sales fall in October* Cable companies fall after Obama's net neutrality statement* Indexes up: Dow 0.16 pct, S&P 0.27 pct, Nasdaq 0.42 pct   (Adds detail on cable stocks, updates prices)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks edged higher on Monday, as a dearth of major market catalysts left little incentive for investors to make big bets after the Dow and S&P 500 advanced for a third straight week to record highs. Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's and network equipment maker Cisco Systems.""We have had a nice run and last week we did see the markets largely go into neutral and take a bit of a pause,"" said Peter Kenny, chief market strategist at Clearpool Group in New York.""Earnings season is coming to a close, there are no economic data releases for the next two days, we've gotten more or less the framing for the market."" McDonald's Corp rose 0.3 percent to $95.35 after its worldwide sales at restaurants open at least 13 months fell 0.5 percent in October but still beat expectations.Gilead Sciences rose 1.8 percent to $108.38 after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 2 percent to $58.18. Thomson Reuters data showed that of 448 companies in the S&P 500 to report earnings, 74.6 percent beat expectations, above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 10 percent over the year-ago period.The Dow gained 7.3 percent while the S&P 500  was up 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011.The Dow Jones industrial average rose 28.32 points, or 0.16 percent, to 17,602.25, the S&P 500 gained 5.48 points, or 0.27 percent, to 2,037.4 and the Nasdaq Composite  added 19.36 points, or 0.42 percent, to 4,651.89.Shares in cable providers fell after U.S. President Barack Obama said the Federal Communications Commission should reclassify broadband to regulate it more like a public utility. Comcast lost 2.9 percent to $53.58, Time Warner  fell 3.1 percent to $139.16, and Cablevision  shed 1.5 percent to $18.63.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue as housing demand strengthened. Its shares rose 3.6 percent to $33.38.       (Editing by Bernadette Baum and Nick Zieminski)",2014-11-10,MRK,"Mon Nov 10, 2014 | 11:06am EST",US STOCKS-Wall Street edges higher after three-week run,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T013Y20141110?type=companyNews
216,"  * Gilead climbs after Merck's hep C drug trial results* McDonald's sales fall in October* Dow off 0.05 pct, S&P up 0.01 pct, Nasdaq off 0.08 pct   (Updates to market open)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks were little changed on Monday, as investors paused in the absence of major market catalysts after the Dow and S&P 500 advanced for a third straight week to fresh record highs.Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's and network equipment maker Cisco Systems. ""We have had a nice run and last week we did see the markets largely go into neutral and take a bit of a pause,"" said Peter Kenny, chief market strategist at Clearpool Group in New York.""Earnings season is coming to a close, there are no economic data releases for the next two days, we've gotten more or less the framing for the market.""McDonald's Corp rose 0.3 percent to $95.35 after its worldwide sales at restaurants open at least 13 months fell 0.5 percent in October but still beat expectations. Gilead Sciences rose 2.1 percent to $108.70 as the biggest boost to the S&P 500 and Nasdaq 100 after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment to just four weeks by adding Gilead's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 2.7 percent to $57.73 as the biggest drag on the Dow and S&P.Thomson Reuters data showed that of 442 companies in the S&P 500 to report earnings, 74.2 percent beat expectations, above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 9.8 percent over the year-ago period.The Dow gained 7.3 percent while the S&P 500  was up 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011. The Dow Jones industrial average fell 8.67 points, or 0.05 percent, to 17,565.26, the S&P 500 gained 0.26 points, or 0.01 percent, to 2,032.18 and the Nasdaq Composite  dropped 3.52 points, or 0.08 percent, to 4,629.01.Alibaba Group shares were up 1.5 percent at $116.26 ahead of ""Singles Day"" in China on Nov. 11, which has become the largest day of online sales in the world.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue as housing demand strengthened. Its shares rose 2.8 percent to $33.12, lifting the PHLX housing index 1.1 percent.GoPro shares fell 2.7 percent to $76.90 after the company filed a common stock offering of up to $800 million.(Editing by Bernadette Baum)",2014-11-10,MRK,"Mon Nov 10, 2014 | 9:56am EST",US STOCKS-Wall Street little changed after three-week rally,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T00VQ20141110?type=companyNews
217,"  * Gilead climbs after Merck's hep C drug trial results* McDonald's sales fall in October* Futures up: Dow 17 pts, S&P 1.75 pts, Nasdaq 9.5 pts   (Adds quote, updates prices)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks were poised for a flat open on Monday, after the Dow and S&P 500 advanced for a third straight week to fresh record highs.Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's as well as network equipment maker Cisco Systems. ""We have had a nice run and last week we did see the markets largely go into neutral and take a bit of a pause,"" said Peter Kenny, chief market strategist at Clearpool Group in New York.""Earnings season is coming to a close, there are no economic data releases for the next two days, we've gotten more or less the framing for the market.""McDonald's Corp said worldwide sales at restaurants open at least 13 months fell 0.5 percent in October, hurt by stiff competition in the United States, economic and political upheaval in Europe and the fallout from a supplier scandal in China. According to Thomson Reuters data through Friday, of 442 companies in the S&P 500 to report earnings, 74.2 percent beat Wall Street expectations, well above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 9.8 percent over the year-ago period.The Dow has risen 7.3 percent while the S&P 500  is up 7.7 percent over past three weeks, the best three-week performance for both indexes since October 2011.S&P 500 e-mini futures were up 1.75 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a flat open. Dow Jones industrial average e-mini futures rose 17 points and Nasdaq 100 e-mini futures added 9.5 points. Alibaba Group shares were up 2.1 percent at $116.99 in premarket trading ahead of ""Singles Day"" in China on Nov. 11, which has become the largest day of online sales in the world.Gilead Sciences rose 2.5 percent to $109.10 before the opening bell after data from a midstage study showed Merck's  attempt to shorten hepatitis C treatment to just four weeks by adding Gilead's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 2.9 percent to $57.65.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue after it sold more homes at higher prices as housing demand strengthened. Its shares rose 2.4 percent to $33 in light premarket trading.GoPro shares slumped 6.8 percent to $73.67 in premarket after the company said it filed a common stock offering of up to $800 million.(Editing by Bernadette Baum)",2014-11-10,MRK,"Mon Nov 10, 2014 | 9:05am EST",US STOCKS-Wall Street set to open flat after three-week run,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T00S320141110?type=companyNews
218,"  * Gilead climbs after Merck's hep C drug trial results* Retailers due to post earnings this week* Futures up: Dow 17 pts, S&P 2.5 pts, Nasdaq 10.25 pts   (Adds premarket movers)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stock index futures edged higher on Monday, after the Dow and S&P 500 advanced for a third straight week to fresh record highs.* Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's as well as network equipment maker Cisco Systems. * McDonald's Corp said worldwide sales at restaurants open at least 13 months fell 0.5 percent in October, hurt by stiff competition in the United States, economic and political upheaval in Europe and the fallout from a supplier scandal in China.* According to Thomson Reuters data through Friday, of 442 companies in the S&P 500 to report earnings, 74.2 percent beat Wall Street expectations, well above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 9.8 percent over the year-ago period.* The Dow has risen 7.3 percent while the S&P 500  is up 7.7 percent over past three weeks, the best three-week performance for both indexes since October 2011. * Alibaba Group shares were up 2.1 percent to $116.99 in premarket trading ahead of ""Singles Day"" in China on Nov. 11, which has become the largest day of online sales in the world. Volume of nearly 700,000 shares made the stock the most actively traded among New York Stock Exchange-listed issues.* Gilead Sciences rose 3 percent to $109.60 before the opening bell after data from a midstage study showed Merck's  attempt to shorten hepatitis C treatment to just four weeks by adding Gilead's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy.* Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue after it sold more homes at higher prices as housing demand strengthened. Its shares rose 2.4 percent to $32.99 in light premarket trading. * KKR & Co plans to sell its North Dakota Bakken oil deposit worth less than $500 million as part of an ongoing downsizing plan, according to people familiar with the matter.* S&P 500 e-minis were up 2.5 points, or 0.12 percent, with 125,321 contracts changing hands.* Nasdaq 100 e-minis were up 10.25 points, or 0.25 percent, in volume of 20,479 contracts.* Dow e-minis were up 17 points, or 0.1 percent, with 20,021 contracts changing hands.   (Editing by Bernadette Baum)",2014-11-10,MRK,"Mon Nov 10, 2014 | 8:21am EST",US STOCKS-Futures inch up after three-week rally; Alibaba active,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T00MM20141110?type=companyNews
219,"   By Bill Berkrot  An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study.Several companies have been working to find ways to further reduce the number of weeks of treatment needed, while keeping cure rates above 90 percent.A just approved pill called Harvoni that combines Sovaldi  with another Gilead drug requires eight weeks of treatment for many patients, and longer for tougher to treat patients.In the ongoing Merck trial of previously untreated patients, only 38.7 percent had no detectable sign of the liver destroying virus after four weeks of treatment with Sovaldi and Merck's grazoprevir/elbasvir combination. Nineteen of the 31 patients in the four-week treatment arm relapsed prior to the planned end of the study, which is 12 weeks after completion of dosing. The preliminary data was set to be presented on Monday at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston.The best result so far in the multi-arm, three-drug study called C-Swift was observed with eight weeks of treatment of patients with cirrhosis in which 94.7 percent had no detectable virus. They will be deemed cured if the virus has not reappeared 12 weeks after stopping treatment.With a six-week regimen in non-cirrhotics, 86.7 percent of patients had no sign of virus up to 8 weeks after completing treatment, according to the interim results. ""These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types,"" Dr. Eric Lawitz, the study's lead investigator, said in a statement.The three drugs each work in a different way to help prevent the virus from replicating. But following failure of the 4-week experiment, Merck said it will turn its attention to studying a combination of three of its own drugs in development rather than involving the Gilead medicine in future studies. The hepatitis C field has been moving at a lightning pace. Only a handful of years ago, patients needed 48 weeks of treatment with drugs that had harsh side effects and only cured about 40 percent of patients.The new all-oral treatments eliminate the need for injectable interferon and its flu-like side effects, as well as another older drug called ribavirin that caused anemia and other problems, while dramatically increasing cure rates and reducing treatment duration.  (Reporting by Bill Berkrot; Editing by Chris Reese)",2014-11-10,MRK,"Sun Nov 9, 2014 | 7:16pm EST",Merck four-week hep C regimen with Gilead's Sovaldi comes up short,http://www.reuters.com//article/us-merck-co-hepatitis-idUSKCN0IU00K20141110?type=companyNews
220,"   By Julie Steenhuysen | CHICAGO  CHICAGO Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia.The study involved individuals with mutations in a gene called NPC1L1, the gene targeted by Zetia, a cholesterol fighter known generically as ezetimibe.While common cholesterol fighters known as statins keep the body from making cholesterol, Zetia blocks the body's ability to absorb cholesterol in the gut. And while there is clear evidence that statins reduce the risk of heart attacks, there is scant evidence to show that Zetia does much more than lower cholesterol.That is where the new genetic study comes in.Researchers at the Broad Institute and Washington University in St. Louis combed through data on some 113,000 people from multiple studies looking for individuals with rare mutations that shut off the activity of NPC1L1. They found 82 people who inherited a single mutated copy of this gene, leaving them with one working copy. Among these individuals, LDL cholesterol, the so-called ""bad"" cholesterol, was 10 percent lower than in individuals in the study with two working copies of the gene.People with the mutated gene also had half the risk of heart disease as people with two working copies. Although the findings cannot be used to draw direct conclusions about Zetia, they do suggest that the drug may be hitting an important target for reducing the risk of heart attacks, study author Dr. Nathan Stitziel of Washington University School of Medicine in St. Louis said in a statement.""Whether ezetimibe specifically is the best way to target NPC1L1 remains an open question,"" he said. That answer may come on Monday when Merck releases the long-awaited results from the large clinical trial called IMPROVE-IT. That trial looks specifically at whether people who took statins plus ezetimibe were less likely to have heart attacks than people who took statins alone. The gene analysis study was funded in part by grants from Merck as well as the National Institutes of Health and the Canadian Institutes of Health.   (Reporting by Julie Steenhuysen; Editing by Cynthia Osterman)",2014-11-12,MRK,"Wed Nov 12, 2014 | 5:02pm EST",U.S. gene study raises hope for Merck cholesterol drug Zetia,http://www.reuters.com//article/us-heart-health-gene-idUSKCN0IW2LZ20141112?type=companyNews
221,"   By Julie Steenhuysen | CHICAGO  CHICAGO Nov 12 Rare mutations in a single gene may help lower cholesterol and reduce the risk of a heart attack by half, U.S. researchers said on Wednesday in a study that could have implications for Merck and Co's closely watched heart drug Zetia.The study involved individuals with mutations in a gene called NPC1L1, the gene targeted by Zetia, a cholesterol fighter known generically as ezetimibe.While common cholesterol fighters known as statins keep the body from making cholesterol, Zetia blocks the body's ability to absorb cholesterol in the gut. And while there is clear evidence that statins reduce the risk of heart attacks, there is scant evidence to show that Zetia does much more than lower cholesterol.That is where the new genetic study comes in. Researchers at the Broad Institute and Washington University in St. Louis combed through data on some 113,000 people from multiple studies looking for individuals with rare mutations that shut off the activity of NPC1L1.They found 82 people who inherited a single mutated copy of this gene, leaving them with one working copy. Among these individuals, LDL cholesterol, the so-called ""bad"" cholesterol, was 10 percent lower than in individuals in the study with two working copies of the gene. People with the mutated gene also had half the risk of heart disease as people with two working copies.Although the findings cannot be used to draw direct conclusions about Zetia, they do suggest that the drug may be hitting an important target for reducing the risk of heart attacks, study author Dr. Nathan Stitziel of Washington University School of Medicine in St. Louis said in a statement. ""Whether ezetimibe specifically is the best way to target NPC1L1 remains an open question,"" he said.That answer may come on Monday when Merck releases the long-awaited results from the large clinical trial called IMPROVE-IT. That trial looks specifically at whether people who took statins plus ezetimibe were less likely to have heart attacks than people who took statins alone.The gene analysis study was funded in part by grants from Merck as well as the National Institutes of Health and the Canadian Institutes of Health.(Reporting by Julie Steenhuysen; Editing by Cynthia Osterman)",2014-11-12,MRK,"Wed Nov 12, 2014 | 5:00pm EST",U.S. gene study raises hope for Merck cholesterol drug Zetia,http://www.reuters.com//article/heart-health-gene-idUSL2N0T22A520141112?type=companyNews
222,"   By Bill Berkrot and Ransdell Pierson  A nine-year, 18,000-patient study of Merck & Co's $4 billion Zetia and Vytorin cholesterol franchise is likely to show some benefit but keep open the question of whether it can significantly reduce heart attacks, strokes and death.    The Improve-It trial is aimed at determining whether Zetia -  which is also combined with Merck's now generic statin Zocor (simvastatin) to make Vytorin - does more than reduce ""bad"" LDL cholesterol in the bloodstream, the basis for which it was approved.Statins have been proven to reduce heart attacks and deaths. Zetia, which lowers LDL in a different way, has been used for a dozen years without any such assurances.Results comparing Vytorin with Zocor alone will be released at the American Heart Association meeting in Chicago next week.""If it's positive, I'm eager to have another drug I can feel confident is helping people,"" said Dr. Harlan Krumholz, a prominent cardiologist at Yale-New Haven Hospital. ""Now, I generally don't use it except as a last resort,""  Krumholz said. ""This drug lowers your cholesterol quite effectively, but we're not sure yet whether it actually improves your health.""Merck this week signaled that it had avoided the worst possible outcome, saying in a regulatory filing it will not have to write down the value of Zetia and Vytorin, which could have been necessary if Zetia harmed patients or provided no benefit. Many drug industry analysts expect Vytorin will show some patient benefit, if not a significant one. Combined sales of Zetia and Vytorin have fallen since 2008 as smaller studies raised concerns about safety and effectiveness.     If Improve-It results are favorable, that sales decline ""will certainly stabilize and potentially improve,"" said Morningstar analyst Damien Conover. Zetia and Vytorin have two more years of U.S. patent life.The study was designed to continue until about 5,200 patients had experienced cardiac-related death, a non-fatal heart attack or stroke or the need for an artery clearing procedure. Due to Zocor's effectiveness, patients already had LDL levels at the recommended target of 70 or below before adding Zetia. Dr. Steve Nissen, chief of cardiology at the Cleveland Clinic, has long criticized that aspect of Improve-It's design.""It's studying the drug in a way that nobody uses it clinically,"" Nissen said. ""We use it when we can't get them to treatment goal, to try to get them there.""  (Reporting by Bill Berkrot; Editing by Michele Gershberg and Cynthia Osterman)",2014-11-12,MRK,"Wed Nov 12, 2014 | 4:57pm EST",Future of Merck cholesterol sales could hang on long-awaited study,http://www.reuters.com//article/us-health-heart-merck-idUSKCN0IW2LD20141112?type=companyNews
223,"   By Bill Berkrot | CHICAGO  CHICAGO After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.The data, released on Monday, proves that Zetia - widely used for a dozen years due to its ability to lower ""bad"" LDL cholesterol - provides important protection to some patients, and supports the theory that bringing LDL down to very low levels adds further benefit.""One of our goals was to test is even lower LDL even better, and the answer is yes,"" said Dr. Christopher Cannon, lead investigator of the 18,144-patient Improve-It study presented at the American Heart Association scientific meeting in Chicago.It remains unclear whether the finding will reinvigorate Merck's $4 billion a year cholesterol franchise of Zetia (ezetimibe) and Vytorin, which combines Zetia with its now-generic statin simvastatin. Several doctors at the meeting said the benefit seen pertains only to the very high risk patients in the study.""This is not a signal that everyone should be on ezetimibe,"" said Dr. Neil Stone from Northwestern University School of Medicine in Chicago. Patients had had a heart attack or a dangerous type of chest pain called unstable angina before joining the study. All had their LDL reduced to a target level of about 70 by simvastatin  with Zetia taking LDL down by another 20 percent.  Zetia taken with simvastatin cut heart attacks by 14 percent and strokes caused by diminished blood flow by 21 percent, compared with simvastatin alone. There was no difference in deaths.""In absolute terms, there are two heart attacks or strokes prevented for every 100 patients treated,"" Cannon said.  Statins, such as Pfizer's Lipitor, have long been known to reduce heart attacks, strokes and deaths. There had been no such assurances for Zetia, which lowers cholesterol in a different way. Sales of Zetia and Vytorin have fallen since 2008 over  safety and effectiveness concerns raised in smaller studies. The Improve-it study should allay any lingering safety fears as there was no difference in cancer, muscle-related problems or liver or gall bladder side effects reported. ""An important factor is this is really long term safety,"" Cannon said, noting some patients received treatment for almost nine years.Merck shares were up nearly 1 percent at $59.58. (Additional reporting by Julie Steenhuysen; Editing by Bernadette Baum and Chris Reese)",2014-11-17,MRK,"Mon Nov 17, 2014 | 12:42pm EST","Merck's Zetia cuts heart attack, stroke risk in long-awaited study",http://www.reuters.com//article/us-health-heart-merck-cholesterol-idUSKCN0J11TX20141117?type=companyNews
224,"  (Adds physician comment, share price)By Bill BerkrotCHICAGO Nov 17 After years of uncertainty, a nearly decade-long study showed that Merck & Co's  cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.The data, released on Monday, proves that Zetia - widely used for a dozen years due to its ability to lower ""bad"" LDL cholesterol - provides important protection to some patients, and supports the theory that bringing LDL down to very low levels adds further benefit.""One of our goals was to test is even lower LDL even better, and the answer is yes,"" said Dr. Christopher Cannon, lead investigator of the 18,144-patient Improve-It study presented at the American Heart Association scientific meeting in Chicago. It remains unclear whether the finding will reinvigorate Merck's $4 billion a year cholesterol franchise of Zetia (ezetimibe) and Vytorin, which combines Zetia with its now-generic statin simvastatin. Several doctors at the meeting said the benefit seen pertains only to the very high risk patients in the study.""This is not a signal that everyone should be on ezetimibe,"" said Dr. Neil Stone from Northwestern University School of Medicine in Chicago.Patients had had a heart attack or a dangerous type of chest pain called unstable angina before joining the study. All had their LDL reduced to a target level of about 70 by simvastatin  with Zetia taking LDL down by another 20 percent. Zetia taken with simvastatin cut heart attacks by 14 percent and strokes caused by diminished blood flow by 21 percent, compared with simvastatin alone. There was no difference in deaths.""In absolute terms, there are two heart attacks or strokes prevented for every 100 patients treated,"" Cannon said. Statins, such as Pfizer's Lipitor, have long been known to reduce heart attacks, strokes and deaths. There had been no such assurances for Zetia, which lowers cholesterol in a different way.Sales of Zetia and Vytorin have fallen since 2008 over  safety and effectiveness concerns raised in smaller studies. The Improve-it study should allay any lingering safety fears as there was no difference in cancer, muscle-related problems or liver or gall bladder side effects reported.""An important factor is this is really long term safety,"" Cannon said, noting some patients received treatment for almost nine years.Merck shares were up nearly 1 percent at $59.58.     (Additional reporting by Julie Steenhuysen; Editing by Bernadette Baum and Chris Reese)",2014-11-17,MRK,"Mon Nov 17, 2014 | 12:41pm EST","UPDATE 1-Merck's Zetia cuts heart attack, stroke risk in long-awaited study",http://www.reuters.com//article/health-heart-merck-cholesterol-idUSL2N0T71KQ20141117?type=companyNews
225,"  * FTSEurofirst 300 up 0.5 percent* Draghi hints at QE, Euro zone banks gain* Merck gains after Pfizer deal* H&M boosted by forecast-beating sales* Weir hit by renewed slump in crude   (Updates with closing prices)By Alistair SmoutEDINBURGH, Nov 17 European shares turned solidly positive on Monday after ECB President Mario Draghi reasserted that he was ready to do more to fight deflation.Shrugging off worries that Japan's economy has unexpectedly slipped into recession, the market also drew confidence from earnings reports, merger and acquisition news and appetite for more volatile stocks. The FTSEurofirst 300 index of top European shares closed 0.5 percent higher at 1,352.01 points, extending gains after the European Central Bank President said unconventional measures could include the purchase of sovereign bonds.Andrew Milligan, head of Global Strategy at Standard Life Investments, said ECB action could prompt a change in his ""neutral"" rating on European equities.""If we feel the ECB is beginning to surprise the markets with more action, then we probably would look at rotating more into European equity,"" Milligan said.""If we felt the ECB were falling further behind the curve, we may have to consider an ""underweight"" rating."" Euro zone banks extended gains after Draghi's comments, up 1.6 percent, with Unicredit and Banca Monte dei Paschi di Siena both up over 3 percent.While Monte Paschi said at the weekend no bids had come in for the troubled lender, traders said that appetite for more volatile, or ""high beta"" stocks was building.""Traders are betting on big swings in the most hammered European stocks such as (Monte Paschi)... The stocks have such big betas that it's an interesting trade in such a range-bound market,"" Saxo Bank trader Pierre Martin said. Pharmaceutical firm Merck rose 3.2 percent after agreeing a deal with Pfizer for sharing rights to develop its experimental immunotherapy drug with the U.S. drugmaker.Veolia also rose strongly, up 2.6 percent, with traders citing a discussion on CNBC on Sunday of new evidence that the earth's groundwater is being pumped out much faster than it can be replenished.Traders said that this could increase the interest in companies with expertise in water management such as Veolia.The moves helped to counteract sentiment dented by Japan's drop into recession, with the economy shrinking an annualised 1.6 percent in July-September following a 7.3 percent drop in the second quarter.Analysts polled by Reuters had expected 2.1 percent growth in the third quarter.Japan's data hit Brent crude, down more than $1 to near $78 a barrel, further pressuring shares in European oil majors and oil services groups.Top faller was Weir Group, which dropped to a 2-1/2 year low. It was down 3.8 percent after a double-downgrade from Exane, who warn that the current oil price could trigger 25 pct reduction in rig count.    (Additional reporting by Blaise Robinson; Editing by Ruth Pitchford)",2014-11-17,MRK,"Mon Nov 17, 2014 | 12:22pm EST",ECB's Draghi helps European shares reverse early losses,http://www.reuters.com//article/markets-stocks-europe-idUSL6N0T74KI20141117?type=companyNews
226,"   By Bill Berkrot | CHICAGO  CHICAGO Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their ""bad"" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.Alirocumab, developed along with French drugmaker Sanofi, belongs to a new class of potent drugs that block a naturally occurring protein called PCSK9 that prevents the liver from removing LDL from the blood.Patients in the 360-subject study, called Odyssey Alternative, on average had LDL levels above 190 and all were deemed statin intolerant due to muscle and skeletal side effects when taking the popular medicines.After 24 weeks of treatment, alirocumab lowered LDL by 45 percent compared with 14.6 percent for Zetia (ezetimibe).Importantly, 42 percent of alirocumab patients got LDL down to target levels versus 4 percent for Zetia. That rose to 51 percent versus 6 when excluding those who didn't complete 24 weeks of treatment. Target goals were for LDL under 70 for very high-risk patients and under 100 for high-risk patients.  ""It's a more potent and more effective lipid lowering drug, getting patients to goal by a 10-fold higher amount. It just blows (Zetia) away,"" said Dr. Patrick Moriarty, the study's lead investigator, who presented the results at the American Heart Association scientific meeting in Chicago.Zetia is used to lower LDL in patients who cannot take highly effective statins, such as Pfizer's Lipitor. They are among the most likely candidates for PCSK9 inhibitors once approved.Curiously, during a four-week preliminary period when all patients were just getting a placebo, 47 dropped out, including 25 complaining of muscular side effects. During the actual treatment period, 18.3 percent of alirocumab patients, 25 percent on Zetia and 25.4 percent who were given Lipitor in a third group discontinued treatment. In an ongoing extension of the trial, with patients aware of what they were taking, the alirocumab discontinuation rate from muscular side effects fell dramatically. That most patients given Lipitor stayed on therapy calls into question their actual statin intolerance.""This shows you the complexity of diagnosing statin intolerance,"" Moriarty said. ""This population is not simple.""Regeneron and Sanofi expect to apply for U.S. and European approval this year. But a patent infringement lawsuit filed by Amgen over its rival drug could complicate that.   (Reporting by Bill Berkrot; Editing by Nick Zieminski)",2014-11-17,MRK,"Mon Nov 17, 2014 | 12:06pm EST",Regeneron drug highly effective for those who can't take statins: study,http://www.reuters.com//article/us-health-heart-regeneron-cholesterol-idUSKCN0J11VL20141117?type=companyNews
227,"   By Bill Berkrot | CHICAGO  CHICAGO Nov 17 Regeneron Corp's  experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their ""bad"" LDL cholesterol down to target levels than Merck & Co's  Zetia, according to data from a clinical trial presented on Monday.Alirocumab, developed along with French drugmaker Sanofi , belongs to a new class of potent drugs that block a naturally occurring protein called PCSK9 that prevents the liver from removing LDL from the blood.Patients in the 360-subject study, called Odyssey Alternative, on average had LDL levels above 190 and all were deemed statin intolerant due to muscle and skeletal side effects when taking the popular medicines.After 24 weeks of treatment, alirocumab lowered LDL by 45 percent compared with 14.6 percent for Zetia (ezetimibe). Importantly, 42 percent of alirocumab patients got LDL down to target levels versus 4 percent for Zetia. That rose to 51 percent versus 6 when excluding those who didn't complete 24 weeks of treatment. Target goals were for LDL under 70 for very high-risk patients and under 100 for high-risk patients.""It's a more potent and more effective lipid lowering drug, getting patients to goal by a 10-fold higher amount. It just blows (Zetia) away,"" said Dr. Patrick Moriarty, the study's lead investigator, who presented the results at the American Heart Association scientific meeting in Chicago.Zetia is used to lower LDL in patients who cannot take highly effective statins, such as Pfizer's Lipitor. They are among the most likely candidates for PCSK9 inhibitors once approved. Curiously, during a four-week preliminary period when all patients were just getting a placebo, 47 dropped out, including 25 complaining of muscular side effects.During the actual treatment period, 18.3 percent of alirocumab patients, 25 percent on Zetia and 25.4 percent who were given Lipitor in a third group discontinued treatment. In an ongoing extension of the trial, with patients aware of what they were taking, the alirocumab discontinuation rate from muscular side effects fell dramatically.That most patients given Lipitor stayed on therapy calls into question their actual statin intolerance.""This shows you the complexity of diagnosing statin intolerance,"" Moriarty said. ""This population is not simple.""Regeneron and Sanofi expect to apply for U.S. and European approval this year. But a patent infringement lawsuit filed by Amgen over its rival drug could complicate that.     (Reporting by Bill Berkrot; Editing by Nick Zieminski)",2014-11-17,MRK,"Mon Nov 17, 2014 | 11:45am EST",Regeneron drug highly effective for those who can't take statins -study,http://www.reuters.com//article/health-heart-regeneron-cholesterol-idUSL2N0T238Q20141117?type=companyNews
228,"  * FTSEurofirst 300 up 0.5 percent* Draghi hints at QE, Euro zone banks gain* Merck gains after Pfizer deal* H&M boosted by forecast-beating sales* Weir hit by renewed slump in crude   (Recasts, adds quotes, detail)By Alistair SmoutEDINBURGH, Nov 17 European shares turned solidly positive on Monday after ECB President Mario Draghi reasserted that he was ready to do more to fight deflation.Shrugging off worries that Japan's economy has unexpectedly slipped into recession, the market also drew confidence from earnings reports, merger and acquisition news and appetite for more volatile stocks. The FTSEurofirst 300 index of top European shares had risen 0.5 percent to 1,351.65 points at 1544 GMT, extending gains after the European Central Bank President said unconventional measures could include the purchase of sovereign bonds.Andrew Milligan, head of Global Strategy at Standard Life Investments, said ECB action could prompt a change in his ""neutral"" rating on European equities.""If we feel the ECB is beginning to surprise the markets with more action, then we probably would look at rotating more into European equity,"" Milligan said.""If we felt the ECB were falling further behind the curve, we may have to consider an ""underweight"" rating."" Euro zone banks extended gains after Draghi's comments, up 1.7 percent, with Unicredit and Banca Monte dei Paschi di Siena both up over 3 percent.While Monte Paschi said at the weekend no bids had come in for the troubled lender, traders said that appetite for more volatile, or ""high beta"" stocks was building.""Traders are betting on big swings in the most hammered European stocks such as (Monte Paschi)... The stocks have such big betas that it's an interesting trade in such a range-bound market,"" Saxo Bank trader Pierre Martin said. Pharmaceutical firm Merck rose 3.7 percent, the index's top riser, after agreeing a deal with Pfizer for sharing rights to develop its experimental immunotherapy drug with the U.S. drugmaker.Veolia also rose strongly, up 2.5 percent, with traders citing a discussion on CNBC on Sunday of new evidence that the earth's groundwater is being pumped out much faster than it can be replenished.Traders said that this could increase the interest in companies with expertise in water management such as Veolia.The moves helped to counteract sentiment dented by Japan's drop into recession, with the economy shrinking an annualised 1.6 percent in July-September following a 7.3 percent drop in the second quarter.Analysts polled by Reuters had expected 2.1 percent growth in the third quarter.Japan's data hit Brent crude, down more than $1 to near $78 a barrel, further pressuring shares in European oil majors and oil services groups.Top faller was Weir Group, which dropped to a 2-1/2 year low. It was down 3.7 percent after a double-downgrade from Exane, who warn that the current oil price could trigger 25 pct reduction in rig count.    (Additional reporting by Blaise Robinson; Editing by Ruth Pitchford)",2014-11-17,MRK,"Mon Nov 17, 2014 | 11:42am EST",ECB's Draghi helps European shares reverse early losses,http://www.reuters.com//article/markets-stocks-europe-idUSL6N0T73Y220141117?type=companyNews
229,"   By Bill Berkrot | CHICAGO  CHICAGO Nov 17 After years of uncertainty, a nearly decade-long study showed that Merck & Co's  cholesterol drug Zetia significantly lowered the risk of heart attacks and strokes in high-risk heart patients when used with a highly effective statin.The data, released Monday, proves that Zetia - widely used for a dozen years due to its ability to lower ""bad"" LDL cholesterol levels - provides important protection to some patients, and supports a theory that bringing LDL down to very low levels adds further benefit.""One of our goals was to test - is even lower LDL even better - and the answer is yes,"" said Dr. Christopher Cannon, lead investigator of the more than 18,000-patient Improve-It study presented at the American Heart Association meeting in Chicago.The finding could reinvigorate Merck's $4 billion a year cholesterol franchise of Zetia and Vytorin, which combines Zetia with its now-generic statin Zocor (simvastatin), over their last two years of U.S. patent protection. In the study, Zetia taken with simvastatin cut heart attacks by 14 percent and strokes caused by diminished blood flow by 21 percent, compared with simvastatin alone.There was no difference in deaths between the two groups. ""In absolute terms, there are two heart attacks or strokes prevented for every 100 patients treated,"" Cannon said.Statins, such as Pfizer's Lipitor, have long been known to reduce heart attacks, strokes and deaths. There had been no such assurances for Zetia, which lowers cholesterol in a different way. Other types of cholesterol drugs have failed to show additional benefit when added to statins in previous studies, making Zetia the first to do so, researchers said.Patients in the study had had a heart attack or a dangerous type of chest pain called unstable angina before joining the study. All had their LDL reduced to a target level of about 70 before half began also taking Zetia, which reduced LDL by another 20 percent.Sales of Zetia and Vytorin have fallen since 2008 over concerns about safety and effectiveness raised in smaller studies. The Improve-it study may allay any lingering safety fears as there was no difference in cancer, muscle-related problems or liver or gall bladder side effects seen.""An important factor is this is really long term safety,"" Cannon said, noting some patients received treatment for nearly nine years.      (Editing by Bernadette Baum)",2014-11-17,MRK,"Mon Nov 17, 2014 | 11:37am EST","Merck's Zetia cuts heart attack, stroke risk in long-awaited study",http://www.reuters.com//article/health-heart-merck-cholesterol-idUSL2N0T71DH20141117?type=companyNews
230,"  * FTSEurofirst 300 up 0.1 percent* Merck gains after Pfizer deal* H&M boosted by forecast-beating sales* Weir hit by renewed slump in crude   (Adds detail, quotes, updates prices)By Alistair SmoutEDINBURGH, Nov 17 European shares reclaimed early losses on Monday as concern over Japan's economy after it unexpectedly slipped into recession proved short-lived.Earnings reports, merger & acquisition news and appetite for more volatile stocks all provided support for the market. The FTSEurofirst 300 index of top European shares edged up 0.1 percent to 1,346.64 points.Pharmaceutical firm Merck rose 3.8 percent, the index's top riser, after agreeing a deal with Pfizer for sharing rights to develop its experimental immunotherapy drug with the U.S. drugmaker.Shares in Hennes & Mauritz, the world's second-biggest fashion retailer, also rose strongly, up 2.4 percent after it posted a 14 percent rise in October sales from a year ago, beating forecasts. Andrew Milligan, head of Global Strategy at Standard Life Investments, said that an encouraging earnings season in Europe pointed to strong economic fundamentals which should help a recovery in European equities before year-end.""A major political shock could stop a recovery in its tracks. But the economic fundamentals are generally positive,"" Milligan said, giving geopolitical tension with Russia over unrest in Ukraine as one example.""Nobody says that Europe and Japan are going to grow strongly into 2015, but it doesn't look like they're on the verge of an extended slow down - rather they've been hit by temporary factors like Ukraine and the sales tax increase."" Japan's economy shrank an annualised 1.6 percent in July-September, following a 7.3 percent drop in the second quarter that was hurt by a sales tax hike hitting consumer spending.Analysts polled by Reuters had expected 2.1 percent growth in the third quarter.Japan's data hit Brent crude, down more than $1 to near $78 a barrel, further pressuring shares in European oil majors and oil services groups.Top faller was Weir Group, which dropped to a 2-1/2 year low. It was down 3.6 percent after a double-downgrade from Exane, who warn that the current oil price could trigger 25 pct reduction in rig count.Italian banks saw strong rises, with Unicredit and Banca Monte dei Paschi di Siena both up over 2 percent.While Monte Paschi said at the weekend no bidders had come in for the troubled lender, traders said that appetite for more volatile  - or ""high beta"" stocks was building.    (Additional reporting by Blaise Robinson)",2014-11-17,MRK,"Mon Nov 17, 2014 | 10:14am EST",European shares pare losses after Japan slips into recession,http://www.reuters.com//article/markets-stocks-europe-idUSL6N0T73OC20141117?type=companyNews
231,"  * Innovative Medicines and MedTech Review to report in 2015* Follows criticism that Britain is too slow to adopt new drugs* Britain eager to promote itself as life-science hub* Merck, Becton Dickinson plan 63 mln stg investmentLONDON, Nov 20 The British government has launched a review to speed the path to market for new drugs and medical devices in an attempt to improve patient care and make the country a more attractive place for investment in life sciences. British manufacturing relies heavily on the pharmaceuticals sector, including domestic giants GlaxoSmithKline and AstraZeneca, but companies complain that the state-run National Health Service (NHS) is too slow to adopt new treatments.The review, announced at a meeting between industry leaders and ministers at Prime Minister David Cameron's Downing Street office on Thursday, aims to tackle the issue by studying innovative models for drug development.This will include an examination of the scope for more collaborative work between companies and regulators to ensure that new medicines and devices are assessed more quickly, with greater input from patient groups and charities such as Cancer Research UK. An independent organisation will be appointed to carry out the Innovative Medicines and MedTech Review, starting work early next year and reporting later in 2015.The Association of the British Pharmaceutical Industry said the initiative is ""a big step in the right direction"" but that it needs to dovetail with the National Institute for Health and Care Excellence (NICE), which assesses whether treatments are sufficiently cost-effective for the NHS. NICE has frequently clashed with industry over its rejection of some expensive new medicines, notably cancer treatments.Cameron first announced a drive to make Britain a leading hub for life sciences in 2011, welcomed at the time by industry.In the latest boost to the sector, United States-based Merck & Co plans to invest at least 42 million pounds ($66 million) in Britain over the next three years, while Becton Dickinson is investing 21 million pounds, the government said.Merck plans a new licensing hub in London and will expand drug research facilities, while Becton Dickinson is to build a plant in southwest England to produce blood separation tubes. (1 US dollar = 0.6382 British pound)   (Reporting by Ben Hirschler; Editing by David Goodman)",2014-11-20,MRK,"Thu Nov 20, 2014 | 7:22am EST",Britain begins review to speed access to new drugs,http://www.reuters.com//article/britain-pharmaceuticals-study-idUSL6N0TA2MQ20141120?type=companyNews
232,"   By Ransdell Pierson  Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.O) experimental vaccine against the Ebola virus.NewLink, whose subsidiary licensed commercial rights to the rVSV-EBOV vaccine in 2010, said it would receive $50 million plus royalties from Merck.Large late-stage trials of the product could begin early next year, said Merck, the No. 2 U.S. drugmaker and one of the world's biggest makers of vaccines.Merck, which will be able to speed up and significantly boost production, will take over development of the vaccine and any follow-on products.The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to it.  The deal between Merck and NewLink, a tiny biotechnology company based in Ames, Iowa, comes as other drugmakers are also racing to test and scale up production of treatments and preventive vaccines for Ebola, which has killed more than 5,400 people this year. It is the worst Ebola outbreak on record. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, are conducting early-stage trials of the NewLink vaccine. The trials involve healthy volunteers and are testing whether the vaccine is safe and provokes a protective immune response.Should those Phase I studies prove favorable, the NIH plans to begin large late-stage trials early next year. The World Health Organization is also coordinating early-stage trials in Switzerland, Germany, Kenya and Gabon.In a regulatory filing on Monday, NewLink said Merck would pay it $30 million upfront and $20 million once larger formal trials begin. The company will also be eligible to receive royalties on sales in certain markets. Shares of NewLink were down 4.3 percent at $33.81 in morning trading, while Merck fell 0.5 percent to $59.34.Rival drugmaker GlaxoSmithKline Plc (GSK.L) is developing its own Ebola vaccine with the NIH and plans to build a stockpile of thousands of doses for emergency deployment if results are good. (Additional reporting by Vidya L Nathan in Bangalore; Editing by Lisa Von Ahn and Siddharth Cavale)",2014-11-24,MRK,"Mon Nov 24, 2014 | 11:47am EST",Merck buys rights to NewLink's experimental Ebola vaccine,http://www.reuters.com//article/us-health-ebola-merck-idUSKCN0J814A20141124?type=companyNews
233,"  (Adds terms of deal, details on WHO-coordinated trials; updates share movement)By Ransdell PiersonNov 24 Merck & Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's  experimental vaccine against the Ebola virus.NewLink, whose subsidiary licensed commercial rights to the rVSV-EBOV vaccine in 2010, said it would receive $50 million plus royalties from Merck.Large late-stage trials of the product could begin early next year, said Merck, the No. 2 U.S. drugmaker and one of the world's biggest makers of vaccines. Merck, which will be able to speed up and significantly boost production, will take over development of the vaccine and any follow-on products.The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to it.The deal between Merck and NewLink, a tiny biotechnology company based in Ames, Iowa, comes as other drugmakers are also racing to test and scale up production of treatments and preventive vaccines for Ebola, which has killed more than 5,400 people this year. It is the worst Ebola outbreak on record. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths.The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, are conducting early-stage trials of the NewLink vaccine. The trials involve healthy volunteers and are testing whether the vaccine is safe and provokes a protective immune response. Should those Phase I studies prove favorable, the NIH plans to begin large late-stage trials early next year. The World Health Organization is also coordinating early-stage trials in Switzerland, Germany, Kenya and Gabon.In a regulatory filing on Monday, NewLink said Merck would pay it $30 million upfront and $20 million once larger formal trials begin. The company will also be eligible to receive royalties on sales in certain markets.Shares of NewLink were down 4.3 percent at $33.81 in morning trading, while Merck fell 0.5 percent to $59.34.Rival drugmaker GlaxoSmithKline Plc is developing its own Ebola vaccine with the NIH and plans to build a stockpile of thousands of doses for emergency deployment if results are good.   (Additional reporting by Vidya L Nathan in Bangalore; Editing by Lisa Von Ahn and Siddharth Cavale)",2014-11-24,MRK,"Mon Nov 24, 2014 | 11:46am EST",UPDATE 2-Merck buys rights to NewLink's experimental Ebola vaccine,http://www.reuters.com//article/health-ebola-merck-idUSL3N0TE3O620141124?type=companyNews
234,"  Nov 24 Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's  experimental Ebola vaccine.Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement. Financial details were not disclosed. The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug. The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015.   (Reporting by Vidya L Nathan in Bangalore; Editing by Siddharth Cavale)",2014-11-24,MRK,"Mon Nov 24, 2014 | 8:16am EST",Merck buys rights to NewLink's experimental Ebola vaccine,http://www.reuters.com//article/health-ebola-merck-idUSL3N0TE3FT20141124?type=companyNews
235,"  * Merck KGaA committed to growing over-the-counter division* Dismisses suggestion business might be sold* Unit head says may consider small bolt-on acquisitionsBy Ben HirschlerLONDON, Nov 28 Merck KGaA aims to keep hold of its consumer healthcare unit, it said on Friday, pledging to develop a business that is expected to generate 2014 sales of $1 billion for the German drugs and chemicals company.The non-prescription market has seen a wave of consolidation this year and a $17 billion deal for Merck to buy laboratory  supplies business Sigma-Aldrich has prompted some bankers to speculate it might consider selling the consumer unit. But the family-controlled company insists it has no intention of quitting.""We really want to stick to that business,"" Uta Kemmerich-Keil, chief executive of Merck Consumer Health, said during a media briefing in London highlighting the unit's strengths.""Our strategy is a pure growth strategy and by the end of this year we will hopefully hit the $1 billion sales mark."" Consumer health is smaller than Merck's other businesses selling prescription drugs, high-tech chemicals and laboratory  equipment but has strong brands like Seven Seas vitamins and Bion probiotics.It also received a boost in January from the transfer of Neurobion and Floratil, for muscle soreness and diarrhoea, from the prescription drug unit Merck Serono. Kemmerich-Keil said she aimed to have at least three leading brands with a minimum 3 percent market share in key target countries, which include a number of emerging markets, like Brazil, where demand for self-medication is growing strongly.While securing strong positions in local markets could involve small bolt-on acquisitions or licensing deals, she sees no need for large-scale acquisitions, despite recent moves by leading players Bayer and GlaxoSmithKline to boost their OTC footprints.""OTC is a local play, so you need to make sure in the markets you are in that you are strong,"" she said. ""It's not important how big the overall business is.""This year's deal-making has seen Bayer acquire the OTC business of Merck's U.S. namesake Merck & Co, following a fiercely contested auction also involving Reckitt Benckiser . GSK has also clinched a complex deal for a stake in Novartis's consumer products, while Perrigo  has agreed to buy Belgian OTC firm Omega Pharma.Following the deals, Germany's Merck now has a No. 11 position in consumer health.   (Additional reporting by Ludwig Burger in Frankfurt; Editing by Greg Mahlich)",2014-11-28,MRK,"Fri Nov 28, 2014 | 9:13am EST","Germany's Merck aims to grow, not sell $1 bln consumer health arm",http://www.reuters.com//article/merck-consumers-idUSL6N0TI29Z20141128?type=companyNews
236,"   By Kate Kelland | LONDON  LONDON The first people vaccinated with an experimental Ebola shot being developed by Merck and NewLink have had no serious side effects so far, but a few experienced mild fever, Swiss researchers said on Tuesday.The shot, one of several being fast-tracked through clinical trials in the hope they can be approved for use in the Ebola epidemic raging in West Africa, is undergoing initial human safety tests at the University Hospitals of Geneva.""After his or her injection, each volunteer was kept under observation for 1.5 hours at the clinical trials unit,"" scientists at the Swiss hospital said in a statement. ""To date, no major side effects have been observed after the injections, which triggered the expected inflammatory responses. They (the inflammatory responses) have been weak to moderate, with limited cases of mild fever,"" it added.Since 10 November, 34 volunteers have been vaccinated with the shot, known as VSV-ZEBOV Ebola vaccine, at the request of the World Health Organization (WHO).  Trials have also begun in the United States, Canada, Germany and Gabon, and similar trials should start soon in Kenya.This is the first data from human testing of the Merck/Newlink shot. It follows positive news last week about a GlaxoSmithKline candidate Ebola vaccine, which caused no serious side effects and produced an immune response in 20 volunteers in early-stage trials. A version of GSK's vaccine targeting only the Zaire strain of Ebola which is causing the current outbreak is undergoing safety trials in Britain, Mali and Switzerland.A trial of an Ebola vaccine from Johnson & Johnson is scheduled to start in January.The Ebola epidemic is the largest ever recorded and has so far infected around 16,000 people, killing almost 6,000 of them, according to latest WHO figures. The vast majority of cases and deaths have been in Guinea, Sierra Leone and Liberia. Some Ebola experts say it is unlikely the epidemic can be brought under control without the use of a vaccine, which if successful could protect healthy people from being infected with the contagious and deadly virus.Merck announced last month that it would buy the rights to NewLink's vaccine for $50 million.  (Editing by Catherine Evans)",2014-12-02,MRK,"Tue Dec 2, 2014 | 11:13am EST",No serious side effects in Merck/Newlink Ebola vaccine test,http://www.reuters.com//article/us-health-ebola-vaccine-idUSKCN0JG0WY20141202?type=companyNews
237,"  (Adds details, background)By Kate KellandLONDON Dec 2 The first people vaccinated with an experimental Ebola shot being developed by Merck and NewLink have had no serious side effects so far, but a few experienced mild fever, Swiss researchers said on Tuesday.The shot, one of several being fast-tracked through clinical trials in the hope they can be approved for use in the Ebola epidemic raging in West Africa, is undergoing initial human safety tests at the University Hospitals of Geneva.""After his or her injection, each volunteer was kept under observation for 1.5 hours at the clinical trials unit,"" scientists at the Swiss hospital said in a statement. ""To date, no major side effects have been observed after the injections, which triggered the expected inflammatory responses. They (the inflammatory responses) have been weak to moderate, with limited cases of mild fever,"" it added.Since 10 November, 34 volunteers have been vaccinated with the shot, known as VSV-ZEBOV Ebola vaccine, at the request of the World Health Organization (WHO).Trials have also begun in the United States, Canada, Germany and Gabon, and similar trials should start soon in Kenya. This is the first data from human testing of the Merck/Newlink shot. It follows positive news last week about a GlaxoSmithKline candidate Ebola vaccine, which caused no serious side effects and produced an immune response in 20 volunteers in early-stage trials.A version of GSK's vaccine targeting only the Zaire strain of Ebola which is causing the current outbreak is undergoing safety trials in Britain, Mali and Switzerland. A trial of an Ebola vaccine from Johnson & Johnson  is scheduled to start in January.The Ebola epidemic is the largest ever recorded and has so far infected around 16,000 people, killing almost 6,000 of them, according to latest WHO figures. The vast majority of cases and deaths have been in Guinea, Sierra Leone and Liberia.Some Ebola experts say it is unlikely the epidemic can be brought under control without the use of a vaccine, which if successful could protect healthy people from being infected with the contagious and deadly virus.Merck announced last month that it would buy the rights to NewLink's vaccine for $50 million.    (Editing by Catherine Evans)",2014-12-02,MRK,"Tue Dec 2, 2014 | 5:58am EST",UPDATE 1-No serious side effects in Merck/Newlink Ebola vaccine test,http://www.reuters.com//article/health-ebola-vaccine-idUSL6N0TM1PJ20141202?type=companyNews
238,"  LONDON Dec 2 The first people vaccinated with an experimental Ebola shot being developed by U.S. drugmaker Merck and Canada's NewLink have had no serious side effects so far but a few experienced mild fever, researchers said on Tuesday.The shot, one of several being rushed through human testing in the hope they can be approved for use in the Ebola epidemic currently raging in West Africa, is going through initial human safety tests at the University Hospitals of Geneva. ""After his or her injection, each volunteer was kept under observation for 1.5 hours at the clinical trials unit,"" the hospital said in a statement. ""To date, no major side effects have been observed after the injections, which triggered the expected inflammatory responses. They (the inflammatory responses) have been weak to moderate, with limited cases of mild fever,"" it added. Since 10 November, 34 volunteers have been vaccinated with the shot, known as VSV-ZEBOV Ebola vaccine, at the request of the World Health Organization (WHO).      (Reporting by Kate Kelland, editing by Andrew Heavens)",2014-12-02,MRK,"Tue Dec 2, 2014 | 5:05am EST",No serious side effects in Merck/Newlink Ebola vaccine test,http://www.reuters.com//article/health-ebola-vaccine-idUSL6N0TM1LX20141202?type=companyNews
239,"   By Bill Berkrot  Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting.In the ongoing study of 29 patients, 66 percent had a meaningful response to the drug, Keytruda, after 24 weeks of treatment, including six patients (21 percent) who achieved complete remission.Six other patients in the Keynote-013 study unveiled on Saturday had stable disease at the time data was analyzed, while the lymphoma progressed in four patients.""The drug is outstanding,"" said Dr. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer Center in New York.""It may be a small patient population, but it is really remarkable,"" he said. ""And it's really well tolerated."" There are about 9,000 new cases of Hodgkin lymphoma in the United States in 2014, according to the Leukemia and Lymphoma Society. About a quarter are likely to relapse after initially successful treatment, highlighting the need for new options.  Keytruda (pembrolizumab) belongs to a new class of drugs called PD-1 inhibitors that have generated great enthusiasm in the medical community. They work by blocking a mechanism tumors use to camouflage themselves from the immune system, allowing it to recognize and attack the cancer. Patients in the study had either had a stem cell transplant or were ineligible for one, and all had been previously treated with the Seattle Genetics Inc drug Adcetris.The average time to response with Keytruda was 12 weeks, according to data being presented at the American Society of Hematology meeting in San Francisco. The median duration of response had not yet been reached. Patients will stay on the drug until their cancer progresses.Keytruda this year was approved to treat advanced melanoma - the deadliest form of skin cancer - making it the first drug from the PD-1 class to reach the U.S. market. Bristol-Myers Squibb Co is developing a rival medicine.    This marks the first Keytruda data reported against a type of blood cancer. It is also being tested in lung, breast, bladder, gastric, and head and neck cancers.The most common side effect was shortness of breath, Moskowitz said. One patient discontinued treatment due to pneumonitis, an inflammation of the lung tissue.     (Reporting by Bill Berkrot; Editing by Marguerita Choy)",2014-12-06,MRK,"Sat Dec 6, 2014 | 1:06pm EST",Merck immunotherapy drug shows promise against lymphoma: study,http://www.reuters.com//article/us-merck-lymphoma-idUSKBN0JK0P220141206?type=companyNews
240,"   By Bill Berkrot  Dec 6 Merck & Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting.In the ongoing study of 29 patients, 66 percent had a meaningful response to the drug, Keytruda, after 24 weeks of treatment, including six patients (21 percent) who achieved complete remission.Six other patients in the Keynote-013 study unveiled on Saturday had stable disease at the time data was analyzed, while the lymphoma progressed in four patients.""The drug is outstanding,"" said Dr. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer Center in New York. ""It may be a small patient population, but it is really remarkable,"" he said. ""And it's really well tolerated.""There are about 9,000 new cases of Hodgkin lymphoma in the United States in 2014, according to the Leukemia and Lymphoma Society. About a quarter are likely to relapse after initially successful treatment, highlighting the need for new options. Keytruda (pembrolizumab) belongs to a new class of drugs called PD-1 inhibitors that have generated great enthusiasm in the medical community. They work by blocking a mechanism tumors use to camouflage themselves from the immune system, allowing it to recognize and attack the cancer.Patients in the study had either had a stem cell transplant or were ineligible for one, and all had been previously treated with the Seattle Genetics Inc drug Adcetris. The average time to response with Keytruda was 12 weeks, according to data being presented at the American Society of Hematology meeting in San Francisco. The median duration of response had not yet been reached. Patients will stay on the drug until their cancer progresses.Keytruda this year was approved to treat advanced melanoma - the deadliest form of skin cancer - making it the first drug from the PD-1 class to reach the U.S. market. Bristol-Myers Squibb Co is developing a rival medicine.This marks the first Keytruda data reported against a type of blood cancer. It is also being tested in lung, breast, bladder, gastric, and head and neck cancers.The most common side effect was shortness of breath, Moskowitz said. One patient discontinued treatment due to pneumonitis, an inflammation of the lung tissue.       (Reporting by Bill Berkrot; Editing by Marguerita Choy)",2014-12-06,MRK,"Sat Dec 6, 2014 | 1:00pm EST",Merck immunotherapy drug shows promise against lymphoma -study,http://www.reuters.com//article/merck-lymphoma-idUSL2N0TN2GL20141206?type=companyNews
241,"  Merck & Co Inc is in talks to acquire Cubist Pharmaceuticals Inc for more than $7 billion in a deal that could be announced as early as next week, the New York Times reported on Friday, citing people briefed on the matter.Merck will likely pay roughly $100 a share for Cubist, valuing the company that makes drugs to fight superbugs, in the range of $7.5 billion, the people said. (nyti.ms/1IbKXcJ)Merck could pay a 33 percent premium for Cubist, the sources told the newspaper, but it was not clear if it would pay for Cubist shares with cash, stock or a combination of the two.Lexington, Massachusetts-based Cubist is valued at about $5.7 billion as of its Friday close of $74.36.The antibiotic maker's shares rose about 22.7 percent to $91.25 on the Nasdaq in extended trade. Up to Friday's close, the stock had nearly doubled over the last three years. Merck's shares were flat.   Both companies were unavailable for comment outside of regular business hours.Cubist reported a 16 percent jump in third-quarter sales in October, driven by strong sales of its antibiotic Cubicin, which generated global sales of more than $1 billion last year. The company received U.S. regulatory approval for its antibiotic Sivextro in June. It awaits an FDA decision on another antibiotic, ceftolozane/tazobactam, on Dec. 21.In June, Merck acquired Idenix Pharmaceuticals for $3.85 billion, to boost its hepatitis C drug portfolio.   (Reporting by Natalie Grover and Siddharth Cavale in Bengaluru; Editing by Lisa Shumaker)",2014-12-06,MRK,"Fri Dec 5, 2014 | 9:31pm EST",Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion: NYT,http://www.reuters.com//article/us-merck-co-m-a-cubist-pharm-idUSKCN0JK01T20141206?type=companyNews
242,"   By Vidya L Nathan and Ben Hirschler  Merck & Co Inc (MRK.N) said it would buy Cubist Pharmaceuticals Inc CBST.O for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.The deal is the latest sign that large pharmaceutical companies are turning their attention back to antibiotics after decades of low investment.The spread of superbugs that evade even the most powerful antibiotics threatens modern medicine, the World Health Organization said in April, warning of ""a post-antibiotic era"" in which common infections were killers once again.The U.S. Centers for Disease Control and Prevention estimated last year that more than 2 million people in the United States are sickened every year by superbug infections, with at least 23,000 dying as a result. (1.usa.gov/1w5Hhml)Merck said on Monday that the deal, which will give it access to Cubist's antibiotic Cubicin, is expected to add more than $1 billion to revenue in 2015 after closing in the first quarter, but will be neutral to non-GAAP earnings per share until 2016.Cubist's third-quarter sales rose 16 percent, driven by strong sales of Cubicin.Cubist may lose patent protection for Cubicin earlier than expected, after a Friday federal court ruling that invalidated four of its patents. If the ruling stands, it will allow Hospira Inc to launch a generic version of the drug in 2016.Merck could not immediately be reached for comment on the ruling. Cubist's lead drug in development, Ceftolozane/Tazobactam, is widely expected to win marketing approval from the U.S. Food and Drug Administration later this month as a treatment for complicated urinary tract infections.Merck will pay $102 per share for Cubist, a premium of 37 percent to the Lexington, Massachussetts-based company's closing share price of $74.36 on Friday. The deal includes assumption of $1.1 billion in debt.""Cubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,"" Merck CEO Kenneth Frazier said in a statement.""Combining this expertise with Merck's strong capabilities and global reach will enable us to create a stronger position in hospital acute care while addressing critical areas of unmet medical need, such as antibiotic resistance."" Merck has said it is focusing on acute care within hospitals - considered a hotbed for superbug infections such as bacterial pneumonia - as a top priority.Many drugmakers have cut investment in the past because antibiotics are typically low-priced and used for only short periods, generating poor returns. That has fueled demands for a rethink of the antibiotic market model. It has also left Cubist as a leading investor in the field, with an annual research budget for antibiotics of $400 million.More recently, however, there have been signs of a revival, with Roche Holding AG ROG.VX, GlaxoSmithKline Plc (GSK.L) and Sanofi SA (SASY.PA) all investing in new approaches to fight superbugs. Cubist shares were trading at $101.04 premarket. Merck shares were unchanged from Friday's close at $61.50.The New York Times, citing people briefed on the matter, first reported the deal on Friday. The Cubist deal is Merck's second big acquisition this year. The company bought Idenix Pharmaceuticals for $3.85 billion in June to boost its hepatitis C drug portfolio.(Top pharmaceutical deals: link.reuters.com/rug63w) (Editing by Ted Kerr)",2014-12-08,MRK,"Mon Dec 8, 2014 | 6:44pm EST",Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com//article/us-cubist-pharma-m-a-merck-idUSKBN0JM19X20141208?type=companyNews
243,"   By Vidya L Nathan and Ben Hirschler  Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.The deal is the latest sign that large pharmaceutical companies are turning their attention back to antibiotics after decades of low investment.The spread of superbugs that evade even the most powerful antibiotics threatens modern medicine, the World Health Organization said in April, warning of ""a post-antibiotic era"" in which common infections were killers once again.The U.S. Centers for Disease Control and Prevention estimated last year that more than 2 million people in the United States are sickened every year by superbug infections, with at least 23,000 dying as a result. (1.usa.gov/1w5Hhml)Merck said on Monday that the deal, which will give it access to Cubist's antibiotic Cubicin, is expected to add more than $1 billion to revenue in 2015 after closing in the first quarter, but will be neutral to non-GAAP earnings per share until 2016.Cubist's third-quarter sales rose 16 percent, driven by strong sales of Cubicin.Cubist may lose patent protection for Cubicin earlier than expected, after a Friday federal court ruling that invalidated four of its patents. If the ruling stands, it will allow Hospira Inc to launch a generic version of the drug in 2016.Merck could not immediately be reached for comment on the ruling. Cubist's lead drug in development, Ceftolozane/Tazobactam, is widely expected to win marketing approval from the U.S. Food and Drug Administration later this month as a treatment for complicated urinary tract infections.Merck will pay $102 per share for Cubist, a premium of 37 percent to the Lexington, Massachussetts-based company's closing share price of $74.36 on Friday.The deal includes assumption of $1.1 billion in debt.""Cubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,"" Merck CEO Kenneth Frazier said in a statement. ""Combining this expertise with Merck's strong capabilities and global reach will enable us to create a stronger position in hospital acute care while addressing critical areas of unmet medical need, such as antibiotic resistance.""Merck has said it is focusing on acute care within hospitals - considered a hotbed for superbug infections such as bacterial pneumonia - as a top priority.Many drugmakers have cut investment in the past because antibiotics are typically low-priced and used for only short periods, generating poor returns. That has fueled demands for a rethink of the antibiotic market model.It has also left Cubist as a leading investor in the field, with an annual research budget for antibiotics of $400 million. More recently, however, there have been signs of a revival, with Roche Holding AG, GlaxoSmithKline Plc and Sanofi SA all investing in new approaches to fight superbugs.Cubist shares were trading at $101.04 premarket. Merck shares were unchanged from Friday's close at $61.50.The New York Times, citing people briefed on the matter, first reported the deal on Friday.The Cubist deal is Merck's second big acquisition this year. The company bought Idenix Pharmaceuticals for $3.85 billion in June to boost its hepatitis C drug portfolio.(Top pharmaceutical deals: link.reuters.com/rug63w)",2014-12-08,MRK,"Mon Dec 8, 2014 | 6:41pm EST",Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com//article/cubist-pharma-ma-merck-idUSL1N0TS0WM20141208?type=companyNews
244,"  * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debt* Deal marks Merck entry into market for drugs to fight superbugs* Offer values Cubist shares at $102, premium of 37 pct   (Adds paragraphs 7-8 with information on federal patent ruling)By Vidya L Nathan and Ben HirschlerDec 8 Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.The deal is the latest sign that large pharmaceutical companies are turning their attention back to antibiotics after decades of low investment.The spread of superbugs that evade even the most powerful antibiotics threatens modern medicine, the World Health Organization said in April, warning of ""a post-antibiotic era"" in which common infections were killers once again.The U.S. Centers for Disease Control and Prevention estimated last year that more than 2 million people in the United States are sickened every year by superbug infections, with at least 23,000 dying as a result. (1.usa.gov/1w5Hhml)Merck said on Monday that the deal, which will give it access to Cubist's antibiotic Cubicin, is expected to add more than $1 billion to revenue in 2015 after closing in the first quarter, but will be neutral to non-GAAP earnings per share until 2016.Cubist's third-quarter sales rose 16 percent, driven by strong sales of Cubicin. Cubist may lose patent protection for Cubicin earlier than expected, after a Friday federal court ruling that invalidated four of its patents. If the ruling stands, it will allow Hospira Inc to launch a generic version of the drug in 2016.Merck could not immediately be reached for comment on the ruling.Cubist's lead drug in development, Ceftolozane/Tazobactam, is widely expected to win marketing approval from the U.S. Food and Drug Administration later this month as a treatment for complicated urinary tract infections.Merck will pay $102 per share for Cubist, a premium of 37 percent to the Lexington, Massachussetts-based company's closing share price of $74.36 on Friday. The deal includes assumption of $1.1 billion in debt.""Cubist is a global leader in antibiotics and has built a strong portfolio of both marketed and late-stage pipeline medicines,"" Merck CEO Kenneth Frazier said in a statement.""Combining this expertise with Merck's strong capabilities and global reach will enable us to create a stronger position in hospital acute care while addressing critical areas of unmet medical need, such as antibiotic resistance.""Merck has said it is focusing on acute care within hospitals - considered a hotbed for superbug infections such as bacterial pneumonia - as a top priority.Many drugmakers have cut investment in the past because antibiotics are typically low-priced and used for only short periods, generating poor returns. That has fueled demands for a rethink of the antibiotic market model. It has also left Cubist as a leading investor in the field, with an annual research budget for antibiotics of $400 million.More recently, however, there have been signs of a revival, with Roche Holding AG, GlaxoSmithKline Plc and Sanofi SA all investing in new approaches to fight superbugs.Cubist shares were trading at $101.04 premarket. Merck shares were unchanged from Friday's close at $61.50.The New York Times, citing people briefed on the matter, first reported the deal on Friday.The Cubist deal is Merck's second big acquisition this year. The company bought Idenix Pharmaceuticals for $3.85 billion in June to boost its hepatitis C drug portfolio.(Top pharmaceutical deals: link.reuters.com/rug63w)(Editing by Ted Kerr)",2014-12-08,MRK,"Mon Dec 8, 2014 | 6:38pm EST",UPDATE 4-Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com//article/cubist-pharma-ma-merck-idUSL3N0TS3VA20141208?type=companyNews
245,"   By Robert Cyran | NEW YORK  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.In the 1990s and 2000s, big pharma lost interest in new antibiotics. Existing drugs worked very well and were cheap, so there seemed little reason to spend heavily to develop new ones. Regulators demanded more stringent trials after one approved drug turned out to have life-threatening side effects. That raised costs further. And a perverse financial logic ruled: antibiotics usually cure patients rapidly, limiting revenue. The pursuit by the likes of Cubist of new ways to treat bacterial diseases looked increasingly lonely.The mood has, however, been changing as bacteria have developed resistance to existing antibiotics. The World Health Organization warned earlier this year that gonorrhea could soon become untreatable. The U.S. Centers for Disease Control and Prevention estimate that the extra cost of treating antibiotic-resistant infections runs up to $35 billion a year. That could rocket higher as infections become harder to contain.In response Uncle Sam is spending more on research and development and U.S. regulators are giving new drugs that combat life-threatening infections an extra five years of market exclusivity. They are also promising to approve new antibiotics quickly. The drive by governments worldwide to tie drug prices to efficacy will help further. New cancer treatments can cost $100,000 but may only add a few months of life. Antibiotics that permanently cure fatal diseases for $3,000 look cheap in comparison. That could mean a renaissance for antibiotics, with profit opportunities to match. But the pace of drug development is still glacial, which makes big drug groups eager to buy companies that already have compounds in clinical trials. Despite the above-average outlook for new antibiotics and the fact that Cubist has one potential blockbuster that just hit the market and another awaiting approval, Merck is paying only about 4.3 times Cubist's estimated revenue for next year.That's about the same multiple as investors give Merck's own business, making it look like a relative bargain. More alarm about superbugs will only make the deal look better.CONTEXT NEWS  - Merck said on Dec. 8 that it would acquire Cubist Pharmaceuticals for $8.4 billion, or $102 per share. The drug company will also take on the antibiotic maker's debt. Merck is paying a 37 percent premium based on Cubist's closing price on Dec. 5, the last day of trading before the deal was announced.- In June, Merck paid $3.9 billion for Idenix, a biotech company developing treatments for hepatitis C. - Company statement: bit.ly/1vEyzg6- Reuters: Merck to take on superbugs with Cubist Pharma buy- For previous columns by the author, Reuters customers can click on    (The author is a Reuters Breakingviews columnist. The opinions expressed are his own.)",2014-12-08,MRK,"Mon Dec 8, 2014 | 3:44pm EST",Breakingviews: Merck bets $8.4 bln on more profitable antibiotics,http://www.reuters.com//article/cubist-pharm-ma-merck-co-breakingviews-idUSL1N0TS1VZ20141208?type=companyNews
246,"   By Saqib Iqbal Ahmed | NEW YORK  NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.One series of trades on Thursday appears to have generated at least a 10-fold windfall profit on paper.Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Cubist shares were up 35 percent at $100.70 on Monday.Open interest in Cubist call options, which convey the right to buy the stock at a fixed price in the future, jumped by 25 percent between Dec. 1 and Dec. 5 to 13,864 contracts, according to Trade Alert data. That ranks among the largest increases in open interest over a five-day period this year for Cubist calls.On average, Cubist options are not very actively traded, but trading volume was unusually heavy on Thursday, said Fred Ruffy, options strategist at WhatsTrading.com.  Ruffy also noted an increase in Cubist's implied volatility, a gauge of the risk of large moves in a stock and a key component to options pricing. Implied volatility jumped to 51.49 percent on Thursday from 43.15 percent on Wednesday, according to Livevol Inc data.One call strike in particular saw a big increase in activity on Thursday. Around 1,000 Cubist calls at the $85 strike and set to expire on Jan. 17 were bought for between $1.25 to $1.50, according to Livevol Inc data.Ahead of those trades on Thursday afternoon, the January 85 calls had fewer than 300 contracts of open interest, according to Reuters data. By the end of the day that had risen to more than 1,300. Since going on the board in October 2013, the average volume of January 85 calls had been about 14 contracts a day, and their largest daily total before Thursday had been 175 contracts. Thursday's volume was more than 45 standard deviations above the norm.""To expect the stock to move past $85 and be willing to pay over a $1 for it with about a month and a half to go suggests that they were expecting some kind of major catalyst,"" said optionMonster.com lead analyst David Russell.Until Monday, the high for Cubist shares was $82.12, set in February this year. With the stock soaring to a record above $100 on the merger news, the January 85 calls are now quoted at about $16, making for a huge profit on the trades, Russell said.One other possible catalyst for the shares involves a possible resolution of a lawsuit surrounding a generic challenge to Cubists lead drug, Cubicin, by Hospira Inc. A settlement or verdict in the case has been seen coming in December or January and analysts tracking the stock had expected that to have big implications for Cubist shares.Cubist did not respond immediately to a request for comment on the unusual options trading activity.  (Editing by Peter Galloway)",2014-12-08,MRK,"Mon Dec 8, 2014 | 12:54pm EST",Cubist options unusually active before Merck deal,http://www.reuters.com//article/us-cubist-m-a-options-idUSKBN0JM20U20141208?type=companyNews
247,"   By Saqib Iqbal Ahmed | NEW YORK  NEW YORK Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.One series of trades on Thursday appears to have generated at least a 10-fold windfall profit on paper.Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Cubist shares were up 35 percent at $100.70 on Monday.Open interest in Cubist call options, which convey the right to buy the stock at a fixed price in the future, jumped by 25 percent between Dec. 1 and Dec. 5 to 13,864 contracts, according to Trade Alert data. That ranks among the largest increases in open interest over a five-day period this year for Cubist calls.On average, Cubist options are not very actively traded, but trading volume was unusually heavy on Thursday, said Fred Ruffy, options strategist at WhatsTrading.com. Ruffy also noted an increase in Cubist's implied volatility, a gauge of the risk of large moves in a stock and a key component to options pricing. Implied volatility jumped to 51.49 percent on Thursday from 43.15 percent on Wednesday, according to Livevol Inc data.One call strike in particular saw a big increase in activity on Thursday. Around 1,000 Cubist calls at the $85 strike and set to expire on Jan. 17 were bought for between $1.25 to $1.50, according to Livevol Inc data. Ahead of those trades on Thursday afternoon, the January 85 calls had fewer than 300 contracts of open interest, according to Reuters data. By the end of the day that had risen to more than 1,300.Since going on the board in October 2013, the average volume of January 85 calls had been about 14 contracts a day, and their largest daily total before Thursday had been 175 contracts. Thursday's volume was more than 45 standard deviations above the norm.""To expect the stock to move past $85 and be willing to pay over a $1 for it with about a month and a half to go suggests that they were expecting some kind of major catalyst,"" said optionMonster.com lead analyst David Russell. Until Monday, the high for Cubist shares was $82.12, set in February this year.With the stock soaring to a record above $100 on the merger news, the January 85 calls are now quoted at about $16, making for a huge profit on the trades, Russell said.One other possible catalyst for the shares involves a possible resolution of a lawsuit surrounding a generic challenge to Cubist's lead drug, Cubicin, by Hospira Inc. A settlement or verdict in the case has been seen coming in December or January and analysts tracking the stock had expected that to have big implications for Cubist shares.Cubist did not respond immediately to a request for comment on the unusual options trading activity.    (Editing by Peter Galloway)",2014-12-08,MRK,"Mon Dec 8, 2014 | 12:50pm EST",Cubist options unusually active before Merck deal,http://www.reuters.com//article/cubist-ma-options-idUSL1N0TS13K20141208?type=companyNews
248,"  * Merck to buy Cubist Pharma for $102 per share* Japan, China data disappoints* McDonald's falls after November sales* Indexes: Dow off 0.06 pct, S&P 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)By Chuck MikolajczakNEW YORK, Dec 8 U.S. stocks were little changed on Monday, as investors weighed the strength of the U.S. economy against global growth concerns following soft data out of China and Japan, while biotechs rose on merger activity. Major indexes opened slightly lower after data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.But signs of strength in the U.S. economy, including Friday's payrolls report, helped investors shake off weakness in global economies. The S&P 500 closed Friday's session with its 49th record of the year, and is up more than 11 percent from an October low. ""Overall, the U.S. numbers still remain pretty strong, we had very strong numbers on Friday from the employment report, that's probably why you are seeing the strength here,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois.""The other side of it, too, is many of these other countries are taking some efforts to stimulate as well. People are looking at is as temporary, and somewhere down the line as those economies get stronger, everybody will be in pretty good shape.""Biotech shares rallied after Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus the assumption of debt. Merck shares were off 1 cent at$61.48 while Cubist shares surged 35.5 percent to $100.75. The Nasdaq biotech index advanced 2.1 percent. Energy was easily the worst performing S&P sector, down 2.7 percent, as Brent crude fell to a five-year low on predictions oversupply would keep building until next year. The index is down more than 10 percent for the year, making it the only one of the 10 major S&P sectors in negative territory for the year.In response to falling oil prices, ConocoPhillips  said its capital budget for 2015 would drop 20 percent to $13.5 billion. Conoco shares lost 3.1 percent to $65.73.The Dow Jones industrial average fell 11.19 points, or 0.06 percent, to 17,947.6, the S&P 500 lost 1.11 points, or 0.05 percent, to 2,074.26 and the Nasdaq Composite  added 8.03 points, or 0.17 percent, to 4,788.79.McDonald's shares lost 3.2 percent to $93.18 after the fast-food restaurant chain reported a steeper-than-expected fall in global same-restaurant sales in November and said fourth quarter results would be hurt by a supplier scandal in China and a stronger dollar.    (Editing by Bernadette Baum)",2014-12-08,MRK,"Mon Dec 8, 2014 | 11:13am EST","US STOCKS-Wall St flat after Japan, China data; biotechs climb",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0TS13420141208?type=companyNews
249,"  * Merck to buy Cubist Pharma for $102 per share* Japan, China data disappoints* McDonald's falls after November sales* Indexes down: Dow 0.12 pct, S&P 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)By Chuck MikolajczakNEW YORK, Dec 8 U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. Data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.The data put a damper on recent enthusiasm over the U.S. economy, after a strong payrolls report on Friday sent the S&P 500 to its 49th record close of the year. The benchmark S&P index has risen for seven weeks, its longest stretch in nearly a year, and is up more than 11 percent from an October low. ""Considering the economic news that came from abroad the markets are really not under severe pressure,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.""While the weakness in the global economy is quite noticeable, in general what we are seeing here is a slower pace of increments as we close out the year. Investors are taking a slightly less aggressive attitude as we approach year-end.""Energy was by far the worst performing S&P sector, down 1.5 percent, as Brent crude fell to a five-year low on predictions oversupply would keep building until next year. The index is down more than 10 percent for the year, making it the only one of the 10 major S&P sectors in negative territory for the year. In response to the falling oil prices, ConocoPhillips  said its capital budget for 2015 would drop 20 percent to $13.5 billion. Conoco shares lost 1.7 percent to $66.71.The Dow Jones industrial average fell 21.73 points, or 0.12 percent, to 17,937.06, the S&P 500 lost 2.24 points, or 0.11 percent, to 2,073.13 and the Nasdaq Composite  added 5.64 points, or 0.12 percent, to 4,786.40.Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus the assumption of debt. Merck shares were slipped 0.3 percent to $61.28 while Cubist shares surged 35.5 percent to $100.79.McDonald's shares lost 3.2 percent to $93.23 as the biggest drag on the Dow Industrials after the fast-food restaurant chain reported a steeper-than-expected fall in global same-restaurant sales in November and said fourth quarter results would be hurt by a supplier scandal in China and a stronger dollar.    (Editing by Bernadette Baum)",2014-12-08,MRK,"Mon Dec 8, 2014 | 9:54am EST","US STOCKS-Wall St slips after Japan, China data; energy drags",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0TS0WJ20141208?type=companyNews
250,"  * Merck to buy Cubist Pharma for $102 per share* Japan, China data disappoints* McDonald's falls after November sales* Futures down: Dow 58 pts, S&P 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)By Chuck MikolajczakNEW YORK, Dec 8 U.S. stocks were poised for a lower open on Monday, putting the S&P 500 on track to pull back from its latest record high, as soft data in China and Japan kindled global growth concerns. Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.The data put a damper on recent enthusiasm over the U.S. economy, after a strong payrolls report on Friday sent the S&P 500 to its 49th record close of the year. The benchmark S&P index has risen for seven weeks, its longest stretch in nearly a year, and is up more than 11 percent from an October low. ""Considering the economic news that came from abroad the markets are really not under severe pressure,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.""While the weakness in the global economy is quite noticeable, in general what we are seeing here is a slower pace of increments as we close out the year. Investors are taking a slightly less aggressive attitude as we approach year-end.""S&P 500 e-mini futures down 7 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a lower open. Dow Jones industrial average e-mini futures fell 58 points and Nasdaq 100 e-mini futures  lost 15.25 points. Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus the assumption of debt. Merck shares were flat at $61.49 in premarket trading while Cubist shares surged 35.9 percent to $101.07.McDonald's shares lost 3 percent to $93.39 before the opening bell after the fast-food restaurant chain reported a steeper-than-expected fall in global same-restaurant sales in November and said fourth quarter results would be hurt by a supplier scandal in China and a stronger dollar.Energy shares may come under pressure on Monday as Brent crude fell to a five-year low on predictions oversupply would keep building until next year. The S&P energy index  is down 9 percent this year, making it the only one of the 10 major S&P sectors in negative territory for the year. The Select Sector SPDR Energy ETF was off 1.3 percent in premarket trading.(Editing by Bernadette Baum)",2014-12-08,MRK,"Mon Dec 8, 2014 | 9:10am EST","US STOCKS-Wall St to open lower after Japan, China data",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0TS0TA20141208?type=companyNews
251,"  * Merck to buy Cubist Pharma for $102 per share* Japan, China data disappoints* McDonald's falls after November sales* Futures down: Dow 56 pts, S&P 6.75 pts, Nasdaq 12.5 pts   (Adds premarket actives data)By Chuck MikolajczakNEW YORK, Dec 8 U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from its latest record high, as soft data in China and Japan kindled global growth concerns. * Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.* The data put a damper on recent enthusiasm over the U.S. economy, after a strong payrolls report on Friday sent the S&P 500 to its 49th record close of the year. The benchmark S&P index has risen for seven weeks, its longest stretch in nearly a year, and is up more than 11 percent from an October low. * Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion. Merck shares were little changed at $61.50 in premarket trading while Cubist shares surged 36 percent to $101.10. Premarket volume of over 700,000 shares placed Cubist at the top of the most active list for Nasdaq-listed stocks before the opening bell and had already exceeded its 50-day average.* McDonald's shares lost 2.4 percent to $94 before the opening bell after the fast-food restaurant chain said global comparable sales fell 2.2 percent in November.* Energy shares may come under pressure on Monday as Brent crude fell to a new five-year low on predictions that oversupply would keep building until next year. The S&P energy index is down over 9 percent for the year, making it the only one of the 10 major S&P sectors in negative territory for the year. Futures snapshot at 8:06 a.m. EST (1306 GMT):* S&P 500 e-minis were down 6.75 points, or 0.33 percent, with 102,323 contracts changing hands.* Nasdaq 100 e-minis were down 12.5 points, or 0.29 percent, in volume of 20,143 contracts.* Dow e-minis were down 56 points, or 0.31 percent, with 16,440 contracts changing hands.   (Editing by Bernadette Baum)",2014-12-08,MRK,"Mon Dec 8, 2014 | 8:16am EST","US STOCKS-Futures lower after China, Japan data disappoints",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0TS0LR20141208?type=companyNews
252,"   By Ransdell Pierson  In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.Merck announced on Monday an agreement to buy Cubist for $8.4 billion, with a focus on Cubist's drugs that address the growing threat of bacteria that are resistant to conventional antibiotics. [ID:nL3N0TS3VA] As many as 14,000 Americans die each year from C. difficile infections, which are spread by spores in hospitals. They take root in patients who have been treated with broad-spectrum antibiotics that kill off ""friendly"" bacteria in the gut, allowing C. difficile bacteria to multiply. C. difficile can cause colitis, including attacks of diarrhea and fever that can recur and are not well controlled by current treatments.Merck's experimental drug, called MK-3415A, combines two antibodies that chew up deadly toxins produced by C. difficile. New data on its effectiveness is expected from two late-stage clinical trials in 2015.  If the data is favorable, Merck could seek approval of the drug - the first antibody treatment for bacterial toxins - by early 2016.""This is a blockbuster market opportunity for Merck,"" said Kevin Kedra, an analyst for Gabelli & Co. Cubist's expertise in turning its biggest product, the antibiotic Cubicin, into a $1 billion-a-year franchise could bode well for Merck. ""Cubist is a company that built itself into an antibiotic power when bigger companies were getting out the business,"" Kedra said.Adam Schechter, head of global human health at Merck, said Cubist's sales force would strengthen Merck's relationships with insurers, gastroentrologists, infectious disease doctors, hospitals and outpatient centers.Cubist has the best-selling treatment for the condition, Dificid, but up to 15 percent of patients have relapses, sending many of them back to the hospital for retreatment. It also faces competition from far cheaper generics, including vancomycin. If Merck's treatment is approved, it is more likely to face competition down the road from products containing human fecal matter. The ""fecal transplants,"" which reintroduce healthy bacteria into the gastrointestinal tract, have proven extremely effective. But it could take years for a commercial version to be approved.""Merck couldn't have a better infrastructure than Cubist to launch its drug,"" said Ori Hershkowitz, a Tel Aviv-based partner for Sphera Funds. ""They know how to negotiate the healthcare system."" (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-12-09,MRK,"Tue Dec 9, 2014 | 6:54pm EST",Cubist sales force seen as potential boon for Merck intestinal drug,http://www.reuters.com//article/us-merck-antibiotics-idUSKBN0JN2NY20141209?type=companyNews
253,"   By Ransdell Pierson  Dec 9 In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co  will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.Merck announced on Monday an agreement to buy Cubist for $8.4 billion, with a focus on Cubist's drugs that address the growing threat of bacteria that are resistant to conventional antibiotics.As many as 14,000 Americans die each year from C. difficile infections, which are spread by spores in hospitals. They take root in patients who have been treated with broad-spectrum antibiotics that kill off ""friendly"" bacteria in the gut, allowing C. difficile bacteria to multiply.C. difficile can cause colitis, including attacks of diarrhea and fever that can recur and are not well controlled by current treatments. Merck's experimental drug, called MK-3415A, combines two antibodies that chew up deadly toxins produced by C. difficile. New data on its effectiveness is expected from two late-stage clinical trials in 2015.If the data is favorable, Merck could seek approval of the drug - the first antibody treatment for bacterial toxins - by early 2016. ""This is a blockbuster market opportunity for Merck,"" said Kevin Kedra, an analyst for Gabelli & Co. Cubist's expertise in turning its biggest product, the antibiotic Cubicin, into a $1 billion-a-year franchise could bode well for Merck.""Cubist is a company that built itself into an antibiotic power when bigger companies were getting out the business,"" Kedra said. Adam Schechter, head of global human health at Merck, said Cubist's sales force would strengthen Merck's relationships with insurers, gastroentrologists, infectious disease doctors, hospitals and outpatient centers.Cubist has the best-selling treatment for the condition, Dificid, but up to 15 percent of patients have relapses, sending many of them back to the hospital for retreatment. It also faces competition from far cheaper generics, including vancomycin.If Merck's treatment is approved, it is more likely to face competition down the road from products containing human fecal matter. The ""fecal transplants,"" which reintroduce healthy bacteria into the gastrointestinal tract, have proven extremely effective. But it could take years for a commercial version to be approved.""Merck couldn't have a better infrastructure than Cubist to launch its drug,"" said Ori Hershkowitz, a Tel Aviv-based partner for Sphera Funds. ""They know how to negotiate the healthcare system.""          (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-12-09,MRK,"Tue Dec 9, 2014 | 6:52pm EST",Cubist sales force seen as potential boon for Merck intestinal drug,http://www.reuters.com//article/merck-antibiotics-idUSL1N0TT2FU20141209?type=companyNews
254,"   By Ransdell Pierson  Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.Merck shares fell 3.7 percent to $59.55 in early trading.   Cubist slid nearly 3 percent to $97.60.Late Friday, Merck said it planned to buy Cubist, whose flagship product is the widely used antibiotic Cubicin for skin infections. The deal would give Merck, the No. 2 U.S. drugmaker, entry into the market for drugs that fight so-called superbugs. U.S. District Judge Gregory Sleet in Delaware invalidated four Cubicin patents on Monday and ruled that Hospira Inc  can launch a generic version of Cubicin as soon as 2016, two years sooner than Wall Street expected. Merck, in a release on Tuesday, said it still expects to complete its purchase of Cubist in the first quarter of 2015, and noted that Sleet's decision ""is subject to appeal.""""The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1 billion of revenue to its 2015 base, with strong growth potential thereafter,"" Merck said. Leerink Partners analyst Seamus Fernandez said late Monday he expected several less expensive generic forms of Cubicin to be introduced in the United States by late 2016, given Sleet's ruling.Fernandez said lost Cubicin sales from the generics suggested the price Merck will pay for Cubist ""looks $2 billion to $3 billion high ... This is a very tough start to a relatively sound strategic deal.""",2014-12-09,MRK,"Tue Dec 9, 2014 | 6:18pm EST","Merck says still plans to buy Cubist, despite patent setback",http://www.reuters.com//article/cubist-pharm-ma-merck-co-idUSL1N0TT0TD20141209?type=companyNews
255,"  (Adds Breakingviews link)Dec 9 Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.Merck shares fell 3.7 percent to $59.55 in early trading.   Cubist slid nearly 3 percent to $97.60.Late Friday, Merck said it planned to buy Cubist, whose flagship product is the widely used antibiotic Cubicin for skin infections. The deal would give Merck, the No. 2 U.S. drugmaker, entry into the market for drugs that fight so-called superbugs. U.S. District Judge Gregory Sleet in Delaware invalidated four Cubicin patents on Monday and ruled that Hospira Inc  can launch a generic version of Cubicin as soon as 2016, two years sooner than Wall Street expected. Merck, in a release on Tuesday, said it still expects to complete its purchase of Cubist in the first quarter of 2015, and noted that Sleet's decision ""is subject to appeal.""""The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1 billion of revenue to its 2015 base, with strong growth potential thereafter,"" Merck said. Leerink Partners analyst Seamus Fernandez said late Monday he expected several less expensive generic forms of Cubicin to be introduced in the United States by late 2016, given Sleet's ruling.Fernandez said lost Cubicin sales from the generics suggested the price Merck will pay for Cubist ""looks $2 billion to $3 billion high ... This is a very tough start to a relatively sound strategic deal.""   (Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)",2014-12-09,MRK,"Tue Dec 9, 2014 | 6:13pm EST","UPDATE 2-Merck says still plans to buy Cubist, despite patent setback",http://www.reuters.com//article/cubist-pharm-ma-merck-co-idUSL1N0TT0TF20141209?type=companyNews
256,"  (Adds Merck, AAR Corp, Entergy, Santander, Spirit Aerosystems)Dec 9 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:** Merck & Co Inc said on Tuesday it will proceed with its planned $8.4 billion purchase of Cubist Pharmaceuticals Inc and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist's top-selling product.** U.S. aviation support company AAR Corp has put German cargo handling firm Telair up for sale, in a deal that could value Telair at up to 800 million euros ($988 million), three sources familiar with the matter said on Tuesday.** Entergy Corp said it would buy a natural gas-fired power generation station in Arkansas for about $948 million as it looks to meet increased demand and continues to modernize its fleet of utilities.**  Spain's Santander is considering buying out the 28 percent of its U.S. auto finance business that is currently listed on the stock market, Bloomberg reported on Tuesday, citing people with knowledge of the matter.** Canadian oil producer Talisman Energy Inc said it had been approached by a number of parties, including Spain's Repsol SA, for various transactions. ** Brazil's Vale SA  said it sold a stake in its Mozambique coal mine to Japanese trader Mitsui & Co Ltd  for $763 million, as it looks to shore up its balance sheet during a period of lower commodity prices.** Heavily indebted Indonesian state-owned carrier PT Merpati Nusantara Airlines is exploring restructuring options including a debt-to-equity swap and finding strategic investors, its chief executive told Reuters.** Britain's Land Securities Group Plc has sold Scottish real estate worth 224.1 million pounds ($350.9 million) to HSBC Holdings Plc as it focuses on larger commercial property assets in and around London. ** Sumitomo Mitsui Financial Group Inc will announce as soon as next week that it will buy Citigroup Inc's  Japanese consumer banking business, Bloomberg reported, citing people with knowledge of the matter.** Dutch pharmaceuticals wholesaler Brocacef said that it was taking over businesses of Mediq, a medical supplies and equipment provider, to create a company with combined sales of 2.1 billion euros ($2.59 billion).** Aircraft fuselage maker Spirit AeroSystems Holdings Inc  said it would pay aero parts supplier Triumph Group Inc  $160 million to take its business that makes wings for two Gulfstream jets. ** Media group Vivendi SA is interested in buying the French magazine titles belonging to Roularta Media Group NV  including the news weekly L'Express, said Chairman Vincent Bollore.** Private equity firm Carlyle Group LP said it bought a majority stake in India's Newgen KnowledgeWorks, a provider of publishing and technical services, for $32.8 million.** Airbus Group NV has agreed to sell its minority stake in Finnish defense company Patria as it presses ahead with efforts to streamline its defense and space activities.** India's Reliance Industries Ltd said it would transfer its textile business into a new joint venture with China's Shandong Ruyi Science and Technology Group Co Ltd (Ruyi).** Italy will sell a first stake of its state rail operator Ferrovie dello Stato in 2016, the company's Chief Executive Michele Elia said.** Indonesian state-owned pharmaceutical firm PT Kimia Farma Tbk said it might merge with peer PT Indofarma Tbk  as part of a government consolidation plan for the sector.($1 = 0.64 British pounds)  ($1 = 0.81 euros)   (Compiled by Anet Josline Pinto in Bengaluru)",2014-12-09,MRK,"Tue Dec 9, 2014 | 4:03pm EST",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0TT3BF20141209?type=companyNews
257,"   By Robert Cyran | NEW YORK  NEW YORK (Reuters Breakingviews) - The M&A frenzy appears to have influenced Merck's risk assessment. Just hours after unveiling its $8.4 billion acquisition of Cubist Pharmaceuticals on Monday, a judge invalidated patents owned by the antibiotics maker. Potential lost sales are reflected in the billions erased from Merck's market value.Cubist's biggest drug is Cubicin, which currently accounts for nearly all the company's estimated $1.2 billion in annual sales. The ruling by a Delaware court means Cubist could face generic competition in the United States as soon as the middle of 2016, instead of waiting until 2020.The healthy 37 percent premium Merck paid for Cubist, and the limited wiggle room it left itself to pull out of the deal, suggests it was undeterred by the outstanding legal danger. There are other known unknowns, too. For one, Cubist will soon go before the U.S. Food and Drug Administration to seek approval of a new antibiotic, which could be a blockbuster. Waiting for confirmation might have increased the takeover tab or left the door open for an interloping suitor. Assuming regulators sign off, though, Merck's experienced presence might smooth the launch. Even so, there is probably a higher cost for its aggression. Cubist is worth less today than it was yesterday. Merck argues the deal still creates value. Investors took a less charitable view, wiping more than $8 billion, or almost the entire purchase price, from Merck's market capitalization. It is probably an overreaction. Absent a successful appeal of the legal ruling, based on existing sales, the foregone Cubicin revenue should add up to no more than $3 billion in a worst-case scenario.Other buyers may want to pay heed to Merck's misstep. There already have been more than $3 trillion of deals announced globally this year, an increase of some 50 percent from a year ago, according to Thomson Reuters. Healthcare has been a leading sector, with more than twice as much activity this year than last. That makes it that much easier for buyers to get caught up in the excitement and look at potential merger liabilities though a rose-colored prism. CONTEXT NEWS  -  A Delaware judge on Dec. 8 invalidated several patents protecting Cubist Pharmaceuticals' Cubicin, allowing rival Hospira to sell the drug as soon as 2016. The patents would have provided market exclusivity until 2020.- Earlier the same day, Merck said it would buy Cubist for $8.4 billion. Following the patent ruling, Merck said it would stand by its agreement. Cubist said it would appeal the court's decision.- Merck shares fell 4.4 percent in morning trading on Dec. 9 and Cubist's were down 3.7 percent.     (The author is a Reuters Breakingviews columnist. The opinions expressed are his own.)",2014-12-09,MRK,"Tue Dec 9, 2014 | 1:07pm EST",Breakingviews: Merck gives in to M&A frenzy risk assessment,http://www.reuters.com//article/cubist-pharm-ma-merck-co-breakingviews-idUSL1N0TT1OQ20141209?type=companyNews
258,"  (Repeating story first published late on Tuesday)By Ransdell PiersonDec 9 In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co  will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.Merck announced on Monday an agreement to buy Cubist for $8.4 billion, with a focus on Cubist's drugs that address the growing threat of bacteria that are resistant to conventional antibiotics.As many as 14,000 Americans die each year from C. difficile infections, which are spread by spores in hospitals. They take root in patients who have been treated with broad-spectrum antibiotics that kill off ""friendly"" bacteria in the gut, allowing C. difficile bacteria to multiply. C. difficile can cause colitis, including attacks of diarrhea and fever that can recur and are not well controlled by current treatments.Merck's experimental drug, called MK-3415A, combines two antibodies that chew up deadly toxins produced by C. difficile. New data on its effectiveness is expected from two late-stage clinical trials in 2015.If the data is favorable, Merck could seek approval of the drug - the first antibody treatment for bacterial toxins - by early 2016. ""This is a blockbuster market opportunity for Merck,"" said Kevin Kedra, an analyst for Gabelli & Co. Cubist's expertise in turning its biggest product, the antibiotic Cubicin, into a $1 billion-a-year franchise could bode well for Merck.""Cubist is a company that built itself into an antibiotic power when bigger companies were getting out the business,"" Kedra said. Adam Schechter, head of global human health at Merck, said Cubist's sales force would strengthen Merck's relationships with insurers, gastroentrologists, infectious disease doctors, hospitals and outpatient centers.Cubist has the best-selling treatment for the condition, Dificid, but up to 15 percent of patients have relapses, sending many of them back to the hospital for retreatment. It also faces competition from far cheaper generics, including vancomycin.If Merck's treatment is approved, it is more likely to face competition down the road from products containing human fecal matter. The ""fecal transplants,"" which reintroduce healthy bacteria into the gastrointestinal tract, have proven extremely effective. But it could take years for a commercial version to be approved.""Merck couldn't have a better infrastructure than Cubist to launch its drug,"" said Ori Hershkowitz, a Tel Aviv-based partner for Sphera Funds. ""They know how to negotiate the healthcare system.""          (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2014-12-10,MRK,"Wed Dec 10, 2014 | 8:50am EST",RPT-Cubist sales force seen as potential boon for Merck intestinal drug,http://www.reuters.com//article/merck-antibiotics-idUSL1N0TU0UU20141210?type=companyNews
259,"  * Merck-NewLink trial in Geneva halted after joint pains* Lausanne says safety data ""satisfactory"" in GSK vaccine trial   (Adds statement on GSK Ebola vaccine, new paras 4-7)By Stephanie NebehayGENEVA, Dec 11 A clinical trial of an Ebola vaccine developed by Merck and NewLink has been halted temporarily as a precautionary measure after four patients complained of joint pains, the University of Geneva Hospital said on Thursday.""They are all fine and being monitored regularly by the medical team leading the study,"" it said in a statement.The trials will resume on Jan. 5, on up to 15 volunteers, after checks to ensure that the joint pain symptoms in hands and feet were ""benign and temporary"", the hospital said.Fifty nine volunteers have been vaccinated so far in the human safety trials in Geneva, which began on Nov. 10. Scientists are racing to develop Ebola vaccines after the world's worst outbreak of the virus has killed more than 6,000 people in West Africa so far this year.Separately, safety data from a trial of a GlaxoSmithKline  Ebola vaccine on 120 volunteers is ""satisfactory"", the University of Lausanne Hospital said on Thursday.The first results of the Lausanne hospital's trial of the GSK vaccine and whether it provides immunity against the virus are expected by the end of December, the university said in a statement. ""The safety data looked satisfactory so far,"" said Professor Blaise Genton, who is leading the GSK trial in Lausanne. ""General symptoms such as fever might be slightly more frequent, though no serious adverse event has been observed so far.""Scientists reported on Nov. 26 in the New England Journal of Medicine that another version of the experimental GSK vaccine caused no serious side effects and produced an immune response in all 20 healthy volunteers who received it in an early-stage trial.The Geneva researchers reported on Dec. 2 that the first people vaccinated with the Merck-NewLink shot had seen no serious side effects, but a few had mild fever. On Thursday, the team said that four patients had reported joint pains in the second week that had lasted a few days. Before it was suspended, this first phase of the trial had been due to continue for another week.""The Geneva team has decided to allow time to understand what is happening. This precaution of momentarily suspending the trial is usual and classic in all clinical trials,"" the team said.It was in close contact with researchers in the United States, Germany, Canada and Gabon who are carrying out the same trial on the Merck-NewLink vaccine, it said. ""These centres have not observed symptoms of inflammation in their volunteers to date.""Marie-Paule Kieny, vaccine expert at the World Health Organisation, said that the delay to the Merck-NewLink trial would allow time to see how widespread the problems are, but the trial should then be able to continue as originally planned.""It's not a setback, not at all,"" Kieny told a briefing.GAVI, the global vaccines alliance, pledged $300 million on Thursday to buy Ebola vaccines.    (Additional reporting by Tom Miles; Editing by Susan Fenton)",2014-12-11,MRK,"Thu Dec 11, 2014 | 11:33am EST",UPDATE 2-Ebola vaccine trial halted temporarily after joint pains -Geneva hospital,http://www.reuters.com//article/health-ebola-vaccine-idUSL6N0TV2SI20141211?type=companyNews
260,"  * NewLink/Merck vaccine trial paused due to joint pains* GAVI pledges up to $300 mln for 12 mln vaccine courses* Further funding of up to $90 mln to help vaccine roll-out   (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment)By Ben Hirschler and Stephanie NebehayLONDON/GENEVA, Dec 11 GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains.Scientists are racing to develop Ebola vaccines in record time but many questions remain unanswered, as evidenced by a decision to pause Swiss tests of the experimental vaccine from NewLink and Merck.GAVI, which is funded by governments and the Bill & Melinda Gates Foundation, said it was ready to begin procurement as soon as the World Health Organization (WHO) recommended a vaccine for use.The world's worst Ebola outbreak has killed more than 6,000 people in West Africa and experts believe millions of doses of vaccine may be needed both to help end the current epidemic and to contain future outbreaks. Officials involved in the Swiss study said the volunteers who had received the NewLink shot were all fine and the WHO played down the problem, pointing out that temporary suspensions were not uncommon in clinical trials.Researchers hope safe and effective vaccines will get a green light as soon as next year, although there is still uncertainty over how well they will work and how many doses are needed.Paying for vaccines is a challenge because the worst affected countries of Sierra Leone, Liberia and Guinea are some of the world's poorest, providing little commercial incentive for manufacturers. STOCKPILES The money now earmarked by Geneva-based GAVI will help bridge the gap and is expected to be enough to procure up to 12 million courses of vaccine. WHO vaccine expert Marie-Paule Kieny said the commitment was ""fantastic"".In addition to helping in the current epidemic, the money could also be used to create stockpiles of Ebola vaccines, similar to those that exist for yellow fever, meningitis and cholera. A further amount of up to $90 million will be made available from GAVI's coffers to help affected countries introduce the vaccines and to rebuild their health systems.GAVI, which was set up in 2000 with private and government donor backing, has a track record of bulk-buying vaccine supplies from manufacturers at a low price for the developing world. Since 2000, around 440 million children have been immunised against a range of diseases through its programmes.GAVI said its board had decided to prepare for procuring Ebola vaccines while still awaiting a green light for the first product, ""in light of the seriousness of the situation and the risks associated with delays in making a vaccine available"".Two vaccines, one from NewLink and Merck and a rival shot from GlaxoSmithKline, are already undergoing human trials and third one, made by Johnson & Johnson, is about to enter clinical testing.""We've had individual discussions with all of the manufacturers and continue to work closely with them,"" GAVI's chief executive, Seth Berkley, told Reuters.GAVI said it would meet the funding needs of the Ebola vaccine programme using a combination of existing and new financing. It also plans to join forces with other initiatives that have already pledged funding to address the Ebola crisis.(Reporting by Ben Hirschler; Editing by Pravin Char and Greg Mahlich)",2014-12-11,MRK,"Thu Dec 11, 2014 | 10:29am EST",UPDATE 2-$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag,http://www.reuters.com//article/health-ebola-vaccine-gavi-idUSL6N0TV24K20141211?type=companyNews
261,"  * Debate over ""prime-boost"" vaccination as epidemic evolves* Two shots offer more protection but cumbersome to deliver* Disease slowdown may weaken clinical trial results* GSK, J&J/Bavarian and Merck/NewLink vaccines studiedBy Ben Hirschler and Kate KellandLONDON, Dec 11 Scientists racing to develop vaccines against Ebola are trying to determine whether they can best fight the disease with a single injection or with two, a calculation that could determine how quickly and effectively a programme can be rolled out.Administering two vaccines, one after the other, would almost certainly give far greater protection than a single shot against a deadly virus that has killed more than 6,000 people in West Africa this year.But it would also make mass immunisations far more complicated in the worst-affected countries of Guinea, Liberia and Sierra Leone, where weak health systems have all but collapsed under the weight of the epidemic.With the epidemic growing exponentially through much of 2014, the initial focus was on developing a single shot that could be tested and deployed as fast as possible.Now, however, with disease transmission rates tailing off markedly in Liberia, there is more debate about a double vaccine programme that would provide greater protection, even if it might take longer and be harder to implement. ""There is now more and more talk about what can we do to prolong vaccine protection,"" said Ripley Ballou, head of Ebola research at GlaxoSmithKline, which has one of the leading vaccine candidates.He still hopes a single-dose vaccine will be of use in the current outbreak, but also sees a need to evaluate the ""prime-boost"" approach of giving a first shot to stimulate the immune system, followed by a second booster a few weeks later.Health officials in London and Washington, as well as non-profit groups like the Wellcome Trust that are also helping fund clinical trials, are liaising closely on the best way forward.""We're trying to decide where it is best to put the money,"" said one senior government adviser. A big Liberia trial, involving up to 30,000 participants, will test single shots of GSK's vaccine, a rival one from NewLink and Merck, and a placebo.Although the Ebola slowdown in Liberia is clearly good news, it means the trial may not see enough new cases of disease to demonstrate the benefit of vaccination.PRODUCTION CAPACITY Other studies are starting to analyse the prime-boost approach. Johnson & Johnson expects to start testing its experimental shot with a booster developed by Denmark's Bavarian Nordic ""very soon"" and its chief scientific officer, Paul Stoffels, is convinced this is the right strategy. ""It is cumbersome, because you need two vaccines, but it is clear that you will get the best protection, both short and long term, from a prime-boost,"" he said.A prime-boost vaccine will be more difficult to make in large quantities, since the booster component from Bavarian needs to be grown in chicken eggs, limiting supply. But past experience suggests it should pack more punch.Tests of similar two-pronged vaccines in other diseases suggest the booster component can increase immune responses around 30-fold for the production of antibodies and up to 10-fold for the body's own disease-fighting T-cells - two of the key elements of the ability to fight off infection - said Adrian Hill, a vaccine expert at Oxford University's Jenner Institute.That extra protection may be needed in West Africa, where infection with malaria could also depress people's immune systems, limiting the effectiveness of immunisation.In the end, the wide programme of vaccine trials scheduled for the first half of 2015 may yield a variety of options, with some experts suggesting prime-boost may be particularly suited for healthcare workers facing regular high exposure and single shots the preferred choice for rapid containment of local cases.So far, the only human data on how well Ebola vaccines might work comes from the United States and Europe, with GSK's shot proving safe and showing some efficacy, although not comprehensive protection. NewLink's experimental shot had no serious side effects but caused some mild fever.With the epidemic still raging, tests are likely to try out combinations of vaccines in an opportunistic way. While their impact may not become clear until later next year, the lessons learned will still be valuable in responding to the next, inevitable, Ebola outbreak.""This disease is going to be endemic in West Africa,"" said GSK's Ballou. ""It's important for those countries either to have routine vaccination or a stockpile option.""   (Editing by Peter Graff)",2014-12-11,MRK,"Thu Dec 11, 2014 | 2:00am EST",One shot or two? Many questions unresolved in Ebola vaccine race,http://www.reuters.com//article/health-ebola-vaccine-idUSL6N0TU2OE20141211?type=companyNews
262,"  (Corrects paragraph 4 to say Merck Ltd is a unit of Merck KGaA, not Merck & Co Inc)MUMBAI Dec 12 India has capped the prices of 52 more drugs, including painkillers and antibiotics, the pricing authority said in a notice.The additional drugs join a list of nearly 400 essential medicines that have so far been placed under price control in India, where a majority of the people live on under $2 a day and health insurance is scarce. The new drugs to come under price control include commonly-used antibiotics and painkillers as well as medicines used for treating cancer and skin disorders, a notice on the National Pharmaceutical Pricing Authority website said. Companies including Lupin Ltd, Cadila Healthcare Ltd and Merck Ltd - the Indian arm of German firm Merck KGaA - are among those selling drugs mentioned in the latest notice, the authority said. Cadila and Lupin, did not immediately respond to a request for comment. Merck's India unit was not immediately reachable.   (Reporting by Zeba Siddiqui; Editing by Anupama Dwivedi)",2014-12-12,MRK,"Fri Dec 12, 2014 | 5:29am EST","CORRECTED-India caps prices of 52 more ""essential"" drugs - pricing authority",http://www.reuters.com//article/india-pharmaceuticals-prices-idUSL3N0TW2NL20141212?type=companyNews
263,"   By Karen Schwartz | NEW YORK  NEW YORK Dec 15 Merck & Co Inc is approaching banks about an $8 billion, 364-day bridge loan that will back the drugmaker's plans to acquire Cubist Pharmaceuticals Inc, sources told Thomson Reuters LPC.JP Morgan and Deutsche Bank are leading the deal.The loan has a drawn cost of LIB+75 if Merck keeps its current rating of AA/A2, sources said. Further details were not available by press time. Merck announced December 8 that it would buy Cubist for $9.5 billion. The transaction will include $1.1 billion of net debt.The Cubist purchase will give Merck access to antibiotic Cubicin, Reuters said. Cubist also has a drug in development for complicated urinary tract infections. The deal signals that large pharmaceutical companies are turning their attention back to antibiotics after decades of low investment, according to Reuters.The Cubist acquisition is Merck's second-largest acquisition this year. The company bought Idenix Pharmaceuticals for $3.85 billion in June.    (Editing By Michelle Sierra and Jon Methven)",2014-12-15,MRK,"Mon Dec 15, 2014 | 4:24pm EST",TRLPC: Merck looks for $8B bridge for Cubist acquisition,http://www.reuters.com//article/merck-bridge-idUSL1N0TZ29F20141215?type=companyNews
264,"   By Amrutha Penumudi  Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck & Co Inc's ertapenem in a late-stage study.Tetraphase shares rose 17.5 percent in after-hours trading.The drug, eravacycline, treats infections caused by gram-negative bacteria, a class of antibiotic-resistant pathogens commonly called superbugs. Tetraphase is also testing the drug against Johnson & Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are expected in mid-2015.The company said it is likely to apply for U.S. regulatory approval for eravacycline by end of next year.If approved, the drug will compete with a slew of new superbug-fighting antibiotics, including Cubist Pharmaceuticals Inc's Zerbaxa, widely expected to get U.S. approval later this month. Actavis Plc and AstraZeneca Plc are also co-developing a drug.  However, analysts believe that there is space for more than one player in the market.""The thing about these drugs is that its not a ""one-size-fits-all"" situation,"" Gabelli & Co analyst Kevin Kedra said. ""Some drugs work better than others against certain bacteria.""Kedra said Tetraphase's drug had more convenient dosing than others, given that it needs to be taken twice a day compared with the three-times-a-day dosing for Cubist's drug. Analysts, including Kedra and WBB Securities' Stephen Brozak, expect eravacycline to eventually rake in $1 billion in sales.After decades of low investment in antibiotics, pharmaceutical companies are turning their attention back to this drug family due to the spread of superbugs.The World Health Organization warned in April of ""a post-antibiotic era"" in which common infections would once again become killers. Merck's offer to buy Cubist for $8.4 billion earlier this month ""is good for the (antibiotic) space in general"", Tetraphase CEO Guy MacDonald said, on a conference call.MacDonald said Tetraphase was looking to commercialize eravacycline on its own in the United States and would look for partners abroad.Tetraphase shares rose 17.5 percent to $38.99 in after-hours trading. They closed up 10.6 percent in regular trade on Wednesday on the Nasdaq, after touching a record high of $33.22 in the session. (Editing by Savio D'Souza)",2014-12-17,MRK,"Wed Dec 17, 2014 | 6:45pm EST","Tetraphase's antibiotic succeeds late-stage trial, shares rise",http://www.reuters.com//article/us-tetraphase-study-idUSKBN0JV2RJ20141217?type=companyNews
265,"  * Drug as effective as Merck's ertapenem in trial* Company says will commercialize drug alone in U.S.* Potential blockbuster say analysts* Shares rise 17.5 pct in extended trading   (Adds details from conference call, analyst quotes)By Amrutha PenumudiDec 17 Tetraphase Pharmaceuticals Inc  said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck & Co Inc's  ertapenem in a late-stage study.Tetraphase shares rose 17.5 percent in after-hours trading. The drug, eravacycline, treats infections caused by gram-negative bacteria, a class of antibiotic-resistant pathogens commonly called superbugs.Tetraphase is also testing the drug against Johnson & Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are expected in mid-2015.The company said it is likely to apply for U.S. regulatory approval for eravacycline by end of next year.If approved, the drug will compete with a slew of new superbug-fighting antibiotics, including Cubist Pharmaceuticals Inc's Zerbaxa, widely expected to get U.S. approval later this month. Actavis Plc and AstraZeneca Plc  are also co-developing a drug. However, analysts believe that there is space for more than one player in the market.""The thing about these drugs is that its not a ""one-size-fits-all"" situation,"" Gabelli & Co analyst Kevin Kedra said. ""Some drugs work better than others against certain bacteria.""Kedra said Tetraphase's drug had more convenient dosing than others, given that it needs to be taken twice a day compared with the three-times-a-day dosing for Cubist's drug. Analysts, including Kedra and WBB Securities' Stephen Brozak, expect eravacycline to eventually rake in $1 billion in sales.After decades of low investment in antibiotics, pharmaceutical companies are turning their attention back to this drug family due to the spread of superbugs.The World Health Organization warned in April of ""a post-antibiotic era"" in which common infections would once again become killers.Merck's offer to buy Cubist for $8.4 billion earlier this month ""is good for the (antibiotic) space in general"", Tetraphase CEO Guy MacDonald said, on a conference call.MacDonald said Tetraphase was looking to commercialize eravacycline on its own in the United States and would look for partners abroad.Tetraphase shares rose 17.5 percent to $38.99 in after-hours trading. They closed up 10.6 percent in regular trade on Wednesday on the Nasdaq, after touching a record high of $33.22 in the session.   (Editing by Savio D'Souza)",2014-12-17,MRK,"Wed Dec 17, 2014 | 6:37pm EST","UPDATE 2-Tetraphase's antibiotic succeeds late-stage trial, shares rise",http://www.reuters.com//article/tetraphase-study-idUSL3N0U15GH20141217?type=companyNews
266,"  Dec 17 Tetraphase Pharmaceuticals Inc  said its antibiotic drug to treat complicated intra-abdominal infections was as effective as Merck & co Inc's  ertapenem in a late-stage study.The drug, eravacycline, treats infections caused by gram-negative bacteria, a type of antibiotic-resistant pathogens, often called superbugs.  Tetraphase shares were up 14.5 percent at $38 in after-hours trading. They closed up 10.6 percent in regular trade on Wednesday, after touching a record high of $33.22 earlier in the session.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio D'Souza) ",2014-12-17,MRK,"Wed Dec 17, 2014 | 4:19pm EST",Tetraphase's antibiotic succeeds in late-stage trial,http://www.reuters.com//article/tetraphase-study-idUSL3N0U15FV20141217?type=companyNews
267,"  * GSK vaccine cuts risk of shingles by 97.2 pct in over 50s* Potentially strong competitor for Merck's Zostavax* Shares in GSK partner Agenus jump 10 percent   (Adds sales figures for Merck vaccine, forecast for GSK product)By Ben HirschlerLONDON, Dec 18 An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost.The data suggests the British company's new shot could be a strong competitor for Merck & Co's established vaccine Zostavax, which is currently the only product on the market. GSK's vaccine, known as HZ/su, reduced the risk of shingles by 97.2 percent in adults aged 50 years and older compared to placebo in the Phase III clinical trial involving more than 16,000 individuals, the drugmaker said on Thursday.That result looks compelling compared to Zostavax, which has showed 69.8 percent efficacy in patients aged 50 to 59 years, and lower efficacy in older people. However, the design of different clinical trials means direct comparisons are tricky.The two vaccines work in different ways. Zostavax is a so-called live attenuated virus vaccine while HZ/su combines a protein found on the virus that causes shingles with an adjuvant, or booster, which is intended to enhance the immunological response. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Shares in Agenus jumped 10 percent in early U.S. trading on news of the good results.GSK has not said when HZ/su might reach the market and a company spokeswoman said more data would be collected on the experimental shot next year. Additional trials to evaluate the ability of HZ/su to prevent shingles are also underway in people aged 70 and older and in immunocompromised patients. The full set of safety data from the Phase III trial is currently being analysed and will be disclosed in the coming months, the company added.Merck's Zostavax, which was approved by the U.S. Food and Drug Administration in 2006, generated sales of $758 million last year and is still growing strongly, since only a minority of elderly people have so far been vaccinated. Its sales are expected to reach $1.1 billion by 2019, according to consensus forecasts compiled by Thomson Reuters Cortellis.With potential superior efficacy, UBS said in a research note that sales of GSK's vaccine might exceed $1 billion a year.Shingles is caused by the varicella-zoster virus, the same virus that causes chickenpox. After an attack of chickenpox, the virus lies dormant in certain nerve tissue but in older people in can reappear in the form of shingles.   (Editing by Vincent Baby)",2014-12-18,MRK,"Thu Dec 18, 2014 | 11:00am EST",UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data,http://www.reuters.com//article/gsk-shingles-idUSL6N0U23MY20141218?type=companyNews
268,"  (Corrects second paragraph to say ""scholarships funded by Merck, Zoetis, Cargill and others this year."")By Duff Wilson and Mimi DwyerDec 23 The pharmaceutical industry has strong ties to veterinary education across the United States, providing financial support to professors, researchers and students.Zoetis, the world's leading animal drug maker, has given $3.6 million in scholarships over the past five years to more than 1,100 U.S. veterinary students. The American Association of Bovine Practitioners, a beef veterinary group, provided $300,000 in grants and scholarships funded by Merck, Zoetis, Cargill and others this year.A four-year veterinary education costs well over $200,000, and students often leave school with significant debt. But five pharmaceutical companies have donated hundreds of thousands of dollars to help veterinary students pay back loans. One condition: that the students practice food-animal medicine for four years. Some students also are paid to serve as representatives of pharmaceutical companies on their campuses. ""I don't think they're pushing anything that's going to affect how we practice as veterinarians, but it certainly could be viewed that way,"" said Alexander Thomson, the Zoetis student representative at Cornell veterinary college. He declined to say how much he is paid.Leading veterinary professors are also accepting money from the pharmaceutical industry for everything from research to company-scripted promotional speaking. Such speaking arrangements are banned by many university medical faculties, according to Eric Campbell, a Harvard University professor who studies conflicts of interest between medical doctors and drug companies. ""The fact that they're being supported by the companies they're supposed to be overseeing raises issues about the impact of those payments,"" he said.Pamela Ruegg, a professor of dairy science at the University of Wisconsin, was paid to speak by Zoetis, among others. Then, she said, Zoetis stopped inviting her to forums when she voiced concerns that antibiotics were being overused on farms. ""They wouldn't sponsor me as a speaker because they're mad at me,"" Ruegg said. ""My message is we have to reduce the amount of antimicrobial use and use it properly."" Last week, however, Ruegg said a Zoetis representative called her to ask if the company could distribute a YouTube video she made and a paper she wrote advocating more ""watchful waiting"" and less antibiotic usage on dairy farms. ""It's a favorable development,"" she said. Zoetis declined to comment.Mark Papich, a professor of clinical pharmacology at North Carolina State's veterinary college, has received speaking and consulting fees, honoraria, research grants or gifts from nearly every pharmaceutical company, a fact he talks about openly.""It's a matter of survival for us to try and get support from the pharmaceutical companies,"" he said.   (Reporting By Duff Wilson and Mimi Dwyer)",2014-12-23,MRK,"Tue Dec 23, 2014 | 11:16am EST",CORRECTED-Connections between drug makers and educators abound,http://www.reuters.com//article/farmaceutical-vets-education-idUSL1N0U60YH20141223?type=companyNews
269,"  GENEVA The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said. An Ebola outbreak, the worst on record of the highly infectious hemorrhagic fever, has killed over 7,900 people over the past year, with more than 20,000 cases recorded mostly in Guinea, Sierra Leone and Liberia, according to the World Health Organization (WHO). The virus is still spreading in West Africa, especially in Sierra Leone. The Geneva hospital announced on Dec. 11 that its vaccine trial had been suspended as a precautionary measure after four patients complained of joint pains. On Monday, the hospital said 10 of 59 volunteers who received the vaccine had felt pains in their joints ""similar to rheumatism"" after some two weeks, but these symptoms had disappeared rapidly without any treatment.Swissmedic, the Swiss regulatory agency, and ethics and safety committees have approved the resumption of the trial at a lower dose, the hospital said in a statement.  ""The second part of this clinical trial will now test a dose of 300,000 vaccine particles, which should be better tolerated by volunteers and will hopefully trigger the production of enough antibodies,"" it said, noting that the initial phase had 10 million to 50 million vaccine particles.""Fortunately"", it said, the Merck-NewLink candidate vaccine ""seems able to induce the production of antibodies at lower doses than those previously used"" in the Geneva trial.  Vaccinations have now resumed for the last 56 volunteers, who will receive either a low dose of the vaccine or a placebo, by groups of 15 each week through January, it said. Geneva researchers are constantly exchanging information with teams carrying out similar studies in Canada, Gabon, Germany and the United States, the hospital said. Final results are expected in March 2015. A separate trial of a GlaxoSmithKline Ebola vaccine on 120 volunteers has proved ""satisfactory"", the University of Lausanne Hospital said on Dec. 11. (Reporting by Stephanie Nebehay; Editing by Mark Heinrich)",2015-01-05,MRK,"Mon Jan 5, 2015 | 7:58am EST",Merck-NewLink Ebola vaccine trial resumes at lower dose: Geneva hospital,http://www.reuters.com//article/us-health-ebola-vaccine-idUSKBN0KE0XP20150105?type=companyNews
270,"  (Adds market value figure in paragraph 3)By Natalie Grover and Vidya L NathanJan 5 Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial.Investment by Big Pharma in antibiotic research has revived as bacteria grow increasingly resistant to existing drugs, leading Merck & Co to bid for Cubist Pharmaceuticals Inc  and casting other antibiotic drug developers as potential targets.Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday.Up to Friday's close, the company's shares had gained 43 percent since Merck's announcement on Dec .8. At Monday's high, Cempra was valued at about $970 million.Cempra Chief Executive Prabha Fernandes, speaking on a call with analysts, reiterated that the company was not looking for partners. The drug is a next-generation version of a class of oft-prescribed antibiotics called macrolides, which are used to fight pathogens that cause community-acquired bacterial pneumonia (CAPB).CAPB is the leading cause of death from infection and is characterized by shortness of breath, cough and fever. About 5-10 million cases are recorded in the United States annually.An oral formulation of solithromycin was as effective as Bayer AG's moxifloxacin 72 hours after dosing, Cempra said on Sunday. WBB Securities' Steve Brozak raised his price target on the stock to $40 from $25, estimating that solithromycin was worth about $1.4 billion to Cempra.On the call, a company executive said there were no signs of any serious adverse reactions in the solithromycin study.Prior-generation macrolides have triggered safety concerns. Sanofi SA's telithromycin, for example, was associated with liver toxicity, while Pfizer Inc's  azithromycin was linked to heart risk.The unparalleled rate at which the oral version of solithromycin is absorbed in the blood, or its oral bioavailability, differentiates it from standard treatments, Fernandes told Reuters in an interview in November.North Carolina-based Cempra is also evaluating an intravenous formulation of solithromycin for CAPB. Cempra expects to update investors on the study in April 2015, Fernandes said.The drug is also the first pediatric antibiotic-in-development in nearly three decades, she said.Solithromycin is commercially licensed to Fujifilm Holdings Corp in Japan.   (Editing by Simon Jennings and Ted Kerr)",2015-01-05,MRK,"Mon Jan 5, 2015 | 10:51am EST",UPDATE 2-Cempra's lead oral antibiotic meets main goal in late-stage trial,http://www.reuters.com//article/cempra-study-idUSL3N0UK2VV20150105?type=companyNews
271,"  GENEVA Jan 5 The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said.An Ebola outbreak, the worst on record of the highly infectious haemorrhagic fever, has killed over 7,900 people over the past year, with more than 20,000 cases recorded mostly in Guinea, Sierra Leone and Liberia, according to the World Health Organization (WHO). The virus is still spreading in West Africa, especially in Sierra Leone.The Geneva hospital announced on Dec. 11 that its vaccine trial had been suspended as a precautionary measure after four patients complained of joint pains. On Monday, the hospital said 10 of 59 volunteers who received the vaccine had felt pains in their joints ""similar to rheumatism"" after some two weeks, but these symptoms had disappeared rapidly without any treatment.Swissmedic, the Swiss regulatory agency, and ethics and safety committees have approved the resumption of the trial at a lower dose, the hospital said in a statement. ""The second part of this clinical trial will now test a dose of 300,000 vaccine particles, which should be better tolerated by volunteers and will hopefully trigger the production of enough antibodies,"" it said, noting that the initial phase had 10 million to 50 million vaccine particles. ""Fortunately"", it said, the Merck-NewLink candidate vaccine ""seems able to induce the production of antibodies at lower doses than those previously used"" in the Geneva trial.Vaccinations have now resumed for the last 56 volunteers, who will receive either a low dose of the vaccine or a placebo, by groups of 15 each week through January, it said. Geneva researchers are constantly exchanging information with teams carrying out similar studies in Canada, Gabon, Germany and the United States, the hospital said. Final results are expected in March 2015.A separate trial of a GlaxoSmithKline Ebola vaccine on 120 volunteers has proved ""satisfactory"", the University of Lausanne Hospital said on Dec. 11.   (Reporting by Stephanie Nebehay; Editing by Mark Heinrich)",2015-01-05,MRK,"Mon Jan 5, 2015 | 7:53am EST",Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital,http://www.reuters.com//article/health-ebola-vaccine-idUSL6N0UK1JQ20150105?type=companyNews
272,"   By Bill Berkrot  Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.Merck said it would file an application with U.S. regulators in the middle of this year seeking expanded use of its new Keytruda treatment for non-small cell lung cancer, the most common form of the deadly disease. That followed a late Sunday announcement by Bristol-Myers that independent monitors halted a trial of its Opdivo treatment for lung cancer when it became clear the drug extended survival compared with standard chemotherapy.  While the magnitude of the benefit was not yet known, it marked the first time the new class of immunotherapy demonstrated an overall survival benefit in lung cancer.       Some industry analysts expect this class, known as PD-1 or PD-L1 inhibitors, to generate more than $30 billion in worldwide annual sales by 2025, with lung cancer seen as the most lucrative use.Keytruda and Opdivo are already approved to treat advanced melanoma, the most deadly form of skin cancer. They work by blocking a mechanism used by tumors to hide from disease fighting immune system cells. Sanford Bernstein analyst Tim Anderson sees Merck closing a perceived gap with Bristol-Myers in using their drugs for lung cancer.""The review time for Merck's application could be on the order of a few months,"" implying approval in the second half of 2015, nearly a year earlier than Wall Street had expected, Anderson said in a note.As a result, ""Merck may only be about six months behind Bristol-Myers in bringing its product to market.""Bristol has not said when it expects an approval decision for Opdivo as a treatment for lung cancer. Leerink Partners analyst Seamus Fernandez said in a research note that Merck's rapid advancement may pose a setback to similar programs from Roche and AstraZeneca. Roche's timeline for seeking regulatory approval remains unclear, Fernandez noted. AstraZeneca, meanwhile, may not be able to secure an accelerated review in lung cancer if the Bristol-Myers or Merck drug is already on the market, potentially adding several months to a decision on its contender.Roche said it expects pivotal data for its PD-L1 drug in lung and bladder cancer in the first half of this year, with potential filings seeking approval in the second half if the trials are successful.  Bahija Jallal of AstraZeneca's MedImmune oncology unit, speaking at the JP Morgan healthcare conference in San Francisco, said the company's focus was on testing combinations of its immunotherapy with its own traditional drugs.""I think we're in a great position because we have biologics on one side and small molecules on the other side,"" Jallal said.Lung cancer is the leading cause of cancer deaths globally, killing more than 1.5 million people each year, according the World Health Organization.Bristol-Myers shares were up 3 percent at $62.17, while Merck shares were off 0.4 percent at $62.27. (Reporting by Bill Berkrot in New York; Additional reporting by Caroline Humer in San Francisco; Editing by Leslie Adler)",2015-01-12,MRK,"Mon Jan 12, 2015 | 3:36pm EST","Merck, Bristol heat up immunotherapy race in lung cancer",http://www.reuters.com//article/us-bristol-myers-merck-co-lung-idUSKBN0KL26320150112?type=companyNews
273,"   By Bill Berkrot  Jan 12 Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.Merck said it would file an application with U.S. regulators in the middle of this year seeking expanded use of its new Keytruda treatment for non-small cell lung cancer, the most common form of the deadly disease.That followed a late Sunday announcement by Bristol-Myers that independent monitors halted a trial of its Opdivo treatment for lung cancer when it became clear the drug extended survival compared with standard chemotherapy.While the magnitude of the benefit was not yet known, it marked the first time the new class of immunotherapy demonstrated an overall survival benefit in lung cancer.Some industry analysts expect this class, known as PD-1 or PD-L1 inhibitors, to generate more than $30 billion in worldwide annual sales by 2025, with lung cancer seen as the most lucrative use. Keytruda and Opdivo are already approved to treat advanced melanoma, the most deadly form of skin cancer. They work by blocking a mechanism used by tumors to hide from disease fighting immune system cells.Sanford Bernstein analyst Tim Anderson sees Merck closing a perceived gap with Bristol-Myers in using their drugs for lung cancer.""The review time for Merck's application could be on the order of a few months,"" implying approval in the second half of 2015, nearly a year earlier than Wall Street had expected, Anderson said in a note. As a result, ""Merck may only be about six months behind Bristol-Myers in bringing its product to market."" Bristol has not said when it expects an approval decision for Opdivo as a treatment for lung cancer.Leerink Partners analyst Seamus Fernandez said in a research note that Merck's rapid advancement may pose a setback to similar programs from Roche and AstraZeneca.Roche's timeline for seeking regulatory approval remains unclear, Fernandez noted. AstraZeneca, meanwhile, may not be able to secure an accelerated review in lung cancer if the Bristol-Myers or Merck drug is already on the market, potentially adding several months to a decision on its contender. Roche said it expects pivotal data for its PD-L1 drug in lung and bladder cancer in the first half of this year, with potential filings seeking approval in the second half if the trials are successful.Bahija Jallal of AstraZeneca's MedImmune oncology unit, speaking at the JP Morgan healthcare conference in San Francisco, said the company's focus was on testing combinations of its immunotherapy with its own traditional drugs.""I think we're in a great position because we have biologics on one side and small molecules on the other side,"" Jallal said.Lung cancer is the leading cause of cancer deaths globally, killing more than 1.5 million people each year, according the World Health Organization.Bristol-Myers shares were up 3 percent at $62.17, while Merck shares were off 0.4 percent at $62.27.   (Reporting by Bill Berkrot in New York; Additional reporting by Caroline Humer in San Francisco; Editing by Leslie Adler)",2015-01-12,MRK,"Mon Jan 12, 2015 | 3:34pm EST","Merck, Bristol heat up immunotherapy race in lung cancer",http://www.reuters.com//article/bristol-myers-merck-co-lung-idUSL1N0UR1ZB20150112?type=companyNews
274,"  Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.The drugmaker is trying to close the gap with competitors in the two lucrative segments. Gilead Sciences Inc's hepatitis C drug, Sovaldi  priced at $84,000 per course  notched up sales of $2.8 billion in the company's latest quarter.Last month, the U.S. Food and Drug Administration approved AbbVie Inc's all-oral hepatitis C treatment, priced lower than Gilead's drugs.Merck said it planned to file an application with the FDA in the first half of the year for marketing approval for grazoprevir/elbasvir, a new two-drug, single-pill combination to treat hepatitis C.The company had said in November that it planned to submit the new drug application sometime in 2015.  Merck also said it would file an application midyear for expanding the use of its new cancer immunotherapy Keytruda to include the treatment of non-small-cell lung cancer, the most common form of the deadly disease. Merck's plan to speed up the drug submissions was first reported by the Wall Street Journal. Keytruda belongs to a new class of drugs, called PD-1 inhibitors, that have generated great enthusiasm in the medical community. They work by blocking a mechanism tumors use to camouflage themselves from the immune system, allowing it to recognize and attack the cancer.The FDA approved Keytruda last year to treat advanced melanoma, the deadliest form of skin cancer, making it the first drug from the PD-1 class to reach the U.S. market. Rival drugmaker Bristol-Myers Squibb Co said on Sunday an independent data monitoring committee concluded that a late-stage study evaluating its skin-cancer drug Opdivo in previously treated patients with advanced, squamous cell non-small-cell lung cancer met its main goal. Merck shares, which have gained 10 percent in the first six trading days of 2015, rose as much as 1.5 percent to touch a more than 13-year high at $63.50 on Monday on the New York Stock Exchange. (Reporting by Supriya Kurane and Ankur Banerjee in Bengaluru; Editing by Gopakumar Warrier)",2015-01-12,MRK,"Mon Jan 12, 2015 | 11:06am EST","Merck speeds up drug-submission plans for Hep C, lung cancer",http://www.reuters.com//article/us-merck-co-cancerdrug-idUSKBN0KL0EA20150112?type=companyNews
275,"  (Changes source, share movement)Jan 12 Merck & Co said it would fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval.The drugmaker is trying to close the gap with competitors in the two lucrative segments.Gilead Sciences Inc's hepatitis C drug, Sovaldi - priced at $84,000 per course - notched up sales of $2.8 billion in the company's latest quarter.Last month, the U.S. Food and Drug Administration approved AbbVie Inc's all-oral hepatitis C treatment, priced lower than Gilead's drugs. Merck said it planned to file an application with the FDA in the first half of the year for marketing approval for grazoprevir/elbasvir, a new two-drug, single-pill combination to treat hepatitis C.The company had said in November that it planned to submit the new drug application sometime in 2015.Merck also said it would file an application midyear for expanding the use of its new cancer immunotherapy Keytruda to include the treatment of non-small-cell lung cancer, the most common form of the deadly disease. Merck's plan to speed up the drug submissions was first reported by the Wall Street Journal.Keytruda belongs to a new class of drugs, called PD-1 inhibitors, that have generated great enthusiasm in the medical community. They work by blocking a mechanism tumors use to camouflage themselves from the immune system, allowing it to recognize and attack the cancer.The FDA approved Keytruda last year to treat advanced melanoma, the deadliest form of skin cancer, making it the first drug from the PD-1 class to reach the U.S. market.Rival drugmaker Bristol-Myers Squibb Co said on Sunday an independent data monitoring committee concluded that a late-stage study evaluating its skin-cancer drug Opdivo in previously treated patients with advanced, squamous cell non-small-cell lung cancer met its main goal.Merck shares, which have gained 10 percent in the first six trading days of 2015, rose as much as 1.5 percent to touch a more than 13-year high at $63.50 on Monday on the New York Stock Exchange.   (Reporting by Supriya Kurane and Ankur Banerjee in Bengaluru; Editing by Gopakumar Warrier)",2015-01-12,MRK,"Mon Jan 12, 2015 | 10:56am EST","UPDATE 1-Merck speeds up drug-submission plans for Hep C, lung cancer",http://www.reuters.com//article/merck-co-cancerdrug-idUSL3N0UR3LU20150112?type=companyNews
276,"  Jan 12 Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in an attempt to close the gap with competitors in two lucrative segments, the Wall Street Journal reported.The drugmaker will file an application midyear for U.S. regulatory approval to expand the use of its new cancer immunotherapy Keytruda to include the treatment of non-small-cell lung cancer, the most common form of the deadly disease, the Journal reported. (on.wsj.com/1B8p4YM)Merck also plans to file an application in the first half of this year for FDA approval to market grazoprevir/elbasvir, a new two-drug, single-pill combination to treat the liver disease hepatitis C, the newspaper said.Merck said in November that it planned to submit the New Drug Application for grazoprevir/elbasvir sometime in 2015. ""The tempo has changed. What we are doing is focusing our efforts more profoundly, increasing the speed at which we complete things,"" the Journal quoted Roger Perlmutter, president of Merck Research Laboratories, as saying. Reuters could not immediately reach Merck for comment outside regular U.S. business hours.Keytruda (pembrolizumab) belongs to a new class of drugs called PD-1 inhibitors that have generated great enthusiasm in the medical community. They work by blocking a mechanism tumors use to camouflage themselves from the immune system, allowing it to recognize and attack the cancer. The U.S. Food and Drug Administration approved Keytruda last year to treat advanced melanoma - the deadliest form of skin cancer - making it the first drug from the PD-1 class to reach the U.S. market.Rival drugmaker Bristol-Myers Squibb Co said on Sunday the independent data monitoring committee concluded that a late-stage study evaluating its skin-cancer drug Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.     (Reporting by Supriya Kurane in Bengaluru; Editing by Gopakumar Warrier)",2015-01-12,MRK,"Mon Jan 12, 2015 | 1:50am EST","Merck speeds up drug-submission plans for Hep C, lung cancer -WSJ",http://www.reuters.com//article/merck-co-cancerdrug-idUSL3N0UR20N20150112?type=companyNews
277,"  Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.Lilly will test its treatments - approved and experimental - in combination with PD-1 inhibitors Keytruda and Opdivo. The treatments are designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1).Bristol-Myers' Opdivo was approved by the U.S. Food and Drugs Administration on Dec. 22. Merck's Keytruda was approved by the FDA on Sept. 4. It is also being tested as a treatment for a form of lung cancer.The deal signed with Merck will cover three studies of Keytruda with Lilly's two approved cancer drugs and one experimental treatment, the companies said. Lilly will conduct two out of the three studies planned with Keytruda. Lilly will test a combination of its experimental drug, galunisertib, and Bristol-Myers' Opdivo. (Reporting by Vidya L Nathan in Bengaluru; Editing by Maju Samuel)",2015-01-13,MRK,"Tue Jan 13, 2015 | 9:05am EST","Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",http://www.reuters.com//article/us-lilly-study-idUSKBN0KM1HC20150113?type=companyNews
278,"  Jan 13 Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.Lilly will test its treatments - approved and experimental - in combination with PD-1 inhibitors Keytruda and Opdivo.The treatments are designed to help the body's own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1). Bristol-Myers' Opdivo was approved by the U.S. Food and Drugs Administration on Dec. 22.Merck's Keytruda was approved by the FDA on Sept. 4. It is also being tested as a treatment for a form of lung cancer. The deal signed with Merck will cover three studies of Keytruda with Lilly's two approved cancer drugs and one experimental treatment, the companies said. Lilly will conduct two out of the three studies planned with Keytruda.Lilly will test a combination of its experimental drug, galunisertib, and Bristol-Myers' Opdivo.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Maju Samuel)",2015-01-13,MRK,"Tue Jan 13, 2015 | 9:02am EST","Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",http://www.reuters.com//article/lilly-study-idUSL3N0US4IG20150113?type=companyNews
279,"   By P.J. Huffstutter and Tom Polansek | CHICAGO  CHICAGO Merck & Co Inc is funding the testing of lower dosages of its controversial cattle growth drug Zilmax, in a move that livestock experts say is crucial if the company is to resume sales of the product to the U.S. beef industry.Nearly 18 months after Merck pulled the drug from the U.S. and Canadian markets after videos and photographs surfaced showing Zilmax-fed cattle turning up in a distressed state, either lame or with hooves missing at slaughterhouses, scientists at Texas Tech University are testing beef carcasses taken from cattle fed different concentrations of Zilmax.The Merck-funded field study and lab work, which have not previously been reported, are designed to test Zilmax at its currently approved dosage of 6.8 grams per ton of feed for a 20-day period prior to slaughter, as well as dosages at about 60 percent and nearly 80 percent of that level, according to the title of the study. At the time Merck pulled Zilmax off the market, it had only one dosage level approved by the U.S. Food and Drug Administration.Merck awarded $1.85 million to the Texas Tech team in October to conduct the research, the university mentioned at the time in a newsletter that got little attention outside of the school. The research is ongoing and the specific time frame of the study was not clear. ""This study is an example of the company's ongoing research efforts to provide additional data on the use of Zilmax,"" the company said in a statement to Reuters.Merck, which says it still sells Zilmax in Mexico and South Africa, declined to comment on why it was testing these particular levels or whether it was collecting data to submit to the FDA. Merck also declined to say how many cattle are being fed Zilmax as part of the tests, or where the animals are being raised or slaughtered. It declined to give any further details. An FDA spokeswoman declined to comment on the study, citing confidentiality regarding drug applications. Texas Tech did not respond to requests for comment. In November, federal regulators approved changes proposed by the company in the way the drug is administered. The company has also been working with cattle feed lot operators on how best to administer the drug.""It looks to me like they're doing studies to determine if the lower dosages are efficacious in improving feed efficiency, growth rate and carcass leanness,"" said David Anderson, former head of swine research at Elanco Animal Health, a unit of Merck rival Eli Lily & Co, when Reuters told him about the study. A similar product called Optaflexx, made by Elanco ""has captured the market,"" said Arizona cattle rancher Harvey Dietrich, co-founder of advocacy group Beef Additive Alert, which is critical of growth-promotants such as Zilmax. ""Merck wants their market share back,"" he added.At the time the videos of the distressed cattle surfaced in 2013, some veterinarians argued that a key problem was that the drug, at its approved dosage, was too potent for some animals. The drug company does not need federal approval to return Zilmax to the market. But all four of the nation's largest beef packers and many meat producers have told Reuters they won't accept Zilmax until Merck can scientifically prove the drug doesn't cause the animal welfare issues seen in the past. One option, say industry experts, would be for Merck to show the FDA that Zilmax is effective and safe at helping cattle gain weight at lower dosages, and petition the agency to alter the product's usage label.The multi-site study that Merck is funding could provide the data needed to make such a petition, according to industry experts. Current labeling covers both dosage and details about its effectiveness on cattle. Major meat packers like Cargill Inc [CARG.UL] and Tyson Foods Inc say they are not processing any meat from Merck's study or slaughtering cattle fed with Zilmax. Spokesmen for Cargill, Tyson, National Beef Packing Co [NBEEF.UL] and JBS USA [JBS.UL] said their companies were not participating in the study.   (Reporting By P.J. Huffstutter and Tom; Polansek in Chicago.; Editing by Martin Howell)",2015-01-19,MRK,"Mon Jan 19, 2015 | 8:02am EST",Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to resume sales,http://www.reuters.com//article/us-merck-co-zilmax-idUSKBN0KS18020150119?type=companyNews
280,"   By Ransdell Pierson  Johnson & Johnson (JNJ.N) surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc (PFE.N) and Merck & Co (MRK.N).J&J, the first large U.S. drugmaker to report fourth-quarter results, on Tuesday said sales fell 0.6 percent to $18.25 billion, but would have risen 3.9 percent if not for the stronger dollar. The 4.5 percent foreign exchange hit compared with an average 0.9 percent headwind in the first three quarters of the year.The diversified healthcare company now expects a foreign currency hit to earnings in 2015 of as much as 42 cents per share, versus the 15 cents to 20 cents it forecast in October.""Foreign exchange will be a focal point for the whole drug group"" in the fourth quarter and 2015, said John Boris, an analyst with Suntrust Robinson Humphrey. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many expect, and said Pfizer and Merck are among the most vulnerable because they both derive more than 60 percent of their sales outside the United States. A spokeswoman for Pfizer declined to comment, saying the company will discuss the impact of foreign exchange when it reports quarterly results on Jan 27. Merck officials could not immediately be reached for comment.J&J shares fell 2.6 percent on Tuesday, while the ARCA Pharmaceutical Index .DRG of U.S. and European drugmakers was little changed. ""The market today is very much focused on J&J, but companies like J&J with a big global footprint are also at risk,"" said Atlantic Equities analyst Richard Purkiss, who cited Pfizer as among the most vulnerable. Indianapolis drugmaker Eli Lilly (LLY.N) said earlier this month it expects foreign exchange ""headwinds"" in 2015, but would not give details until it reports quarterly earnings on Jan. 30. Almost 55 percent of its sales are from outside the United States.The dollar .DXY gained nearly 13 percent against a basket of major currencies in 2014, its strongest performance since 1997. For U.S.-based companies, the stronger dollar hurts the value of sales in overseas markets.  Boris said sales of innovative new drugs from J&J and rival drugmakers - such as treatments for cancer, diabetes and hepatitis C - could still mitigate the foreign currency impact and help them deliver double-digit industry earnings growth over the next five years. (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2015-01-20,MRK,"Tue Jan 20, 2015 | 6:09pm EST",Johnson & Johnson's forex warning a sign for rival drugmakers,http://www.reuters.com//article/us-johnson-johnson-results-currency-idUSKBN0KT2KQ20150120?type=companyNews
281,"   By Ransdell Pierson  Jan 20 Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co.J&J, the first large U.S. drugmaker to report fourth-quarter results, on Tuesday said sales fell 0.6 percent to $18.25 billion, but would have risen 3.9 percent if not for the stronger dollar. The 4.5 percent foreign exchange hit compared with an average 0.9 percent headwind in the first three quarters of the year.The diversified healthcare company now expects a foreign currency hit to earnings in 2015 of as much as 42 cents per share, versus the 15 cents to 20 cents it forecast in October.""Foreign exchange will be a focal point for the whole drug group"" in the fourth quarter and 2015, said John Boris, an analyst with Suntrust Robinson Humphrey. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many expect, and said Pfizer and Merck are among the most vulnerable because they both derive more than 60 percent of their sales outside the United States. A spokeswoman for Pfizer declined to comment, saying the company will discuss the impact of foreign exchange when it reports quarterly results on Jan 27. Merck officials could not immediately be reached for comment.J&J shares fell 2.6 percent on Tuesday, while the ARCA Pharmaceutical Index of U.S. and European drugmakers was little changed. ""The market today is very much focused on J&J, but companies like J&J with a big global footprint are also at risk,"" said Atlantic Equities analyst Richard Purkiss, who cited Pfizer as among the most vulnerable.Indianapolis drugmaker Eli Lilly said earlier this month it expects foreign exchange ""headwinds"" in 2015, but would not give details until it reports quarterly earnings on Jan. 30. Almost 55 percent of its sales are from outside the United States. The dollar gained nearly 13 percent against a basket of major currencies in 2014, its strongest performance since 1997. For U.S.-based companies, the stronger dollar hurts the value of sales in overseas markets.Boris said sales of innovative new drugs from J&J and rival drugmakers - such as treatments for cancer, diabetes and hepatitis C - could still mitigate the foreign currency impact and help them deliver double-digit industry earnings growth over the next five years.(Reporting by Ransdell Pierson; Editing by Leslie Adler)",2015-01-20,MRK,"Tue Jan 20, 2015 | 6:06pm EST",Johnson & Johnson's forex warning a sign for rival drugmakers,http://www.reuters.com//article/johnsonjohnson-results-currency-idUSL1N0UZ20P20150120?type=companyNews
282,"  LONDON Jan 23 Europe recommended seven new drugs for approval on Friday, including two antibiotics for skin infections and a new treatment option for HIV.Regulator European Medicines Agency gave the green light to The Medicines Company's oritavancin and Cubist Pharmaceuticals tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. It also recommended for approval Merck & Co's  combination of lamivudine and raltegravir for HIV, and Santen's   ciclosporin for severe keretitis. The Medicines Company's drug cangrelor for the reduction of thrombotic cardiovascular events was also recommended for approval, as was its Raplixa, a fibrinogen and thrombin powder, for improvement of haemostasis. Novo Nordisk, the world's biggest insulin maker, said on late Thursday it has received a positive opinion from the European regulatory authorities for its obesity treatment Saxenda.    (Reporting by Paul Sandle, Editing by Kate Holton)",2015-01-23,MRK,"Fri Jan 23, 2015 | 7:44am EST",Europe recommends seven new medicines for approval,http://www.reuters.com//article/europe-medicine-approvals-idUSL6N0V224W20150123?type=companyNews
283,"  (Repeating to additional subscribers)By Tim McLaughlinFeb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows.The companies, all members of the S&P 500, and including some of the biggest names in Corporate America such as autos giant General Motors and drug maker Merck & Co Inc , together carry at least $11 billion of monetary assets in the Venezuelan currency, the bolivar, on their books.The official rate is at 6.3 bolivars to the dollar and there are two other rates in the government system - known as SICAD 1 and SICAD 2 - at about 12 and 50. The black market rate, though, was at about 190 bolivars to the dollar on Sunday, according to the website dolartoday.com.The problem is that the dollar value of the assets as disclosed in many of the companies' accounts is based on either the rates at 6.3 or 12 and only a limited number of transactions are allowed at those rates. The assets would be worth a lot fewer dollars at the 50 rate in the government system and the dollar value would almost be wiped out at the black market rate.The currency system is also about to be shaken up following an announcement by Venezuela President Nicolas Maduro on Jan. 21, leading to fears of a further devaluation.American companies will also have additional exposure to the bolivar that isn't disclosed because they don't see the size of that exposure as material to their results. The Reuters analysis also doesn't look at the thousands of publicly traded and private American companies that aren't in the S&P 500 and will in some cases have bolivar assets.BLACK MARKET RATE  Some leading American companies have already decided that the stronger exchange rates - the official rate at 6.3 and the SICAD 1 exchange market at 12 - are not reflective of the currency conditions they face in the South American country.Diaper and tissue maker Kimberly-Clark Corp recently announced a charge of $462 million for its Venezuelan business, leading to a fourth-quarter loss for the company, after it concluded that the appropriate exchange rate was the SICAD 2 exchange rate at 50 rather than the 6.3 it had previously used.Using the stronger exchange rates is unrealistic because of how hard it is to repatriate profits earned in Venezuela back to the United States at any rate, let alone those rates, securities analysts say. Citigroup Inc says it has not been able to buy U.S. dollars from the Venezuelan government since 2008.Companies can seek dollars at the official rate if they are using those dollars to import raw materials for production of priority goods such as food and medicine, and some can buy dollars at the SICAD 1 rate at around 12 bolivars to the dollar through auctions that are typically held several times per month but are only targeted at specific sectors. As tumbling oil prices have left Venezuela with fewer dollars, its currency board has steadily reduced approval for repatriation of dividends at the official rate - leaving companies with growing quantities of bolivars trapped by currency controls.""It's a huge deal and companies will get hit big,"" said Ali Dibadji, an analyst at Sanford C. Bernstein & Co Inc. ""Take a look at what Kimberly-Clark did last week and what Clorox did a few months ago by getting out of Venezuela.""Cleaning and household products maker Clorox last year decided to exit Venezuela altogether. Its CEO Don Knauss said at the time: ""We saw no hope that we could create a sustaining business in that country."" The currency issues are hurting many U.S. companies much more than their sales might suggest. Many of the companies in the analysis have been getting between 1-3 percent of their global revenue from Venezuela.Ford Motor Co and oil services company Schlumberger NV   took big-ticket hits to their quarterly profits because of their Venezuelan operations. Ford took a fourth-quarter charge of $800 million and Schlumberger $472 million.A Ford spokeswoman said that it still values its Venezuela assets at about 12 bolivars per US dollar. But for Ford, the currency system and other conditions are so tough in the South American country that it has made an accounting change that will allow it to ring fence its Venezuela business so that it doesn't have a direct impact on the company's operating results.Schlumberger, which previously used the 6.3 rate, said it is now using the SICAD 2 rate of 50 as it ""best represents the economics of Schlumberger's business activity in Venezuela.""Another S&P 500 company to switch to the 50 rate from 6.3 in recent weeks was industrial gases producer Praxair Inc, which took a fourth-quarter charge of $131 million as a result. It also said the switch will hurt its revenue and earnings in 2015. ANOTHER DEVALUATION? Those changes don't reflect the prospect of another currency devaluation in Venezuela, as recently telegraphed by Maduro, who is struggling to keep a lid on consumer prices amid a 64 percent inflation rate and a plunge in oil revenue. The official rate was last devalued by 32 percent to the current 6.3 from 4.3 in February 2013, at that time the fifth devaluation in a decade.Maduro said in the Jan 21 announcement he would merge the two existing SICAD rates (the ones at 12 and 50 per U.S. dollar). He also would introduce another new rate to offer dollars via private brokers to vie with the black market rate. There has yet to be a further announcement providing details of the new system and the rates.Currency uncertainties aside, foreign companies face a myriad of other problems in Venezuela, from weak demand to shortages of many goods, difficulty in importing parts and products, and relying on the government to approve price increases to keep pace with hyperinflation.Most of the S&P 500 bolivar exposure is concentrated among 10 companies that have disclosed about $7.3 billion in assets linked to the country's currency system, according to the Reuters analysis of their latest quarterly financial statements.But if those companies used Venezuela's SICAD 2 currency rate, the one at about 50 bolivars to the dollar, their assets would decline by as much as $5.8 billion. All of these companies currently either use the rates at 6.3 and 12.It would be far worse if they used Venezuela's black market rate of about 190 for the currency. The companies' bolivar assets would be worth only a tiny fraction of their current estimated value if they used that rate.GM, which ranked No. 1 out of the group analyzed, with $1.5 billion in Venezuela exposure, said it is closely monitoring conditions there. ""We have nothing to announce at this time,"" spokesman Tom Henderson said.Some U.S. companies, such as Merck, justify valuing their Venezuela assets at the most preferential rate because they are providing essential services and goods, like medicine, to the country. They report some success in translating bolivars into dollars at the 6.3 rate. Merck did not respond to a message seeking comment.Still, some of these same companies have prepared their investors for a currency hit in their latest round of quarterly disclosures. PepsiCo Inc said it would take an after-tax charge of up to $440 million if it revalued its Venezuela assets at the 50 rate. As of early September, the company disclosed $505 million in bolivar-denominated net monetary assets.""I do think that more companies may consider exiting Venezuela if the inability to remove cash or take prices to offset devaluations persist,"" said Dibadji, the Sanford Bernstein analyst.   (Reporting by Tim McLaughlin, additional reporting by Jim Finkle and Richard Valdmanis in Boston; Ashley Lau in New York and Brian Ellsworth in Caracas; Editing by Linda Stern and Martin Howell)",2015-02-02,MRK,"Mon Feb 2, 2015 | 12:56pm EST","RPT-INSIGHT-US companies face billions in Venezuela currency losses, Reuters analysis shows",http://www.reuters.com//article/venezuela-usa-corporations-insight-graph-idUSL1N0VC1FW20150202?type=companyNews
284,"  (Repeating to additional subscribers)By Tim McLaughlinFeb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows.The companies, all members of the S&P 500, and including some of the biggest names in Corporate America such as autos giant General Motors and drug maker Merck & Co Inc , together carry at least $11 billion of monetary assets in the Venezuelan currency, the bolivar, on their books.The official rate is at 6.3 bolivars to the dollar and there are two other rates in the government system - known as SICAD 1 and SICAD 2 - at about 12 and 50. The black market rate, though, was at about 190 bolivars to the dollar on Sunday, according to the website dolartoday.com.The problem is that the dollar value of the assets as disclosed in many of the companies' accounts is based on either the rates at 6.3 or 12 and only a limited number of transactions are allowed at those rates. The assets would be worth a lot fewer dollars at the 50 rate in the government system and the dollar value would almost be wiped out at the black market rate.The currency system is also about to be shaken up following an announcement by Venezuela President Nicolas Maduro on Jan. 21, leading to fears of a further devaluation.American companies will also have additional exposure to the bolivar that isn't disclosed because they don't see the size of that exposure as material to their results. The Reuters analysis also doesn't look at the thousands of publicly traded and private American companies that aren't in the S&P 500 and will in some cases have bolivar assets.BLACK MARKET RATE  Some leading American companies have already decided that the stronger exchange rates - the official rate at 6.3 and the SICAD 1 exchange market at 12 - are not reflective of the currency conditions they face in the South American country.Diaper and tissue maker Kimberly-Clark Corp recently announced a charge of $462 million for its Venezuelan business, leading to a fourth-quarter loss for the company, after it concluded that the appropriate exchange rate was the SICAD 2 exchange rate at 50 rather than the 6.3 it had previously used.Using the stronger exchange rates is unrealistic because of how hard it is to repatriate profits earned in Venezuela back to the United States at any rate, let alone those rates, securities analysts say. Citigroup Inc says it has not been able to buy U.S. dollars from the Venezuelan government since 2008.Companies can seek dollars at the official rate if they are using those dollars to import raw materials for production of priority goods such as food and medicine, and some can buy dollars at the SICAD 1 rate at around 12 bolivars to the dollar through auctions that are typically held several times per month but are only targeted at specific sectors. As tumbling oil prices have left Venezuela with fewer dollars, its currency board has steadily reduced approval for repatriation of dividends at the official rate - leaving companies with growing quantities of bolivars trapped by currency controls.""It's a huge deal and companies will get hit big,"" said Ali Dibadji, an analyst at Sanford C. Bernstein & Co Inc. ""Take a look at what Kimberly-Clark did last week and what Clorox did a few months ago by getting out of Venezuela.""Cleaning and household products maker Clorox last year decided to exit Venezuela altogether. Its CEO Don Knauss said at the time: ""We saw no hope that we could create a sustaining business in that country."" The currency issues are hurting many U.S. companies much more than their sales might suggest. Many of the companies in the analysis have been getting between 1-3 percent of their global revenue from Venezuela.Ford Motor Co and oil services company Schlumberger NV   took big-ticket hits to their quarterly profits because of their Venezuelan operations. Ford took a fourth-quarter charge of $800 million and Schlumberger $472 million.A Ford spokeswoman said that it still values its Venezuela assets at about 12 bolivars per US dollar. But for Ford, the currency system and other conditions are so tough in the South American country that it has made an accounting change that will allow it to ring fence its Venezuela business so that it doesn't have a direct impact on the company's operating results.Schlumberger, which previously used the 6.3 rate, said it is now using the SICAD 2 rate of 50 as it ""best represents the economics of Schlumberger's business activity in Venezuela.""Another S&P 500 company to switch to the 50 rate from 6.3 in recent weeks was industrial gases producer Praxair Inc, which took a fourth-quarter charge of $131 million as a result. It also said the switch will hurt its revenue and earnings in 2015. ANOTHER DEVALUATION? Those changes don't reflect the prospect of another currency devaluation in Venezuela, as recently telegraphed by Maduro, who is struggling to keep a lid on consumer prices amid a 64 percent inflation rate and a plunge in oil revenue. The official rate was last devalued by 32 percent to the current 6.3 from 4.3 in February 2013, at that time the fifth devaluation in a decade.Maduro said in the Jan 21 announcement he would merge the two existing SICAD rates (the ones at 12 and 50 per U.S. dollar). He also would introduce another new rate to offer dollars via private brokers to vie with the black market rate. There has yet to be a further announcement providing details of the new system and the rates.Currency uncertainties aside, foreign companies face a myriad of other problems in Venezuela, from weak demand to shortages of many goods, difficulty in importing parts and products, and relying on the government to approve price increases to keep pace with hyperinflation.Most of the S&P 500 bolivar exposure is concentrated among 10 companies that have disclosed about $7.3 billion in assets linked to the country's currency system, according to the Reuters analysis of their latest quarterly financial statements.But if those companies used Venezuela's SICAD 2 currency rate, the one at about 50 bolivars to the dollar, their assets would decline by as much as $5.8 billion. All of these companies currently either use the rates at 6.3 and 12.It would be far worse if they used Venezuela's black market rate of about 190 for the currency. The companies' bolivar assets would be worth only a tiny fraction of their current estimated value if they used that rate.GM, which ranked No. 1 out of the group analyzed, with $1.5 billion in Venezuela exposure, said it is closely monitoring conditions there. ""We have nothing to announce at this time,"" spokesman Tom Henderson said.Some U.S. companies, such as Merck, justify valuing their Venezuela assets at the most preferential rate because they are providing essential services and goods, like medicine, to the country. They report some success in translating bolivars into dollars at the 6.3 rate. Merck did not respond to a message seeking comment.Still, some of these same companies have prepared their investors for a currency hit in their latest round of quarterly disclosures. PepsiCo Inc said it would take an after-tax charge of up to $440 million if it revalued its Venezuela assets at the 50 rate. As of early September, the company disclosed $505 million in bolivar-denominated net monetary assets.""I do think that more companies may consider exiting Venezuela if the inability to remove cash or take prices to offset devaluations persist,"" said Dibadji, the Sanford Bernstein analyst.   (Reporting by Tim McLaughlin, additional reporting by Jim Finkle and Richard Valdmanis in Boston; Ashley Lau in New York and Brian Ellsworth in Caracas; Editing by Linda Stern and Martin Howell)",2015-02-02,MRK,"Mon Feb 2, 2015 | 7:00am EST","RPT-INSIGHT-US companies face billions in Venezuela currency losses, Reuters analysis shows",http://www.reuters.com//article/venezuela-usa-corporations-insight-graph-idUSL1N0VC05120150202?type=companyNews
285,"   By Tim McLaughlin  Feb 2 At least 40 major U.S. companies have substantial exposure to Venezuela's deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows.The companies, all members of the S&P 500, and including some of the biggest names in Corporate America such as autos giant General Motors and drug maker Merck & Co Inc , together carry at least $11 billion of monetary assets in the Venezuelan currency, the bolivar, on their books.The official rate is at 6.3 bolivars to the dollar and there are two other rates in the government system - known as SICAD 1 and SICAD 2 - at about 12 and 50. The black market rate, though, was at about 190 bolivars to the dollar on Sunday, according to the website dolartoday.com.The problem is that the dollar value of the assets as disclosed in many of the companies' accounts is based on either the rates at 6.3 or 12 and only a limited number of transactions are allowed at those rates. The assets would be worth a lot fewer dollars at the 50 rate in the government system and the dollar value would almost be wiped out at the black market rate.The currency system is also about to be shaken up following an announcement by Venezuela President Nicolas Maduro on Jan. 21, leading to fears of a further devaluation.American companies will also have additional exposure to the bolivar that isn't disclosed because they don't see the size of that exposure as material to their results. The Reuters analysis also doesn't look at the thousands of publicly traded and private American companies that aren't in the S&P 500 and will in some cases have bolivar assets.BLACK MARKET RATE  Some leading American companies have already decided that the stronger exchange rates - the official rate at 6.3 and the SICAD 1 exchange market at 12 - are not reflective of the currency conditions they face in the South American country.Diaper and tissue maker Kimberly-Clark Corp recently announced a charge of $462 million for its Venezuelan business, leading to a fourth-quarter loss for the company, after it concluded that the appropriate exchange rate was the SICAD 2 exchange rate at 50 rather than the 6.3 it had previously used.Using the stronger exchange rates is unrealistic because of how hard it is to repatriate profits earned in Venezuela back to the United States at any rate, let alone those rates, securities analysts say. Citigroup Inc says it has not been able to buy U.S. dollars from the Venezuelan government since 2008.Companies can seek dollars at the official rate if they are using those dollars to import raw materials for production of priority goods such as food and medicine, and some can buy dollars at the SICAD 1 rate at around 12 bolivars to the dollar through auctions that are typically held several times per month but are only targeted at specific sectors. As tumbling oil prices have left Venezuela with fewer dollars, its currency board has steadily reduced approval for repatriation of dividends at the official rate - leaving companies with growing quantities of bolivars trapped by currency controls.""It's a huge deal and companies will get hit big,"" said Ali Dibadji, an analyst at Sanford C. Bernstein & Co Inc. ""Take a look at what Kimberly-Clark did last week and what Clorox did a few months ago by getting out of Venezuela.""Cleaning and household products maker Clorox last year decided to exit Venezuela altogether. Its CEO Don Knauss said at the time: ""We saw no hope that we could create a sustaining business in that country."" The currency issues are hurting many U.S. companies much more than their sales might suggest. Many of the companies in the analysis have been getting between 1-3 percent of their global revenue from Venezuela.Ford Motor Co and oil services company Schlumberger NV   took big-ticket hits to their quarterly profits because of their Venezuelan operations. Ford took a fourth-quarter charge of $800 million and Schlumberger $472 million.A Ford spokeswoman said that it still values its Venezuela assets at about 12 bolivars per US dollar. But for Ford, the currency system and other conditions are so tough in the South American country that it has made an accounting change that will allow it to ring fence its Venezuela business so that it doesn't have a direct impact on the company's operating results.Schlumberger, which previously used the 6.3 rate, said it is now using the SICAD 2 rate of 50 as it ""best represents the economics of Schlumberger's business activity in Venezuela.""Another S&P 500 company to switch to the 50 rate from 6.3 in recent weeks was industrial gases producer Praxair Inc, which took a fourth-quarter charge of $131 million as a result. It also said the switch will hurt its revenue and earnings in 2015. ANOTHER DEVALUATION? Those changes don't reflect the prospect of another currency devaluation in Venezuela, as recently telegraphed by Maduro, who is struggling to keep a lid on consumer prices amid a 64 percent inflation rate and a plunge in oil revenue. The official rate was last devalued by 32 percent to the current 6.3 from 4.3 in February 2013, at that time the fifth devaluation in a decade.Maduro said in the Jan 21 announcement he would merge the two existing SICAD rates (the ones at 12 and 50 per U.S. dollar). He also would introduce another new rate to offer dollars via private brokers to vie with the black market rate. There has yet to be a further announcement providing details of the new system and the rates.Currency uncertainties aside, foreign companies face a myriad of other problems in Venezuela, from weak demand to shortages of many goods, difficulty in importing parts and products, and relying on the government to approve price increases to keep pace with hyperinflation.Most of the S&P 500 bolivar exposure is concentrated among 10 companies that have disclosed about $7.3 billion in assets linked to the country's currency system, according to the Reuters analysis of their latest quarterly financial statements.But if those companies used Venezuela's SICAD 2 currency rate, the one at about 50 bolivars to the dollar, their assets would decline by as much as $5.8 billion. All of these companies currently either use the rates at 6.3 and 12.It would be far worse if they used Venezuela's black market rate of about 190 for the currency. The companies' bolivar assets would be worth only a tiny fraction of their current estimated value if they used that rate.GM, which ranked No. 1 out of the group analyzed, with $1.5 billion in Venezuela exposure, said it is closely monitoring conditions there. ""We have nothing to announce at this time,"" spokesman Tom Henderson said.Some U.S. companies, such as Merck, justify valuing their Venezuela assets at the most preferential rate because they are providing essential services and goods, like medicine, to the country. They report some success in translating bolivars into dollars at the 6.3 rate. Merck did not respond to a message seeking comment.Still, some of these same companies have prepared their investors for a currency hit in their latest round of quarterly disclosures. PepsiCo Inc said it would take an after-tax charge of up to $440 million if it revalued its Venezuela assets at the 50 rate. As of early September, the company disclosed $505 million in bolivar-denominated net monetary assets.""I do think that more companies may consider exiting Venezuela if the inability to remove cash or take prices to offset devaluations persist,"" said Dibadji, the Sanford Bernstein analyst.   (Reporting by Tim McLaughlin, additional reporting by Jim Finkle and Richard Valdmanis in Boston; Ashley Lau in New York and Brian Ellsworth in Caracas; Editing by Linda Stern and Martin Howell)",2015-02-02,MRK,"Mon Feb 2, 2015 | 1:00am EST","INSIGHT-US companies face billions in Venezuela currency losses, Reuters analysis shows",http://www.reuters.com//article/venezuela-usa-corporations-idUSL1N0V91W320150202?type=companyNews
286,"  * Crude down sharply after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes: Dow up 0.04 pct, S&P down 0.4 pct, Nasdaq down 0.2 pct   (Updates to close)By Caroline ValetkevitchNEW YORK, Feb 4 The S&P 500 and Nasdaq ended lower on Wednesday, snapping a two-day rally as energy shares slid with oil prices and as investors' anxiety about the euro zone returned in the closing minutes of trading.The benchmark index added to losses late in the session after the European Central Bank abruptly cancelled its acceptance of Greek bonds in return for funding. The move means the Greek central bank will have to provide its banks with tens of billions of euros of additional emergency liquidity in coming weeks. ""It's kind of reconfirming what we've thought for a while, which is that there is going to be a liquidity crunch if they don't resolve this Greek situation,"" said Larry Peruzzi, senior equity trader at Cabrera Capital Markets Inc in Boston.""They make a little bit of progress and then they kind of fall back.""Shares of the Global X FTSE Greece 20 exchange-traded fund  dropped 10.4 percent, with volume spiking late in the session. The euro also fell on the news, while the S&P financial index turned lower and ended down 0.3 percent. The Dow ended in positive territory, lifted by shares of Walt Disney, up 8 percent to $101.64 after quarterly profit topped analysts' expectations.The S&P 500 energy index was off 1.6 percent as oil prices declined after a four-day surge of nearly 20 percent. U.S. crude sank 8.7 percent to settle at $48.45 following a new build in U.S. crude stockpiles.The Dow Jones industrial average rose 6.62 points, or 0.04 percent, to 17,673.02, the S&P 500 lost 8.52 points, or 0.42 percent, to 2,041.51 and the Nasdaq Composite  dropped 11.04 points, or 0.23 percent, to 4,716.70. The day's dip followed a two-day gain of 2.8 percent for the S&P 500, driven largely by the rebound in energy shares.Big biotechnology names declined. Leading them lower was Gilead Sciences, whose stock dropped 8.2 percent to $98.43, a day after the drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs.The news fueled concerns the sector would face increasing price pressure. The Nasdaq Biotech Index was down 1.8 percent. Gilead was also the biggest drag on the S&P 500 and Nasdaq.About 7.8 billion shares changed hands on U.S. exchanges, below the 8.1 billion average for the last five sessions, according to BATS Global Markets.Declining issues outnumbered advancing ones on the NYSE by 1,993 to 1,079, for a 1.85-to-1 ratio; on the Nasdaq, 1,677 issues fell and 1,054 advanced for a 1.59-to-1 ratio.The S&P 500 was posting 37 new 52-week highs and 3 lows; the Nasdaq Composite was recording 79 new highs and 34 lows.     (Additonal reporting by Sinead Carew; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,MRK,"Wed Feb 4, 2015 | 5:06pm EST","US STOCKS-Wall St ends lower with oil prices, renewed Greece worries",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE2SK20150204?type=companyNews
287,"   By Ransdell Pierson  Merck & Co on Wednesday said U.S. regulators intend to rescind the ""breakthrough therapy"" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.The Food and Drug Administration gives the designation to medicines it deems likely to demonstrate ""substantial improvement"" over existing drugs. The designation has hastened approval of some drugs by two to three months. Analysts said Merck's two-drug treatment would likely now require a standard 10-month review.Merck, in its fourth-quarter earnings report, said it plans to discuss the matter with the FDA and still expects to seek U.S. approval in the first half of 2015. The treatment consists of a protease inhibitor called MK-5172 and a so-called NS5A inhibitor called MK-8742 that together had received the FDA's ""breakthrough therapy"" designation. In a recent mid-stage trial, Merck's combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C. Merck said late-stage trials are now complete, and will support approval.""Based upon data today, we believe we will be able to compete in the marketplace,"" Adam Schechter, head of global human health for Merck, said in an interview.The setback for Merck follows recent approvals of costly oral treatments for the liver disease from Gilead Sciences Inc and AbbVie Inc that have wiped out all signs of the virus in well over 90 percent of patients after eight or 12 weeks.""The breakthrough therapy designation is meant for drugs that address an unmet medical need, but we now have two virtual cures for hepatitis C on the market"" from Gilead and AbbVie, said Edward Jones analyst Ashtyn Evans. Evans said Merck's combination treatment will likely undergo a standard FDA review. She predicted, however, that Merck's array of experimental hepatitis C drugs will eventually claim a 15 to 20 percent global market share, with annual sales in the billions of dollars.Shares of the second-biggest U.S. drugmaker fell 3.5 percent on Wednesday, also hurt by a weaker-than-expected profit forecast for 2015 which the company blamed on the stronger dollar.TAKING BIGGER AIM   In the face of such potent rival hepatitis C medicines, Merck in June announced it would ramp up its involvement in the lucrative field by buying Idenix Pharmaceuticals Inc for $3.85 billion and combining the two companies' most promising drugs to produce a faster, more effective cure.          Idenix had three hepatitis C drugs in development, most notably a pill in early-stage trials called IDX21437, which Merck has renamed MK-3682. Like Gilead's Sovaldi, it is a nucleotide inhibitor, or ""nuc,"" that blocks a protein needed by the hepatitis C virus to replicate.Merck is conducting a mid-stage trial to study combinations of MK-3682 and MK-5172 (grazoprevir) with either MK-8742 (elbasvir) or another drug called MK-8408. It hopes to begin larger late-stage trials of the triplet therapies this year. Gilead introduced Sovaldi in late 2013 at a cost of $1,000 a pill, and reported fourth-quarter sales of $1.73 billion for the drug. Gilead later introduced Harvoni, a pill combining Sovaldi with another treatment, and it captured sales of $2.11 billion in the quarter.AbbVie launched its Viekira Pak treatment late last year. Since then, it has battled Gilead for market share by offering discounts to insurers and other group payers.Late on Tuesday, Gilead disclosed that its discounts will average 46 percent this year, up sharply from analyst expectations of 25 to 30 percent. Shares of Gilead and AbbVie both tumbled after the news.As many as 3.2 million people in the United States are estimated to be infected with the hepatitis C virus, which can lead to severe liver disease.Merck on Wednesday reported slightly disappointing fourth-quarter sales and predicted 2015 earnings below analyst forecasts. It cited the negative impact of the stronger dollar, as most of its U.S. rivals have done in their own cautious forecasts.   (Reporting by Ransdell Pierson; Editing by W Simon, Paul Simao and David Gregorio)",2015-02-04,MRK,"Wed Feb 4, 2015 | 2:44pm EST","Merck says hepatitis C treatment to lose ""breakthrough"" status",http://www.reuters.com//article/us-merck-co-results-idUSKBN0L81BX20150204?type=companyNews
288,"  * Crude down sharply after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes: Dow up 0.1 pct, S&P off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)By Caroline ValetkevitchNEW YORK, Feb 4 The S&P 500 and Nasdaq eased on Wednesday in the wake of a two-day rally as energy shares followed oil prices lower and Gilead and other biotech names declined.Walt Disney kept the Dow in positive territory.  Disney shares jumped 8 percent to $101.64 after quarterly profit topped analysts' expectations. The S&P 500 energy index was off 1.8 percent as oil prices declined after a four-day surge of nearly 20 percent. U.S. crude was down 8.2 percent following a new build in U.S. crude stockpiles.The day's dip in stocks follows a 2-day gain of 2.8 percent for the S&P 500, driven largely by the jump in energy shares.""It does seem as if the trading world has focused in on the price of crude oil as being the best barometer of what's going on in terms of economic activity,"" said Eric Kuby, chief investment officer of North Star Investment Management Corp in  Chicago.Leading biotechnology shares lower was Gilead Sciences , whose stock dropped 7.7 percent to $98.82, a day after the drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers. The news fueled concerns the sector would face increasing price pressure. The Nasdaq Biotech Index was down 1.5 percent. Gilead was also the biggest drag on the S&P 500 and Nasdaq.Also in the healthcare space, Merck shares lost 2.8 percent to $59.32 after the drugmaker reported slightly disappointing fourth quarter sales.At 2:15 p.m., the Dow Jones industrial average rose 22.09 points, or 0.13 percent, to 17,688.49, the S&P 500  lost 6.22 points, or 0.3 percent, to 2,043.81 and the Nasdaq Composite dropped 3.37 points, or 0.07 percent, to 4,724.37. Shares of cable and telecom operators jumped after Federal Communications Commission Chairman Tom Wheeler, in an op-ed on Wired.com, said he aims to establish the ""strongest open Internet protections ever proposed by the FCC"" that would apply to both wireless and wired broadband providers.  Shares of Comcast were up 3.1 percent at $57.10.Helping the shares was the regulator's assertion that he would not regulate rates for network operators even under the new rules, said MoffettNathanson analyst Craig Moffett.Shares of Apple were up 1.1 percent at $119.95 and its market capitalization topped $700 billion.On the economic front, U.S. labor market data disappointed. The ADP National Employment Report showed private employers added 213,000 jobs in January, short of the 225,000 estimate.Declining issues outnumbered advancing ones on the NYSE by 1,967 to 1,083, for a 1.82-to-1 ratio; on the Nasdaq, 1,510 issues fell and 1,185 advanced, for a 1.27-to-1 ratio favoring decliners.The benchmark S&P 500 was posting 34 new 52-week highs and 3 new lows; the Nasdaq Composite was recording 70 new highs and 27 new lows.    (Additonal reporting by Sinead Carew; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,MRK,"Wed Feb 4, 2015 | 2:35pm EST","US STOCKS-S&P, Nasdaq slip after 2-day run up; energy drops with oil",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE24N20150204?type=companyNews
289,"  (New throughout, adds analyst comments, details on Merck hepatitis C drugs)By Ransdell PiersonFeb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the ""breakthrough therapy"" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.The Food and Drug Administration gives the designation to medicines it deems likely to demonstrate ""substantial improvement"" over existing drugs. The designation has hastened approval of some drugs by two to three months.Analysts said Merck's two-drug treatment would likely now require a standard 10-month review.Merck, in its fourth-quarter earnings report, said it plans to discuss the matter with the FDA and still expects to seek U.S. approval in the first half of 2015. The treatment consists of a protease inhibitor called MK-5172 and a so-called NS5A inhibitor called MK-8742 that together had received the FDA's ""breakthrough therapy"" designation.In a recent mid-stage trial, Merck's combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C. Merck said late-stage trials are now complete, and will support approval.""Based upon data today, we believe we will be able to compete in the marketplace,"" Adam Schechter, head of global human health for Merck, said in an interview. The setback for Merck follows recent approvals of costly oral treatments for the liver disease from Gilead Sciences Inc  and AbbVie Inc that have wiped out all signs of the virus in well over 90 percent of patients after eight or 12 weeks.""The breakthrough therapy designation is meant for drugs that address an unmet medical need, but we now have two virtual cures for hepatitis C on the market"" from Gilead and AbbVie, said Edward Jones analyst Ashtyn Evans.Evans said Merck's combination treatment will likely undergo a standard FDA review. She predicted, however, that Merck's array of experimental hepatitis C drugs will eventually claim a 15 to 20 percent global market share, with annual sales in the billions of dollars.Shares of the second-biggest U.S. drugmaker fell 3.5 percent on Wednesday, also hurt by a weaker-than-expected profit forecast for 2015 which the company blamed on the stronger dollar. TAKING BIGGER AIM In the face of such potent rival hepatitis C medicines, Merck in June announced it would ramp up its involvement in the lucrative field by buying Idenix Pharmaceuticals Inc for $3.85 billion and combining the two companies' most promising drugs to produce a faster, more effective cure. Idenix had three hepatitis C drugs in development, most notably a pill in early-stage trials called IDX21437, which Merck has renamed MK-3682. Like Gilead's Sovaldi, it is a nucleotide inhibitor, or ""nuc,"" that blocks a protein needed by the hepatitis C virus to replicate.Merck is conducting a mid-stage trial to study combinations of MK-3682 and MK-5172 (grazoprevir) with either MK-8742 (elbasvir) or another drug called MK-8408. It hopes to begin larger late-stage trials of the triplet therapies this year.Gilead introduced Sovaldi in late 2013 at a cost of $1,000 a pill, and reported fourth-quarter sales of $1.73 billion for the drug. Gilead later introduced Harvoni, a pill combining Sovaldi with another treatment, and it captured sales of $2.11 billion in the quarter.AbbVie launched its Viekira Pak treatment late last year. Since then, it has battled Gilead for market share by offering discounts to insurers and other group payers.Late on Tuesday, Gilead disclosed that its discounts will average 46 percent this year, up sharply from analyst expectations of 25 to 30 percent. Shares of Gilead and AbbVie both tumbled after the news.As many as 3.2 million people in the United States are estimated to be infected with the hepatitis C virus, which can lead to severe liver disease.Merck on Wednesday reported slightly disappointing fourth-quarter sales and predicted 2015 earnings below analyst forecasts. It cited the negative impact of the stronger dollar, as most of its U.S. rivals have done in their own cautious forecasts.    (Reporting by Ransdell Pierson; Editing by W Simon, Paul Simao and David Gregorio)",2015-02-04,MRK,"Wed Feb 4, 2015 | 2:10pm EST","UPDATE 3-Merck says hepatitis C treatment to lose ""breakthrough"" status",http://www.reuters.com//article/merck-co-results-idUSL1N0VE0Q920150204?type=companyNews
290,"  * Crude falls after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes: Dow up 0.1 pct, S&P off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)By Caroline ValetkevitchNEW YORK, Feb 4 The S&P 500 and Nasdaq eased on Wednesday, in the wake of a two-day rally, as Gilead and other biotech names declined and energy shares reversed course with oil prices.Walt Disney kept the Dow in positive territory.  Disney shares jumped 8.3 percent to $101.86 after quarterly profit topped analysts' expectations. Leading biotechnology shares lower was Gilead Sciences , whose stock dropped 7.5 percent, a day after the drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price.The news fueled concerns the sector would face increasing price pressure, The Nasdaq Biotech Index was down 1.4 percent. Gilead was also the biggest drag on the S&P 500 and Nasdaq.Also in the healthcare space, Merck shares lost 4 percent after the drugmaker reported slightly disappointing fourth quarter sales. The S&P 500 energy index was off 1.5 percent as oil prices declined after a four-day surge of nearly 20 percent. U.S. crude was down 5.3 percent at $50.23 following a new build in U.S. crude stockpiles.The day's dip move follows a 2-day gain of 2.8 percent for the S&P 500, driven largely by a jump in energy shares.""It does seem as if the trading world has focused in on the price of crude oil as being the best barometer of what's going on in terms of economic activity,"" said Eric Kuby, chief investment officer, North Star Investment Management Corp., Chicago. At 12:49 p.m., the Dow Jones industrial average rose 9.49 points, or 0.05 percent, to 17,675.89, the S&P 500  lost 7.08 points, or 0.35 percent, to 2,042.95 and the Nasdaq Composite dropped 10.55 points, or 0.22 percent, to 4,717.19.Shares of cable and telecom operators rose sharply after Federal Communications Commission Chairman Tom Wheeler, in an op-ed published on Wired.com, said he aims to establish the ""strongest open Internet protections ever proposed by the FCC"" that would apply, for the first time, to both wireless and wired broadband providers. Shares of Comcast  were up 2.4 percent.On the economic front, U.S. labor market data disappointed. The ADP National Employment Report showed private employers added 213,000 jobs in January, short of the 225,000 estimate.Declining issues outnumbered advancing ones on the NYSE by 1,894 to 1,095, for a 1.73-to-1 ratio; on the Nasdaq, 1,465 issues fell and 1,182 advanced, for a 1.24-to-1 ratio favoring decliners.The S&P 500 was posting 31 new 52-week highs and 2 new lows; the Nasdaq Composite was recording 68 new highs and 23 new lows.     (Additonal reporting by Sinead Carew; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,MRK,"Wed Feb 4, 2015 | 1:05pm EST","US STOCKS-S&P, Nasdaq down after 2-day run up; biotechs, energy fall",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE1UA20150204?type=companyNews
291,"  * Crude falls after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes: Dow up 0.16 pct, S&P off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)By Chuck MikolajczakNEW YORK, Feb 4 U.S. stocks dipped on Wednesday, in the wake of a two-day rally for the S&P 500, as oil prices declined and labor market data disappointed.The ADP National Employment Report showed private employers added 213,000 jobs in January, short of the 225,000 estimate. Oil prices declined after a four-day surge of nearly 20 percent as a new build in U.S. crude stockpiles put a global glut back in focus. U.S. crude was down 5.1 percent to $50.37 and Brent was off 3.6 percent to $55.83. The S&P energy index lost 1.4 percent.""We've had an enormous rally in oil the past couple of days. Today it's down, so that definitely seems to be it,"" said Randy Frederick, managing director of trading and derivatives for Charles Schwab in Austin, Texas.""Given that we've had a huge rally in the S&P the last couple of days it wouldn't surprise me to see a relatively flat day, which is kind of what we've got.""Separate reports on the services sector showed growth, with both financial data firm Markit's final January reading and data from the Institute for Supply Management topping expectations. Merck shares lost 4 percent to $58.57 as the biggest drag on the Dow after the drugmaker reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts.But Disney helped keep the Dow in positive territory, up 7.2 percent to $100.88 after quarterly profit topped Wall Street's estimates.The S&P 500 gained 2.8 percent over the past two sessions as oil prices bounced and on hopes of a Greek debt deal, but the index has been a trading range of 1,972 to 2,093 since mid-December and is nearly flat since Dec. 31. Despite the tight range, equities have been more volatile in 2015, with the daily trading range often double its average over the past year. The Dow Jones industrial average rose 28.39 points, or 0.16 percent, to 17,694.79, the S&P 500 lost 4.42 points, or 0.22 percent, to 2,045.61 and the Nasdaq Composite  dropped 14.85 points, or 0.31 percent, to 4,712.89.Gilead Sciences shares dropped 9.5 percent to $96.99, dragging the Nasdaq lower. The drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price.Chipotle Mexican Grill slumped 7.6 percent to $671.50. Sales growth at established restaurants slowed in the fourth quarter and slightly missed Wall Street's estimate.According to Thomson Reuters data, of the 273 companies in the S&P 500 that have reported earnings, 73.3 percent have topped expectations, above the 69 percent beat rate for the past four quarters.Declining issues outnumbered advancing ones on the NYSE by 1,738 to 1,161, for a 1.50-to-1 ratio; on the Nasdaq, 1,390 issues fell and 1,120 advanced, for a 1.24-to-1 ratio favoring decliners.The S&P 500 posted 27 new 52-week highs and 2 lows; the Nasdaq Composite recorded 50 new highs and 18 lows.     (Reporting by Chuck Mikolajczak; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,MRK,"Wed Feb 4, 2015 | 11:10am EST",US STOCKS-Wall St dips after 2-day run as energy rally stalls,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE1HK20150204?type=companyNews
292,"  * Crude falls after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes off: Dow 0.2 pct, S&P 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)By Chuck MikolajczakNEW YORK, Feb 4 U.S. stocks lost ground in early trade on Wednesday, in the wake of a two-day rally for the S&P 500, as oil prices declined and labor market data disappointed.The ADP National Employment Report showed private employers added 213,000 jobs in January, falling short of the median forecasts of analysts of 225,000 jobs. Oil prices declined after a four-day rally of nearly 20 percent as a new build in U.S. crude stockpiles put a global glut back in focus. U.S. crude was down 3.3 percent to $51.32 and Brent was off 2.6 percent to $56.43. The S&P energy index lost 1.7 percent as the worst performing S&P sector.""Oil has been the big driver. We have seen oil moving strongly since last Friday and certainly the energy sector was leading the market higher,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois.Merck shares lost 2.3 percent to $59.63 as one of the biggest drags on the Dow after the drugmaker reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts, citing the stronger dollar.But fellow Dow component Disney gained 5.6 percent to $99.36 after quarterly profit topped Wall Street's estimates. The S&P 500 gained 2.8 percent over two sessions as oil prices bounced and on hopes of a Greek debt deal, although the index has been a trading range of 1,972 to 2,093 since mid-December and is nearly flat since Dec. 31. Despite the tight range, equities have been more volatile in 2015, with the daily trading range often double its average over the past year.The Dow Jones industrial average fell 34.55 points, or 0.2 percent, to 17,631.85, the S&P 500 lost 9.54 points, or 0.47 percent, to 2,040.49 and the Nasdaq Composite  dropped 27.70 points, or 0.59 percent, to 4,700.04.Financial data firm Markit said the final reading of its Purchasing Managers Index for the service sector rose to 54.2 in January, though companies reported the weakest new business growth in more than five years. At 10 a.m. (1500 GMT), the Institute for Supply Management will release its reading on the services sector.Gilead Sciences shares dropped 9.9 percent to $96.61, dragging the Nasdaq lower. The drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price.General Motors reported fourth-quarter earnings well above Wall Street expectations and said it plans to raise its quarterly dividend by 20 percent, sending shares up 3 percent to $35.01.Chipotle Mexican Grill slumped 7.3 percent to $673.52. Sales growth at established restaurants slowed in the fourth quarter and slightly missed Wall Street's estimate.NYSE declining issues outnumbered advancers 1,986 to 698, for a 2.85-to-1 ratio; on the Nasdaq, 1,440 issues fell and 717 advanced, a 2.01-to-1 ratio.The S&P 500 posted 16 new 52-week highs and no new lows; the Nasdaq Composite recorded 21 new highs and 10 new lows.     (Reporting by Chuck Mikolajczak; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,MRK,"Wed Feb 4, 2015 | 9:49am EST",US STOCKS-Wall St down after 2-day run after ADP as energy drags,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE17620150204?type=companyNews
293,"  * Crude falls after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Futures off: Dow 18 pts, S&P 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)By Chuck MikolajczakNEW YORK, Feb 4 U.S. stocks were poised to dip at the open on Wednesday, in the wake of a two-day rally for the S&P 500, as oil prices declined and labor market data disappointed.The ADP National Employment Report showed private employers added 213,000 jobs in January, falling short of the median forecasts of analysts of 225,000 jobs. Oil prices declined after a four-day rally of nearly 20 percent as a new build in U.S. crude stockpiles put a global glut back in focus. U.S. crude was down 3.3 percent to $51.32 and Brent was off 2.6 percent to $56.43. Contract driller Transocean fell 1.9 percent to $18.05 in premarket trade.""Oil has been the big driver. We have seen oil moving strongly since last Friday and certainly the energy sector was leading the market higher,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois.""People may be taking a bit of a wait-and-see attitude here to see if oil drops further or if it holds where it is at."" Merck shares lost 2.2 percent to $59.70 before the opening bell after the drugmaker reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts, citing the stronger dollar.But fellow Dow component Disney gained 4.9 percent to $98.70 after quarterly profit topped Wall Street's estimates.The S&P 500 has gained 2.8 percent over two sessions as oil prices bounced and on hopes of a Greek debt deal, although the index has been locked in a trading range of 1,972 to 2,093 since mid-December and is nearly flat since Dec. 31. Despite the tight range, equities have been more volatile in 2015, with the daily trading range in the index often double its average over the past year. S&P 500 e-mini futures were down 6.25 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a lower open. Dow Jones industrial average e-mini futures fell 18 points and Nasdaq 100 e-mini futures lost 14.5 points.Later in the session at 9:45 a.m. (1445 GMT), financial data firm Markit will release its final January reading on the services sector. At 10 a.m. (1500 GMT), the Institute for Supply Management will release its reading on the services sector.Gilead Sciences shares dropped 7.5 percent to $99.20 in premarket. The drugmaker posted quarterly results and said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price.General Motors reported fourth-quarter earnings well above Wall Street expectations and said it plans to raise its quarterly dividend by 20 percent, sending shares up 4 percent to $35.35 in premarket.Chipotle Mexican Grill slumped 6.1 percent to $682 in premarket after sales growth at established restaurants slowed in the fourth quarter and slightly missed Wall Street's estimate.    (Reporting by Chuck Mikolajczak; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,MRK,"Wed Feb 4, 2015 | 9:12am EST","US STOCKS-Wall St to open lower after 2-day run, ADP data",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE0SW20150204?type=companyNews
294,"  Feb 4 Merck & Co on Wednesday reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts, citing the negative impact of the stronger dollar, as most of its U.S. rivals have done in making their own cautious forecasts.Merck said it expects full-year 2015 earnings of $3.32 to $3.47 per share, excluding special items, with foreign exchange factors crimping earnings by 27 cents per share. Wall Street had predicted $3.49 per share.The second-biggest U.S. drugmaker on Wednesday said it earned $7.32 billion, or $2.54 per share, in the fourth quarter. That compared with $781 million, or 26 cents per share, in the year-earlier period. Excluding special items, the company earned 87 cents per share. Analysts, on average, expected 85 cents per share, according to Thomson Reuters I/B/E/S. Company revenue of $10.48 billion trailed Wall Street expectations of $10.5 billion, held back by lower sales of its Remicade arthritis drug, now facing competition from cheaper generics. (Reporting by Ransdell Pierson Editing by W Simon)",2015-02-04,MRK,"Wed Feb 4, 2015 | 7:27am EST","Merck issues cautious 2015 forecast, citing dollar",http://www.reuters.com//article/merck-co-results-idUSL1N0VD29V20150204?type=companyNews
295,"   By Joseph Ax | NEW YORK  NEW YORK A former Merck & Co Inc finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.Zachary Zwerko, 32, pleaded guilty to four counts in New York federal court, including conspiracy and securities fraud, as part of a plea deal with the government.The friend, David Post, a fellow graduate of Rutgers Business School, pleaded guilty in October and agreed to cooperate with investigators. Prosecutors accused Zwerko of giving Post advance information between 2012 and 2014 about Merck's acquisition of Idenix Pharmaceuticals, as well as tips that Ardea BioSciences and ViroPharma Inc were potential acquisition targets.AstraZeneca Plc acquired Ardea in 2012, while Shire Plc purchased ViroPharma in 2013. Post used the tips to make more than $737,000 in illicit profits while paying Zwerko a total of $57,000 for the information, prosecutors said. The office of Manhattan U.S. Attorney Preet Bharara has charged 92 people since 2009 in a wide-ranging crackdown on insider trading.Zwerko is scheduled to be sentenced on May 15 by U.S. District Judge Alvin Hellerstein. The plea agreement stipulates that federal sentencing guidelines recommend a prison sentence between 37 and 46 months, though he is free to argue for a shorter term. No sentencing date has been scheduled for Post.Zwerko and Post also face related civil charges from the U.S. Securities and Exchange Commission.",2015-02-19,MRK,"Thu Feb 19, 2015 | 5:00pm EST",Ex-Merck analyst pleads guilty to U.S. insider trading charges,http://www.reuters.com//article/insidertrading-merck-co-plea-idUSL1N0VT30A20150219?type=companyNews
296,"   By Joseph Ax | NEW YORK  NEW YORK Feb 19 A former Merck & Co Inc  finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.Zachary Zwerko, 32, pleaded guilty to four counts in New York federal court, including conspiracy and securities fraud, as part of a plea deal with the government.The friend, David Post, a fellow graduate of Rutgers Business School, pleaded guilty in October and agreed to cooperate with investigators. Prosecutors accused Zwerko of giving Post advance information between 2012 and 2014 about Merck's acquisition of Idenix Pharmaceuticals, as well as tips that Ardea BioSciences and ViroPharma Inc were potential acquisition targets.AstraZeneca Plc acquired Ardea in 2012, while Shire Plc purchased ViroPharma in 2013. Post used the tips to make more than $737,000 in illicit profits while paying Zwerko a total of $57,000 for the information, prosecutors said. The office of Manhattan U.S. Attorney Preet Bharara has charged 92 people since 2009 in a wide-ranging crackdown on insider trading.Zwerko is scheduled to be sentenced on May 15 by U.S. District Judge Alvin Hellerstein. The plea agreement stipulates that federal sentencing guidelines recommend a prison sentence between 37 and 46 months, though he is free to argue for a shorter term. No sentencing date has been scheduled for Post.Zwerko and Post also face related civil charges from the U.S. Securities and Exchange Commission.   (Reporting by Joseph Ax; Editing by Lisa Shumaker)",2015-02-19,MRK,"Thu Feb 19, 2015 | 4:55pm EST",Ex-Merck analyst pleads guilty to U.S. insider trading charges,http://www.reuters.com//article/insidertrading-merck-co-plea-idUSL1N0VT2TM20150219?type=companyNews
297,"  * Biosimilars launched by Celltrion, Hospira and Mundipharma* New products are copies of J&J and Merck's Remicade* Biosimilars expected to disrupt market for biotech medicines   (Adds detail on price discount, paragraph 7)By Ben HirschlerLONDON, Feb 25 Cheap versions of a top-selling drug for rheumatoid arthritis and Crohn's disease are being launched across major European markets in an important advance for a new type of medicines known as biosimilars.The products from South Korean firm Celltrion  and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson & Johnson  and Merck & Co.The potential of biosimilars to grab substantial business from original brands was a key factor behind Pfizer's  decision this month to buy Hospira for about $15 billion. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of  relevant Remicade patents.Hospira is to sell its product Inflectra in markets including Austria, Britain, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain and Sweden.Copies of Remicade have been on sale for several months in some smaller European markets, such as Norway, but the move into major economies is a big step forward for products that could disrupt the multibillion-dollar biotechnology industry.PRICE DISCOUNT  Paul Greenland, head of biologics at Hospira, said that biosimilars are likely to be priced about 20-30 percent cheaper than originals.Because biotech drugs are made from living cells it is impossible to manufacture exact copies, as happens with simple chemical medicines, so regulators have come up with the notion of approving products that are similar enough to do the job.Remicade, which has annual European sales of about 2 billion euros ($2.3 billion), and the two biosimilar copies all contain an antibody known as infliximab. There has been a fierce debate for many years on how rapidly biosimilars will be adopted by doctors and the take-up of Remsima and Inflectra in the likes of Germany, France and Britain will be an important test.Many more biosimilar copies of drugs for diseases ranging from cancer to eye disorders are now in development, posing a threat to leading biotech drugmakers such as Roche and AbbVie.Citigroup analyst Andrew Baum predicted this month that biosimilars would result in at least $110 billion of value being transferred from innovator companies to copycat producers between 2015 and 2025.The upside for society is that they could generate an estimated $50 billion in savings for healthcare systems, Citi says.Jorgen Jahnsen, professor of medicine and gastroenterology at the University of Oslo, said that in Norway the use of biosimilar infliximab had already enabled the healthcare system to make considerable savings.Another test for biosimilars is looming in the United States, where a Food and Drug Administration advisory committee will decide on March 17 whether to recommend Celltrion's biosimilar version of Remicade. ($1 = 0.8797 euros)   (Editing by David Goodman)",2015-02-25,MRK,"Wed Feb 25, 2015 | 8:50am EST",UPDATE 1-Biosimilar copies of blockbuster drug launch in major EU markets,http://www.reuters.com//article/health-biosimilars-europe-idUSL5N0VZ3RN20150225?type=companyNews
298,"  * Biosimilars launched by Celltrion, Hospira and Mundipharma* New products are copies of J&J and Merck's Remicade* Biosimilars expected to disrupt market for biotech medicinesBy Ben HirschlerLONDON, Feb 25 Cheap versions of a top-selling drug for rheumatoid arthritis and Crohn's disease are being launched across major European markets in an important advance for a new type of medicines known as biosimilars.The products from South Korean firm Celltrion  and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson & Johnson  and Merck & Co.The potential of biosimilars to grab substantial business from original brands was a key factor behind Pfizer's  decision this month to buy Hospira for about $15 billion. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of  relevant Remicade patents.Hospira is to sell its product Inflectra in markets including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain and Sweden.Copies of Remicade have been on sale for several months in some smaller European markets, such as Norway, but the move into major economies is a big step forward for products that could disrupt the multibillion-dollar biotechnology industry. Because biotech drugs are made from living cells it is impossible to manufacture exact copies, as happens with simple chemical medicines, so regulators have come up with the notion of approving products that are similar enough to do the job.Remicade, which has annual European sales of about 2 billion euros ($2.3 billion), and the two biosimilar copies all contain an antibody known as infliximab.There has been a fierce debate for many years on how rapidly biosimilars will be adopted by doctors and the take-up of Remsima and Inflectra in the likes of Germany, France and Britain will be an important test. Many more biosimilar copies of drugs for diseases ranging from cancer to eye disorders are now in development, posing a threat to leading biotech drugmakers such as Roche and AbbVie.Citigroup analyst Andrew Baum predicted this month that biosimilars would result in at least $110 billion of value being transferred from innovator companies to copycat producers between 2015 and 2025.The upside for society is that they could generate an estimated $50 billion in savings for healthcare systems, Citi says.Jorgen Jahnsen, professor of medicine and gastroenterology at the University of Oslo, said that in Norway the use of biosimilar infliximab had already enabled the healthcare system to make considerable savings.Another test for biosimilars is looming in the United States, where a Food and Drug Administration advisory committee will decide on March 17 whether to recommend Celltrion's biosimilar version of Remicade. ($1 = 0.8797 euros)   (Editing by David Goodman)",2015-02-25,MRK,"Wed Feb 25, 2015 | 3:31am EST",Biosimilar copies of blockbuster drug launch in major EU markets,http://www.reuters.com//article/health-biosimilars-europe-idUSL5N0VZ17L20150225?type=companyNews
299,"   By Kate Kelland and Tom Miles | LONDON/GENEVA  LONDON/GENEVA Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday.Signaling global health authorities' determination to see through trials despite a sharp drop in cases in the West Africa epidemic, the WHO said a second shot, developed by GlaxoSmithKline will be tested ""in a sequential study, as supply becomes available"".More than 23,900 confirmed and suspected cases of Ebola have been reported since the outbreak began in December 2013, including some 9,800 deaths. Nearly 500 health workers have been among the dead in what is the worst ever Ebola epidemic.All three worst-hit countries - Guinea, Liberia and Sierra Leone - aim to conduct final-stage trials of vaccines, and Liberia is already testing the GlaxoSmithKline and Merck-NewLink shots, while Sierra Leone is expected to announce plans soon.But recent steep declines in new Ebola cases will make it far harder to prove whether experimental vaccines work, as the vaccine's effect will be difficult to establish. The WHO, however, said it was committed to pushing ahead.""The Ebola epidemic shows signs of receding but we cannot let down our guard until we reach zero cases,"" said Marie-Paule Kieny, head of the WHO's Ebola research and development effort. ""An effective vaccine to control current flare-ups could be the game-changer to finally end this epidemic and an insurance policy for any future ones.""The trial in the Basse Guine region, which has Guinea's most cases, will use a ""ring vaccination"" strategy similar to that used to eradicate smallpox in the 1970s. This involves vaccinating everyone who has been in contact with a newly diagnosed person or ""index"" case. ""Testing investigational medicines during an epidemic is incredibly challenging, but this approach gives us the best possible chance of finding a safe and effective vaccine in time to save lives,"" said Jeremy Farrar, director of Wellcome Trust, the medical charity that has led the push for Ebola vaccines. In Liberia, where no new cases have been reported for 13 days, the government says the trial is a ""resounding success"". But local media has reported that some residents are refusing measles and polio vaccinations amid rumors of a deliberate plot to infect them with Ebola. (Additional reporting by James Harding Giahyue in Monrovia and Emma Farge in Dakar; Editing by Louise Ireland)",2015-03-05,MRK,"Thu Mar 5, 2015 | 7:19am EST",Guinea to start final trials of Ebola vaccines this week,http://www.reuters.com//article/us-health-ebola-vaccine-idUSKBN0M10ZD20150305?type=companyNews
300,"  * Experimental shots from Merck-Newlink and GSK to be tested* Guinea trial to take use ""ring vaccination"" stategy* WHO says effective Ebola shot could be a ""game-changer""   (Adds details of ""ring vaccination"" plans, quotes)By Kate Kelland and Tom MilesLONDON/GENEVA, March 5 Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday.Signalling global health authorities' determination to see through trials despite a sharp drop in cases in the West Africa epidemic, the WHO said a second shot, developed by GlaxoSmithKline will be tested ""in a sequential study, as supply becomes available"". More than 23,900 confirmed and suspected cases of Ebola have been reported since the outbreak began in December 2013, including some 9,800 deaths. Nearly 500 health workers have been among the dead in what is the worst ever Ebola epidemic.All three worst-hit countries - Guinea, Liberia and Sierra Leone - aim to conduct final-stage trials of vaccines, and Liberia is already testing the GlaxoSmithKline and Merck-NewLink shots, while Sierra Leone is expected to announce plans soon.But recent steep declines in new Ebola cases will make it far harder to prove whether experimental vaccines work, as the vaccine's effect will be difficult to establish. The WHO, however, said it was committed to pushing ahead.""The Ebola epidemic shows signs of receding but we cannot let down our guard until we reach zero cases,"" said Marie-Paule Kieny, head of the WHO's Ebola research and development effort. ""An effective vaccine to control current flare-ups could be the game-changer to finally end this epidemic and an insurance policy for any future ones.""The trial in the Basse Guine region, which has Guinea's most cases, will use a ""ring vaccination"" strategy similar to that used to eradicate smallpox in the 1970s. This involves vaccinating everyone who has been in contact with a newly diagnosed person or ""index"" case.""Testing investigational medicines during an epidemic is incredibly challenging, but this approach gives us the best possible chance of finding a safe and effective vaccine in time to save lives,"" said Jeremy Farrar, director of Wellcome Trust, the medical charity that has led the push for Ebola vaccines.In Liberia, where no new cases have been reported for 13 days, the government says the trial is a ""resounding success"".But local media has reported that some residents are refusing measles and polio vaccinations amid rumours of a deliberate plot to infect them with Ebola.    (Additional reporting by James Harding Giahyue in Monrovia and Emma Farge in Dakar; Editing by Louise Ireland)",2015-03-05,MRK,"Thu Mar 5, 2015 | 7:12am EST",UPDATE 2-Guinea to start final trials of Ebola vaccines this week,http://www.reuters.com//article/health-ebola-vaccine-idUSL5N0W729620150305?type=companyNews
301,"  GENEVA, March 5 Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7, the final stage of testing, the World Health Organization said on Thursday. A second vaccine, developed by GlaxoSmithKline will be tested ""in a sequential study, as supply becomes available"", the WHO said.   (Reporting by Tom Miles; Editing by Robin Pomeroy)  ",2015-03-05,MRK,"Thu Mar 5, 2015 | 5:02am EST",Merck-NewLink Ebola vaccine Phase III trial to start March 7,http://www.reuters.com//article/health-ebola-vaccine-idUSL5N0W725E20150305?type=companyNews
302,"  LONDON Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in Europe, is the first medicine to be made available to patients in Britain under a new early access scheme.The Medicines and Healthcare Products Regulatory Agency said on Wednesday that the treatment had been cleared to treat adults and children from 12 years of age with advanced melanoma, the deadliest form of skin cancer, after other drugs had failed.Keytruda, or pembrolizumab, was accepted under the scheme based on the significance of early study findings and unmet medical need. It had already received a ""promising innovative medicine"" designation in Britain in October 2014.The British initiative, which has similarities with a U.S. scheme that has accelerated the development of so-called ""breakthrough"" medicines, follows criticism that Britain's state-run healthcare system is too slow to adopt new treatments. The new early access program is funded by drug companies. While Keytruda is already approved in the United States, Merck's application for marketing authorization in Europe is still under review.  (Reporting by Ben Hirschler; editing by Jason Neely)",2015-03-11,MRK,"Wed Mar 11, 2015 | 3:51am EDT",Merck cancer drug is first approved under UK early access scheme,http://www.reuters.com//article/us-health-britain-cancer-merck-co-idUSKBN0M70M320150311?type=companyNews
303,"  LONDON, March 11 Merck & Co's cancer drug Keytruda, which works by boosting the immune system but has yet to be licensed in Europe, is the first medicine to be made available to patients in Britain under a new early access scheme.The Medicines and Healthcare Products Regulatory Agency said on Wednesday that the treatment had been cleared to treat adults and children from 12 years of age with advanced melanoma, the deadliest form of skin cancer, after other drugs had failed.Keytruda, or pembrolizumab, was accepted under the scheme based on the significance of early study findings and unmet medical need. It had already received a ""promising innovative medicine"" designation in Britain in October 2014. The British initiative, which has similarities with a U.S. scheme that has accelerated the development of so-called ""breakthrough"" medicines, follows criticism that Britain's state-run healthcare system is too slow to adopt new treatments. The new early access programme is funded by drug companies. While Keytruda is already approved in the United States, Merck's application for marketing authorisation in Europe is still under review.(Reporting by Ben Hirschler; editing by Jason Neely)",2015-03-11,MRK,"Wed Mar 11, 2015 | 3:38am EDT",Merck cancer drug is first approved under UK early access scheme,http://www.reuters.com//article/health-britain-cancer-merck-co-idUSL5N0WD10N20150311?type=companyNews
304,"  Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.Merck on Friday said it expects a so-called complete response letter from the U.S. Food and Drug Administration by April 22. Such letters indicate that the agency is unwilling to approve a drug until certain conditions are met.A March 18 meeting of an independent FDA medical advisory panel to discuss the company's resubmitted marketing application has been canceled, Merck said, adding that the company will continue to work with the FDA as the agency completes its review.Sugammadex, which reverses the effects of muscle relaxants after surgery, is already approved in more than 50 countries. Cowen & Co, a brokerage, has estimated that sugammadex, if approved in the United States, could capture annual sales of $550 million by 2020, which would make it a moderate-sized product for Merck. It is sold overseas under the brand name Bridion. It was developed by Schering Plough, a rival U.S. drugmaker acquired by Merck in 2009, and has been billed by the drugmakers for years as a potential major advance in speeding recovery of patients from anesthesia. The FDA rejected the injectable drug in 2008, citing concerns about a possible association with allergic reactions and bleeding.  (Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings and Richard Chang)",2015-03-13,MRK,"Fri Mar 13, 2015 | 5:35pm EDT",Merck expects to be denied approval for sugammadex injection again,http://www.reuters.com//article/us-merck-co-fda-idUSKBN0M92GE20150313?type=companyNews
305,"  (Adds details on drug, FDA plans)March 13 Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.Merck on Friday said it expects a so-called complete response letter from the U.S. Food and Drug Administration by April 22. Such letters indicate that the agency is unwilling to approve a drug until certain conditions are met.A March 18 meeting of an independent FDA medical advisory panel to discuss the company's resubmitted marketing application has been canceled, Merck said, adding that the company will continue to work with the FDA as the agency completes its review. Sugammadex, which reverses the effects of muscle relaxants after surgery, is already approved in more than 50 countries. Cowen & Co, a brokerage, has estimated that sugammadex, if approved in the United States, could capture annual sales of $550 million by 2020, which would make it a moderate-sized product for Merck. It is sold overseas under the brand name Bridion.It was developed by Schering Plough, a rival U.S. drugmaker acquired by Merck in 2009, and has been billed by the drugmakers for years as a potential major advance in speeding recovery of patients from anesthesia. The FDA rejected the injectable drug in 2008, citing concerns about a possible association with allergic reactions and bleeding.(Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings and Richard Chang)",2015-03-13,MRK,"Fri Mar 13, 2015 | 5:33pm EDT",UPDATE 1-Merck expects to be denied approval for sugammadex injection again,http://www.reuters.com//article/merck-co-fda-idUSL4N0WF5B820150313?type=companyNews
306,"  March 13 Merck & Co Inc said it expected to be denied U.S. approval for its sugammadex injection, after the U.S. Food and Drug Administration said it would conduct additional site inspections related to a study of the drug.The company said it now expected to receive a complete response letter by April 22, when the FDA is expected to make its final decision. A meeting of an independent panel to the FDA scheduled for  March 18 to discuss the company's resubmitted marketing application has been canceled, Merck said on Friday. Sugammadex, which reverses the effects of muscle relaxants after surgery, is already approved in more than 50 countries. The FDA rejected the drug in 2008, citing concerns about a possible association with allergic reactions and bleeding.     (Reporting by Natalie Grover in Bengaluru; Editing by Simon Jennings)",2015-03-13,MRK,"Fri Mar 13, 2015 | 4:37pm EDT",Merck expects to be denied approval for sugammadex injection again,http://www.reuters.com//article/merck-co-fda-idUSL4N0WF59O20150313?type=companyNews
307,"  FRANKFURT, March 20 Germany's Merck KGaA  will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.The publication said Oschmann, 57, would take on the new role after the group's annual shareholder meeting in April 2016 or in September next year at the latest, when Kley's current contract expires.The German drugs and chemicals maker last September appointed Oschmann, the head of its pharma business at the time, as deputy chief executive from January, sharing strategic management functions and representation of the company with Kley, who is 63. A Merck spokeswoman said a decision on Kley's succession has not yet been made and that this would be a matter for the family-controlled group's board of partners. She declined to comment further. Merck, which is also the world's largest maker of liquid crystals for flat-panel displays, is buying Sigma-Aldrich , putting it on track to become the world's second-largest lab supplies maker after Thermo Fisher. Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc's emerging markets operations. The two companies share historic roots but are under separate ownership since World War One.   (Reporting by Georgina Prodhan; Editing by Ludwig Burger and Greg Mahlich)",2015-03-20,MRK,"Fri Mar 20, 2015 | 7:11am EDT",Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin,http://www.reuters.com//article/merck-board-idUSL6N0WM21D20150320?type=companyNews
308,"  (The following statement was released by the rating agency) CHICAGO, April 13 (Fitch) Fitch Ratings has downgraded Merck & Co.'s (Merck)  long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating  Outlook to Stable from Negative. In addition, the company's short-term IDR has  been affirmed at 'F1'. Merck had $21.7 billion in outstanding debt at Dec. 31, 2014. A full list of  Fitch's ratings actions follows at the end of this release.  KEY RATING DRIVERS --Fitch expects MRK's leverage (total debt/EBITDA) to remain above 1.7x for the  next several years, a level consistent with an 'A' rating given the company's  scale and strong industry position.    --Fitch believes Merck will pursue targeted acquisitions as opposed to large  transformative ones. An improving pipeline and narrowing strategic focus reduces  the need to do big deals, as evidenced by the recent acquisition of Cubicin  Pharmaceuticals (Cubist).  --Fitch expects Merck will continue to favor share repurchases over  deleveraging, with the possibility of further debt-funded stock buybacks being  an overhang on the credit profile. The company has roughly $11.7 billion  remaining on its existing repurchase authorizations as of March 24, 2015. --Sales at risk to patent expiries through 2017 are roughly 23% of 2014  revenues. About one-quarter of those sales are generated by biologics, which  tend have significantly less market share erosion upon patent expiration than do  traditional small-molecule drugs. --Merck continues to make progress in building its late-stage pipeline, with  approximately 17 new molecular entities (NMEs) in phase 3 development or  registration. --Januvia/Janumet, Merck's largest prescription drug franchise, continued to  post low single-digit growth during 2014, despite ongoing competitive headwinds  in the diabetes treatment market.  --Fitch forecasts that Merck will generate $3.7 billion-$3.8 billion in free  cash flow (FCF)/(cash flow from operations minus capital expenditures minus  dividends) during 2015 as improving margins offset soft revenue. Aggressive Capital Deployment Drives Downgrade: Fitch believes that Merck's  operating outlook is favorable. This includes an improving drug development  pipeline, recently good results in securing FDA approvals for new therapeutic  products, and a manageable percentage of sales at risk to near-term patent  expiration.  Higher leverage (total debt-to-EBITDA of 1.8x pro forma for the Cubist  acquisition versus 1x in 2011) is partly the result of the effects of the U.S.  branded-drug patent cliff on the company's top line and EBITDA in 2012-2013.  However, the company has not prioritized deleveraging as the business profile  has recovered, instead choosing to be aggressive in returning cash to  shareholders.  Cubist Acquistion Expands Presence in Hospital Setting: Merck's January 2015  $8.4 billion acquisition of Cubist plus roughly $1.1 billion in net debt expands  its presence in the anti-infective market, particularly in the hospital setting.  The transaction also adds two of Cubist's pipeline products, bevenopran  (opioid-induced constipation) and surotomycin (clostridium difficile), to  Merck's drug development efforts. The acquisition was largely funded with $8  billion in new debt, which Merck issued in February 2015.  The Cubist acquisition is an example of the types of targeted acquisitions that  Fitch believes Merck will continue to pursue. A large, transformational type of  transaction is relatively less likely given the company's favorable operating  outlook.  Diabetes Franchise Growth Continues: Combined sales of Januvia and Janumet  continued to grow during 2014 by roughly 3% year-over-year. Favorable clinical  data, a growing number of diabetic patients, and investment in the franchise has  helped to support the underlying growth in sales. The positive trend has  occurred despite increasing competition from other recently introduced branded  pharmaceuticals within the diabetes market.  Patent Exposure Manageable: The company faces a significant number of patent  expiries during the next two years, but Fitch views the risk as manageable as  roughly only 23% of total firm sales are at risk. In addition, Remicade, which  accounts for about 5.6% of total firm sales, is a biologic that will probably  experience less rapid sales losses to generic competition compared to  traditional small-molecule pharmaceuticals. Expanding Late-Stage Pipeline: Fitch expects Merck to continue to build its  late-stage pipeline with NMEs to treat cancers, bacterial and viral infections,  diabetes, cardiovascular disorders, central nervous afflictions, osteoporosis  and allergies.  While most of these projects are internally developed, Merck has partnered with  other innovator firms to take advantage of technological advancements that were  discovered and cultivated externally. The landscape for drug development is  expanding, particularly as more is learned about how genetics influence the  development, prevention and treatment of disease. As such, Fitch believes that  it is a responsibility, and strategically advantageous, for firms to look  externally as well as internally regarding new drug development. Share Repurchases to Continue: Fitch forecasts continued shareholder-friendly  actions during the near term, some of which may be funded by debt. Merck has  occasionally funded its share repurchases with debt. During 2014, the company  purchased a net $6.1 billion of its common stock, compared to $5.3 billion  during the prior LTM period.  On March 24, 2015, Merck announced its board authorized an additional $10  billion share repurchase program and stated that it had $1.7 billion remaining  on a May 2013 program. Positive FCF Expected: Fitch forecasts that Merck will continue to generate $3.7  billion-$3.8 billion in FCF (cash flow from operations of $10.3 billion minus  capital expenditures of $1.2 billion minus dividends of $5.4 billion) during  2015. Improving margins driven by sales mix and strong cost control efforts  should more than offset expected soft top-line growth.  KEY ASSUMPTIONS Fitch's key assumptions within the rating case for Merck include: -- Declining revenue, driven by weak utilization in developed markets, the  divestiture of the consumer business and foreign exchange headwinds. Somewhat  offsetting the decline are relatively stronger demand in emerging markets, a  moderating patent cliff and incremental revenue from pipeline commercialization.  --Margin improvement driven by a focus on costs and an improving sales mix  benefiting from the divestiture of the lower margin consumer health business. --Annual FCF (cash flow from operations minus capital expenditures minus  dividends) of $3.7 billion to $3.8 billion during 2015. --Targeted acquisitions with no strategic, transformative transactions. --Continued significant capital deployment to share repurchases. --Leverage to range between 1.8x-2x during the next two years driven by an  additional $8 billion in debt issued in February 2015 to fund the Cubist  acquisition.  LIQUIDITY Fitch expects Merck to maintain adequate liquidity through strong FCF generation  and ample access to the credit markets. FCF for the LTM ending Dec. 31, 2014 was  $1.3 billion. At the end of the period, Merck had approximately $15.7 billion in  cash/short-term investments (U.S.: 10%-20% of total balances/OUS: 80%-90% of  total balances) and full availability on its $6 billion revolver, maturing in  August 2019.  At Dec. 31, 2014, Merck had roughly $21.7 billion in debt outstanding, although  the company issued an additional $8 billion in debt in February 2015. After the  issuance the company had roughly $30.5 billion in debt outstanding, with $2.7  billion maturing in 2015, $2.4 billion in 2016, $0.3 billion in 2017 and $3  billion in 2018. Fitch expects near- to mid-term maturities will be satisfied  primarily through refinancing in the public debt markets. RATING SENSITIVITIES Positive: Future developments that may, individually or collectively, lead to  positive rating action include the following: --Improving operations including new product development that support long-term  positive revenue growth and margin stability/increases; --An operational profile that would consitently generate significantly positive  FCF; --Cash deployment strategy that maintains gross debt leverage below 1.7x,  including managing through operational stress such as patent expiries. Negative: Future developments that may, individually or collectively, lead to  negative rating action include the following: --Material and lasting deterioration in operations and FCF, possibly driven by  patent expiries not being offset by new product development; --Leveraging acquisitions without the prospect of timely debt/leverage  reduction; --Persistent leverage above 2.2x. RATING ACTIONS Fitch has downgraded Merck's ratings as follows:   --Long-term IDR to 'A' from 'A+';  --Senior unsecured debt rating to 'A' from 'A+'; --Bank loan rating to 'A' from 'A+'. Fitch has also affirmed Merck's short-term ratings as follows: --Short-term IDR at 'F1'; --Commercial paper rating at 'F1'. The Rating Outlook on the long-term ratings is Stable. Contact: Primary Analyst Bob Kirby, CFA Director +1-312-368-3147  Fitch Ratings, Inc., 70 West Madison Street, Chicago, IL 60602 Secondary Analyst Gregory Dickerson Director +1-212-908-0220 Committee Chairperson Megan Neuburger Managing Director +1-212-908-0515 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com; Elizabeth Fogerty, New York, Tel: +1 (212) 908  0526, Email: elizabeth.fogerty@fitchratings.com. Additional information is available at 'www.fitchratings.com'.  Applicable Criteria and Related Research: --'Corporate Rating Methodology' (May 28, 2014). Applicable Criteria and Related Research:  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2015-04-13,MRK,"Mon Apr 13, 2015 | 12:21pm EDT",Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable,http://www.reuters.com//article/idUSFit91948120150413?type=companyNews
309,"  FRANKFURT Germany's Merck (MRCG.DE) aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich SIAL.O, its finance chief told daily Boersen-Zeitung.""We want to reduce the loans very aggressively within two to three years to stabilize our credit rating and to regain financial leeway for further acquisitions,"" Marcus Kuhnert told the paper in an interview published on Saturday.The German drugs and chemicals maker is funding the biggest takeover in its history from about $2 billion to $3 billion in cash and the issue of new debt securities. It plans to close the deal in the middle of this year. Kuhnert said that after the deal, net debt would be more than three times its earnings before interest, depreciation and amortization (EBITDA) at 12 billion euros ($13 billion) and that Merck wanted to improve the ratio as soon as possible. He said he wanted the ratio lower than two times EBITDA by the end of 2017. ""Then we can talk about smaller and mid-sized acquisitions again,"" Kuhnert said.  (Reporting by Kirsti Knolle; Editing by Louise Ireland)",2015-04-18,MRK,"Sat Apr 18, 2015 | 11:27am EDT",Merck aims to quickly repay up to $5 billion in loans: CFO in Boersen-Zeitung,http://www.reuters.com//article/us-merck-debt-idUSKBN0N90J320150418?type=companyNews
310,"  FRANKFURT, April 18 Germany's Merck  aims to quickly repay the up to $5 billion in bank loans it needed to fund the $17 billion acquisition of U.S. lab supplies company Sigma-Aldrich, its finance chief told daily Boersen-Zeitung.""We want to reduce the loans very aggressively within two to three years to stabilise our credit rating and to regain financial leeway for further acquisitions,"" Marcus Kuhnert told the paper in an interview published on Saturday. The German drugs and chemicals maker is funding the biggest takeover in its history from about $2 billion to $3 billion in cash and the issue of new debt securities. It plans to close the deal in the middle of this year. Kuhnert said that after the deal, net debt would be more than three times its earnings before interest, depreciation and amortisation (EBITDA) at 12 billion euros ($13 billion) and that Merck wanted to improve the ratio as soon as possible. He said he wanted the ratio lower than two times EBITDA by the end of 2017. ""Then we can talk about smaller and mid-sized acquisitions again,"" Kuhnert said.   (Reporting by Kirsti Knolle; Editing by Louise Ireland)",2015-04-18,MRK,"Sat Apr 18, 2015 | 11:18am EDT",Merck aims to quickly repay up to $5 bln in loans -CFO in Boersen-Zeitung,http://www.reuters.com//article/merck-debt-idUSL5N0XF0AL20150418?type=companyNews
311,"   By Deena Beasley  Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.The company said it has filed for U.S. Food and Drug Administration approval of the drug as a treatment for patients with non-small cell lung cancer (NSCLC) whose disease has worsened despite previous treatment.Keytruda, also known as pembrolizumab, belongs to a new class of drugs designed to help the immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1.On Friday, Bristol-Myers Squibb Co said a trial of its PD-1 inhibitor, Opdivo, was stopped early after the drug proved to work better than chemotherapy in previously treated patients with non-squamous NSCLC. Opdivo is already approved for treating the less-common squamous NSCLC, as well as metastatic melanoma. Merck said its FDA lung cancer filing is for patients with both squamous and non-squamous NSCLC. Lung cancer, which kills nearly 160,000 Americans annually, is seen as the biggest opportunity for the PD-1 drugs, which analysts expect to reach billions of dollars in sales.Merck's Phase 1 study of 495 patients with NSCLC, the most common form of the disease, found that 45 percent of patients with high levels of PD-L1 responded to Keytruda, compared with 16.5 percent of patients with PD-L1 levels of 1 percent to 49 percent.For patients with PD-L1 below 1 percent, the response rate - defined as tumor shrinkage of at least 30 percent - was 10.7 percent. Researchers said about a quarter of trial patients had PD-L1 expression in at least half of their tumor cells. Overall, 19 percent of trial patients responded to the drug. Side effects of Keytruda included thyroid problems. One patient died from pneumonitis, or lung inflammation, which was seen in 3.6 percent of trial patients. The Merck results were presented at a meeting of the American Association for Cancer Research and published in the New England Journal of Medicine.Researchers also presented results from a trial showing that Keytruda improved the length of time before advanced skin cancer worsened by 42 percent and extended patient survival by 34 percent compared with treatment with ipilimumab, a different immunotherapy sold by Bristol-Myers under the brand name Yervoy. (This story corrects generic name of Yervoy to ipilimumab in paragraph 12) (Reporting by Deena Beasley; Editing by Dan Grebler)",2015-04-19,MRK,"Sun Apr 19, 2015 | 12:28pm EDT","Merck's Keytruda shrinks lung cancer tumors, FDA approval sought",http://www.reuters.com//article/us-merck-co-cancer-lung-idUSKBN0NA0JS20150419?type=companyNews
312,"  (Corrects generic name of Yervoy to ipilimumab in paragraph 12)By Deena BeasleyApril 19 Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.The company said it has filed for U.S. Food and Drug Administration approval of the drug as a treatment for patients with non-small cell lung cancer (NSCLC) whose disease has worsened despite previous treatment.Keytruda, also known as pembrolizumab, belongs to a new class of drugs designed to help the immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1.On Friday, Bristol-Myers Squibb Co said a trial of its PD-1 inhibitor, Opdivo, was stopped early after the drug proved to work better than chemotherapy in previously treated patients with non-squamous NSCLC. Opdivo is already approved for treating the less-common squamous NSCLC, as well as metastatic melanoma.Merck said its FDA lung cancer filing is for patients with both squamous and non-squamous NSCLC.Lung cancer, which kills nearly 160,000 Americans annually, is seen as the biggest opportunity for the PD-1 drugs, which analysts expect to reach billions of dollars in sales.Merck's Phase 1 study of 495 patients with NSCLC, the most common form of the disease, found that 45 percent of patients with high levels of PD-L1 responded to Keytruda, compared with 16.5 percent of patients with PD-L1 levels of 1 percent to 49 percent. For patients with PD-L1 below 1 percent, the response rate - defined as tumor shrinkage of at least 30 percent - was 10.7 percent.Researchers said about a quarter of trial patients had PD-L1 expression in at least half of their tumor cells. Overall, 19 percent of trial patients responded to the drug.Side effects of Keytruda included thyroid problems. One patient died from pneumonitis, or lung inflammation, which was seen in 3.6 percent of trial patients.The Merck results were presented at a meeting of the American Association for Cancer Research and published in the New England Journal of Medicine.Researchers also presented results from a trial showing that Keytruda improved the length of time before advanced skin cancer worsened by 42 percent and extended patient survival by 34 percent compared with treatment with ipilimumab, a different immunotherapy sold by Bristol-Myers under the brand name Yervoy.  (Reporting by Deena Beasley; Editing by Dan Grebler)",2015-04-19,MRK,"Sun Apr 19, 2015 | 12:26pm EDT","CORRECTED-Merck's Keytruda shrinks lung cancer tumors, FDA approval sought",http://www.reuters.com//article/merck-co-cancer-lung-idUSL2N0XE15R20150419?type=companyNews
313,"   By Deena Beasley  Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease.Keytruda, also known as pembrolizumab, is currently approved by the FDA for patients with advanced melanoma who are no longer responding to other therapies.The drug is part of a new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells. Merck said the FDA submission is based on trial data in patients for which testing showed that at least half of their tumor cells contained PD-L1. Those trial results will be presented later on Sunday at a meeting of the American Association for Cancer Research in Philadelphia.Keytruda was previously designated by the FDA as a ""breakthrough therapy"" for advanced NSCLC. Merck said it is seeking approval for use of the drug in patients whose disease has worsened after treatment with chemotherapy or other medications. Merck also said a pre-marketing authorization was submitted by Dako North America, a unit of Agilent Technologies Co,  for a companion test to diagnose patient levels of PD-L1.  (Reporting By Deena Beasley; Editing by Diane Craft)",2015-04-19,MRK,"Sun Apr 19, 2015 | 8:02am EDT",Merck files for FDA approval of Keytruda in lung cancer,http://www.reuters.com//article/us-merck-fda-lungcancer-idUSKBN0NA0HI20150419?type=companyNews
314,"   By Deena Beasley | April 19  April 19 Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease.Keytruda, also known as pembrolizumab, is currently approved by the FDA for patients with advanced melanoma who are no longer responding to other therapies. The drug is part of a new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.Merck said the FDA submission is based on trial data in patients for which testing showed that at least half of their tumor cells contained PD-L1. Those trial results will be presented later on Sunday at a meeting of the American Association for Cancer Research in Philadelphia. Keytruda was previously designated by the FDA as a ""breakthrough therapy"" for advanced NSCLC. Merck said it is seeking approval for use of the drug in patients whose disease has worsened after treatment with chemotherapy or other medications. Merck also said a pre-marketing authorization was submitted by Dako North America, a unit of Agilent Technologies Co,  for a companion test to diagnose patient levels of PD-L1.(Reporting By Deena Beasley; Editing by Diane Craft)",2015-04-19,MRK,"Sun Apr 19, 2015 | 8:00am EDT",Merck files for FDA approval of Keytruda in lung cancer,http://www.reuters.com//article/merck-fda-lungcancer-idUSL2N0XG00Y20150419?type=companyNews
315,"   By Deena Beasley | April 24  April 24 Merck and Co Inc presented trial results on Friday showing that a once-daily combination of two experimental pills cured 95 percent of previously untreated hepatitis C patients after 12 weeks.The trial included patients infected with the most common form of the liver-destroying virus, genotype 1, along with less common genotypes 4 and 6. It also involved patients with and without liver cirrhosis.Cure rates, defined as sustained virologic response 12 weeks after treatment, were 92 percent for patients with genotype 1a; 99 percent for genotype 1b; 100 percent for genotype 4; and 80 percent for genotype 6. Cures were achieved in 97 percent of cirrhotic patients and 94 percent of non-cirrhotic patients.Gilead Sciences Inc's Harvoni, currently the only hepatitis C drug that does not need to be taken with antiviral pill ribavirin, is approved only for genotype 1 patients, which account for about 70 percent of U.S. infections. ""We have a really high efficacy regimen in a single tablet without ribavirin,"" said Eliav Barr, Merck's vice president, infectious diseases. ""Current data that have been out there have really focused on a standard population for HCV.""Merck said it still aims to submit an application for the grazoprevir/elbasvir regimen to the U.S. Food and Drug Administration in the first half of this year. The agency has granted Merck ""breakthrough therapy"" designation for the treatment in genotype 1 HCV patients with end stage renal disease who are on hemodialysis and for genotype 4 HCV patients. Results from the 412-patient trial were presented at a meeting of the European Association for the Study of the Liver in Vienna and published in Annals of Internal Medicine.Gilead secured an early lead in the lucrative market for oral hepatitis C drugs - first with Sovaldi, and now Harvoni, which has a list price of $94,500 for 12 weeks. AbbVie Inc  entered the market last year with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co , forcing Gilead to discount its own contract prices. Hepatitis C infects an estimated 3.2 million Americans.""HCV is a huge population. There is going to be a need for a lot of players here to make sure we eliminate the disease,"" Barr said. ""We will have a really strong offering for patients, payers, and physicians.""(Reporting By Deena Beasley)",2015-04-24,MRK,"Fri Apr 24, 2015 | 1:00am EDT",Merck oral hepatitis C regimen shows 95 pct cure rate,http://www.reuters.com//article/merck-hepatitis-c-idUSL1N0XK23A20150424?type=companyNews
316,"  (Adds analyst comment)By Bill BerkrotApril 27 Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud of uncertainty from its biggest product.Merck shares rose nearly 4 percent in after-hours trading following the announcement. Januvia had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet.The Tecos study involved 14,724 patients with type 2 diabetes and a history of heart disease. Januvia plus regular care led to no significant difference in a composite of time to the first cardiovascular-related death, non-fatal heart attack, non-fatal stroke, or unstable angina requiring hospitalization compared with usual care alone, Merck said. Significantly, among the secondary goals of the study, there was no increase in hospitalization for heart failure in the Januvia group versus placebo, Merck said. That could give Januvia a leg up on rival drugs that have shown a potential heart failure connection.Full details of the study are expected to be presented at a major diabetes meeting in Boston in June, the company said. Sanford Bernstein analyst Tim Anderson said uncertainty over the Tecos study had been an overhang on Merck shares.With Monday's initial results, ""a psychological overhang has been removed and the threat of major downside has been eliminated,"" Anderson said in a research note. Earlier this month, a panel of expert advisers to the U.S. Food and Drug Administration voted that two similar diabetes drugs, AstraZeneca Plc's Onglyza and Nesina from Takeda Pharmaceutical Co Ltd, had acceptable cardiovascular risk profiles. However, they recommended that product information labels warn about the risk of heart failure.The two rival medicines and Januvia belong to a class of diabetes treatments known as DPP-4 inhibitors.The Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute. It was undertaken after heart safety concerns were raised over other diabetes medicines.Merck shares rose as much as 3.8 percent to $59.25 in extended trading from their New York Stock Exchange close at $57.10.    (Reporting by Bill Berkrot, additional reporting by Ransdell Pierson; Editing by G Crosse, Alan Crosby and Andre Grenon)",2015-04-27,MRK,"Mon Apr 27, 2015 | 6:48pm EDT",UPDATE 2-Merck diabetes drug Januvia meets heart safety target,http://www.reuters.com//article/merck-co-diabetes-idUSL1N0XO2M520150427?type=companyNews
317,"   By Bill Berkrot  Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud of uncertainty from its biggest product.Merck shares rose nearly 4 percent in after-hours trading following the announcement on Januvia, which had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet.In the Tecos study of 14,724 patients with type 2 diabetes and a history of heart disease, Januvia plus regular care led to no significant difference in a composite of time to the first cardiovascular-related death, non-fatal heart attack, non-fatal stroke, or unstable angina requiring hospitalization compared with usual care alone, Merck said.Among secondary goals of the study, there was no increase in hospitalization for heart failure in the Januvia group versus placebo, Merck said. Full details of the study are expected to be presented at a major diabetes meeting in Boston in June, the company said.The Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute, and was undertaken after heart safety concerns were raised over other diabetes medicines.Earlier this month, a panel of expert advisers to the U.S. Food and Drug Administration voted that two similar diabetes drugs, AstraZeneca Plc's Onglyza and Nesina from Takeda Pharmaceutical Co, had acceptable cardiovascular risk profiles, although they recommended that their product information labels warn about the risk of heart failure. The two rival medicines and Januvia belong to a class of diabetes treatments known as DPP-4 inhibitors.Merck shares rose 3.8 percent to $59.25 in extended trading from their New York Stock Exchange close at $57.10.  (This version of the story adds study details and background) (Reporting by Bill Berkrot, additional reporting by Ransdell Pierson; Editing by G Crosse and Alan Crosby)",2015-04-27,MRK,"Mon Apr 27, 2015 | 6:13pm EDT",Merck's diabetes drug Januvia succeeds in heart safety trial,http://www.reuters.com//article/us-merck-co-diabetes-idUSKBN0NI29820150427?type=companyNews
318,"  April 27 Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the company on Monday, likely removing a cloud of uncertainty from its biggest product.In after-hours trading, Merck shares rose nearly 4 percent after the announcement on Januvia, which had sales of about $4 billion in 2014.In the Tecos study of 14,724 patients with type 2 diabetes and a history of heart disease, Januvia plus regular care led to no significant difference in a composite of time to the first cardiovascular-related death, non-fatal heart attack, non-fatal stroke, or unstable angina requiring hospitalization compared with usual care alone, Merck said.   (Reporting by Bill Berkrot, editing by G Crosse)",2015-04-27,MRK,"Mon Apr 27, 2015 | 5:29pm EDT",Merck's diabetes drug Januvia succeeds in heart safety trial,http://www.reuters.com//article/merck-co-diabetes-idUSL1N0XO2KK20150427?type=companyNews
319,"   By Ransdell Pierson and Bill Berkrot | April 28  April 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales of Opdivo, a therapy that helps the immune system fight cancer, totaled $40 million in the first quarter of the year. That was below Wall Street forecasts of $50 million.Merck said its Keytruda treatment had quarterly sales of $83 million, topping Wall Street estimates of about $70 million, helped by early compassionate use patients converting to paying customers following approval.""When investors saw Opdivo's number was below Keytruda's, that caused concern,"" said John Boris, an analyst with Suntrust Robinson Humphrey. Merck shares closed up 5 percent, though the gains were mostly attributed to positive new safety data on its top-selling Januvia diabetes treatment.Boris and other industry analysts said the early sales data represent only the first skirmish in a long battle for market share between Bristol-Myers and Merck. Some expect both drugs will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.In addition, excitement over Bristol-Myers' cancer treatments have pushed shares to trade at 28.5 times expected 2016 per share earnings, Boris said. That compares with a multiple of 15.1 for Merck and 17.6 for the pharmaceutical sector.""Based on price per fundamentals, we like the value of Merck versus Bristol at the moment,"" said Les Funtleyder, healthcare portfolio manager for ESquared Asset Management, which currently holds Merck but not Bristol shares. Ori Hershkovitz, a managing partner at Nexthera Capital in New York, said Bristol-Myers is trading more like a high-flying biotech.""The minute biotech gets pummeled, Bristol bears the brunt,"" he said, noting biotech stocks have retreated sharply in recent weeks on fears they were overly inflated.EARLY ADVANTAGE  Opdivo was approved in December to treat advanced melanoma. In March, it received clearance to treat a common form of lung cancer, giving Bristol an early-mover advantage in a much larger market.Keytruda has been approved for advanced melanoma since September and awaits regulatory approval in lung cancer.Both drugs work by blocking a protein called PD-1, helping the immune system recognize and destroy cancer cells. Roche Holding AG, AstraZeneca Plc and Pfizer Inc  are also developing similar treatments. Boris forecast Opdivo annual sales reaching $7 billion by 2020 and said Tuesday's weakness in Bristol shares represents a buying opportunity. Opdivo has been shown to prolong survival in melanoma and lung cancer, according to clinical trial data.Keytruda has not yet demonstrated a survival benefit but is expected to do so in coming trials. Boris predicted it will capture annual sales of $3.7 billion by 2020.Bristol Chief Scientific Officer Francis Cuss told analysts on Tuesday that strong data on Opdivo along with the U.S. approvals in lung cancer and melanoma and expected European approval ""really puts us in a very strong competitive position.""The company recently reported strong results from a combination of Opdivo and its older immunotherapy Yervoy in advanced melanoma. It plans to apply for approval of the combination therapy by mid-year.Merck head of global human health, Adam Schechter, told analysts that the market will be big enough to handle several competitors, ""so I don't think it should be looked at as one company versus the other.""Pfizer is racing to catch up with Merck and Bristol-Myers, by beginning late-stage trials this year of its PD-1 inhibitor and conducting trials of four other immuno-oncology drugs.PD-1 treatments ""will be the workhorses for the foreseeable future, but they will need to be added to standard therapies or to (other) immuno-oncology treatments,"" Pfizer Chief Executive Ian Read said in an interview. ""That's where the market will be, and we will be well positioned with those combination agents.""     (Reporting by Ransdell Pierson and Bill Berkrot, editing by Michele Gershberg and Andrew Hay)",2015-04-28,MRK,"Tue Apr 28, 2015 | 6:49pm EDT",Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com//article/bristolmyers-merck-cancer-idUSL1N0XP34H20150428?type=companyNews
320,"   By Ransdell Pierson and Bill Berkrot  Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales of Opdivo, a therapy that helps the immune system fight cancer, totaled $40 million in the first quarter of the year. That was below Wall Street forecasts of $50 million.Merck said its Keytruda treatment had quarterly sales of $83 million, topping Wall Street estimates of about $70 million, helped by early compassionate use patients converting to paying customers following approval.""When investors saw Opdivo's number was below Keytruda's, that caused concern,"" said John Boris, an analyst with Suntrust Robinson Humphrey. Merck shares closed up 5 percent, though the gains were mostly attributed to positive new safety data on its top-selling Januvia diabetes treatment.       Boris and other industry analysts said the early sales data represent only the first skirmish in a long battle for market share between Bristol-Myers and Merck. Some expect both drugs will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.In addition, excitement over Bristol-Myers' cancer treatments have pushed shares to trade at 28.5 times expected 2016 per share earnings, Boris said. That compares with a multiple of 15.1 for Merck and 17.6 for the pharmaceutical sector. ""Based on price per fundamentals, we like the value of Merck versus Bristol at the moment,"" said Les Funtleyder, healthcare portfolio manager for ESquared Asset Management, which currently holds Merck but not Bristol shares.Ori Hershkovitz, a managing partner at Nexthera Capital in New York, said Bristol-Myers is trading more like a high-flying biotech. ""The minute biotech gets pummeled, Bristol bears the brunt,"" he said, noting biotech stocks have retreated sharply in recent weeks on fears they were overly inflated.EARLY ADVANTAGE Opdivo was approved in December to treat advanced melanoma. In March, it received clearance to treat a common form of lung cancer, giving Bristol an early-mover advantage in a much larger market.  Keytruda has been approved for advanced melanoma since September and awaits regulatory approval in lung cancer. Both drugs work by blocking a protein called PD-1, helping the immune system recognize and destroy cancer cells. Roche Holding AG, AstraZeneca Plc and Pfizer Inc are also developing similar treatments.Boris forecast Opdivo annual sales reaching $7 billion by 2020 and said Tuesday's weakness in Bristol shares represents a buying opportunity. Opdivo has been shown to prolong survival in melanoma and lung cancer, according to clinical trial data.Keytruda has not yet demonstrated a survival benefit but is expected to do so in coming trials. Boris predicted it will capture annual sales of $3.7 billion by 2020. Bristol Chief Scientific Officer Francis Cuss told analysts on Tuesday that strong data on Opdivo along with the U.S. approvals in lung cancer and melanoma and expected European approval ""really puts us in a very strong competitive position.""The company recently reported strong results from a combination of Opdivo and its older immunotherapy Yervoy in advanced melanoma. It plans to apply for approval of the combination therapy by mid-year.Merck head of global human health, Adam Schecter, told analysts that the market will be big enough to handle several competitors, ""so I don't think it should be looked at as one company versus the other.""Pfizer is racing to catch up with Merck and Bristol-Myers, by beginning late-stage trials this year of its PD-1 inhibitor and conducting trials of four other immuno-oncology drugs.PD-1 treatments ""will be the workhorses for the foreseeable future, but they will need to be added to standard therapies or to (other) immuno-oncology treatments,"" Pfizer Chief Executive Ian Read said in an interview. ""That's where the market will be, and we will be well positioned with those combination agents.""   (Reporting by Ransdell Pierson and Bill Berkrot, editing by Michele Gershberg and Andrew Hay)",2015-04-28,MRK,"Tue Apr 28, 2015 | 6:43pm EDT",Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com//article/us-bristolmyers-merck-cancer-idUSKBN0NJ2PG20150428?type=companyNews
321,"  (New throughout, updates prices and market activity to close of U.S. trading)* U.S. shares helped by Merck earnings, IBM dividend hike* Dollar hits 8-week lows against basket of major currencies* Oil pares gains on expected higher U.S. crude stockpiles* U.S. Federal Reserve meeting keeps traders cautiousBy Sam ForgioneNEW YORK, April 28 Two of three major U.S. stock indexes rose modestly on Tuesday as Merck posted strong earnings and IBM raised its dividend, while European stocks slid on weak corporate results and oil prices were flat to lower on expectations that U.S. crude stockpiles have reached record highs.Merck shares jumped more than 5 percent after the U.S. drugmaker beat quarterly earnings estimates. IBM  shares rose 1.9 percent and were the biggest positive influence on the Dow after the company hiked its quarterly dividend by 18 percent. Losses in Apple shares weighed on the Nasdaq. Data showing U.S. single-family home prices rose more than expected in February contributed to the afternoon rebound, although the data was released earlier in the session when some weak corporate results depressed U.S. shares.""The market, in between the earnings reports, is still always looking at the macro trends,"" said Margaret Patel, senior portfolio manager at Wells Capital Management in Boston. ""The housing numbers were very positive for the economy.""In Europe, however, disappointing corporate earnings handed shares their biggest daily decline in over a week, with paper maker UPM-Kymmene slipping after results while a new share issue hit Commerzbank.Oil prices seesawed as traders weighed security scares in the Middle East and support from a weak dollar against expectations that U.S. crude stockpiles have reached record highs. Iranian forces boarded a Marshall Islands-flagged cargo ship in the Gulf on Tuesday, the Pentagon said, an event which spurred a brief rally in oil prices.""Tensions are so high in that region with the impending Iran-U.S. nuclear deal that any event implied to be U.S.-linked has an immediate effect on oil prices,"" said John Kilduff, partner at New York energy hedge fund Again Capital.Brent crude fell 19 cents in U.S. trading to settle at $64.64 a barrel. U.S. crude settled up 7 cents at $57.06 per barrel. The start of the Federal Reserve's two-day policy meeting injected some caution into markets. Analysts expect soft U.S. data will nudge the U.S. central bank toward a dovish monetary policy.The dollar index, which measures the greenback against a basket of major currencies, fell to an eight-week low of 96.011 after an unexpectedly weak U.S. consumer confidence report for April.The Dow Jones industrial average closed up 72.17 points, or 0.4 percent, at 18,110.14. The S&P 500 closed up 5.84 points, or 0.28 percent, at 2,114.76. The Nasdaq Composite closed down 4.82 points, or 0.1 percent, at 5,055.42.MSCI's all-country world stock index, which tracks shares in 45 nations, was last up 0.44 points or 0.1 percent, to 442.61.Europe's broad FTSEurofirst 300 index closed down 1.49 percent at 1,618.26.U.S. Treasury yields rose as investors reduced bond holdings to make room for government and corporate supply. Benchmark 10-year U.S. Treasury notes were last down 19/32 in price to yield 1.99 percent, from a yield of 1.92 percent late Monday.U.S. gold futures for June delivery settled up $10.70 an ounce at $1,213.90.    (Reporting by Sam Forgione; Additional reporting by Tanya Agrawal in Bengaluru and Gertrude Chavez-Dreyfuss and Barani Krishnan in New York; Editing by Nick Zieminski)",2015-04-28,MRK,"Tue Apr 28, 2015 | 4:40pm EDT",GLOBAL MARKETS-U.S. shares rebound; oil pares gains after Iran ship seizure,http://www.reuters.com//article/markets-global-idUSL1N0XP2KH20150428?type=companyNews
322,"   By Caroline Valetkevitch  The Dow and S&P 500 ended a volatile session higher on Tuesday, helped by strong earnings from Merck and gains in IBM after it boosted its dividend, while the Nasdaq fell with Apple.Adding to volatility just before the close, shares of Twitter (TWTR.N) dropped as much as 24 percent after its results were published early. The stock closed down 18.2 percent at $42.27.IBM (IBM.N) shares rose 1.9 percent to $173.92, giving the Dow its biggest boost. The company hiked its quarterly dividend by 18 percent, the biggest increase in five years. Shares also closed above their 200-day moving average, a bullish technical signal.Apple (AAPL.O) swung between gains and losses a day after reporting results. The stock hit a record high in early trading but shares ended down 1.6 percent at $130.56, weighing on the Nasdaq.""There continues to be the bull-bear push, even with the good numbers you saw from Merck,"" and other companies, said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.""Apple's numbers were phenomenal, but yet the stock is down,"" he added. ""I think people were expecting a blowout quarter ... so it's kind of a sell-the-news situation.""   The Dow Jones industrial average .DJI rose 72.17 points, or 0.4 percent, to 18,110.14, the S&P 500 .SPX gained 5.84 points, or 0.28 percent, to 2,114.76 and the Nasdaq Composite .IXIC dropped 4.82 points, or 0.1 percent, to 5,055.42.Merck (MRK.N) jumped 5 percent, its biggest percentage increase since January 2014, after reporting better-than-expected results and releasing favorable data late Monday about the safety of its Januvia diabetes drug. Whirlpool (WHR.N) fell 7.1 percent to $183.70, the biggest percentage decliner in the S&P 500, after the company cut its 2015 profit and sales forecast, blaming the strong dollar and Brazil's stagnating economy. U.S. first-quarter earnings are now on track to post a slight gain after the mostly stronger-than-expected results, defying forecasts for the first profit decline since 2009, Thomson Reuters data showed.Contributing to day's volatility, Iranian Revolutionary Guards forces boarded a Marshall Islands-flagged cargo ship in the Gulf, U.S. officials said. That spurred a brief rally in oil prices.Investors await the outcome of a two-day Federal Reserve meeting that ends on Wednesday, hoping for clues on when the central bank will hike interest rates.  Helping the market early in the session, U.S. single-family home prices rose more than expected in February from a year earlier, according to a survey.Advancing issues outnumbered declining ones on the NYSE by 1,906 to 1,121, for a 1.70-to-1 ratio; on the Nasdaq, 1,657 issues rose and 1,065 fell, for a 1.56-to-1 ratio favoring advancers.The S&P 500 posted nine new 52-week highs and no new lows; the Nasdaq Composite recorded 63 new highs and 39 new lows. About 6.6 billion shares changed hands on U.S. exchanges, above the 6.3 billion daily average for the month to date, according to BATS Global Markets.  (Editing by Savio D'Souza and Nick Zieminski)",2015-04-28,MRK,"Tue Apr 28, 2015 | 4:34pm EDT","Dow, S&P 500 end up with Merck, IBM; Nasdaq slips with Apple",http://www.reuters.com//article/us-markets-stocks-idUSKBN0NJ18T20150428?type=companyNews
323,"  * Apple shares dip in volatile trading* Merck has best day since January 2014* Feb U.S. single-family home prices rise* Dow up 0.4 pct, S&P up 0.28 pct, Nasdaq down 0.1 pct   (Updates to close)By Caroline ValetkevitchApril 28 The Dow and S&P 500 ended a volatile session higher on Tuesday, helped by strong earnings from Merck and gains in IBM after it boosted its dividend, while the Nasdaq fell with Apple.Adding to volatility just before the close, shares of Twitter dropped as much as 24 percent after its results were published early. The stock closed down 18.2 percent at $42.27.IBM shares rose 1.9 percent to $173.92, giving the Dow its biggest boost. The company hiked its quarterly dividend by 18 percent, the biggest increase in five years.  Shares also closed above their 200-day moving average, a bullish technical signal. Apple swung between gains and losses a day after reporting results. The stock hit a record high in early trading but shares ended down 1.6 percent at $130.56, weighing on the Nasdaq.""There continues to be the bull-bear push, even with the good numbers you saw from Merck,"" and other companies, said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.""Apple's numbers were phenomenal, but yet the stock is down,"" he added. ""I think people were expecting a blowout quarter ... so it's kind of a sell-the-news situation."" The Dow Jones industrial average rose 72.17 points, or 0.4 percent, to 18,110.14, the S&P 500 gained 5.84 points, or 0.28 percent, to 2,114.76 and the Nasdaq Composite  dropped 4.82 points, or 0.1 percent, to 5,055.42.Merck jumped 5 percent, its biggest percentage increase since January 2014, after reporting better-than-expected results and releasing favorable data late Monday about the safety of its Januvia diabetes drug.Whirlpool fell 7.1 percent to $183.70, the biggest percentage decliner in the S&P 500, after the company cut its 2015 profit and sales forecast, blaming the strong dollar and Brazil's stagnating economy.U.S. first-quarter earnings are now on track to post a slight gain after the mostly stronger-than-expected results, defying forecasts for the first profit decline since 2009, Thomson Reuters data showed. Contributing to day's volatility, Iranian Revolutionary Guards forces boarded a Marshall Islands-flagged cargo ship in the Gulf, U.S. officials said. That spurred a brief rally in oil prices.Investors await the outcome of a two-day Federal Reserve meeting that ends on Wednesday, hoping for clues on when the central bank will hike interest rates.Helping the market early in the session, U.S. single-family home prices rose more than expected in February from a year earlier, according to a survey.Advancing issues outnumbered declining ones on the NYSE by 1,906 to 1,121, for a 1.70-to-1 ratio; on the Nasdaq, 1,657 issues rose and 1,065 fell, for a 1.56-to-1 ratio favoring advancers.The S&P 500 posted nine new 52-week highs and no new lows; the Nasdaq Composite recorded 63 new highs and 39 new lows.About 6.6 billion shares changed hands on U.S. exchanges, above the 6.3 billion daily average for the month to date, according to BATS Global Markets.    (Editing by Savio D'Souza and Nick Zieminski)",2015-04-28,MRK,"Tue Apr 28, 2015 | 4:33pm EDT","US STOCKS-Dow, S&P 500 end up with Merck, IBM; Nasdaq slips with Apple",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XP33N20150428?type=companyNews
324,"  * Apple shares fall in volatile trading* Merck on track for its best day since January 2014* Feb U.S. single-family home prices rise* Dow up 0.3 pct, S&P up 0.2 pct, Nasdaq down 0.04 pct   (Updates to late afternoon)By Caroline ValetkevitchApril 28 The Dow and S&P 500 inched higher on Tuesday afternoon, helped by strong earnings from Merck and gains in IBM after it boosted its dividend.IBM shares rose 1.9 percent to $174.04, breaking above the stock's 200-day moving average and giving the Dow its biggest boost. The company hiked its quarterly dividend by 18 percent, the biggest increase in five years. Merck jumped 5.3 percent to $60.11, on track for its best day since January 2014, after reporting better-than-expected results and releasing favorable data late Monday about the safety of its Januvia diabetes drug.Apple kept trading volatile as it swung between gains and losses a day after reporting results. The stock hit a record high in early trading but shares were last down 1.5 percent at $130.63, weighing on the Nasdaq.""We're continuing to essentially tread water. Apple's numbers were phenomenal but yet the stock is down. Why is that? I think people were expecting a blowout quarter ... so it's kind of a sell-the-news situation,"" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. U.S. first-quarter earnings are now on track to post a slight gain after stronger-than-expected results from companies such as Apple, defying forecasts for the first profit decline since 2009, Thomson Reuters data showed.At 2:36 p.m., the Dow Jones industrial average rose 48.31 points, or 0.27 percent, to 18,086.28, the S&P 500  gained 4.07 points, or 0.19 percent, to 2,112.99 and the Nasdaq Composite dropped 2.03 points, or 0.04 percent, to 5,058.22.Adding to the positive tone, U.S. single-family home prices rose more than expected in February from a year earlier, according to a survey. adding to the volatility in the stock market: Iranian Revolutionary Guards forces boarded a Marshall Islands-flagged cargo ship in the Gulf, U.S. officials said. That spurred a brief rally in oil prices.Investors are awaiting the results of a two-day Federal Reserve meeting that ends on Wednesday for clues on when the central bank will hike interest rates.Whirlpool fell 6.5 percent to $184.96 after cutting its 2015 profit and sales forecast, blaming the strong dollar and Brazil's stagnating economy.Advancing issues outnumbered declining ones on the NYSE by 1,823 to 1,164, for a 1.57-to-1 ratio; on the Nasdaq, 1,624 issues rose and 1,076 fell, for a 1.51-to-1 ratio favoring advancers.The S&P 500 index was posting 9 new 52-week highs and no new lows; the Nasdaq Composite was recording 55 new highs and 36 new lows.     (Editing by Savio D'Souza and Nick Zieminski)",2015-04-28,MRK,"Tue Apr 28, 2015 | 3:03pm EDT","US STOCKS-Wall St edges up with Merck, IBM; Nasdaq slips with Apple",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XP2F820150428?type=companyNews
325,"  (Updates prices, changes comment)* U.S. shares helped by Merck earnings, IBM dividend hike* Dollar hits 8-week lows against basket of major currencies* Oil pares gains on expected higher U.S. crude stockpiles* U.S. Federal Reserve meeting keeps traders cautiousBy Sam ForgioneNEW YORK, April 28 U.S. shares rebounded in afternoon trading on Tuesday, boosted by strong earnings from Merck and a dividend hike by IBM, while oil prices pared gains on expectations that U.S. crude stockpiles have reached record highs.Merck shares jumped 5.2 percent after the U.S. drugmaker beat quarterly earnings estimates. IBM shares rose 1.8 percent, the biggest positive influence on the Dow, after the company hiked its quarterly dividend by 18 percent. Data showing U.S. single-family home prices rose more than expected in February contributed to the afternoon rebound, although the data was released earlier in the session when some weak corporate results depressed U.S. shares.""So far, the first quarter earnings have surpassed expectations and the housing numbers came in strong,"" said John Augustine, chief investment officer at Huntington Bank in Columbus, Ohio, which oversees more than $12.6 billion in assets. ""So anytime you have any good economic data, the markets react positively.""Disappointing corporate earnings handed European shares their biggest daily decline in over a week, however, with paper maker UPM-Kymmene slipping after results while a new share issue hit Commerzbank. Oil prices seesawed as traders weighed security scares in the Middle East and support from a weak dollar against expectations that U.S. crude stockpiles have reached record highs. Iranian forces boarded a Marshall Islands-flagged cargo ship in the Gulf on Tuesday, the Pentagon said, an event which spurred earlier gains in oil prices.Brent crude was last down 8 cents at $64.75 a barrel. U.S. crude was last up 7 cents at $57.06 per barrel.The start of the Federal Reserve's two-day policy meeting injected some caution into markets. Analysts expect recent soft U.S. data will nudge the U.S. central bank towards a dovish monetary policy.The dollar index, which measures the greenback against a basket of major currencies, fell to an eight-week low of 96.011 after an unexpectedly weak U.S. consumer confidence report for April. ""The current period of dollar weakness appears to be gaining momentum and accordingly likely has further to run,"" said Camilla Sutton, chief currency strategist at Scotiabank in Toronto.The Dow Jones industrial average was last up 50.58 points, or 0.28 percent, at 18,088.55. The S&P 500 was up 4.17 points, or 0.2 percent, at 2,113.09. The Nasdaq Composite  was up 0.46 points, or 0.01 percent, at 5,060.71.MSCI's all-country world stock index, which tracks shares in 45 nations, was last up 0.39 points or 0.09 percent, at 442.56.Europe's broad FTSEurofirst 300 index closed down 1.49 percent at 1,618.26.Safe-haven U.S. Treasury yields rose after the stronger-than-expected data on the U.S. housing sector. Benchmark 10-year U.S. Treasury notes were last down 17/32 in price to yield 1.98 percent, from a yield of 1.92 percent late Monday.Spot gold prices rose $12.05 or 1.00 percent, to $1,213.60 an ounce.       (Reporting by Sam Forgione; Additional reporting by Marc Jonesin London, Tanya Agrawal in Bengaluru and Gertrude Chavez-Dreyfuss and Barani Krishnan in New York; Editing by Nick Zieminski)",2015-04-28,MRK,"Tue Apr 28, 2015 | 2:38pm EDT",GLOBAL MARKETS-U.S. shares edge higher; oil pares gains after Iran ship seizure,http://www.reuters.com//article/markets-global-idUSL1N0XP29020150428?type=companyNews
326,"  * Apple hits record high in erratic trading* Merck on track for its best day since January 2014* Feb U.S. single-family home prices rise* Indexes up: Dow 0.4 pct, S&P 0.3 pct, Nasdaq 0.2 pct   (Updates to early afternoon, changes comment)By Tanya AgrawalApril 28 U.S. stocks held on to their gains in early afternoon trading on Tuesday, reversing earlier declines, on strong earnings from Merck, better-than-expected housing data and a dividend hike from IBM.The markets swung between gains and losses in early trading, led by Apple. Apple hit a record high early after its strong results. The shares then fell as much as 2.3 percent, weighing on all three major indices, before recovering to trade up 0.1 percent at $132.85A majority of the ten S&P 500 sectors were up in afternoon trading, led by a 1.4 percent rise in the teleservices index . U.S. single-family home prices rose more than expected in February from a year earlier, according to a survey.""So far, the first quarter earnings have surpassed expectations and the housing numbers came in strong,"" said John Augustine, chief investment officer at Huntington Bank in Columbus, Ohio, which oversees more than $12.6 billion in funds.""So any time you have any good economic data, the markets react positively.""U.S. companies are on track to post a slight gain in earnings for the first quarter after stronger-than-expected results from companies such as Apple, reversing forecasts for the first profit decline since 2009, according to Thomson Reuters data. Merck jumped 5.2 percent to $60.10, on track for its best day since January 2014, after reporting better-than-expected results and releasing favorable data late Monday about the safety of its Januvia diabetes drug.IBM shares rose 1.8 percent to $173.92 and were the biggest positive influence on the Dow after the company hiked its quarterly dividend by 18 percent, the biggest increase in five years.Earlier in the session, a report said an Iranian ""force"" seized a U.S. cargo ship after opening fire on it in the Gulf, spurring a brief rally in oil prices and adding to the volatility in the stock market.""I think any kind of international question about how things will fare or relationships with other countries absolutely has an impact,"" said Peter Anderson, portfolio manager at Congress Asset Management in Boston, which oversees about $7 billion in assets under management. ""The non-resolution of things can really make the market edgy in terms of volatility.""At 13:30 p.m. EDT (1730 GMT) the Dow Jones industrial average was up 62.92 points, or 0.35 percent, at 18,100.89, the S&P 500 was up 5.31 points, or 0.25 percent, at 2,114.23 and the Nasdaq Composite was up 9.84 points, or 0.19 percent, at 5,070.09.Investors are also awaiting the results of a two-day Federal Reserve meeting that ends on Wednesday for clues on when the central bank will hike interest rates.JetBlue Airways soared 6.5 percent to $21 after forecasting a surprise rise in April unit revenue.Coach slumped 7.4 percent to $39.11, putting it on track for its steepest fall since June, after its quarterly sales fell short of estimates.Whirlpool fell 6.5 percent to $184.96 after cutting its 2015 profit and sales forecast, blaming the strong dollar and Brazil's stagnating economy.Advancing issues outnumbered declining ones on the NYSE by 1,870 to 1,097, for a 1.70-to-1 ratio on the upside; on the Nasdaq, 1,693 issues rose and 977 fell for a 1.73-to-1 ratio favoring advancers.   (Additional reporting by Caroline Valetkevitch; Editing by Savio D'Souza)",2015-04-28,MRK,"Tue Apr 28, 2015 | 1:40pm EDT",US STOCKS-Wall St moves higher after erratic early trading,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XP6ON20150428?type=companyNews
327,"   By Ransdell Pierson  Merck & Co's (MRK.N) shares jumped almost 5 percent after the U.S. drugmaker reported better-than-expected quarterly results and released favorable data late Monday about the safety of its Januvia diabetes drug.The second-largest U.S. drugmaker on Tuesday said it earned $953 million, or 33 cents per share, in the first quarter. That compared with $1.71 billion, or 57 cents per share, in the year earlier period.Excluding special items, Merck earned 85 cents per share, well above the average analyst estimate of 75 cents per share, according to Thomson Reuters I/B/E/S. The company incurred significantly higher costs related to acquisitions and divestitures, while having smaller tax benefits than a year ago.Company sales fell 8 percent to $9.43 billion, but would have fallen only 3 percent if not for the stronger dollar. Sales topped Wall Street expectations of $9.07 billion, helped by hedging against foreign currency fluctuations.Despite its strong first-quarter results, Merck only slightly raised its 2015 earnings forecast, to between $3.35 and $3.48 per share, excluding special items. It had forecast earnings of $3.32 to $3.47 per share. Januvia sales rose 3 percent in the quarter to $884 million, while a related drug called Janumet rose 7 percent to $509 million.Late on Monday, Merck said Januvia achieved the main goal of a long-awaited heart safety study according to preliminary results, which likely removed a cloud of uncertainty from its biggest product.The Tecos study involved 14,724 patients with type 2 diabetes and a history of heart disease. Januvia plus regular care led to no significant difference in a composite of time to the first cardiovascular-related death, non-fatal heart attack, non-fatal stroke, or unstable angina requiring hospitalization compared with usual care alone. Significantly, there was no increase in hospitalization for heart failure in the Januvia group versus placebo. Analysts said that could give Januvia a leg up on rival drugs that have shown a potential heart failure connection. Sales of Merck's animal health products rose 2 percent to $829 million, but would have risen 13 percent if not for the stronger dollar. ""Overall, a solid Q1 with raised guidance,"" Sanford Bernstein analyst Tim Anderson said of Merck's report. Among large U.S. drugmakers, he said, only Merck and Bristol-Myers Squibb Co (BMY.N) have raised their 2015 forecasts.The two companies are leaders in immuno-oncology, drugs that harness the immune system to fight cancer. (Reporting by Ransdell Pierson; Editing by Nick Zieminski)",2015-04-28,MRK,"Tue Apr 28, 2015 | 12:30pm EDT","Merck shares jump on strong earnings, Januvia safety data",http://www.reuters.com//article/us-merck-results-idUSKBN0NJ18220150428?type=companyNews
328,"  * Apple hits record high in erratic trading* Merck on track for its best day since January 2014* Feb U.S. single-family home prices rise* Indexes up: Dow 0.3 pct, S&P 0.2 pct, Nasdaq 0.2 pct   (Adds details, comment, updates prices)By Tanya AgrawalApril 28 U.S. stocks edged up in volatile trading on Tuesday, reversing earlier declines, on strong earnings from Merck, better-than-expected housing data and a dividend hike from IBM.A majority of the ten S&P 500 sectors were up, with the teleservices index gaining 1 percent.Apple hit a record high early on Tuesday, a day after posting strong results. The shares then fell as much as 2.3 percent, weighing on all three major indices, before recovering to trade up 0.3 percent at $133.06 U.S. single-family home prices rose more than expected in February from a year earlier, according to a closely watched survey.""So far, the first quarter earnings have surpassed expectations and the housing numbers came in strong,"" said John Augustine, Chief investment officer at Huntington Bank in Columbus, Ohio which oversees more than $12.6 billion in funds.""So any time you have any good economic data, the markets react positively.""Merck rose 4.8 percent to $59.85, on track for its best day since January 2014, after reporting better-than-expected results and releasing favorable data late Monday about the safety of its Januvia diabetes drug. IBM shares ticked up 1 percent to $172.46 and were the second biggest positive influence on the Dow after Merck. IBM hiked its quarterly dividend by 18 percent, its biggest increase in five years.Investors were also awaiting the results of a two-day Federal Reserve meeting that ends on Wednesday for clues on when the central bank will hike interest rates.Earlier in the session, a report said an Iranian ""force"" seized a U.S. cargo ship after opening fire on it in the Gulf, spurring a brief rally in oil prices. ""We are on the lookout for that and that sort of geopolitical issue always drags the markets down and has certainly made people very nervous,"" said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburg.At 12:21 p.m. EDT (1621 GMT) the Dow Jones industrial average was up 49.68 points, or 0.28 percent, at 18,087.65, the S&P 500 was up 3.41 points, or 0.16 percent, at 2,112.33 and the Nasdaq Composite was up 7.76 points, or 0.15 percent, at 5,068.01.Coach shares slumped 7.4 percent to $39.11, putting it on track for its steepest fall since June, after the handbag and accessories maker's quarterly sales fell short of estimates.Dow component Pfizer and home appliances maker Whirlpool both cut forecasts, blaming the strong dollar. Whirlpool fell 5.7 percent to $186.41 while Pfizer slipped 0.4 percent to $34.44.The dollar gained about 23 percent against a basket of major currencies over the financial year ended March 31, hurting companies with large overseas operations.United Parcel Service rose 3.5 percent to $100.89 after it reported higher first-quarter net profit due to price increases and productivity improvements, and reaffirmed its earnings outlook for 2015.Advancing issues outnumbered declining ones on the NYSE by 1,784 to 1,143, for a 1.56-to-1 ratio on the upside; on the Nasdaq, 1,645 issues rose and 974 fell for a 1.69-to-1 ratio favoring advancers.   (Additional reporting by Caroline Valetkevitch; Editing by Savio D'Souza)",2015-04-28,MRK,"Tue Apr 28, 2015 | 12:26pm EDT",US STOCKS-Wall St reverses course to trade higher,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XP6JW20150428?type=companyNews
329,"  (Repeats Tuesday story with no changes to text.)By Ransdell Pierson and Bill BerkrotApril 28 Investors betting that Bristol-Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.Bristol shares fell as much as 2.7 percent and closed off 1 percent after reporting sales of Opdivo, a therapy that helps the immune system fight cancer, totaled $40 million in the first quarter of the year. That was below Wall Street forecasts of $50 million.Merck said its Keytruda treatment had quarterly sales of $83 million, topping Wall Street estimates of about $70 million, helped by early compassionate use patients converting to paying customers following approval.""When investors saw Opdivo's number was below Keytruda's, that caused concern,"" said John Boris, an analyst with Suntrust Robinson Humphrey. Merck shares closed up 5 percent, though the gains were mostly attributed to positive new safety data on its top-selling Januvia diabetes treatment.Boris and other industry analysts said the early sales data represent only the first skirmish in a long battle for market share between Bristol-Myers and Merck. Some expect both drugs will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.In addition, excitement over Bristol-Myers' cancer treatments have pushed shares to trade at 28.5 times expected 2016 per share earnings, Boris said. That compares with a multiple of 15.1 for Merck and 17.6 for the pharmaceutical sector. ""Based on price per fundamentals, we like the value of Merck versus Bristol at the moment,"" said Les Funtleyder, healthcare portfolio manager for ESquared Asset Management, which currently holds Merck but not Bristol shares.Ori Hershkovitz, a managing partner at Nexthera Capital in New York, said Bristol-Myers is trading more like a high-flying biotech.""The minute biotech gets pummeled, Bristol bears the brunt,"" he said, noting biotech stocks have retreated sharply in recent weeks on fears they were overly inflated. EARLY ADVANTAGE Opdivo was approved in December to treat advanced melanoma. In March, it received clearance to treat a common form of lung cancer, giving Bristol an early-mover advantage in a much larger market.Keytruda has been approved for advanced melanoma since September and awaits regulatory approval in lung cancer.Both drugs work by blocking a protein called PD-1, helping the immune system recognize and destroy cancer cells. Roche Holding AG, AstraZeneca Plc and Pfizer Inc  are also developing similar treatments. Boris forecast Opdivo annual sales reaching $7 billion by 2020 and said Tuesday's weakness in Bristol shares represents a buying opportunity. Opdivo has been shown to prolong survival in melanoma and lung cancer, according to clinical trial data.Keytruda has not yet demonstrated a survival benefit but is expected to do so in coming trials. Boris predicted it will capture annual sales of $3.7 billion by 2020.Bristol Chief Scientific Officer Francis Cuss told analysts on Tuesday that strong data on Opdivo along with the U.S. approvals in lung cancer and melanoma and expected European approval ""really puts us in a very strong competitive position.""The company recently reported strong results from a combination of Opdivo and its older immunotherapy Yervoy in advanced melanoma. It plans to apply for approval of the combination therapy by mid-year.Merck head of global human health, Adam Schechter, told analysts that the market will be big enough to handle several competitors, ""so I don't think it should be looked at as one company versus the other.""Pfizer is racing to catch up with Merck and Bristol-Myers, by beginning late-stage trials this year of its PD-1 inhibitor and conducting trials of four other immuno-oncology drugs.PD-1 treatments ""will be the workhorses for the foreseeable future, but they will need to be added to standard therapies or to (other) immuno-oncology treatments,"" Pfizer Chief Executive Ian Read said in an interview. ""That's where the market will be, and we will be well positioned with those combination agents.""     (Reporting by Ransdell Pierson and Bill Berkrot, editing by Michele Gershberg and Andrew Hay)",2015-04-29,MRK,"Wed Apr 29, 2015 | 7:00am EDT",RPT-Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com//article/bristolmyers-merck-cancer-idUSL1N0XP3O820150429?type=companyNews
330,"   By Brendan Pierson  A class action accusing Merck & Co Inc of concealing from investors the risks of its now-withdrawn painkiller Vioxx may go forward, a federal judge has ruled. U.S. District Judge Stanley Chesler of the District of New Jersey ruled Wednesday that whether the New Jersey-based drugmaker knowingly misled investors was a question for a jury, denying the company's summary judgment motion.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1PkkfVf",2015-05-14,MRK,"Wed May 13, 2015 | 8:23pm EDT",Merck loses bid to escape investor lawsuit over Vioxx,http://www.reuters.com//article/health-vioxx-securities-idUSL1N0Y500W20150514?type=companyNews
331,"  MUMBAI India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday.The court has, however, allowed Glenmark to continue to sell existing inventory, according to the document posted on the Supreme Court's website after a hearing.The decision against Glenmark comes two years after Switzerland's Novartis AG was denied patent protection for its cancer treatment Glivec in a landmark decision by India's Supreme Court that was widely seen as boosting the local generic drugs industry.Anti-diabetes drugs are the top-selling therapy area in India, where about 65 million people live with the disease and that number is expected to reach 100 million by 2030.Merck sued Glenmark in 2013 for infringing a patent it has on sitagliptin, the chemical compound in Januvia and Janumet, both of which the company has been selling in India since 2008. A month's dose of Merck's drugs costs about 1,300 Indian rupees ($20) and 1,900 Indian rupees ($30), respectively. Merck has licensed the drugs to Sun Pharmaceutical Industries Ltd for sale in India.Glenmark sells the medicines under the brand names Zita and Zita-met at a nearly 30 percent discount to Merck's price.  Glenmark is barred from producing sitagliptin until the next hearing on the case, the order said.Spokespersons for Glenmark and Merck declined to comment.  ""This is an interim sort of measure taken by the court, and the decision on the patent of sitagliptin is subject to final orders,"" said Ameet Hariani, managing partner at Mumbai-based law firm Hariani & Co. (Reporting by Zeba Siddiqui and Nivedita Bhattacharjee; editing by David Clarke)",2015-05-15,MRK,"Fri May 15, 2015 | 8:40am EDT",Indian court bars Glenmark from selling Merck drug copies,http://www.reuters.com//article/us-glenmark-phrm-merck-co-lawsuit-idUSKBN0O011S20150515?type=companyNews
332,"  Thomson Reuters May 15, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For events after May 19 please click on                    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  15 May     01:00        Bank of Marin BanAnnual Shareholders Meeting 15 May     13:00           Clear Channel Outdoor Inc Annual Shareholders Meeting 15 May     13:00           Forum Energy Technologies Inc Annual Shareholders Meeting 15 May     13:00           Newfield Exploration Co Annual Shareholders Meeting 15 May     13:30           Aetna Inc Annual Shareholders Meeting 15 May                     Campus Crest Communities Inc Annual Shareholders Meeting 15 May     12:00          BioAmber Inc Annual Shareholders Meeting 15 May     12:00            Western Union Co Annual Shareholders Meeting 15 May     12:00           WEX Inc Annual Shareholders Meeting 15 May     12:30           Intercontinental Exchange Inc Annual Shareholders Meeting 15 May     14:00           American Water Works Company Inc Annual Shareholders Meeting 15 May     14:00        Chefs Warehouse Inc Annual Shareholders Meeting 15 May     14:00           Macquarie Infrastructure Extraordinary Shareholders Meeting 15 May     14:00         Memorial Resource Development Annual Shareholders Meeting 15 May     14:00           Progressive Annual Shareholders Meeting 15 May     14:00           Tanger Factory Outlet Centers Inc Annual Shareholders Meeting 15 May     14:00           Terex Annual Shareholders Meeting 15 May     14:00           Westlake Chemical Annual Shareholders Meeting 15 May     14:30           John Bean Technologies Annual Shareholders Meeting 15 May     14:30           Quest Diagnostics Inc Annual Shareholders Meeting 15 May     15:00          Banc of California Inc Annual Shareholders Meeting 15 May     15:00            CF Industries Inc Annual Shareholders Meeting 15 May     15:00          Cypress Semiconductor Annual Shareholders Meeting 15 May     15:00           Dril-Quip Inc Annual Shareholders Meeting 15 May     15:00           J C Penney Company Inc Annual Shareholders Meeting 15 May     15:00             Macys Inc Annual Shareholders Meeting 15 May     15:00        QCR Inc Annual Shareholders Meeting 15 May     15:00        Rosetta Resources Inc Annual Shareholders Meeting 15 May     15:00           Transocean Ltd Annual Shareholders Meeting 15 May     15:00           Waste Connections Inc Annual Shareholders Meeting 15 May     15:00        West Annual Shareholders Meeting 15 May     15:30           CBRE Group Inc Annual Shareholders Meeting 15 May     17:00        Commercial Vehicle Group Inc Annual Shareholders Meeting 15 May     18:00        Seattle Genetics Inc Annual Shareholders Meeting 15 May     19:00          Roundy's Inc Annual Shareholders Meeting 16 May     22:00        First Interstate Bancsystem Inc Annual Shareholders Meeting 16 May     14:00           Dillard's Inc Annual Shareholders Meeting 16 May     15:00           American Works at NAIC's BetterInvesting National Convention 17 May     22:00            Laclede Group Inc at American Gas Forum 17 May                     Alliant Energy at American Gas Forum 17 May                     Atmos Energy at American Gas Forum 17 May                     Avista at American Gas Forum 17 May                     Black Hills at American Gas Forum 17 May                     Chesapeake Utilities at American Gas Forum 17 May                      Consolidated Edison Inc at American Gas Forum 17 May                  Delta Natural Gas Company Inc at American Gas Forum 17 May                      Eversource Energy at American Gas Forum 17 May                     Integrys Energy Group Inc at American Gas Forum 17 May                      Laclede Group Inc at American Gas Forum 17 May                     MDU Resources Group Inc at American Gas Forum 17 May                  MGE Energy Inc at American Gas Forum 17 May                     National Fuel Gas Co at American Gas Forum 17 May                     New Jersey Resources at American Gas Forum 17 May                      NiSource Inc at American Gas Forum 17 May                     Piedmont Natural Gas Company Inc at American Gas Forum 17 May                     Questar at American Gas Forum 17 May                     Sempra Energy at American Gas Forum 17 May                     South Jersey Industries Inc at American Gas Forum 17 May                     Southwest Gas at American Gas Forum 17 May                      Spectra Energy at American Gas Forum 17 May                      TECO Energy Inc at American Gas Forum 17 May                     UGI at American Gas Forum 17 May                     UIL at American Gas Forum 17 May                     Unitil at American Gas Forum 17 May                     Vectren at American Gas Forum 17 May                     WGL Inc at American Gas Forum 17 May                     Wisconsin Energy at American Gas Forum 17 May                     Xcel Energy Inc at American Gas Forum 17 May     21:15           Chesapeake Utilities at American Gas Forum 18 May     13:00           3M Co at Electrical Products Group Conf 18 May     13:00        Infinity Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     13:00          Targa Resources Annual Shareholders Meeting 18 May     13:00           Tenet Healthcare at UBS Global Healthcare Conf 18 May     13:20          Care.com Inc at JPMorgan Conf 18 May     13:20        Cavium Inc at JPMorgan Conf 18 May     13:20           EMC at JPMorgan Conf 18 May     13:20            MasterCard Inc at JPMorgan Conf 18 May     13:20           Neustar Inc at JPMorgan Conf 18 May     13:20          T-Mobile US Inc at JPMorgan Conf 18 May     13:20        Virtusa at JPMorgan Conf 18 May     13:30        Akebia Therapeutics Inc at UBS Global Healthcare Conf 18 May     13:30        Bank of The Ozarks Inc Annual Shareholders Meeting 18 May     13:30           Cambrex at UBS Global Healthcare Conf 18 May     13:30        Esperion Therapeutics Inc at UBS Global Healthcare Conf 18 May     22:00        Geron Annual Shareholders Meeting 18 May     22:00        International Bancshares Annual Shareholders Meeting 18 May                  AcelRx Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May                     Ameren at American Gas Forum 18 May                  Bruker at UBS Global Healthcare Conf 18 May                     CenterPoint Energy Inc at American Gas Forum 18 May                    Civitas Solutions Inc at UBS Global Healthcare Conf 18 May                     CMS Energy at American Gas Forum (One-on-One Meeting) 18 May                     DTE Energy Co at American Gas Forum (One on One Meetings) 18 May                     Empire District Electric Co at American Gas Forum 18 May                  Gas Natural Inc at American Gas Forum 18 May                      Intralinks Inc at JPMorgan Conf 18 May                     NCR at JPMorgan Conf 18 May                     NorthWestern at American Gas Forum:One-on-One Meeting 18 May                     Oasis Petroleum Inc at UBS Global Oil and Gas Conf 18 May                     ONE Gas Inc at American Gas Forum - One-on-One Meetings 18 May                     PG&E at American Gas Forum 18 May                     Public Service Enterprise Group Inc at American Gas Forum 18 May                  RTI Surgical Inc at UBS Global Healthcare Conf 18 May                    U.S. Physical Therapy Inc at UBS Global Healthcare Conf 18 May     11:30           Honeywell International Inc at Electrical Products Group Conf 18 May     12:00             AT&T Inc at JPMorgan Conf 18 May     12:00         VWR at UBS Global Healthcare Conf 18 May     12:30        Ophthotech at UBS Global Healthcare Conf 18 May     12:40        Viacom Inc at JPMorgan Conf 18 May     14:00        Cogent Communications Inc at JPMorgan Conf 18 May     14:00       Comcast at JPMorgan Conf 18 May     14:00            Consolidated Edison Inc Annual Shareholders Meeting 18 May     14:00        CoStar Group Inc at JPMorgan Conf 18 May     14:00        Cree Inc at JPMorgan Conf 18 May     14:00           Danaher at Electrical Products Group Conf 18 May     14:00      Genesis Healthcare at UBS Global Healthcare Conf 18 May     14:00           Global Payments Inc at JPMorgan Conf 18 May     14:00        NetScout Systems Inc at JPMorgan Conf 18 May     14:00        OraSure Technologies Inc at UBS Global Healthcare Conf 18 May     14:00           PerkinElmer Inc at UBS Global Healthcare Conf 18 May     14:00        Prothena PLC at UBS Global Healthcare Conf 18 May     14:00         Texas Instruments Inc at JPMorgan Conf 18 May     14:00        Ultimate Software Group Inc Annual Shareholders Meeting 18 May     14:30           Actavis PLC at UBS Global Healthcare Conf 18 May     14:30        Integra LifeSciences at UBS Global Healthcare Conf 18 May     14:30           Universal Health Services Inc at UBS Global Healthcare Conf 18 May     14:40        ANSYS Inc at JPMorgan Conf 18 May     14:40           CenturyLink Inc at JPMorgan Conf 18 May     14:40          Facebook Inc at JPMorgan Conf 18 May     14:40        Maxim Integrated Products Inc at JPMorgan Conf 18 May     14:40        Synaptics Inc at JPMorgan Conf 18 May     14:40          TriNet Group Inc at JPMorgan Conf 18 May     14:45           Stanley Black & Decker Inc at Electrical Products Group Conf 18 May     15:00           AMN Healthcare Services Inc at UBS Global Healthcare Conf 18 May     15:00        LDR Holding at UBS Global Healthcare Conf 18 May     15:00           Waters at UBS Global Healthcare Conf 18 May     15:20           Box Inc at JPMorgan Conf 18 May     15:20           Diebold Inc at JPMorgan Conf 18 May     15:20           International Business Machines at JPMorgan Conf 18 May     15:20        Orbotech Ltd at JPMorgan Conf 18 May     15:20        Qualys Inc at JPMorgan Conf 18 May     15:20        Sinclair Broadcast Group Inc at JPMorgan Conf 18 May     15:30        Achillion Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     15:30        PAREXEL International at UBS Global Healthcare Conf 18 May     15:30          Perrigo Company PLC at UBS Global Healthcare Conf 18 May     15:30           Roper Technologies Inc at Electrical Products Group Conf 18 May     16:00            Consolidated Edison Inc at American Gas Forum 18 May     16:00        Grand Canyon Education Inc Annual Shareholders Meeting 18 May     16:00           MDU Resources Group Inc at American Gas Forum 18 May     16:00           Omnicom Group Inc Annual Shareholders Meeting 18 May     16:00           Questar at American Gas Forum 18 May     16:00           South Jersey Industries Inc at American Gas Forum 18 May     16:30           WESCO International Inc at Electrical Products Group Conf 18 May     16:45           DTE Energy Co at American Gas Forum 18 May     16:45           National Fuel Gas Co at American Gas Forum 18 May     16:45           Northwest Natural Gas Co at American Gas Forum 18 May     17:00        Epizyme Inc at UBS Global Healthcare Conf 18 May     17:00           Health Care REIT Inc at UBS Global Healthcare Conf 18 May     17:00        IPC Healthcare Inc at UBS Global Healthcare Conf 18 May     17:00        Veracyte Inc Annual Shareholders Meeting 18 May     17:15           Eaton PLC at Electrical Products Group Conf 18 May     17:30        Alimera Sciences Inc at UBS Global Healthcare Conf 18 May     17:30        AngioDynamics Inc at UBS Global Healthcare Conf 18 May     17:30           CMS Energy at American Gas Forum 18 May     17:30        K2M Group Inc at UBS Global Healthcare Conf 18 May     17:30        Medivation Inc at UBS Global Healthcare Conf 18 May     17:30           ONE Gas Inc at American Gas Forum 18 May     17:30        PacWest BanAnnual Shareholders Meeting 18 May     17:30        PacWest BanCourt Meeting 18 May     17:30           Unitil at American Gas Forum 18 May     18:00        Halozyme Therapeutics Inc at UBS Global Healthcare Conf 18 May     18:00           Rockwell Automation Inc at Electrical Products Group Conf 18 May     18:10           American Tower at JPMorgan Conf 18 May     18:10            Broadridge Financial Solutions Inc at JPMorgan Conf 18 May     18:10          Everyday Health Inc at JPMorgan Conf 18 May     18:10        Medidata Solutions Inc at JPMorgan Conf 18 May     18:10        Paychex Inc at JPMorgan Conf 18 May     18:15           NorthWestern at American Gas Forum 18 May     18:15           Southwest Gas at American Gas Forum 18 May     18:15            TECO Energy Inc at American Gas Forum 18 May     18:15           WGL Inc at American Gas Forum 18 May     18:30           Aetna Inc at UBS Global Healthcare Conf 18 May     18:30        Biospecifics Technologies at UBS Global Healthcare Conf 18 May     18:45           SPX at Electrical Products Group Conf 18 May     18:50        Dealertrack Technologies Inc at JPMorgan Conf 18 May     18:50           Freescale Semiconductor Ltd at JPMorgan Conf 18 May     18:50        HomeAway Inc at JPMorgan Conf 18 May     18:50          HubSpot Inc at JPMorgan Conf 18 May     18:50           Interpublic Group of Companies Inc at JPMorgan Conf 18 May     18:50           WEX Inc at JPMorgan Conf 18 May     19:00        AMAG Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     19:30           Alliance Data Systems at JPMorgan Conf 18 May     19:30         Foundation Medicine Inc at UBS Global Healthcare Conf 18 May     19:30           Gannett Co Inc at JPMorgan Conf 18 May     19:30        LogMeIn Inc at JPMorgan Conf 18 May     19:30           RingCentral Inc at JPMorgan Conf 18 May     19:30        ShoreTel Inc at JPMorgan Conf 18 May     19:30           VeriFone Systems Technology, Media and Telecom Conf 18 May     19:30           West Pharmaceutical Services Inc at UBS Global Healthcare Conf 18 May     08:00       Nexus AG Annual Shareholders Meeting 18 May     20:00        Insmed Inc at UBS Global Healthcare Conf 18 May     20:00            Spectra Energy at American Gas Forum 18 May     20:00           UIL at American Gas Forum 18 May     20:00           Vectren at American Gas Forum 18 May     20:10        CyrusOne Inc at JPMorgan Conf 18 May     20:10        EnerNOC Inc at JPMorgan Conf 18 May     20:10          Guidewire Software Inc at JPMorgan Conf 18 May     20:10           Heartland Payment Systems Inc at JPMorgan Conf 18 May     20:10        iRobot at JPMorgan Conf 18 May     20:10          Model N Inc at JPMorgan Conf 18 May     20:10          Tribune Media Co at JPMorgan Conf 18 May     20:30        LegacyTexas Financial Group Inc Annual Shareholders Meeting 18 May     20:45           AGL Resources Inc at American Gas Forum 18 May     20:45           Black Hills at American Gas Forum 18 May     21:00           Motorola Solutions Inc Annual Shareholders Meeting 18 May     21:30           UGI at American Gas Forum 19 May     13:00        American National Bankshares Inc Annual Shareholders Meeting 19 May     13:00        Cerulean Pharma Inc at UBS Global Healthcare Conf 19 May     13:00        Chimerix Inc at UBS Global Healthcare Conf 19 May     13:00        Cross Country Healthcare Inc at UBS Global Healthcare Conf 19 May     13:00        CSG Systems International Inc Annual Shareholders Meeting 19 May     13:00        Dyax Annual Shareholders Meeting 19 May     13:00            Dynex Capital Inc Annual Shareholders Meeting 19 May     13:00           Hanover Insurance Group Inc Annual Shareholders Meeting 19 May     13:00        Inteliquent Inc Annual Shareholders Meeting 19 May     13:00        IRIDEX at UBS Global Healthcare Conf 19 May     13:00        Kratos Defense and Security Annual Shareholders Meeting 19 May     13:00        Landstar System Inc Annual Shareholders Meeting 19 May     13:00        Sirius XM Inc Annual Shareholders Meeting 19 May     13:00           Textron Inc at Electrical Products Group Conf 19 May     13:00           United States Cellular Annual Shareholders Meeting 19 May     13:00        Xenoport Inc Annual Shareholders Meeting 19 May     13:05           Newfield Exploration Co at UBS Global Oil and Gas Conf 19 May     13:15           CYS Investments Inc at Wells Fargo Conf 19 May     13:15          Ladder Capital at Wells Fargo Conf 19 May     13:20           Corning Inc at JPMorgan Conf 19 May     13:20        Fortinet Inc at JPMorgan Conf 19 May     13:20           Mosaic Co at Barclays Americas Select Conf 19 May     13:20        National CineMedia Inc at JPMorgan Conf 19 May     13:20             Pandora Media Inc at JPMorgan Conf 19 May     13:20           PulteGroup Inc at JPMorgan Conf 19 May     13:20             Sprint at JPMorgan Conf 19 May     13:20        Symantec at JPMorgan Conf 19 May     13:30          Puma Biotechnology Inc at UBS Global Healthcare Conf 19 May     13:30           Senior Housing Properties Trust Annual Shareholders Meeting 19 May     13:30           Vishay Intertechnology Inc Annual Shareholders Meeting 19 May     13:45           Eastman Chemical Co at Goldman Sachs Basic Materials Conf 19 May     10:00         Somero Enterprises Inc Annual Shareholders Meeting 19 May     22:00        Columbia Sportswear Co Annual Shareholders Meeting 19 May     10:10        Cisco Systems Inc at Barclays Americas Select Conf 19 May                     Air Products and Chemicals at Goldman Sachs Conf 19 May                     Alaska Air Group Inc at Wolfe Trahan Transport Conf 19 May                  Allegiant Travel Co at Wolfe Trahan Transport Conf 19 May                  AmTrust Financial Services Inc at SunTrust RobinsonConf 19 May                  Ares Capital at SunTrust RobinsonConf 19 May                  BOK Financial at SunTrust RobinsonConf 19 May                     BorgWarner Inc at Barclays Americas Select Conf 19 May                     California Resources at UBS Global Oil and Gas Conf 19 May                     Cash America International Inc at Wells Fargo Conf 19 May                     Celadon Group Inc at Wolfe Trahan Transport Conf 19 May                  Celladon at Wolfe Trahan Transport Conf 19 May                  Check Point Software Technologies Ltd at JPMorgan Conf 19 May                   Cheniere Energy Inc at Barclays Americas Select Conf 19 May                     Chesapeake Energy at UBS Global Oil and Gas Conf 19 May                     Chesapeake Energy at Barclays Americas Select Conf 19 May                     Chimera Investment at Wells Fargo Conf 19 May                     Con-way Inc at Wolfe Trahan Transport Conf 19 May                  Covenant Transportation at Wolfe Trahan Transport Conf 19 May                     CSX at Wolfe Trahan Transport Conf 19 May                  Echo Global Logistics Inc at Wolfe Trahan Transport Conf 19 May                  Encore Capital Group Inc at SunTrust RobinsonConf 19 May                  Expeditors International Inc at Wolfe Trahan Transport Conf 19 May                     F.N.B. at SunTrust RobinsonConf 19 May                   Fifth Street Finance at SunTrust RobinsonConf 19 May                  First NBC Bank Holding Co at SunTrust RobinsonConf 19 May                  Forward Air at Wolfe Trahan Transport Conf 19 May                     Genesee & Wyoming Inc at Wolfe Trahan Transport Conf 19 May                  Glacier BanInc at SunTrust RobinsonConf 19 May                  Golub Capital BDC Inc at SunTrust RobinsonConf 19 May                  Hancock Holding Co at SunTrust RobinsonConf 19 May                    Hawaiian Inc at Wolfe Trahan Transport Conf 19 May                  Healthcare Services Group Inc at UBS Global Healthcare Conf 19 May                  J B Hunt Transport Services Inc at Wolfe Trahan Transport Conf 19 May                  JetBlue Airways at Wolfe Trahan Transport Conf 19 May                     Knight Transportation Inc at Wolfe Trahan Transport Conf 19 May                    Main Street Capital at SunTrust RobinsonConf 19 May                      Morgan Stanley Annual Shareholders Meeting 19 May                     Occidental Petroleum at UBS Global Oil and Gas Conf 19 May                  Old Dominion Freight Line Inc at Wolfe Trahan Transport Conf 19 May                   Old National Banat SunTrust RobinsonConf 19 May                  PennantPark Investment at SunTrust RobinsonConf 19 May                    PennyMac Financial Services at Wells Fargo Conf 19 May                     PennyMac Mortgage Investment Trust at Wells Fargo Conf 19 May                  People's United Financial Inc at SunTrust RobinsonConf 19 May                  Pinnacle Financial Partners Inc at SunTrust RobinsonConf 19 May                      Prosperity Bancshares Inc at SunTrust RobinsonConf 19 May                      Regions Financial at SunTrust RobinsonConf 19 May                  Renasant at SunTrust RobinsonConf 19 May                    Roadrunner Transportation at Wolfe Trahan Transport Conf 19 May                       Ryder System Inc at Wolfe Trahan Transport Conf 19 May                  Saia Inc at Wolfe Trahan Transport Conf 19 May                  Sandy Spring BanInc at SunTrust RobinsonConf 19 May                     Schlumberger NV at UBS Global Oil and Gas Conf 19 May                  Solar Capital Ltd at SunTrust RobinsonConf 19 May                   South State at SunTrust RobinsonConf 19 May                      Southern Co at Wolfe Trahan Transport Conf 19 May                  Spirit Airlines Inc at Wolfe Trahan Transport Conf 19 May                  State Bank Financial at SunTrust RobinsonConf 19 May                    TPG Specialty Lending Inc at SunTrust RobinsonConf 19 May                     Union Pacific at Wolfe Trahan Transport Conf 19 May                  United Community Banks Inc at SunTrust RobinsonConf 19 May                     United Continental Inc at Wolfe Trahan Transport Conf 19 May                     United Parcel Service Inc at Wolfe Trahan Transport Conf 19 May                     Unum Group at SunTrust RobinsonConf 19 May                    Virgin America Inc at Wolfe Trahan Transport Conf 19 May                  Werner Enterprises Inc at Wolfe Trahan Transport Conf 19 May                     Westinghouse Air Brake at Wolfe Trahan Transport Conf 19 May                     XPO Logistics Inc at Wolfe Trahan Transport Conf 19 May     11:45        Cornerstone OnDemand Inc at JPMorgan Conf 19 May     11:45             Genpact Ltd at JPMorgan Conf 19 May     11:45           Lions Gate Entertainment at JPMorgan Conf 19 May     11:45         SciQuest Inc at JPMorgan Conf 19 May     11:45            Verizon Communications Inc at JPMorgan Conf 19 May     00:00        Cathay General BanAnnual Shareholders Meeting 19 May     12:00        Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     12:00         American Airlines Group Inc at Wolfe Trahan Transport Conf 19 May     12:00           Community Health Systems Inc Annual Shareholders Meeting 19 May     12:00        Cosi Inc Annual Shareholders Meeting 19 May     12:00           EOG Resources Inc at Barclays Americas Select Conf 19 May     12:00            FirstEnergy Annual Shareholders Meeting 19 May     12:00        Houghton Mifflin Harcourt Co Annual Shareholders Meeting 19 May     12:00            Laboratory of America at UBS Global Healthcare Conf 19 May     12:00           Masco at JPMorgan Conf 19 May     12:00           PharMerica at UBS Global Healthcare Conf 19 May     12:00           Southwest Airlines Co at Wolfe Trahan Transport Conf 19 May     12:00        Sykes Enterprises Inc Annual Shareholders Meeting 19 May     12:00           Western Alliance BanAnnual Shareholders Meeting 19 May     12:00        Zions Banat Barclays Americas Select Conf 19 May     12:30          Anthem Inc at UBS Global Healthcare Conf 19 May     12:30        Array Biopharma Inc at UBS Global Healthcare Conf 19 May     12:30            Diamond Offshore Drilling Inc Annual Shareholders Meeting 19 May     12:30        Kite Pharma Inc at UBS Global Healthcare Conf 19 May     12:30           Nationstar Mortgage Inc at Wells Fargo Conf 19 May     12:35           Huntsman at Goldman Sachs Basic Materials Conf 19 May     12:40           Meritage Homes at JPMorgan Conf 19 May     12:40        Northern Trust at Barclays Americas Select Conf 19 May     12:40        Yahoo! Inc at JPMorgan Conf 19 May     14:00           B&G Foods Inc Annual Shareholders Meeting 19 May     14:00           Boston Properties Inc Annual Shareholders Meeting 19 May     14:00           Capstead Mortgage at Wells Fargo Conf 19 May     14:00           CARBO Ceramics Inc Annual Shareholders Meeting 19 May     14:00        Career Education Annual Shareholders Meeting 19 May     14:00        Carrizo Oil & Gas Annual Shareholders Meeting 19 May     14:00           CDI Annual Shareholders Meeting 19 May     14:00        Epizyme Inc Annual Shareholders Meeting 19 May     14:00         Fairchild Semiconductor International Inc at JPMorgan Conf 19 May     14:00        Gilead Sciences Inc at UBS Global Healthcare Conf 19 May     14:00        Gogo Inc at JPMorgan Conf 19 May     14:00        HSN Inc Annual Shareholders Meeting 19 May     14:00           JPMorgan Chase & Co Annual Shareholders Meeting 19 May     14:00          Kate Spade & Co Annual Shareholders Meeting 19 May     14:00           Laredo Petroleum Inc Annual Shareholders Meeting 19 May     14:00           Lexington Realty Trust Annual Shareholders Meeting 19 May     14:00           MDC Inc Annual Shareholders Meeting 19 May     14:00         MoneyGram International Inc at JPMorgan Conf 19 May     14:00           Outfront Media Inc at JPMorgan Conf 19 May     14:00           Principal Financial Group Inc Annual Shareholders Meeting 19 May     14:00        Qlik Technologies Inc at JPMorgan Conf 19 May     14:00           Range Resources Annual Shareholders Meeting 19 May     14:00          Starwood Waypoint Residential Trust at Wells Fargo Conf 19 May     14:00        Synchronoss Technologies Inc at JPMorgan Conf 19 May     14:00        Texas Capital Bancshares Inc Annual Shareholders Meeting 19 May     14:00        Trimble Navigation Ltd at JPMorgan Conf 19 May     14:00        TripAdvisor Inc at JPMorgan Conf 19 May     14:00          U.S. Physical Therapy Inc Annual Shareholders Meeting 19 May     14:00           XPO Logistics Inc Annual Shareholders Meeting 19 May     14:00           Xylem Inc at Electrical Products Group Conf 19 May     14:15           Western Inc at UBS Global Oil and Gas Conf 19 May     14:20            Celanese at Goldman Sachs Basic Materials Conf 19 May     14:20           Westlake Chemical at Goldman Sachs Basic Materials Conf 19 May     14:30        Alphatec Inc at UBS Global Healthcare Conf 19 May     14:30           Ellington Financial LLC Annual Shareholders Meeting 19 May     14:30        Health Insurance Innovations Inc Annual Shareholders Meeting 19 May     14:30           Merck & Co Inc at UBS Global Healthcare Conf 19 May     14:40        AMC Networks Inc at JPMorgan Conf 19 May     14:40           Crown Castle International at JPMorgan Conf 19 May     14:40        KineMed Inc at Biocentury BioEquity Europe 19 May     14:40          LinkedIn at JPMorgan Conf 19 May     14:40        Marketo Inc at JPMorgan Conf 19 May     14:40        MKS Instruments Inc at JPMorgan Conf 19 May     14:40        SanDisk at JPMorgan Conf 19 May     14:40           SolarWinds Inc at JPMorgan Conf 19 May     14:40        Stratasys Ltd at JPMorgan Conf 19 May     14:45           MFA Financial Inc at Wells Fargo Conf 19 May     14:45            Walker & Dunlop Inc at Wells Fargo Conf 19 May     14:55           D.R. Horton Inc at JPMorgan Conf 19 May     15:00         Avis Budget Group Inc Annual Shareholders Meeting 19 May     15:00            Cigna at UBS Global Healthcare Conf 19 May     15:00           Continental Resources Inc Annual Shareholders Meeting 19 May     15:00          CorEnergy Infrastructure Trust Inc Annual Shareholders Meeting 19 May     15:00           DineEquity Inc Annual Shareholders Meeting 19 May     15:00          Ellington Residential Mortgage REIT Annual Shareholders Meeting 19 May     15:00           Felcor Lodging Trust Inc Annual Shareholders Meeting 19 May     15:00           Group 1 Automotive Inc Annual Shareholders Meeting 19 May     15:00        Hologic Inc at UBS Global Healthcare Conf 19 May     15:00        Infinity Property and Casualty Annual Shareholders Meeting 19 May     15:00        Insight Enterprises Inc Annual Shareholders Meeting 19 May     15:00          Jones Energy Inc at UBS Global Oil and Gas Conf 19 May     15:00          Quad/Graphics Inc Annual Shareholders Meeting 19 May     15:00       Rush Enterprises Inc Annual Shareholders Meeting 19 May     15:00        Vertex Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     15:10           Ecolab Inc at Goldman Sachs Basic Materials Conf 19 May     15:15        YRC Worldwide Inc at Wolfe Trahan Transport Conf 19 May     15:20         Frontier Communications at JPMorgan Conf 19 May     15:20        HomeAway Inc at Barclays Americas Select Conf 19 May     15:20        Linear Technology at JPMorgan Conf 19 May     15:20           Omnicom Group Inc at JPMorgan Conf 19 May     15:20        Rovi at JPMorgan Conf 19 May     15:20        Syntel Inc at JPMorgan Conf 19 May     15:20        Web.com Group Inc at JPMorgan Conf 19 May     15:20            Western Union Co at JPMorgan Conf 19 May     15:30          Ares Commercial Real Estate at Wells Fargo Conf 19 May     15:30           Cliffs Natural Resources Inc Annual Shareholders Meeting 19 May     15:30        Concert Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     15:30           Invesco Mortgage Capital Inc at Wells Fargo Conf 19 May     15:30           MaxLinear Inc Annual Shareholders Meeting 19 May     15:30           Service International at UBS Global Healthcare Conf 19 May     15:30           United Technologies at Electrical Products Group Conf 19 May     16:00           Allstate Annual Shareholders Meeting 19 May     16:00        Boulder Brands Inc Annual Shareholders Meeting 19 May     16:00          Juniper Networks Inc Annual Shareholders Meeting 19 May     16:00        MGE Energy Inc Annual Shareholders Meeting 19 May     16:00           Mid-America Apartment Communities Annual Shareholders Meeting 19 May     16:00        Nanometrics Inc Annual Shareholders Meeting 19 May     16:00        Newport Annual Shareholder Meeting 19 May     16:00           Southwestern Energy Co Annual Shareholders Meeting 19 May     16:00           Pinnacle Entertainment Inc Annual Shareholders Meeting 19 May     16:30        Salem Media Group Inc Annual Shareholders Meeting 19 May     16:30          Starwood Property Trust Inc at Wells Fargo Conf 19 May     17:00        Biogen Inc at UBS Global Healthcare Conf 19 May     17:00        Echelon Annual Shareholders Meeting 19 May     17:00        Financial Engines Inc Annual Shareholders Meeting 19 May     17:00           Gap Inc Annual Shareholders Meeting 19 May     17:00        Henry Schein Inc at UBS Global Healthcare Conf 19 May     17:00        Isis Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     17:00        LifePoint Hospitals Inc at UBS Global Healthcare Conf 19 May     17:10           PolyOne at Goldman Sachs Basic Materials Conf 19 May     17:15           Dover at Electrical Products Group Conf 19 May     17:15           Lennar at JPMorgan Conf 19 May     17:30          Axiall Annual Shareholders Meeting 19 May     17:30        Biomarin Pharmaceutical Inc at UBS Global Healthcare Conf 19 May     17:30        Core-Mark Holding Company Inc Annual Shareholders Meeting 19 May     17:30           Devon Energy at UBS Global Oil and Gas Conf 19 May     17:30        GoPro Inc at JPMorgan Conf 19 May     17:30        NuVasive at the UBS Global Healthcare Conf 19 May     17:30           Redwood Trust Inc Annual Shareholders Meeting 19 May     17:45           Apollo Commercial Real Estate Finance Inc at Wells Fargo Conf 19 May     17:45           Hatteras Financial at Wells Fargo Conf 19 May     17:55           USG at JPMorgan Conf 19 May     06:00        Healthways Inc Annual Shareholders Meeting 19 May     18:00           3D Systems Annual Shareholders Meeting 19 May     18:00           Community Health Systems Inc at UBS Global Healthcare Conf 19 May     18:00        Flushing Financial Annual Shareholders Meeting 19 May     18:00        Immune Design at UBS Global Healthcare Conf 19 May     18:00        Impax Laboratories Inc at UBS Global Healthcare Conf 19 May     18:00            Ingersoll-Rand PLC at Electrical Products Group Conf 19 May     18:00           Ryman Hospitality Properties at Nomura Conf 19 May     18:00        Seattle Genetics Inc at UBS Global Healthcare Conf 19 May     18:00        Skyworks Solutions Inc Annual Shareholders Meeting 19 May     18:10        Akamai Technologies Inc at JPMorgan Conf 19 May     18:10           DigitalGlobe Inc at JPMorgan Conf 19 May     18:10          Paycom Software Inc at JPMorgan Conf 19 May     18:10        SBA Communications at JPMorgan Conf 19 May     18:10             Visa Inc at JPMorgan Conf 19 May     18:15        C.H. Robinson Worldwide Inc at Wolfe Trahan Transport Conf 19 May     18:20           W. R. Grace & Co at Goldman Sachs Basic Materials Conf 19 May     18:30          Hannon Armstrong Sustainable Capital Inc at Wells Fargo Conf 19 May     18:30           Stryker at UBS Global Healthcare Conf 19 May     18:30           TeamHealth Inc at UBS Global Healthcare Conf 19 May     18:30           Western Asset Mortgage Capital at Wells Fargo Conf 19 May     18:35           Hovnanian Enterprises at JPMorgan Conf 19 May     06:45        Fifth Third Banat Barclays Americas Select Conf 19 May     06:45        Hain Celestial Group Inc at JPMorgan Consumer and Retail Conf 19 May     18:50          A10 Networks Inc at JPMorgan Conf 19 May     18:50        Aspen Technology Inc at JPMorgan Conf 19 May     18:50           Cinemark Inc at JPMorgan Conf 19 May     18:50        Expedia Inc at JPMorgan Conf 19 May     18:50             Intelsat SA at JPMorgan Conf 19 May     18:50        Ultimate Software Group Inc at JPMorgan Conf 19 May     18:50        Xilinx Inc at JPMorgan Conf 19 May     18:55           Ball at Goldman Sachs Basic Materials Conf 19 May     19:00        ChemoCentryx Inc at UBS Global Healthcare Conf 19 May     19:00        Incyte at UBS Global Healthcare Conf 19 May     19:00        Interface Inc Annual Shareholders Meeting 19 May     19:15          AG Mortgage Investment Trust Inc at Wells Fargo Conf 19 May     07:30           General Mills Inc at Barclays Americas Select Conf 19 May     07:30           U.S. Banat Barclays Americas Select Conf 19 May     19:30          Chegg Inc at JPMorgan Conf 19 May     19:30        Lam Research at JPMorgan Conf 19 May     19:30        Lamar Advertising Co at JPMorgan Conf 19 May     19:30           Mettler-Toledo International Inc at UBS Global Healthcare Conf 19 May     19:30          New Relic Inc at JPMorgan Conf 19 May     19:30        Sangamo BioSciences Inc at UBS Global Healthcare Conf 19 May     19:30        Threshold Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     19:30        Verint Systems Inc at JPMorgan Conf 19 May     19:30         Windstream Inc at JPMorgan Conf 19 May     19:55           KB Home at JPMorgan Conf 19 May     20:00           Denbury Resources Inc Annual Shareholders Meeting 19 May     20:00           Essex Property Trust Inc Annual Shareholders Meeting 19 May     20:00        Exact Sciences at UBS Global Healthcare Conf 19 May     20:00        GTX Inc at UBS Global Healthcare Conf 19 May     20:00        Intercept Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     20:00        Preferred Bank Annual Shareholders Meeting 19 May     20:00          Springleaf Inc Annual Shareholders Meeting 19 May     20:00           Swift Energy Company Annual Shareholders Meeting 19 May     08:10            Colgate-Palmolive Co at Barclays Americas Select Conf 19 May     20:10           Digital Realty Trust Inc at JPMorgan Conf 19 May     20:10        Microchip Technology Inc at JPMorgan Conf 19 May     20:10        Zebra Technologies at JPMorgan Conf 19 May     20:30        Momenta Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     20:30        Sunesis Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     08:50           Wells Fargo & Co at Barclays Americas Select Conf 19 May     21:00          Diamond Resorts International Inc Annual Shareholders Meeting 19 May     21:30        Omnicell Inc Annual Shareholders Meeting 19 May     21:30            SM Energy Co Annual Shareholders Meeting           FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-05-15,MRK,"Fri May 15, 2015 | 11:25am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0Y66KB20150515?type=companyNews
333,"  Thomson Reuters May 15, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For events after May 19 please click on                    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  15 May     01:00        Bank of Marin BanAnnual Shareholders Meeting 15 May     13:00           Clear Channel Outdoor Inc Annual Shareholders Meeting 15 May     13:00           Forum Energy Technologies Inc Annual Shareholders Meeting 15 May     13:00           Newfield Exploration Co Annual Shareholders Meeting 15 May     13:30           Aetna Inc Annual Shareholders Meeting 15 May                     Campus Crest Communities Inc Annual Shareholders Meeting 15 May     12:00          BioAmber Inc Annual Shareholders Meeting 15 May     12:00            Western Union Co Annual Shareholders Meeting 15 May     12:00           WEX Inc Annual Shareholders Meeting 15 May     12:30           Intercontinental Exchange Inc Annual Shareholders Meeting 15 May     14:00           American Water Works Company Inc Annual Shareholders Meeting 15 May     14:00        Chefs Warehouse Inc Annual Shareholders Meeting 15 May     14:00           Macquarie Infrastructure Extraordinary Shareholders Meeting 15 May     14:00         Memorial Resource Development Annual Shareholders Meeting 15 May     14:00           Progressive Annual Shareholders Meeting 15 May     14:00           Tanger Factory Outlet Centers Inc Annual Shareholders Meeting 15 May     14:00           Terex Annual Shareholders Meeting 15 May     14:00           Westlake Chemical Annual Shareholders Meeting 15 May     14:30           John Bean Technologies Annual Shareholders Meeting 15 May     14:30           Quest Diagnostics Inc Annual Shareholders Meeting 15 May     15:00          Banc of California Inc Annual Shareholders Meeting 15 May     15:00            CF Industries Inc Annual Shareholders Meeting 15 May     15:00          Cypress Semiconductor Annual Shareholders Meeting 15 May     15:00           Dril-Quip Inc Annual Shareholders Meeting 15 May     15:00           J C Penney Company Inc Annual Shareholders Meeting 15 May     15:00             Macys Inc Annual Shareholders Meeting 15 May     15:00        QCR Inc Annual Shareholders Meeting 15 May     15:00        Rosetta Resources Inc Annual Shareholders Meeting 15 May     15:00           Transocean Ltd Annual Shareholders Meeting 15 May     15:00           Waste Connections Inc Annual Shareholders Meeting 15 May     15:00        West Annual Shareholders Meeting 15 May     15:30           CBRE Group Inc Annual Shareholders Meeting 15 May     17:00        Commercial Vehicle Group Inc Annual Shareholders Meeting 15 May     18:00        Seattle Genetics Inc Annual Shareholders Meeting 15 May     19:00          Roundy's Inc Annual Shareholders Meeting 16 May     22:00        First Interstate Bancsystem Inc Annual Shareholders Meeting 16 May     14:00           Dillard's Inc Annual Shareholders Meeting 16 May     15:00           American Works at NAIC's BetterInvesting National Convention 17 May     22:00            Laclede Group Inc at American Gas Forum 17 May                     Alliant Energy at American Gas Forum 17 May                     Atmos Energy at American Gas Forum 17 May                     Avista at American Gas Forum 17 May                     Black Hills at American Gas Forum 17 May                     Chesapeake Utilities at American Gas Forum 17 May                      Consolidated Edison Inc at American Gas Forum 17 May                  Delta Natural Gas Company Inc at American Gas Forum 17 May                      Eversource Energy at American Gas Forum 17 May                     Integrys Energy Group Inc at American Gas Forum 17 May                      Laclede Group Inc at American Gas Forum 17 May                     MDU Resources Group Inc at American Gas Forum 17 May                  MGE Energy Inc at American Gas Forum 17 May                     National Fuel Gas Co at American Gas Forum 17 May                     New Jersey Resources at American Gas Forum 17 May                      NiSource Inc at American Gas Forum 17 May                     Piedmont Natural Gas Company Inc at American Gas Forum 17 May                     Questar at American Gas Forum 17 May                     Sempra Energy at American Gas Forum 17 May                     South Jersey Industries Inc at American Gas Forum 17 May                     Southwest Gas at American Gas Forum 17 May                      Spectra Energy at American Gas Forum 17 May                      TECO Energy Inc at American Gas Forum 17 May                     UGI at American Gas Forum 17 May                     UIL at American Gas Forum 17 May                     Unitil at American Gas Forum 17 May                     Vectren at American Gas Forum 17 May                     WGL Inc at American Gas Forum 17 May                     Wisconsin Energy at American Gas Forum 17 May                     Xcel Energy Inc at American Gas Forum 17 May     21:15           Chesapeake Utilities at American Gas Forum 18 May     13:00           3M Co at Electrical Products Group Conf 18 May     13:00        Infinity Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     13:00          Targa Resources Annual Shareholders Meeting 18 May     13:00           Tenet Healthcare at UBS Global Healthcare Conf 18 May     13:20          Care.com Inc at JPMorgan Conf 18 May     13:20        Cavium Inc at JPMorgan Conf 18 May     13:20           EMC at JPMorgan Conf 18 May     13:20            MasterCard Inc at JPMorgan Conf 18 May     13:20           Neustar Inc at JPMorgan Conf 18 May     13:20          T-Mobile US Inc at JPMorgan Conf 18 May     13:20        Virtusa at JPMorgan Conf 18 May     13:30        Akebia Therapeutics Inc at UBS Global Healthcare Conf 18 May     13:30        Bank of The Ozarks Inc Annual Shareholders Meeting 18 May     13:30           Cambrex at UBS Global Healthcare Conf 18 May     13:30        Esperion Therapeutics Inc at UBS Global Healthcare Conf 18 May     22:00        Geron Annual Shareholders Meeting 18 May     22:00        International Bancshares Annual Shareholders Meeting 18 May                  AcelRx Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May                     Ameren at American Gas Forum 18 May                  Bruker at UBS Global Healthcare Conf 18 May                     CenterPoint Energy Inc at American Gas Forum 18 May                    Civitas Solutions Inc at UBS Global Healthcare Conf 18 May                     CMS Energy at American Gas Forum (One-on-One Meeting) 18 May                     DTE Energy Co at American Gas Forum (One on One Meetings) 18 May                     Empire District Electric Co at American Gas Forum 18 May                  Gas Natural Inc at American Gas Forum 18 May                      Intralinks Inc at JPMorgan Conf 18 May                     NCR at JPMorgan Conf 18 May                     NorthWestern at American Gas Forum:One-on-One Meeting 18 May                     Oasis Petroleum Inc at UBS Global Oil and Gas Conf 18 May                     ONE Gas Inc at American Gas Forum - One-on-One Meetings 18 May                     PG&E at American Gas Forum 18 May                     Public Service Enterprise Group Inc at American Gas Forum 18 May                  RTI Surgical Inc at UBS Global Healthcare Conf 18 May                    U.S. Physical Therapy Inc at UBS Global Healthcare Conf 18 May     11:30           Honeywell International Inc at Electrical Products Group Conf 18 May     12:00             AT&T Inc at JPMorgan Conf 18 May     12:00         VWR at UBS Global Healthcare Conf 18 May     12:30        Ophthotech at UBS Global Healthcare Conf 18 May     12:40        Viacom Inc at JPMorgan Conf 18 May     14:00        Cogent Communications Inc at JPMorgan Conf 18 May     14:00       Comcast at JPMorgan Conf 18 May     14:00            Consolidated Edison Inc Annual Shareholders Meeting 18 May     14:00        CoStar Group Inc at JPMorgan Conf 18 May     14:00        Cree Inc at JPMorgan Conf 18 May     14:00           Danaher at Electrical Products Group Conf 18 May     14:00      Genesis Healthcare at UBS Global Healthcare Conf 18 May     14:00           Global Payments Inc at JPMorgan Conf 18 May     14:00        NetScout Systems Inc at JPMorgan Conf 18 May     14:00        OraSure Technologies Inc at UBS Global Healthcare Conf 18 May     14:00           PerkinElmer Inc at UBS Global Healthcare Conf 18 May     14:00        Prothena PLC at UBS Global Healthcare Conf 18 May     14:00         Texas Instruments Inc at JPMorgan Conf 18 May     14:00        Ultimate Software Group Inc Annual Shareholders Meeting 18 May     14:30           Actavis PLC at UBS Global Healthcare Conf 18 May     14:30        Integra LifeSciences at UBS Global Healthcare Conf 18 May     14:30           Universal Health Services Inc at UBS Global Healthcare Conf 18 May     14:40        ANSYS Inc at JPMorgan Conf 18 May     14:40           CenturyLink Inc at JPMorgan Conf 18 May     14:40          Facebook Inc at JPMorgan Conf 18 May     14:40        Maxim Integrated Products Inc at JPMorgan Conf 18 May     14:40        Synaptics Inc at JPMorgan Conf 18 May     14:40          TriNet Group Inc at JPMorgan Conf 18 May     14:45           Stanley Black & Decker Inc at Electrical Products Group Conf 18 May     15:00           AMN Healthcare Services Inc at UBS Global Healthcare Conf 18 May     15:00        LDR Holding at UBS Global Healthcare Conf 18 May     15:00           Waters at UBS Global Healthcare Conf 18 May     15:20           Box Inc at JPMorgan Conf 18 May     15:20           Diebold Inc at JPMorgan Conf 18 May     15:20           International Business Machines at JPMorgan Conf 18 May     15:20        Orbotech Ltd at JPMorgan Conf 18 May     15:20        Qualys Inc at JPMorgan Conf 18 May     15:20        Sinclair Broadcast Group Inc at JPMorgan Conf 18 May     15:30        Achillion Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     15:30        PAREXEL International at UBS Global Healthcare Conf 18 May     15:30          Perrigo Company PLC at UBS Global Healthcare Conf 18 May     15:30           Roper Technologies Inc at Electrical Products Group Conf 18 May     16:00            Consolidated Edison Inc at American Gas Forum 18 May     16:00        Grand Canyon Education Inc Annual Shareholders Meeting 18 May     16:00           MDU Resources Group Inc at American Gas Forum 18 May     16:00           Omnicom Group Inc Annual Shareholders Meeting 18 May     16:00           Questar at American Gas Forum 18 May     16:00           South Jersey Industries Inc at American Gas Forum 18 May     16:30           WESCO International Inc at Electrical Products Group Conf 18 May     16:45           DTE Energy Co at American Gas Forum 18 May     16:45           National Fuel Gas Co at American Gas Forum 18 May     16:45           Northwest Natural Gas Co at American Gas Forum 18 May     17:00        Epizyme Inc at UBS Global Healthcare Conf 18 May     17:00           Health Care REIT Inc at UBS Global Healthcare Conf 18 May     17:00        IPC Healthcare Inc at UBS Global Healthcare Conf 18 May     17:00        Veracyte Inc Annual Shareholders Meeting 18 May     17:15           Eaton PLC at Electrical Products Group Conf 18 May     17:30        Alimera Sciences Inc at UBS Global Healthcare Conf 18 May     17:30        AngioDynamics Inc at UBS Global Healthcare Conf 18 May     17:30           CMS Energy at American Gas Forum 18 May     17:30        K2M Group Inc at UBS Global Healthcare Conf 18 May     17:30        Medivation Inc at UBS Global Healthcare Conf 18 May     17:30           ONE Gas Inc at American Gas Forum 18 May     17:30        PacWest BanAnnual Shareholders Meeting 18 May     17:30        PacWest BanCourt Meeting 18 May     17:30           Unitil at American Gas Forum 18 May     18:00        Halozyme Therapeutics Inc at UBS Global Healthcare Conf 18 May     18:00           Rockwell Automation Inc at Electrical Products Group Conf 18 May     18:10           American Tower at JPMorgan Conf 18 May     18:10            Broadridge Financial Solutions Inc at JPMorgan Conf 18 May     18:10          Everyday Health Inc at JPMorgan Conf 18 May     18:10        Medidata Solutions Inc at JPMorgan Conf 18 May     18:10        Paychex Inc at JPMorgan Conf 18 May     18:15           NorthWestern at American Gas Forum 18 May     18:15           Southwest Gas at American Gas Forum 18 May     18:15            TECO Energy Inc at American Gas Forum 18 May     18:15           WGL Inc at American Gas Forum 18 May     18:30           Aetna Inc at UBS Global Healthcare Conf 18 May     18:30        Biospecifics Technologies at UBS Global Healthcare Conf 18 May     18:45           SPX at Electrical Products Group Conf 18 May     18:50        Dealertrack Technologies Inc at JPMorgan Conf 18 May     18:50           Freescale Semiconductor Ltd at JPMorgan Conf 18 May     18:50        HomeAway Inc at JPMorgan Conf 18 May     18:50          HubSpot Inc at JPMorgan Conf 18 May     18:50           Interpublic Group of Companies Inc at JPMorgan Conf 18 May     18:50           WEX Inc at JPMorgan Conf 18 May     19:00        AMAG Pharmaceuticals Inc at UBS Global Healthcare Conf 18 May     19:30           Alliance Data Systems at JPMorgan Conf 18 May     19:30         Foundation Medicine Inc at UBS Global Healthcare Conf 18 May     19:30           Gannett Co Inc at JPMorgan Conf 18 May     19:30        LogMeIn Inc at JPMorgan Conf 18 May     19:30           RingCentral Inc at JPMorgan Conf 18 May     19:30        ShoreTel Inc at JPMorgan Conf 18 May     19:30           VeriFone Systems Technology, Media and Telecom Conf 18 May     19:30           West Pharmaceutical Services Inc at UBS Global Healthcare Conf 18 May     08:00       Nexus AG Annual Shareholders Meeting 18 May     20:00        Insmed Inc at UBS Global Healthcare Conf 18 May     20:00            Spectra Energy at American Gas Forum 18 May     20:00           UIL at American Gas Forum 18 May     20:00           Vectren at American Gas Forum 18 May     20:10        CyrusOne Inc at JPMorgan Conf 18 May     20:10        EnerNOC Inc at JPMorgan Conf 18 May     20:10          Guidewire Software Inc at JPMorgan Conf 18 May     20:10           Heartland Payment Systems Inc at JPMorgan Conf 18 May     20:10        iRobot at JPMorgan Conf 18 May     20:10          Model N Inc at JPMorgan Conf 18 May     20:10          Tribune Media Co at JPMorgan Conf 18 May     20:30        LegacyTexas Financial Group Inc Annual Shareholders Meeting 18 May     20:45           AGL Resources Inc at American Gas Forum 18 May     20:45           Black Hills at American Gas Forum 18 May     21:00           Motorola Solutions Inc Annual Shareholders Meeting 18 May     21:30           UGI at American Gas Forum 19 May     13:00        American National Bankshares Inc Annual Shareholders Meeting 19 May     13:00        Cerulean Pharma Inc at UBS Global Healthcare Conf 19 May     13:00        Chimerix Inc at UBS Global Healthcare Conf 19 May     13:00        Cross Country Healthcare Inc at UBS Global Healthcare Conf 19 May     13:00        CSG Systems International Inc Annual Shareholders Meeting 19 May     13:00        Dyax Annual Shareholders Meeting 19 May     13:00            Dynex Capital Inc Annual Shareholders Meeting 19 May     13:00           Hanover Insurance Group Inc Annual Shareholders Meeting 19 May     13:00        Inteliquent Inc Annual Shareholders Meeting 19 May     13:00        IRIDEX at UBS Global Healthcare Conf 19 May     13:00        Kratos Defense and Security Annual Shareholders Meeting 19 May     13:00        Landstar System Inc Annual Shareholders Meeting 19 May     13:00        Sirius XM Inc Annual Shareholders Meeting 19 May     13:00           Textron Inc at Electrical Products Group Conf 19 May     13:00           United States Cellular Annual Shareholders Meeting 19 May     13:00        Xenoport Inc Annual Shareholders Meeting 19 May     13:05           Newfield Exploration Co at UBS Global Oil and Gas Conf 19 May     13:15           CYS Investments Inc at Wells Fargo Conf 19 May     13:15          Ladder Capital at Wells Fargo Conf 19 May     13:20           Corning Inc at JPMorgan Conf 19 May     13:20        Fortinet Inc at JPMorgan Conf 19 May     13:20           Mosaic Co at Barclays Americas Select Conf 19 May     13:20        National CineMedia Inc at JPMorgan Conf 19 May     13:20             Pandora Media Inc at JPMorgan Conf 19 May     13:20           PulteGroup Inc at JPMorgan Conf 19 May     13:20             Sprint at JPMorgan Conf 19 May     13:20        Symantec at JPMorgan Conf 19 May     13:30          Puma Biotechnology Inc at UBS Global Healthcare Conf 19 May     13:30           Senior Housing Properties Trust Annual Shareholders Meeting 19 May     13:30           Vishay Intertechnology Inc Annual Shareholders Meeting 19 May     13:45           Eastman Chemical Co at Goldman Sachs Basic Materials Conf 19 May     10:00         Somero Enterprises Inc Annual Shareholders Meeting 19 May     22:00        Columbia Sportswear Co Annual Shareholders Meeting 19 May     10:10        Cisco Systems Inc at Barclays Americas Select Conf 19 May                     Air Products and Chemicals at Goldman Sachs Conf 19 May                     Alaska Air Group Inc at Wolfe Trahan Transport Conf 19 May                  Allegiant Travel Co at Wolfe Trahan Transport Conf 19 May                  AmTrust Financial Services Inc at SunTrust RobinsonConf 19 May                  Ares Capital at SunTrust RobinsonConf 19 May                  BOK Financial at SunTrust RobinsonConf 19 May                     BorgWarner Inc at Barclays Americas Select Conf 19 May                     California Resources at UBS Global Oil and Gas Conf 19 May                     Cash America International Inc at Wells Fargo Conf 19 May                     Celadon Group Inc at Wolfe Trahan Transport Conf 19 May                  Celladon at Wolfe Trahan Transport Conf 19 May                  Check Point Software Technologies Ltd at JPMorgan Conf 19 May                   Cheniere Energy Inc at Barclays Americas Select Conf 19 May                     Chesapeake Energy at UBS Global Oil and Gas Conf 19 May                     Chesapeake Energy at Barclays Americas Select Conf 19 May                     Chimera Investment at Wells Fargo Conf 19 May                     Con-way Inc at Wolfe Trahan Transport Conf 19 May                  Covenant Transportation at Wolfe Trahan Transport Conf 19 May                     CSX at Wolfe Trahan Transport Conf 19 May                  Echo Global Logistics Inc at Wolfe Trahan Transport Conf 19 May                  Encore Capital Group Inc at SunTrust RobinsonConf 19 May                  Expeditors International Inc at Wolfe Trahan Transport Conf 19 May                     F.N.B. at SunTrust RobinsonConf 19 May                   Fifth Street Finance at SunTrust RobinsonConf 19 May                  First NBC Bank Holding Co at SunTrust RobinsonConf 19 May                  Forward Air at Wolfe Trahan Transport Conf 19 May                     Genesee & Wyoming Inc at Wolfe Trahan Transport Conf 19 May                  Glacier BanInc at SunTrust RobinsonConf 19 May                  Golub Capital BDC Inc at SunTrust RobinsonConf 19 May                  Hancock Holding Co at SunTrust RobinsonConf 19 May                    Hawaiian Inc at Wolfe Trahan Transport Conf 19 May                  Healthcare Services Group Inc at UBS Global Healthcare Conf 19 May                  J B Hunt Transport Services Inc at Wolfe Trahan Transport Conf 19 May                  JetBlue Airways at Wolfe Trahan Transport Conf 19 May                     Knight Transportation Inc at Wolfe Trahan Transport Conf 19 May                    Main Street Capital at SunTrust RobinsonConf 19 May                      Morgan Stanley Annual Shareholders Meeting 19 May                     Occidental Petroleum at UBS Global Oil and Gas Conf 19 May                  Old Dominion Freight Line Inc at Wolfe Trahan Transport Conf 19 May                   Old National Banat SunTrust RobinsonConf 19 May                  PennantPark Investment at SunTrust RobinsonConf 19 May                    PennyMac Financial Services at Wells Fargo Conf 19 May                     PennyMac Mortgage Investment Trust at Wells Fargo Conf 19 May                  People's United Financial Inc at SunTrust RobinsonConf 19 May                  Pinnacle Financial Partners Inc at SunTrust RobinsonConf 19 May                      Prosperity Bancshares Inc at SunTrust RobinsonConf 19 May                      Regions Financial at SunTrust RobinsonConf 19 May                  Renasant at SunTrust RobinsonConf 19 May                    Roadrunner Transportation at Wolfe Trahan Transport Conf 19 May                       Ryder System Inc at Wolfe Trahan Transport Conf 19 May                  Saia Inc at Wolfe Trahan Transport Conf 19 May                  Sandy Spring BanInc at SunTrust RobinsonConf 19 May                     Schlumberger NV at UBS Global Oil and Gas Conf 19 May                  Solar Capital Ltd at SunTrust RobinsonConf 19 May                   South State at SunTrust RobinsonConf 19 May                      Southern Co at Wolfe Trahan Transport Conf 19 May                  Spirit Airlines Inc at Wolfe Trahan Transport Conf 19 May                  State Bank Financial at SunTrust RobinsonConf 19 May                    TPG Specialty Lending Inc at SunTrust RobinsonConf 19 May                     Union Pacific at Wolfe Trahan Transport Conf 19 May                  United Community Banks Inc at SunTrust RobinsonConf 19 May                     United Continental Inc at Wolfe Trahan Transport Conf 19 May                     United Parcel Service Inc at Wolfe Trahan Transport Conf 19 May                     Unum Group at SunTrust RobinsonConf 19 May                    Virgin America Inc at Wolfe Trahan Transport Conf 19 May                  Werner Enterprises Inc at Wolfe Trahan Transport Conf 19 May                     Westinghouse Air Brake at Wolfe Trahan Transport Conf 19 May                     XPO Logistics Inc at Wolfe Trahan Transport Conf 19 May     11:45        Cornerstone OnDemand Inc at JPMorgan Conf 19 May     11:45             Genpact Ltd at JPMorgan Conf 19 May     11:45           Lions Gate Entertainment at JPMorgan Conf 19 May     11:45         SciQuest Inc at JPMorgan Conf 19 May     11:45            Verizon Communications Inc at JPMorgan Conf 19 May     00:00        Cathay General BanAnnual Shareholders Meeting 19 May     12:00        Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     12:00         American Airlines Group Inc at Wolfe Trahan Transport Conf 19 May     12:00           Community Health Systems Inc Annual Shareholders Meeting 19 May     12:00        Cosi Inc Annual Shareholders Meeting 19 May     12:00           EOG Resources Inc at Barclays Americas Select Conf 19 May     12:00            FirstEnergy Annual Shareholders Meeting 19 May     12:00        Houghton Mifflin Harcourt Co Annual Shareholders Meeting 19 May     12:00            Laboratory of America at UBS Global Healthcare Conf 19 May     12:00           Masco at JPMorgan Conf 19 May     12:00           PharMerica at UBS Global Healthcare Conf 19 May     12:00           Southwest Airlines Co at Wolfe Trahan Transport Conf 19 May     12:00        Sykes Enterprises Inc Annual Shareholders Meeting 19 May     12:00           Western Alliance BanAnnual Shareholders Meeting 19 May     12:00        Zions Banat Barclays Americas Select Conf 19 May     12:30          Anthem Inc at UBS Global Healthcare Conf 19 May     12:30        Array Biopharma Inc at UBS Global Healthcare Conf 19 May     12:30            Diamond Offshore Drilling Inc Annual Shareholders Meeting 19 May     12:30        Kite Pharma Inc at UBS Global Healthcare Conf 19 May     12:30           Nationstar Mortgage Inc at Wells Fargo Conf 19 May     12:35           Huntsman at Goldman Sachs Basic Materials Conf 19 May     12:40           Meritage Homes at JPMorgan Conf 19 May     12:40        Northern Trust at Barclays Americas Select Conf 19 May     12:40        Yahoo! Inc at JPMorgan Conf 19 May     14:00           B&G Foods Inc Annual Shareholders Meeting 19 May     14:00           Boston Properties Inc Annual Shareholders Meeting 19 May     14:00           Capstead Mortgage at Wells Fargo Conf 19 May     14:00           CARBO Ceramics Inc Annual Shareholders Meeting 19 May     14:00        Career Education Annual Shareholders Meeting 19 May     14:00        Carrizo Oil & Gas Annual Shareholders Meeting 19 May     14:00           CDI Annual Shareholders Meeting 19 May     14:00        Epizyme Inc Annual Shareholders Meeting 19 May     14:00         Fairchild Semiconductor International Inc at JPMorgan Conf 19 May     14:00        Gilead Sciences Inc at UBS Global Healthcare Conf 19 May     14:00        Gogo Inc at JPMorgan Conf 19 May     14:00        HSN Inc Annual Shareholders Meeting 19 May     14:00           JPMorgan Chase & Co Annual Shareholders Meeting 19 May     14:00          Kate Spade & Co Annual Shareholders Meeting 19 May     14:00           Laredo Petroleum Inc Annual Shareholders Meeting 19 May     14:00           Lexington Realty Trust Annual Shareholders Meeting 19 May     14:00           MDC Inc Annual Shareholders Meeting 19 May     14:00         MoneyGram International Inc at JPMorgan Conf 19 May     14:00           Outfront Media Inc at JPMorgan Conf 19 May     14:00           Principal Financial Group Inc Annual Shareholders Meeting 19 May     14:00        Qlik Technologies Inc at JPMorgan Conf 19 May     14:00           Range Resources Annual Shareholders Meeting 19 May     14:00          Starwood Waypoint Residential Trust at Wells Fargo Conf 19 May     14:00        Synchronoss Technologies Inc at JPMorgan Conf 19 May     14:00        Texas Capital Bancshares Inc Annual Shareholders Meeting 19 May     14:00        Trimble Navigation Ltd at JPMorgan Conf 19 May     14:00        TripAdvisor Inc at JPMorgan Conf 19 May     14:00          U.S. Physical Therapy Inc Annual Shareholders Meeting 19 May     14:00           XPO Logistics Inc Annual Shareholders Meeting 19 May     14:00           Xylem Inc at Electrical Products Group Conf 19 May     14:15           Western Inc at UBS Global Oil and Gas Conf 19 May     14:20            Celanese at Goldman Sachs Basic Materials Conf 19 May     14:20           Westlake Chemical at Goldman Sachs Basic Materials Conf 19 May     14:30        Alphatec Inc at UBS Global Healthcare Conf 19 May     14:30           Ellington Financial LLC Annual Shareholders Meeting 19 May     14:30        Health Insurance Innovations Inc Annual Shareholders Meeting 19 May     14:30           Merck & Co Inc at UBS Global Healthcare Conf 19 May     14:40        AMC Networks Inc at JPMorgan Conf 19 May     14:40           Crown Castle International at JPMorgan Conf 19 May     14:40        KineMed Inc at Biocentury BioEquity Europe 19 May     14:40          LinkedIn at JPMorgan Conf 19 May     14:40        Marketo Inc at JPMorgan Conf 19 May     14:40        MKS Instruments Inc at JPMorgan Conf 19 May     14:40        SanDisk at JPMorgan Conf 19 May     14:40           SolarWinds Inc at JPMorgan Conf 19 May     14:40        Stratasys Ltd at JPMorgan Conf 19 May     14:45           MFA Financial Inc at Wells Fargo Conf 19 May     14:45            Walker & Dunlop Inc at Wells Fargo Conf 19 May     14:55           D.R. Horton Inc at JPMorgan Conf 19 May     15:00         Avis Budget Group Inc Annual Shareholders Meeting 19 May     15:00            Cigna at UBS Global Healthcare Conf 19 May     15:00           Continental Resources Inc Annual Shareholders Meeting 19 May     15:00          CorEnergy Infrastructure Trust Inc Annual Shareholders Meeting 19 May     15:00           DineEquity Inc Annual Shareholders Meeting 19 May     15:00          Ellington Residential Mortgage REIT Annual Shareholders Meeting 19 May     15:00           Felcor Lodging Trust Inc Annual Shareholders Meeting 19 May     15:00           Group 1 Automotive Inc Annual Shareholders Meeting 19 May     15:00        Hologic Inc at UBS Global Healthcare Conf 19 May     15:00        Infinity Property and Casualty Annual Shareholders Meeting 19 May     15:00        Insight Enterprises Inc Annual Shareholders Meeting 19 May     15:00          Jones Energy Inc at UBS Global Oil and Gas Conf 19 May     15:00          Quad/Graphics Inc Annual Shareholders Meeting 19 May     15:00       Rush Enterprises Inc Annual Shareholders Meeting 19 May     15:00        Vertex Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     15:10           Ecolab Inc at Goldman Sachs Basic Materials Conf 19 May     15:15        YRC Worldwide Inc at Wolfe Trahan Transport Conf 19 May     15:20         Frontier Communications at JPMorgan Conf 19 May     15:20        HomeAway Inc at Barclays Americas Select Conf 19 May     15:20        Linear Technology at JPMorgan Conf 19 May     15:20           Omnicom Group Inc at JPMorgan Conf 19 May     15:20        Rovi at JPMorgan Conf 19 May     15:20        Syntel Inc at JPMorgan Conf 19 May     15:20        Web.com Group Inc at JPMorgan Conf 19 May     15:20            Western Union Co at JPMorgan Conf 19 May     15:30          Ares Commercial Real Estate at Wells Fargo Conf 19 May     15:30           Cliffs Natural Resources Inc Annual Shareholders Meeting 19 May     15:30        Concert Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     15:30           Invesco Mortgage Capital Inc at Wells Fargo Conf 19 May     15:30           MaxLinear Inc Annual Shareholders Meeting 19 May     15:30           Service International at UBS Global Healthcare Conf 19 May     15:30           United Technologies at Electrical Products Group Conf 19 May     16:00           Allstate Annual Shareholders Meeting 19 May     16:00        Boulder Brands Inc Annual Shareholders Meeting 19 May     16:00          Juniper Networks Inc Annual Shareholders Meeting 19 May     16:00        MGE Energy Inc Annual Shareholders Meeting 19 May     16:00           Mid-America Apartment Communities Annual Shareholders Meeting 19 May     16:00        Nanometrics Inc Annual Shareholders Meeting 19 May     16:00        Newport Annual Shareholder Meeting 19 May     16:00           Southwestern Energy Co Annual Shareholders Meeting 19 May     16:00           Pinnacle Entertainment Inc Annual Shareholders Meeting 19 May     16:30        Salem Media Group Inc Annual Shareholders Meeting 19 May     16:30          Starwood Property Trust Inc at Wells Fargo Conf 19 May     17:00        Biogen Inc at UBS Global Healthcare Conf 19 May     17:00        Echelon Annual Shareholders Meeting 19 May     17:00        Financial Engines Inc Annual Shareholders Meeting 19 May     17:00           Gap Inc Annual Shareholders Meeting 19 May     17:00        Henry Schein Inc at UBS Global Healthcare Conf 19 May     17:00        Isis Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     17:00        LifePoint Hospitals Inc at UBS Global Healthcare Conf 19 May     17:10           PolyOne at Goldman Sachs Basic Materials Conf 19 May     17:15           Dover at Electrical Products Group Conf 19 May     17:15           Lennar at JPMorgan Conf 19 May     17:30          Axiall Annual Shareholders Meeting 19 May     17:30        Biomarin Pharmaceutical Inc at UBS Global Healthcare Conf 19 May     17:30        Core-Mark Holding Company Inc Annual Shareholders Meeting 19 May     17:30           Devon Energy at UBS Global Oil and Gas Conf 19 May     17:30        GoPro Inc at JPMorgan Conf 19 May     17:30        NuVasive at the UBS Global Healthcare Conf 19 May     17:30           Redwood Trust Inc Annual Shareholders Meeting 19 May     17:45           Apollo Commercial Real Estate Finance Inc at Wells Fargo Conf 19 May     17:45           Hatteras Financial at Wells Fargo Conf 19 May     17:55           USG at JPMorgan Conf 19 May     06:00        Healthways Inc Annual Shareholders Meeting 19 May     18:00           3D Systems Annual Shareholders Meeting 19 May     18:00           Community Health Systems Inc at UBS Global Healthcare Conf 19 May     18:00        Flushing Financial Annual Shareholders Meeting 19 May     18:00        Immune Design at UBS Global Healthcare Conf 19 May     18:00        Impax Laboratories Inc at UBS Global Healthcare Conf 19 May     18:00            Ingersoll-Rand PLC at Electrical Products Group Conf 19 May     18:00           Ryman Hospitality Properties at Nomura Conf 19 May     18:00        Seattle Genetics Inc at UBS Global Healthcare Conf 19 May     18:00        Skyworks Solutions Inc Annual Shareholders Meeting 19 May     18:10        Akamai Technologies Inc at JPMorgan Conf 19 May     18:10           DigitalGlobe Inc at JPMorgan Conf 19 May     18:10          Paycom Software Inc at JPMorgan Conf 19 May     18:10        SBA Communications at JPMorgan Conf 19 May     18:10             Visa Inc at JPMorgan Conf 19 May     18:15        C.H. Robinson Worldwide Inc at Wolfe Trahan Transport Conf 19 May     18:20           W. R. Grace & Co at Goldman Sachs Basic Materials Conf 19 May     18:30          Hannon Armstrong Sustainable Capital Inc at Wells Fargo Conf 19 May     18:30           Stryker at UBS Global Healthcare Conf 19 May     18:30           TeamHealth Inc at UBS Global Healthcare Conf 19 May     18:30           Western Asset Mortgage Capital at Wells Fargo Conf 19 May     18:35           Hovnanian Enterprises at JPMorgan Conf 19 May     06:45        Fifth Third Banat Barclays Americas Select Conf 19 May     06:45        Hain Celestial Group Inc at JPMorgan Consumer and Retail Conf 19 May     18:50          A10 Networks Inc at JPMorgan Conf 19 May     18:50        Aspen Technology Inc at JPMorgan Conf 19 May     18:50           Cinemark Inc at JPMorgan Conf 19 May     18:50        Expedia Inc at JPMorgan Conf 19 May     18:50             Intelsat SA at JPMorgan Conf 19 May     18:50        Ultimate Software Group Inc at JPMorgan Conf 19 May     18:50        Xilinx Inc at JPMorgan Conf 19 May     18:55           Ball at Goldman Sachs Basic Materials Conf 19 May     19:00        ChemoCentryx Inc at UBS Global Healthcare Conf 19 May     19:00        Incyte at UBS Global Healthcare Conf 19 May     19:00        Interface Inc Annual Shareholders Meeting 19 May     19:15          AG Mortgage Investment Trust Inc at Wells Fargo Conf 19 May     07:30           General Mills Inc at Barclays Americas Select Conf 19 May     07:30           U.S. Banat Barclays Americas Select Conf 19 May     19:30          Chegg Inc at JPMorgan Conf 19 May     19:30        Lam Research at JPMorgan Conf 19 May     19:30        Lamar Advertising Co at JPMorgan Conf 19 May     19:30           Mettler-Toledo International Inc at UBS Global Healthcare Conf 19 May     19:30          New Relic Inc at JPMorgan Conf 19 May     19:30        Sangamo BioSciences Inc at UBS Global Healthcare Conf 19 May     19:30        Threshold Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     19:30        Verint Systems Inc at JPMorgan Conf 19 May     19:30         Windstream Inc at JPMorgan Conf 19 May     19:55           KB Home at JPMorgan Conf 19 May     20:00           Denbury Resources Inc Annual Shareholders Meeting 19 May     20:00           Essex Property Trust Inc Annual Shareholders Meeting 19 May     20:00        Exact Sciences at UBS Global Healthcare Conf 19 May     20:00        GTX Inc at UBS Global Healthcare Conf 19 May     20:00        Intercept Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     20:00        Preferred Bank Annual Shareholders Meeting 19 May     20:00          Springleaf Inc Annual Shareholders Meeting 19 May     20:00           Swift Energy Company Annual Shareholders Meeting 19 May     08:10            Colgate-Palmolive Co at Barclays Americas Select Conf 19 May     20:10           Digital Realty Trust Inc at JPMorgan Conf 19 May     20:10        Microchip Technology Inc at JPMorgan Conf 19 May     20:10        Zebra Technologies at JPMorgan Conf 19 May     20:30        Momenta Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     20:30        Sunesis Pharmaceuticals Inc at UBS Global Healthcare Conf 19 May     08:50           Wells Fargo & Co at Barclays Americas Select Conf 19 May     21:00          Diamond Resorts International Inc Annual Shareholders Meeting 19 May     21:30        Omnicell Inc Annual Shareholders Meeting 19 May     21:30            SM Energy Co Annual Shareholders Meeting           FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-05-15,MRK,"Fri May 15, 2015 | 11:20am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0Y66JB20150515?type=companyNews
334,"  (Adds details from court order)MUMBAI May 15 India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday.The court has, however, allowed Glenmark to continue to sell existing inventory, according to the document posted on the Supreme Court's website after a hearing.The decision against Glenmark comes two years after Switzerland's Novartis AG was denied patent protection for its cancer treatment Glivec in a landmark decision by India's Supreme Court that was widely seen as boosting the local generic drugs industry. Anti-diabetes drugs are the top-selling therapy area in India, where about 65 million people live with the disease and that number is expected to reach 100 million by 2030.Merck sued Glenmark in 2013 for infringing a patent it has on sitagliptin, the chemical compound in Januvia and Janumet, both of which the company has been selling in India since 2008. A month's dose of Merck's drugs costs about 1,300 Indian rupees ($20) and 1,900 Indian rupees ($30), respectively. Merck has licensed the drugs to Sun Pharmaceutical Industries Ltd  for sale in India.Glenmark sells the medicines under the brand names Zita and Zita-met at a nearly 30 percent discount to Merck's price. Glenmark is barred from producing sitagliptin until the next hearing on the case, the order said.Spokespersons for Glenmark and Merck declined to comment.""This is an interim sort of measure taken by the court, and the decision on the patent of sitagliptin is subject to final orders,"" said Ameet Hariani, managing partner at Mumbai-based law firm Hariani & Co. ($1 = 63.6500 Indian rupees)   (Reporting by Zeba Siddiqui and Nivedita Bhattacharjee; editing by David Clarke)",2015-05-15,MRK,"Fri May 15, 2015 | 8:36am EDT",UPDATE 1-Indian court bars Glenmark from selling Merck drug copies,http://www.reuters.com//article/glenmark-phrm-merck-co-lawsuit-idUSL3N0Y65JM20150515?type=companyNews
335,"  MUMBAI May 15 India's Supreme Court has blocked Glenmark Pharmaceuticals Ltd from selling copies of U.S. drugmaker Merck & Co Inc's diabetes drugs Januvia and Janumet, sources with knowledge of the matter said after a court hearing on Friday.The court has, however, allowed Glenmark to continue to sell existing inventory, the sources said.  Merck sued Glenmark in 2013 for infringing a patent it has on sitagliptin, the chemical compound in Januvia and Janumet. Glenmark sells the medicines under the brand names Zita and Zita-met.   (Reporting by Zeba Siddiqui and Nivedita Bhattacharjee in Mumbai) ",2015-05-15,MRK,"Fri May 15, 2015 | 6:48am EDT",India's Supreme Court bars Glenmark from selling copies of Merck diabetes drugs-sources,http://www.reuters.com//article/glenmark-phrm-merck-co-lawsuit-idUSI8N0WQ00120150515?type=companyNews
336,"   By Tom Polansek | NEW YORK  NEW YORK Brazil's JBS SA, the world's largest meatpacker, this year will look at opportunities for acquisitions in North and South America and Australia, Chief Executive Wesley Batista said on Wednesday.Batista, in a wide-ranging interview with Reuters at a BMO investor conference in New York, also predicted that Zilmax, a controversial growth enhancer for cattle, will not return to market. Zilmax's maker, Merck & Co, could not immediately be reached.Batista's comments about the search for potential deals come after the company said in recent months that it was focused on organic growth, not on acquisitions.JBS will ""for sure"" be looking at potential acquisitions in the chicken, pork and branded, packaged food sectors during 2015, Batista said. ""I cannot say that, second half of this year, we are not going to be preparing ourselves, to (maybe) look something for late this year or next year,"" he added.JBS in November struck a deal to buy Primo Group, a leading producer of ham, sausage and bacon in Australia and New Zealand, for A$1.45 billion ($1.25 billion) in a bid to increase its access to fast-growing Asian markets. Four months later, JBS' director of investor relations, Jerry O'Callaghan, told analysts the company's top priority for 2015 was to focus on organic growth. Last week, Batista said on a conference call that the company was open to deals but still ""very focused on our current business.""""I'm more focused on some internal things, but this does not mean we are not going to be looking,"" he said on Wednesday.Regarding Zilmax, Batista predicted the product will not return to use in U.S. beef production after Merck suspended sales in 2013. Major beef processors at the time stopped accepting cattle fed Zilmax following reports it may cause lameness. Merck has previously said Zilmax is safe and that it planned to resume sales after doing more tests.""It's not going to happen,"" Batista said about a return of Zilmax.Reuters reported in 2013 that packer Tyson Foods Inc had stopped taking Zilmax-fed livestock after more than two dozen animals that had been fed the drug arrived at one of its slaughterhouses with missing hooves. ""The product was not a good fit for cattle production,"" Batista said. ""Everybody stopped. Some issues came about animal welfare and this kind of thing, and they just decided to stop. I don't see this changing.""(This story has been corrected to change million to billion in paragraph 6) (Reporting by Tom Polansek; Editing by Leslie Adler)",2015-05-21,MRK,"Wed May 20, 2015 | 10:28pm EDT","Brazil's JBS looking for deals in Americas, Australia: CEO",http://www.reuters.com//article/us-jbs-acquistions-ceo-idUSKBN0O52VW20150521?type=companyNews
337,"  European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.Merck's drug, also known as pembrolizumab, was endorsed on Friday by the European Medicines Agency (EMA) for the treatment of melanoma.Both Keytruda and Opdivo are already approved in the United States.The EMA said Keytruda was recommended for use on its own for the treatment of advanced melanoma, the most aggressive type of skin cancer, in both first-line and previously treated patients. (bit.ly/1FrWjYm) Keytruda and Opdivo belong to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism tumors use to hide from the immune system. It is expected to be one of the most commercially successful new drugs to reach major markets this year.  Although Keytruda is still waiting for final regulatory approval in Europe, some patients in Britain are receiving it through a new early-access scheme, under which highly promising new drugs are made available free of charge ahead of formal licensing. Friday's positive European opinion on Keytruda is an intermediary step on the drug's path to market, since it now has to be sent to the European Commission for formal adoption. After that, decisions on price and reimbursement will taken by individual governments around Europe.  (Reporting by Ben Hirschler in London and Esha Vaish in Bengaluru; Editing by Sriraj Kalluvila)",2015-05-22,MRK,"Fri May 22, 2015 | 7:28am EDT",Merck follows Bristol with EU green light for immune cancer drug,http://www.reuters.com//article/us-health-cancer-merck-co-idUSKBN0O71AL20150522?type=companyNews
338,"  May 22 European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.Merck's drug, also known as pembrolizumab, was endorsed on Friday by the European Medicines Agency (EMA) for the treatment of melanoma.Both Keytruda and Opdivo are already approved in the United States. The EMA said Keytruda was recommended for use on its own for the treatment of advanced melanoma, the most aggressive type of skin cancer, in both first-line and previously treated patients. (bit.ly/1FrWjYm) Keytruda and Opdivo belong to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism tumours use to hide from the immune system. It is expected to be one of the most commercially successful new drugs to reach major markets this year. Although Keytruda is still waiting for final regulatory approval in Europe, some patients in Britain are receiving it through a new early-access scheme, under which highly promising new drugs are made available free of charge ahead of formal licensing.Friday's positive European opinion on Keytruda is an intermediary step on the drug's path to market, since it now has to be sent to the European Commission for formal adoption. After that, decisions on price and reimbursement will taken by individual governments around Europe.   (Reporting by Ben Hirschler in London and Esha Vaish in Bengaluru; Editing by Sriraj Kalluvila)",2015-05-22,MRK,"Fri May 22, 2015 | 7:22am EDT",Merck follows Bristol with EU green light for immune cancer drug,http://www.reuters.com//article/health-cancer-merck-co-idUSL3N0YD3VV20150522?type=companyNews
339,"  Thomson Reuters May 25, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, no click on Related Co Data, now click on Co Events.             ** For events after May 27 please click on                    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  26 May     13:00        Silgan Holdings Annual Shareholders Meeting 26 May     13:00           Merck & Co Annual Shareholders Meeting 26 May                  Matrix Service Co at Johnson Conf 26 May                  NetScout Systems at DA Davidson Technology Forum 26 May                    Roadrunner Transportation at KeyBanc Capital Markets 26 May     14:00        First Financial Bancorp Annual Shareholders Meeting 26 May     14:00        Healthcare Group Annual Shareholders Meeting 26 May     03:00        Boart Longyear Ltd Annual Shareholders Meeting 26 May     15:00        Diodes Annual Shareholders Meeting 26 May     15:00           DigitalGlobe Annual Shareholders Meeting 26 May     16:30        MoSys Annual Shareholders Meeting 26 May     17:00           Extra Space Storage Annual Shareholders Meeting 26 May     18:00         DreamWorks Animation SKG Annual Shareholders Meeting 26 May     19:00        Seacoast Banking Corp. of Florida Annual Shareholders Meeting 27 May     13:00           AOL Annual Shareholders Meeting 27 May     13:00           Apache Corp at Sanford Strategic Decisions Conf 27 May     13:00           BlackRock at Sanford Strategic Decisions Conf 27 May     13:00          Compass Diversified Holdings Annual Shareholders Meeting 27 May     13:00       Discovery Communications at Sanford Strategic Decisions Conf 27 May     13:00           DuPont Fabros Technology Annual Shareholders Meeting 27 May     13:00        Fuel Systems Solutions Annual Shareholders Meeting 27 May     13:00           Huntington Ingalls at Sanford Strategic Decisions Conf 27 May     13:00           Kindred Healthcare Annual Shareholders Meeting 27 May     13:00            Knowles Corp at Craig-Hallum Capital Group Conf 27 May     13:00        Lincoln Electric Holdings at KeyBanc Capital Markets 27 May     13:00             Ryder System at KeyBanc Capital Markets 27 May     13:00        SEI Investments Co Annual Shareholders Meeting 27 May     13:00           Universal American Corp Annual Shareholders Meeting 27 May     13:00           Boston Beer Co Annual Shareholders Meeting 27 May     13:30            Astoria Financial Corp Annual Shareholders Meeting 27 May     13:30           Gray Television Annual Shareholders Meeting 27 May     13:30          Level 3 Communications at Cowen Conf 27 May     13:30        MB Financial Annual Shareholders Meeting 27 May     13:30        Orbotech Ltd at Cowen Conf 27 May     13:30             Pandora Media at Cowen Conf 27 May     13:30        RPX Corp at Cowen Conf 27 May     13:30          Travelport Worldwide Ltd at Cowen Conf 27 May     13:30        Virtusa Corp at Cowen Conf 27 May     13:50        Nutrisystem at Citi Global Consumer Conf 27 May                     Asbury Automotive Group at Craig-Hallum Capital Group Conf 27 May                  Atmel Corp at Craig-Hallum Capital Group Conf 27 May                     Autozone at Citi Global Consumer Conf 27 May                  Axcelis Technologies at Craig-Hallum Capital Group Conf 27 May                  AXT at DA Davidson Technology Forum 27 May                  Boingo Wireless at DA Davidson Technology Forum 27 May                     BorgWarner at KeyBanc Capital Markets 27 May                  Bottomline Technologies (DE) at Craig-Hallum Capital Group Conf 27 May                  Cadence Design Systems at DA Davidson Technology Forum 27 May                  CalAmp Corp at Craig-Hallum Capital Group Conf 27 May                    Calix at Craig-Hallum Capital Group Conf 27 May                  Callidus Software at Craig-Hallum Capital Group Conf 27 May                  Capstone Turbine Corp at Craig-Hallum Capital Group Conf 27 May                  Capstone Turbine Corp at Cowen Conf 27 May                    Care.com at Craig-Hallum Capital Group Conf 27 May                     Concho Resources at BMO Capital Markets Global Energy 27 May                  Electro Scientific Industries at DA Davidson Technology Forum 27 May                  Endurance International at Craig-Hallum Capital Group Conf 27 May                  Entegris at DA Davidson Technology Forum 27 May                  F5 Networks at DA Davidson Technology Forum 27 May                  FormFactor at DA Davidson Technology Forum 27 May                  FuelCell Energy at Cowen Conf 27 May                  ID Systems at Cowen Conf 27 May                  II-VI at DA Davidson Technology Forum 27 May                  inContact at Craig-Hallum Capital Group Conf 27 May                  InnerWorkings at Craig-Hallum Capital Group Conf 27 May                    Inphi Corp at Craig-Hallum Capital Group Conf 27 May                  Internap Corp at DA Davidson Technology Forum 27 May                     Interpublic Group of Companies at Nomura Media Summit 27 May                      Intralinks Holdings at Craig-Hallum Capital Group Conf 27 May                  IPG Photonics Corp at DA Davidson Technology Forum 27 May                  Jamba at Craig-Hallum Capital Group Conf 27 May                     Knight Transportation at KeyBanc Capital Markets 27 May                  Lattice Semiconductor Corp at Craig-Hallum Capital Group Conf 27 May                  Limelight Networks at DA Davidson Technology Forum 27 May                     Lions Gate Entertainment Corp at Cowen Conf 27 May                  Mattson Technology at Craig-Hallum Capital Group Conf 27 May                  Mentor Graphics Corp at DA Davidson Technology Forum 27 May                    NeoPhotonics Corp at Craig-Hallum Capital Group Conf 27 May                  NetApp at DA Davidson Technology Forum 27 May                     Oxford Industries at Citi Global Consumer Conf 27 May                  Pacific Ethanol at Craig-Hallum Capital Group Conf 27 May                  PDF Solutions at DA Davidson Technology Forum 27 May                  Photronics at DA Davidson Technology Forum 27 May                  Power Solutions at Craig-Hallum Capital Group Conf 27 May                  QLogic Corp at DA Davidson Technology Forum 27 May                  Qorvo at DA Davidson Technology Forum 27 May                     Quanta at Johnson Rice Energy Infrastructure & Oil Service Conf 27 May                     Quantum Corp at Craig-Hallum Capital Group Conf 27 May                  Radisys Corp at DA Davidson Technology Forum 27 May                     Range Resources at BMO Capital Markets Global Energy  27 May                     Republic at KeyBanc Capital Markets 27 May                     Rogers Corp at DA Davidson Technology Forum 27 May                  Rubicon Technology at DA Davidson Technology Forum 27 May                    Rudolph Technologies at DA Davidson Technology Forum 27 May                     Schlumberger NV at BMO Capital Markets Global Energy  27 May                  Sears Hometown and Outlet Stores Annual Shareholders Meeting 27 May                  ShoreTel at Craig-Hallum Capital Group Conf 27 May                   Silicon Graphics Corp at DA Davidson Technology Forum 27 May                  Spectranetics Corp at Craig-Hallum Capital Group Conf 27 May                    Springleaf Holdings at American Financial Association 27 May                  Super Micro Computer at DA Davidson Technology Forum 27 May                  Synopsys at DA Davidson Technology Forum 27 May                  TechTarget at Craig-Hallum Capital Group Conf 27 May                  Telenav at Craig-Hallum Capital Group Conf 27 May                     Teradyne at DA Davidson Technology Forum 27 May                  Towerstream Corp at DA Davidson Technology Forum 27 May                   TriMas Corp at KeyBanc Capital Markets 27 May                  United Online at The Benchmark Company Investor Conf 27 May                  Werner Enterprises at KeyBanc Capital Markets 27 May                    Zayo Group Holdings at DA Davidson Technology Forum 27 May     23:00           City National Corp Extraordinary Shareholders Meeting 27 May     00:00        Akamai Technologies at DA Davidson Technology Forum 27 May     00:00        Akamai Technologies at Craig-Hallum Capital Group Conf 27 May     00:00        Cabot Microelectronics Corp at DA Davidson Technology Forum 27 May     00:00           United Parcel Service at Sanford Strategic Decisions Conf 27 May     12:00           Bank of America Corp at Sanford Strategic Decisions Conf 27 May     12:00        BroadSoft at Cowen Conf 27 May     12:00           Cooper Tire & Rubber Co at KeyBanc Capital Markets 27 May     12:00          CubeSmart Annual Shareholders Meeting 27 May     12:00          Exar Corp at Cowen Conf 27 May     12:00        FireEye at Cowen Conf 27 May     12:00           Honeywell International at Sanford Strategic Decisions Conf 27 May     12:00        IAC/InterActiveCorp at Cowen Conf 27 May     12:00           McDonald's Corp at Sanford Strategic Decisions Conf 27 May     12:00          Nielsen NV at Sanford Strategic Decisions Conf 27 May     12:00           Norfolk Southern Corp at Sanford Strategic Decisions Conf 27 May     12:00        Pericom Semiconductor Corp at Cowen Conf 27 May     12:00           Range Resources Corp at Sanford Strategic Decisions Conf 27 May     12:00          Zayo Group Holdings at Cowen Conf 27 May     12:10        Mondelez International at Citi Global Consumer Conf 27 May     12:30        Mattress Firm Holding Corp Annual Shareholders Meeting 27 May     12:35        Aratana Therapeutics at Stifel Dental & Veterinary Conf 27 May     12:45        Citrix Systems at Cowen Conf 27 May     12:45        Lumos Networks Corp at Cowen Conf 27 May     12:45        Marvell Technology Group Ltd at Cowen Conf 27 May     12:45        Qlik Technologies at Cowen Conf 27 May     12:45        Rovi Corp at Cowen Conf 27 May     14:00        Alexion Pharmaceuticals at Sanford Strategic Decisions Conf 27 May     14:00           American Express Co at American Financial Association 27 May     14:00        Curis Annual Shareholders Meeting 27 May     14:00        Dime Community Bancshares Annual Shareholders Meeting 27 May     14:00            Dollar General Corp Annual Shareholders Meeting 27 May     14:00           Fidelity National Information Annual Shareholders Meeting 27 May     14:00            General Dynamics Corp at Sanford Strategic Decisions Conf 27 May     14:00      General Motors Financial at American Financial Association 27 May     14:00           JAVELIN Mortgage Investment Corp Annual Shareholders Meeting 27 May     14:00           Las Vegas Sands Corp at Sanford Strategic Decisions Conf 27 May     14:00        Medidata Solutions Annual Shareholders Meeting 27 May     14:00          Micron Technology at Sanford Strategic Decisions Conf 27 May     14:00        NetScout Systems at DA Davidson Technology Forum 27 May     14:00           Northstar Realty Finance Corp Annual Shareholders Meeting 27 May     14:00           ProAssurance Corp Annual Shareholders Meeting 27 May     14:00           Questar Corp Annual Shareholders Meeting 27 May     14:00            Southern Co Annual Shareholders Meeting 27 May     14:00           Tenneco at KeyBanc Capital Markets 27 May     14:00             Visa at Sanford Strategic Decisions Conf 27 May     14:00           Yum! Brands at Sanford Strategic Decisions Conf 27 May     14:15           Alliance Data Systems Corp at Cowen Conf 27 May     14:15           Digital Realty Trust at Cowen Conf 27 May     14:15        Glu Mobile at Cowen Conf        27 May     14:15        Novatel Wireless at Cowen Conf 27 May     14:15          Yelp at Cowen Conf 27 May     14:30           Exxon Mobil Corp Annual Shareholders Meeting 27 May     14:35           TreeHouse Foods at Citi Global Consumer Conf 27 May     14:45        F5 Networks at DA Davidson Technology Forum 27 May     14:45        Thomson Reuters Corp at Nomura Media Summit 27 May     15:00           Ametek at KeyBanc Capital Markets 27 May     15:00           BioMed Realty Trust Annual Shareholders Meeting 27 May     15:00        CalAmp Corp at Cowen Conf 27 May     15:00          Delphi Automotive PLC at KeyBanc Capital Markets 27 May     15:00           Discover Financial at Sanford Strategic Decisions Conf 27 May     15:00        Exelixis Annual Shareholders Meeting 27 May     15:00           Lockheed Martin Corp at Sanford Strategic Decisions Conf 27 May     15:00          NOW Annual Shareholders Meeting 27 May     15:00          Taylor Morrison Home Corp Annual Shareholders Meeting 27 May     15:00         Texas Instruments at Sanford Strategic Decisions Conf 27 May     15:20        Hain Celestial Group at Citi Global Consumer Conf 27 May     15:30          Trupanion at Stifel Dental & Veterinary Conf 27 May     15:40           Harley-Davidson at American Financial Association 27 May     16:00        Dynavax Technologies Corp Annual Shareholders Meeting 27 May     16:00        Global Indemnity PLC Annual Shareholders Meeting 27 May     16:00         Intermolecular Annual Shareholders Meeting 27 May     16:00           Intrepid Potash Annual Shareholders Meeting 27 May     16:00           VMware Annual Shareholders Meeting 27 May     16:00           Ducommun Annual Shareholders Meeting 27 May     16:30        Henry Schein at Stifel Dental & Veterinary Conf 27 May     17:00           Acadia Realty Trust Annual Shareholders Meeting 27 May     17:00          Aerohive Networks Annual Shareholders Meeting 27 May     17:00        Ensign Group Annual Shareholders Meeting 27 May     17:00        Illumina Annual Shareholders Meeting 27 May     17:00          Opower Annual Shareholders Meeting 27 May     17:00        Polycom Annual Shareholders Meeting 27 May     17:00        State Bank Financial Corp Annual Shareholders Meeting 27 May     17:00        Wilshire Bancorp Annual Shareholders Meeting 27 May     17:05        B/E Aerospace at KeyBanc Capital Markets 27 May     17:15        Marketo at DA Davidson Technology Forum 27 May     17:30        Equinix Annual Shareholders Meeting 27 May     17:30        Hanmi Financial Corp Annual Shareholders Meeting 27 May     17:30        Interactive Intelligence Group Annual Shareholders Meeting 27 May     18:00        Autobytel at Cowen Conf 27 May     18:00        Biogen at Sanford Strategic Decisions Conf 27 May     18:00            Boeing Co at Sanford Strategic Decisions Conf 27 May     18:00           Capstead Mortgage Corp Annual Shareholders Meeting 27 May     18:00        Cognizant Technology Solutions Corp at Cowen Conf 27 May     18:00           Dana Holding Corp at KeyBanc Capital Markets 27 May     18:00           Edison International at Sanford Strategic Decisions Conf 27 May     18:00           JPMorgan Chase & Co at Sanford Strategic Decisions Conf 27 May     18:00        Qualcomm at Cowen Conf 27 May     18:00          Tableau Software at Cowen Conf 27 May     18:00        WebMD Health Corp at Cowen Conf 27 May     18:30        EnerNOC Annual Shareholders Meeting 27 May     18:45        Broadcom Corp at Cowen Conf 27 May     18:45          EPAM Systems at Cowen Conf 27 May     18:45           Salesforce.com at Cowen Conf 27 May     18:45        Synaptics at Cowen Conf 27 May     07:00        Atlas Air Worldwide Holdings Annual Shareholders Meeting 27 May     19:00           Apollo Global Management at Sanford Strategic Decisions Conf 27 May     19:00            E I du Pont de Nemours at Sanford Strategic Decisions Conf 27 May     19:00           EOG Resources at Sanford Strategic Decisions Conf 27 May     19:00           HCI Group Annual Shareholders Meeting 27 May     19:00           Stanley Black & Decker at Sanford Strategic Decisions Conf 27 May     19:00        Starbucks Corp at Sanford Strategic Decisions Conf 27 May     19:00        Support.com Annual Shareholders Meeting 27 May     19:10          Springleaf Holdings at American Financial Association 27 May     19:30        Control4 Corp at Cowen Conf 27 May     19:30        M/A-COM Technology Solutions Holdings at Cowen Conf 27 May     19:30           Rackspace Hosting at Cowen Conf 27 May     19:30        SunPower Corp at Cowen Conf 27 May     19:30           World Wrestling Entertainment at Cowen Conf 27 May     19:45        Cogent Communications Holdings at DA Davidson Technology Forum 27 May     08:00       Globalcom Telecommunications PLC Annual Shareholders Meeting 27 May     20:00           Ecolab at Sanford Strategic Decisions Conf 27 May     20:00            General Electric Co at Sanford Strategic Decisions Conf 27 May     20:00        Microsemi Corp at Sanford Strategic Decisions Conf 27 May     20:00        Patterson Companies at Stifel Dental & Veterinary Conf 27 May     20:00        Regeneron Pharmaceuticals at Sanford Strategic Decisions Conf 27 May     21:00        Barrett Business Annual Shareholders Meeting 27 May     21:00          Silver Spring Networks Annual Shareholders Meeting            FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-05-26,MRK,"Tue May 26, 2015 | 9:04am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0YG2KE20150526?type=companyNews
340,"  BRUSSELS May 27 German drugmaker Merck  has offered concessions in a bid to convince European Union antitrust regulators to clear its proposed $17 billion acquisition of U.S. peer Sigma-Aldrich Corp.Earlier this month, Merck said the European Commission expressed concerns ""of a limited nature"" over its biggest ever takeover. It submitted concessions on May 22, according to a filing on the EU executive's website. No details were provided. The EU competition watchdog will now decide by June 15 instead of June 1 whether to approve the takeover.  Companies typically offer to sell overlapping assets or provide rivals access to technologies or patents to allay regulatory worries that the merged entity may have an excessive market share.   (Reporting by Foo Yun Chee. Editing by Jane Merriman)",2015-05-27,MRK,"Wed May 27, 2015 | 7:51am EDT",Merck offers EU concessions over $17 bln Sigma-Aldrich buy,http://www.reuters.com//article/sigmaaldrich-ma-merck-eu-idUSL5N0YI2NZ20150527?type=companyNews
341,"   By Deena Beasley and Bill Berkrot  New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body's immune system to fight cancer can be used.Results from key clinical trials will be presented starting Friday in Chicago at the annual meeting of the American Society of Clinical Oncology. These will include studies aimed at defining ahead of time which patients are likely to benefit from the costly drugs. At the forefront will be rival drugs from Bristol-Myers Squibb Co and Merck and Co designed to block a protein known as Programmed Death receptor (PD-1) that is used by tumors to evade the body's natural defenses.""It's going to be an important meeting to get some more (details) on the PD-1 and PD-L1 drugs,"" said Morningstar analyst Damien Conover. Bristol's Opdivo, or nivolumab, was approved by the U.S. Food and Drug Administration in December to treat advanced melanoma. In March, it also received clearance to treat a form of lung cancer, giving Bristol an early advantage in the much larger market. Merck's Keytruda, or pembrolizumab, has been approved for advanced melanoma since September and is awaiting regulatory approval in lung cancer treatment. First-quarter sales of both drugs surprised Wall Street, with Keytruda sales reaching $83 million, compared to $40 million for Opdivo, suggesting an early advantage for Merck in what many expect will be a years-long battle for market share.  Other drugmakers working on similar treatments include Roche Holding AG, AstraZeneca Plc and Pfizer Inc. Many industry experts expect the entire class will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.On Friday, the ASCO conference will feature studies looking at Opdivos use against advanced liver cancer and non-squamous, non-small cell lung cancer (NSCLC), the most common form of lung cancer. Results will also be presented from a trial of Keytruda in head and neck cancer.  ""Bristol's in a really good position,"" said Leerink Partners analyst Seamus Fernandez. ""My expectation is that they're going to be and will continue to be the leader in the lung cancer space."" Lung cancer, the most common cancer worldwide, is the largest cause of cancer deaths in the United States. At the same time, he said, Merck may bolster its argument that Keytruda has proven the broadest possible use to date, with ""clear activity in 13 different tumor types.Other data points that will be closely watched by oncologists and investors include whether the level of PD-1 protein in a tumor can predict how well the new immunotherapies will work. Earlier this month, Roche said that a mid-stage trial of its experimental immunotherapy, MPDL3280A, showed it doubled the likelihood of survival for lung cancer patients with the highest levels PD-L1.  A separate trial of Merck's Keytruda to be released at ASCO was designed to see whether a higher number of genetic mutations in a tumor can lead to better results in treating colorectal and other cancers.Doctors at the meeting will also hear more on the potential for combining different types of immunotherapies to make them more effective, as well as the high costs associated with multiple treatment regimens. Treatment with Opdivo or Keytruda alone in the United States, for example, costs about $12,500 per month, or $150,000 a year.""Really the name of the game is having overall survival data in your label,"" said Suntrust Robinson Humphrey analyst John Boris.  (Reporting by Deena Beasley in Los Angeles and Bill Berkrot in New York; Editing by Diane Craft)",2015-05-28,MRK,"Thu May 28, 2015 | 7:16am EDT","New drugs from Bristol, Merck at forefront of cancer meeting",http://www.reuters.com//article/us-cancer-asco-immunotherapies-idUSKBN0OD18L20150528?type=companyNews
342,"   By Bill Berkrot  A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday.A quarter of the 132 patients who received the drug, Keytruda (pembrolizumab), saw their tumors shrink by at least 30 percent. Fifty-six percent of patients experienced at least some tumor shrinkage in the ongoing single drug Phase I study dubbed Keynote-012, researchers reported.""This is remarkable because we don't usually see this level of activity with new agents. We have a track record of failure,"" said Dr. Tanguy Seiwert, lead investigator of the study from the University of Chicago.Advanced head and neck cancer is currently treated with Eli Lilly's Erbitux, known chemically as cetuximab, which typically has a response rate of 10 percent to 13 percent.""The only thing that works is cetuximab and this looks at least twice as good,"" said Seiwert, who was presenting the Keytruda data at the American Society of Clinical Oncology meeting in Chicago. Merck shares rose more than 1 percent to $60.43 on the New York Stock Exchange.Keytruda and Opdivo from Bristol-Myers Squibb Co are at the forefront of a promising new class of drugs called PD-1 inhibitors that block a mechanism tumors use to evade the immune system. Keytruda is approved to treat advanced melanoma and awaits a decision for use in lung cancer. It is being tested against 30 types of cancer alone and in various combinations.While overall survival data was not yet available, Keytruda and Opdivo have extended survival for some patients in other cancers. ""Response rate doesn't do this justice,"" Seiwert said. ""A fraction of those patients will probably have long term survival. It can really make a difference for some patients who have incurable metastatic disease.""The drug appeared to work as well for patients whose cancer tested positive for human papillomavirus as those who were HPV negative. Some older treatments may be less effective in HPV positive patients, researchers said.  Keytruda was well tolerated with few side effects, Seiwert said. Serious immune-related side effects, such as inflammation of the lungs or colon, were reported in a very small number of patients in the study.Head and neck cancer is the sixth most common cancer worldwide. Patients with recurrent or metastatic head and neck cancer are usually expected to live about 10 to 12 months.    (Reporting by Bill Berkrot in New York; Editing by Diane Craft)",2015-05-29,MRK,"Fri May 29, 2015 | 2:36pm EDT",Merck immunotherapy appears effective in head and neck cancer-study,http://www.reuters.com//article/us-cancer-asco-merck-headandneck-idUSKBN0OE2AY20150529?type=companyNews
343,"  (Adds stock move)By Bill BerkrotMay 29 A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday.A quarter of the 132 patients who received the drug, Keytruda (pembrolizumab), saw their tumors shrink by at least 30 percent. Fifty-six percent of patients experienced at least some tumor shrinkage in the ongoing single drug Phase I study dubbed Keynote-012, researchers reported.""This is remarkable because we don't usually see this level of activity with new agents. We have a track record of failure,"" said Dr. Tanguy Seiwert, lead investigator of the study from the University of Chicago.Advanced head and neck cancer is currently treated with Eli Lilly's Erbitux, known chemically as cetuximab, which typically has a response rate of 10 percent to 13 percent. ""The only thing that works is cetuximab and this looks at least twice as good,"" said Seiwert, who was presenting the Keytruda data at the American Society of Clinical Oncology meeting in Chicago.Merck shares rose more than 1 percent to $60.43 on the New York Stock Exchange. Keytruda and Opdivo from Bristol-Myers Squibb Co are at the forefront of a promising new class of drugs called PD-1 inhibitors that block a mechanism tumors use to evade the immune system. Keytruda is approved to treat advanced melanoma and awaits a decision for use in lung cancer. It is being tested against 30 types of cancer alone and in various combinations.While overall survival data was not yet available, Keytruda and Opdivo have extended survival for some patients in other cancers.""Response rate doesn't do this justice,"" Seiwert said. ""A fraction of those patients will probably have long term survival. It can really make a difference for some patients who have incurable metastatic disease."" The drug appeared to work as well for patients whose cancer tested positive for human papillomavirus as those who were HPV negative. Some older treatments may be less effective in HPV positive patients, researchers said.Keytruda was well tolerated with few side effects, Seiwert said. Serious immune-related side effects, such as inflammation of the lungs or colon, were reported in a very small number of patients in the study.Head and neck cancer is the sixth most common cancer worldwide. Patients with recurrent or metastatic head and neck cancer are usually expected to live about 10 to 12 months.(Reporting by Bill Berkrot in New York; Editing by Diane Craft)",2015-05-29,MRK,"Fri May 29, 2015 | 2:35pm EDT",UPDATE 1-Merck immunotherapy appears effective in head and neck cancer-study,http://www.reuters.com//article/cancer-asco-merck-headandneck-idUSL1N0YK1SP20150529?type=companyNews
344,"   By Bill Berkrot  A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday.A quarter of the 132 patients who received the drug, Keytruda (pembrolizumab), saw their tumors shrink by at least 30 percent. Fifty-six percent of patients experienced at least some tumor shrinkage in the ongoing single drug Phase I study dubbed Keynote-012, researchers reported.""This is remarkable because we don't usually see this level of activity with new agents. We have a track record of failure,"" said Dr. Tanguy Seiwert, lead investigator of the study from the University of Chicago.Advanced head and neck cancer is currently treated with Eli Lilly's Erbitux, known chemically as cetuximab, which typically has a response rate of 10 percent to 13 percent.""The only thing that works is cetuximab and this looks at least twice as good,"" said Seiwert, who was presenting the Keytruda data at the American Society of Clinical Oncology meeting in Chicago. Merck shares rose more than 1 percent to $60.43 on the New York Stock Exchange.Keytruda and Opdivo from Bristol-Myers Squibb Co are at the forefront of a promising new class of drugs called PD-1 inhibitors that block a mechanism tumors use to evade the immune system. Keytruda is approved to treat advanced melanoma and awaits a decision for use in lung cancer. It is being tested against 30 types of cancer alone and in various combinations.While overall survival data was not yet available, Keytruda and Opdivo have extended survival for some patients in other cancers. ""Response rate doesn't do this justice,"" Seiwert said. ""A fraction of those patients will probably have long term survival. It can really make a difference for some patients who have incurable metastatic disease.""The drug appeared to work as well for patients whose cancer tested positive for human papillomavirus as those who were HPV negative. Some older treatments may be less effective in HPV positive patients, researchers said.  Keytruda was well tolerated with few side effects, Seiwert said. Serious immune-related side effects, such as inflammation of the lungs or colon, were reported in a very small number of patients in the study.Head and neck cancer is the sixth most common cancer worldwide. Patients with recurrent or metastatic head and neck cancer are usually expected to live about 10 to 12 months.    (Reporting by Bill Berkrot in New York; Editing by Diane Craft)",2015-05-31,MRK,"Sat May 30, 2015 | 9:55pm EDT",Merck immunotherapy appears effective in head and neck cancer: study,http://www.reuters.com//article/us-cancer-asco-merck-headandneck-idUSKBN0OE2AY20150531?type=companyNews
345,"   By Brendan Pierson  Two former Merck & Co Inc scientists accusing the drugmaker of falsifying tests of its exclusive mumps vaccine said in a court filing on Monday that Merck is refusing to respond to questions about the efficacy of the vaccine.Attorneys at Constantine Cannon, who represent the scientists, asked U.S. Magistrate Judge Lynne Sitarski of the Eastern District of Pennsylvania to compel Merck to respond to their discovery request, which asks the company to give the efficacy of the vaccine as a percentage.Instead of answering the question, the letter said, Merck has been consistently evasive, using ""cut-and-paste"" answers saying it cannot run a new clinical trial to determine the current efficacy, and providing only data from 50 years ago.""Merck should not be permitted to raise as one of its principal defenses that its vaccine has a high efficacy, which is accurately represented on the product's label, but then refuse to answer what it claims that efficacy actually is,"" the letter said. A representative of Merck could not immediately be reached for comment.The two scientists, Stephen Krahling and Joan Wlochowski, filed their whistleblower lawsuit in 2010 claiming Merck, the only company licensed by the Food and Drug Administration to sell a mumps vaccine in the United States, skewed tests of the vaccine by adding animal antibodies to blood samples. As a result, they said, Merck was able to produce test results showing that the vaccine was 95 percent effective, even though more accurate tests would have shown a lower success rate. The plaintiffs said these false results kept competitors from trying to produce their own mumps vaccines, since they were unable to match the effectiveness Merck claimed.In 2012, Alabama-based Chatom Primary Care and two individual doctors, all purchasers of the vaccine, filed a proposed antitrust class action based on the allegations in the whistleblower suit. The two suits are now being coordinated before U.S. District Judge C. Darnell Jones and Magistrate Judge Sitarski. The case is United States ex rel Krahling et al v. Merck & Co Inc, U.S. District Court, Eastern District of Pennsylvania, No. 10-4374.For whistleblowers: Gordon Schnell of Constantine CannonFor Merck: Lisa Dykstra of Morgan Lewis & Bockius",2015-06-04,MRK,"Thu Jun 4, 2015 | 10:06am EDT",Merck accused of stonewalling in mumps vaccine antitrust lawsuit,http://www.reuters.com//article/health-vaccine-idUSL1N0YQ0W820150604?type=companyNews
346,"  June 12 Laboratorios Farmaceuticos Rovi SA  :* Signs an agreement with Merck Sharp & Dohme SA (MSD)  to market Orvatez in Spain * Says Orvatez combines two active principle ingredients, ezetimibe and atorvastatin, which act by inhibiting two sources of origin of cholesterol  Source text: bit.ly/1L2hSQA  Further company coverage:    (Gdynia Newsroom)",2015-06-12,MRK,"Fri Jun 12, 2015 | 7:02am EDT",BRIEF-Rovi signs deal with Merck to market Orvatez in Spain,http://www.reuters.com//article/idUSFWN0YX04C20150612?type=companyNews
347,"  (Adds Cigna Corp, Merck, DHI Group)June 15 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** United Technologies Corp said it was exiting the helicopter business and would decide by the end of the third quarter whether to spin off or sell its $8 billion Sikorsky Aircraft unit, the largest provider of helicopters to the U.S. military.** Two activist investors on Monday urged DHI Group Inc , which offers specialized career websites, to sell itself and said they had already spoken with potential buyers. Barington Capital Group LP and Ancora Advisors LLC said DHI, formerly Dice Holdings, lagged behind its peers but could perform better under new management.** The European Commission said on Monday that it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp, following the U.S. company's pledges to sell assets in Germany.** Health insurer Cigna Corp has rebuffed a takeover offer from Anthem Inc, people familiar with the matter told the Wall Street Journal on Monday. The companies have been in discussions for months, sources told WSJ, adding that within the last 10 days Anthem has made two takeover bids for Cigna.** Slovenian state firm SDH, which is coordinating the sale of Telekom Slovenia, rejected on Monday UK investment firm Cinven's bid for state-owned Telekom, SDH said in a statement. It said the bid was rejected because Cinven, which was the only bidder for Telekom, last week attached additional conditions to its binding bid sent in on May 20.** Cox Automotive Inc, the owner of Autotrader platform and Kelley Blue Book car valuation service, said it would buy Dealertrack Technologies Inc in a deal valued at $4 billion.** Dragon Oil Plc said it agreed to an increased takeover offer by Emirates National Oil Co (ENOC) after the Dubai-based group increased its offer to buy out the company's minority shareholders.  ENOC's offer values Dragon Oil at around 3.7 billion pounds ($5.75 billion). ** Canadian retailer Hudson's Bay Co is buying German department store chain Kaufhof from Metro AG  for 2.8 billion euros ($3.2 billion) as a launch pad to expand into Europe.** Indian mining and energy group Vedanta Ltd made a $2.3 billion offer on Sunday to buy out minority shareholders in cash-rich oil unit Cairn India Ltd, a deal that helps parent Vedanta Resources Plc repay hefty debts.** German property firm Deutsche Annington Immobilien SE  will buy regional rival Suedewo for 1.9 billion euros ($2.13 billion) and launch a 2.25 billion euro capital increase to fund the acquisition, the company said in a statement late on Sunday. ** Drugstore operator CVS Health Corp said it will acquire Target Corp's U.S. pharmacy and clinics businesses for about $1.9 billion to boost sales and prescription volumes.** Charterhouse Capital Partners said it had agreed to sell its stake in environmental consultancy Environmental Resources Management to Canadian pension fund Omers for an enterprise value of $1.7 billion.** Australian Internet provider TPG Telecom Ltd  formally bid A$1.56 billion ($1.2 billion) for smaller rival iiNet Ltd, setting the stage for it to become industry goliath Telstra Corp Ltd's most serious rival.** Saudi Arabia's Public Investment Fund signed an agreement to acquire a 38 percent stake in builder POSCO Engineering & Construction Co Ltd for about 1.24 trillion won ($1.11 billion), POSCO E&C's parent Posco said on Monday. ** Standard Pacific Corp and Ryland Group Inc  said they would merge to become the fourth-largest homebuilder in the United States. The merged company would have a market capitalization of about $5.2 billion and an enterprise value of about $8.2 billion.** A Malaysian opposition lawmaker urged Felda Global Ventures Holdings Bhd to call off its deal to buy a non-controlling stake in Indonesia's PT Eagle High Plantations  for $680 million.** Unilever NV  said it plans to raise its stake in its Nigerian unit to up to 75 percent in a 192.6 million euro ($216 million) offer to minority shareholders, but would not de-list its subsidiary.** Australian pay-TV company Foxtel will spend up to A$77 million ($59 million) for a 15 percent stake in struggling free-to-air broadcaster Ten Network Holdings Ltd, Foxtel said in a statement.** British travel agent Thomas Cook Group Plc said it had agreed to set-up a joint venture with Fosun International Ltd to develop domestic, inbound and outbound tourism activities for the Chinese market under Thomas Cook brands.** Chinese investment fund Fosun International Ltd  is interested in buying the Polish unit of Austrian lender Raiffeisen, two banking sources familiar with the matter said.** India's fourth-largest telecom operator Reliance Communications Ltd said it was in exclusive talks for a potential merger with Russian conglomerate Sistema's  Indian mobile phone operations through a stock swap.($1 = 0.89 euros)  ($1 = 0.64 pounds)  ($1 = A$1.29)  ($1 = 1,116.80 won)   (Compiled by Anet Josline Pinto and Rosmi Shaji in Bengaluru)",2015-06-15,MRK,"Mon Jun 15, 2015 | 4:00pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0Z15AA20150615?type=companyNews
348,"  BRUSSELS The European Commission said on Monday it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company's pledges to sell assets in Germany.In May, Merck said the European Commission expressed concerns ""of a limited nature"" over its biggest evertakeover. Merck submitted concessions on May 22, according to a filing on the EU executive's website. ""The decision is conditional on the divestment of certain Sigma-Aldrich assets, including manufacturing assets in Germany, the rights to certain brands and a sales force,"" the Commission said in a statement. ""The Commission had concerns that the merged entity would have faced insufficient competitive pressure from the remaining players in the markets for certain laboratory chemicals, with a risk of price rises. The commitments offered by the companies address these concerns.""   (Reporting by Robin Emmott, editing by David Evans)",2015-06-15,MRK,"Mon Jun 15, 2015 | 1:52pm EDT",European Commission approves Merck's $17 billion Sigma-Aldrich buy,http://www.reuters.com//article/us-sigma-aldrich-merck-m-a-eu-idUSKBN0OV2G820150615?type=companyNews
349,"  BRUSSELS, June 15 The European Commission said on Monday it had approved German drugmaker Merck's $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company's pledges to sell assets in Germany.In May, Merck said the European Commission expressed concerns ""of a limited nature"" over its biggest ever takeover. Merck submitted concessions on May 22, according to a filing on the EU executive's website. ""The decision is conditional on the divestment of certain Sigma-Aldrich assets, including manufacturing assets in Germany, the rights to certain brands and a sales force,"" the Commission said in a statement.  ""The Commission had concerns that the merged entity would have faced insufficient competitive pressure from the remaining players in the markets for certain laboratory chemicals, with a risk of price rises. The commitments offered by the companies address these concerns.""    (Reporting by Robin Emmott, editing by David Evans)",2015-06-15,MRK,"Mon Jun 15, 2015 | 1:40pm EDT",European Commission approves Merck's $17 bln Sigma-Aldrich buy,http://www.reuters.com//article/sigma-aldrich-merck-ma-eu-idUSL5N0Z14D820150615?type=companyNews
350,"   By Kylie Gumpert  Merck Manuals, the widely used health guides provided by drugmaker Merck & Co, are moving to a digital-only format in 10 different languages as part of an effort to educate the global community on medical issues.The new version of Merck Manuals debuted in the U.S. in April, offering free online access to both professional and consumer audiences. The professional manuals have been distributed in print since 1899 and most recently carried a price tag of nearly $80.New websites will launch in other English-speaking countries in July, while sites translated into nine other languages are expected in the next 12 to 18 months. An English-language mobile app is set to launch by at least early 2016, with translated apps to follow, the company said. Outside of the U.S. and Canada, the sites and apps will be known as MSD Manuals. By offering both professional and consumer-oriented content free of charge, users can find what they are looking for in as much detail as they need, said Merck Manuals editor-in-chief Robert Porter. The information is compiled by hundreds of medical experts across the world. We would like to show information as a universal right, not a commodity, Porter said in an interview.     Over 100 videos for performing medical procedures will be included in the professional mobile app, so if youre up the Amazon and havent delivered a baby in a while, well have that available"" for healthcare providers, Porter said.The switch to digital is also an effort to help readers quickly access authoritative health content among the hundreds of results that can pop up in an Internet search.  In a survey of over 2,000 people conducted for Merck Manuals by Harris Poll, 28 percent of Americans say that overwhelming amounts of information online is their biggest barrier to increasing medical knowledge, while 79 percent believe that having access to the same information as their doctor would improve how they understand their health.The new U.S. websites have had about 4 million unique visitors since their April launch, and Merck Manuals will continue to invest millions of dollars each year to maintain the digital publication. (Reporting by Kylie Gumpert; Editing by Michele Gershberg and Phil Berlowitz)",2015-06-16,MRK,"Tue Jun 16, 2015 | 5:58pm EDT","Merck Manuals health guides go digital, and free, in global push",http://www.reuters.com//article/us-health-merck-co-idUSKBN0OW2RW20150616?type=companyNews
351,"   By Kylie Gumpert | June 16  June 16 Merck Manuals, the widely used health guides provided by drugmaker Merck & Co, are moving to a digital-only format in 10 different languages as part of an effort to educate the global community on medical issues.The new version of Merck Manuals debuted in the U.S. in April, offering free online access to both professional and consumer audiences. The professional manuals have been distributed in print since 1899 and most recently carried a price tag of nearly $80.New websites will launch in other English-speaking countries in July, while sites translated into nine other languages are expected in the next 12 to 18 months. An English-language mobile app is set to launch by at least early 2016, with translated apps to follow, the company said. Outside of the U.S. and Canada, the sites and apps will be known as MSD Manuals.By offering both professional and consumer-oriented content free of charge, users can find what they are looking for in as much detail as they need, said Merck Manuals editor-in-chief Robert Porter. The information is compiled by hundreds of medical experts across the world. ""We would like to show information as a universal right, not a commodity,"" Porter said in an interview.Over 100 videos for performing medical procedures will be included in the professional mobile app, ""so if you're up the Amazon and haven't delivered a baby in a while, we'll have that available"" for healthcare providers, Porter said. The switch to digital is also an effort to help readers quickly access authoritative health content among the hundreds of results that can pop up in an Internet search.In a survey of over 2,000 people conducted for Merck Manuals by Harris Poll, 28 percent of Americans say that overwhelming amounts of information online is their biggest barrier to increasing medical knowledge, while 79 percent believe that having access to the same information as their doctor would improve how they understand their health.The new U.S. websites have had about 4 million unique visitors since their April launch, and Merck Manuals will continue to invest millions of dollars each year to maintain the digital publication.   (Reporting by Kylie Gumpert; Editing by Michele Gershberg and Phil Berlowitz)",2015-06-16,MRK,"Tue Jun 16, 2015 | 5:52pm EDT","Merck Manuals health guides go digital, and free, in global push",http://www.reuters.com//article/health-merck-co-idUSL1N0Z123920150616?type=companyNews
352,"   By Nate Raymond | NEW YORK  NEW YORK Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.Manhattan U.S. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare providers for uses the Food and Drug Administration had not approved as safe and effective.While the FDA had approved AzaSite for treating bacterial conjunctivitis, or pink eye, Inspire sought more revenue by marketing the drug for the non-approved treatment of another eye condition, blepharitis, according to a lawsuit.The lawsuit said that Inspire from 2008 through May 2011 misleadingly marketed to doctors purported anti-inflammatory properties of AzaSite that were not supported by substantial evidence or clinical experience. The marketing caused doctors to prescribe AzaSite for uses not covered by federal healthcare programs, which paid millions of dollars in false claims, the lawsuit said.As part of the settlement, which will go to the United States and various state governments, Inspire made several admissions related to its conduct, Bharara's office said. Lainie Keller, a Merck spokeswoman, said the company was ""glad to put this behind us,"" adding that the conduct at issue occurred prior to Merck acquiring Inspire, which it later sold to Akorn Inc in 2013.The case was initiated in 2010 by a purported whistleblower, Jill DeGuzman, under the False Claims Act, and the United States subsequently intervened in it. DeGuzman's lawyer did not immediately respond to a request for comment. The case is U.S. v. Inspire Pharmaceuticals Inc, U.S. District Court, Southern District of New York, No. 10-7450. (Reporting by Nate Raymond in New York; Editing by Chris Reese)",2015-06-17,MRK,"Wed Jun 17, 2015 | 6:10pm EDT",Merck to pay $5.9 million for misleading marketing of pink eye drug: U.S,http://www.reuters.com//article/us-merck-lawsuit-settlement-idUSKBN0OX2SQ20150617?type=companyNews
353,"   By Nate Raymond | NEW YORK  NEW YORK Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.Manhattan U.S. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare providers for uses the Food and Drug Administration had not approved as safe and effective.While the FDA had approved AzaSite for treating bacterial conjunctivitis, or pink eye, Inspire sought more revenue by marketing the drug for the non-approved treatment of another eye condition, blepharitis, according to a lawsuit. The lawsuit said that Inspire from 2008 through May 2011 misleadingly marketed to doctors purported anti-inflammatory properties of AzaSite that were not supported by substantial evidence or clinical experience.The marketing caused doctors to prescribe AzaSite for uses not covered by federal healthcare programs, which paid millions of dollars in false claims, the lawsuit said. As part of the settlement, which will go to the United States and various state governments, Inspire made several admissions related to its conduct, Bharara's office said. Lainie Keller, a Merck spokeswoman, said the company was ""glad to put this behind us,"" adding that the conduct at issue occurred prior to Merck acquiring Inspire, which it later sold to Akorn Inc in 2013.The case was initiated in 2010 by a purported whistleblower, Jill DeGuzman, under the False Claims Act, and the United States subsequently intervened in it. DeGuzman's lawyer did not immediately respond to a request for comment.The case is U.S. v. Inspire Pharmaceuticals Inc, U.S. District Court, Southern District of New York, No. 10-7450.",2015-06-17,MRK,"Wed Jun 17, 2015 | 6:09pm EDT",Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com//article/merck-lawsuit-settlement-idUSL1N0Z32Z820150617?type=companyNews
354,"  (Adds details on case, comment from Merck)By Nate RaymondNEW YORK, June 17 Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.Manhattan U.S. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare providers for uses the Food and Drug Administration had not approved as safe and effective. While the FDA had approved AzaSite for treating bacterial conjunctivitis, or pink eye, Inspire sought more revenue by marketing the drug for the non-approved treatment of another eye condition, blepharitis, according to a lawsuit.The lawsuit said that Inspire from 2008 through May 2011 misleadingly marketed to doctors purported anti-inflammatory properties of AzaSite that were not supported by substantial evidence or clinical experience. The marketing caused doctors to prescribe AzaSite for uses not covered by federal healthcare programs, which paid millions of dollars in false claims, the lawsuit said.As part of the settlement, which will go to the United States and various state governments, Inspire made several admissions related to its conduct, Bharara's office said. Lainie Keller, a Merck spokeswoman, said the company was ""glad to put this behind us,"" adding that the conduct at issue occurred prior to Merck acquiring Inspire, which it later sold to Akorn Inc in 2013.The case was initiated in 2010 by a purported whistleblower, Jill DeGuzman, under the False Claims Act, and the United States subsequently intervened in it. DeGuzman's lawyer did not immediately respond to a request for comment.The case is U.S. v. Inspire Pharmaceuticals Inc, U.S. District Court, Southern District of New York, No. 10-7450.   (Reporting by Nate Raymond in New York; Editing by Chris Reese)",2015-06-17,MRK,"Wed Jun 17, 2015 | 6:06pm EDT",UPDATE 1-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com//article/merck-lawsuit-settlement-idUSL1N0Z32WR20150617?type=companyNews
355,"  (Corrects first and second paragraphs to show Inspire Pharmaceuticals is no longer owned by Merck)NEW YORK, June 17 Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.  Manhattan U.S. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare providers for uses the Food and Drug Administration had not approved as safe and effective.   (Reporting by Nate Raymond in New York; Editing by Chris Reese) ",2015-06-17,MRK,"Wed Jun 17, 2015 | 5:40pm EDT",CORRECTED-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com//article/merck-lawsuit-settlement-idUSL1N0Z32U820150617?type=companyNews
356,"  NEW YORK, June 17 A unit of Merck & Co Inc  has agreed to pay $5.9 million to resolve claims that it fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday. Manhattan U.S. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011, promoted its drug AzaSite to healthcare providers for uses the Food and Drug Administration had not approved as safe and effective.   (Reporting by Nate Raymond in New York; Editing by Chris Reese)  ",2015-06-17,MRK,"Wed Jun 17, 2015 | 4:29pm EDT",Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com//article/merck-lawsuit-settlement-idUSL1N0Z32I320150617?type=companyNews
357,"  * German Merck aims to be leading OLED player by 2018* Lays cornerstone for new 30 mln eur OLED plant* Merck is market leader in liquid crystals   (Adds details on competitors, investment) DARMSTADT, Germany, June 19 Germany's Merck  aims to be a leading maker of OLED (organic light-emitting diode) materials by 2018, its head of chemicals said on Friday.""We invested significant sums in this technology at an early stage,"" Bernd Reckmann said in a statement. Merck, which dominates the market for liquid crystals for displays, is one of dozens of players in the nascent OLED market. Others include Universal Display, Dow Chemical  and BASF Future Business OLEDs are used in displays for mobile phones, digital cameras and other gadgets and are popular for portable devices that are used outdoors because their high light output makes them easy to read in sunlight and they use little battery power.Merck on Friday laid the cornerstone for a new OLED production plant in Darmstadt, in which it is investing 30 million euros ($34 million). ($1 = 0.8839 euros)   (Reporting by Ludwig Burger; Writing by Georgina Prodhan; Editing by Thomas Atkins)",2015-06-19,MRK,"Fri Jun 19, 2015 | 6:03am EDT",UPDATE 1-Merck aims to be leader in OLED materials by 2018,http://www.reuters.com//article/merck-oleds-idUSL5N0Z51J720150619?type=companyNews
358,"  DARMSTADT, Germany, June 19 Germany's Merck  aims to be a leading maker of OLED (organic light-emitting diode) materials by 2018, its head of chemicals said on Friday.""We invested significant sums in this technology at an early stage,"" Bernd Reckmann said in a statement. Merck, which dominates the market for liquid crystals for displays, is one of dozens of players in the nascent OLED market. OLEDs are used in displays for mobile phones, digital cameras and other gadgets and are popular for portable devices that are used outdoors because their high light output makes them easy to read in sunlight and they use little battery power. (Reporting by Ludwig Burger; Writing by Georgina Prodhan; Editing by Thomas Atkins)",2015-06-19,MRK,"Fri Jun 19, 2015 | 5:15am EDT",Merck aims to be leader in OLED materials by 2018,http://www.reuters.com//article/merck-oleds-idUSF9N0YA00520150619?type=companyNews
359,"  BRUSSELS, July 22 Belgian biotech group Ablynx  on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion).Large pharmaceutical groups such as Merck & Co often team up with smaller companies like Ablynx to develop new treatments. A so-called milestone payment is due whenever a programme passes a certain trial phase or clinical tests are successful. Ablynx, which produces so-called nanobody medicines derived from llama antibodies, said it had expanded its research agreement with Merck & Co by 12 programmes for which it could receive up to 340 million euros each if successful.  The group added it would get a 13 million euro upfront payment for signing the deal expansion. The initial agreement with the U.S. group, signed in February 2014, contained payments of up to 1.7 billion euros.   ($1 = 0.9142 euros)   (Reporting by Robert-Jan Bartunek; Editing by Anand Basu)",2015-07-22,MRK,"Wed Jul 22, 2015 | 1:49am EDT",Belgium's Ablynx triples cooperation deal with Merck & Co,http://www.reuters.com//article/ablynx-merck-co-idUSL5N1020DB20150722?type=companyNews
360,"  July 22 Ablynx NV :* Significantly expands its immuno-oncology collaboration with Merck & Co Inc* Expanded deal includes new targets and target combinations directed against immune checkpoint modulators * Expanding size and scope of deal to include up to 12 additional Nanobody programmes * Under terms of this four year expansion, Ablynx will receive a 13 million euro  ($14.22 million) upfront payment * Ablynx will be eligible to receive additional exclusivity fees, depending on the number of programmes for which Merck decides to exercise its licensing option, plus development, regulatory and commercial milestone payments of up to 340 million euros per programme, as well as tiered royalties on annual net sales upon commercialisation of any Nanobody products  Source text for Eikon:  Further company coverage:   ($1 = 0.9139 euros)   (Gdynia Newsroom:)",2015-07-22,MRK,"Wed Jul 22, 2015 | 1:18am EDT",BRIEF-Ablynx expands its immuno-oncology collaboration with Merck & Co,http://www.reuters.com//article/idUSFWN10101R20150722?type=companyNews
361,"  Merck & Co Inc (MRK.N) reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.The company also said it expects to reap benefits from its $8.4 billion purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin. Cubicin sales for the second quarter were $293 million.Sales of Merck's diabetes drug, Januvia, rose 1.3 percent to $1.6 billion in the quarter ended June 30.The company's cancer treatment from a promising class of new drugs, Keytruda, brought in sales of $110 million, helping the drugmaker edge past the average analyst estimate for revenue.The 124-year-old company raised its forecast to $3.45-$3.55 per share from $3.35-$3.48 per share. Analysts on average were expecting $3.45 per share, according to Thomson Reuters I/B/E/S. In the second quarter, Merck's net income fell nearly 66 percent to $687 million, or 24 cents per share, for the second quarter, from $2 billion, or 68 cents per share, from a year earlier.The latest reported quarter included charges of $1.45 billion related to the Cubist deal.Excluding items, the company earned 86 cents per share. Revenue fell 10.5 percent to $9.79 billion. Analysts on average had expected a profit of 81 cents per share on revenue of $9.8 billion, according to Thomson Reuters I/B/E/S.Separately, the company said it would buy privately held drug developer cCAM Biotherapeutics for $95 million to boost its immuno-oncology pipeline. The deal also includes milestone payments of $510 million.Merck's shares were up marginally at $57.50 on Tuesday in premarket trading. They had fallen about 1 percent this year through Monday's close, compared with a 9 percent rise in the S&P 500 healthcare index .SPXHC. (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty)",2015-07-28,MRK,"Tue Jul 28, 2015 | 8:01am EDT","Merck raises forecast on strong sales of diabetes, cancer drugs",http://www.reuters.com//article/us-merck-co-results-idUSKCN0Q217420150728?type=companyNews
362,"  (Adds details, background, share movement)July 28 Merck & Co Inc reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.The company also said it expects to reap benefits from its $8.4 billion purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin. Cubicin sales for the second quarter were $293 million.Sales of Merck's diabetes drug, Januvia, rose 1.3 percent to $1.6 billion in the quarter ended June 30.The company's cancer treatment from a promising class of new drugs, Keytruda, brought in sales of $110 million, helping the drugmaker edge past the average analyst estimate for revenue. The 124-year-old company raised its forecast to $3.45-$3.55 per share from $3.35-$3.48 per share. Analysts on average were expecting $3.45 per share, according to Thomson Reuters I/B/E/S.In the second quarter, Merck's net income fell nearly 66 percent to $687 million, or 24 cents per share, for the second quarter, from $2 billion, or 68 cents per share, from a year earlier. The latest reported quarter included charges of $1.45 billion related to the Cubist deal.Excluding items, the company earned 86 cents per share. Revenue fell 10.5 percent to $9.79 billion. Analysts on average had expected a profit of 81 cents per share on revenue of $9.8 billion, according to Thomson Reuters I/B/E/S.Separately, the company said it would buy privately held drug developer cCAM Biotherapeutics for $95 million to boost its immuno-oncology pipeline.The deal also includes milestone payments of $510 million.Merck's shares were up marginally at $57.50 on Tuesday in premarket trading. They had fallen about 1 percent this year through Monday's close, compared with a 9 percent rise in the S&P 500 healthcare index.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty)",2015-07-28,MRK,"Tue Jul 28, 2015 | 8:00am EDT","UPDATE 1-Merck raises forecast on strong sales of diabetes, cancer drugs",http://www.reuters.com//article/merck-co-results-idUSL3N10840E20150728?type=companyNews
363,"  July 28 Merck & Co Inc reported a nearly 11 percent drop in quarterly revenue as a strong dollar and the sale of its consumer care business overshadowed strong demand for its diabetes drugs.The U.S. drugmaker's net income fell nearly 66 percent to $687 million, or 24 cents per share, for the second quarter, from $2 billion, or 68 cents per share, from a year earlier. The latest reported quarter included charges of $1.45 billion related to its acquisition of Cubist Pharmaceuticals.  Revenue fell 10.5 percent to $9.79 billion.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty)",2015-07-28,MRK,"Tue Jul 28, 2015 | 7:16am EDT",Strong dollar weighs on Merck revenue,http://www.reuters.com//article/merck-co-results-idUSL3N1083U920150728?type=companyNews
364,"  FRANKFURT/BERLIN Aug 24 The DAX top-30 index  looked set to open 3.6 percent lower on Monday, according to premarket data from brokerage Lang & Schwarz at 0603 GMT.The following are some of the factors that may move German stocks:CHINESE MARKET Chinese stocks dived more than 8 percent on Monday morning, with the Shanghai index giving up all its gains for the year on investor disappointment that Beijing held back expected policy support at the weekend after markets shed 11 percent last week.BAYER Indicated 2.8 percent lowerPlastics business Covestro, which is being spun off by Bayer, still has excess capacity that finance chief Frank Lutz said offers opportunities for growth, according to an interview in Boersen-Zeitung.CONTINENTAL Indicated 3.8 percent lowerThe autoparts and tyre maker, along with auto supplier Robert Bosch, is interested in working on open standards with mapping business HERE, which Daimler, BMW and Volkswagen's premium division Audi  agreed to buy earlier this month, the Automobilwoche magazine reported.E.ON, RWE, ENBW E.ON indicated 3.1 percent lowerRWE indicated 2.2 percent lowerNo indication available for EnBWGermany's utilities have plans to shut down a total of 57 power plants, including gas- and coal-fired plants as well as hydroelectric plants, daily Bild reported, citing figures from regulator Bundesnetzagentur. DEUTSCHE BANK Indicated 3.5 percent lowerA probe by Deutsche Bank into questionable share trades involving its Moscow unit has prompted further enquiries into whether a senior staff member took bribes, a source familiar with the situation said on Friday.LUFTHANSA Indicated 2.6 percent lowerHarry Hohmeister, chief executive of airline Swiss, could take up a leadership position at German owner Lufthansa and be replaced by a Lufthansa executive, Swiss paper NZZ am Sontag reported, citing several sources.MERCK Indicated 3.3 percent lower The pharma firm has decided to close down Bangalore GeNei, a firm it had bought in 2009, the Economic Times reported.TELEFONICA DEUTSCHLAND No indication availableThe telecoms firm is making three of its call centres legally separate entities as part of a restructuring following the takeover of E-Plus.ROCKET INTERNET No indication availableGermany's Delivery Hero, the online food takeaway service, has ruled out a stock market listing for this year but could be ready by next year, its chief executive said in an interview. ANALYSTS' VIEWS HENKEL - Goldman Sachs raises to ""neutral"" from ""sell"", cuts target price to 95.50 from 96.50 eurosFRAPORT - RBC raises to ""outperform"" from ""sector perform"", lifts target price to 65 from 57 eurosNEMETSCHEK - Berenberg raises the stock to ""buy"" from ""hold"", lifts its price target to 35 from 28.50 eurosOVERSEAS STOCK MARKETS Dow Jones minus 3.1 pct, S&P 500 minus 3.2 pct, Nasdaq minus 3.5 pct. at Friday's close.Nikkei minus 4.6 pct at Monday's close. Shanghai stocks minus 7.1 pct at 0607 GMT.BERLIN AIRPORT Management of Berlin's new international airport on Friday denied its opening could be delayed by the insolvency of the German unit of an engineering contractor working on the project.GERMAN ECONOMIC DATA No economic data scheduled.EUROPEAN FACTORS TO WATCH DIARIES REUTERS TOP NEWS    (Reporting by Maria Sheahan, Jonathan Gould and Emma Thomasson)",2015-08-24,MRK,"Mon Aug 24, 2015 | 2:10am EDT",German stocks - Factors to watch on August 24,http://www.reuters.com//article/germany-markets-stocks-idUSL5N10W1O920150824?type=companyNews
365,"  A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013.The most frequent number of cases, 28, occurred with Januvia, known generically as sitagliptin. Five cases were reported with AstraZeneca Plc's Onglyza (saxagliptin), two with Boehringer Ingelheim's Tradjenta (linagliptin), and one with Takeda Pharmaceutical's Nesina (alogliptin).A spokesman for Merck, Steven Cragle, said the reason the number of cases was higher with Januvia is that it was the first to market and is the most widely prescribed, accounting for about 80 percent of DPP-4 prescriptions in the United States.""Merck takes all safety information seriously and we worked closely with the FDA on this request,"" Cragle said. ""We are confident in the safety profile of sitagliptin."" Boehringer Ingelheim spokeswoman Emily Geary said clinical trials of Tradjenta ""do not show an imbalance between linagliptin and placebo in musculoskeletal and connective tissue disorders or, more specifically, in joint disorders.""A spokesman for AstraZeneca, Andrew Davis, said the company ""works with health authorities and scientific experts to help ensure patients and physicians have a clear understanding of the risk benefit profile of our medications."" A spokesman for Takeda did not immediately respond to a request for comment. The FDA said that in 20 of the cases the DPP-4 inhibitor was suspected as a cause of the pain and was discontinued within a month after the onset of symptoms. In eight of the remaining 13 cases, a period of 44 days to a year elapsed between the onset of symptoms and discontinuation of the drug. The drugs are used to lower blood sugar in adults with type 2 diabetes. The FDA said patients should not stop taking their drugs but should contact their doctor if they experience severe and persistent joint pain. (Reporting by Toni Clarke in Washington; editing by Andrew Hay and Dan Grebler)",2015-08-28,MRK,"Fri Aug 28, 2015 | 4:44pm EDT",FDA warns of severe joint pain risk with DPP-4 diabetes drugs,http://www.reuters.com//article/us-diabetes-drugs-warning-idUSKCN0QX25E20150828?type=companyNews
366,"  (Adds company comments)Aug 28 A class of diabetes drugs that include Merck & Co Inc's Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013.The most frequent number of cases, 28, occurred with Januvia, known generically as sitagliptin. Five cases were reported with AstraZeneca Plc's Onglyza (saxagliptin), two with Boehringer Ingelheim's Tradjenta (linagliptin), and one with Takeda Pharmaceutical's Nesina (alogliptin). A spokesman for Merck, Steven Cragle, said the reason the number of cases was higher with Januvia is that it was the first to market and is the most widely prescribed, accounting for about 80 percent of DPP-4 prescriptions in the United States.""Merck takes all safety information seriously and we worked closely with the FDA on this request,"" Cragle said. ""We are confident in the safety profile of sitagliptin."" Boehringer Ingelheim spokeswoman Emily Geary said clinical trials of Tradjenta ""do not show an imbalance between linagliptin and placebo in musculoskeletal and connective tissue disorders or, more specifically, in joint disorders.""A spokesman for AstraZeneca, Andrew Davis, said the company ""works with health authorities and scientific experts to help ensure patients and physicians have a clear understanding of the risk benefit profile of our medications."" A spokesman for Takeda did not immediately respond to a request for comment.The FDA said that in 20 of the cases the DPP-4 inhibitor was suspected as a cause of the pain and was discontinued within a month after the onset of symptoms. In eight of the remaining 13 cases, a period of 44 days to a year elapsed between the onset of symptoms and discontinuation of the drug.The drugs are used to lower blood sugar in adults with type 2 diabetes. The FDA said patients should not stop taking their drugs but should contact their doctor if they experience severe and persistent joint pain.   (Reporting by Toni Clarke in Washington; editing by Andrew Hay and Dan Grebler)",2015-08-28,MRK,"Fri Aug 28, 2015 | 4:23pm EDT",UPDATE 1-FDA warns of severe joint pain risk with DPP-4 diabetes drugs,http://www.reuters.com//article/diabetes-drugs-warning-idUSL1N1131OD20150828?type=companyNews
367,"  Aug 28 A class of diabetes drugs that include Merck & Co Inc's Januvia have been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013.The most frequent number of cases, 28, occurred with Januvia, known generically as sitagliptin. Five cases were reported with AstraZeneca Plc's Onglyza (saxagliptin) two  with Boehringer Ingelheim's Tradjenta (linagliptin) and one with Takeda Pharmaceutical's Nesina (alogliptin). The FDA said that in 20 of the cases the DPP-4 inhibitor was suspected as a cause of the pain and was discontinued within a month after the onset of symptoms. In eight of the remaining 13 cases, a period of 44 days to a year elapsed between the onset of symptoms and discontinuation of the drug. The drugs are used to lower blood sugar in adults with type 2 diabetes. The FDA said patients should not stop taking their drugs but should contact their doctor if they experience severe and persistent joint pain. (Reporting by Toni Clarke in Washington; Editing by Andrew Hay)",2015-08-28,MRK,"Fri Aug 28, 2015 | 1:37pm EDT",FDA warns of severe joint pain risk with DPP-4 diabetes drugs,http://www.reuters.com//article/diabetes-drugs-warning-idUSL1N1131GD20150828?type=companyNews
368,"  LONDON Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immunotherapy drug Keytruda, after the U.S. drugmaker promised to supply it to the state health service at a discounted price.The move comes amid controversy over access to costly cancer medicines in the country. On Friday, a fund that helps patients receive cancer drugs not routinely paid for by the National Health Service said it would no longer pay for a number of medicines.In the case of Merck's drug, the National Institute for Health and Care Excellence (NICE) said in final draft guidance that it should made available for certain patients with advanced melanoma. The drug costs about $150,000 for a year of treatment in the United States but will sell for less in Britain. The scale of the discount being offered to Britain's health service is commercially confidential, NICE said.   Keytruda is a so-called anti PD-1 inhibitor, which works by making cancer cells visible to the immune system and so open to attack. The drug received a speedy assessment in Britain under a recently introduced early access scheme for promising new treatments.  (Reporting by Ben Hirschler; Editing by Mark Potter)",2015-09-07,MRK,"Mon Sep 7, 2015 | 6:00am EDT",UK backs use of Merck cancer immunotherapy after price discount,http://www.reuters.com//article/us-merck-co-cancer-britain-idUSKCN0R710I20150907?type=companyNews
369,"  LONDON, Sept 7 Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immunotherapy drug Keytruda, after the U.S. drugmaker promised to supply it to the state health service at a discounted price.The move comes amid controversy over access to costly cancer medicines in the country. On Friday, a fund that helps patients receive cancer drugs not routinely paid for by the National Health Service said it would no longer pay for a number of medicines. In the case of Merck's drug, the National Institute for Health and Care Excellence (NICE) said in final draft guidance that it should made available for certain patients with advanced melanoma. The drug costs about $150,000 for a year of treatment in the United States but will sell for less in Britain. The scale of the discount being offered to Britain's health service is commercially confidential, NICE said. Keytruda is a so-called anti PD-1 inhibitor, which works by making cancer cells 'visible' to the immune system and so open to attack. The drug received a speedy assessment in Britain under a recently introduced early access scheme for promising new treatments.   (Reporting by Ben Hirschler; Editing by Mark Potter)",2015-09-07,MRK,"Mon Sep 7, 2015 | 5:55am EDT",UK backs use of Merck cancer immunotherapy after price discount,http://www.reuters.com//article/merck-co-cancer-britain-idUSL5N11D1HY20150907?type=companyNews
370,"   By Brendan Pierson  A Delaware federal judge has disqualified an expert retained by New Jersey-based drugmaker Merck & Co in patent litigation against two generic rivals because the expert previously helped defend Apotex Inc against Merck's lawsuit over the same drug. U.S. District Judge Sue Robinson on Thursday ruled that allowing the expert, Jeremy Cockcroft, to work for Merck would risk exposing Apotex's confidential information.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1NZ18OV",2015-09-08,MRK,"Tue Sep 8, 2015 | 8:00am EDT",Judge nixes Apotex's former expert in new role for Merck,http://www.reuters.com//article/health-expert-idUSL1N11E0L620150908?type=companyNews
371,"  Merck & Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia, which is taken once a day.The late-stage study compared 25 mg of the drug, omarigliptin, to 100 mg of Januvia. Both treatments belong to a family of drugs called DPP-4 inhibitors that help lower blood sugar levels.Fifty-one percent of patients taking omarigliptin reached required sugar levels at week 24, compared with 49 percent of those who took Januvia. Merck, which has already applied for marketing approval for the drug in Japan, said it would submit its application in the United States by the end of 2015.Januvia, among Merck's best-selling drugs, raked in sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva)",2015-09-16,MRK,"Wed Sep 16, 2015 | 10:53am EDT",Merck's once-weekly diabetes drug found effective in study,http://www.reuters.com//article/us-merck-co-study-idUSKCN0RG21320150916?type=companyNews
372,"  (Adds American Diabetes Association comment)By Ransdell PiersonSept 17 Eli Lilly and Co's new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke, a finding that could make it a mainstay diabetes treatment and triple its use, according to researchers and analysts.Lilly shares jumped as much as 9 percent after data from the trial was released Thursday at a medical meeting in Stockholm.""This is the first diabetes therapy to show robust effect in reducing cardiovascular death. It really is big news,"" said Dr. Bernard Zinman, director of the Diabetes Centre at Mount Sinai Hospital in Toronto, who led the three-year study of 7,000 people.Because about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care. Type 2 diabetes is the most common form of the disease and is linked to obesity.Jardiance, a once-a-day pill which won U.S. approval last year, belongs to a new family of treatments called SGLT2 inhibitors that include Johnson & Johnson's Invokana and AstraZeneca Plc's Farxiga. They lower blood sugar by inhibiting reabsorption of glucose in the kidneys.Jardiance was developed jointly with Germany's privately held Boehringer Ingelheim. Zinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.About 26 million Americans have type 2 diabetes, according to federal data for 2014. The vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.""The big news here is that the drug reduced cardiovascular stuff. That has not been the case with all things in diabetes,"" said David Marrero, president of health care and education at the American Diabetes Association. ""It is probably going to be a more popular drug because of that.""JARDIANCE COULD BOOST EARNINGS  Sanford Bernstein analyst Tim Anderson more than tripled his annual sales forecast for Jardiance and combination drugs containing it to $2.7 billion by 2020. He cut his 2020 sales forecast for Merck & Co Inc's Januvia, the leading member of a competing class of oral diabetes drugs called DPP-4 inhibitors, to $6 billion from $7.8 billion.Anderson estimates Jardiance could boost Lilly's earnings per share by 8 percent on average across 2016 to 2020.In the study, patients taking Jardiance had a 38 percent reduction in cardiovascular death, including from heart attacks and strokes. There was no significant difference in non-fatal heart attacks or non-fatal strokes.Those taking Jardiance had a 32 percent lower risk of dying from any cause, and a 35 percent lower rate of hospitalizations from heart failure. The benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.""This is a wonderful thing,"" said Dr. Jerome Tolbert of Mount Sinai Beth Israel Hospital in New York. He has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.Zinman noted that Jardiance, like other SGLT2 drugs, causes weight loss and reduced blood pressure, besides lowering both blood sugar levels and body fat, and also reduces swelling, which all help the cardiovascular system.Lilly and Boehringer last month disclosed that Jardiance met its primary study goal, becoming the first diabetes drug to show heart-protective results in a large cardiovascular trial. But they did not unveil detailed data until Thursday at the medical meeting.Shares of Lily closed up 6.5 percent at $89.98 on Thursday, after rising as high as $92.83.In calculating the combined number of cardiac deaths, non-fatal heart attacks and non-fatal strokes, 14 percent fewer events were seen in patients taking Jardiance in combination with standard treatments, compared with patients who took standard treatments alone, meeting the study's main goal.Standard treatments included statins, which lower cholesterol, and blood pressure drugs.   (Reporting by Ransdell Pierson in New York; Additional reporting by Deena Beasley in Los Angeles; Editing by Michele Gershberg, Jeffrey Benkoe and Lisa Shumaker)",2015-09-17,MRK,"Thu Sep 17, 2015 | 6:20pm EDT",UPDATE 3-Lilly diabetes drug slashes deaths in patients with heart risk,http://www.reuters.com//article/eli-lilly-diabetes-idUSL1N11N1MK20150917?type=companyNews
373,"   By Vidya L Nathan  Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments.About 38.5 percent of the patients in a mid-stage study, whose disease had progressed or returned after prior therapy, survived for a year after being given the Advaxis vaccine, the biotech company said on Thursday.Advaxis shares, which had risen about 19 percent in the past three days, closed up 0.5 percent at $19.71 on Thursday. However, the stock slumped as much as 28 percent just after the data was reported.""The initial reaction was mostly driven by expectations for a higher 12-month survival,"" FBR & Co analyst Vernon Bernardino said.""However, that probably was driven by a whisper number which moved the stock up 20 percent in the last five trading sessions."" Bernardino said the 38.5 percent survival rate Advaxis reported on Thursday was higher than the 27 percent rate its reported from earlier studies.Advaxis said there were no serious adverse events but about 15 percent of patients experienced hypotension and cytokine release syndrome, and one patient experienced lung infection and sepsis.Patients with persistent or recurrent metastatic cervical cancer survive for about four to seven months after prior treatments fail, said Dr. Tom Herzog, clinical director at the University of Cincinnati Cancer Institute. Cervical cancer is one of the leading causes of cancer deaths among women globally. About 12,000 new cases of cervical cancer are diagnosed each year in the United States.Positive results from the mid-stage study project Advaxis' lead cancer therapy, axalimogene filolisbac, as a direct competitor to Roche AG's blockbuster treatment Avastin.Advaxis' vaccine was being tested as a standalone treatment for persistent or recurrent metastatic cervical cancer related to the human papilomavirus. The study was sponsored by the Gynecologic Oncology Group, a not-for-profit group. The results mirror an earlier study conducted by the company in cervical cancer patients in India.Zacks Investment analysts have said they expected the therapy to be approved in the United States in late 2017 or early 2018.Advaxis is testing axalimogene filolisbac as a treatment for head and neck cancer and cervical cancer in combination with other immunotherapies being developed by AstraZeneca PLC and Incyte Corp. (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian and Savio D'Souza)",2015-09-17,MRK,"Thu Sep 17, 2015 | 4:41pm EDT",Advaxis therapy improves survival rates in cervical cancer patients,http://www.reuters.com//article/us-advaxis-study-idUSKCN0RH2JR20150917?type=companyNews
374,"   By Vidya L Nathan | Sept 17  Sept 17 Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments.About 38.5 percent of the patients in a mid-stage study, whose disease had progressed or returned after prior therapy, survived for a year after being given the Advaxis vaccine, the biotech company said on Thursday.Patients with persistent or recurrent metastatic cervical cancer survive for about four to seven months after prior treatments fail, said Dr. Tom Herzog, clinical director at the University of Cincinnati Cancer Institute.Cervical cancer is one of the leading causes of cancer deaths among women globally. About 12,000 new cases of cervical cancer are diagnosed each year in the United States. Positive results from the mid-stage study project Advaxis' lead cancer therapy, axalimogene filolisbac, as a direct competitor to Roche AG's blockbuster treatment Avastin.Advaxis' vaccine was being tested as a standalone treatment for persistent or recurrent metastatic cervical cancer related to the human papilomavirus. The study was sponsored by the Gynecologic Oncology Group, a not-for-profit group.The results mirror an earlier study conducted by the company in cervical cancer patients in India. Analysts from Zacks Investment have said they expected the therapy to be approved in the United States in late 2017 or early 2018.Avastin, approved to treat seven types of cancer globally, generated sales of 6.42 billion Swiss francs ($6.61 billion) in 2014. Advaxis is testing axalimogene filolisbac as a treatment for head and neck cancer and cervical cancer in combination with other immunotherapies being developed by AstraZeneca PLC  and Incyte Corp.Analysts at MLV & Co said they valued Advaxis at $1.2 billion, based on the company's technology platform and candidates.Apart from axalimogene filolisbac, Advaxis has therapies in its pipeline to treat prostate cancer in combination with Merck & Co's blockbuster Keytruda, and another treatment to treat tumors caused by the excess mutation of a particular protein.Advaxis shares, which have risen about 19 percent in the three sessions leading up to the data presentation, were up as much as 11 percent at $21.76 on Thursday in midday trading.  ($1 = 0.9716 Swiss francs)   (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)",2015-09-17,MRK,"Thu Sep 17, 2015 | 2:15pm EDT",Advaxis therapy improves survival rates in cervical cancer patients,http://www.reuters.com//article/advaxis-study-idUSL4N11M4T820150917?type=companyNews
375,"  (Adds futures prices, company news items)     LONDON, Sept 25 European equity futures rose on Friday, although the region's major indexes could still end the week with a loss following blows dealt to the market this week by an emissions test debacle at Volkswagen and new signs of a slowdown in China.     The prospect of a U.S interest rate rise has also weighed on equities, and Federal Reserve head Janet Yellen said late on Thursday she expects the U.S. central bank to begin raising interest rates later this year as long as inflation remains stable and the U.S. economy is strong enough to boost employment.      Nevertheless, European equity futures were up on Friday, partly helped by firmer oil prices. Futures on the euro zone's blue-chip Euro STOXX 50, Germany's DAX, France's CAC and Britain's FTSE 100 were all up between 1.4-1.6 percent.      Volkswagen shares will be in focus again in the wake of the company's U.S. emissions test rigging scandal.      Volkswagen will name Matthias Mueller, the head of its Porsche sports car brand, as its chief executive, a source close to the matter said on Thursday. California was also preparing a major enforcement action against Volkswagen over its admitted cheating on tailpipe emissions tests.   ------------------------------------------------------------------------------  MARKET SNAPSHOT AT 0620 GMT                                                                                          LAST    PCT CHG  NET CHG  S&P 500                                      1,932.24    -0.34 %    -6.52  NIKKEI                                      17,880.51     1.76 %   308.68                                                                             EUR/USD                                        1.1153    -0.68 %  -0.0076  USD/JPY                                        120.43     0.31 %   0.3700  10-YR US TSY                                    2.141         --     0.02  YLD                                                                 10-YR BUND YLD                                  0.618         --     0.03  SPOT GOLD                                   $1,146.90    -0.58 %   -$6.72  US CRUDE                                       $45.30     0.87 %     0.39     > Asian shares erase gains, dollar gains as Yellen revives rate talk     > US STOCKS-Wall St ends lower as Caterpillar, health stocks weigh    > Nikkei edges down after weak inflation data, China woes    > TREASURIES-U.S. bonds rise on stock losses, economic worries    > FOREX-Dollar rebounds after Yellen keeps alive 2015 Fed rate hike view     > PRECIOUS-Gold dips as Yellen says Fed on track to hike rates this year     > METALS-London copper eyes largest weekly drop in two months    > Oil prices stable as firm Chinese seasonal demand offsets weak Japan data             COMPANY NEWS:     ACCOR :     The French hotel group is considering the possibility of transfering some 80 hotels in a new entity in which it would hold a minority stake, according to Les Echos newspaper.          ADIDAS :     Nike Inc's first-quarter profits outpaced expectations as surprisingly steep China growth boosted the world's largest sportswear maker, despite fears of a slowdown in the world's second-biggest economy. Nike is a major rival of Adidas.           BAYER :     Dozens of women urged the U.S. Food and Drug Administration on Thursday to withdraw Bayer AG's permanent contraceptive device, Essure, saying not enough is known about its potential to harm users.           HELLA :     The company kept its outlook for lower operating profit in its fiscal 2015/16 year due to the failure of a supplier in China.           LLOYDS :     Britain's government has reduced its holding in Lloyds Banking Group  to below 12 percent, taking the bank closer to full privatisation following a taxpayer bailout in the 2008/09 financial crisis.           MERCK :     Merck and Pfizer signed an agreement with agilent technologies company Dako, to cooperate on the development of the investigational anti-PD-L1 antibody Avelumab.          NOVARTIS :     Novartis said the heart drug Entresto had been backed by the EU regulator.            RANDSTAD :     Randstad said it would acquire Risesmart.           ROTHSCHILD/PARIS ORLEANS :     Private bank and asset manager the Edmond de Rothschild Group said on Thursday it would press ahead with legal action against a rival branch of the banking dynasty over use of the Rothschild name. Shareholders in the rival business, whose holding company is known as Paris Orleans, voted on Thursday to change that name to Rothschild & Co with immediate effect.                VOLKSWAGEN :     Volkswagen will name Matthias Mueller, the head of its Porsche sports car brand, as its chief executive, a source close to the matter said on Thursday. California was also preparing a major enforcement action against Volkswagen over its admitted cheating on tailpipe emissions tests.       The Mint newspaper also reported on Friday that the Indian government had ordered a probe into Volkswagen emissions.    (Reporting by Sudip Kar-Gupta)   ",2015-09-25,MRK,"Fri Sep 25, 2015 | 2:20am EDT",European Factors to Watch-Futures rise but markets could still have weekly loss,http://www.reuters.com//article/markets-factors-europe-idUSL5N11V09720150925?type=companyNews
376,"  FRANKFURT, Sept 25 The DAX top-30 index  looked set to open 1.7 percent higher on Friday, according to premarket data from brokerage Lang & Schwarz at 0605 GMT.The following are some of the factors that may move German stocks:VOLKSWAGEN Indicated 3.1 percent higherVolkswagen's supervisory board is expected to name a new chief executive to replace Martin Winterkorn, who resigned this week after the carmaker admitted it deceived U.S. regulators about how much its diesel cars pollute.Separately, California said it was gearing up for ""major enforcement action"" against VW and expected a recall of cars not in compliance with emissions rules.Also separately, at least 29 U.S. state attorneys general on Thursday initiated a multi-state investigation of Volkswagen over its representations to consumers over their diesel vehicles, according to a spokeswoman for Illinois Attorney General Lisa Madigan. As part of the probe, the group will send subpoenas to Volkswagen, she said.Australia and India also said they would look into whether Volkswagen misled consumers over its emissions claims.DEUTSCHE BANK Indicated 0.9 percent higherDeutsche Bank AG must face a U.S. government lawsuit seeking to recoup more than $190 million over an alleged tax fraud 15 years ago, after a federal judge on Thursday turned down the German's bank's request to dismiss the case.BAYER Indicated 1.6 percent higherDozens of women urged the U.S. Food and Drug Administration on Thursday to withdraw Bayer AG's permanent contraceptive device, Essure, saying not enough is known about its potential to harm users. ADIDAS Indicated 2.8 percent higherNike Inc's first-quarter profits outpaced expectations as surprisingly steep China growth boosted the world's largest sportswear maker, despite fears of a slowdown in the world's second-biggest economy.MERCK Indicated 1.2 percent higherMerck and Pfizer signed an agreement with agilent technologies company Dako, to cooperate on the development of  the investigational anti-PD-L1 antibody Avelumab.HELLA  Indicated 2.3 percent higherThe company kept its outlook for lower operating profit in its fiscal 2015/16 year due to the failure of a supplier in China.ANNUAL GENERAL MEETINGS HELLA - 0.77 eur/shr dividend proposedSTROEER - 1.3 eur/shr dividend proposedANALYSTS' VIEWS EVONIK - HSBC raises to ""buy"" from ""hold"" STROEER - Jefferies starts with ""buy""FED Federal Reserve Chair Janet Yellen said on Thursday she expects the U.S. central bank to begin raising interest rates later this year as long as inflation remains stable and the U.S. economy is strong enough to boost employment.OVERSEAS STOCK MARKETS Dow Jones -0.5 pct, S&P 500 -0.3 pct, Nasdaq  -0.4 pct at Thursday's close.Nikkei +1.1 pct, Shanghai stocks -1.8 pct.Time: 5.14 GMT.GERMAN ECONOMIC DATA No economic data scheduled.EUROPEAN FACTORS TO WATCH DIARIES REUTERS TOP NEWS    (Reporting by Jonathan Gould and Harro ten Wolde)",2015-09-25,MRK,"Fri Sep 25, 2015 | 2:07am EDT",German stocks - Factors to watch on September 25,http://www.reuters.com//article/germany-markets-stocks-idUSL5N11U1QC20150925?type=companyNews
377,"  (Adds company news items)     LONDON, Sept 25 European stocks were seen opening higher on Friday, although the region's major indexes could still end the week with a loss following blows dealt to the market this week by an emissions test debacle at Volkswagen and new signs of a slowdown in China.     The prospect of a U.S interest rate rise has also weighed on equity markets, and Federal Reserve head Janet Yellen said late on Thursday that she expects the U.S. central bank to begin raising interest rates later this year as long as inflation remains stable and the U.S. economy is strong enough to boost employment.      Financial spreadbetters expected Britain's FTSE 100 to open up by 59-69 points, or 1-1.2 percent higher. Germany's DAX was seen opening up by 119-143 points, or 1.3-1.5 percent higher, while France's CAC 40  was seen up by 53 points, or 1.2 percent higher.     Volkswagen shares will be in focus again in the wake of the company's U.S. emissions test rigging scandal.      Volkswagen will name Matthias Mueller, the head of its Porsche sports car brand, as its chief executive, a source close to the matter said on Thursday. California was also preparing a major enforcement action against Volkswagen over its admitted cheating on tailpipe emissions tests.   ------------------------------------------------------------------------------  MARKET SNAPSHOT AT 0521 GMT                                                                            LAST    PCT CHG  NET CHG  S&P 500                               1,932.24    -0.34 %    -6.52  NIKKEI                               17,759.53     1.07 %    187.7                                                                      EUR/USD                                 1.1165    -0.57 %  -0.0064  USD/JPY                                 120.25     0.16 %   0.1900  10-YR US TSY                             2.143         --     0.02  YLD                                                          10-YR BUND YLD                           0.604         --     0.01  SPOT GOLD                            $1,147.00    -0.57 %   -$6.62  US CRUDE                                $45.26     0.78 %     0.35     > Asian shares erase gains, dollar gains as Yellen revives rate talk     > US STOCKS-Wall St ends lower as Caterpillar, health stocks weigh    > Nikkei edges down after weak inflation data, China woes    > TREASURIES-U.S. bonds rise on stock losses, economic worries    > FOREX-Dollar rebounds after Yellen keeps alive 2015 Fed rate hike view     > PRECIOUS-Gold dips as Yellen says Fed on track to hike rates this year     > METALS-London copper eyes largest weekly drop in two months    > Oil prices stable as firm Chinese seasonal demand offsets weak Japan data             COMPANY NEWS:     ACCOR :     The French hotel group is considering the possibility of transfering some 80 hotels in a new entity in which it would hold a minority stake, according to Les Echos newspaper.          ADIDAS :     Nike Inc's first-quarter profits outpaced expectations as surprisingly steep China growth boosted the world's largest sportswear maker, despite fears of a slowdown in the world's second-biggest economy. Nike is a major rival of Adidas.           BAYER :     Dozens of women urged the U.S. Food and Drug Administration on Thursday to withdraw Bayer AG's permanent contraceptive device, Essure, saying not enough is known about its potential to harm users.           HELLA :     The company kept its outlook for lower operating profit in its fiscal 2015/16 year due to the failure of a supplier in China.           MERCK :     Merck and Pfizer signed an agreement with agilent technologies company Dako, to cooperate on the development of the investigational anti-PD-L1 antibody Avelumab.          NOVARTIS :     Novartis said the heart drug Entresto had been backed by the EU regulator.            ROTHSCHILD/PARIS ORLEANS :     Private bank and asset manager the Edmond de Rothschild Group said on Thursday it would press ahead with legal action against a rival branch of the banking dynasty over use of the Rothschild name. Shareholders in the rival business, whose holding company is known as Paris Orleans, voted on Thursday to change that name to Rothschild & Co with immediate effect.                VOLKSWAGEN :     Volkswagen will name Matthias Mueller, the head of its Porsche sports car brand, as its chief executive, a source close to the matter said on Thursday. California was also preparing a major enforcement action against Volkswagen over its admitted cheating on tailpipe emissions tests.     (Reporting by Sudip Kar-Gupta)   ",2015-09-25,MRK,"Fri Sep 25, 2015 | 1:31am EDT",European Factors to Watch-Shares seen opening higher,http://www.reuters.com//article/markets-factors-europe-idUSL5N11V08O20150925?type=companyNews
378,"  Merck & CO said its Type 2 diabetes drug had been approved in Japan, marking the first approval for the once-weekly drug.The drug, omarigliptin, belongs to the same class of drugs as Merck's bestseller Januvia, which is to be taken once a day. Both drugs are aimed at lowering blood sugar levels.Januvia had sales of about $4 billion in 2014. Merck said this month it would submit an application for U.S. marketing approval for omarigliptin by the end of the year   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2015-09-28,MRK,"Mon Sep 28, 2015 | 8:19am EDT",Merck's once-weekly diabetes drug approved in Japan,http://www.reuters.com//article/us-merck-co-diabetesdrug-idUSKCN0RS1E320150928?type=companyNews
379,"  Sept 28 Merck & CO said its Type 2 diabetes drug had been approved in Japan, marking the first approval for the once-weekly drug.The drug, omarigliptin, belongs to the same class of drugs as Merck's bestseller Januvia, which is to be taken once a day. Both drugs are aimed at lowering blood sugar levels. Januvia had sales of about $4 billion in 2014.  Merck said this month it would submit an application for U.S. marketing approval for omarigliptin by the end of the year   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2015-09-28,MRK,"Mon Sep 28, 2015 | 8:17am EDT",Merck's once-weekly diabetes drug approved in Japan,http://www.reuters.com//article/merck-co-diabetesdrug-idUSL3N11Y3M220150928?type=companyNews
380,"  Sept 28 Merck* Says is progressing toward completion of Sigma - Aldrich acquisition * Says  closing is expected within the next two months * Says  it had obtained all necessary antitrust approvals,  with the approval of the European Commission being conditional upon the sale of parts  of Sigma - Aldrich'S solvents and inorganics business * Says negotiations with potential buyers  of parts  of Sigma - Aldrich'S business are in the final stage  Further company coverage:",2015-09-28,MRK,"Mon Sep 28, 2015 | 2:13am EDT",BRIEF-Merck KGaA says closing of Sigma-Aldrich takeover expected soon,http://www.reuters.com//article/idUSFWN11V01720150928?type=companyNews
381,"  (Corrects second bullet point to say Merck started investigating novel immunotherapy alone, not together with Pfizer)Oct 1 (Reuters) -* Says avelumab alliance with Pfizer on track * Says it started investigating a novel, potential first-in- class bi-functional immunotherapy in clinical trials * Says working towards at least one additional launch per year in 2017-2022 for avelumab * Says it expects more than 3,000 patients treated with  avelumab by 2016  Further company coverage:    (Frankfurt Newsroom; Editing by Greg Mahlich)",2015-10-01,MRK,"Thu Oct 1, 2015 | 9:20am EDT",Corrected-Merck KGaA says avelumab alliance with Pfizer on track,http://www.reuters.com//article/idUSL5N1212WZ20151001?type=companyNews
382,"   By Deena Beasley and Natalie Grover  The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker.The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the drug, and includes a companion diagnostic, made by a unit of Agilent Technologies Inc, to measure those protein levels. A Merck spokeswoman said clinical trials found that 22 percent of patients with this type of cancer had PD-L1 scores of at least 50 percent.""The restricted label is generally in line with expectations and is likely to broaden over time as data from additional trials support Keytruda's efficacy in a larger patient population,"" JP Morgan analyst Chris Schott said in a research note.The FDA decision ""has the potential to transform the way that lung cancer is treated,"" Dr. Edward Garon, associate clinical professor at the University of California, Los Angeles and a lead investigator on Keytruda clinical trials, said in a statement. Merck said the price of Keytruda for health insurers and other payers is around $12,500 per month, or $150,000 a year.Keytruda and another similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system. By blocking the interaction, the drugs aim to enable the patient's own immune system to attack the cancer.Wall Street analysts expect cancer immunotherapies to earn combined annual sales of over $20 billion by 2020. Bristol's Opdivo is approved by the FDA to treat melanoma as well as squamous non-small cell lung cancer, a smaller subset of the disease, but without a requirement for protein testing.Keytruda, now approved for both squamous and non-squamous non-small cell lung cancer, is also approved to treat patients with advanced melanoma. (1.usa.gov/1P9wW3p)  Lung cancer is the leading cause of cancer deaths in the United States with an estimated 221,000 new cases diagnosed and 158,000 deaths this year, according to the National Cancer Institute.Shares of Merck rose 1.6 percent, or 77 cents, to close at $50.14 Friday on the New York Stock Exchange, while shares of Bristol-Myers rose 3.6 percent, or $2.18, to close at $62.23. (Reporting by Natalie Grover in Bengaluru and Deena Beasley in Los Angeles; Editing by Bernadette Baum and Lisa Shumaker)",2015-10-02,MRK,"Fri Oct 2, 2015 | 4:21pm EDT",FDA expands approval of Merck's Keytruda to lung cancer,http://www.reuters.com//article/us-merck-co-fda-idUSKCN0RW20W20151002?type=companyNews
383,"  (Adds analyst comment, updates share prices)By Deena Beasley and Natalie GroverOct 2 The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker.The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the drug, and includes a companion diagnostic, made by a unit of Agilent Technologies Inc, to measure those protein levels. A Merck spokeswoman said clinical trials found that 22 percent of patients with this type of cancer had PD-L1 scores of at least 50 percent.""The restricted label is generally in line with expectations and is likely to broaden over time as data from additional trials support Keytruda's efficacy in a larger patient population,"" JP Morgan analyst Chris Schott said in a research note.The FDA decision ""has the potential to transform the way that lung cancer is treated,"" Dr. Edward Garon, associate clinical professor at the University of California, Los Angeles and a lead investigator on Keytruda clinical trials, said in a statement. Merck said the price of Keytruda for health insurers and other payers is around $12,500 per month, or $150,000 a year.Keytruda and another similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system. By blocking the interaction, the drugs aim to enable the patient's own immune system to attack the cancer. Wall Street analysts expect cancer immunotherapies to earn combined annual sales of over $20 billion by 2020.Bristol's Opdivo is approved by the FDA to treat melanoma as well as squamous non-small cell lung cancer, a smaller subset of the disease, but without a requirement for protein testing.Keytruda, now approved for both squamous and non-squamous non-small cell lung cancer, is also approved to treat patients with advanced melanoma. (1.usa.gov/1P9wW3p) Lung cancer is the leading cause of cancer deaths in the United States with an estimated 221,000 new cases diagnosed and 158,000 deaths this year, according to the National Cancer Institute.Shares of Merck rose 1.6 percent, or 77 cents, to close at $50.14 Friday on the New York Stock Exchange, while shares of Bristol-Myers rose 3.6 percent, or $2.18, to close at $62.23.(Reporting by Natalie Grover in Bengaluru and Deena Beasley in Los Angeles; Editing by Bernadette Baum and Lisa Shumaker)",2015-10-02,MRK,"Fri Oct 2, 2015 | 4:19pm EDT",UPDATE 3-U.S. FDA expands approval of Merck's Keytruda to lung cancer,http://www.reuters.com//article/merck-co-fda-idUSL3N12235920151002?type=companyNews
384,"  Oct 2 The U.S. Food and Drug Administration granted accelerated approval for Merck & Co's  immunotherapy, Keytruda, in patients with a form of lung cancer.Keytruda and another similar treatment from Bristol-Myers Squibb Co called Opdivo block a protein called PD-1, whose natural function is to put checks on the immune system. Wall Street analysts expect such drugs to capture combined annual sales of over $20 billion by 2020. Keytruda was approved last year to treat patients with advanced melanoma. (1.usa.gov/1P9wW3p) (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)",2015-10-02,MRK,"Fri Oct 2, 2015 | 2:01pm EDT",FDA approves Merck's Keytruda for use in lung cancer,http://www.reuters.com//article/merck-co-fda-idUSL3N12234H20151002?type=companyNews
385,"  (Corrects to add RIC in first bullet) Bionomics Ltd :  * Merck investment and pain partnership extended    * Merck &co., inc. to make US$9 million investment in Bionomics  * Says extended its strategic collaboration with Merck & co., inc., Kenilworth NJ  * Says separately, Merck & co., will also purchase 21.7 million ordinary shares at A$0.5938, a 29% premium to bionomics' closing price on 7 October 2015  * Says collaboration the discovery and development of drug candidates for the treatment of chronic and neuropathic pain  * Source text for Eikon   ",2015-10-08,MRK,"Wed Oct 7, 2015 | 9:04pm EDT","REFILE-BRIEF-Bionomics announces extension of strategic collaboration with Merck & Co., Inc",http://www.reuters.com//article/bionomics-brief-idUSWNBS01FQZ20151008?type=companyNews
386,"   By Nate Raymond | NEW YORK  NEW YORK A former Merck & Co Inc  employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.Zachary Zwerko, a former senior finance analyst at Merck who was involved with performing work on potential corporate deals, was also ordered by U.S. District Judge Alvin Hellerstein in Manhattan to pay more than $694,000.The case was the latest in a string of insider trading prosecutions pursued under Manhattan U.S. Attorney Preet Bharara, whose office confirmed Zwerko's sentence. Bharara's office since 2009 has secured convictions of 83 people.Zwerko, of Cambridge, Massachusetts, was sentenced to 37 months in prison. He pleaded guilty to conspiracy and securities fraud charges in February. His plea followed that of David Post, a friend from Rutgers Business School and a former BNY Mellon product manager, who pleaded guilty in October 2014.Prosecutors said Zwerko in 2010 proposed passing along information about drug company deals to Post to trade on in exchange for a cut in the profits. After some time passed, Zwerko began funneling information to Post, resulting in him buying shares of Ardea BioSciences Inc, which while not bought by Merck was ultimately acquired by AstraZeneca Plc in 2012, prosecutors said.Post's trading that time resulted in $105,000 in profits, prosecutors said, and Zwerko subsequently passed along tips on five other transactions. While some of Post's trades were not profitable, his trading in 2014 ahead of Merck's acquisition of Idenix Pharmaceuticals resulted in a major windfall of $579,000, which he had planned to split with Zwerko, prosecutors said.In total, the insider trading scheme generated illegal profits of at least $737,000, and Post paid Zwerko $57,000 as part of his expected cut, prosecutors said.The case is U.S. v. Post, U.S. District Court, Southern District of New York, No. 14-cr-00715.",2015-10-14,MRK,"Tue Oct 13, 2015 | 8:33pm EDT",Ex-Merck employees gets 3 years in prison for insider trading,http://www.reuters.com//article/merck-insidertrading-idUSL1N12E00X20151014?type=companyNews
387,"   By Zeba Siddiqui | MUMBAI  MUMBAI India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years.While Indian firms have launched a few such products on the domestic market, where regulatory barriers are relatively low, they are being overtaken by European, American and South Korean firms in the race to supply lucrative Western markets.Just three Indian groups - Biocon Ltd, Dr Reddy's Laboratories Ltd and Intas Pharamceuticals Ltd - are working with partners on so-called biosimilars aimed at the United States and Europe.Biotech drugs, which require genetic engineering, account for a growing share of new drugs and the future sales of copycat products will also switch to this category of pharmaceuticals from simple small-molecule pills like aspirin.The global biosimilars market is predicted to have sales of $25 billion by 2020, according to a 2014 Thomson Reuters report.""Biosimilars is a big opportunity,"" said Sujay Shetty, leader of the life sciences practice at PwC India. ""But unlike generics, it is not yet an opportunity (for Indian companies) in the U.S.""Copying chemical-based drugs has long been the bedrock of India's $15 billion pharmaceuticals industry. Biotech drugs, however, are more difficult to make and cannot be replicated exactly, which is why regulators have come up with the notion of versions that are similar enough to do the job.That also means regulators will be eagle-eyed on quality, posing a challenge to Indian companies, which have been distracted in recent years by manufacturing problems that have led to some drugs being barred from key overseas markets.Many, including the country's biggest drugmaker Sun Pharmaceutical Industries Ltd, are still struggling to fix issues at their generic drug factories. ""FAR BEHIND"" Biosimilars have been available in India since the early 2000s, well before their 2006 arrival in Europe and the recent introduction of a regulatory pathway in the United States, where the first biosimilar was launched only last month.But India's experience has not been problem-free. Intas, for example, recently received reports of some patients on its biosimilar version of Roche's eye drug Lucentis developing inflammation barely two months after the drug's launch. An Intas spokesman said the problem was found to be in the drug's ""cold chain logistics"" distribution channel and has restricted supply of the drug.Arun Chandavarkar, the chief executive of Biocon, seen by analysts as the front-runner among Indian firms developing biosimilars, believes the cost and complexity of developing biosimilars will be a deterrent for many Indian players.""At this time, there can't be too many companies willing to put in that much effort and investment,"" he said.The three Indian companies that have stated plans to make biosimilars for the United States and Europe are all partnered with larger Western firms.Biocon has a tie-up with Mylan Inc and is testing four molecules in global Phase III trials, for which it plans to seek approvals in the United States and Europe starting in fiscal 2017, Chandavarkar said. Dr Reddy's is developing biosimilars such as rituximab and pegfilgrastim for use in cancer treatment under a pact with Germany's Merck KGaA and said it plans to launch its first biosimilar in the United States by 2018.A spokesman at Intas, which developed pegfilgrastim in partnership with Canada's Apotex Inc, told Reuters the company was considering partnering with a Swiss drugmaker to launch the product in the United States. It declined to name the firm.Chandru Chawla, head of Cipla Ltd's new ventures unit, said India's ""fundamental disadvantage"" over United States, Europe and South Korea was that biotechnology never evolved in India to the extent that chemistry did.""In terms of having the right knowledge ecosystem and the pools of talent, India is far behind,"" he said.Globally, Western pharmaceutical firms such as Novartis AG; Pfizer Inc, in partnership with South Korea's Celltrion Inc; and Merck & Co with partner Samsung Bioepis, are leading in the race to dominate the Western biosimilars market.""South Korea has made very significant strides in a very short period of time,"" said Cartikeya Reddy, Dr Reddy's executive vice president for biologics. ""In this regard they have indeed pulled ahead of Indian companies."" (Editing by Ben Hirschler and Rachel Armstrong)",2015-10-14,MRK,"Wed Oct 14, 2015 | 5:04pm EDT",India risks missing boat as biosimilars shake up drug industry,http://www.reuters.com//article/us-india-biosimilars-idUSKCN0S82OQ20151014?type=companyNews
388,"  * Only a handful of Indian firms making biosimilars for US, EU* Dr Reddy's sees launching first biosimilar in US by 2018* Global biosimilars sales seen at $25 billion by 2020By Zeba SiddiquiMUMBAI, Oct 15 India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years.While Indian firms have launched a few such products on the domestic market, where regulatory barriers are relatively low, they are being overtaken by European, American and South Korean firms in the race to supply lucrative Western markets.Just three Indian groups - Biocon Ltd, Dr Reddy's Laboratories Ltd and Intas Pharamceuticals Ltd - are working with partners on so-called biosimilars aimed at the United States and Europe.Biotech drugs, which require genetic engineering, account for a growing share of new drugs and the future sales of copycat products will also switch to this category of pharmaceuticals from simple small-molecule pills like aspirin.The global biosimilars market is predicted to have sales of $25 billion by 2020, according to a 2014 Thomson Reuters report.""Biosimilars is a big opportunity,"" said Sujay Shetty, leader of the life sciences practice at PwC India. ""But unlike generics, it is not yet an opportunity (for Indian companies) in the U.S."" Copying chemical-based drugs has long been the bedrock of India's $15 billion pharmaceuticals industry. Biotech drugs, however, are more difficult to make and cannot be replicated exactly, which is why regulators have come up with the notion of versions that are similar enough to do the job.That also means regulators will be eagle-eyed on quality, posing a challenge to Indian companies, which have been distracted in recent years by manufacturing problems that have led to some drugs being barred from key overseas markets.Many, including the country's biggest drugmaker Sun Pharmaceutical Industries Ltd, are still struggling to fix issues at their generic drug factories.""FAR BEHIND""  Biosimilars have been available in India since the early 2000s, well before their 2006 arrival in Europe and the recent introduction of a regulatory pathway in the United States, where the first biosimilar was launched only last month.But India's experience has not been problem-free. Intas, for example, recently received reports of some patients on its biosimilar version of Roche's eye drug Lucentis developing inflammation barely two months after the drug's launch.An Intas spokesman said the problem was found to be in the drug's ""cold chain logistics"" distribution channel and has restricted supply of the drug.Arun Chandavarkar, the chief executive of Biocon, seen by analysts as the front-runner among Indian firms developing biosimilars, believes the cost and complexity of developing biosimilars will be a deterrent for many Indian players. ""At this time, there can't be too many companies willing to put in that much effort and investment,"" he said.The three Indian companies that have stated plans to make biosimilars for the United States and Europe are all partnered with larger Western firms.Biocon has a tie-up with Mylan Inc and is testing four molecules in global Phase III trials, for which it plans to seek approvals in the United States and Europe starting in fiscal 2017, Chandavarkar said.Dr Reddy's is developing biosimilars such as rituximab and pegfilgrastim for use in cancer treatment under a pact with Germany's Merck KGaA and said it plans to launch its first biosimilar in the United States by 2018.A spokesman at Intas, which developed pegfilgrastim in partnership with Canada's Apotex Inc, told Reuters the company was considering partnering with a Swiss drugmaker to launch the product in the United States. It declined to name the firm.Chandru Chawla, head of Cipla Ltd's new ventures unit, said India's ""fundamental disadvantage"" over United States, Europe and South Korea was that biotechnology never evolved in India to the extent that chemistry did.""In terms of having the right knowledge ecosystem and the pools of talent, India is far behind,"" he said.Globally, Western pharmaceutical firms such as Novartis AG  ; Pfizer Inc, in partnership with South Korea's Celltrion Inc ; and Merck & Co with partner Samsung Bioepis, are leading in the race to dominate the Western biosimilars market.""South Korea has made very significant strides in a very short period of time,"" said Cartikeya Reddy, Dr Reddy's executive vice president for biologics. ""In this regard they have indeed pulled ahead of Indian companies.""   (Editing by Ben Hirschler and Rachel Armstrong)",2015-10-14,MRK,"Wed Oct 14, 2015 | 5:00pm EDT",India risks missing boat as biosimilars shake up drug industry,http://www.reuters.com//article/india-biosimilars-idUSL3N12E1V020151014?type=companyNews
389,"  FRANKFURT Germany's Merck KGaA said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America.In the United States and Canada, where its U.S. namesake Merck & Co Inc holds the rights to the Merck name, the German company will continue to operate as EMD Serono in the biopharmaceutical business, as EMD Performance Materials in the high-tech materials business, as well as EMD Millipore in the life science business.Merck KGaA and Merck & Co Inc share historic roots but are under separate ownership since World War One.      (Reporting by Ludwig Burger; Editing by Kirsti Knolle)",2015-10-14,MRK,"Wed Oct 14, 2015 | 4:12am EDT",Germany's Merck KGaA scraps unit brands,http://www.reuters.com//article/us-merck-brand-idUSKCN0S80PC20151014?type=companyNews
390,"  FRANKFURT Oct 14 Germany's Merck KGaA  said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America.In the United States and Canada, where its U.S. namesake Merck & Co Inc holds the rights to the Merck name, the German company will continue to operate as EMD Serono in the biopharmaceutical business, as EMD Performance Materials in the high-tech materials business, as well as EMD Millipore in the life science business. Merck KGaA and Merck & Co Inc share historic roots but are under separate ownership since World War One.  (Reporting by Ludwig Burger; Editing by Kirsti Knolle)",2015-10-14,MRK,"Wed Oct 14, 2015 | 3:15am EDT",Germany's Merck KGaA scraps unit brands,http://www.reuters.com//article/merck-brand-idUSFWN12D01C20151014?type=companyNews
391,"   By Nate Raymond | NEW YORK  NEW YORK A former Merck & Co Inc employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.Zachary Zwerko, a former senior finance analyst at Merck who was involved with performing work on potential corporate deals, was also ordered by U.S. District Judge Alvin Hellerstein in Manhattan to pay more than $694,000.The case was the latest in a string of insider trading prosecutions pursued under Manhattan U.S. Attorney Preet Bharara, whose office confirmed Zwerko's sentence. Bharara's office since 2009 has secured convictions of 83 people.Zwerko, of Cambridge, Massachusetts, was sentenced to 37 months in prison. He pleaded guilty to conspiracy and securities fraud charges in February. His plea followed that of David Post, a friend from Rutgers Business School and a former BNY Mellon product manager, who pleaded guilty in October 2014.Prosecutors said Zwerko in 2010 proposed passing along information about drug company deals to Post to trade on in exchange for a cut in the profits.After some time passed, Zwerko began funneling information to Post, resulting in him buying shares of Ardea BioSciences Inc, which while not bought by Merck was ultimately acquired by AstraZeneca Plc in 2012, prosecutors said. Post's trading that time resulted in $105,000 in profits, prosecutors said, and Zwerko subsequently passed along tips on five other transactions.While some of Post's trades were not profitable, his trading in 2014 ahead of Merck's acquisition of Idenix Pharmaceuticals resulted in a major windfall of $579,000, which he had planned to split with Zwerko, prosecutors said. In total, the insider trading scheme generated illegal profits of at least $737,000, and Post paid Zwerko $57,000 as part of his expected cut, prosecutors said.The case is U.S. v. Post, U.S. District Court, Southern District of New York, No. 14-cr-00715. (Reporting by Nate Raymond in New York; Editing by Leslie Adler)",2015-10-14,MRK,"Tue Oct 13, 2015 | 8:32pm EDT",Ex-Merck employees gets three years in prison for insider trading,http://www.reuters.com//article/us-merck-insidertrading-idUSKCN0S801720151014?type=companyNews
392,"   By Nate Raymond | NEW YORK  NEW YORK Oct 13 A former Merck & Co Inc  employee was sentenced to more than three years in prison on Tuesday for engaging in an insider trading scheme by tipping a friend at Bank of New York Mellon Corp about potential pharmaceutical mergers.Zachary Zwerko, a former senior finance analyst at Merck who was involved with performing work on potential corporate deals, was also ordered by U.S. District Judge Alvin Hellerstein in Manhattan to pay more than $694,000.The case was the latest in a string of insider trading prosecutions pursued under Manhattan U.S. Attorney Preet Bharara, whose office confirmed Zwerko's sentence. Bharara's office since 2009 has secured convictions of 83 people.Zwerko, of Cambridge, Massachusetts, was sentenced to 37 months in prison. He pleaded guilty to conspiracy and securities fraud charges in February. His plea followed that of David Post, a friend from Rutgers Business School and a former BNY Mellon product manager, who pleaded guilty in October 2014.Prosecutors said Zwerko in 2010 proposed passing along information about drug company deals to Post to trade on in exchange for a cut in the profits. After some time passed, Zwerko began funneling information to Post, resulting in him buying shares of Ardea BioSciences Inc, which while not bought by Merck was ultimately acquired by AstraZeneca Plc in 2012, prosecutors said.Post's trading that time resulted in $105,000 in profits, prosecutors said, and Zwerko subsequently passed along tips on five other transactions. While some of Post's trades were not profitable, his trading in 2014 ahead of Merck's acquisition of Idenix Pharmaceuticals resulted in a major windfall of $579,000, which he had planned to split with Zwerko, prosecutors said.In total, the insider trading scheme generated illegal profits of at least $737,000, and Post paid Zwerko $57,000 as part of his expected cut, prosecutors said.The case is U.S. v. Post, U.S. District Court, Southern District of New York, No. 14-cr-00715.   (Reporting by Nate Raymond in New York; Editing by Leslie Adler)",2015-10-14,MRK,"Tue Oct 13, 2015 | 8:29pm EDT",Ex-Merck employees gets 3 years in prison for insider trading,http://www.reuters.com//article/merck-insidertrading-idUSL1N11M2AE20151014?type=companyNews
393,"  Oct 15 Ablynx NV :* Achieves first milestone in immuno-oncology collaboration with Merck & Co., Inc.  * To receive 3.5 million euros ($4.02 million) milestone payment  Source text for Eikon:  Further company coverage:   ($1 = 0.8708 euros)   (Gdynia Newsroom) ",2015-10-15,MRK,"Thu Oct 15, 2015 | 1:18am EDT",BRIEF-Ablynx gets first milestone in immuno-oncology deal with Merck & Co.,http://www.reuters.com//article/idUSFWN12E02F20151015?type=companyNews
394,"  FRANKFURT Merck (MRCG.DE) has cleared a major anti-trust hurdle to its planned $17 billion acquisition of Sigma-Aldrich SIAL.O with the latter's agreed sale of assets to Honeywell (HON.N), the German drugmaker said on Tuesday.Merck said U.S. life science company Sigma-Aldrich would sell parts of its solvents and inorganics business in Europe to industrial group Honeywell, which said separately it would pay about 105 million euros ($119 million) for the assets.""This is another key step towards completing the acquisition of Sigma-Aldrich,"" Merck executive board member Bernd Reckmann said in a statement on Tuesday.Merck said it still expected to close the acquisition of Sigma-Aldrich, its biggest takeover, by the end of November. The European Commission has to approve the asset sale to Honeywell in order for Merck to close the bigger transaction. Merck aims to boost its lab-supplies business with the all-cash deal which was agreed more than a year ago.  ($1 = 0.8790 euros)  (Reporting by Georgina Prodhan; editing by Jason Neely)",2015-10-20,MRK,"Tue Oct 20, 2015 | 6:57am EDT",Merck clears major hurdle to Sigma-Aldrich takeover,http://www.reuters.com//article/us-sigma-aldrich-m-a-merck-honeywell-int-idUSKCN0SE18F20151020?type=companyNews
395,"  FRANKFURT Oct 20 Merck has cleared a major anti-trust hurdle to its planned $17 billion acquisition of Sigma-Aldrich with the latter's agreed sale of assets to Honeywell, the German drugmaker said on Tuesday.Merck said U.S. life science company Sigma-Aldrich would sell parts of its solvents and inorganics business in Europe to industrial group Honeywell, which said separately it would pay about 105 million euros ($119 million) for the assets.""This is another key step towards completing the acquisition of Sigma-Aldrich,"" Merck executive board member Bernd Reckmann said in a statement on Tuesday. Merck said it still expected to close the acquisition of Sigma-Aldrich, its biggest takeover, by the end of November. The European Commission has to approve the asset sale to Honeywell in order for Merck to close the bigger transaction. Merck aims to boost its lab-supplies business with the all-cash deal which was agreed more than a year ago.($1 = 0.8790 euros)   (Reporting by Georgina Prodhan; editing by Jason Neely)",2015-10-20,MRK,"Tue Oct 20, 2015 | 6:55am EDT",Merck clears major hurdle to Sigma-Aldrich takeover,http://www.reuters.com//article/sigma-aldrich-ma-merck-honeywell-intl-idUSL8N12K2C820151020?type=companyNews
396,"   By Deena Beasley | LOS ANGELES  LOS ANGELES Oct 21 Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc have put a spotlight on the little-known and fast-growing specialty pharmacy industry.Shares of Valeant fell 19 percent on Wednesday after influential short-seller Citron Research accused the company of using specialty pharmacies, through a network led by its partner Philidor Rx Services, to inflate its revenue, an allegation the drugmaker denied.Specialty pharmacies are designed to deliver medications with unique handling, storage and distribution requirements, often for patients with complex conditions such as cancer, multiple sclerosis or rheumatoid arthritis. They can provide more detailed guidance for patients on how to take the drugs. Specialty drugs are often expensive, sometimes priced at over $100,000 a year.The industry has been growing quickly as drugmakers shift research and sales efforts to more complex medications. Pembroke Consulting estimated early this year that the number of accredited specialty pharmacies would jump by nearly 100 to a total of 250 in 2015.In the past, drugmakers were directly involved in distribution of their products. Merck & Co, for example, owned a pharmacy service company known as Medco. But it spun off that business in 2003, partly due to concerns over potential conflicts of interest.Medco was later acquired by Express Scripts Holding Co , which is now the largest U.S. pharmacy benefits manager. A New York Times report earlier this week said that Valeant worked with Philidor Rx Services, based in Hatboro, Pennsylvania, to increase sales, and prices, for treatments that don't meet the specialty criterion, including drugs for acne and toenail fungus, and that regular pharmacies may not prescribe.The same day, Valeant disclosed that a growing percentage of its revenue is coming from products dispensed through specialty pharmacies, and that it had purchased an option to acquire Philidor. Valeant is Philidor's main customer.""We find specialty pharmacies improve patients' access to medicines at an affordable price, and help ensure physicians are able to prescribe the medications they believe most appropriate for their patients,"" Valeant Chief Executive Michael Pearson told investors on a conference call.He said that for many of the company's skin products, Philidor and other specialty pharmacies fill a customer's prescription before reimbursement is worked out with an insurer, and that Valeant only recognizes revenue from the products once the drug reaches a patient. Pearson also described how Valeant's relationship with another specialty pharmacy, R&O Pharmacy LLC of Camarillo, California, turned sour. Valeant said it had shipped $69 million worth of medications at wholesale prices to R&O, and that the pharmacy ""is currently improperly holding significant amounts it receives"" from insurers.R&O has sued Valeant in California over its efforts to claim the money, saying it has no contractual relationship with the drugmaker. Representatives of R&O declined to comment.Citron alleged that R&O and Philidor may actually be the same company, and that the two were used by Valeant to create phantom accounts to inflate revenue. In a statement, Philidor said R&O is part of its network of affiliated pharmacies and that it provides services to those partners including call center functions, help with insurance claims, technical support and ""certain management services."" ""Philidor does not currently have a direct equity ownership in R&O Pharmacy or the affiliated pharmacies, but does have a contractual right to acquire the pharmacies now or in the future subject to regulatory approval,"" the statement said.Scott Knoer, chief pharmacy officer at the Cleveland Clinic, said the web of relationships raises concern. Cleveland Clinic and other hospitals have been hit financially by Valeant price increases on heart drugs Isuprel and Nitropress.""There would be an inherent conflict of interest if a specialty pharmacy is owned by someone making the drug,"" Knoer said. ""There could be pressure on the pharmacy to start patients on the drug, or continue patients on it, or not stop them"" as warranted.While concerns over Valeant's ties to its specialty pharmacies hit rival stocks on Wednesday, both Allergan Plc  and Endo International Plc were quick to say their businesses did not operate in the same manner.Allergan said about 3 percent of its U.S. sales of branded drugs are distributed through specialty pharmacies, most of which are specialty products that require careful handling.Endo said it uses specialty pharmacies mainly for branded products that need to be administered by doctors, and that drugs distributed through this channel represent about 3 percent of the company's projected total revenue for 2015. It said any specialty pharmacies that it works with are fully independent of the company.   (Additional reporting by Caroline Humer and Ransdell Pierson in New York; Editing by Michele Gershberg and Leslie Adler)",2015-10-22,MRK,"Wed Oct 21, 2015 | 8:33pm EDT",Specialty pharmacies in spotlight as Valeant ties questioned,http://www.reuters.com//article/valeant-pharmacies-industry-idUSL1N12L3B720151022?type=companyNews
397,"   By Ransdell Pierson  Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer. Keytruda thereby met its main goal of the study.Patients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said. Those whose tumors expressed PD-L1, but not at high levels, did not show such a statistically  significant benefit in progression-free survival. Safety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary ""topline"" information from the results.More detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug's package insert label.   U.S. regulators in October approved Keytruda on an accelerated basis for patients with advanced non-small cell lung cancer whose tumors produce PD-L1. The approval was contingent on the company providing more detailed data in the future on Keytruda's safety and effectiveness.Keytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system. By blocking the interaction, the drugs aim to enable the patient's own immune system to recognize and therefore attack the cancer. Wall Street analysts expect cancer immunotherapies to earn combined annual sales of over $20 billion by 2020. (Reporting by Ransdell Pierson; Editing by James Dalgleish)",2015-10-26,MRK,"Mon Oct 26, 2015 | 11:03am EDT",Merck's Keytruda extends survival in lung cancer study,http://www.reuters.com//article/us-merck-keytruda-lung-idUSKCN0SK1VB20151026?type=companyNews
398,"   By Ransdell Pierson  Oct 26 Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer. Keytruda thereby met its main goal of the study.Patients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said. Those whose tumors expressed PD-L1, but not at high levels, did not show such a statistically  significant benefit in progression-free survival. Safety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary ""topline"" information from the results. More detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug's package insert label.U.S. regulators in October approved Keytruda on an accelerated basis for patients with advanced non-small cell lung cancer whose tumors produce PD-L1. The approval was contingent on the company providing more detailed data in the future on Keytruda's safety and effectiveness. Keytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system. By blocking the interaction, the drugs aim to enable the patient's own immune system to recognize and therefore attack the cancer.Wall Street analysts expect cancer immunotherapies to earn combined annual sales of over $20 billion by 2020.   (Reporting by Ransdell Pierson; Editing by James Dalgleish)",2015-10-26,MRK,"Mon Oct 26, 2015 | 10:58am EDT",Merck's Keytruda extends survival in lung cancer study,http://www.reuters.com//article/merck-keytruda-lung-idUSL1N12Q16O20151026?type=companyNews
399,"  Merck & Co Inc (MRK.N) on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.Combined sales of diabetes drug Januvia and a related pill called Janumet, which have struggled to grow in the past year, jumped 10 percent to $1.58 billion in the third quarter after only a 1 percent rise in the previous period. Adam Schechter, Merck's head of global human health, said in a conference call with analysts that the treatments for type 2 diabetes got a $100 million boost from stocking by wholesalers. But he cautioned that the gain would hamper their sales in the fourth quarter and beyond.Schechter said the volume of Januvia sales rose 4 percent in the quarter, which he called an encouraging trend.Keytruda, the company's new advanced melanoma and lung cancer treatment from a promising class of immuno-oncology drugs, brought in sales of $159 million.""Merck continues to execute well in oncology with Keytruda,"" BMO Capital Markets analyst Alex Arfaei said in a research note. He predicted the drug, which blocks a protein called PD-1 that allows tumors to hide from the immune system, would achieve annual sales of about $9 billion by 2023 as a treatment for multiple types of cancer. Merck Chief Executive Officer Ken Frazier said negative media reports about Valeant Pharmaceuticals International (VRX.TO) (VRX.N) and other companies that have dramatically raised prices of their prescription drugs had created ""a lot of noise"" without seriously tarnishing the industry's reputation.""People recognize the industry is important,"" Frazier said on the conference call. ""Our innovations are critical to society.""  Merck, whose shares were up 1.2 percent in morning trading, said its net income doubled to $1.83 billion, or 64 cents per share, from $895 million, or 31 cents per share, a year earlier.Excluding special items, including restructuring and acquisitions, earnings of 96 cents per share exceeded the analysts' average estimate of 91 cents, according to Thomson Reuters I/B/E/S.Revenue fell 5 percent to $10.07 billion, slightly below Wall Street forecasts of $10.08 billion. Excluding the impact of a strong dollar and other factors, revenue would have risen 4 percent, Merck said.Merck raised its 2015 profit forecast to a range of $3.55 to $3.60 per share. It had previously expected $3.45 to $3.55.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2015-10-27,MRK,"Tue Oct 27, 2015 | 10:57am EDT","Merck profit tops estimates on strong diabetes, cancer drug sales",http://www.reuters.com//article/us-merck-co-results-idUSKCN0SL18P20151027?type=companyNews
400,"  (Adds link to graphic, updates share movement)Oct 27 Merck & Co Inc on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.Combined sales of diabetes drug Januvia and a related pill called Janumet, which have struggled to grow in the past year, jumped 10 percent to $1.58 billion in the third quarter after only a 1 percent rise in the previous period.Adam Schechter, Merck's head of global human health, said in a conference call with analysts that the treatments for type 2 diabetes got a $100 million boost from stocking by wholesalers. But he cautioned that the gain would hamper their sales in the fourth quarter and beyond.Schechter said the volume of Januvia sales rose 4 percent in the quarter, which he called an encouraging trend.Keytruda, the company's new advanced melanoma and lung cancer treatment from a promising class of immuno-oncology drugs, brought in sales of $159 million. ""Merck continues to execute well in oncology with Keytruda,"" BMO Capital Markets analyst Alex Arfaei said in a research note. He predicted the drug, which blocks a protein called PD-1 that allows tumors to hide from the immune system, would achieve annual sales of about $9 billion by 2023 as a treatment for multiple types of cancer.Merck Chief Executive Officer Ken Frazier said negative media reports about Valeant Pharmaceuticals International   and other companies that have dramatically raised prices of their prescription drugs had created ""a lot of noise"" without seriously tarnishing the industry's reputation. ""People recognize the industry is important,"" Frazier said on the conference call. ""Our innovations are critical to society.""Merck, whose shares were up 1.2 percent in morning trading, said its net income doubled to $1.83 billion, or 64 cents per share, from $895 million, or 31 cents per share, a year earlier.Excluding special items, including restructuring and acquisitions, earnings of 96 cents per share exceeded the analysts' average estimate of 91 cents, according to Thomson Reuters I/B/E/S. Revenue fell 5 percent to $10.07 billion, slightly below Wall Street forecasts of $10.08 billion.Excluding the impact of a strong dollar and other factors, revenue would have risen 4 percent, Merck said.Merck raised its 2015 profit forecast to a range of $3.55 to $3.60 per share. It had previously expected $3.45 to $3.55.(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2015-10-27,MRK,"Tue Oct 27, 2015 | 10:55am EDT","UPDATE 3-Merck profit tops estimates on strong diabetes, cancer drug sales",http://www.reuters.com//article/merck-co-results-idUSL3N12R3TU20151027?type=companyNews
401,"  Merck & Co Inc* Says januvia sales got a $100 million boost in third quarter from timing of customer buying * Merck says boost to januvia from timing of third quarter purchases will have adverse impact in fourth quarter, beyond * Merck says januvia had volume growth of 4 percent in third quarter, company encouraged by volume trends * Rival jardiance  Source text for Eikon:  Further company coverage:",2015-10-27,MRK,"Tue Oct 27, 2015 | 9:30am EDT",BRIEF-Merck says expects januvia to retain strong position as add-on diabetes therapy despite favorable data seen with lilly's rival jardiance,http://www.reuters.com//article/idUSL1N12R0WP20151027?type=companyNews
402,"  Oct 27 Drugmaker Merck & Co Inc reported a near 5 percent drop in quarterly revenue as a strong dollar offset strong demand for its diabetes drugs.The U.S. drugmaker's net income doubled to $1.83 billion, or 64 cents per share, for the third quarter ended Sept. 30 from $895 million, or 31 cents per share, a year earlier.  Revenue fell to $10.07 billion from $10.56 billion. Excluding the impact of a strong dollar revenue and other items, revenue would have risen 4 percent, the company said.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza) ",2015-10-27,MRK,"Tue Oct 27, 2015 | 6:56am EDT","Merck revenue down 5 pct, hurt by strong dollar",http://www.reuters.com//article/merck-co-results-idUSL3N12R3SR20151027?type=companyNews
403,"  FRANKFURT Oct 29 German drugmaker Bayer  saw underlying core earnings gain 28 percent in the third quarter, bolstered by sales of new drugs and the purchase of Merck & Co's consumer health business.Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.52 billion euros ($2.76 billion), above market expectations of 2.31 billion euros. Bayer still expects 2015 adjusted EBITDA to grow by ""a high-teens percentage"", including positive currency effects of about 4 percent. It lowered its 2015 revenue target to roughly 46 billion euros from 47 billion euros previous, anticipating less of a boost from currency effects than previously. ($1 = 0.9140 euros)   (Reporting by Ludwig Burger; Editing by Maria Sheahan)",2015-10-29,MRK,"Thu Oct 29, 2015 | 2:52am EDT",Bayer adj EBITDA up 28 pct on new drugs,http://www.reuters.com//article/bayer-results-idUSFWN12S05E20151029?type=companyNews
404,"   By Natalie Grover and Samantha Kareen Nair  Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said. The drug, which goes by the chemical name of sugammadex, has repeatedly been rejected by the FDA due to concerns about potentially dangerous allergic reactions, even though it is approved in more than 75 countries.The company acquired the drug when it bought U.S. drugmaker Schering Plough, which developed sugammadex, in 2009. Merck shares were down 1 percent on Friday, after the company said in a separate statement on Thursday that it had received a civil investigation demand from a U.S. Attorney's Office in Pennsylvania over the pricing of its asthma medicine, Dulera.Independent advisers to the FDA said in a meeting on Friday that they were satisfied with the potential hypersensitivity and cardiac risk associated with the drug when it was used in a monitored setting.  Panelists underscored the fact that existing agents carried similar risks.A majority of the voters suggested additional studies to evaluate risks in vulnerable populations such as the elderly and obese, pediatric and pregnant patients.Sugammadex, an injectable drug, is sold in over 50 countries. More than 12 million doses of the drug have been sold as of April 22 since it was first approved in 2008 in Europe.  FDA staff had noted on Wednesday that hypersensitivity related to the drug appeared to increase with higher doses, but not with repeated exposure. (1.usa.gov/1kzg2PA)Brokerage Cowen & Co estimates that sugammadex, if approved in the United States, could generate annual sales of $550 million in the country by 2020.  This will make the drug, sold overseas under the brand name Bridion, a moderate-sized product for Merck. The FDA usually follows the panel's recommendations, but is not obligated to do so. The agency is expected to make its final decision on the drug by Dec. 19. Kenilworth, New Jersey-based Merck's shares were trading at $54.46 in late afternoon trading on the New York Stock Exchange.  (Reporting by Natalie Grover and Samantha Kareen Nair in Bengaluru; Editing by Kirti Pandey)",2015-11-06,MRK,"Fri Nov 6, 2015 | 3:18pm EST",FDA panel backs Merck & Co drug to reverse muscle relaxant effect,http://www.reuters.com//article/us-merck-co-fda-idUSKCN0SV2O020151106?type=companyNews
405,"   By Ransdell Pierson  U.S. drugmakers Merck & Co and Eli Lilly & Co are being investigated by federal prosecutors over their drug-pricing practices, the companies disclosed.The exact nature of the investigations and where they might lead was not immediately clear.Lilly, in an Oct. 30 regulatory filing, said the Philadelphia U.S. Attorney's Office and the civil division of the U.S. Department of Justice are investigating its distribution agreements with wholesalers. The agreements are used to determine Average Manufacturer Prices that are the basis of required rebates to the Medicaid healthcare program.Under federal law, the government's Medicaid program for the indigent receives about a 23 percent rebate to the average wholesale price. Lilly spokesman Mark Taylor said the Indianapolis company is cooperating with the investigations. He noted that drugmakers every three months are required to provide the U.S. Centers for Medicare and Medicaid Services the average prices its wholesalers pay for their products.""This inquiry is not in regard to our list prices, or how we price our medicines in general,"" Taylor said. The exact nature of the investigation and where it may lead was not immediately clear.Merck, in a regulatory filing late on Thursday, said it had received a civil investigative demand for information from the Philadelphia U.S. Attorney's Office, relating to pricing of its asthma inhaler product, Dulera. (1.usa.gov/1kyPGgR) Merck said it was cooperating with the investigation, but declined further comment.The regulatory disclosures come as a U.S. Senate panel moves ahead with a probe into drug pricing by companies, including Valeant Pharmaceuticals International Inc  and Turing Pharmaceuticals.Drugmakers' shares fell sharply in the past few weeks after Democratic presidential candidate Hillary Clinton criticized drug pricing on her campaign trail.Shares of Lilly were down 0.3 percent, while Merck fell 1 percent in afternoon trading on the New York Stock Exchange, amid a 0.9 percent decline for the ARCA Pharmaceutical Index of large U.S. and European drugmakers.   (additional reporting by Vidya L.  Nathan in Bengaluru)",2015-11-06,MRK,"Fri Nov 6, 2015 | 3:12pm EST","U.S. agencies investigate Merck, Lilly drug pricing",http://www.reuters.com//article/merck-co-pricing-idUSL1N1311PH20151106?type=companyNews
406,"  (Adds details, background; updates shares)By Natalie Grover and Samantha Kareen NairNov 6 Merck & Co's drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said.The drug, which goes by the chemical name of sugammadex, has repeatedly been rejected by the FDA due to concerns about potentially dangerous allergic reactions, even though it is approved in more than 75 countries.The company acquired the drug when it bought U.S. drugmaker Schering Plough, which developed sugammadex, in 2009.Merck shares were down 1 percent on Friday, after the company said in a separate statement on Thursday that it had received a civil investigation demand from a U.S. Attorney's Office in Pennsylvania over the pricing of its asthma medicine, Dulera. Independent advisers to the FDA said in a meeting on Friday that they were satisfied with the potential hypersensitivity and cardiac risk associated with the drug when it was used in a monitored setting.Panelists underscored the fact that existing agents carried similar risks. A majority of the voters suggested additional studies to evaluate risks in vulnerable populations such as the elderly and obese, pediatric and pregnant patients.Sugammadex, an injectable drug, is sold in over 50 countries. More than 12 million doses of the drug have been sold as of April 22 since it was first approved in 2008 in Europe.FDA staff had noted on Wednesday that hypersensitivity related to the drug appeared to increase with higher doses, but not with repeated exposure. (1.usa.gov/1kzg2PA) Brokerage Cowen & Co estimates that sugammadex, if approved in the United States, could generate annual sales of $550 million in the country by 2020.This will make the drug, sold overseas under the brand name Bridion, a moderate-sized product for Merck.The FDA usually follows the panel's recommendations, but is not obligated to do so. The agency is expected to make its final decision on the drug by Dec. 19.Kenilworth, New Jersey-based Merck's shares were trading at $54.46 in late afternoon trading on the New York Stock Exchange.   (Reporting by Natalie Grover and Samantha Kareen Nair in Bengaluru; Editing by Kirti Pandey)",2015-11-06,MRK,"Fri Nov 6, 2015 | 3:10pm EST",UPDATE 2-FDA panel backs Merck & Co drug to reverse muscle relaxant effect,http://www.reuters.com//article/merck-co-fda-idUSL3N13160120151106?type=companyNews
407,"  (Adds Lilly comment, details on Medicaid rebates)Nov 6 U.S. drugmakers Merck & Co and Eli Lilly & Co are being investigated by federal prosecutors over their drug-pricing practices, the companies disclosed.The exact nature of the investigations and where they might lead was not immediately clear.Lilly, in an Oct. 30 regulatory filing, said the Philadelphia U.S. Attorney's Office and the civil division of the U.S. Department of Justice are investigating its distribution agreements with wholesalers. The agreements are used to determine Average Manufacturer Prices that are the basis of required rebates to the Medicaid healthcare program.Under federal law, the government's Medicaid program for the indigent receives about a 23 percent rebate to the average wholesale price. Lilly spokesman Mark Taylor said the Indianapolis company is cooperating with the investigations. He noted that drugmakers every three months are required to provide the U.S. Centers for Medicare and Medicaid Services the average prices its wholesalers pay for their products.""This inquiry is not in regard to our list prices, or how we price our medicines in general,"" Taylor said. The exact nature of the investigation and where it may lead was not immediately clear.Merck, in a regulatory filing late on Thursday, said it had received a civil investigative demand for information from the Philadelphia U.S. Attorney's Office, relating to pricing of its asthma inhaler product, Dulera. (1.usa.gov/1kyPGgR) Merck said it was cooperating with the investigation, but declined further comment.The regulatory disclosures come as a U.S. Senate panel moves ahead with a probe into drug pricing by companies, including Valeant Pharmaceuticals International Inc  and Turing Pharmaceuticals.Drugmakers' shares fell sharply in the past few weeks after Democratic presidential candidate Hillary Clinton criticized drug pricing on her campaign trail.Shares of Lilly were down 0.3 percent, while Merck fell 1 percent in afternoon trading on the New York Stock Exchange, amid a 0.9 percent decline for the ARCA Pharmaceutical Index of large U.S. and European drugmakers.   (Reporting by Ransdell Pierson in New York; additional reporting by Vidya L.  Nathan in Bengaluru; Editing by Andrew Hay)",2015-11-06,MRK,"Fri Nov 6, 2015 | 3:09pm EST","UPDATE 1-U.S. agencies investigate Merck, Lilly drug pricing",http://www.reuters.com//article/merck-co-pricing-idUSL1N13120V20151106?type=companyNews
408,"  Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed.Merck, in a regulatory filing late on Thursday, said it had received a civil investigative demand from the attorney's office over the pricing of its asthma inhaler product, Dulera. (1.usa.gov/1kyPGgR)Merck said it was cooperating with the investigation.Eli Lilly & Co also disclosed in a regulatory filing last week that the Pennsylvania Attorney's Office and the U.S. Department of Justice were investigating the company's distribution deals with wholesalers. Lilly said the investigation was looking into the company's drug pricing in Medicaid rebate programs. The company said it was responding to the federal agencies. (1.usa.gov/1kfpZCg)Merck's disclosure comes days after a U.S. Senate panel launched a probe into drug pricing by companies including Valeant Pharmaceuticals International Inc and Turing Pharmaceuticals. Drugmakers' shares fell sharply in the past few weeks after Democratic presidential candidate Hillary Clinton criticized drug pricing on her campaign trail. Shares of both Merck and Lilly were down 1 percent in afternoon trading on the New York Stock Exchange. (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey; Editing by Saumyadeb Chakrabarty)",2015-11-06,MRK,"Fri Nov 6, 2015 | 12:20pm EST","U.S. federal agencies investigate Merck, Lilly drug pricing",http://www.reuters.com//article/us-merck-co-pricing-idUSKCN0SV2C120151106?type=companyNews
409,"  (Adds Eli Lilly investigation, shares)Nov 6 Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed.Merck, in a regulatory filing late on Thursday, said it had received a civil investigative demand from the attorney's office over the pricing of its asthma inhaler product, Dulera. (1.usa.gov/1kyPGgR)Merck said it was cooperating with the investigation. Eli Lilly & Co also disclosed in a regulatory filing last week that the Pennsylvania Attorney's Office and the U.S. Department of Justice were investigating the company's distribution deals with wholesalers. Lilly said the investigation was looking into the company's drug pricing in Medicaid rebate programs. The company said it was responding to the federal agencies. (1.usa.gov/1kfpZCg)Merck's disclosure comes days after a U.S. Senate panel launched a probe into drug pricing by companies including Valeant Pharmaceuticals International Inc  and Turing Pharmaceuticals. Drugmakers' shares fell sharply in the past few weeks after Democratic presidential candidate Hillary Clinton criticized drug pricing on her campaign trail.Shares of both Merck and Lilly were down 1 percent in afternoon trading on the New York Stock Exchange.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey; Editing by Saumyadeb Chakrabarty)",2015-11-06,MRK,"Fri Nov 6, 2015 | 12:19pm EST","UPDATE 1-U.S. federal agencies investigate Merck, Lilly drug pricing",http://www.reuters.com//article/merck-co-pricing-idUSL3N1315R920151106?type=companyNews
410,"  Nov 6 Merck & Co is being investigated by the U.S. Attorney's Office in Pennsylvania over contracting and pricing of its asthma inhaler product, Dulera, the company said.Merck, in a regulatory filing late on Thursday, said it had received a civil investigative demand from the Attorney's Office and that it was cooperating with the investigation. (1.usa.gov/1kyPGgR) The news comes days after a bipartisan probe was launched into pharmaceutical pricing by companies including Valeant Pharmaceuticals International Inc  and Turing Pharmaceuticals. Concerns about drug pricing have loomed over drugmakers since last year, weighing on their stocks. Drugmakers' shares fell sharply in the past few weeks after Democratic presidential candidate Hillary Clinton criticized the price rises on her campaign trail.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey)",2015-11-06,MRK,"Fri Nov 6, 2015 | 11:56am EST",Merck & Co under Pennsylvania Attorney's Office probe over pricing,http://www.reuters.com//article/merck-co-pricing-idUSL3N1315PX20151106?type=companyNews
411,"   By Vidya L Nathan  Drugmakers Merck & Co and Eli Lilly & Co are being investigated by the U.S. Attorney's Office in Pennsylvania and other federal agencies over drug pricing practices, the companies disclosed.Merck, in a regulatory filing late on Thursday, said it had received a civil investigative demand from the attorney's office over the pricing of its asthma inhaler product, Dulera. (1.usa.gov/1kyPGgR)Merck said it was cooperating with the investigation. Eli Lilly & Co also disclosed in a regulatory filing last week that the Pennsylvania Attorney's Office and the U.S. Department of Justice were investigating the company's distribution deals with wholesalers. Lilly said the investigation was looking into the company's drug pricing in Medicaid rebate programs. The company said it was responding to the federal agencies. (1.usa.gov/1kfpZCg)Merck's disclosure comes days after a U.S. Senate panel launched a probe into drug pricing by companies including Valeant Pharmaceuticals International Inc and Turing Pharmaceuticals. Drugmakers' shares fell sharply in the past few weeks after Democratic presidential candidate Hillary Clinton criticized drug pricing on her campaign trail.Shares of both Merck and Lilly were down 1 percent in afternoon trading on the New York Stock Exchange.",2015-11-07,MRK,"Fri Nov 6, 2015 | 8:22pm EST","U.S. federal agencies investigate Merck, Lilly drug pricing",http://www.reuters.com//article/us-merck-co-pricing-idUSKCN0SV2C120151107?type=companyNews
412,"   By Rosmi Shaji  Drugmaker Merck & Co Inc said the U.S. Court of Appeals for the Federal Circuit invalidated four patents related to the antibiotic, Cubicin, that expire in 2019 and 2020.The drugmaker had sued Hospira, now a unit of Pfizer Inc , in March 2012, saying Hospira's application to sell a generic version of the antibiotic infringed five patents. Thursday's decision will keep a Cubicin generic out of the market only until June 2016. The court invalidated four of Merck's patents that would have protected the drug's market share up to 2020.New Jersey-based Merck said it would review the court's decision and consider steps including seeking a further review by the Federal Circuit or Supreme Court. Merck obtained rights to Cubicin through its $8.4-billion acquisition of Cubist Pharmaceuticals in December 2014. The antibiotic, which was approved by the U.S. Food and Drug Administration in 2003, generated sales of about $325 million in the quarter ended Sept 30.Merck's shares were little changed at $53.36 in afternoon trading on the New York Stock Exchange.",2015-11-12,MRK,"Thu Nov 12, 2015 | 1:13pm EST",U.S. appeals court invalidates four Merck Cubicin patents,http://www.reuters.com//article/merck-co-patent-idUSL1N1372A620151112?type=companyNews
413,"  NEW YORK Nov 12 A former Bank of New York Mellon Corp employee was sentenced on Thursday to six months in prison after admitting to illegally making $737,000 trading on tips a friend at Merck & Co Inc supplied him about potential pharmaceutical mergers. David Post, 42, was also ordered by U.S. District Judge Alvin Hellerstein in Manhattan to pay more than $787,600 in fines and forfeit proceeds in light of his guilty plea in October 2014 to charges including securities fraud.   (Reporting by Nate Raymond in New York; editing by Grant McCool)  ",2015-11-12,MRK,"Thu Nov 12, 2015 | 1:23pm EST",Ex-BNY Mellon employee sentenced to 6 months in U.S. prison,http://www.reuters.com//article/bony-mellon-insidertrading-idUSL1N1372AI20151112?type=companyNews
414,"  Nov 12 Drugmaker Merck & Co Inc said the U.S. Court of Appeals for the Federal Circuit invalidated four patents related to the antibiotic, Cubicin, that expire in 2019 and 2020.The drugmaker had sued Hospira, now a unit of Pfizer Inc , in March 2012, saying Hospira's application to sell a generic version of the antibiotic infringed five patents.Thursday's decision will keep a Cubicin generic out of the market only until June 2016. The court invalidated four of Merck's patents that would have protected the drug's market share up to 2020. New Jersey-based Merck said it would review the court's decision and consider steps including seeking a further review by the Federal Circuit or Supreme Court. Merck obtained rights to Cubicin through its $8.4-billion acquisition of Cubist Pharmaceuticals in December 2014. The antibiotic, which was approved by the U.S. Food and Drug Administration in 2003, generated sales of about $325 million in the quarter ended Sept 30.Merck's shares were little changed at $53.36 in afternoon trading on the New York Stock Exchange.    (Reporting by Rosmi Shaji in Bengaluru; Editing by Anil D'Silva)",2015-11-12,MRK,"Thu Nov 12, 2015 | 1:03pm EST",U.S. appeals court invalidates four Merck Cubicin patents,http://www.reuters.com//article/merck-co-patent-idUSL3N13759T20151112?type=companyNews
415,"   By Ludwig Burger and Ben Hirschler | FRANKFURT/LONDON  FRANKFURT/LONDON A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology.German and U.S. firms are leading the way in synthetic messenger RNA, or mRNA technology, a new approach to tackling a range of hard-to-treat diseases.In theory, the promise of mRNA is enormous, ranging from cancer to infectious diseases to heart and kidney disorders, since it could be used to tackle the 80 percent of proteins that are difficult to affect with existing medicines.Despite a recent sell-off in biotech stocks, sparked by U.S. Democratic Presidential candidate Hillary Clinton's threat to crack down on drug pricing, enthusiasm for mRNA, is rising.Four-year-old Moderna Therapeutics, based in Massachusetts, which raised a record-breaking $450 million in a private funding round in January, valuing it at $3 billion, has so far hogged the limelight but German companies are flexing their muscles.Privately-held CureVac in the university town of Tuebingen, which already has backing from Microsoft co-founder Bill Gates thanks to its vaccine work, last week raised $110 million from new investors, valuing it at $1.6 billion.And Mainz-based BioNTech clinched a deal possibly worth up to $1.5 billion with Sanofi to use mRNA to fight cancer. BioNTech is owned by the Struengmann family who sold generic drugmaker Hexal to Novartis in 2005. Driving the point home, the third International mRNA Health Conference is being held in Berlin this week. Moderna, CureVac and BioNTech are all sponsoring the event.Today's biotech medicines use complex proteins or antibodies to treat disease, while traditional tablets such as aspirin or Viagra are simple chemicals. Harnessing synthetic mRNA is a different model altogether. In effect, mRNA serves as software that can be injected into the body to instruct ribosomes, the ""3D-printers"" found inside cells, to churn out desired proteins.""This is a radically different approach from conventional approaches, where therapeutic proteins are produced outside the human body and active ingredients need to be isolated, purified and cooled and then be inserted back into the human body at great complexity and cost,"" said CureVac co-founder and CEO Ingmar Hoerr.LONG-TERM BET Single-stranded RNA, which helps to relay information encoded in double-helix DNA molecules, for a long time attracted only academic interest because it was seen as too unstable to handle.  But advances in chemistry have increased both stability and potency, paving the way to the creation of potential drugs, although big challenges remain to prove their clinical value.""It's still a long-term bet,"" said Andy Smith, chief investment officer at fund manager Mann Bioinvest. ""I don't think it is ready for prime time just yet."" Still, ever more big pharmaceutical companies are lining up to do deals with mRNA firms.Some of the most advanced work to date has been in vaccines, where CureVac is a leader with clinical trials in prostate cancer and rabies. Overall, the company has tested its products on more than 300 clinical trial participants and its relatively maturity means it could be the first mRNA player to go public.The company says it is getting ready for a possible initial public offering, but declines to say when. Moderna has yet to start clinical trials, although it has ambitious plans for parallel studies with multiple drug candidates, alongside partners including AstraZeneca, Merck & Co and Alexion.Marcus Schindler, vice president for cardiovascular and metabolic drug discovery at AstraZeneca, is particularly excited about the promise of mRNA in producing a radical new treatment for heart failure, by regenerating cardiac tissue.AstraZeneca plans to start testing mRNA as an agent to improve coronary blood flow in human trials in 2016. This  follows promising data in animals that suggests synthetic mRNA can be delivered accurately and produce the right amount of protein.""The field is moving very rapidly,"" Schindler said. ""I predict it will have a significant impact."" As a chemically synthesized product, Schindler believes mRNA should be cheaper to make than current costly antibody drugs.But potential obstacles remain in the form of optimizing drug delivery and possible side effects, while the history of biotech advances suggests some unforeseen setbacks are likely as the technology moves into large clinical trials.  Other companies working in the mRNA area include Argos Therapeutics, eTheRNA, Ethris and Factor Bioscience. (editing by David Stamp)",2015-11-12,MRK,"Thu Nov 12, 2015 | 5:40am EST","Germany, U.S. in hot pursuit of 'messenger' drug molecules",http://www.reuters.com//article/us-health-biotech-messenger-molecule-idUSKCN0T114420151112?type=companyNews
416,"  * Messenger RNA attracts hundreds of millions of dollars* Potential for technology highlighted at Berlin conferenceBy Ludwig Burger and Ben HirschlerFRANKFURT/LONDON, Nov 12 A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology.German and U.S. firms are leading the way in synthetic messenger RNA, or mRNA technology, a new approach to tackling a range of hard-to-treat diseases.In theory, the promise of mRNA is enormous, ranging from cancer to infectious diseases to heart and kidney disorders, since it could be used to tackle the 80 percent of proteins that are difficult to affect with existing medicines.Despite a recent sell-off in biotech stocks, sparked by U.S. Democratic Presidential candidate Hillary Clinton's threat to crack down on drug pricing, enthusiasm for mRNA, is rising.Four-year-old Moderna Therapeutics, based in Massachusetts, which raised a record-breaking $450 million in a private funding round in January, valuing it at $3 billion, has so far hogged the limelight but German companies are flexing their muscles.Privately-held CureVac in the university town of Tuebingen, which already has backing from Microsoft co-founder Bill Gates thanks to its vaccine work, last week raised $110 million from new investors, valuing it at $1.6 billion.And Mainz-based BioNTech clinched a deal possibly worth up to $1.5 billion with Sanofi to use mRNA to fight cancer. BioNTech is owned by the Struengmann family who sold generic drugmaker Hexal to Novartis in 2005. Driving the point home, the third International mRNA Health Conference is being held in Berlin this week. Moderna, CureVac and BioNTech are all sponsoring the event.Today's biotech medicines use complex proteins or antibodies to treat disease, while traditional tablets such as aspirin or Viagra are simple chemicals. Harnessing synthetic mRNA is a different model altogether.In effect, mRNA serves as software that can be injected into the body to instruct ribosomes, the ""3D-printers"" found inside cells, to churn out desired proteins.""This is a radically different approach from conventional approaches, where therapeutic proteins are produced outside the human body and active ingredients need to be isolated, purified and cooled and then be inserted back into the human body at great complexity and cost,"" said CureVac co-founder and CEO Ingmar Hoerr. LONG-TERM BET Single-stranded RNA, which helps to relay information encoded in double-helix DNA molecules, for a long time attracted only academic interest because it was seen as too unstable to handle.But advances in chemistry have increased both stability and potency, paving the way to the creation of potential drugs, although big challenges remain to prove their clinical value.""It's still a long-term bet,"" said Andy Smith, chief investment officer at fund manager Mann Bioinvest. ""I don't think it is ready for prime time just yet."" Still, ever more big pharmaceutical companies are lining up to do deals with mRNA firms.Some of the most advanced work to date has been in vaccines, where CureVac is a leader with clinical trials in prostate cancer and rabies. Overall, the company has tested its products on more than 300 clinical trial participants and its relatively maturity means it could be the first mRNA player to go public.The company says it is getting ready for a possible initial public offering, but declines to say when.Moderna has yet to start clinical trials, although it has ambitious plans for parallel studies with multiple drug candidates, alongside partners including AstraZeneca, Merck & Co and Alexion.Marcus Schindler, vice president for cardiovascular and metabolic drug discovery at AstraZeneca, is particularly excited about the promise of mRNA in producing a radical new treatment for heart failure, by regenerating cardiac tissue.AstraZeneca plans to start testing mRNA as an agent to improve coronary blood flow in human trials in 2016. This  follows promising data in animals that suggests synthetic mRNA can be delivered accurately and produce the right amount of protein.""The field is moving very rapidly,"" Schindler said. ""I predict it will have a significant impact."" As a chemically synthesised product, Schindler believes mRNA should be cheaper to make than current costly antibody drugs.But potential obstacles remain in the form of optimising drug delivery and possible side effects, while the history of biotech advances suggests some unforeseen setbacks are likely as the technology moves into large clinical trials.Other companies working in the mRNA area include Argos Therapeutics, eTheRNA, Ethris and Factor Bioscience.  ($1 = 0.9325 euros)   (editing by David Stamp)",2015-11-12,MRK,"Thu Nov 12, 2015 | 5:33am EST","Germany, U.S. in hot pursuit of ""messenger"" drug molecules",http://www.reuters.com//article/health-biotech-messenger-molecule-idUSL8N13646A20151112?type=companyNews
417,"  (Adds Skyway Concession, Perrigo, Blackstone Group, BHF Kleinwort Benson, Dixy Group)Nov 13 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:** Three of Canada's largest pension fund managers said they would acquire the operator of the Chicago Skyway toll road for $2.8 billion.The Canada Pension Plan Investment Board, Ontario Municipal Employees Retirement System and Ontario Teachers' Pension Plan will each own a one-third interest in Skyway Concession Co LLC, which has an agreement to operate the road until 2104.** Perrigo Co Plc's shareholders rejected Mylan NV's $26 billion hostile bid, ending the Netherlands-based generic drug maker's seven-month pursuit of its smaller rival.** U.S. asset manager Blackstone Group LP said it was acquiring Japan Residential Investment Company, which owns residential assets in Japan, in a deal worth about $450 million, including debt.Blackstone is also seeking a buyer for its Meerwind Sued/Ost offshore wind park in Germany, hoping to benefit from a surge in deal activity in the sector, three people familiar with the matter told Reuters. ** The European Central Bank is set to decide soon on who can bid for BHF Kleinwort Benson in a deal seen as a test case its attitude towards a bigger role for Chinese financial investors, people familiar with the matter told Reuters.** Russia's competition watchdog FAS has blocked food retailer Dixy Group's bid to buy a controlling stake in tobacco and spirits chain Bristol.** OakNorth Bank, a British lender to small businesses and entrepreneurs, said Mumbai-based Indiabulls Group had bought a 40 percent stake in the company for 66 million pounds ($100 million), boosting its capital base to over 85 million pounds. ** Syngenta AG, the world's largest agrichemicals company, has rejected a $42 billion takeover offer by state-owned China National Chemical Corp, Bloomberg reported on Thursday.** France has offered to limit its voting rights at Renault  in a bid to end its power struggle with the carmaker and partner Nissan, but their combined CEO Carlos Ghosn remains determined to push through changes that would give the Japanese company more say over the alliance, sources said.** Private equity firm TowerBrook Capital Partners LP, which acquired U.S. women's apparel retailer J.Jill Group six months ago, is considering an exit through a potential initial public offering of the company, Bloomberg reported. ** Garuda Indonesia will decide whether to buy 30 wide-body jets worth potentially $9 billion from either Airbus  or arch-rival Boeing by end-2015, the airline's chief executive said in an interview on Friday.** Dish Network Corp said the proposed merger of Charter Communications and Time Warner Cable Inc  was not in the public interest, in a reply filed with the Federal Communications Commission.** Sumitomo Mitsui Financial Group (SMFG) has decided to buy General Electric Co's Japan-based leasing business for 500 billion to 600 billion yen ($4.89 billion), the Nikkei business daily reported on Friday.** Manulife Financial Corp, Canada's biggest insurer, is interested in a range of insurance and asset management acquisition opportunities across several markets in Asia, a top executive said on Thursday.** Britain's 'bad bank', which is running down the loans of two bailed out lenders, said it had agreed to sell a 13 billion pound ($19.78 billion) asset portfolio to affiliates of Cerberus Capital Management LP.** Poland's Alior Bank, controlled by Eastern Europe's largest insurer PZU, plans to take over the local units of HSBC, RBS, DZ Bank, and SK Bank Wolomin, the daily Rzeczpospolita reported on Friday.** Warsaw-listed commercial real estate developer GTC  is in exclusive talks to buy two income generating properties in Poland and Hungary, as it looks around Eastern Europe to return to a growth path, it said on Friday.** Telecom Italia Chief Executive Marco Patuano said he met last week with French entrepreneur Xavier Niel, who has been building a stake in the group, and that they discussed ""industrial strategy"" and the potential of the Italian market.     (Compiled by Rachel Chitra and Kshitiz Goliya in Bengaluru)",2015-11-13,MRK,"Fri Nov 13, 2015 | 4:13pm EST",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N1383VO20151113?type=companyNews
418,"  Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib.The recommendation comes a month after Eli Lilly & Co stopped testing a similar cholesterol drug, belonging to a class of drugs called CETP inhibitors.Merck said on Friday that the committee reviewed safety and efficacy data from the large study, including a futility analysis.A futility analysis is done to gauge if a study is likely to succeed or fail. Merck is now the only major drugmaker still aggressively developing a CETP inhibitor - drugs aimed at raising HDL, or ""good cholesterol"" levels in the blood and cutting levels of LDL, or ""bad cholesterol"".Lilly stopped testing the drug for cholesterol due to low likelihood of it meeting the main goal of the study.  In 2006, Pfizer Inc also scrapped a study on a similar drug, after the treatment was linked to higher death rates. Merck's shares were little changed at $53 in premarket trading on Friday. (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey)",2015-11-13,MRK,"Fri Nov 13, 2015 | 8:35am EST",Panel recommends Merck & Co continue cholesterol drug study,http://www.reuters.com//article/us-merck-co-study-idUSKCN0T21J020151113?type=companyNews
419,"  (Adds details, background, shares)Nov 13 Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib.The recommendation comes a month after Eli Lilly & Co  stopped testing a similar cholesterol drug, belonging to a class of drugs called CETP inhibitors.Merck said on Friday that the committee reviewed safety and efficacy data from the large study, including a futility analysis. A futility analysis is done to gauge if a study is likely to succeed or fail. Merck is now the only major drugmaker still aggressively developing a CETP inhibitor - drugs aimed at raising HDL, or ""good cholesterol"" levels in the blood and cutting levels of LDL, or ""bad cholesterol"".Lilly stopped testing the drug for cholesterol due to low likelihood of it meeting the main goal of the study. In 2006, Pfizer Inc also scrapped a study on a similar drug, after the treatment was linked to higher death rates.Merck's shares were little changed at $53 in premarket trading on Friday.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey)",2015-11-13,MRK,"Fri Nov 13, 2015 | 8:34am EST",UPDATE 1-Panel recommends Merck & Co continue cholesterol drug study,http://www.reuters.com//article/merck-co-study-idUSL3N1384HP20151113?type=companyNews
420,"  Nov 13 Merck & Co said an independent data monitoring committee recommended that the company continue a study of its experimental cholesterol drug, anacetrapib. The company said on Friday that the committee reviewed safety and efficacy data from the large study, including a futility analysis.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey)  ",2015-11-13,MRK,"Fri Nov 13, 2015 | 8:12am EST",Panel recommends Merck continue cholesterol drug study,http://www.reuters.com//article/merck-co-study-idUSL3N1384GI20151113?type=companyNews
421,"   By P.J. Huffstutter | CHICAGO  CHICAGO Merck & Co Inc's animal health unit will buy privately held Harrisvaccines Inc to expand its portfolio of animal vaccines as the U.S. livestock industry seeks new defenses against diseases, the companies said on Thursday.Financial details were not disclosed.The deal, which is expected to close by year-end, follows rival Zoetis Inc's agreement, announced on Nov. 2, to buy Pharmaq, a market leader in vaccines for farmed fish, for $765 million.Harrisvaccines, based in Ames, Iowa, is best known for developing a vaccine called ""iPED"" in 2013 to fight Porcine Epidemic Diarrhea virus, or PEDv. It was one of the first U.S. companies to develop a vaccine to fight the disease, which wiped out an estimated 10 percent of the U.S. pig population over two years. It also received the first conditional license from the U.S. Department of Agriculture (USDA) to sell its vaccine to veterinarians and swine farmers.Merck Animal Health's project to develop a PEDv vaccine is ongoing, the company said on Thursday. Zoetis also has been granted a conditional license from the USDA to sell its PEDv vaccine. In October, Harrisvaccines was one of two drug firms to be awarded a USDA contract to manufacture doses of avian influenza vaccine for poultry, in preparation for the potential return of the fast-spreading virus later this year.  (Reporting by P.J. Huffstutter in Chicago; Editing by Richard Chang)",2015-11-13,MRK,"Thu Nov 12, 2015 | 7:55pm EST",Merck to buy Harrisvaccines to boost livestock vaccine portfolio,http://www.reuters.com//article/us-harrisvaccines-m-a-merck-co-idUSKCN0T202O20151113?type=companyNews
422,"   By P.J. Huffstutter | CHICAGO  CHICAGO Nov 12 Merck & Co Inc's animal health unit will buy privately held Harrisvaccines Inc to expand its portfolio of animal vaccines as the U.S. livestock industry seeks new defenses against diseases, the companies said on Thursday.Financial details were not disclosed.The deal, which is expected to close by year-end, follows rival Zoetis Inc's agreement, announced on Nov. 2, to buy Pharmaq, a market leader in vaccines for farmed fish, for $765 million. Harrisvaccines, based in Ames, Iowa, is best known for developing a vaccine called ""iPED"" in 2013 to fight Porcine Epidemic Diarrhea virus, or PEDv.It was one of the first U.S. companies to develop a vaccine to fight the disease, which wiped out an estimated 10 percent of the U.S. pig population over two years. It also received the first conditional license from the U.S. Department of Agriculture (USDA) to sell its vaccine to veterinarians and swine farmers. Merck Animal Health's project to develop a PEDv vaccine is ongoing, the company said on Thursday. Zoetis also has been granted a conditional license from the USDA to sell its PEDv vaccine.In October, Harrisvaccines was one of two drug firms to be awarded a USDA contract to manufacture doses of avian influenza vaccine for poultry, in preparation for the potential return of the fast-spreading virus later this year.(Reporting by P.J. Huffstutter in Chicago; Editing by Richard Chang)",2015-11-13,MRK,"Thu Nov 12, 2015 | 7:46pm EST",Merck to buy Harrisvaccines to boost livestock vaccine portfolio,http://www.reuters.com//article/harrisvaccines-ma-merck-co-idUSL1N1373UE20151113?type=companyNews
423,  Dec 14 (Reuters) -* Merck says acquires ormet circuits * Merck says acquisition to enhance position as semiconductor materials supplier  * Merck says deal complements existing integrated circuit materials business unit  Further company coverage:    (Frankfurt newsroom),2015-12-14,MRK,"Mon Dec 14, 2015 | 4:09am EST","BRIEF-Merck says acquires Ormet Circuits, no purchase price disclosed",http://www.reuters.com//article/idUSFWN14005920151214?type=companyNews
424,"  Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.The Food and Drug Administration said on Tuesday it approved the drug, Bridion, to reverse the effects of deep paralysis caused by rocuronium and vecuronium, muscle relaxants used at the beginning of surgery to help doctors insert a breathing tube.Analysts expect the drug, known generically as sugammadex, to generate annual sales of $557 million by 2020 according to Thomson Reuters data.Bridion's path to approval has been rocky. The product was originally developed by Organon BioSciences, which was acquired by Schering-Plough in 2007. Merck acquired the drug when it bought Schering-Plough in 2009. In 2008 the FDA declined to approve it, citing concerns about potential allergic reactions and bleeding. A 2013 advisory to discuss the drug was abruptly canceled after the agency said it needed more time to review the company's revised application. In a statement announcing its approval, the FDA warned that clinicians ""should be aware of the possibility of a hypersensitivity reaction or anaphylaxis and should intervene as appropriate.""The agency also noted that cases of abnormally slow heart action, in some cases resulting in cardiac arrest, have been reported within minutes of administration of the drug and that patients should be closely monitored.  (Reporting by Toni Clarke in Washington; Editing by James Dalgleish)",2015-12-15,MRK,"Tue Dec 15, 2015 | 4:04pm EST",FDA approves Merck drug to reverse effects of muscle relaxants,http://www.reuters.com//article/us-merck-co-fda-bridion-idUSKBN0TY2TK20151215?type=companyNews
425,"  Dec 15 Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.The Food and Drug Administration said on Tuesday it approved the drug, Bridion, to reverse the effects of deep paralysis caused by rocuronium and vecuronium, muscle relaxants used at the beginning of surgery to help doctors insert a breathing tube.Analysts expect the drug, known generically as sugammadex, to generate annual sales of $557 million by 2020 according to Thomson Reuters data. Bridion's path to approval has been rocky. The product was originally developed by Organon BioSciences, which was acquired by Schering-Plough in 2007. Merck acquired the drug when it bought Schering-Plough in 2009. In 2008 the FDA declined to approve it, citing concerns about potential allergic reactions and bleeding. A 2013 advisory to discuss the drug was abruptly canceled after the agency said it needed more time to review the company's revised application. In a statement announcing its approval, the FDA warned that clinicians ""should be aware of the possibility of a hypersensitivity reaction or anaphylaxis and should intervene as appropriate.""The agency also noted that cases of abnormally slow heart action, in some cases resulting in cardiac arrest, have been reported within minutes of administration of the drug and that patients should be closely monitored.   (Reporting by Toni Clarke in Washington; Editing by James Dalgleish)",2015-12-15,MRK,"Tue Dec 15, 2015 | 4:01pm EST",FDA approves Merck drug to reverse effects of muscle relaxants,http://www.reuters.com//article/merck-co-fda-bridion-idUSL1N1442FA20151215?type=companyNews
426,"  Merck & Co Inc.'s drug to reverse the effects of muscle relaxants used during surgery has won U.S. approval.The Food and Drug Administration said on Tuesday it approved the drug, Bridion, to reverse the effects of deep paralysis caused by rocuronium and vecuronium, muscle relaxants used at the beginning of surgery to help doctors insert a breathing tube.Analysts expect the drug, known generically as sugammadex, to generate annual sales of $557 million by 2020 according to Thomson Reuters data.Bridion's path to approval has been rocky. The product was originally developed by Organon BioSciences, which was acquired by Schering-Plough in 2007. Merck acquired the drug when it bought Schering-Plough in 2009. In 2008 the FDA declined to approve it, citing concerns about potential allergic reactions and bleeding. A 2013 advisory to discuss the drug was abruptly canceled after the agency said it needed more time to review the company's revised application. In a statement announcing its approval, the FDA warned that clinicians ""should be aware of the possibility of a hypersensitivity reaction or anaphylaxis and should intervene as appropriate.""The agency also noted that cases of abnormally slow heart action, in some cases resulting in cardiac arrest, have been reported within minutes of administration of the drug and that patients should be closely monitored.  (Reporting by Toni Clarke in Washington; Editing by James Dalgleish)",2015-12-16,MRK,"Tue Dec 15, 2015 | 9:25pm EST",FDA approves Merck drug to reverse effects of muscle relaxants,http://www.reuters.com//article/us-merck-co-fda-bridion-idUSKBN0TY2TK20151216?type=companyNews
427,  Jan 7 Biocartis Group NV : * Biocartis and Merck to collaborate on new liquid biopsy technology for ras biomarker testing  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)  ,2016-01-07,MRK,"Thu Jan 7, 2016 | 2:09am EST",BRIEF-Biocartis Group announces collaboration with Merck,http://www.reuters.com//article/idUSFWN14P02R20160107?type=companyNews
428,"  JERUSALEM Israeli biopharmaceutical company BioLineRX Ltd said on Tuesday it would collaborate with U.S. industry heavyweight Merck to test a combination of drugs for the treatment of pancreatic cancer.The companies will partner in a mid-stage study to evaluate the safety and efficacy of the combination of BioLineRx's BL-8040 and Merck's Keytruda in patients with metastatic pancreatic adenocarcinoma.""Because certain tumors exhibit only a modest response to existing immunotherapies, we are increasingly seeing clinical studies involving combinations of immuno-oncology agents with other classes of drugs,"" said Kinneret Savitsky, BioLineRx's chief executive.BL-8040 acts against CXCR4 receptors that are involved in tumor progression, the company said. It has been shown in several clinical trials to mobilize immune cells and to be effective at inducing direct tumor cell death. Keytruda, an antibody, works by increasing the ability of the body's immune system to help detect and fight tumor cells, said Merck, which is known as MSD outside the United States and Canada. Pancreatic adenocarcinoma accounts for most cases of pancreatic cancer, according to the American Cancer Society.  Specific symptoms often do not develop until the disease has reached an advanced stage, which is reflected in a low five-year survival rate.The study is due to start by mid-2016 and both companies will have the option to expand the collaboration to include a pivotal registration study, BioLineRX said.  (Reporting by Ari Rabinovitch; editing by David Clarke)",2016-01-12,MRK,"Tue Jan 12, 2016 | 8:36am EST","Merck, BioLineRX to study drug combo to fight pancreatic cancer",http://www.reuters.com//article/us-bioline-rx-merck-co-idUSKCN0UQ1ND20160112?type=companyNews
429,"  JERUSALEM Jan 12 Israeli biopharmaceutical company BioLineRX Ltd said on Tuesday it would collaborate with U.S. industry heavyweight Merck to test a combination of drugs for the treatment of pancreatic cancer.The companies will partner in a mid-stage study to evaluate the safety and efficacy of the combination of BioLineRx's BL-8040 and Merck's Keytruda in patients with metastatic pancreatic adenocarcinoma.""Because certain tumors exhibit only a modest response to existing immunotherapies, we are increasingly seeing clinical studies involving combinations of immuno-oncology agents with other classes of drugs,"" said Kinneret Savitsky, BioLineRx's  chief executive. BL-8040 acts against CXCR4 receptors that are involved in tumor progression, the company said. It has been shown in several clinical trials to mobilise immune cells and to be effective at inducing direct tumor cell death. Keytruda, an antibody, works by increasing the ability of the body's immune system to help detect and fight tumor cells, said Merck, which is known as MSD outside the United States and Canada. Pancreatic adenocarcinoma accounts for most cases of pancreatic cancer, according to the American Cancer Society.  Specific symptoms often do not develop until the disease has reached an advanced stage, which is reflected in a low five-year survival rate.The study is due to start by mid-2016 and both companies will have the option to expand the collaboration to include a pivotal registration study, BioLineRX said.   (Reporting by Ari Rabinovitch; editing by David Clarke)",2016-01-12,MRK,"Tue Jan 12, 2016 | 8:18am EST","Merck, BioLineRX to study drug combo to fight pancreatic cancer",http://www.reuters.com//article/bioline-rx-merck-co-idUSL8N14W30O20160112?type=companyNews
430,"  FRANKFURT Germany's Merck KGaA said it won a British court's backing in its quest to keep U.S. namesake drugmaker Merck & Co Inc from doing business under the Merck name outside North America, part of an increasingly bitter legal feud.Merck KGaA of Germany, maker of multiple sclerosis drug Rebif and liquid crystals for display screens, and Merck & Co, which is about 2.5 times as big by sales, share historic roots but have been under separate ownership since World War One.The companies struck an agreement in 1955 and amended it in 1970, giving Merck & Co. the rights to the Merck name in the United States and Canada and handing the rights everywhere else in the world to Merck KGaA. Under the deal, Merck & Co agreed to call itself MSD, or Merck Sharp & Dohme, outside North America, with Merck KGaA  operating as EMD, short for Emanuel Merck, Darmstadt, in North America.""In its judgment the English High Court stated that MSD had breached an agreement with the company by using 'Merck' alone in the UK either as a trade mark or a name, online or offline,"" the German group said in a statement on Friday. The emergence of the Internet and global electronic media that can be viewed across continents has exposed gaping holes in the decades-old agreement.In the British lawsuit, Germany's Merck objected to Merck & Co's use of domaine names such as merckresponsibility.com merckformothers.com in Britain and to Merck & Co's Britain-based staff using a merck.com email address, among other practices.A Merck & Co spokeswoman said in an emailed statement the company disagreed with the ruling: ""This decision reflects one step in a litigation process taking place in a number of countries, and will be appealed."" She said a French court recently ruled that the U.S. group's use of Merck in employee email addresses and the title Merck Manual did not infringe Merck KGaA's rights, whereas certain uses of Merck on French websites were found to be an infringement.Merck & Co, in turn, would fight Merck KGaA in a U.S. court ""regarding their improper use of the name 'Merck' in the United States,"" the email continued. In a sign of defiance and growing frustration over what it sees as unfair use of the Merck name outside North America, the family-controlled German group, which traces its roots to a 17th century pharmacy, has started using the claim ""Merck  The Original"".($1 = 0.9123 euros) (Reporting by Ludwig Burger; Editing by Elaine Hardcastle)",2016-01-15,MRK,"Fri Jan 15, 2016 | 12:15pm EST",Fight over Merck name sees German firm win in British court,http://www.reuters.com//article/us-merckkgaa-name-idUSKCN0UT239?type=companyNews
431,"  FRANKFURT Germany's Merck KGaA said it won a British court's backing in its quest to keep U.S. namesake drugmaker Merck & Co Inc from doing business under the Merck name outside North America, part of an increasingly bitter legal feud.Merck KGaA of Germany, maker of multiple sclerosis drug Rebif and liquid crystals for display screens, and Merck & Co, which is about 2.5 times as big by sales, share historic roots but have been under separate ownership since World War One.The companies struck an agreement in 1955 and amended it in 1970, giving Merck & Co. the rights to the Merck name in the United States and Canada and handing the rights everywhere else in the world to Merck KGaA. Under the deal, Merck & Co agreed to call itself MSD, or Merck Sharp & Dohme, outside North America, with Merck KGaA  operating as EMD, short for Emanuel Merck, Darmstadt, in North America.""In its judgment the English High Court stated that MSD had breached an agreement with the company by using 'Merck' alone in the UK either as a trade mark or a name, online or offline,"" the German group said in a statement on Friday. The emergence of the Internet and global electronic media that can be viewed across continents has exposed gaping holes in the decades-old agreement.In the British lawsuit, Germany's Merck objected to Merck & Co's use of domaine names such as merckresponsibility.com merckformothers.com in Britain and to Merck & Co's Britain-based staff using a merck.com email address, among other practices.A Merck & Co spokeswoman said in an emailed statement the company disagreed with the ruling: ""This decision reflects one step in a litigation process taking place in a number of countries, and will be appealed."" She said a French court recently ruled that the U.S. group's use of Merck in employee email addresses and the title Merck Manual did not infringe Merck KGaA's rights, whereas certain uses of Merck on French websites were found to be an infringement.Merck & Co, in turn, would fight Merck KGaA in a U.S. court ""regarding their improper use of the name 'Merck' in the United States,"" the email continued. In a sign of defiance and growing frustration over what it sees as unfair use of the Merck name outside North America, the family-controlled German group, which traces its roots to a 17th century pharmacy, has started using the claim ""Merck  The Original"".($1 = 0.9123 euros) (Reporting by Ludwig Burger; Editing by Elaine Hardcastle)",2016-01-15,MRK,"Fri Jan 15, 2016 | 12:15pm EST",Fight over Merck name sees German firm win in British court,http://www.reuters.com//article/merckkgaa-name-idUSL8N14Z3KJ?type=companyNews
432,"   By Ransdell Pierson  U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.The drug was approved by U.S. regulators in 1999 as a new type of treatment for pain and quickly became a blockbuster product, ultimately used by an estimated 20 million Americans.  But the company in 2004 recalled Vioxx from the market after a colon-polyp prevention study showed it more than doubled the risk of heart attacks or stroke after 18 months of use.After thousands of former users of Vioxx sued Merck, claiming they had been harmed by the drug, Merck in 2008 settled most remaining product-liability lawsuits for $4.85 billion. But other litigation continued, including a multi-district class action lawsuit pending against Merck in New Jersey federal court, which alleged Merck kept investors in the dark about negative data from earlier company-sponsored trials of the medicine. Merck on Friday said it had agreed to settle that lawsuit by paying $830 million to investors who bought Merck stock between May 21, 1999 and October 29, 2004, plus pay an additional amount for attorneys' fees.The company's cash payment for the settlement and fees will be about $680 million, after reimbursement from insurance policies, Merck said, and the company will record a charge for that amount in the fourth quarter of 2015. Merck, in a statement, said the settlement did not constitute any admission of liability or wrongdoing by the drugmaker.The company said it still faces other individual securities lawsuits related to Vioxx.",2016-01-15,MRK,"Fri Jan 15, 2016 | 10:05am EST",Merck agrees to pay $830 mln to settle Vioxx securities lawsuit,http://www.reuters.com//article/merck-vioxx-settlement-idUSL2N14Z1F6?type=companyNews
433,"  U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.The drug was approved by U.S. regulators in 1999 as a new type of treatment for pain and quickly became a blockbuster product, ultimately used by an estimated 20 million Americans.  But the company in 2004 recalled Vioxx from the market after a colon-polyp prevention study showed it more than doubled the risk of heart attacks or stroke after 18 months of use.After thousands of former users of Vioxx sued Merck, claiming they had been harmed by the drug, Merck in 2008 settled most remaining product-liability lawsuits for $4.85 billion.But other litigation continued, including a multi-district class action lawsuit pending against Merck in New Jersey federal court, which alleged Merck kept investors in the dark about negative data from earlier company-sponsored trials of the medicine. Merck on Friday said it had agreed to settle that lawsuit by paying $830 million to investors who bought Merck stock between May 21, 1999 and October 29, 2004, plus pay an additional amount for attorneys' fees.The company's cash payment for the settlement and fees will be about $680 million, after reimbursement from insurance policies, Merck said, and the company will record a charge for that amount in the fourth quarter of 2015. Merck, in a statement, said the settlement did not constitute any admission of liability or wrongdoing by the drugmaker. The company said it still faces other individual securities lawsuits related to Vioxx. (Reporting by Ransdell Pierson; Editing by Nick Zieminski)",2016-01-15,MRK,"Fri Jan 15, 2016 | 9:38am EST",Merck agrees to pay $830 million to settle Vioxx securities lawsuit,http://www.reuters.com//article/us-merck-vioxx-settlement-idUSKCN0UT1PX?type=companyNews
434,"  U.S. drugmaker Merck & Co on Friday said it would pay $830 million to settle a federal class action lawsuit involving allegations the company failed to adequately inform investors about heart risks from its now-recalled Vioxx pain medication.The drug was approved by U.S. regulators in 1999 as a new type of treatment for pain and quickly became a blockbuster product, ultimately used by an estimated 20 million Americans.  But the company in 2004 recalled Vioxx from the market after a colon-polyp prevention study showed it more than doubled the risk of heart attacks or stroke after 18 months of use.After thousands of former users of Vioxx sued Merck, claiming they had been harmed by the drug, Merck in 2008 settled most remaining product-liability lawsuits for $4.85 billion.But other litigation continued, including a multi-district class action lawsuit pending against Merck in New Jersey federal court, which alleged Merck kept investors in the dark about negative data from earlier company-sponsored trials of the medicine. Merck on Friday said it had agreed to settle that lawsuit by paying $830 million to investors who bought Merck stock between May 21, 1999 and October 29, 2004, plus pay an additional amount for attorneys' fees.The company's cash payment for the settlement and fees will be about $680 million, after reimbursement from insurance policies, Merck said, and the company will record a charge for that amount in the fourth quarter of 2015. Merck, in a statement, said the settlement did not constitute any admission of liability or wrongdoing by the drugmaker. The company said it still faces other individual securities lawsuits related to Vioxx. (Reporting by Ransdell Pierson; Editing by Nick Zieminski)",2016-01-15,MRK,"Fri Jan 15, 2016 | 9:38am EST",Merck agrees to pay $830 mln to settle Vioxx securities lawsuit,http://www.reuters.com//article/merck-vioxx-settlement-idUSL2N14Z13C?type=companyNews
435,"   By Ben Hirschler and Kate Kelland | DAVOS/LONDON  DAVOS/LONDON The Gavi global alliance for vaccines and immunization group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus.Gavi said the agreement would help the U.S. drugmaker take the experimental Ebola vaccine through late-stage clinical trials to licensing and then through pre-qualification by the World Health Organization (WHO).If approved, Merck's so-called VSV-ZEBOV live attenuated Ebola Zaire vaccine would become one of the world's first licensed Ebola shots and Gavi would be able to start buying it to create a stockpile for future outbreaks, it said in a statement issued at the World Economic Forum in Davos.A vast epidemic of Ebola which swept through three countries in West Africa last year killed more than 11,300 people and infected more than 28,600. ""The suffering caused by the Ebola crisis was a wake-up call to many in the global health community,"" said Gavi's chief executive Seth Berkley.""New threats require smart solutions and our innovative financing agreement with Merck will ensure that we are ahead of the curve for future Ebola outbreaks.""The deal was agreed on the understanding that the vaccine will be submitted for a license by the end of 2017. Speaking to Reuters in Davos, Berkley said the advance commitment should give a positive signal to drugmakers developing products that may not have an immediate market""It's critical that we give confidence to companies that when they make this type of effort, there is somebody to buy it,"" he said.As part of the agreement, Merck will ensure that 300,000 doses of the vaccine are available from May 2016 to be used in expanded use clinical trials as well as for emergency use as needed while development work on the shot continues. Until the West Africa Ebola epidemic, which swiftly became the largest in history, previous outbreaks of the disease have infected far smaller numbers, usually fewer than 1,000 people. Initial results from a clinical trial in Guinea of the vaccine, which tested it on some 4,000 people who had been in close contact with a confirmed Ebola case, showed complete protection after 10 days.Merck says it has already submitted an application through WHO's Emergency Use Assessment and Listing (EUAL) procedure which, if approved, would allow for the vaccine to be used if there is another Ebola emergency before it is licensed.Jeremy Farrar, director of Britain's Wellcome Trust global health charity which co-funded clinical trials of the Merck shot, said the ""remarkable results"" from those trials, as well as promising progress of other vaccine candidates, were ""among the few positive outcomes to emerge from the epidemic"". The WHO announced last week that no new Ebola cases had been reported in the three worst affected countries of Guinea, Liberia and Sierra Leone in the preceding 42 days. Yet shortly after the WHO announcement - which included a warning that sporadic flare-ups could occur - Sierra Leone reported an Ebola-related death.Farrar said such instances show how an Ebola vaccine could yet be useful in this outbreak, even in its final stages.""As we saw with the new confirmed case just last week, the Ebola epidemic is likely to have a long tail and it's possible that several more isolated cases will emerge in the coming weeks and months,"" he said in a statement.""This vaccine...could still play an important role in containing any additional flare ups of this outbreak, as well as being available to help prevent future epidemics."" (Editing by Greg Mahlich)",2016-01-20,MRK,"Wed Jan 20, 2016 | 5:48am EST",Vaccines alliance signs $5 million advance deal for Merck's Ebola shot,http://www.reuters.com//article/us-health-ebola-vaccine-idUSKCN0UY0OT?type=companyNews
436,"   By Ben Hirschler and Kate Kelland | DAVOS/LONDON  DAVOS/LONDON The Gavi global alliance for vaccines and immunization group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus.Gavi said the agreement would help the U.S. drugmaker take the experimental Ebola vaccine through late-stage clinical trials to licensing and then through pre-qualification by the World Health Organization (WHO).If approved, Merck's so-called VSV-ZEBOV live attenuated Ebola Zaire vaccine would become one of the world's first licensed Ebola shots and Gavi would be able to start buying it to create a stockpile for future outbreaks, it said in a statement issued at the World Economic Forum in Davos.A vast epidemic of Ebola which swept through three countries in West Africa last year killed more than 11,300 people and infected more than 28,600. ""The suffering caused by the Ebola crisis was a wake-up call to many in the global health community,"" said Gavi's chief executive Seth Berkley.""New threats require smart solutions and our innovative financing agreement with Merck will ensure that we are ahead of the curve for future Ebola outbreaks.""The deal was agreed on the understanding that the vaccine will be submitted for a license by the end of 2017. Speaking to Reuters in Davos, Berkley said the advance commitment should give a positive signal to drugmakers developing products that may not have an immediate market""It's critical that we give confidence to companies that when they make this type of effort, there is somebody to buy it,"" he said.As part of the agreement, Merck will ensure that 300,000 doses of the vaccine are available from May 2016 to be used in expanded use clinical trials as well as for emergency use as needed while development work on the shot continues. Until the West Africa Ebola epidemic, which swiftly became the largest in history, previous outbreaks of the disease have infected far smaller numbers, usually fewer than 1,000 people. Initial results from a clinical trial in Guinea of the vaccine, which tested it on some 4,000 people who had been in close contact with a confirmed Ebola case, showed complete protection after 10 days.Merck says it has already submitted an application through WHO's Emergency Use Assessment and Listing (EUAL) procedure which, if approved, would allow for the vaccine to be used if there is another Ebola emergency before it is licensed.Jeremy Farrar, director of Britain's Wellcome Trust global health charity which co-funded clinical trials of the Merck shot, said the ""remarkable results"" from those trials, as well as promising progress of other vaccine candidates, were ""among the few positive outcomes to emerge from the epidemic"". The WHO announced last week that no new Ebola cases had been reported in the three worst affected countries of Guinea, Liberia and Sierra Leone in the preceding 42 days. Yet shortly after the WHO announcement - which included a warning that sporadic flare-ups could occur - Sierra Leone reported an Ebola-related death.Farrar said such instances show how an Ebola vaccine could yet be useful in this outbreak, even in its final stages.""As we saw with the new confirmed case just last week, the Ebola epidemic is likely to have a long tail and it's possible that several more isolated cases will emerge in the coming weeks and months,"" he said in a statement.""This vaccine...could still play an important role in containing any additional flare ups of this outbreak, as well as being available to help prevent future epidemics."" (Editing by Greg Mahlich)",2016-01-20,MRK,"Wed Jan 20, 2016 | 5:48am EST",Vaccines alliance signs $5 mln advance deal for Merck's Ebola shot,http://www.reuters.com//article/health-ebola-vaccine-idUSL8N1533S6?type=companyNews
437,"   By Ben Hirschler | DAVOS, Switzerland  DAVOS, Switzerland U.S. drugmaker Merck & Co is eager to do deals to bring in promising experimental medicines and believes a recent correction in biotechnology stocks should throw up new opportunities.""Prices have come back somewhat. That is a positive thing,"" Chief Executive Kenneth Frazier told Reuters in Davos on Friday.""In particular, some of the early-stage companies are struggling to get the next round of financing as people start to be a little less willing to pay for the promise of growth, so that gives us opportunities.""Frazier said he was looking for small and medium-sized  ""bolt-on"" deals to bring in new drugs, although such transactions could still be sizeable.""At our size, I would say a $10 billion or $20 billion deal would qualify as a bolt-on,"" he said in an interview on the sidelines of the World Economic Forum annual meeting. With a strong balance sheet, Merck has plenty of room for maneuver when it comes to capital allocation, leading some analysts to speculate it might also step up share repurchases.Frazier said finding value-creating acquisitions of external science ranked as his ""number two"" priority, coming behind funding for ongoing research but ahead of returning cash to shareholders.Last year, Merck did a record number of deals, though most were on the small side. Its last major deal was an agreement to buy antibiotics specialist Cubist for more than $8 billion in December 2014. Merck is not alone in chasing promising acquisitions. The wider healthcare sector saw its biggest deal-making streak ever in 2015, with global transactions totaling $673 billion, according to Thomson Reuters data.The downturn in biotech stocks has been driven in part by fears among investors of a political backlash against high drug prices. Frazier said much of the anger surrounding the issue had been sparked by ""a few bad actors"" exploiting market failures to extract excessive profits. But he acknowledged there were also wider concerns about the affordability of medicines.""Right now we are in the middle of a presidential election season and the rhetoric level is pretty high,"" he said.""But I do think people in Congress hear from their constituents at home about the challenges they have with paying for their drugs and so I think there will be pressure to do something.""      (Reporting by Ben Hirschler; Editing by Mark Potter)",2016-01-22,MRK,"Fri Jan 22, 2016 | 11:14am EST",Merck sees deal opportunities as biotech funding gets tighter,http://www.reuters.com//article/us-merck-co-m-a-ceo-idUSKCN0V0205?type=companyNews
438,"  Jan 28 U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc.The Food and Drug Administration approved the drug, Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4.Zepatier will compete with drugs that include Gilead Sciences Inc's $94,500-per-treatment Harvoni.Merck officials did not immediately respond to a request for the price of the new drug.The Merck drug's FDA label says liver-related blood tests should be performed prior to starting therapy and at certain times during treatment. Gilead secured an early lead in the lucrative market for oral hepatitis C drugs - first with the $1,000-per-pill Sovaldi, and now Harvoni. AbbVie Inc followed in late 2014 with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co, forcing Gilead to discount its own contract prices.Hepatitis C infects an estimated 3.2 million Americans.  (Reporting by Deena Beasley; Editing by Leslie Adler)",2016-01-28,MRK,"Thu Jan 28, 2016 | 6:10pm EST",U.S. FDA approves Merck's new hepatitis C pill,http://www.reuters.com//article/merck-co-hepatitis-fda-idUSL2N15C2EO?type=companyNews
439,"   By Ransdell Pierson  Bristol-Myers Squibb Co (BMY.N) on Thursday positioned itself as a potential earnings pacesetter in 2016, with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers.Bolstered by blistering sales of its Opdivo immuno-oncology drug and its Eliquis blood clot preventer, Bristol-Myers  expects earnings this year of $2.30 to $2.40 per share. It earned $2.01 per share last year.In contrast, Eli Lilly and Co (LLY.N) on Thursday predicted relatively flat 2016 earnings following strong gains last year, when sales of new cancer and diabetes drugs offset sharp declines in older medicines.Swiss rivals Roche Holding AG ROG.VX and Novartis AG NOVN.VX have also predicted flat 2016 earnings, while Johnson & Johnson (JNJ.N) expects growth of 3.6 percent to 6.2 percent, driven by sales of newer medicines.Merck & Co (MRK.N) and Pfizer Inc (PFE.N) have not yet provided 2016 earnings expectations, but Thomson Reuters I/B/E/S expects them next week to forecast growth of 4.2 percent and 8 percent, respectively.Bristol-Myers, whose $17 billion in annual sales are far below its industry peers, has downsized in recent years by selling off its diabetes drugs and cutting costs. ""They've made courageous decisions to streamline expenses, and their reduced revenue base will also fuel earnings growth,"" said Guggenheim Partners analyst Tony Butler.Ashtyn Evans, an analyst with Edward Jones, said she expects Opdivo eventually to generate annual sales of more than $8 billion.Half of Bristol-Myers' revenue will likely come from Opdivo and other cancer drugs by 2020, Evans said, allowing the company to generate average annual earnings growth in the 20 percent range for the next three to five years. ""Bristol is a lot different than it was just a few years ago,"" Evans said, citing its razor focus on potentially lucrative immuno-oncology drugs, while also developing cardiovascular and anti-inflammation medicines.Sales of Eliquis, which Bristol-Myers markets with Pfizer Inc (PFE.N), more than doubled to $602 million in the quarter.The pill was approved in 2012 to prevent blood clots among patients with an irregular heartbeat called atrial fibrillation. Growing numbers of doctors are prescribing it as a safer and more-effective alternative to longstanding oral therapy warfarin. Bristol's better-than-expected quarterly earnings were also due to soaring sales of Opdivo, a new treatment for melanoma, lung cancer and kidney cancer that is also being tested against other cancers. Sales of the injectable medicine, which was approved in late 2014 and works by taking the brakes off the immune system, jumped to $475 million.    The Princeton, New Jersey-based company said on Thursday it had halted a large trial of Opdivo after a monitoring committee concluded that head and neck cancer patients taking the drug survived longer than those taking standard chemotherapy.Analysts said Opdivo could pick up $1 billion in eventual sales for head and neck cancer, if it is approved for that indication. Earlier on Thursday, Roche spooked investors by forecasting stagnant 2016 earnings. Analysts cited concern that growth could slow for Roche's three big cancer treatments: Herceptin, Rituxan and Avastin.Novartis on Wednesday also forecast flat 2016 results, amid generic competition for its Gleevec leukemia drug and disappointing sales of new heart failure medicine, Entresto. (Reporting by Ransdell Pierson in New York; Editing by Matthew Lewis)",2016-01-28,MRK,"Thu Jan 28, 2016 | 4:45pm EST","Bristol-Myers set to lead earnings parade in 2016, beyond",http://www.reuters.com//article/us-usa-health-results-idUSKCN0V62X5?type=companyNews
440,"   By Deena Beasley and Caroline Humer  Jan 29 U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.The Food and Drug Administration on Thursday approved Merck's Zepatier for treatment of patients infected with the most common form of the liver-destroying virus, genotype 1, as well as the less common genotype 4.The list price for the new drug is $54,600 for a 12-week regimen - compared with $94,500 for Gilead Sciences Inc's  Harvoni. A multi-pill regimen, Viekira Pak, from AbbVie Inc has a list price near $83,000.AbbVie in late 2014 secured an exclusive contract with Express Scripts Holding Co, the largest manager of U.S.  prescription drug plans, which forced Gilead to discount its own contract prices with a range of other payers. Merck said it priced Zepatier in line with net prices for competing drugs. ""We look forward to working with Merck,"" Express Scripts said in an emailed statement on Friday. ""Having multiple, clinically effective options allows us to again leverage competition and make medicine more affordable for our clients while ensuring appropriate patient access.""No changes have been made as yet to Express Scripts' preferred formulary, but Harvoni will be added to its Medicare formulary on March 1. CVS Health Corp, the No. 2 drug benefit manager, which now gives preferred status to Gilead's hepatitis C drugs, said in an email that it is ""employing a strategic assessment of the therapy landscape and engaging with drugmakers to evaluate options.""Shares of Gilead were down 5 percent at $83.00 in Friday Nasdaq trading - their lowest since June 2014. Merck shares were up 2 percent at $50.35 on the New York Stock Exchange. Analysts estimate that Gilead, with $14 billion in hepatitis C drug sales for the first nine months of 2015, controls about 93 percent of the U.S. market, compared with AbbVie's 7 percent.""Given Merck's interest in participating in such a large market, we model and fully expect increased price competition and we also view Merck's list price as a rational way to stay out of the drug pricing spotlight,"" Leerink analyst Seamus Fernandez said in a research note.UBS has forecast that Merck will get 8 percent of the U.S.  genotype 1 market this year, rising to 15 percent in 2019.Both Zepatier and Viekira Pak require periodic liver function tests. In addition, Harvoni remains the only eight-week treatment option for genotype 1 patients.   (Reporting by Deena Beasley; Editing by Andrew Hay)",2016-01-29,MRK,"Fri Jan 29, 2016 | 1:40pm EST",Payers see price leverage with entry of Merck hepatitis C drug,http://www.reuters.com//article/merck-co-gilead-sciences-hepatitis-idUSL2N15D1MX?type=companyNews
441,"   By Deena Beasley  U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.The list price for Zepatier will be $54,600 for a 12-week regimen, which Merck said it expects ""to be in the range of net prices"" for comparable treatments.Gilead Sciences Inc, which secured an early lead in the lucrative market for oral hepatitis C drugs with the $1,000-per-pill Sovaldi, currently sells an enhanced version of that drug as a single-tablet regimen called Harvoni at a list price of $94,500. AbbVie Inc followed in late 2014 with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co, forcing Gilead to discount its own contract prices. Gilead has continued to dominate the market with hepatitis C drug sales of more than $14 billion in the first nine months of 2015.The Food and Drug Administration approved Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4. The new drug's FDA label says liver-related blood tests should be performed prior to starting therapy and at certain times during treatment.Clinical trials found that 12 or 16 weeks of treatment with Merck's Zepatier reduced the virus to undetectable levels, which is considered a cure, in more than 94 percent of patients, the FDA said in a statement. Hepatitis C infects an estimated 3.2 million Americans. (Reporting by Deena Beasley; Editing by Leslie Adler, Bernard Orr)",2016-01-29,MRK,"Thu Jan 28, 2016 | 7:50pm EST",FDA approves Merck's new hepatitis C pill,http://www.reuters.com//article/us-merck-co-hepatitis-fda-idUSKCN0V631S?type=companyNews
442,"   By Deena Beasley  U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.The list price for Zepatier will be $54,600 for a 12-week regimen, which Merck said it expects ""to be in the range of net prices"" for comparable treatments.Gilead Sciences Inc, which secured an early lead in the lucrative market for oral hepatitis C drugs with the $1,000-per-pill Sovaldi, currently sells an enhanced version of that drug as a single-tablet regimen called Harvoni at a list price of $94,500. AbbVie Inc followed in late 2014 with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co, forcing Gilead to discount its own contract prices. Gilead has continued to dominate the market with hepatitis C drug sales of more than $14 billion in the first nine months of 2015.The Food and Drug Administration approved Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4. The new drug's FDA label says liver-related blood tests should be performed prior to starting therapy and at certain times during treatment.Clinical trials found that 12 or 16 weeks of treatment with Merck's Zepatier reduced the virus to undetectable levels, which is considered a cure, in more than 94 percent of patients, the FDA said in a statement. Hepatitis C infects an estimated 3.2 million Americans. (Reporting by Deena Beasley; Editing by Leslie Adler, Bernard Orr)",2016-01-29,MRK,"Thu Jan 28, 2016 | 7:50pm EST",UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill,http://www.reuters.com//article/merck-co-hepatitis-fda-idUSL2N15C3PV?type=companyNews
443,"   By Ransdell Pierson  Merck & Co Inc (MRK.N) on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent.    Sales of Januvia and a related drug called Janumet, the company's biggest franchise, fell 12 percent to $1.45 billion. Merck said wholesalers had stocked up in the prior quarter, and the products face growing competition from other oral diabetes treatments.But Adam Schechter, the company's head of global human health, said Januvia sales should increase this year, excluding the effects of a stronger dollar, which reduces the value of revenue from overseas. Januvia sales did not suffer after recent data showed Eli Lilly & Co's (LLY.N) rival Jardiance drug sharply reduced deaths among diabetics at risk of heart attack, Schechter said.Sales of Remicade, which is facing competition outside the United States from cheaper biosimilars, dropped 29 percent to $396 million. In a conference call with analysts, Schechter said the drug's market share was shrinking, and the trend would accelerate.   ""Our initial read on the earnings and guidance reaffirms our neutral stance on (Merck) as pressure on key products such as Januvia and Remicade will likely limit near-term growth,"" Credit Suisse analyst Vamil Divan said.Merck is counting on Keytruda, a recently approved treatment for melanoma and lung cancer, to boost its earnings for years to come. The medicine, which takes the brakes off the immune system, is competing with Bristol-Myers Squibb Co's (BMY.N) similar Opdivo treatment, which is picking up sales faster.    Keytruda sales rose to $214 million in the fourth quarter, about half Opdivo's $475 million in revenue in that period.     Merck, the second-largest U.S. drugmaker behind Pfizer Inc (PFE.N), forecast full-year earnings of $3.60 to $3.75 per share, excluding special items. The analysts' average estimate was $3.72, according to Thomson Reuters I/B/E/S.     Merck said it expected 2016 revenue of $38.7 billion to $40.2 billion. Wall Street had forecast $40.25 billion.     Fourth-quarter revenue fell 3 percent to $10.22 billion, below analysts' expectations of $10.35 billion. Sales would have risen 4 percent if not for the stronger dollar.Net income fell to $976 million from $7.32 billion.    Excluding costs from last year's acquisition of Cubist Pharmaceuticals and other special items, earnings of 93 cents per share topped Wall Street's forecast of 91 cents. Analysts largely attributed the profit beat to a lower tax rate. (Additional reporting by Amrutha Penumudi in Bengaluru; Editing by Lisa Von Ahn)",2016-02-03,MRK,"Wed Feb 3, 2016 | 12:56pm EST",Merck gives cautious 2016 outlook as sales of top medicines lag,http://www.reuters.com//article/us-merck-co-results-idUSKCN0VC1AX?type=companyNews
444,"   By Ransdell Pierson  Merck & Co Inc (MRK.N) on Wednesday issued a cautious 2016 outlook and reported disappointing fourth-quarter sales of its Januvia diabetes treatment and its Remicade arthritis drug, sending its shares down nearly 3 percent.    Sales of Januvia and a related drug called Janumet, the company's biggest franchise, fell 12 percent to $1.45 billion. Merck said wholesalers had stocked up in the prior quarter, and the products face growing competition from other oral diabetes treatments.But Adam Schechter, the company's head of global human health, said Januvia sales should increase this year, excluding the effects of a stronger dollar, which reduces the value of revenue from overseas. Januvia sales did not suffer after recent data showed Eli Lilly & Co's (LLY.N) rival Jardiance drug sharply reduced deaths among diabetics at risk of heart attack, Schechter said.Sales of Remicade, which is facing competition outside the United States from cheaper biosimilars, dropped 29 percent to $396 million. In a conference call with analysts, Schechter said the drug's market share was shrinking, and the trend would accelerate.   ""Our initial read on the earnings and guidance reaffirms our neutral stance on (Merck) as pressure on key products such as Januvia and Remicade will likely limit near-term growth,"" Credit Suisse analyst Vamil Divan said.Merck is counting on Keytruda, a recently approved treatment for melanoma and lung cancer, to boost its earnings for years to come. The medicine, which takes the brakes off the immune system, is competing with Bristol-Myers Squibb Co's (BMY.N) similar Opdivo treatment, which is picking up sales faster.    Keytruda sales rose to $214 million in the fourth quarter, about half Opdivo's $475 million in revenue in that period.     Merck, the second-largest U.S. drugmaker behind Pfizer Inc (PFE.N), forecast full-year earnings of $3.60 to $3.75 per share, excluding special items. The analysts' average estimate was $3.72, according to Thomson Reuters I/B/E/S.     Merck said it expected 2016 revenue of $38.7 billion to $40.2 billion. Wall Street had forecast $40.25 billion.     Fourth-quarter revenue fell 3 percent to $10.22 billion, below analysts' expectations of $10.35 billion. Sales would have risen 4 percent if not for the stronger dollar.Net income fell to $976 million from $7.32 billion.    Excluding costs from last year's acquisition of Cubist Pharmaceuticals and other special items, earnings of 93 cents per share topped Wall Street's forecast of 91 cents. Analysts largely attributed the profit beat to a lower tax rate. (Additional reporting by Amrutha Penumudi in Bengaluru; Editing by Lisa Von Ahn)",2016-02-03,MRK,"Wed Feb 3, 2016 | 12:56pm EST",UPDATE 3-Merck gives cautious 2016 outlook as sales of top medicines lag,http://www.reuters.com//article/merck-co-results-idUSL3N15I48X?type=companyNews
445,"  Feb 3 Merck & Co Inc* Says it expects global Januvia/Janumet sales to rise in 2016, when excluding negative impact of strong dollar * Says Januvia unlikely to be significantly hurt in 2016 by favorable heart data seen with Lilly's Jardiance * Says drugs from Jardiance's SGLT2 class not hurting sales of DPP-4 inhibitors like Januvia * Says expects accelerating declines in Remicade market share due to competition from cheaper biosimilars  Source text for Eikon:  Further company coverage:    (Reporting by Ransdell Pierson)",2016-02-03,MRK,"Wed Feb 3, 2016 | 9:14am EST","BRIEF-Merck sees accelerating declines for Remicade, due to biosimilars",http://www.reuters.com//article/idUSL2N15I11D?type=companyNews
446,"  Feb 3 Merck & Co Inc reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.Net income fell to $981 million, or 35 cents per share, for the fourth quarter ended Dec. 31 from $7.32 billion, or $2.54 per share, from a year earlier. On an adjusted basis, the company earned 93 cents per share.  Revenue fell to $10.22 billion from $10.48 billion.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)",2016-02-03,MRK,"Wed Feb 3, 2016 | 6:57am EST",Merck revenue falls as dollar strengthens,http://www.reuters.com//article/merck-co-results-idUSL3N15I47Z?type=companyNews
447,"  Feb 15 Drugmaker Merck & Co Inc said the U.S. Food and Drug Administration declined to approve its claim that cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.The company said that after receiving a complete response letter from the FDA, it will review the letter and determine its next steps.Merck noted in a statement that both drugs are indicated to reduce LDL, or ""bad,"" cholesterol, but ""The effect of Zetia on cardiovascular morbidity and mortality has not been determined."" The company said the FDA determined that Vytorin, which is a combination of Zetia and the cholesterol drug simvastatin, has no additional benefit on cardiovascular diseases beyond those already been established for simvastatin. The applications were based on the results of Merck's Improve-IT study. The FDA's decision follows a recommendation in December by one of its advisory committees that Merck should not be allowed to claim that Vytorin reduces the risk of heart attacks and strokes in patients with coronary heart disease.    (Reporting by Kshitiz Goliya in Bengaluru; Editing by Leslie Adler)",2016-02-16,MRK,"Mon Feb 15, 2016 | 7:53pm EST",Merck says U.S. FDA reject its claim that Zetia and Vytorin cut heart risk,http://www.reuters.com//article/merck-co-zetia-fda-idUSL3N15U435?type=companyNews
448,"   By Brendan Pierson  A federal judge has narrowed an antitrust class action brought by drug wholesalers alleging that Schering-Plough Corp, now owned by Merck, paid generic rivals to stay out of the market for its potassium supplement K-Dur. U.S. District Judge Stanley Chesler in New Jersey ruled Thursday that no antitrust claims could arise from Schering's $10 million 1998 settlement with generic drugmaker ESI-Lederle, then a division of Wyeth and since bought by Baxter Healthcare, because the deal is not alleged to have delayed ESI from launching a generic.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1TcD0vz",2016-02-26,MRK,"Fri Feb 26, 2016 | 6:22pm EST",Judge trims antitrust case against Merck over potassium drug,http://www.reuters.com//article/health-merck-idUSL2N1652GT?type=companyNews
449,  March 7 Neuron Bio SA :* Has been designated as a reference laboratory for Merck Millipore for marketing of Milliplex technology used for biomarkers determination Source text: bit.ly/1M2edSU  Further company coverage:    (Gdynia Newsroom),2016-03-07,MRK,"Mon Mar 7, 2016 | 2:11am EST",BRIEF-Neuron Bio designated as reference laboratory for Merck Millipore,http://www.reuters.com//article/idUSFWN16F00G?type=companyNews
450,"  PARIS Sanofi SA and Merck & Co Inc said on Tuesday they were ending a 22-year-old joint venture to sell vaccines in Europe, arguing they would do better by managing their product portfolios independently.The Sanofi Pasteur MSD venture, which is owned 50/50 by the French and U.S. drugmakers, had sales of 824 million euros ($908 million) in 2015 but its revenues have been relatively flat recently.The decision marks a further step by Sanofi's new Chief Executive Olivier Brandicourt to reshape the group, following a $20 billion deal to swap Sanofi's animal health unit for Boehringer Ingelheim's operations in consumer health.Sanofi and Merck said they expected the unwinding of the vaccines joint venture to be completed by the end of 2016, subject to local labor laws and regulatory approvals.  Financial terms of the termination were not disclosed, but Sanofi said in a statement that any impact on jobs would be managed responsibly.""After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently,"" the firms said. Sanofi Pasteur MSD is a major supplier of flu vaccines in Europe and also distributes Gardasil to protect against cervical cancer. Other big product lines include vaccines against shingles, hepatitis, yellow fever and childhood diseases.  The joint venture is headquartered in Lyon, France, next door to Sanofi's own vaccine business, called Sanofi Pasteur. (Reporting by Matthias Blamont and Ben Hirschler; Editing by James Regan and Keith Weir)",2016-03-08,MRK,"Tue Mar 8, 2016 | 8:47am EST",Sanofi and Merck pull the plug on European vaccines venture,http://www.reuters.com//article/us-sanofi-merck-idUSKCN0WA1MP?type=companyNews
451,"  PARIS Sanofi SA and Merck & Co Inc said on Tuesday they were ending a 22-year-old joint venture to sell vaccines in Europe, arguing they would do better by managing their product portfolios independently.The Sanofi Pasteur MSD venture, which is owned 50/50 by the French and U.S. drugmakers, had sales of 824 million euros ($908 million) in 2015 but its revenues have been relatively flat recently.The decision marks a further step by Sanofi's new Chief Executive Olivier Brandicourt to reshape the group, following a $20 billion deal to swap Sanofi's animal health unit for Boehringer Ingelheim's operations in consumer health.Sanofi and Merck said they expected the unwinding of the vaccines joint venture to be completed by the end of 2016, subject to local labor laws and regulatory approvals.  Financial terms of the termination were not disclosed, but Sanofi said in a statement that any impact on jobs would be managed responsibly.""After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently,"" the firms said. Sanofi Pasteur MSD is a major supplier of flu vaccines in Europe and also distributes Gardasil to protect against cervical cancer. Other big product lines include vaccines against shingles, hepatitis, yellow fever and childhood diseases.  The joint venture is headquartered in Lyon, France, next door to Sanofi's own vaccine business, called Sanofi Pasteur. (Reporting by Matthias Blamont and Ben Hirschler; Editing by James Regan and Keith Weir)",2016-03-08,MRK,"Tue Mar 8, 2016 | 8:47am EST",UPDATE 1-Sanofi and Merck pull the plug on European vaccines venture,http://www.reuters.com//article/sanofi-merck-idUSL5N16G39K?type=companyNews
452,"  PARIS, March 8 Sanofi said on Tuesday that it was ending its joint vaccines operations in Europe with U.S partner Merck in order to allow both companies to pursue different strategies.The French drugmaker said the project would be completed by the end of 2016. Financial terms of the termination were not disclosed, but Sanofi said in a statement that any impact on jobs would be managed ""responsibly"". ""After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently,"" Sanofi said.  Sanofi Pasteur, the company's vaccines division, set up the 50/50 joint venture in 1994.   (Reporting by Matthias Blamont; Editing by James Regan)",2016-03-08,MRK,"Tue Mar 8, 2016 | 8:13am EST",Sanofi Pasteur and Merck end European vaccines venture,http://www.reuters.com//article/sanofi-merck-idUSFWN16G019?type=companyNews
453,"  FRANKFURT, March 8 The DAX top-30 index  looked set to open 0.6 percent lower on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0716 GMT.The following are some of the factors that may move German stocks:MERCK Indicated unchangedGerman drugs and chemicals maker Merck KGaA raised the prospect of an increase of more than 10 percent in adjusted core earnings this year, expecting additional profit from the takeover of lab supplies maker Sigma-Aldrich to offset higher expenses on drug development.RWE Indicated 2.3 percent lowerGermany's second-largest utility said it would radically restructure its British unit npower in a response to widening losses and a rapid outflow of customers that are increasingly switching to cheaper rivals. SYMRISE Indicated 0.7 percent lowerSymrise posted a 23 percent rise in EBITDA and said it planned to an EBITDA margin of between 19 percent to 22 percent by end 2020.DIALOG SEMICONDUCTOR  Indicated 5 percent lowerDialog said it expected its gross margin to remain broadly in line with that achieved in 2015 after reporting underlying EBITDA rose 33 percent to $359.5 million.OVERSEAS STOCK MARKETS Dow Jones +0.4 pct, S&P 500 +0.1 pct, Nasdaq  -0.2 pct at close. Nikkei -0.76 pct, Shanghai stocks -0.7 pct.Time: 6.27 GMT.GERMAN ECONOMIC DATA German industrial output rose strongly in January, showing the engine room of Europe's largest economy began 2016 in solid form despite financial market turmoil that has hit business morale.EUROPEAN FACTORS TO WATCH DIARIES REUTERS TOP NEWS  ($1 = 0.9109 euros)   (Reporting by Jonathan Gould and Edward Taylor)",2016-03-08,MRK,"Tue Mar 8, 2016 | 2:26am EST",German stocks - Factors to watch on March 8,http://www.reuters.com//article/germany-stocks-factors-idUSL5N16F3OK?type=companyNews
454,"   By Rory Carroll and Andrew Chung | SAN JOSE  SAN JOSE A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.The verdict in federal court in San Jose, California, is a major setback for Gilead, whose drugs Sovaldi and Harvoni brought in $19.2 billion in worldwide sales last year. Merck has demanded more than $2 billion in damages and a royalty of 10 percent of Gilead's sales going forward. The jury must now decide exactly how much Gilead owes. In a statement, Gilead spokeswoman Michele Rest said, ""Although we are disappointed by the jury's verdict today, there are a number of remaining issues to be decided by the jury and the judge.""Merck spokeswoman Lainie Keller said the verdict ""accurately reflects the evidence in this case,"" adding that strong patent protection is essential to innovation. The trial, which began on March 7, came as pharmaceutical companies race to capture a slice of the lucrative market for the newest hepatitis C treatments, which can cure well over 90 percent of patients with the liver disease. Insurers, politicians and patient groups have denounced the list prices of the drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen. In January, the U.S. Food and Drug Administration approved Merck's Zepatier drug.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-03-22,MRK,"Tue Mar 22, 2016 | 5:46pm EDT",Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com//article/gilead-sciences-merck-co-verdict-idUSL2N16U2A5?type=companyNews
455,"   By Andrew Chung | NEW YORK, March 22  NEW YORK, March 22 A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.  The verdict in federal court in San Jose, California, is a major setback for Gilead, whose drugs Sovaldi and Harvoni brought in $19.2 billion in worldwide sales last year. Merck has demanded more than $2 billion in damages and a royalty of 10 percent of Gilead's sales going forward. The jury must now decide exactly how much Gilead owes.   (Reporting by Andrew Chung; Editing by Jonathan Oatis) ",2016-03-22,MRK,"Tue Mar 22, 2016 | 5:27pm EDT",Merck patents on Hepatitis C treatment found valid in dispute with Gilead,http://www.reuters.com//article/gilead-sciences-merck-co-verdict-idUSL2N16U26U?type=companyNews
456,"   By Rory Carroll and Andrew Chung | SAN JOSE  SAN JOSE Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.After returning its verdict in favor of Merck on Tuesday, the jury in San Jose, California immediately began hearing evidence on how much Gilead owes Merck for infringing the patents.Bruce Genderson, an attorney for Merck, said the company is seeking a 10 percent royalty on Gilead's U.S. sales of nearly $21 billion for 2014 and 2015. Merck has also asked for a royalty of 10 percent going forward on Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, which generated $19.2 billion in worldwide sales last year.  Following the verdict, Gilead shares fell $1.92 to $91.80 in after-hours trading. Merck rose 57 cents to $53.60.In a statement, Gilead spokeswoman Michele Rest said, ""Although we are disappointed by the jurys verdict today, there are a number of remaining issues to be decided by the jury and the judge."" She declined to comment on any potential appeal. A spokeswoman for Merck said the verdict ""accurately reflects the evidence in this case."" The trial, which began on March 7, came as pharmaceutical companies race to capture a slice of the lucrative market for the newest hepatitis C treatments, which can cure well over 90 percent of patients with the liver disease. Insurers, politicians and patient groups have denounced the list prices of the drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen. In January, the U.S. Food and Drug Administration approved Merck's Zepatier drug.In 2013 Merck contacted Gilead saying the active ingredient in Gilead's drugs, sofosbuvir, infringed Merck's patents, according to court papers.  Foster City, California-based Gilead then asked the U.S. District Court for the Northern District of California in San Jose to declare the patents invalid, saying they do not clearly describe any disease fighting effects. Merck, based in Kenilworth, New Jersey, countersued for infringement. Gilead said in court filings that Merck played no role in sofosbuvir's discovery, but that when its breakthrough potential became clear, ""Merck came knocking on Gileads door with its two patents in hand."" Last month, U.S. District Judge Beth Labson Freeman ruled that the sale and use of Gilead's drugs infringe Merck's patents.   Michael Yee, biotech analyst for RBC Capital Markets, said ""while it does not sound good that Gilead could theoretically owe billions of dollars in financial damages...it is a small amount relative to Gilead's $127 billion market cap."" He said he expected Gilead to appeal. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; additional reporting by Bill Berkrot; Editing by Alexia Garamfalvi, Chris Reese and Diane Craft)",2016-03-23,MRK,"Wed Mar 23, 2016 | 4:41am EDT",Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com//article/us-gilead-sciences-merck-co-verdict-idUSKCN0WO353?type=companyNews
457,"   By Rory Carroll and Andrew Chung | SAN JOSE  SAN JOSE Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.After returning its verdict in favor of Merck on Tuesday, the jury in San Jose, California immediately began hearing evidence on how much Gilead owes Merck for infringing the patents.Bruce Genderson, an attorney for Merck, said the company is seeking a 10 percent royalty on Gilead's U.S. sales of nearly $21 billion for 2014 and 2015. Merck has also asked for a royalty of 10 percent going forward on Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, which generated $19.2 billion in worldwide sales last year.  Following the verdict, Gilead shares fell $1.92 to $91.80 in after-hours trading. Merck rose 57 cents to $53.60.In a statement, Gilead spokeswoman Michele Rest said, ""Although we are disappointed by the jurys verdict today, there are a number of remaining issues to be decided by the jury and the judge."" She declined to comment on any potential appeal. A spokeswoman for Merck said the verdict ""accurately reflects the evidence in this case."" The trial, which began on March 7, came as pharmaceutical companies race to capture a slice of the lucrative market for the newest hepatitis C treatments, which can cure well over 90 percent of patients with the liver disease. Insurers, politicians and patient groups have denounced the list prices of the drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen. In January, the U.S. Food and Drug Administration approved Merck's Zepatier drug.In 2013 Merck contacted Gilead saying the active ingredient in Gilead's drugs, sofosbuvir, infringed Merck's patents, according to court papers.  Foster City, California-based Gilead then asked the U.S. District Court for the Northern District of California in San Jose to declare the patents invalid, saying they do not clearly describe any disease fighting effects. Merck, based in Kenilworth, New Jersey, countersued for infringement. Gilead said in court filings that Merck played no role in sofosbuvir's discovery, but that when its breakthrough potential became clear, ""Merck came knocking on Gileads door with its two patents in hand."" Last month, U.S. District Judge Beth Labson Freeman ruled that the sale and use of Gilead's drugs infringe Merck's patents.   Michael Yee, biotech analyst for RBC Capital Markets, said ""while it does not sound good that Gilead could theoretically owe billions of dollars in financial damages...it is a small amount relative to Gilead's $127 billion market cap."" He said he expected Gilead to appeal. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; additional reporting by Bill Berkrot; Editing by Alexia Garamfalvi, Chris Reese and Diane Craft)",2016-03-23,MRK,"Wed Mar 23, 2016 | 4:41am EDT",UPDATE 3-Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com//article/gilead-sciences-merck-co-verdict-idUSL2N16U28H?type=companyNews
458,"  SAN JOSE, Calif., March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. The damages amount was far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs, Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015.    (Reporting by Andrew Chung; Editing by Sandra Maler)  ",2016-03-24,MRK,"Thu Mar 24, 2016 | 7:59pm EDT",Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com//article/gilead-sciences-merck-co-damages-idUSL2N16W1AM?type=companyNews
459,"   By Rory Carroll and Andrew Chung | SAN JOSE, Calif.,/NEW YORK  SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015.Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.Merck, which in January won approval on its own hepatitis C drug, Zepatier, is also asking for a 10 percent royalty on Gilead's sales going forward. That issue will be argued in a separate non-jury trial before U.S. District Judge Beth Labson Freeman starting next week. Gilead spokeswoman Michele Rest said the company does not believe Merck is entitled to any damages. ""In the event the judge maintains the jury's verdict, we will appeal,"" she said.In a statement, Merck said, ""We are pleased that the jury recognized that patent protections are essential to the development of new medical treatments.""In after-hours trading, Merck shares were down 50 cents to $52.57. Gilead shares gained slightly. Insurers, politicians and patient groups have denounced the list prices of the new drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen.Gilead obtained the active ingredient in its drugs,   sofosbuvir, by acquiring Pharmasset, Inc in 2011. Merck said Pharmasset developed the chemical from a Merck patent that was filed in 2002. Gilead, meanwhile, said Merck's patents were derived from Pharmasset's work. After Merck, based in Kenilworth, New Jersey, demanded royalties in 2013, Gilead and Merck sued each other in the U.S. District Court for the Northern District of California. Last month, Freeman ruled that Gilead's drugs infringe Merck's patents.In calculating damages, jurors said they sought a middle ground. ""We worked to get to something we could all agree so we weren't hurting one side or the other,"" juror Cody Shump, a 20-year-old San Jose resident, told Reuters.Merck's partner and co-owner of the patents, Ionis Pharmaceuticals Inc, will get 20 percent of the damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-03-25,MRK,"Thu Mar 24, 2016 | 10:51pm EDT",Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com//article/gilead-sciences-merck-co-damages-idUSL2N16X011?type=companyNews
460,"   By Rory Carroll and Andrew Chung | SAN JOSE, Calif.,/NEW YORK  SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015. Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease. Merck, which in January won approval on its own hepatitis C drug, Zepatier, is also asking for a 10 percent royalty on Gilead's sales going forward. That issue will be argued in a separate non-jury trial before U.S. District Judge Beth Labson Freeman starting next week. Gilead spokeswoman Michele Rest said the company does not believe Merck is entitled to any damages. ""In the event the judge maintains the jury's verdict, we will appeal,"" she said. In a statement, Merck said, ""We are pleased that the jury recognized that patent protections are essential to the development of new medical treatments.""In after-hours trading, Merck shares were down 50 cents to $52.57. Gilead shares gained slightly.Insurers, politicians and patient groups have denounced the list prices of the new drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen.  Gilead obtained the active ingredient in its drugs,   sofosbuvir, by acquiring Pharmasset, Inc in 2011. Merck said Pharmasset developed the chemical from a Merck patent that was filed in 2002. Gilead, meanwhile, said Merck's patents were derived from Pharmasset's work. After Merck, based in Kenilworth, New Jersey, demanded royalties in 2013, Gilead and Merck sued each other in the U.S. District Court for the Northern District of California. Last month, Freeman ruled that Gilead's drugs infringe Merck's patents. In calculating damages, jurors said they sought a middle ground. ""We worked to get to something we could all agree so we werent hurting one side or the other,"" juror Cody Shump, a 20-year-old San Jose resident, told Reuters.  Merck's partner and co-owner of the patents, Ionis Pharmaceuticals Inc (IONS.O), will get 20 percent of the damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; Editing by Alexia Garamfalvi, Diane Craft and Leslie Adler)",2016-03-25,MRK,"Thu Mar 24, 2016 | 9:58pm EDT",Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute,http://www.reuters.com//article/us-gilead-sciences-merck-co-damages-idUSKCN0WR00V?type=companyNews
461,"   By Rory Carroll and Andrew Chung | SAN JOSE, Calif.,/NEW YORK  SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015. Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease. Merck, which in January won approval on its own hepatitis C drug, Zepatier, is also asking for a 10 percent royalty on Gilead's sales going forward. That issue will be argued in a separate non-jury trial before U.S. District Judge Beth Labson Freeman starting next week. Gilead spokeswoman Michele Rest said the company does not believe Merck is entitled to any damages. ""In the event the judge maintains the jury's verdict, we will appeal,"" she said. In a statement, Merck said, ""We are pleased that the jury recognized that patent protections are essential to the development of new medical treatments.""In after-hours trading, Merck shares were down 50 cents to $52.57. Gilead shares gained slightly.Insurers, politicians and patient groups have denounced the list prices of the new drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen.  Gilead obtained the active ingredient in its drugs,   sofosbuvir, by acquiring Pharmasset, Inc in 2011. Merck said Pharmasset developed the chemical from a Merck patent that was filed in 2002. Gilead, meanwhile, said Merck's patents were derived from Pharmasset's work. After Merck, based in Kenilworth, New Jersey, demanded royalties in 2013, Gilead and Merck sued each other in the U.S. District Court for the Northern District of California. Last month, Freeman ruled that Gilead's drugs infringe Merck's patents. In calculating damages, jurors said they sought a middle ground. ""We worked to get to something we could all agree so we werent hurting one side or the other,"" juror Cody Shump, a 20-year-old San Jose resident, told Reuters.  Merck's partner and co-owner of the patents, Ionis Pharmaceuticals Inc (IONS.O), will get 20 percent of the damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; Editing by Alexia Garamfalvi, Diane Craft and Leslie Adler)",2016-03-25,MRK,"Thu Mar 24, 2016 | 9:58pm EDT",UPDATE 3-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com//article/gilead-sciences-merck-co-damages-idUSL2N16X009?type=companyNews
462,"   By Andrew Chung  By Andrew Chung Gilead Sciences Inc on Wednesday will attempt to wipe out $200 million in damages for infringing two Merck & Co patents with its blockbuster hepatitis C treatments by claiming that Merck was dishonest in obtaining the patents, an argument that attorneys say could be difficult to prove. A bench trial on Wednesday will pit Gilead's Fish & Richardson attorneys against Merck's lawyers from Williams & Connolly, on Gilead's claim that Merck has ""unclean hands"" because it used Gilead's technology in its own patent applications and so should be precluded from enforcing its patents. Merck says the jury has already found that its patents are valid, foreclosing any unclean hands defense. To read the full story on Westlaw Practitioner Insights, click here: bit.ly/1RN28ZM",2016-03-29,MRK,"Tue Mar 29, 2016 | 7:06am EDT",Gilead says Merck 'deceitful' in hepatitis C drug patent fight,http://www.reuters.com//article/ip-gilead-hearing-idUSL2N1710BZ?type=companyNews
463,  April 11 Merck & Co Inc* Merck & Co Inc says CEO Kenneth C. Frazier's total compensation for FY 2015 was $24.2 mln vs $25 mln in FY 2014 - SEC Filing  * Merck & Co Inc says CFO Robert M. Davis's total compensation for FY 2015 was $7.3 mln vs $12.8 mln in FY 2014 - SEC Filing   Source text [1.usa.gov/1ViJ9Xq] Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-04-11,MRK,"Mon Apr 11, 2016 | 6:38pm EDT",BRIEF-Merck & Co says CEO Kenneth C. Frazier's total compensation for 2015 was $24.2 MLN,http://www.reuters.com//article/idUSFWN17E0OO?type=companyNews
464,  April 14 H-Farm Spa :* Says Merck launches Merck for Health project in partnership with H-Farm  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom) ,2016-04-14,MRK,"Thu Apr 14, 2016 | 3:50am EDT",BRIEF-Merck launches Merck for Health project in partnership with H-farm,http://www.reuters.com//article/idUSFWN17H0E8?type=companyNews
465,"  April 18 Merck Says  Fourth Designation For Keytruda Follows Breakthrough Status In Advanced Melanoma, Non* Merck receives breakthrough therapy designation from u.s. Food and drug administration for keytruda (pembrolizumab) in classical hodgkin lymphoma (chl)  * Small cell lung cancer, colorectal cancer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-04-18,MRK,"Mon Apr 18, 2016 | 8:16am EDT",BRIEF-Merck receives breakthrough therapy designation from FDA for use of Keytruda in classical hodgkin lymphoma,http://www.reuters.com//article/idUSASC08LFM?type=companyNews
466,  April 19 Merck & Co Inc :* Merck Animal Health to acquire worldwide rights to Whisper Veterinary Stethoscope System  * Terms of acquisition were not disclosed  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-04-19,MRK,"Tue Apr 19, 2016 | 5:20pm EDT",BRIEF-Merck Animal Health to buy worldwide rights to Whisper Veterinary Stethoscope System,http://www.reuters.com//article/idUSASD08E6S?type=companyNews
467,  April 25 Merck* Says phase III tailor landmark study  demonstrates  significant  benefits of erbitux in combination  with  folfox over folfox alone * Says marks a major milestone  of merck's  oncology  strategy including expansion  in growth markets  * Says will  work with relevant authorities  to make erbitux available  for patients in china as a first - line treatment  as soon  as possible  Further company coverage:    (Frankfurt Newsroom),2016-04-25,MRK,"Mon Apr 25, 2016 | 2:11am EDT",BRIEF-Merck KGaA publishes Chinese Phase III study for Erbitux,http://www.reuters.com//article/idUSFWN17P14N?type=companyNews
468,"   By Brendan Pierson  A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc(MRK.N) of underpaying female sales representatives to go forward as a collective action.The lawsuit is seeking at least $250 million in damages.U.S. District Judge Michael Shipp in Trenton, New Jersey, on Wednesday granted conditional certification to a proposed class of current and former representatives under the federal Equal Pay Act, which requires women and men to be paid equally for the same work.The complaint alleges that Merck systematically paid female sales representatives less than their male peers, denied them promotions and subjected them to sexual harassment and an otherwise hostile work environment.Employees who become pregnant or have children were often pressured to leave the company, the complaint says. A collective action under the Equal Pay Act requires potential class members to opt in, unlike a traditional class action in which class members must opt out. Shipp's order allows notices to be sent to potential members so they can opt in.The class includes women who worked in certain sales representative positions going back to 2009. It would still require final approval later in the case for class members to win damages. However, Shipp ruled that the four former sales representatives who brought the lawsuit had already made a ""modest factual showing"" of how Merck's policies affected them and other employees similarly.""We're glad that women across the country are going to have an opportunity to join this case,"" said Russell Kornblith, an attorney for the plaintiffs.""We remain confident that this case lacks merit,"" Merck said in a statement emailed by spokeswoman Lainie Keller. ""The company will continue to vigorously defend itself, and remains fully committed to providing equal employment opportunities for all employees."" The lawsuit, filed in 2013 in New Jersey U.S. District Court, also includes claims under Title VII of the Civil Rights Act. The plaintiffs are seeking to bring those claims as a class action, though no class has yet been certified.The case is Smith et al v. Merck & Co Inc, U.S. District Court, District of New Jersey, No. 3:13-cv-02970. (Reporting By Brendan Pierson in New York; Editing by David Gregorio)",2016-04-27,MRK,"Wed Apr 27, 2016 | 9:17pm EDT",UPDATE 1-Merck sex discrimination case could be collective action -judge,http://www.reuters.com//article/usa-merck-co-discrimination-idUSL2N17U2SD?type=companyNews
469,"   By Brendan Pierson  A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.The lawsuit is seeking at least $250 million in damages.U.S. District Judge Michael Shipp in Trenton, New Jersey, on Wednesday granted conditional certification to a proposed class of current and former representatives under the federal Equal Pay Act, which requires women and men to be paid equally for the same work.The complaint alleges that Merck systematically paid female sales representatives less than their male peers, denied them promotions and subjected them to sexual harassment and an otherwise hostile work environment. Employees who become pregnant or have children were often pressured to leave the company, the complaint says.A collective action under the Equal Pay Act requires potential class members to opt in, unlike a traditional class action in which class members must opt out. Shipp's order allows notices to be sent to potential members so they can opt in. The class includes women who worked in certain sales representative positions going back to 2009. It would still require final approval later in the case for class members to win damages.However, Shipp ruled that the four former sales representatives who brought the lawsuit had already made a ""modest factual showing"" of how Merck's policies affected them and other employees similarly. ""We're glad that women across the country are going to have an opportunity to join this case,"" said Russell Kornblith, an attorney for the plaintiffs.A Merck spokeswoman could not immediately be reached for comment.The lawsuit, filed in 2013 in New Jersey U.S. District Court, also includes claims under Title VII of the Civil Rights Act. The plaintiffs are seeking to bring those claims as a class action, though no class has yet been certified.The case is Smith et al v. Merck & Co Inc, U.S. District Court, District of New Jersey, No. 3:13-cv-02970.",2016-04-27,MRK,"Wed Apr 27, 2016 | 6:07pm EDT",Merck sex discrimination case could be collective action -judge,http://www.reuters.com//article/usa-merck-co-discrimination-idUSL2N17U2MZ?type=companyNews
470,"   By Brendan Pierson | April 27  April 27 A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc of underpaying female sales representatives to go forward as a collective action.The lawsuit is seeking at least $250 million in damages.U.S. District Judge Michael Shipp in Trenton, New Jersey, on Wednesday granted conditional certification to a proposed class of current and former representatives under the federal Equal Pay Act, which requires women and men to be paid equally for the same work.The complaint alleges that Merck systematically paid female sales representatives less than their male peers, denied them promotions and subjected them to sexual harassment and an otherwise hostile work environment. Employees who become pregnant or have children were often pressured to leave the company, the complaint says.A collective action under the Equal Pay Act requires potential class members to opt in, unlike a traditional class action in which class members must opt out. Shipp's order allows notices to be sent to potential members so they can opt in. The class includes women who worked in certain sales representative positions going back to 2009. It would still require final approval later in the case for class members to win damages.However, Shipp ruled that the four former sales representatives who brought the lawsuit had already made a ""modest factual showing"" of how Merck's policies affected them and other employees similarly. ""We're glad that women across the country are going to have an opportunity to join this case,"" said Russell Kornblith, an attorney for the plaintiffs.A Merck spokeswoman could not immediately be reached for comment.The lawsuit, filed in 2013 in New Jersey U.S. District Court, also includes claims under Title VII of the Civil Rights Act. The plaintiffs are seeking to bring those claims as a class action, though no class has yet been certified.The case is Smith et al v. Merck & Co Inc, U.S. District Court, District of New Jersey, No. 3:13-cv-02970.   (Reporting By Brendan Pierson in New York; Editing by David Gregorio)",2016-04-27,MRK,"Wed Apr 27, 2016 | 6:04pm EDT",Merck sex discrimination case could be collective action -judge,http://www.reuters.com//article/usa-merck-co-discrimination-idUSL2N17U2H3?type=companyNews
471,"   By Brendan Pierson  A federal judge has granted preliminary approval for a lawsuit accusing Merck & Co Inc(MRK.N) of underpaying female sales representatives to go forward as a collective action.The lawsuit is seeking at least $250 million in damages.U.S. District Judge Michael Shipp in Trenton, New Jersey, on Wednesday granted conditional certification to a proposed class of current and former representatives under the federal Equal Pay Act, which requires women and men to be paid equally for the same work.The complaint alleges that Merck systematically paid female sales representatives less than their male peers, denied them promotions and subjected them to sexual harassment and an otherwise hostile work environment.Employees who become pregnant or have children were often pressured to leave the company, the complaint says. A collective action under the Equal Pay Act requires potential class members to opt in, unlike a traditional class action in which class members must opt out. Shipp's order allows notices to be sent to potential members so they can opt in.The class includes women who worked in certain sales representative positions going back to 2009. It would still require final approval later in the case for class members to win damages. However, Shipp ruled that the four former sales representatives who brought the lawsuit had already made a ""modest factual showing"" of how Merck's policies affected them and other employees similarly.""We're glad that women across the country are going to have an opportunity to join this case,"" said Russell Kornblith, an attorney for the plaintiffs.""We remain confident that this case lacks merit,"" Merck said in a statement emailed by spokeswoman Lainie Keller. ""The company will continue to vigorously defend itself, and remains fully committed to providing equal employment opportunities for all employees."" The lawsuit, filed in 2013 in New Jersey U.S. District Court, also includes claims under Title VII of the Civil Rights Act. The plaintiffs are seeking to bring those claims as a class action, though no class has yet been certified.The case is Smith et al v. Merck & Co Inc, U.S. District Court, District of New Jersey, No. 3:13-cv-02970. (Reporting By Brendan Pierson in New York; Editing by David Gregorio)",2016-04-28,MRK,"Wed Apr 27, 2016 | 9:17pm EDT",Merck sex discrimination case could be collective action: judge,http://www.reuters.com//article/us-usa-merck-co-discrimination-idUSKCN0XO2RI?type=companyNews
472,  May 5 Merck & Co Inc * Says European launch of its new Zepatier hepatitis C drug may may be delayed until late 2016 or 2017 after EU regulator cited inadequate record-keeping by a third party manufacturer  Source text for Eikon:  Further company coverage:    (Reporting by Ransdell Pierson)  ,2016-05-05,MRK,"Thu May 5, 2016 | 9:41am EDT",BRIEF-Merck says EU Zepatier launch may be delayed,http://www.reuters.com//article/idUSL2N1820O2?type=companyNews
473,  May 5 Merck & Co Inc* Says on conference call that third party manufacturer of its new Zepatier hepatitis C drug cited by EU regulators for inadquate record keeping  * Says does not believe recordkeeping lapses by manufacturer will affect supply of Zepatier to U.S. market  Source text for Eikon:  Further company coverage:    (Reporting by Ransdell Pierson) ,2016-05-05,MRK,"Thu May 5, 2016 | 9:10am EDT",BRIEF-Merck says EU manufacturer of Zepatier cited for recordkeeping lapses,http://www.reuters.com//article/idUSL2N1820JP?type=companyNews
474,"  (Repeats to show photo availability)By Ransdell PiersonMay 5 Merck & Co Inc on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug.But the second-largest U.S. drugmaker beat first-quarter earnings forecasts because of cost controls and a weakening dollar, and it slightly raised its full-year profit outlook.Combined sales of Januvia and a related combination medicine called Janumet edged up 1 percent to $1.41 billion, $30 million shy of Wall Street expectations. Demand for the drugs, Merck's biggest franchise and former sparkplugs for company growth, has waned due to new competition, including from Eli Lilly & Co's  Jardiance and other members of a family of medicines called SGLT-2 inhibitors. Remicade sales fell 30 percent to $349 million, $25 million below forecasts. The injectable treatment for rheumatoid arthritis faces escalating competition in Europe from cheaper biosimilars.A bright spot in the earnings report was Keytruda, a new cancer treatment that works by taking the brakes off the immune system. Its sales rose to $249 million from $83 million a year earlier, slightly above expectations.But Keytruda sales are ramping up more slowly than those of Bristol-Myers Squibb Co's similar new immuno-oncology product called Opdivo, which also treats melanoma and lung cancer and is being tested for an array of other types of cancer. Its sales jumped to $704 million in the quarter. For Merck, ""pressure on important marketed products such as Januvia and Remicade will likely limit near-term growth opportunities"" and offset faster-growing products like Keytruda, Credit Suisse analyst Vamil Divan said in a research note.Sales of animal health products were flat at $829 million, about $20 million below Wall Street forecasts, but would have risen 9 percent if not for the weakening dollar, which reduces sales outside the United States, Merck said. Total revenue slipped 1 percent to $9.31 billion, below the average estimate of $9.46 billion among analysts surveyed by Thomson Reuters I/B/E/S.Net income rose to $1.12 billion, or 40 cents per share, from $953 million, or 33 cents per share, a year earlier.Excluding special items, Merck earned 89 cents per share,  beating Wall Street expectations by 4 cents.Merck raised its full-year earnings forecast to a range of $3.65 to $3.77 per share from its prior outlook of $3.60 to$3.75. It increased the low end of its sales forecast to $39.0 billion from $38.7 billion while keeping the top end at $40.2 billion.   (Additional reporting by Natalie Grover in Bengaluru; Editing by Lisa Von Ahn)",2016-05-05,MRK,"Thu May 5, 2016 | 8:52am EDT","RPT-UPDATE 2-Merck sales disappoint as Januvia, Remicade fall short",http://www.reuters.com//article/merck-co-results-idUSL2N1820K0?type=companyNews
475,"   By Ransdell Pierson  Merck & Co Inc (MRK.N) on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug.    But the second-largest U.S. drugmaker beat first-quarter earnings forecasts because of cost controls and a weakening dollar, and it slightly raised its full-year profit outlook.    Combined sales of Januvia and a related combination medicine called Janumet edged up 1 percent to $1.41 billion, $30 million shy of Wall Street expectations. Demand for the drugs, Merck's biggest franchise and former sparkplugs for company growth, has waned due to new competition, including from Eli Lilly & Co's (LLY.N) Jardiance and other members of a family of medicines called SGLT-2 inhibitors.    Remicade sales fell 30 percent to $349 million, $25 million below forecasts. The injectable treatment for rheumatoid arthritis faces escalating competition in Europe from cheaper biosimilars.      A bright spot in the earnings report was Keytruda, a new cancer treatment that works by taking the brakes off the immune system. Its sales rose to $249 million from $83 million a year earlier, slightly above expectations.     But Keytruda sales are ramping up more slowly than those of Bristol-Myers Squibb Co's (BMY.N) similar new immuno-oncology product called Opdivo, which also treats melanoma and lung cancer and is being tested for an array of other types of cancer. Its sales jumped to $704 million in the quarter.    For Merck, ""pressure on important marketed products such as Januvia and Remicade will likely limit near-term growth opportunities"" and offset faster-growing products like Keytruda, Credit Suisse analyst Vamil Divan said in a research note.     Sales of animal health products were flat at $829 million, about $20 million below Wall Street forecasts, but would have risen 9 percent if not for the weakening dollar, which reduces sales outside the United States, Merck said. Total revenue slipped 1 percent to $9.31 billion, below the average estimate of $9.46 billion among analysts surveyed by Thomson Reuters I/B/E/S.Net income rose to $1.12 billion, or 40 cents per share, from $953 million, or 33 cents per share, a year earlier. Excluding special items, Merck earned 89 cents per share,  beating Wall Street expectations by 4 cents.Merck raised its full-year earnings forecast to a range of $3.65 to $3.77 per share from its prior outlook of $3.60 to$3.75. It increased the low end of its sales forecast to $39.0 billion from $38.7 billion while keeping the top end at $40.2 billion. (Additional reporting by Natalie Grover in Bengaluru; Editing by Lisa Von Ahn)",2016-05-05,MRK,"Thu May 5, 2016 | 8:49am EDT","Merck sales disappoint as Januvia, Remicade fall short",http://www.reuters.com//article/us-merck-co-results-idUSKCN0XW0YK?type=companyNews
476,"  May 5 Merck* Announces First Quarter 2016 financial results* Sees fy 2016 gaap earnings per share $1.96 to $2.23* Q1 non-GAAP earnings per share $0.89* Q1 GAAP earnings per share $0.40* Sees FY 2016 non-gaap earnings per share $3.65 to $3.77 * Sees FY 2016 revenue $39 billion to $40.2 billion* Q1 earnings per share view $0.85 -- Thomson Reuters I/B/E/S* First-Quarter pharmaceutical sales declined 2 percent to $8.1 billion, including a 4 percent negative impact from foreign exchange * Fy2016 revenue view $39.85 billion -- Thomson Reuters I/B/E/S* Continues to expect 2016 full-year GAAP EPS to be between $1.96 and $2.23 * Narrows and raises 2016 full-year non-GAAP EPS to be between $3.65 and $3.77* First-Quarter 2016 worldwide sales were $9.3 billion, a decrease of 1 percent* Fy2016 earnings per share view $3.71 -- Thomson Reuters I/B/E/S* Qtrly Januvia / Janumet sales $1,412 million versus $1,393 million* Qtrly Remicade  sales $349 million versus $501 million  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-05,MRK,"Thu May 5, 2016 | 6:57am EDT",BRIEF-Merck Q1 earnings per share $0.40,http://www.reuters.com//article/idUSASC08N4X?type=companyNews
477,  May 12 Merck & Co Inc * Merck to present Phase 3 data on investigational medicines Ertugliflozin and MK-1293 at the 76th scientific sessions of the American Diabetes Association  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-05-12,MRK,"Thu May 12, 2016 | 8:38am EDT",BRIEF-Merck to present Phase 3 data on Ertugliflozin and MK-1293,http://www.reuters.com//article/idUSASC08P7D?type=companyNews
478,"   By Brendan Pierson  A Merck & Co patent on a crystallized form of a B vitamin is invalid because Merck offered to sell the formula to an American company in 1998, a federal appeals court has ruled, reversing a lower court judge. The ruling, handed down Friday by a three-judge panel of the U.S. Court of Appeals for the Federal Circuit, is a victory for Actavis Inc. The generic drugmaker was sued by New Jersey-based Merck and Germany-based Bayer AG, which licenses the patent from Merck, over its plan to make generic versions of Bayer's birth control drugs Safyral and Beyaz.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/24Upr6B",2016-05-16,MRK,"Mon May 16, 2016 | 7:05am EDT",Merck B vitamin formula patent invalid due to on-sale bar - Federal Circuit,http://www.reuters.com//article/health-merck-idUSL2N18D0A2?type=companyNews
479,  May 24 Merck & Co Inc * Sets quarterly dividend of $0.46 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-05-24,MRK,"Tue May 24, 2016 | 2:36pm EDT",BRIEF-Merck sets quarterly dividend of 46 cents per share,http://www.reuters.com//article/idUSFWN18L0JL?type=companyNews
480,  May 27 Merck & Co Inc:* Shareholder proposal requesting report on disposal of unused or expired drugs was defeated at annual meeting  * Shareholder proposal requesting an independent board chairman rejected by shareholders - SEC filing  Source text: (1.usa.gov/1sfOMtA) Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-27,MRK,"Fri May 27, 2016 | 2:01pm EDT",BRIEF-Merck shareholder proposal for report on disposal of unused or expired drugs defeated,http://www.reuters.com//article/idUSFWN18O0D3?type=companyNews
481,  May 27 Merck & Co Inc : * Merck receives positive CHMP opinion for Zepatier(tm) (Elbasvir and Grazoprevir) in the European Union  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-05-27,MRK,"Fri May 27, 2016 | 7:59am EDT",BRIEF-Merck receives positive CHMP opinion for Zepatier in the EU,http://www.reuters.com//article/idUSFWN18O09U?type=companyNews
482,"   By Andrew Chung | NEW YORK  NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc  from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, based on findings that Merck's patents were valid.U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset, Inc, a company Gilead bought in 2011.Freeman also said Merck cannot enforce the patents because Merck's own lawyer gave inconsistent and untruthful testimony during the trial. ""Merck's acts are even more egregious because the main perpetrator of its misconduct was its attorney,"" she said.In a statement, Merck spokeswoman Lainie Keller said Gilead's allegations against the patents are without merit and the company would appeal. ""The judge's ruling does not reflect the facts of this case."" Gilead feels ""vindicated"" by the decision, spokeswoman Michele Rest said.Gilead had also been facing a demand from Merck for an ongoing royalty of at least 12 percent of all future sales of the drugs, according to court papers. Gilead made $23 billion on the two pills in the U.S. alone over the last two years. Pharmaceutical firms such as Merck, which recently launched its own hepatitis C drug, Zepatier, are trying to chip away at Gilead's dominant position in the market for a new generation of drugs, which cure the liver disease in well over 90 percent of patients.Some policy makers and insurers have criticized their costs. Harvoni, for instance, lists at $1,125 per pill before discounts and $94,000 for a 12-week regimen.The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs. After the jury verdict, Freeman separately dealt with Foster City, California-based Gilead's accusations of Merck's unethical conduct in obtaining the patents.Merck, based in Kenilworth, New Jersey, countered that it had already known of the technology Gilead claimed was Pharmasset's.Merck's partner in the suit and co-owner of the patents, Ionis Pharmaceuticals Inc, stood to receive 20 percent of any damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-06-07,MRK,"Tue Jun 7, 2016 | 6:57am EDT",Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N18Z01W?type=companyNews
483,"   By Andrew Chung | NEW YORK  NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni. The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, based on findings that Merck's patents were valid. U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset, Inc, a company Gilead bought in 2011.Freeman also said Merck cannot enforce the patents because Merck's own lawyer gave inconsistent and untruthful testimony during the trial. ""Merck's acts are even more egregious because the main perpetrator of its misconduct was its attorney,"" she said.In a statement, Merck spokeswoman Lainie Keller said Gilead's allegations against the patents are without merit and the company would appeal. ""The judge's ruling does not reflect the facts of this case."" Gilead feels ""vindicated"" by the decision, spokeswoman Michele Rest said.Gilead had also been facing a demand from Merck for an ongoing royalty of at least 12 percent of all future sales of the drugs, according to court papers. Gilead made $23 billion on the two pills in the U.S. alone over the last two years.Pharmaceutical firms such as Merck, which recently launched its own hepatitis C drug, Zepatier, are trying to chip away at Gilead's dominant position in the market for a new generation of drugs, which cure the liver disease in well over 90 percent of patients. Some policy makers and insurers have criticized their costs. Harvoni, for instance, lists at $1,125 per pill before discounts and $94,000 for a 12-week regimen. The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs.After the jury verdict, Freeman separately dealt with Foster City, California-based Gilead's accusations of Merck's unethical conduct in obtaining the patents.  Merck, based in Kenilworth, New Jersey, countered that it had already known of the technology Gilead claimed was Pharmasset's. Merck's partner in the suit and co-owner of the patents, Ionis Pharmaceuticals Inc, stood to receive 20 percent of any damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung; Editing by Bernard Orr and Andrew Hay)",2016-06-07,MRK,"Tue Jun 7, 2016 | 6:06am EDT",Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/us-gilead-sciences-merck-co-ruling-idUSKCN0YT01A?type=companyNews
484,"   By Andrew Chung | NEW YORK  NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni. The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, based on findings that Merck's patents were valid. U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset, Inc, a company Gilead bought in 2011.Freeman also said Merck cannot enforce the patents because Merck's own lawyer gave inconsistent and untruthful testimony during the trial. ""Merck's acts are even more egregious because the main perpetrator of its misconduct was its attorney,"" she said.In a statement, Merck spokeswoman Lainie Keller said Gilead's allegations against the patents are without merit and the company would appeal. ""The judge's ruling does not reflect the facts of this case."" Gilead feels ""vindicated"" by the decision, spokeswoman Michele Rest said.Gilead had also been facing a demand from Merck for an ongoing royalty of at least 12 percent of all future sales of the drugs, according to court papers. Gilead made $23 billion on the two pills in the U.S. alone over the last two years.Pharmaceutical firms such as Merck, which recently launched its own hepatitis C drug, Zepatier, are trying to chip away at Gilead's dominant position in the market for a new generation of drugs, which cure the liver disease in well over 90 percent of patients. Some policy makers and insurers have criticized their costs. Harvoni, for instance, lists at $1,125 per pill before discounts and $94,000 for a 12-week regimen. The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs.After the jury verdict, Freeman separately dealt with Foster City, California-based Gilead's accusations of Merck's unethical conduct in obtaining the patents.  Merck, based in Kenilworth, New Jersey, countered that it had already known of the technology Gilead claimed was Pharmasset's. Merck's partner in the suit and co-owner of the patents, Ionis Pharmaceuticals Inc, stood to receive 20 percent of any damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung; Editing by Bernard Orr and Andrew Hay)",2016-06-07,MRK,"Tue Jun 7, 2016 | 6:06am EDT",UPDATE 2-Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N18Z00Z?type=companyNews
485,"   By Andrew Chung | NEW YORK, June 6  NEW YORK, June 6 A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.  The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, after finding Merck's patents were valid.    (Reporting by Andrew Chung; Editing by Leslie Adler) ",2016-06-07,MRK,"Mon Jun 6, 2016 | 8:32pm EDT",Gileads escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N18Z009?type=companyNews
486,"  Merck & Co's experimental drug to treat the most common cause of hospital-associated infectious diarrhea warrants approval, an advisory panel to the U.S. Food and Drug Administration said on Thursday.The panel voted 10-5, with one abstention, that the drug, bezlotoxumab, was effective in preventing a recurrence of infection with Clostridium difficile, or C. difficile, a germ that causes inflammation of the colon and potentially fatal diarrhea.The FDA is not obliged to follow the advice of its advisory panels but typically does.The panel's vote follows an internal review by FDA staff which found an apparent decrease in recurrence of C. difficile but expressed concern as to whether the drug could hurt the cure rate of the initial C. difficile episode.Panelists who voted in favor of the drug acknowledged the FDA's concerns but said they were persuaded there was a need for new targeted therapies and this one seems effective. ""We haven't had a new drug for C. difficile in our armamentarium for some time,"" Dr. Joanna Schaenman, assistant professor of medicine at UCLA David Geffen School of Medicine, said.Spores from C. difficile bacteria cling to surfaces and can spread easily in hospitals and nursing homes. The germ infected nearly 500,000 people in 2011 and killed 15,000, according to the Centers for Disease Control.C. difficile is typically treated with antibiotics. But these kill good bacteria in the gut, setting up a vicious cycle in which low levels of good bacteria make it more difficult for the body to fend off the bad C. difficile germ.  Bezlotoxumab is designed to neutralize C. difficile toxin B, suppressing symptoms long enough for the body's natural flora to replenish and preventing the need for additional cycles of antibiotics.Still, not all panelists were convinced, saying the drug had been tested on too few people to be sure it was really helping achieve a sustained cure, and they worry the drug could even impede a cure. Dr. Lindsey Baden, director of clinical research at Brigham and Women's Hospital and the panel's acting chair, said the drug was promising but so far, ""the level of proof is not there yet.""The FDA is due to make its decision by July 23. (Reporting by Toni Clarke in Washington; Editing by David Gregorio and Matthew Lewis)",2016-06-09,MRK,"Thu Jun 9, 2016 | 6:07pm EDT",U.S. panel backs approval for Merck infectious diarrhea drug,http://www.reuters.com//article/us-merck-co-fda-idUSKCN0YV2ER?type=companyNews
487,"  June 9 Merck & Co Inc* Merck to acquire Afferent Pharmaceuticals * Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals * Under terms, Merck, through unit, to acquire outstanding stock of Afferent for an upfront payment of $500 million in cash * Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with attainment of certain milestones  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-06-09,MRK,"Thu Jun 9, 2016 | 5:35pm EDT",BRIEF-Merck to acquire Afferent Pharmaceuticals,http://www.reuters.com//article/idUSASC08TJF?type=companyNews
488,"  June 9 Agenus Inc :* Agenus announces lead product candidate selection in its collaboration with Merck * Based on this milestone and under terms of agreement, Agenus received a $2 million milestone payment from Merck  * Merck has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-06-09,MRK,"Thu Jun 9, 2016 | 9:16am EDT",BRIEF-Agenus announces lead product candidate selection in Merck collaboration,http://www.reuters.com//article/idUSFWN1910JN?type=companyNews
489,"  Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.An independent data monitoring board recommended that the late-stage trial be stopped due to the favorable results, Merck said, thereby allowing patients who were taking chemotherapy to switch over to the company's treatment.Keytruda, which takes the brakes off the immune system by blocking a protein called PD-1, is already approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer.Patients enrolled in the trial had tumors with high levels of PD-L1, a related protein whose presence may help identify which patients are most likely to respond to Keytruda and similar drugs called checkpoint inhibitors.    Merck hopes the new data will allow its injectable drug, which has a list price of about $150,000 a year, to be used earlier as a treatment for the most common form of lung cancer.Bristol-Myers Squibb Co's approved rival Opdivo is also being tested as a so-called first line treatment for NSCLC, with data expected later this year. Opdivo's studies have enrolled patients regardless of their PD-L1 levels, helping assure its wider use and greater sales than Keytruda.John Boris, an analyst with Suntrust Robinson Humphrey, on Thursday forecast that Keytruda will generate annual sales of $7 billion by 2021. But he predicted Keytruda will have only 25 to 30 percent of the first-line NSCLC market, while Opdivo commands a 65 to 70 percent market share. Shares of Merck rose 2.1 percent in afternoon trading on the New York Stock Exchange, amid slight gains for the ARCA Pharmaceutical Index of large drugmakers.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Marguerita Choy)",2016-06-16,MRK,"Thu Jun 16, 2016 | 1:54pm EDT",Merck's Keytruda prolongs life in big lung-cancer study,http://www.reuters.com//article/us-merck-keytruda-lung-idUSKCN0Z21OQ?type=companyNews
490,"  Advanced lung cancer patients who took Merck & Co Inc's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.An independent data monitoring board recommended that the late-stage trial be stopped due to the favorable results, Merck said, thereby allowing patients who were taking chemotherapy to switch over to the company's treatment.Keytruda, which takes the brakes off the immune system by blocking a protein called PD-1, is already approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer.Patients enrolled in the trial had tumors with high levels of PD-L1, a related protein whose presence may help identify which patients are most likely to respond to Keytruda and similar drugs called checkpoint inhibitors.    Merck hopes the new data will allow its injectable drug, which has a list price of about $150,000 a year, to be used earlier as a treatment for the most common form of lung cancer.Bristol-Myers Squibb Co's approved rival Opdivo is also being tested as a so-called first line treatment for NSCLC, with data expected later this year. Opdivo's studies have enrolled patients regardless of their PD-L1 levels, helping assure its wider use and greater sales than Keytruda.John Boris, an analyst with Suntrust Robinson Humphrey, on Thursday forecast that Keytruda will generate annual sales of $7 billion by 2021. But he predicted Keytruda will have only 25 to 30 percent of the first-line NSCLC market, while Opdivo commands a 65 to 70 percent market share. Shares of Merck rose 2.1 percent in afternoon trading on the New York Stock Exchange, amid slight gains for the ARCA Pharmaceutical Index of large drugmakers.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Marguerita Choy)",2016-06-16,MRK,"Thu Jun 16, 2016 | 1:54pm EDT",UPDATE 1-Merck's Keytruda prolongs life in big lung-cancer study,http://www.reuters.com//article/merck-co-keytruda-lung-idUSL1N1981CJ?type=companyNews
491,"  June 16 Advanced lung cancer patients who took Merck & Co's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday.An independent data monitoring board recommended that the late-stage trial be stopped due to the favorable results, Merck said, thereby allowing patients who were taking chemotherapy to switch over to the company's treatment. Keytruda, which takes the brakes off the immune system by blocking a protein called PD-1, is already approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer. Merck hopes the new data will allow the injectable drug, which has a list price of about $150,000 a year, to be used earlier as a treatment for the most common form of lung cancer.  The company, whose shares rose 1.1 percent in early trading, said it would provide detailed data from the study at an upcoming medical meeting.    (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2016-06-16,MRK,"Thu Jun 16, 2016 | 9:36am EDT",Merck's Keytruda prolongs life in big lung-cancer study,http://www.reuters.com//article/merck-keytruda-lung-idUSL1N1980OY?type=companyNews
492,"  June 16 Merck & Co Inc* Merck's keytruda (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer* Keynote-024 trial met its primary endpoint * Safety profile of keytruda in this trial was consistent with that observed in previously reported studies in patients with advanced nsclc * Based on these results, an independent data monitoring committee (dmc) has recommended that trial be stopped * Independent data monitoring committee  recommended patients receiving chemotherapy in keynote-024 be offered opportunity to receive keytruda.* Keytruda was superior compared to chemotherapy for primary endpoint of progression-free survival, and secondary endpoint of overall survival  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-06-16,MRK,"Thu Jun 16, 2016 | 6:50am EDT","BRIEF-Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients",http://www.reuters.com//article/idUSFWN198090?type=companyNews
493,"  June 20 Merck & Co Inc* Phase 2 study of Relebactam, in combination with Imipenem/Cilastatin for complicated urinary tract infections met primary endpoint  * Two pivotal Phase 3 clinical studies of Relebactam in combination with Imipenem/Cilastatin currently ongoing and recruiting patients  Source text for Eikon:  Further company coverage: ",2016-06-20,MRK,"Mon Jun 20, 2016 | 12:50pm EDT","BRIEF-Merck announces results of study of Relebactam, in combination with Imipenem/Cilastatin",http://www.reuters.com//article/idUSB8N19C02S?type=companyNews
494,  June 27 Merck & Co Inc* Merck receives chmp positive opinion for keytruda (pembrolizumab) for the treatment of advanced non-small cell lung cancer (nsclc)  * Small cell lung cancer (NSCLC)  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-06-27,MRK,"Mon Jun 27, 2016 | 6:25am EDT",BRIEF-Merck receives CHMP positive opinion for Keytruda in advanced non-small cell lung cancer,http://www.reuters.com//article/idUSASC08VBB?type=companyNews
495,  June 29 Merck & Co Inc * Merck and Moderna announce strategic collaboration to advance novel MRNA-based personalized cancer vaccines with keytruda (pembrolizumab) for the treatment of multiple types of cancer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ,2016-06-29,MRK,"Wed Jun 29, 2016 | 7:32am EDT",BRIEF-Merck and Moderna announce strategic collaboration,http://www.reuters.com//article/idUSFWN19L09Z?type=companyNews
496,"   By Andrew Chung  Gilead Sciences Inc may have scored a dramatic and unexpected win over Merck & Co earlier this month in a patent dispute over the world's best-selling hepatitis C cure, but the war over this highly lucrative class of treatments has only just begun. Gilead, the world's biggest biotechnology company, faces separate intellectual property attacks against its drugs for the liver disease, Sovaldi and Harvoni, on several other fronts, both in the United States and around the world.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/29390ho",2016-06-29,MRK,"Wed Jun 29, 2016 | 7:17am EDT","After hepatitis C patent win over Merck, Gilead faces other foes",http://www.reuters.com//article/ip-gilead-lawsuits-idUSL1N19L0B3?type=companyNews
497,  June 30 Merck & Co In* Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients  * Financial terms of agreements were not disclosed  Source text for Eikon: [ID: patients] Further company coverage: ,2016-06-30,MRK,"Thu Jun 30, 2016 | 9:28am EDT","BRIEF-Merck, Premier Inc collaborate to improve care for osteoporosis patients",http://www.reuters.com//article/idUSFWN19M0P5?type=companyNews
498,"   By Barbara Grzincic  Lawyers for longtime users of an osteoporosis drug will ask a federal appeals court on Thursday to revive their claims that Merck & Co., Inc. waited too long to warn of the risk of unusual leg fractures associated with its use. More than 1,000 plaintiffs whose cases were consolidated want the 3rd U.S. Circuit Court of Appeals to reverse a lower-court ruling that tossed their failure-to-warn claims, leaving only 20 active cases in the ""Fosamax Femur"" multidistrict litigation.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/294TSE5",2016-06-30,MRK,"Thu Jun 30, 2016 | 7:14am EDT",3rd Circuit to weigh Fosamax warning lawsuits against Merck,http://www.reuters.com//article/merck-labeling-case-idUSL1N19M0B8?type=companyNews
499,"  July 1 Merck Animal Health:* Will acquire approximately 93 pct of shares of Valle S.A. at closing, in exchange for a payment of $400 mln  * To acquire a controlling interest in Valle S.A  Source text for Eikon: ",2016-07-01,MRK,"Fri Jul 1, 2016 | 1:38pm EDT",BRIEF-Merck Animal Health to buy controlling interest in Valle S.A,http://www.reuters.com//article/idUSFWN19N0FH?type=companyNews
500,  (Adds full name of German company Merck KGaA)July 6 Pfizer Inc : * Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer * New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-nave women * First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780),2016-07-07,MRK,"Thu Jul 7, 2016 | 11:56am EDT",REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial,http://www.reuters.com//article/idUSFWN19S06Y?type=companyNews
501,"   By Brendan Pierson  Merck & Co has appealed a California federal judge's order that overturned a $200 million verdict it won in a patent case against Gilead Sciences over Gilead's lucrative hepatitis C drugs on the grounds that Merck engaged in extensive misconduct. On Tuesday, the same day Merck filed its notice of appeal, Gilead asked U.S. District Judge Beth Labson Freeman in San Jose to rule that Merck's patents were invalid as a matter of law, renewing a motion it filed before the verdict in the case.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/29jZ42d",2016-07-07,MRK,"Thu Jul 7, 2016 | 7:06am EDT",Merck appeals order reversing its $200 mln verdict against Gilead,http://www.reuters.com//article/health-merck-idUSL1N19T0BF?type=companyNews
502,  July 11 Merck & Co Inc* Merck's Healthcare Services & Solutions invests in majority stake in Staywell  * Terms of transaction were not disclosed.  Source text for Eikon:  Further company coverage: ,2016-07-11,MRK,"Mon Jul 11, 2016 | 7:26am EDT",BRIEF- Merck's Healthcare invests majority stake in Staywell,http://www.reuters.com//article/idUSFWN19X0H7?type=companyNews
503,"  LONDON British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research.The charity said on Friday that a private equity fund managed by DRI Capital had acquired a portion of its royalty entitlement on the worldwide sales of the medicine. Keytruda is one of a promising class of new treatments that stimulate the bodys immune system to fight cancer. It is an antibody-based medicine and was ""humanized"" by scientists at MRC Technology.   (Reporting by Ben Hirschler. Editing by Jane Merriman)",2016-07-14,MRK,"Thu Jul 14, 2016 | 7:24pm EDT",UK charity pockets $150 million from Merck cancer immunotherapy drug,http://www.reuters.com//article/us-merck-britain-charity-idUSKCN0ZU2RD?type=companyNews
504,"  LONDON British medical charity MRC Technology has pocketed $150 million by selling part of its royalty interest in Merck & Co's successful cancer drug Keytruda, allowing it to plough fresh funds into new research.The charity said on Friday that a private equity fund managed by DRI Capital had acquired a portion of its royalty entitlement on the worldwide sales of the medicine. Keytruda is one of a promising class of new treatments that stimulate the bodys immune system to fight cancer. It is an antibody-based medicine and was ""humanized"" by scientists at MRC Technology.   (Reporting by Ben Hirschler. Editing by Jane Merriman)",2016-07-14,MRK,"Thu Jul 14, 2016 | 7:24pm EDT",UK charity pockets $150 mln from Merck cancer immunotherapy drug,http://www.reuters.com//article/merck-britain-charity-idUSL8N1A03PM?type=companyNews
505,"   By Brendan Pierson  U.S. Supreme Court Chief Justice John Roberts issued a stay on Thursday of an appeals court decision that would allow Actavis PLC to launch generic versions of Bayer AG's birth control drugs Safyral and Beyaz in response to an application from Bayer and Merck & Co. The companies had asked for a stay on Tuesday, arguing that the U.S. Court of Appeals for the Federal Circuit in May wrongly held that a patent on B vitamin formulation used in the drugs is invalid under the so-called on-sale bar because Merck confidentially offered to sell the formulation to another company in 1998. The companies said they are planning to file a writ of certiorari appealing that decision.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2aeLSlu",2016-07-21,MRK,"Thu Jul 21, 2016 | 4:50pm EDT",Ruling invalidating Merck patent over on-sale bar stayed,http://www.reuters.com//article/health-beyaz-idUSL1N1A725M?type=companyNews
506,"  July 21 Merck & Co Inc :* Fda has requested submission of new data and analyses from modify I and modify II clinical trials previously submitted * Merck provides regulatory update on Biologics licensing application for investigational agent Bezlotoxumab * Merck provides regulatory update on Biologics licensing application for investigational agent Bezlotoxumab * New Bezlotoxumab PDUFA date will be Oct. 23, 2016.  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-21,MRK,"Thu Jul 21, 2016 | 4:46pm EDT",BRIEF-Merck provides regulatory update on Biologics application,http://www.reuters.com//article/idUSASC08XTD?type=companyNews
507,"  July 22 Merck & Co Inc* Says European Medicines Agency (EMA) has accepted file for investigational once-daily formulation of isentress for review* Resulted in non-inferior efficacy and safety to a regimen containing approved twice-daily formulation * Efficacy and safety data in previously untreated adults with hiv-1 infection for investigational once-daily formulation of isentress * Says EMA accepts file application, plans underway to submit for licensure to FDA this year * Study showed comparable rates of reported drug-related clinical adverse events and rates of discontinuation between two treatment groups* Says plans to submit applications for licensure in several countries, including united states later this year  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-22,MRK,"Fri Jul 22, 2016 | 7:41am EDT",BRIEF-Merck says EMA has accepted file for formulation of Isentress for review,http://www.reuters.com//article/idUSFWN1A80KD?type=companyNews
508,"  July 26 Enigma Biomedical Group Inc:* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240  * Announced a research collaboration agreement with Biogen Inc and Merck  Source text for Eikon: ",2016-07-25,MRK,"Mon Jul 25, 2016 | 5:28pm EDT",BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck,http://www.reuters.com//article/idUSFWN1AB0S6?type=companyNews
509,"  July 25 Merck & Co Inc* Merck is responsible for research, development, manufacturing, and regulatory efforts in support of v920  * Merck receives breakthrough therapy designation from fda and prime status from ema for investigational ebola zaire vaccine (v920)  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-07-25,MRK,"Mon Jul 25, 2016 | 9:18am EDT",BRIEF-Merck designated breakthrough therapy by FDA and gets prime status from EMA for ebola vaccine,http://www.reuters.com//article/idUSASC08Y0D?type=companyNews
510,  July 26 Merck & Co Inc : * Sets quarterly dividend of $0.46 per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-07-26,MRK,"Tue Jul 26, 2016 | 2:18pm EDT",BRIEF-Merck sets quarterly dividend of $0.46 per share,http://www.reuters.com//article/idUSFWN1AC0Z4?type=companyNews
511,"  July 27 Alk Abello A/S :* Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement* Said all rights to GRASTEK, RAGWITEK and investigational house dust mite SLIT-tablets for USA, Canada and Mexico to revert to ALK at no fee following six- month transition period* Ongoing registration processes for investigational HDM SLIT-tablet will continue * North America remains major business opportunity and ALK will now undertake full strategic analysis before deciding on revised strategy* Transaction has no impact on ALK's full-year outlook for 2016 * Acting CEO and Chairman Steen Riisgaard said: ""The timing of this move is unexpected"" Source text: bit.ly/2avKbQ0Further company coverage:(Gdynia Newsroom)",2016-07-27,MRK,"Wed Jul 27, 2016 | 1:25am EDT",BRIEF-Merck plans to end partnership agreement with Alk Abello,http://www.reuters.com//article/idUSL8N1AD0KM?type=companyNews
512,"   By Andrew Chung  Gilead Sciences Inc urged a California federal judge on Tuesday to not put off a decision on whether it is owed $15.5 million in legal fees in a patent fight over a lucrative cure for hepatitis C with drugmaker Merck & Co. Gilead, represented by Fish & Richardson, said U.S. District Judge Beth Labson Freeman in San Jose would be following 9th U.S. Circuit Court of Appeals precedent by ruling on attorneys' fees immediately and not waiting for Merck's appeal of its loss in the case.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2aj0UVi",2016-07-28,MRK,"Thu Jul 28, 2016 | 6:53am EDT","Gilead, Merck lock horns on legal fees in hepatitis C patent fight",http://www.reuters.com//article/ip-gilead-fees-idUSL1N1AE0CY?type=companyNews
513,"  Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).Pharmacy benefit managers, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications.When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing. ""We are cooperating with this investigation,"" the company said in a regulatory filing on Thursday. Lilly did not disclose the name of any PBM in the filing. (bit.ly/2atPwoI) The investigation comes nearly three months after federal prosecutors sought information from Johnson & Johnson, Merck & Co and Endo International Plc about their contracts with pharmacy benefit managers.  (Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty)",2016-07-28,MRK,"Thu Jul 28, 2016 | 2:42pm EDT",U.S. probes contracts between Eli Lilly and PBMs,http://www.reuters.com//article/us-eli-lilly-probe-idUSKCN1082D8?type=companyNews
514,"  Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).Pharmacy benefit managers, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications.When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing. ""We are cooperating with this investigation,"" the company said in a regulatory filing on Thursday. Lilly did not disclose the name of any PBM in the filing. (bit.ly/2atPwoI) The investigation comes nearly three months after federal prosecutors sought information from Johnson & Johnson, Merck & Co and Endo International Plc about their contracts with pharmacy benefit managers.  (Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty)",2016-07-28,MRK,"Thu Jul 28, 2016 | 2:42pm EDT",UPDATE 1-U.S. probes contracts between Eli Lilly and PBMs,http://www.reuters.com//article/eli-lilly-probe-idUSL4N1AE5C5?type=companyNews
515,"   By Brendan Pierson  Merck & Co Inc has asked a New Jersey federal judge to order law firm Sanford Heisler, which is representing plaintiffs in a sex discrimination lawsuit against the company, to stop what it called misleading communications to potential class members. In an emergency motion for a cease and desist order filed Tuesday in the U.S. District Court for the District of New Jersey, Merck said press releases issued by the firm soliciting potential class members had undermined the official notice to potential class members approved by the court.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2ayaANP",2016-07-28,MRK,"Thu Jul 28, 2016 | 6:52am EDT",Merck seeks to curb plaintiff firm's 'misleading' communications,http://www.reuters.com//article/health-merck-idUSL1N1AE0CU?type=companyNews
516,"   By Ransdell Pierson  Merck & Co (MRK.N) reported better-than-expected quarterly earnings, fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment, sending its shares up 2 percent in premarket trading.       The second-biggest U.S. drugmaker said revenue grew 1 percent in the second quarter to $9.84 billion, above analysts' average estimate of $9.78 billion.    Keytruda, a recently approved treatment for melanoma and lung cancer that Merck is counting on to boost its earnings for years to come, posted sales of $314 million, about $20 million more than analysts had forecast.     The medicine, which takes the brakes off the immune system, is competing with Bristol-Myers Squibb Co's (BMY.N) similar Opdivo treatment. They belong to a new family of medicines called PD-1 inhibitors.Keytruda was approved in October 2015 for patients with advanced lung cancer who had failed to benefit from previous treatments. A recent clinical trial suggested Keytruda is also effective in previously untreated patients, spurring hopes U.S. regulators will soon expand approved use of the drug to that far larger population.        Combined sales of Januvia and a related diabetes drug called Janumet rose 2 percent to $1.63 billion, topping forecasts by about $56 million.  But the medicines, facing growing competition, are no longer big earnings drivers for Merck.MIXED RATINGS  Merck's new Zepatier treatment for hepatitis C, which has been on the U.S. market for about six months, contributed $112 million in sales during the quarter.Credit Suisse analyst Vamil Divan said growing sales of newer drugs like Keytruda and Zepatier will likely be offset by future declines for older products, including Januvia and cholesterol fighters, Vytorin and Zetia. He has a ""neutral"" rating on the drugmaker. But J.P.Morgan analyst Chris Schott maintained his ""overweight"" rating on Merck, citing confidence in prospects for Keytruda, which is also being studied for many other types of cancer. Merck earned $1.21 billion, or 43 cents per share, in the quarter. That compared with $688 million, or 24 cents per share, in the year-earlier period, when Merck took charges for its acquisition of Cubist Pharmaceuticals.    Excluding special items, the company earned 93 cents per share, ahead of the average analyst estimate of 91 cents, according to Thomson Reuters I/B/E/S. Merck now expects full-year earnings per share of $3.67 to $3.77, excluding special items. It previously forecast $3.65 to $3.77 per share.  (Additional reporting by Ankur Banerjee in Bengaluru; Editing by Bernadette Baum)",2016-07-29,MRK,"Fri Jul 29, 2016 | 9:16am EDT","Merck quarterly results beat forecasts, shares rise",http://www.reuters.com//article/us-merck-co-results-idUSKCN10917E?type=companyNews
517,"   By Ransdell Pierson  Merck & Co (MRK.N) reported better-than-expected quarterly earnings, fueled by sales of its new Keytruda immuno-oncology drug and Januvia diabetes treatment, sending its shares up 2 percent in premarket trading.       The second-biggest U.S. drugmaker said revenue grew 1 percent in the second quarter to $9.84 billion, above analysts' average estimate of $9.78 billion.    Keytruda, a recently approved treatment for melanoma and lung cancer that Merck is counting on to boost its earnings for years to come, posted sales of $314 million, about $20 million more than analysts had forecast.     The medicine, which takes the brakes off the immune system, is competing with Bristol-Myers Squibb Co's (BMY.N) similar Opdivo treatment. They belong to a new family of medicines called PD-1 inhibitors.Keytruda was approved in October 2015 for patients with advanced lung cancer who had failed to benefit from previous treatments. A recent clinical trial suggested Keytruda is also effective in previously untreated patients, spurring hopes U.S. regulators will soon expand approved use of the drug to that far larger population.        Combined sales of Januvia and a related diabetes drug called Janumet rose 2 percent to $1.63 billion, topping forecasts by about $56 million.  But the medicines, facing growing competition, are no longer big earnings drivers for Merck.MIXED RATINGS  Merck's new Zepatier treatment for hepatitis C, which has been on the U.S. market for about six months, contributed $112 million in sales during the quarter.Credit Suisse analyst Vamil Divan said growing sales of newer drugs like Keytruda and Zepatier will likely be offset by future declines for older products, including Januvia and cholesterol fighters, Vytorin and Zetia. He has a ""neutral"" rating on the drugmaker. But J.P.Morgan analyst Chris Schott maintained his ""overweight"" rating on Merck, citing confidence in prospects for Keytruda, which is also being studied for many other types of cancer. Merck earned $1.21 billion, or 43 cents per share, in the quarter. That compared with $688 million, or 24 cents per share, in the year-earlier period, when Merck took charges for its acquisition of Cubist Pharmaceuticals.    Excluding special items, the company earned 93 cents per share, ahead of the average analyst estimate of 91 cents, according to Thomson Reuters I/B/E/S. Merck now expects full-year earnings per share of $3.67 to $3.77, excluding special items. It previously forecast $3.65 to $3.77 per share.  (Additional reporting by Ankur Banerjee in Bengaluru; Editing by Bernadette Baum)",2016-07-29,MRK,"Fri Jul 29, 2016 | 9:16am EDT","UPDATE 2-Merck quarterly results beat forecasts, shares rise",http://www.reuters.com//article/merck-co-results-idUSL4N1AF4EM?type=companyNews
518,"  July 29 Merck & Co Inc reported a 1 percent rise in quarterly revenue, driven by higher sales of its cancer drug, Keytruda.Net income soared to $1.21 billion, or 43 cents per share, in the second quarter, from $688 million, or 24 cents per share, a year earlier.  The company's revenue rose to $9.84 billion from $9.79 billion.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Maju Samuel) ",2016-07-29,MRK,"Fri Jul 29, 2016 | 6:54am EDT",Merck & Co reports 1 pct rise in quarterly revenue,http://www.reuters.com//article/merck-co-results-idUSL4N1AF4DW?type=companyNews
519,"  July 29 Merck Announces Second* Q2 januvia/janumet sales $ 1,634 million versus $1,412 million in q1* Second-Quarter pharmaceutical sales increased 2 percent to $8.7 billion* Raised bottom end of its full-year 2016 non-gaap eps range* Full-Year 2016 gaap eps range reflects impact of intangible asset impairment charges and higher restructuring costs incurred in q2* Fy2016 earnings per share view $3.72, revenue view $39.49 billion -- Thomson Reuters I/B/E/S* Merck & co inc qtrly keytruda total sales $314 million versus  $110 million * Fy 2016 revenue outlook includes an approximately 2 percent negative impact from foreign exchange at current exchange rates* Quarter 2016 financial results* Q2 non-gaap earnings per share $0.93 * Q2 gaap earnings per share $0.43* Q2 sales $9.8 billion versus i/b/e/s view $9.78 billion* Q2 earnings per share view $0.91 -- Thomson Reuters I/B/E/S * Sees fy 2016 non-gaap earnings per share $3.67 to $3.77* Sees fy 2016 gaap earnings per share $1.98 to $2.08* Q2 remicade sales $339 million versus $455 million* Merck has narrowed its full-year 2016 revenue range to be between $39.1 billion and $40.1 billion* Lowered its full-year 2016 gaap eps range* As of june 30, 2016, merck had approximately 68,000 employees worldwide  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780)",2016-07-29,MRK,"Fri Jul 29, 2016 | 6:50am EDT",BRIEF-Merck Q2 adjusted earnings per share $0.93,http://www.reuters.com//article/idUSASC08ZGX?type=companyNews
520,"   By Brendan Pierson  A federal judge has declined to bar the plaintiffs' firm Sanford Heisler from soliciting potential collective action members in a sex discrimination lawsuit against Merck & Co Inc after the firm said it is not planning any more communications to solicit members, denying a motion on Friday by the drugmaker as moot. Merck said in a motion last Tuesday that Sanford Heisler's communications with potential class members were misleading. The New Jersey-based drugmaker had asked U.S. District Judge Michael Shipp in Trenton, New Jersey to block the firm from further communications during the opt-in period, which ends Aug. 12, and to order it to retract earlier communications.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2at2NyA",2016-08-01,MRK,"Mon Aug 1, 2016 | 5:44pm EDT",Merck motion to bar plaintiff firm's communications denied as moot,http://www.reuters.com//article/health-merck-idUSL1N1AI1QX?type=companyNews
521,"  Aug 1 British quantum dots maker Nanoco Group Plc said it had entered into a non-exclusive licence deal with Merck for the German drugmaker to use its technology in digital displays, sending its shares up as much as 10 percent.Nanoco has been hunting for a new licensing deal for the past few months since it switched from exclusive to non-exclusive its deal with Dow Chemical Co for commercial production of quantum dots to be used in digital displays. Under the license, Merck would be able to immediately start marketing Nanoco's cadmium-free quantum dots and ultimately establish its own production facility, Nanoco said in a statement on Monday. The British firm did not disclose the financial details of the deal, but said it would receive a licence fee and royalties on Merck's sales of the Nanoco cadmium-free quantum dots manufactured. Quantum dots are semiconductor crystals 10,000 times finer than a human hair. They convert electrical energy into light and can be manipulated to produce precise colours, and are mostly used in television sets.   (Reporting by Esha Vaish in Bengaluru; Editing by Sunil Nair)",2016-08-01,MRK,"Mon Aug 1, 2016 | 3:31am EDT",Nanoco signs deal with Merck for use of quantum dot technology,http://www.reuters.com//article/nanoco-group-deals-merck-idUSL3N1AI2RN?type=companyNews
522,  Aug 2 Merck & Co Inc * Merck's KEYTRUDA (pembrolizumab) approved by the European Commission for patients with advanced non-small cell lung cancer (nsclc) whose tumors express pd-l1  Source text for Eikon:  Further company coverage:  ,2016-08-02,MRK,"Tue Aug 2, 2016 | 5:54pm EDT",BRIEF-European Commission approves Merck's anti-PD-1 therapy KEYTRUDA,http://www.reuters.com//article/idUSFWN1AJ0VR?type=companyNews
523,"   By Chuck Mikolajczak | NEW YORK  NEW YORK Wall Street stocks fell on Tuesday, with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth.Shares of Ford (F.N) and General Motors (GM.N) dropped more than 4 percent each after the two major U.S. automakers reported July vehicle sales slightly below expectations.The automakers' declines pulled the S&P consumer discretionary sector .SPLRCD down 1.5 percent as the worst- performing of the 10 major S&P groups. Data showed U.S. consumer spending rose more than expected in June as households bought a range of goods and services.However, personal income rose only 0.2 percent, missing estimates of 0.3 percent, while inflation remained below the Federal Reserve's 2 percent target. That could keep the central bank on a cautious path to hiking interest rates. ""People are starting to see that things arent quite as rosy as they might have thought in the month of July with that big run up,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois. The S&P 500 climbed 3.6 percent in July, its best month since March.   Another drop in U.S. crude CLc1 below $40 a barrel also weighed on sentiment, as the commodity settled down 1.4 percent at $39.51. Pfizer (PFE.N), was the biggest percentage decliner on the Dow, after the largest U.S. drugmaker reported better-than-expected quarterly results but revenue from its branded patent-protected medicines was disappointing.       The Dow Jones industrial average .DJI fell 90.74 points, or 0.49 percent, to 18,313.77, the S&P 500 .SPX lost 13.81 points, or 0.64 percent, to 2,157.03 and the Nasdaq Composite .IXIC dropped 46.46 points, or 0.9 percent, to 5,137.73. CVS (CVS.N) jumped more than 5 percent to $98.57 after the drugstore chain operator's quarterly profit beat estimates.Of the 353 companies in the S&P 500 that have reported earnings through Tuesday morning, 71 percent have topped analyst expectations, according to Thomson Reuters data. Earnings for the second quarter are expected to show a decline of 2.6 percent, an improvement from the expected 4.5 percent decline on July 1. Equities pared early losses after a report in the Wall Street Journal that biotechnology giant Biogen Inc (BIIB.O) has drawn takeover interest from drug companies, including Merck & Co Inc (MRK.N) and Allergan Plc (AGN.N). Biogen shares surged 9.4 percent to $330.11 and the Nasdaq biotechnology index .NBI climbed 0.2 percent after falling as much as 1.8 percent.    Declining issues outnumbered advancing ones on the NYSE by a 3.35-to-1 ratio; on Nasdaq, a 2.97-to-1 ratio favored decliners.The S&P 500 posted 14 new 52-week highs and 1 new low; the Nasdaq Composite recorded 54 new highs and 38 new lows.  About 7.45 billion shares changed hands on U.S. exchanges, compared with the 6.64 billion daily average over the last 20 sessions.  (Reporting by Chuck Mikolajczak; Editing by Chris Reese and Dan Grebler)",2016-08-02,MRK,"Tue Aug 2, 2016 | 4:32pm EDT",Wall St. falls as weak auto sales spur growth jitters,http://www.reuters.com//article/us-usa-stocks-idUSKCN10D14A?type=companyNews
524,"   By Chuck Mikolajczak | NEW YORK  NEW YORK Wall Street stocks fell on Tuesday, with each of the major indexes notching their worst day in about a month as economic data and weaker-than-expected auto sales spurred concerns about growth.Shares of Ford (F.N) and General Motors (GM.N) dropped more than 4 percent each after the two major U.S. automakers reported July vehicle sales slightly below expectations.The automakers' declines pulled the S&P consumer discretionary sector .SPLRCD down 1.5 percent as the worst- performing of the 10 major S&P groups. Data showed U.S. consumer spending rose more than expected in June as households bought a range of goods and services.However, personal income rose only 0.2 percent, missing estimates of 0.3 percent, while inflation remained below the Federal Reserve's 2 percent target. That could keep the central bank on a cautious path to hiking interest rates. ""People are starting to see that things arent quite as rosy as they might have thought in the month of July with that big run up,"" said Peter Jankovskis, co-chief investment officer at OakBrook Investments LLC in Lisle, Illinois. The S&P 500 climbed 3.6 percent in July, its best month since March.   Another drop in U.S. crude CLc1 below $40 a barrel also weighed on sentiment, as the commodity settled down 1.4 percent at $39.51. Pfizer (PFE.N), was the biggest percentage decliner on the Dow, after the largest U.S. drugmaker reported better-than-expected quarterly results but revenue from its branded patent-protected medicines was disappointing.       The Dow Jones industrial average .DJI fell 90.74 points, or 0.49 percent, to 18,313.77, the S&P 500 .SPX lost 13.81 points, or 0.64 percent, to 2,157.03 and the Nasdaq Composite .IXIC dropped 46.46 points, or 0.9 percent, to 5,137.73. CVS (CVS.N) jumped more than 5 percent to $98.57 after the drugstore chain operator's quarterly profit beat estimates.Of the 353 companies in the S&P 500 that have reported earnings through Tuesday morning, 71 percent have topped analyst expectations, according to Thomson Reuters data. Earnings for the second quarter are expected to show a decline of 2.6 percent, an improvement from the expected 4.5 percent decline on July 1. Equities pared early losses after a report in the Wall Street Journal that biotechnology giant Biogen Inc (BIIB.O) has drawn takeover interest from drug companies, including Merck & Co Inc (MRK.N) and Allergan Plc (AGN.N). Biogen shares surged 9.4 percent to $330.11 and the Nasdaq biotechnology index .NBI climbed 0.2 percent after falling as much as 1.8 percent.    Declining issues outnumbered advancing ones on the NYSE by a 3.35-to-1 ratio; on Nasdaq, a 2.97-to-1 ratio favored decliners.The S&P 500 posted 14 new 52-week highs and 1 new low; the Nasdaq Composite recorded 54 new highs and 38 new lows.  About 7.45 billion shares changed hands on U.S. exchanges, compared with the 6.64 billion daily average over the last 20 sessions.  (Reporting by Chuck Mikolajczak; Editing by Chris Reese and Dan Grebler)",2016-08-02,MRK,"Tue Aug 2, 2016 | 4:32pm EDT",US STOCKS-Wall St falls as weak auto sales spur growth jitters,http://www.reuters.com//article/usa-stocks-idUSL1N1AJ1W0?type=companyNews
525,"  (Adds Biogen, Enbridge, Tesla, Singapore Exchange, Tullett Prebon)Aug 2 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:** Biotechnology giant Biogen Inc has drawn takeover interest from drug companies including Merck & Co Inc  and Allergan Plc, the Wall Street Journal reported, citing people familiar with the matter.** Canadian energy firm Enbridge has won the auction for a stake in EnBW's Hohe See, one of Europe's largest offshore wind power projects, a person familiar with the matter told Reuters on Tuesday.** Elon Musk and key institutional investors will probably tighten their control over electric car maker Tesla Motors Inc  after it acquires sister company SolarCity Inc , a Reuters analysis shows.** Private equity firm Carlyle Group said it could make a pair of acquisitions in Japan worth $2 billion apiece, a strategic departure from a previous focus on smaller deals as big Japanese firms are gearing up for spinoffs of larger assets. ** British bookmaker William Hill Plc said on Tuesday it bought software maker Grand Parade Ltd for 13.6 million pounds ($18 million) in cash and stock.** Japan's Nidec Corp said it would buy U.S. Emerson Electric Co's motors and electric power generation unit for $1.2 billion, seeking to expand its industrial and commercial businesses as the market for consumer goods such as smartphones and laptops slows. ** Singapore Exchange Ltd (SGX) is readying a formal offer to buy London's Baltic Exchange following months of discussions that culminated in exclusive talks between both parties, sources familiar with the matter said on Tuesday.** Britain's competition watchdog said it would not refer French insurer AXA's sale of its UK investment and pensions business to Phoenix Group for further investigation.Competition and Markets Authority (CMA) has also accepted in principle merger undertakings between Tullett Prebon Plc  and ICAP Plc. ** Banco Santander has made an offer to take over Royal Bank of Scotland's Williams & Glyn business, two sources familiar with the matter told Reuters on Tuesday, as part of a long-standing plan to grow its market share in Britain.** A merger between Chinese ride-hailing firm Didi Chuxing and the China unit of U.S. rival Uber could face its first hiccup after China's commerce ministry (Mofcom) said on Tuesday it had not received a necessary application to allow the deal to go ahead.** China's Sinopec Corp said on Tuesday it would sell half of its premium natural gas pipeline business to investors, a move spurred by Beijing's reform push to boost efficiency and increase infrastructure investment in cleaner fuel.** The new boss of Fresenius SE & Co KGaA, who in his previous job as head of finance worked on several takeover deals for the diversified German healthcare group, said large transactions might well remain his hallmark.** Indian drugmaker Lupin Ltd said it had agreed to buy a portfolio of 21 drugs from Japan's Shionogi & Co Ltd  for 15.4 billion yen ($150 million), expanding its presence in its third-largest market.    (Compiled by Manish Parashar in Bengaluru)",2016-08-02,MRK,"Tue Aug 2, 2016 | 4:05pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N1AJ3E6?type=companyNews
526,"  (Adds dropped word 'percent' in third paragraph)Aug 2 Biotechnology giant Biogen Inc  has drawn takeover interest from drug companies including Merck & Co Inc and Allergan Plc, the Wall Street Journal reported, citing people familiar with the matter. The talks were informal and preliminary, the Journal said, adding the talks might not result in a deal, in part because Biogen may not be interested. (on.wsj.com/2aKYrnp) Biogen's shares shot up nearly 9 percent on Tuesday. Biogen, Merck and Allergan were not immediately available for comment.   (Reporting by Anya George Tharakan in Bengaluru; Editing by Savio D'Souza)",2016-08-02,MRK,"Tue Aug 2, 2016 | 2:58pm EDT","REFILE-Biogen draws takeover interest from Merck, Allergan - WSJ",http://www.reuters.com//article/biogen-ma-idUSL3N1AJ4MM?type=companyNews
527,"  Aug 2 (Reuters) - * Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan Plc- WSJ, citing sources  Source (on.wsj.com/2b0s6q9)   (Bengaluru Newsroom: +1-646-223-8780)  ",2016-08-02,MRK,"Tue Aug 2, 2016 | 2:47pm EDT",BRIEF-Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan - WSJ,http://www.reuters.com//article/idUSFWN1AJ0U4?type=companyNews
528,"  (Adds Wal-Mart, Biogen, Aetna, Time Warner, Titan Cement, LOT, Irving Oil; Updates Fiat, Petrobras)Aug 3 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:** Wal-Mart Stores Inc is in talks to buy Jet.com, a year-old online rival, as part of a multibillion-dollar revamp of its e-commerce division aimed at boosting online sales growth. The online retailer could be worth as much as $3 billion.** U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter.** Samsung Electronics could buy Fiat Chrysler Automobiles' parts maker, Magneti Marelli, for more than $3 billion, Bloomberg said in a source-based report.** TIAA, the financial services firm seeking to expand in internet banking, has been in exclusive negotiations to acquire U.S. online lender EverBank Financial Corp Inc for $2.5 billion, people familiar with the matter said. ** Health insurer Aetna Inc, which is seeking to save its merger with rival Humana, urged a judge to hear its case in the fall and before hearing a second merger of two other insurance companies that antitrust enforcers are trying to stop.** Brazil's state-run oil company Petroleo Brasileiro SA  could get up to 2.5 billion reais ($768.07 million) from the sale of its liquefied natural gas distributor Liquigs Distribuidora SA, a local daily reported.Also, Brazil's Gouvea Vieira family plans to team up with a Brazilian investment fund to bid for control of the BR Distribuidora fuels distribution unit of Petroleo Brasileiro, the family's most prominent member said.** Time Warner Inc disclosed a 10 percent stake in video streaming site Hulu on Wednesday, setting its sights on the web TV market. The company, which also owns the Warner Bros movie studio, is paying $583 million for the Hulu stake. ** Allergan Plc said it would sell its Anda Inc distribution business to Israel's Teva Pharmaceutical Industries Ltd for $500 million, a day after Teva completed its $40.5 billion acquisition of the Dublin-based company's generics business.** LafargeHolcim Ltd has agreed to sell to Huaxin Cement Co Ltd most of the non-listed Chinese cement assets of Lafarge China Cement Ltd for an estimated 208 million Swiss francs ($215 million), the Swiss-French cement group said.** Greece's Titan Cement said on Wednesday it is buying a stake in Brazilian cement manufacturer Companhia Industrial de Cimento Apodi for about $100 million.** The European Commission authorized a joint venture in the Netherlands between British telecoms firm Vodafone  and U.S. cable operator Liberty Global in exchange for concessions. ** German postal and logistics company Deutsche Post DHL Group said it was selling its long-distance bus unit, Postbus, to market leader Flixbus due to tough competition.** Sun Life Financial Inc said it will acquire the pension business of FWD Hong Kong in the latest stage of its rapid expansion in Asia.** Poland is in talks with potential investors from China over selling a stake in the state airline LOT, Deputy Prime Minister Mateusz Morawiecki said on Wednesday.** Irving Oil said on Wednesday it agreed to buy Ireland's only refinery from Phillips 66, a deal that will extend the Canadian company's reach across the Atlantic.** The founding family of Japan's Idemitsu Kosan Co  has bought a stake in Showa Shell Sekiyu KK, in a bid to block Idemitsu management's billion-dollar plan to take over the rival oil refiner, the family's lawyer said.    (Compiled by Manish Parashar in Bengaluru)",2016-08-03,MRK,"Wed Aug 3, 2016 | 4:00pm EDT",Deals of the day-Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N1AK3J4?type=companyNews
529,"   By Ransdell Pierson  Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine.Shares of Bristol-Myers fell almost 16 percent to $63.54 on Friday after the company announced failure of the late-stage trial. Shares of Merck gained 8.7 percent to $62.89. ""This is the worst-case scenario"" for Opdivo and Bristol-Myers, Leerink analyst Seamus Fernandez said in a research note. ""There appears to be no silver lining.""Opdivo had been considered the clear leader in a costly new class of medicines called checkpoint inhibitors that work by taking the brakes off the immune system. Its second-quarter sales of $840 million were more than double those of Merck's Keytruda. Opdivo won approval in March 2015 for treatment of patients with advanced non-small cell lung cancer who had previously failed to benefit from chemotherapy. Six months later, Keytruda received approval for a similar patient population. Meanwhile, both companies raced to complete large trials to see if their drugs, which each cost about $150,000 a year, would also benefit patients who had never previously been treated for the most common form of lung cancer. The trials compared the drugs against chemotherapy. ""Obviously the results of this trial are disappointing,"" Bristol-Myers Chief Executive Giovanni Caforio said in an interview, saying that the data suggests there is no role in the foreseeable future for Opdivo as a standalone medicine for previously untreated lung cancer.Patients in the Opdivo trial had tumors with low levels of PD-L1, a protein whose presence may help identify those most likely to benefit from checkpoint inhibitors. Those in the successful Merck trial, by contrast, were only enrolled if they were shown to have high levels of PD-L1 and represented a smaller percentage of the lung cancer population.Caforio said the best hope now for Opdivo in front-line treatment of lung cancer is combination therapy. The company is conducting a late-stage study with more than 2,000 patients in which Opdivo will be combined with Bristol-Myers' other approved immunotherapy, Yervoy. The data is expected by early 2018. ""That study will provide the definitive answer of the role of combination immunotherapy in the front-line lung cancer setting,"" he said.Data in June from a large clinical study showed Keytruda was effective in newly treated patients, not only in delaying progression of lung cancer symptoms but also in prolonging survival. The trial was stopped so that all patients could receive Keytruda.The data spurred hopes that U.S. regulators would soon expand approved use of the Merck drug. Complete data for the study has not yet been released.  Now that Bristol-Myers' drug has failed in that effort, Merck's medicine could have a better chance to catch up with Opdivo's far larger sales. Sanford Bernstein analyst Tim Anderson said Opdivo, Keytruda and similar drugs in development had been expected to capture peak annual combined sales of $10 billion to $15 billion from lung cancer, with Bristol-Myers winning the lion's share.""Today's news very much helps level the playing field and is a major boost for Merck,"" Anderson said in a research note.Opdivo and Keytruda are also approved to treat advanced melanoma and are being studied against a wide range of other types of cancer. (Additional reporting by Natalie Grover in Bengaluru; Editing by Bernard Orr and Leslie Adler)",2016-08-05,MRK,"Fri Aug 5, 2016 | 3:19pm EDT",Bristol-Myers' Opdivo fails lung cancer trial; shares plunge,http://www.reuters.com//article/us-bristol-myers-study-idUSKCN10G1GA?type=companyNews
530,"   By Ransdell Pierson  Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine.Shares of Bristol-Myers fell almost 16 percent to $63.54 on Friday after the company announced failure of the late-stage trial. Shares of Merck gained 8.7 percent to $62.89. ""This is the worst-case scenario"" for Opdivo and Bristol-Myers, Leerink analyst Seamus Fernandez said in a research note. ""There appears to be no silver lining.""Opdivo had been considered the clear leader in a costly new class of medicines called checkpoint inhibitors that work by taking the brakes off the immune system. Its second-quarter sales of $840 million were more than double those of Merck's Keytruda. Opdivo won approval in March 2015 for treatment of patients with advanced non-small cell lung cancer who had previously failed to benefit from chemotherapy. Six months later, Keytruda received approval for a similar patient population. Meanwhile, both companies raced to complete large trials to see if their drugs, which each cost about $150,000 a year, would also benefit patients who had never previously been treated for the most common form of lung cancer. The trials compared the drugs against chemotherapy. ""Obviously the results of this trial are disappointing,"" Bristol-Myers Chief Executive Giovanni Caforio said in an interview, saying that the data suggests there is no role in the foreseeable future for Opdivo as a standalone medicine for previously untreated lung cancer.Patients in the Opdivo trial had tumors with low levels of PD-L1, a protein whose presence may help identify those most likely to benefit from checkpoint inhibitors. Those in the successful Merck trial, by contrast, were only enrolled if they were shown to have high levels of PD-L1 and represented a smaller percentage of the lung cancer population.Caforio said the best hope now for Opdivo in front-line treatment of lung cancer is combination therapy. The company is conducting a late-stage study with more than 2,000 patients in which Opdivo will be combined with Bristol-Myers' other approved immunotherapy, Yervoy. The data is expected by early 2018. ""That study will provide the definitive answer of the role of combination immunotherapy in the front-line lung cancer setting,"" he said.Data in June from a large clinical study showed Keytruda was effective in newly treated patients, not only in delaying progression of lung cancer symptoms but also in prolonging survival. The trial was stopped so that all patients could receive Keytruda.The data spurred hopes that U.S. regulators would soon expand approved use of the Merck drug. Complete data for the study has not yet been released.  Now that Bristol-Myers' drug has failed in that effort, Merck's medicine could have a better chance to catch up with Opdivo's far larger sales. Sanford Bernstein analyst Tim Anderson said Opdivo, Keytruda and similar drugs in development had been expected to capture peak annual combined sales of $10 billion to $15 billion from lung cancer, with Bristol-Myers winning the lion's share.""Today's news very much helps level the playing field and is a major boost for Merck,"" Anderson said in a research note.Opdivo and Keytruda are also approved to treat advanced melanoma and are being studied against a wide range of other types of cancer. (Additional reporting by Natalie Grover in Bengaluru; Editing by Bernard Orr and Leslie Adler)",2016-08-05,MRK,"Fri Aug 5, 2016 | 3:19pm EDT",UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge,http://www.reuters.com//article/bristol-myers-study-idUSL4N1AM1PC?type=companyNews
531,"   By Ben Hirschler | LONDON  LONDON AstraZeneca (AZN.L) shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer (PFE.N) in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.The British firm's stock has been on a roll recently, helped by a falling pound and speculation that Switzerland's Novartis (NOVN.S) might be next to launch a bid. However, the shares were lifted to a high of 55.05 pounds by the misfortunes of Bristol-Myers Squibb (BMY.N).The failure of Bristol's immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck & Co (MRK.N) and AstraZeneca. Analysts at Leerink, Jefferies and Deutsche Bank said the negative result with Opdivo increased the potential market opportunity for AstraZeneca's keenly watched combination of durvalumab and tremelimumab.Crucial clinical trial results with durvalumab, both on its own and in combination with tremelimumab, are due next year. Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system. And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals. Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again, with speculation turning last week to Novartis as a bidder.  (Editing by Dale Hudson)",2016-08-05,MRK,"Fri Aug 5, 2016 | 10:43am EDT","AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes",http://www.reuters.com//article/us-astrazeneca-cancer-idUSKCN10G1L6?type=companyNews
532,"  Aug 5 Merck Announces U.S. FDA Filing Acceptance Of New Drug Application (NDA) For Mk* 1293, an investigational follow-on biologic insulin Glargine * Merck announces U.S. FDA filing acceptance of new drug application (NDA) for mk-1293, an investigational follow-on biologic insulin Glargine  * Marketing authorization application to European medicines agency currently under review  Source text for Eikon:  Further company coverage:",2016-08-05,MRK,"Fri Aug 5, 2016 | 8:15am EDT",BRIEF-Merck announces U.S. FDA filing acceptance of new drug application (NDA) for mk-1293,http://www.reuters.com//article/idUSASC09177?type=companyNews
533,"  (Corrects headline to say the FDA approved Keytruda for a type of head and neck cancer. The drug is already approved for other types of cancers)Aug 5 Merck & Co Inc* Based on its mechanism of action, Keytruda can cause fetal harm when administered to a pregnant woman * Continued approval for indication for Keytruda may be contingent upon verification, description of clinical benefit in confirmatory trials * FDA approves Merck's Keytruda (pembrolizumab) for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy * Immune-mediated adverse reactions occurred with keytruda including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis* Under FDA's accelerated approval regulations, this indication for keytruda approved based on tumor response rate, durability of response  Source text for Eikon:  Further company coverage:",2016-08-08,MRK,"Mon Aug 8, 2016 | 11:43am EDT",CORRECTED-BRIEF-Merck & Co says FDA approves Keytruda for a type of head and neck cancer (Aug 5),http://www.reuters.com//article/idUSFWN1AM1FK?type=companyNews
534,"   By Anya George Tharakan  Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled.In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices. In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case. Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease. The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-08-12,MRK,"Thu Aug 11, 2016 | 8:46pm EDT",Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N1AT01I?type=companyNews
535,"  Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled.In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices.In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case.  Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.  (Reporting by Anya George Tharakan in Bengaluru; Editing by Leslie Adler)",2016-08-12,MRK,"Thu Aug 11, 2016 | 8:43pm EDT",Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com//article/us-gilead-sciences-merck-co-ruling-idUSKCN10N02Y?type=companyNews
536,"  Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled.In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices.In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case.  Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.  (Reporting by Anya George Tharakan in Bengaluru; Editing by Leslie Adler)",2016-08-12,MRK,"Thu Aug 11, 2016 | 8:43pm EDT",Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL3N1AT05H?type=companyNews
537,"  Aug 24 Merck & Co Inc * Biothera pharmaceuticals expands relationship with Merck, enters collaboration for combination cancer immunotherapy trials in multiple indications  Source text for Eikon:  Further company coverage:  ",2016-08-24,MRK,"Wed Aug 24, 2016 | 11:26am EDT",BRIEF-Biothera Pharmaceuticals expands relationship with Merck,http://www.reuters.com//article/idUSFWN1B50GT?type=companyNews
538,"   By Barbara Grzincic  A federal judge in Delaware has struck down Merck & Co's patent infringement claims against Actavis' Warner Chilcott unit, which is seeking to sell a generic version of the NuvaRing contraceptive. U.S. District Judge Gregory Sleet in Wilmington, Delaware found on Friday that the claims Merck asserted under the NuvaRing patent were obvious, and therefore invalid, in light of an earlier patent application by the device's inventor.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2bEvkQP",2016-08-30,MRK,"Mon Aug 29, 2016 | 8:20pm EDT",Judge invalidates Merck's NuvaRing patent claims,http://www.reuters.com//article/ip-merck-nuvaring-idUSL1N1BB00E?type=companyNews
539,"  Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke. While the drug, odanacatib, reduces the risk of osteoporotic fractures, the increased risk of stroke in a late-stage study in postmenopausal women does not support further development or regulatory approval, the company said on Friday.Osteoporosis, which means ""porous bone"", occurs when bones become weak and brittle.    About one in two women and up to one in four men aged 50 and older will break a bone due to osteoporosis, according to the Virginia-based National Osteoporosis Foundation.  Merck had said in 2014 that treatment with the once-weekly odanacatib had resulted in higher cases of stroke versus placebo in the key late-stage study. (bit.ly/2c9Z9JA)   (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)",2016-09-02,MRK,"Fri Sep 2, 2016 | 7:52am EDT",Merck scraps development of osteoporosis drug due to stroke risk,http://www.reuters.com//article/us-merck-co-study-idUSKCN1181E6?type=companyNews
540,"  Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke. While the drug, odanacatib, reduces the risk of osteoporotic fractures, the increased risk of stroke in a late-stage study in postmenopausal women does not support further development or regulatory approval, the company said on Friday.Osteoporosis, which means ""porous bone"", occurs when bones become weak and brittle.    About one in two women and up to one in four men aged 50 and older will break a bone due to osteoporosis, according to the Virginia-based National Osteoporosis Foundation.  Merck had said in 2014 that treatment with the once-weekly odanacatib had resulted in higher cases of stroke versus placebo in the key late-stage study. (bit.ly/2c9Z9JA)   (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)",2016-09-02,MRK,"Fri Sep 2, 2016 | 7:52am EDT",UPDATE 1-Merck scraps development of osteoporosis drug due to stroke risk,http://www.reuters.com//article/merck-co-study-idUSL3N1BE3OV?type=companyNews
541,"  Sept 2 Merck & Co Inc :* Merck provides update on odanacatib development program* Discontinuing development of odanacatib * Will not seek regulatory approval for use of odanacatib * To discontinue development after independent adjudication of major adverse cardiovascular events confirmed an increased risk of stroke * Merck & Co Inc says ""at same time, believe that increased risk of stroke in our phase 3 trial does not support further development""  Source text for Eikon:  Further company coverage:",2016-09-02,MRK,"Fri Sep 2, 2016 | 7:36am EDT",BRIEF-Merck provides update on odanacatib development program,http://www.reuters.com//article/idUSASC09587?type=companyNews
542,"  (Corrects dateline to Sept 2 from Sept 1)Sept 2 Merck & Co Inc said it would cease the development of its experimental osteoporosis drug after an independent analysis confirmed that the therapy was associated with an increased risk of stroke.  While the drug, odanacatib, reduces the risk of osteoporotic fractures, the increased risk of stroke in a late-stage study in postmenopausal women does not support regulatory approval, the company said on Friday.    (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva) ",2016-09-02,MRK,"Fri Sep 2, 2016 | 7:20am EDT",REFILE-Merck aborts development of osteoporosis drug due to stroke risk,http://www.reuters.com//article/merck-co-study-idUSL3N1BE3N4?type=companyNews
543,"  Sept 7 Aralez Pharmaceuticals Inc* Aralez acquires united states and canadian rights to Zontivity from Merck* Says Merck will continue to distribute product on behalf of Aralez * Says asset purchase agreement entered into between Merck, and Aralez Pharmaceuticals Trading DAC, unit of Aralez * Says asset purchase agreement included an initial upfront payment of $25 million, which was paid from cash on hand * Product rights, packaging, labeling and other responsibilities transferred to Aralez Pharmaceuticals Trading DAC  Source text for Eikon:  Further company coverage:    (Bangalore.newsroom@thomsonreuters.com)",2016-09-07,MRK,"Wed Sep 7, 2016 | 8:52am EDT","BRIEF-Aralez acquires U.S., Canadian rights to Zontivity from Merck",http://www.reuters.com//article/idUSFWN1BJ0C5?type=companyNews
544,"  Sept 15 Merck & Co Inc* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes * Merck and Pfizer plan to submit NDA for ertugliflozin, two fixed-dose combinations (Ertugliflozin plus Januvia and Ertugliflozin plus metformin) by end of 2016  * Additional regulatory submissions outside of to happen in 2017  Source text for Eikon:  Further company coverage:",2016-09-15,MRK,"Thu Sep 15, 2016 | 8:58am EDT","BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint",http://www.reuters.com//article/idUSFWN1BR05I?type=companyNews
545,  Sept 16 Merck says* Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis * Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with cladribine tablets merck  * Clarity and clarity extension studies confirmed that 20 days of oral dosing over two years was effective in reducing frequency of relapses and slowing disability progression for up to four years  Source text for Eikon:  Further company coverage:,2016-09-16,MRK,"Fri Sep 16, 2016 | 6:43am EDT",BRIEF-Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis,http://www.reuters.com//article/idUSFWN1BS06D?type=companyNews
546,"  Sept 19 Sanofi :* Files suit in  U.S. To defend paten rights on Lantus and Lantus Solostar * Sanofi  announced that it filed a patent infringement suit against Merck Sharp & Dohme Corp  * Suit was triggered by a notification received from Merck in early August, in which Merck stated that it had filed an nda (505(b)(2) new drug application) with FDA for an insulin glargine drug product  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",2016-09-19,MRK,"Mon Sep 19, 2016 | 1:08am EDT",BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar,http://www.reuters.com//article/idUSFWN1BS0EU?type=companyNews
547,  Sept 20 Bayer AG* Bayer says had underestimated risk from emerging markets volatility related to purchase of merck & co consumer care business  * Bayer says saw stronger business disruption than anticipated during integration of Merck & Co otc business  Further company coverage: ,2016-09-20,MRK,"Tue Sep 20, 2016 | 2:02am EDT",BRIEF-Bayer says Merck & Co integration disrupts business more than expected,http://www.reuters.com//article/idUSL8N1BW0JG?type=companyNews
548,"   By Ludwig Burger | FRANKFURT  FRANKFURT German drugmaker Bayer (BAYGn.DE) said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto (MON.N) stirred criticism it might neglect its pharmaceuticals business.Bayer now expects annual peak sales of more than 5 billion euros ($5.6 billion) for stroke prevention pill Xarelto, jointly sold with Johnson & Johnson (JNJ.N), where it had previously seen about 3.5 billion.For the eye medicine Eylea, jointly developed with Regeneron (REGN.O), it now sees peak sales potential of more than 2.5 billion euros, up from at least 1.5 billion previously.Also underpinned by cancer drug Xofigo and pulmonary hypertension treatment Adempas, the group's prescription drugs unit aims to increase earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, to 32-34 percent of sales in 2018, up from 30.1 percent last year. The smaller animal health unit could also slightly increase margins, Bayer said.In consumer health, previously boosted by the acquisition of brands from Merck & Co (MRK.N), it now sees sales adjusted for currency swings growing by between 4 and 5 percent by the end of 2018 and an adjusted EBITDA margin of about 25 percent, up from 24 percent in 2015.Bayer has ""underestimated the country risk from Emerging Markets volatility"", the company said in presentation slides. It also cited ""stronger business disruption than anticipated during the integration of Merck Consumer Care and Dihon in China"", referring to a Chinese non-prescription drugs unit it acquired in 2014.""2018 EBITDA guidance for Pharma and Animal Health may ... offer some upside against consensus, though the consumer margin guidance may disappoint slightly,"" Jefferies analysts said in a note to investors. Bayer shares were seen 1.5 percent higher in premarket trading at brokerage Lang & Schwarz, where the overall German market was seen little changed ahead of the official market open at 0700 GMT.     (Reporting by Ludwig Burger; editing by Tina Bellon and Jason Neely)",2016-09-20,MRK,"Tue Sep 20, 2016 | 3:09am EDT",UPDATE 1-Bayer raises sales targets for top-selling drugs after Monsanto deal,http://www.reuters.com//article/bayer-pharmaceuticals-idUSL8N1BW0QG?type=companyNews
549,"  Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.Opdivo, which competes with Merck & Co's Keytruda, belongs to a costly new class of medicines called PD-1 checkpoint inhibitors that work by taking the brakes off the immune system.The collaboration involves Nektar's NKTR-214, an experimental immuno-stimulatory therapy designed to increase the expression of PD-1 on immune cells. The trials will evaluate the potential for the combination to improve on the current standard-of-care to treat melanoma and cancers of the kidney, colorectal system, bladder and the most common form of lung cancer.Opdivo is already approved to treat advanced melanoma and lung cancer, and is being studied for other cancers.   (Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)",2016-09-27,MRK,"Tue Sep 27, 2016 | 7:44am EDT",Bristol-Myers to test Opdivo with Nektar drug for several cancers,http://www.reuters.com//article/uk-bristol-myers-nektar-idUSKCN11X17M?type=companyNews
550,"   By Andrew Chung  The U.S. Supreme Court on Friday will consider a bid by drugmaker Merck & Co to change how a federal appeals court reviews decisions on patent validity made by the U.S. Patent and Trademark Office. Merck, represented by Alston & Bird, is hoping that the court, if it takes the case, will agree that the U.S. Court of Appeals for the Federal Circuit is using a standard of review that is too deferential to the factual findings made by the PTO in its inter partes review procedure, which led its patent on a folic acid treatment to be invalidated.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2dJTH2x",2016-10-07,MRK,"Fri Oct 7, 2016 | 6:51am EDT",Merck asks justices to change how Federal Circuit reviews PTO trials,http://www.reuters.com//article/ip-merck-gnosis-idUSL2N1CD0B8?type=companyNews
551,"   By Ben Hirschler | COPENHAGEN  COPENHAGEN Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy alone in pre-selected patients whose tumors had been tested using a biomarker.And when given with two older chemotherapy drugs in non-selected patients, it was almost twice as likely to shrink tumors as chemotherapy alone.Another similar drug from Roche also demonstrated broad efficacy as a so-called second-line option in patients who had received prior treatment.""Remember this day. It's a new day for lung cancer treatment,"" Stefan Zimmermann of Lausanne's University Hospital told reporters at the European Society for Medical Oncology (ESMO) congress as the results were presented.An editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become ""a new standard of care"".   The various findings suggest that treating lung cancer - the biggest cancer killer globally - with powerful new immune system-boosting medicines is going to involve more permutations than some experts originally expected.Rival drugmaker Bristol-Myers Squibb had tried a catch-all approach with its Opdivo drug but it failed to help previously untreated patients when given on its own in a trial that included people with low levels of a protein called PD-L1.Keytruda, as a sole agent, was targeted only at patients with high PD-L1, making them more receptive to immunotherapy.Lead researcher Martin Reck of Germany's Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard ""from today"". U.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24. Merck had already said in June that Keytruda worked in the trial but the scale of the benefit was only disclosed at ESMO.COMBINATION THERAPY The second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study. Many experts have been skeptical about this approach and investors' expectations, up until now, have been quite low.In the event, researchers reported that Merck's combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumors shrink versus 29 percent.Patients in this trial were not selected by PD-L1 expression but the study did find that those with higher PD-L1 had a higher response.Roger Perlmutter, Merck's head of research, said both trials suggested Keytruda could offer a broad array of patients meaningful improvement over standard platinum-based chemotherapy, which is now more than two decades old.Drugs like Keytruda and Opdivo work by taking the brakes off the immune system and allowing the body's natural killer cells to home in on tumors. They are expected to sell tens of billions of dollars in the years ahead, with lung cancer the largest market.Up until now, Bristol has dominated the field but investors have started to shift their bets, with forecasts for Opdivo declining while those for Keytruda have risen.The current consensus forecast among analysts is for Keytruda sales to reach $8 billion in 2021, with Opdivo selling $10.5 billion, according to Thomson Reuters data.Results of Bristol's failed Opdivo trial, which included patients with tumors testing only 5 percent or higher for PD-L1 against the 50 percent cut-off used by Merck, were also presented at ESMO.These showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant. Overall survival was 14.4 months with Opdivo versus 13.2 months. The failure of Opdivo to work for ""all comers"" in lung cancer was first announced in August, without any details. It was a major setback for Bristol, wiping out around a quarter of the company's market value, and it has caused investors to rethink prospects for immunotherapy treatments.Many now believe that combination therapy is the way ahead, with Bristol and AstraZeneca working primarily on using two immunotherapies together, while Roche and Merck look at adding chemotherapy.   (Reporting by Ben Hirschler; Editing by Stephen Powell and Susan Fenton)",2016-10-09,MRK,"Sun Oct 9, 2016 | 5:18am EDT","'New day' in lung cancer as Merck drug shines, works with chemo",http://www.reuters.com//article/us-health-cancer-merck-co-idUSKCN12904Q?type=companyNews
552,"  * Keytruda cuts risk of death 40 pct in big lung cancer study* Drug also improves outcomes when given with chemotherapyBy Ben HirschlerCOPENHAGEN, Oct 9 Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy alone in pre-selected patients whose tumours had been tested using a biomarker.In contrast to rival Bristol-Myers Squibb, whose Opdivo drug failed to help such first-line patients, Keytruda was targeted at people who express high levels of a protein called PD-L1, which makes them more receptive to immunotherapy.U.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24. Merck had already said in June that Keytruda worked in the trial but the scale of the benefit was only disclosed at the annual European Society for Medical Oncology (ESMO) congress.The second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomised Phase II study.Many experts have been sceptical about this approach and investors' expectations, up until now, have been quite low.In the event, researchers reported that Merck's combination cut the risk of disease progression or death by 47 percent compared to chemotherapy alone after 10.6 months, while 55 percent of patients saw their tumours shrink versus 29 percent. Patients in this trial were not selected by PD-L1 expression but the study did find that those with higher PD-L1 had a higher response.Roger Perlmutter, Merck's head of research, said both trials suggested Keytruda could offer a broad array of patients meaningful improvement over standard platinum-based chemotherapy, which is now more than two decades old.Drugs like Keytruda and Opdivo work by taking the brakes off the immune system and allowing the body's natural killer cells to home in on tumours. They are expected to sell tens of billions of dollars in the years ahead, with lung cancer, the biggest cancer killer globally, viewed as the largest market.Results of Bristol's failed Opdivo trial, which included patients with tumours testing only 5 percent or higher for PD-L1 against the 50 percent cut-off used by Merck, were also presented at ESMO.These showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant. Overall survival was 14.4 months with Opdivo versus 13.2 months.The failure of Opdivo to work for ""all comers"" in lung cancer was first announced in August, without any details. It was a major setback for Bristol, wiping out around a quarter of the company's market value, and it has caused investors to rethink prospects for immunotherapy treatments.Many now believe that combination therapy is the way ahead, with Bristol and AstraZeneca working primarily on using two immunotherapies together, while Roche and Merck look at adding chemotherapy.Results of Merck's two trials were published online in the New England Journal of Medicine and the Lancet Oncology journal.   (Reporting by Ben Hirschler; Editing by Stephen Powell)",2016-10-09,MRK,"Sun Oct 9, 2016 | 2:15am EDT",Merck drug shines in lung cancer and also works with chemo,http://www.reuters.com//article/health-cancer-merck-co-idUSL5N1CE0J7?type=companyNews
553,"   By Brendan Pierson  A Delaware federal judge has invalidated Merck & Co Inc patent claims on its antibiotic Invanz in a challenge from rival Hospira Inc, which is seeking to sell a generic version of the drug. U.S. District Judge Richard Andrews in Wilmington, Delaware ruled Friday that all asserted claims of the patent, which cover a process for making the drug and was set to expire in 2020, were obvious. The patent has other claims that were not at issue in the case, and are not directly affected by the ruling.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2e4BxpV",2016-10-10,MRK,"Mon Oct 10, 2016 | 6:02pm EDT",Judge upholds Merck antibiotic patents against Hospira challenge,http://www.reuters.com//article/health-invanz-idUSL1N1CG1M9?type=companyNews
554,"   By Ransdell Pierson and Bill Berkrot  New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday.    The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent.    The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on strong benefits shown by Keytruda in a similar late-stage lung cancer study. Both trials tested the drugs that help the immune system to recognize and fight cancer as an initial treatment for advanced lung cancer. They are already approved for patients whose disease had progressed following chemotherapy, but approval as a so called first-line therapy could greatly increase the number of patients taking them.Opdivo had been considered the leader among the new class of medicines. It generated $840 million of sales in the second quarter, more than double those of Keytruda.The view of the rival drugs began to change in August, with the surprise announcement by Bristol-Myers that Opdivo had failed to best older chemotherapies in the Phase III trial.Details of the trial unveiled at the European Society for Medical Oncology meeting in Copenhagen only heightened those   concerns. Patients on Opdivo went 4.2 months before their disease worsened versus 5.9 months for those on chemo, although the difference was not deemed statistically significant.""This data represented a worst-case scenario for Opdivo,"" Sanford Bernstein analyst Tim Anderson said in a research note.  The Opdivo trial enrolled patients regardless of their tumor's level of PD-L1 expression, a protein targeted by the drug whose presence may help identify those most likely to benefit from treatment with the new medicines.Meanwhile, researchers reported that Keytruda halved the risk of disease progression in previously untreated patients, and cut overall deaths by 40 percent compared to chemotherapy.Patients in the Merck trial were only enrolled if they were shown to have high levels of PD-L1, a narrower segment of the lung cancer population than those in the Bristol-Myers study. ""Merck will completely 'own' the segment of first-line lung cancer patients who have high PD-L1 expression levels, and Bristol Myers will capture nothing really,"" Anderson said.Doctors are allowed to prescribe medicines for not yet approved uses, but analysts said they expect current off-label prescribing of Opdivo in first-line lung cancer to dry up now.In addition, competition in second-line lung cancer is soon expected to intensify with the anticipated approval of Roche's immunotherapy Tecentriq, which is now approved to treat bladder cancer. Both Keytruda and Tecentriq are given every three weeks, while Opdivo is administered every two weeks, which is seen as a convenience disadvantage.   ""The nearly inexplicable failure of (Opdivo) at every level of PD-L1 expression ... puts Merck in the driver's seat in first-line lung cancer for at least the next 12-18 months,"" said Leerink Partners analyst Seamus Fernandez.Calling the Keytruda data ""stunning, Fernandez said, ""We fully expect Merck to retain a significant place at the table long term.""   Bristol shares, which had already lost one quarter of their value since the initial trial data was disclosed in August, fell 10 percent $49.85, while Merck shares were up 1.7 percent at $63.84 after earlier rising more than 3 percent to a near 15-year high.Opdivo is also approved for advanced melanoma, kidney cancer and a type of Hodgkin lymphoma, while Keytruda is also approved for advanced melanoma, plus head and neck cancer. But lung cancer is considered by far the biggest market for cancer drugs. (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Bernadette Baum and Cynthia Osterman)",2016-10-10,MRK,"Tue Oct 11, 2016 | 1:29am EDT",UPDATE 1-Bristol lung-cancer setback puts rival Merck drug in driver seat,http://www.reuters.com//article/bristolmyers-merck-stocks-idUSL1N1CG0XE?type=companyNews
555,"  Oct 11 Aetna Inc* Aetna and Merck sign a unique value-based contract for Januvia and Janumet * Says Merck also agrees to collaborate on Aetnacare * Says Aetnacare program will initially target patients with diabetes and hypertension in mid-Atlantic markets * Says Merck's rebates on Januvia, Janumet to be based in part on products' contributions to helping commercial members with type 2 diabetes achieve treatment objectives  Source text for Eikon:  Further company coverage:",2016-10-11,MRK,"Tue Oct 11, 2016 | 9:50am EDT",BRIEF-Aetna and Merck sign a contract for Januvia and Janumet,http://www.reuters.com//article/idUSFWN1CH0RR?type=companyNews
556,"   By Ransdell Pierson and Bill Berkrot  New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday.    The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent.    The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on strong benefits shown by Keytruda in a similar late-stage lung cancer study. Both trials tested the drugs that help the immune system to recognize and fight cancer as an initial treatment for advanced lung cancer. They are already approved for patients whose disease had progressed following chemotherapy, but approval as a so called first-line therapy could greatly increase the number of patients taking them.Opdivo had been considered the leader among the new class of medicines. It generated $840 million of sales in the second quarter, more than double those of Keytruda.The view of the rival drugs began to change in August, with the surprise announcement by Bristol-Myers that Opdivo had failed to best older chemotherapies in the Phase III trial.Details of the trial unveiled at the European Society for Medical Oncology meeting in Copenhagen only heightened those   concerns. Patients on Opdivo went 4.2 months before their disease worsened versus 5.9 months for those on chemo, although the difference was not deemed statistically significant.""This data represented a worst-case scenario for Opdivo,"" Sanford Bernstein analyst Tim Anderson said in a research note.  The Opdivo trial enrolled patients regardless of their tumor's level of PD-L1 expression, a protein targeted by the drug whose presence may help identify those most likely to benefit from treatment with the new medicines.Meanwhile, researchers reported that Keytruda halved the risk of disease progression in previously untreated patients, and cut overall deaths by 40 percent compared to chemotherapy.Patients in the Merck trial were only enrolled if they were shown to have high levels of PD-L1, a narrower segment of the lung cancer population than those in the Bristol-Myers study. ""Merck will completely 'own' the segment of first-line lung cancer patients who have high PD-L1 expression levels, and Bristol Myers will capture nothing really,"" Anderson said.Doctors are allowed to prescribe medicines for not yet approved uses, but analysts said they expect current off-label prescribing of Opdivo in first-line lung cancer to dry up now.In addition, competition in second-line lung cancer is soon expected to intensify with the anticipated approval of Roche's immunotherapy Tecentriq, which is now approved to treat bladder cancer. Both Keytruda and Tecentriq are given every three weeks, while Opdivo is administered every two weeks, which is seen as a convenience disadvantage.   ""The nearly inexplicable failure of (Opdivo) at every level of PD-L1 expression ... puts Merck in the driver's seat in first-line lung cancer for at least the next 12-18 months,"" said Leerink Partners analyst Seamus Fernandez.Calling the Keytruda data ""stunning, Fernandez said, ""We fully expect Merck to retain a significant place at the table long term.""   Bristol shares, which had already lost one quarter of their value since the initial trial data was disclosed in August, fell 10 percent $49.85, while Merck shares were up 1.7 percent at $63.84 after earlier rising more than 3 percent to a near 15-year high.Opdivo is also approved for advanced melanoma, kidney cancer and a type of Hodgkin lymphoma, while Keytruda is also approved for advanced melanoma, plus head and neck cancer. But lung cancer is considered by far the biggest market for cancer drugs. (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Bernadette Baum and Cynthia Osterman)",2016-10-11,MRK,"Tue Oct 11, 2016 | 1:29am EDT",Bristol lung-cancer setback puts rival Merck drug in driver seat,http://www.reuters.com//article/us-bristolmyers-merck-stocks-idUSKCN12A1V6?type=companyNews
557,  Oct 12 Ablynx Nv* Ablynx announces second extension of its Ion channel research collaboration with Merck & Co * Ablynx - extension agreement will trigger a EUR 1 million milestone payment to Ablynx  * Ablynx - Merck will extend their funding of research collaboration at Ablynx to September 2018  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom),2016-10-12,MRK,"Wed Oct 12, 2016 | 1:05am EDT",BRIEF-Ablynx extends research collaboration with Merck & Co,http://www.reuters.com//article/idUSFWN1CH12H?type=companyNews
558,"  Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.The trial evaluated the efficacy and safety of the drug, letermovir, for prevention of cytomegalovirus infection in adult recipients of a stem cell transplant.The drug was administered once daily, either in oral tablet or IV formulation, to patients and continued for about 100 days after the transplant. Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.   (Reporting by Shailesh Kuber; Editing by Martina D'Couto)",2016-10-19,MRK,"Wed Oct 19, 2016 | 7:50am EDT",Merck's antiviral drug meets main goal in late-stage trial,http://www.reuters.com//article/us-merck-co-trial-idUSKCN12J1CB?type=companyNews
559,"  Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.The trial evaluated the efficacy and safety of the drug, letermovir, for prevention of cytomegalovirus infection in adult recipients of a stem cell transplant.The drug was administered once daily, either in oral tablet or IV formulation, to patients and continued for about 100 days after the transplant. Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.   (Reporting by Shailesh Kuber; Editing by Martina D'Couto)",2016-10-19,MRK,"Wed Oct 19, 2016 | 7:50am EDT",UPDATE 1-Merck's antiviral drug meets main goal in late-stage trial,http://www.reuters.com//article/merck-co-trial-idUSL4N1CP3O6?type=companyNews
560,"  Oct 19 Merck & Co Inc :* Merck announces pivotal phase 3 study of letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients, met primary endpoint * Merck announces pivotal phase 3 study of letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (cmv) infection in high-risk bone marrow transplant patients, met primary endpoint  * Merck & co inc - phase 3 study with letermovir met its primary endpoint  Source text for Eikon:  Further company coverage:",2016-10-19,MRK,"Wed Oct 19, 2016 | 7:19am EDT",BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint,http://www.reuters.com//article/idUSASC09BQU?type=companyNews
561,  Oct 20 Advaxis Inc :* Advaxis initiates combination portion of phase 1/2 study with Merck  * Advaxis Inc says commencement of part B keynote-046 study to evaluate keytruda in combination with ADXS-PSA  Source text for Eikon:  Further company coverage: ,2016-10-20,MRK,"Thu Oct 20, 2016 | 7:47am EDT",BRIEF-Advaxis initiates combination portion of phase 1/2 study with Merck,http://www.reuters.com//article/idUSFWN1CQ0KB?type=companyNews
562,"  BRUSSELS Oct 20 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS NoneNEW LISTINGS -- Cinema chain AMC UK, which is a unit of U.S. company AMC Entertainment Holdings Inc, which in turn is owned by China's Dalian Wanda Group, to acquire Odeon and UCI Cinemas Holdings Ltd from Terra Firma Investments (notified Oct. 19/deadline Nov. 25/simplified)EXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE OCT 20 -- U.S. pulp and paper company International Paper Co  to acquire Weyerhaeuser's pulp business (notified Sept. 15/deadline Oct. 20)OCT 21 -- German tourism company TUI AG to acquire French peer Transat France's French and Greek tour operating units (notified Sept. 16/deadline Oct. 21)OCT 26 -- U.S. laser tools and systems maker Coherent to acquire laser developer and manufacturer Rofin-Sinar Technologies (notified Sept. 7/deadline extended to Oct. 26 from Oct. 12 after the companies offered concessions)-- Dutch staffing company Randstad to acquire U.S. peer Monster Worldwide (notified Sept. 21/deadline Oct. 26)OCT 28 -- French minerals company Imerys to acquire alumina producer Alteo ARC and Alufin GmbH Tabularoxid from Alteo Holding SAS (notified Sept. 9/deadline extended to Oct. 28 from Oct. 14 after the companies offered concessions)-- Chinese state-owned company China National Chemical Corp (ChemChina) to acquire Swiss pesticides and seeds group Syngenta (notified Sept. 23/deadline Oct. 28)OCT 31 -- Dutch paint and coatings maker Akzo Nobel to acquire Germany chemical company BASF's industrial coasting business (notified Sept. 26/deadline Oct. 31)NOV 3 -- Private equity firm CVC and the Canada Pension Plan Investment Board to jointly acquire U.S. specialty pet retailer Petco Holdings (notified Sept. 27/deadline Nov. 3/simplified)-- Alliance Automotive Group to acquire auto distributor FPS Distributor (notified Sept. 27/deadline Nov. 3)-- German furniture and household goods retailer Steinhoff International and its peer Grupo Pikolin to jointly acquire Belgian furniture wholesaler Cofel (notified Sept. 27/deadline Nov. 3/simplified) NOV 4 -- French chemicals company Arkema to acquire sealants and adhesives maker Den Braven (notified Sept. 28/deadline Nov. 4)NOV 7 -- Private equity firm Apollo Global Management to acquire U.S. cloud services provider Rackspace Hosting  (notified Sept. 29/Nov. 7/simplified)-- Private equity firm Axcel IV, Danish pension fund PFA Pension and three other pension funds PKA to jointly acquire Danish ship financing company DSF (notified Sept. 29/deadline Nov. 7/simplified)-- Air transport services provider HNA Aviation to acquire German aircraft maintenance services provider SR Technics (notified Sept. 29/deadline NOv. 7/simplified)-- German carmaker Daimler to acquire Dutch company Athlon Car Lease International (notified Sept. 29/deadline Nov. 7/simplified)NOV 9 -- German drugmaker Boehringer Ingelheim to acquire French peer Sanofi's animal health business (notified Sept. 19/deadline extended to Nov. 9 from Oct. 24 )-- German shipping company Hapag-Lloyd to merge with Kuwait-based United Arab Shipping Co (notified Oct. 3/deadline Nov. 9)-- U.S. medical devices maker Abbott Laboratories to acquire U.S. peer St Jude (notified Oct. 3/deadline Nov. 9)NOV 11 -- Private investment firm Clayton, Dubilier & Rice to acquire medical home care equipment maker Drive Devilbiss Healthcare (notified Oct. 5/deadline Nov. 11/simplified) NOV 14 -- Canada Pension Plan Investment Board to acquire a 39.99 percent stake in Glencore Agriculture Ltd from mining company Glencore (notified Oct. 6/deadline Nov. 14/simplified)NOV 15 -- French drugmaker Sanofi unit Sanofi Pasteur SA to acquire sole control of some human vaccines and immunoglobulins which it now jointly owns with U.S. drugmaker Merck & Co (notified Oct. 7/deadline Nov. 15/simplified)-- Buyout firm Carlyle to acquire a minority stake in German clinic chain Schoen Klinik (notified Oct. 7/deadline Nov. 15)NOV 16 -- Optima Bidco (Jersey) Ltd, the parent of petrol station operator Euro Garages, to acquire petrol station and convenience store operator EFR Group B.V. (notified Oct. 10/deadline Nov. 16/simplified)-- French car parts supplier Valeo to acquire German clutch maker FTE Group (notified Oct. 10/deadline Nov. 16)NOV 17 -- Platinum Equity Group to acquire power and infrastructure management products provider Emerson Network Power Business (notified Oct. 11/Nov. 17/simplified)-- Private equity firm Naxicap to acquire German personnel services provider TimePartner (notified Oct. 11/deadline Nov. 17/simplified)NOV 18  -- Swiss hotel services provider Kuoni GTA to acquire hotel distribution and destination management provider MTS Globe (notified Oct. 12/deadline Nov. 18)NOV 21 -- German supermarket chain Metro to acquire French food service delivery company Colruyt France SAS (notified Oct. 13/deadline Nov. 21/simplified)NOV 22 -- U.S. oil services company FMC Technologies to merge with French oil services company Technip  (notified Oct. 14/deadline Nov. 22)-- U.S. software company Microsoft to acquire social network LinkedIn (notified Oct. 14/deadline Nov. 22)-- French household equipment maker Groupe SEB to acquire German peer WMF from private equity firm KKR  (notified Oct. 14/deadline Nov. 22)NOV 23 -- French investment firm Ardian to acquire German car parts maker Weber Automotive (notified Oct. 17/deadline Nov. 23/simplifiedFEB 6 -- U.S. chemicals company Dow Chemical to merge with DuPont (notified June 22/deadline Feb. 6)FEB 13 -- Deutsche Boerse and the London Stock Exchange  plan to merge (notified Aug. 24/deadline extended to Feb. 13 from Sept. 28 after the European Commission opened an in-depth investigation)FEB 23 -- German cement producers Heidelbergcement and Schwenk to jointly acquire Mexican peer Cemex's  Croatian unit (notified Sept. 5/deadline extended to Feb. 23 from Oct. 10 after the European Commission opened an in-depth investigation)SUSPENDED -- Azerbaijan's state energy company SOCAR to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission opens a detailed second-stage investigation for up to 90 additional working days, which it may extend to 105 working days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2016-10-20,MRK,"Thu Oct 20, 2016 | 8:57am EDT",EU mergers and takeovers (Oct 20),http://www.reuters.com//article/eu-mergers-idUSL8N1CQ53R?type=companyNews
563,"   By John Miller | ZURICH  ZURICH Roche said on Thursday strong sales of new medicines like cancer immunotherapy drug Tecentriq would help to sustain the company's growth as patents on older drugs start to expire.Chief Executive Severin Schwan is betting he can stay ahead of the sales erosion with new medicines that include five launched in 2016 alone.""That is an unprecedented number of launches of new medicines in a short period of time,"" Schwan said on a conference call after Roche reported third-quarter sales figures. ""Our product pipeline is developing very well.""The Swiss drugmaker's three established cancer blockbusters Rituxan, Herceptin and Avastin, which account for annual sales of nearly 20 billion Swiss francs ($21 billion), all face biosimilar competition by the end of the decade.But so far this year, Tecentriq has won approval for bladder and lung cancer, Alecensa for lung cancer, Cotellic for skin cancer and Venclaxta for chronic lymphocytic leukaemia. Roche's multiple sclerosis drug Ocrevus is slated for U.S. approval before the year is over. Tecentriq has brought in 77 million Swiss francs ($78 million) since its U.S. approval in May for bladder cancer. That revenue is due to accelerate after the U.S. Food and Drug Administration this week gave the a green light for the drug to be used against lung cancer. Analysts are counting on it, too, as revenue growth from broad-based cancer drug Avastin, Rituxan for blood cancer, and breast cancer therapy Herceptin begins to slow.All three missed analyst expectations in the third quarter, and Avastin in particular, which fell 3 percent in the third quarter, led by a decline in the United States.  Overall, quarterly sales at the world's biggest maker of cancer drugs rose 3 percent to 12.48 billion francs, missing the average estimate of 12.68 billion in a Reuters poll of analysts.""The momentum seems weakening in the haematology and breast cancer franchises in the U.S. and Japanese territories,"" Bruno Bulic, an analyst at Baader Helvea, said. ""We see the entry of Tecentriq coming timely."" He has a ""buy"" recommendation on Roche's shares.They fell 0.2 percent by 0930 GMT, in line with the decline of the European health care sector index. Schwan still expected Roche's 2016 sales to grow by a low- to mid-single digit percentage rate at constant exchange rates, with core earnings rising faster than sales. The company also confirmed its full-year outlook.He declined to comment on Novartis's efforts to sell its $14 billion stake in Roche, saying any disposal was a matter for his cross-town rival to resolve. Novartis Chief Executive Joe Jimenez has said he may sell the stake without demanding a premium.($1 = 0.9889 Swiss francs) (Editing by Michael Shields and Jane Merriman)",2016-10-20,MRK,"Thu Oct 20, 2016 | 10:53am EDT",UPDATE 2-Roche bets on new cancer drugs to offset patent expiries,http://www.reuters.com//article/roche-results-idUSL8N1CQ0PV?type=companyNews
564,"  Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the trial early.The blockbuster drug's benefit in patients with urothelial cancer, the most common form of bladder cancer, surpassed that of chemotherapy, meeting the main study goal of overall survival.Bladder cancer occurs when cells in the urinary bladder start to grow uncontrollably. Urothelial carcinoma starts in the cells lining the bladder. Patients enrolled in the trial suffered from an advanced form of the cancer despite undergoing chemotherapy.Keytruda, which belongs to a new class of medicines called PD-1 inhibitors that help the immune system unmask hidden cancer cells, generated second-quarter sales of $314 million. The drug, along with rival Bristol-Myers Squibb & Co's Opdivo, is already approved to treat a common form of lung cancer.Analysts expect that the treatments will rake in tens of billions of dollars in sales in the years ahead, as they are tested for other types of cancer. A newer entrant to the immunotherapy space is Roche Holding AG, whose drug Tecentriq won U.S. approval in May for bladder cancer, followed by lung cancer this week.  (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)",2016-10-21,MRK,"Fri Oct 21, 2016 | 7:48am EDT",Merck's Keytruda succeeds in key bladder cancer trial,http://www.reuters.com//article/us-merck-co-study-idUSKCN12L1BX?type=companyNews
565,"  Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the trial early.The blockbuster drug's benefit in patients with urothelial cancer, the most common form of bladder cancer, surpassed that of chemotherapy, meeting the main study goal of overall survival.Bladder cancer occurs when cells in the urinary bladder start to grow uncontrollably. Urothelial carcinoma starts in the cells lining the bladder. Patients enrolled in the trial suffered from an advanced form of the cancer despite undergoing chemotherapy.Keytruda, which belongs to a new class of medicines called PD-1 inhibitors that help the immune system unmask hidden cancer cells, generated second-quarter sales of $314 million. The drug, along with rival Bristol-Myers Squibb & Co's Opdivo, is already approved to treat a common form of lung cancer.Analysts expect that the treatments will rake in tens of billions of dollars in sales in the years ahead, as they are tested for other types of cancer. A newer entrant to the immunotherapy space is Roche Holding AG, whose drug Tecentriq won U.S. approval in May for bladder cancer, followed by lung cancer this week.  (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)",2016-10-21,MRK,"Fri Oct 21, 2016 | 7:48am EDT",UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial,http://www.reuters.com//article/merck-co-study-idUSL4N1CR3JS?type=companyNews
566,"  Oct 21 Merck & Co Inc -* Merck's keynote-045 studying Keytruda (pembrolizumab) in advanced bladder cancer (urothelial cancer) meets primary endpoint and stops early * Keytruda shows improved overall survival compared with chemotherapy in urothelial cancer  * In trial, keytruda was superior compared to investigator choice chemotherapy  Source text for Eikon:  Further company coverage:",2016-10-21,MRK,"Fri Oct 21, 2016 | 7:32am EDT",BRIEF-Merck's bladder cancer drug meets primary endpoint and stops early,http://www.reuters.com//article/idUSASC09CAC?type=companyNews
567,  Oct 24 Merck & Co Inc* FDA approves Merck's KEYTRUDA (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-l1 expression (tumor proportion score  of 50 percent or more) with no EGFR or ALK genomic tumor aberrati  * Merck & Co Inc - FDA also approves a labeling update for KEYTRUDA for treatment of patients with metastatic NSCLC whose tumors express PD-l1  Source text for Eikon:  Further company coverage: ,2016-10-24,MRK,"Mon Oct 24, 2016 | 6:14pm EDT",BRIEF-Merck & Co says FDA also approves a labeling update for Keytruda for treatment of patients with metastatic NSCLC,http://www.reuters.com//article/idUSASC09CNH?type=companyNews
568,"  BRUSSELS Oct 24 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- German furniture and household goods retailer Steinhoff International and its peer Grupo Pikolin to jointly acquire Belgian furniture wholesaler Cofel (approved Oct. 21)-- Private equity firm CVC and the Canada Pension Plan Investment Board to jointly acquire U.S. specialty pet retailer Petco Holdings (approved Oct. 21)-- Private equity firm Apollo Global Management to acquire U.S. cloud services provider Rackspace Hosting  (approved Oct. 21)NEW LISTINGS -- Canada Pension Plan Investment Board and real estate developer Hammerson to acquire joint control of UK shopping centre Grand Central, which is now solely owned by Hammerson (notified Oct. 21/deadline Nov. 28/simplified)EXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE OCT 26 -- U.S. laser tools and systems maker Coherent to acquire laser developer and manufacturer Rofin-Sinar Technologies (notified Sept. 7/deadline extended to Oct. 26 from Oct. 12 after the companies offered concessions)-- Dutch staffing company Randstad to acquire U.S. peer Monster Worldwide (notified Sept. 21/deadline Oct. 26)OCT 28 -- French minerals company Imerys to acquire alumina producer Alteo ARC and Alufin GmbH Tabularoxid from Alteo Holding SAS (notified Sept. 9/deadline extended to Oct. 28 from Oct. 14 after the companies offered concessions)-- Chinese state-owned company China National Chemical Corp (ChemChina) to acquire Swiss pesticides and seeds group Syngenta (notified Sept. 23/deadline Oct. 28)OCT 31 -- Dutch paint and coatings maker Akzo Nobel to acquire Germany chemical company BASF's industrial coasting business (notified Sept. 26/deadline Oct. 31)NOV 3 -- Alliance Automotive Group to acquire auto distributor FPS Distributor (notified Sept. 27/deadline Nov. 3)NOV 4 -- French chemicals company Arkema to acquire sealants and adhesives maker Den Braven (notified Sept. 28/deadline Nov. 4)NOV 7  -- Private equity firm Axcel IV, Danish pension fund PFA Pension and three other pension funds PKA to jointly acquire Danish ship financing company DSF (notified Sept. 29/deadline Nov. 7/simplified)-- Air transport services provider HNA Aviation to acquire German aircraft maintenance services provider SR Technics (notified Sept. 29/deadline NOv. 7/simplified)-- German carmaker Daimler to acquire Dutch company Athlon Car Lease International (notified Sept. 29/deadline Nov. 7/simplified)NOV 9 -- German drugmaker Boehringer Ingelheim to acquire French peer Sanofi's animal health business (notified Sept. 19/deadline extended to Nov. 9 from Oct. 24 )-- German shipping company Hapag-Lloyd to merge with Kuwait-based United Arab Shipping Co (notified Oct. 3/deadline Nov. 9)-- U.S. medical devices maker Abbott Laboratories to acquire U.S. peer St Jude (notified Oct. 3/deadline Nov. 9)NOV 11 -- Private investment firm Clayton, Dubilier & Rice to acquire medical home care equipment maker Drive Devilbiss Healthcare (notified Oct. 5/deadline Nov. 11/simplified)NOV 14 -- Canada Pension Plan Investment Board to acquire a 39.99 percent stake in Glencore Agriculture Ltd from mining company Glencore (notified Oct. 6/deadline Nov. 14/simplified)NOV 15  -- French drugmaker Sanofi unit Sanofi Pasteur SA to acquire sole control of some human vaccines and immunoglobulins which it now jointly owns with U.S. drugmaker Merck & Co (notified Oct. 7/deadline Nov. 15/simplified)-- Buyout firm Carlyle to acquire a minority stake in German clinic chain Schoen Klinik (notified Oct. 7/deadline Nov. 15)NOV 16 -- Optima Bidco (Jersey) Ltd, the parent of petrol station operator Euro Garages, to acquire petrol station and convenience store operator EFR Group B.V. (notified Oct. 10/deadline Nov. 16/simplified)-- French car parts supplier Valeo to acquire German clutch maker FTE Group (notified Oct. 10/deadline Nov. 16)NOV 17 -- Platinum Equity Group to acquire power and infrastructure management products provider Emerson Network Power Business (notified Oct. 11/Nov. 17/simplified)-- Private equity firm Naxicap to acquire German personnel services provider TimePartner (notified Oct. 11/deadline Nov. 17/simplified)NOV 18 -- Swiss hotel services provider Kuoni GTA to acquire hotel distribution and destination management provider MTS Globe (notified Oct. 12/deadline Nov. 18)NOV 21 -- German supermarket chain Metro to acquire French food service delivery company Colruyt France SAS (notified Oct. 13/deadline Nov. 21/simplified) NOV 22 -- Diamond Offshore Wind Holdings, which is part of Japan's Mitsubishi Corp, Eneco Holding NV unit Eneco Wind Belgium and Elicio subsidiary and Belgian wind farm producer ELNU to jointly acquire wind farm operator Norther NV (notified Oct. 14/deadline Nov. 22/simplified)-- U.S. oil services company FMC Technologies to merge with French oil services company Technip  (notified Oct. 14/deadline Nov. 22)-- U.S. software company Microsoft to acquire social network LinkedIn (notified Oct. 14/deadline Nov. 22)-- French household equipment maker Groupe SEB to acquire German peer WMF from private equity firm KKR  (notified Oct. 14/deadline Nov. 22)NOV 23 -- French investment firm Ardian to acquire German car parts maker Weber Automotive (notified Oct. 17/deadline Nov. 23/simplifiedNOV 25 -- Cinema chain AMC UK, which is a unit of U.S. company AMC Entertainment Holdings Inc, which in turn is owned by China's Dalian Wanda Group, to acquire Odeon and UCI Cinemas Holdings Ltd from Terra Firma Investments (notified Oct. 19/deadline Nov. 25/simplified)FEB 6 -- U.S. chemicals company Dow Chemical to merge with DuPont (notified June 22/deadline Feb. 6)FEB 13 -- Deutsche Boerse and the London Stock Exchange  plan to merge (notified Aug. 24/deadline extended to March 6 from Feb. 13 after the companies asked for more time)FEB 23 -- German cement producers Heidelbergcement and Schwenk to jointly acquire Mexican peer Cemex's  Croatian unit (notified Sept. 5/deadline extended to Feb. 23 from Oct. 10 after the European Commission opened an in-depth investigation)SUSPENDED -- Azerbaijan's state energy company SOCAR to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission opens a detailed second-stage investigation for up to 90 additional working days, which it may extend to 105 working days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2016-10-24,MRK,"Mon Oct 24, 2016 | 12:35pm EDT",EU mergers and takeovers (Oct 24),http://www.reuters.com//article/eu-mergers-idUSL8N1CU5CA?type=companyNews
569,"   By Ben Hirschler | LONDON  LONDON GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market.Shingrix is viewed by analysts as among the British company's most promising experimental products, since it has shown greater protection among older recipients than Merck & Co's rival shot Zostavax.GSK itself highlighted Shingrix as one of its top near-term pipeline hopes last November, during its first research and development day in more than a decade.The company, which will see Emma Walmsley take over as chief executive in 2017, is seeking to revitalise a drug portfolio hit by falling sales of best-selling inhaled lung treatment Advair.In clinical trials, GSK's vaccine remained 90 percent effective in people over age 70, even four years after injections. Zostavax efficacy, by contrast, varies between 18 and 70 percent, and it declines noticeably in older people. People who are 70 years or older are often most at risk from shingles, a painful, itchy rash that results from the reactivation of latent chickenpox virus.The impressive trial results should put Shingrix in a strong competitive position, analysts believe, even though it requires two doses, against just one for Zostavax, and it is also linked to more injection site reactions. Analysts, on average, predict that worldwide sales of Shingrix will reach 856 million pounds ($1.05 billion) in 2021, according to consensus forecasts compiled by Thomson Reuters.Sales of Zostavax, the only shingles vaccine on the market at present, totalled $749 million in 2015.GSK's vaccine contains a component from U.S. biotech firm Agenus, which is entitled to royalties on future sales.  GSK said it planned to file Shingrix for European and Canadian approval before the end of this year, with Japan following in 2017.($1 = 0.8191 pounds) (Editing by Susan Fenton and Jason Neely)",2016-10-24,MRK,"Mon Oct 24, 2016 | 3:16am EDT",UPDATE 1-GSK files potential $1 bln shingles vaccine for U.S. approval,http://www.reuters.com//article/gsk-shingles-idUSL8N1CU0T7?type=companyNews
570,"  Merck & Co Inc (MRK.N) reported better-than-expected quarterly revenue due to higher sales of its vaccines and cancer drug Keytruda, which won an early U.S. approval on Monday for use in previously untreated lung cancer patients.Shares of Merck, which also raised its full-year profit and revenue forecasts, were up 1.23 percent at $61.50 in premarket trading on Tuesday.The second-largest U.S. drugmaker is betting on Keytruda to boost earnings as expectations for the drug have been building since its success in treating selected untreated patients.The approval from the U.S. Food and Drug Administration confirms Merck's leading position in the hot area of medicines that fight tumors by harnessing the body's immune system.Annual sales of the drug are now expected to reach $8.1 billion in 2021, according to consensus forecasts compiled by Thomson Reuters. Third-quarter sales of Keytruda, which is already approved to treat advanced melanoma and some forms of lung cancer, rose to $356 million from $159 million, slightly below the consensus estimate of $376 million, according to Evercore ISI.Merck said the company's total sales increased 5 percent to $10.54 billion, above analysts' average estimate of $10.18 billion, according to Thomson Reuters I/B/E/S.Sales for its Gardasil vaccine rose 38 percent to $860 million, well above Evercore's consensus estimate of $635.6 million. Net income attributable to Merck rose to $2.18 billion, or 78 cents per share, for the third quarter ended Sept. 30, from $1.83 billion, or 64 cents per share, a year earlier.Excluding items, the company earned $1.07 per share, beating the average estimate of 99 cents per share. Merck said it has raised its full-year 2016 GAAP earnings to $2.02-$2.09 per share from $1.98-$2.08 per share. The full-year revenue range was also raised to $39.7 billion-$40.2 billion from $39.1 billion-$40.1 billion.Up to Monday's close of $60.75, Merck's stock had risen 15 percent this year, compared with a 3.5 percent fall in the S&P 500 Healthcare index .SPXHC. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta and Martina D'Couto)",2016-10-25,MRK,"Tue Oct 25, 2016 | 8:36am EDT",UPDATE 3-Merck predicts lung cancer dominance for Keytruda immunotherapy,http://www.reuters.com//article/merck-co-results-idUSL4N1CV3WV?type=companyNews
571,"  Merck & Co Inc (MRK.N) reported better-than-expected quarterly revenue due to higher sales of its vaccines and cancer drug Keytruda, which won an early U.S. approval on Monday for use in previously untreated lung cancer patients.Shares of Merck, which also raised its full-year profit and revenue forecasts, were up 1.23 percent at $61.50 in premarket trading on Tuesday.The second-largest U.S. drugmaker is betting on Keytruda to boost earnings as expectations for the drug have been building since its success in treating selected untreated patients.The approval from the U.S. Food and Drug Administration confirms Merck's leading position in the hot area of medicines that fight tumors by harnessing the body's immune system.Annual sales of the drug are now expected to reach $8.1 billion in 2021, according to consensus forecasts compiled by Thomson Reuters. Third-quarter sales of Keytruda, which is already approved to treat advanced melanoma and some forms of lung cancer, rose to $356 million from $159 million, slightly below the consensus estimate of $376 million, according to Evercore ISI.Merck said the company's total sales increased 5 percent to $10.54 billion, above analysts' average estimate of $10.18 billion, according to Thomson Reuters I/B/E/S.Sales for its Gardasil vaccine rose 38 percent to $860 million, well above Evercore's consensus estimate of $635.6 million. Net income attributable to Merck rose to $2.18 billion, or 78 cents per share, for the third quarter ended Sept. 30, from $1.83 billion, or 64 cents per share, a year earlier.Excluding items, the company earned $1.07 per share, beating the average estimate of 99 cents per share. Merck said it has raised its full-year 2016 GAAP earnings to $2.02-$2.09 per share from $1.98-$2.08 per share. The full-year revenue range was also raised to $39.7 billion-$40.2 billion from $39.1 billion-$40.1 billion.Up to Monday's close of $60.75, Merck's stock had risen 15 percent this year, compared with a 3.5 percent fall in the S&P 500 Healthcare index .SPXHC. (Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta and Martina D'Couto)",2016-10-25,MRK,"Tue Oct 25, 2016 | 8:36am EDT","Merck quarterly revenue beats, raises full-year forecast",http://www.reuters.com//article/us-merck-co-results-idUSKCN12P1BO?type=companyNews
572,"  Oct 25 Merck & Co Inc :    Q3 non-gaap earnings per share $1.07* Q3 gaap earnings per share $0.78* Q3 sales $10.5 billion versus I/B/E/S view $10.18 billion* Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S* Sees fy 2016 non-gaap earnings per share $3.71 to $3.78* Sees fy 2016 gaap earnings per share $2.02 to $2.09 * Full-Year 2016 non-gaap eps to be between $3.71 and $3.78* Sees full-year 2016 gaap eps to be between $2.02 and $2.09* Sees full-year 2016 non-gaap eps to be between $3.71 and $3.78 * Q3 remicade sales $311 million versus $442 million* Merck & co inc qtrly keytruda sales $356 million versus $159 million* Merck & co inc - qtrly januvia/janumet sales $1,554 million, down 1 percent * Third-Quarter pharmaceutical sales increased 6 percent to $9.4 billion* Narrowed and raised its full-year 2016 revenue range to be between $39.7 billion and $40.2 billion* Fy2016 earnings per share view $3.75, revenue view $39.70 billion -- Thomson Reuters I/B/E/S* Merck & co - full-year 2016 revenue range includes an approximately 2 percent negative impact from foreign exchange at mid-october exchange rates* Merck & co inc - full-year 2016 revenue forecast includes approximately 2 percent negative impact from foreign exchange at mid-october exchange rates  Source text for Eikon:  Further company coverage:    (Bangalore.newsroom@thomsonreuters.com)",2016-10-25,MRK,"Tue Oct 25, 2016 | 7:24am EDT",BRIEF-Merck & Co Q3 non-gaap EPS $1.07,http://www.reuters.com//article/idUSASC09CRZ?type=companyNews
573,"  Oct 25 - Merck & Co Inc reported a 19.6 percent rise in quarterly net profit, driven primarily by higher demand for its new cancer drug Keytruda.Net income attributable rose to $2.18 billion, or 78 cents per share, for the third quarter from $1.83 billion, or 64 cents per share, a year earlier. Revenue rose to $10.54 billion from $10.07 billion. Merck is betting on Keytruda to boost earnings as demand wanes for its diabetes franchise, Januvia and a related combination medicine called Janumet, and Remicade arthritis drug. The company said on Monday the U.S. Food and Drug Administration approved Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment.       (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)",2016-10-25,MRK,"Tue Oct 25, 2016 | 6:54am EDT",Merck reports 19.6 pct jump in quarterly profit,http://www.reuters.com//article/merck-co-results-idUSL4N1CV3W6?type=companyNews
574,"  BRUSSELS Oct 25 The following are mergers under review by the European Commission and a brief guide to the EU merger process:APPROVALS AND WITHDRAWALS -- German carmaker Daimler to acquire Dutch company Athlon Car Lease International (approved Oct. 24)-- Air transport services provider HNA Aviation to acquire German aircraft maintenance services provider SR Technics (approved Oct. 24)NEW LISTINGS NoneEXTENSIONS AND OTHER CHANGES NoneFIRST-STAGE REVIEWS BY DEADLINE OCT 26 -- U.S. laser tools and systems maker Coherent to acquire laser developer and manufacturer Rofin-Sinar Technologies (notified Sept. 7/deadline extended to Oct. 26 from Oct. 12 after the companies offered concessions)-- Dutch staffing company Randstad to acquire U.S. peer Monster Worldwide (notified Sept. 21/deadline Oct. 26)OCT 28 -- French minerals company Imerys to acquire alumina producer Alteo ARC and Alufin GmbH Tabularoxid from Alteo Holding SAS (notified Sept. 9/deadline extended to Oct. 28 from Oct. 14 after the companies offered concessions)-- Chinese state-owned company China National Chemical Corp (ChemChina) to acquire Swiss pesticides and seeds group Syngenta (notified Sept. 23/deadline Oct. 28)OCT 31 -- Dutch paint and coatings maker Akzo Nobel to acquire Germany chemical company BASF's industrial coasting business (notified Sept. 26/deadline Oct. 31)NOV 3 -- Alliance Automotive Group to acquire auto distributor FPS Distributor (notified Sept. 27/deadline Nov. 3)NOV 4 -- French chemicals company Arkema to acquire sealants and adhesives maker Den Braven (notified Sept. 28/deadline Nov. 4)NOV 7 -- Private equity firm Axcel IV, Danish pension fund PFA Pension and three other pension funds PKA to jointly acquire Danish ship financing company DSF (notified Sept. 29/deadline Nov. 7/simplified) NOV 9 -- German drugmaker Boehringer Ingelheim to acquire French peer Sanofi's animal health business (notified Sept. 19/deadline extended to Nov. 9 from Oct. 24 )-- German shipping company Hapag-Lloyd to merge with Kuwait-based United Arab Shipping Co (notified Oct. 3/deadline Nov. 9)-- U.S. medical devices maker Abbott Laboratories to acquire U.S. peer St Jude (notified Oct. 3/deadline Nov. 9)NOV 11 -- Private investment firm Clayton, Dubilier & Rice to acquire medical home care equipment maker Drive Devilbiss Healthcare (notified Oct. 5/deadline Nov. 11/simplified)NOV 14 -- Canada Pension Plan Investment Board to acquire a 39.99 percent stake in Glencore Agriculture Ltd from mining company Glencore (notified Oct. 6/deadline Nov. 14/simplified)NOV 15 -- French drugmaker Sanofi unit Sanofi Pasteur SA to acquire sole control of some human vaccines and immunoglobulins which it now jointly owns with U.S. drugmaker Merck & Co (notified Oct. 7/deadline Nov. 15/simplified)-- Buyout firm Carlyle to acquire a minority stake in German clinic chain Schoen Klinik (notified Oct. 7/deadline Nov. 15) NOV 16 -- Optima Bidco (Jersey) Ltd, the parent of petrol station operator Euro Garages, to acquire petrol station and convenience store operator EFR Group B.V. (notified Oct. 10/deadline Nov. 16/simplified)-- French car parts supplier Valeo to acquire German clutch maker FTE Group (notified Oct. 10/deadline Nov. 16)NOV 17 -- Platinum Equity Group to acquire power and infrastructure management products provider Emerson Network Power Business (notified Oct. 11/Nov. 17/simplified)-- Private equity firm Naxicap to acquire German personnel services provider TimePartner (notified Oct. 11/deadline Nov. 17/simplified)NOV 18 -- Swiss hotel services provider Kuoni GTA to acquire hotel distribution and destination management provider MTS Globe (notified Oct. 12/deadline Nov. 18)NOV 21 -- German supermarket chain Metro to acquire French food service delivery company Colruyt France SAS (notified Oct. 13/deadline Nov. 21/simplified)NOV 22 -- Diamond Offshore Wind Holdings, which is part of Japan's Mitsubishi Corp, Eneco Holding NV unit Eneco Wind Belgium and Elicio subsidiary and Belgian wind farm producer ELNU to jointly acquire wind farm operator Norther NV (notified Oct. 14/deadline Nov. 22/simplified) -- U.S. oil services company FMC Technologies to merge with French oil services company Technip  (notified Oct. 14/deadline Nov. 22)-- U.S. software company Microsoft to acquire social network LinkedIn (notified Oct. 14/deadline Nov. 22)-- French household equipment maker Groupe SEB to acquire German peer WMF from private equity firm KKR  (notified Oct. 14/deadline Nov. 22)NOV 23 -- French investment firm Ardian to acquire German car parts maker Weber Automotive (notified Oct. 17/deadline Nov. 23/simplifiedNOV 25 -- Cinema chain AMC UK, which is a unit of U.S. company AMC Entertainment Holdings Inc, which in turn is owned by China's Dalian Wanda Group, to acquire Odeon and UCI Cinemas Holdings Ltd from Terra Firma Investments (notified Oct. 19/deadline Nov. 25/simplified)NOV 28 -- Canada Pension Plan Investment Board and real estate developer Hammerson to acquire joint control of UK shopping centre Grand Central, which is now solely owned by Hammerson (notified Oct. 21/deadline Nov. 28/simplified)FEB 6 -- U.S. chemicals company Dow Chemical to merge with DuPont (notified June 22/deadline Feb. 6)FEB 13 -- Deutsche Boerse and the London Stock Exchange  plan to merge (notified Aug. 24/deadline extended to March 6 from Feb. 13 after the companies asked for more time)FEB 23 -- German cement producers Heidelbergcement and Schwenk to jointly acquire Mexican peer Cemex's  Croatian unit (notified Sept. 5/deadline extended to Feb. 23 from Oct. 10 after the European Commission opened an in-depth investigation)SUSPENDED -- Azerbaijan's state energy company SOCAR to buy stakes in Greek natural gas grid operator DESFA from Greek natural gas utility DEPA (notified Oct. 1/deadline suspended on Jan. 21)GUIDE TO EU MERGER PROCESS DEADLINES: The European Commission has 25 working days after a deal is filed for a first-stage review. It may extend that by 10 working days to 35 working days, to consider either a company's proposed remedies or an EU member state's request to handle the case.Most mergers win approval but occasionally the Commission opens a detailed second-stage investigation for up to 90 additional working days, which it may extend to 105 working days.SIMPLIFIED: Under the simplified procedure, the Commission announces the clearance of uncontroversial first-stage mergers without giving any reason for its decision. Cases may be reclassified as non-simplified - that is, ordinary first-stage reviews - until they are approved.   (Compiled by Foo Yun Chee)",2016-10-25,MRK,"Tue Oct 25, 2016 | 6:25am EDT",EU mergers and takeovers (Oct 25),http://www.reuters.com//article/eu-mergers-idUSL8N1CV3J7?type=companyNews
575,"  Oct 24 Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment.The drug has been approved for treating metastatic non-small cell lung cancer (NSCLC) patients with high-levels of a protein known for suppressing the immune system called PD-L1.Keytruda works by taking the brakes off the immune system by blocking the interaction between PD-L1 and another protein, PD-1. The drug has already been approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer. Monday's announcement gives Merck the only approved first-line treatment for lung cancer, one of the biggest markets for cancer drugs. Rival Bristol-Myers Squibb Co's drug Opdivo failed a late-stage trial for the same indication. The approval was based on data from a late-stage study which showed Keytruda achieved superior progression-free and overall survival compared to chemotherapy in patients whose tumors expressed high levels of the protein, Merck said. Doctors are currently allowed to prescribe medicines for not yet approved uses but FDA's approval of Keytruda could greatly increase the number of patients taking the drug.Shares of Kenilworth, New Jersey-based drugmaker fell 0.7 percent in aftermarket trade. Up to Monday's close, the stock had gained more than 15 percent of its value year to date.    (Reporting by Dipika Jain in Bengaluru; Editing by Lisa Shumaker)",2016-10-25,MRK,"Mon Oct 24, 2016 | 10:20pm EDT",U.S. FDA approves Merck's lung cancer drug as first-line treatment,http://www.reuters.com//article/merck-co-fda-idUSL1N1CU20V?type=companyNews
576,  Oct 26 Merck & Co Inc :* Merck prices EUR 1.0 billion debt offering * priced a EUR 1.0 billion public offering of two series of euro-denominated senior unsecured notes  * priced notes include EUR 500 million of 0.500% notes due Nov. 2024 and EUR 500 million of 1.375% notes due Nov. 2036  Source text for Eikon:  Further company coverage:,2016-10-26,MRK,"Wed Oct 26, 2016 | 1:34pm EDT",BRIEF-Merck prices EUR 1 bln debt offering,http://www.reuters.com//article/idUSASC09DAM?type=companyNews
577,"  (The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) (This is a correction of a release issued Oct. 27,  2016. It clarifies that Merck's existing ratings were not affirmed as was stated  in the original release.)  Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro  notes offering. A complete list of ratings follows at the end of this press  release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent  expiries should support intermediate- to long-term growth.  --Fitch believes that Merck will pursue targeted acquisitions as opposed to  large transformative ones. An improving pipeline and narrowing strategic focus  reduces the need to do big deals.  --Fitch expects Merck will continue favor share repurchases to deleveraging,  with the possibility of further debt-funded stock buybacks. --Fitch forecasts that Merck will generate solid FCF during the forecast period  supported by improving margins and moderate revenue growth. New Products/ Growth Opportunities: Products approved during the last three  years should help to drive intermediate- to long-term, top-line growth for  Merck. Most importantly, Keytruda (skin and lung cancer) is gaining traction in  the market, supported by an ongoing stream of clinical data, but facing  competition from a Bristol-Myers product and potentially similar drugs that may  receive approval during the next few years. Merck is also evaluating Keytruda's  safety and efficacy in other cancers and in combination with other oncolytics.  Bridion (post-surgical recovery), Belsomra (insomnia), Grastek (allergies) and  Rawitek (allergies) are unique-acting therapies, which should provide these two  drugs competitive positions. Zontivitiy (cardiovascular) and Zepatier (hepatitis  C) have entered increasingly crowded segments but should be able to gain some  share from both newer and older treatments. Expanding Late-Stage Pipeline: Fitch expects Merck to continue to build its  late-stage pipeline with new molecular entities (NMEs) to treat cancers,  bacterial and viral infections, diabetes, cardiovascular disorders, central  nervous afflictions, osteoporosis, and other diseases. While the majority of  these projects are internally developed, Merck has partnered with other  innovator firms to take advantage of technological advancements that were  discovered externally. The landscape for drug development is expanding,  particularly as developers learn more about how genetics influence the  development, prevention and treatment of disease. As such, Fitch believes that  it is responsible and strategically advantageous for firms to look externally as  well as internally regarding new drug development. Patent Exposure Manageable: The company has and will continue to face some  significant patent expiries during the next year, but Fitch views the risk as  manageable with roughly 18% of total firm sales are at risk. In addition,  Remicade, which accounts for about 4.2% of total firm sales, is a biologic that  has experienced less rapid sales losses to generic competition compared to  traditional small-molecule pharmaceuticals. Vytorin and Zetia, however, are  small molecules and account for roughly 10% of total revenues. Fitch expects  these two products will lose significant sales shortly after their patents  expire, as is typically the case for small-molecule drugs. Solid Free Cash Flow Expected: Fitch forecasts that Merck will generate $5.7  billion - $5.9 billion in free cash flow (FCF) during 2016. Improving margins  driven by an improving sales mix and strong cost control should more than offset  expected soft near-term, top-line growth. Fitch expects FCF to incrementally  increase during the multi-year forecast period. Targeted Acquisition Most Likely: Fitch looks for Merck to pursue mainly  targeted acquisitions in the intermediate term. The company has improved its  operational and financial prospects through successfully gaining regulatory  approvals on late-stage pipeline projects and has continued to back fill its  pipeline with new and advancing projects. An improved growth and profitability  profile decreases the need for the company to execute large strategic business  combinations. Share Repurchases to Continue: Fitch assumes continued shareholder friendly  actions during the near term, some of which the company may fund with debt.  Merck has occasionally funded its share repurchases with debt. During 2015, the  company purchased a net $3.7 billion of its common stock, compared to $6.1  billion during the prior LTM period. The repurchases were executed under a $15  billion program authorized in May 2013 as well as an additional $10 billion  authorized in March 2015. As of June 30, 2016, the 2013 allotment was fully  utilized, with $6.9 billion remaining on the $10 billion extension. KEY ASSUMPTIONS Fitch's key assumptions within the rating case for Merck's 'A' rating include  the following: --Incrementally increasing revenue during the forecast period, driven by newer  products, largely offset in the near term by foreign exchange headwinds and  select product patent expirations.  --EBITDA operating margin improvement driven by a focus on costs and an  improving sales mix.  --Annual FCF (cash flow from operations minus capital expenditures minus  dividends) of roughly $5.9 billion during 2016. --Targeted acquisitions prioritized over strategic, transformative transactions. --Continued significant share repurchases. --Leverage to range between 1.7x - 1.9x during the next two years. RATING SENSITIVITIES Positive: Future developments that may, individually or collectively, lead to  positive rating action include the following: --Improving operations including new product development that support long-term  positive revenue growth and margin stability/increases; --An operational profile that would consistently generate significantly positive  FCF; --Cash deployment strategy that maintains gross debt leverage below 1.7x,  including managing through operational stress such as patent expiries. Negative: Future developments that may, individually or collectively, lead to  negative rating action include the following: --Material and lasting deterioration in operations and FCF, possibly driven by  patent expiries not being offset by new product development; --Leveraging acquisitions without the prospect of timely debt/leverage  reduction; --Persistent leverage above 2.2x. LIQUIDITY Adequate Liquidity: Fitch looks for Merck to maintain adequate liquidity through  strong FCF generation and ample access to the credit markets. FCF for the LTM  ending June 30, 2016 was $4.7 billion. At the end of the period, Merck had  approximately $11.8 billion in cash/short-term investments (U.S.: 10% - 20% of  total balances/OUS: 80% - 90% of total balances) and full availability on its $6  billion revolver, maturing in August 2019.  Manageable Debt Maturities: As of June 30, 2016, the company had $24.1 billion  in debt outstanding, with $234 million maturing in 2016, $317 million in 2017,  $3 billion in 2018 and $1.3 billion in 2019. Fitch expects near- to mid-term  maturities will be satisfied primarily through refinancing in the public debt  markets. FULL LIST OF RATINGS Fitch currently rates Merck as follows: Merck & Co., Inc. --Long-Term Issuer Default Rating (IDR) 'A'; --Senior unsecured credit facility 'A';  --Senior unsecured debt 'A'; --Short-Term IDR 'F1'; --Commercial paper 'F1'. The Rating Outlook is Stable. Contact:  Primary Analyst Bob Kirby, CFA Director  +1-312-368-3147  Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602 Secondary Analyst Gregory Dickerson  Director  +1-212-908-0220 Committee Chairperson Megan Neuburger Managing Director +1-212-908-0501 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Summary of Financial Statement Adjustments - Financial statement adjustments  that depart materially from those contained in the published financial  statements of the relevant rated entity or obligor are disclosed below: --Historical and projected EBITDA is adjusted to add back non-cash stock based  compensation. During the LTM period ended March 31, 2016, Fitch added back $304  million in non-cash stock based compensation to its EBITDA calculation and $214  million in restructuring costs to gross profit. Date of Relevant Committee: July 7, 2016 Additional information is available on www.fitchratings.com. Applicable Criteria  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage - Effective from 17 August 2015 to 27 September 2016 (pub. 17  Aug 2015) here Additional Disclosures  Solicitation Status  here Endorsement Policy  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:   here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE,  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF  CONDUCT SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE. Copyright  2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its  subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824,  (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or  in part is prohibited except by permission. All rights reserved. In issuing and  maintaining its ratings and in making other reports (including forecast  information), Fitch relies on factual information it receives from issuers and  underwriters and from other sources Fitch believes to be credible. Fitch  conducts a reasonable investigation of the factual information relied upon by it  in accordance with its ratings methodology, and obtains reasonable verification  of that information from independent sources, to the extent such sources are  available for a given security or in a given jurisdiction. The manner of Fitch's  factual investigation and the scope of the third-party verification it obtains  will vary depending on the nature of the rated security and its issuer, the  requirements and practices in the jurisdiction in which the rated security is  offered and sold and/or the issuer is located, the availability and nature of  relevant public information, access to the management of the issuer and its  advisers, the availability of pre-existing third-party verifications such as  audit reports, agreed-upon procedures letters, appraisals, actuarial reports,  engineering reports, legal opinions and other reports provided by third parties,  the availability of independent and competent third- party verification sources  with respect to the particular security or in the particular jurisdiction of the  issuer, and a variety of other factors. Users of Fitch's ratings and reports  should understand that neither an enhanced factual investigation nor any  third-party verification can ensure that all of the information Fitch relies on  in connection with a rating or a report will be accurate and complete.  Ultimately, the issuer and its advisers are responsible for the accuracy of the  information they provide to Fitch and to the market in offering documents and  other reports. In issuing its ratings and its reports, Fitch must rely on the  work of experts, including independent auditors with respect to financial  statements and attorneys with respect to legal and tax matters. Further, ratings  and forecasts of financial and other information are inherently forward-looking  and embody assumptions and predictions about future events that by their nature  cannot be verified as facts. As a result, despite any verification of current  facts, ratings and forecasts can be affected by future events or conditions that  were not anticipated at the time a rating or forecast was issued or affirmed.  The information in this report is provided ""as is"" without any representation or  warranty of any kind, and Fitch does not represent or warrant that the report or  any of its contents will meet any of the requirements of a recipient of the  report. A Fitch rating is an opinion as to the creditworthiness of a security.  This opinion and reports made by Fitch are based on established criteria and  methodologies that Fitch is continuously evaluating and updating. Therefore,  ratings and reports are the collective work product of Fitch and no individual,  or group of individuals, is solely responsible for a rating or   a report. The  rating does not address the risk of loss due to risks other than credit risk,  unless such risk is specifically mentioned. Fitch is not engaged in the offer or  sale of any security. All Fitch reports have shared authorship. Individuals  identified in a Fitch report were involved in, but are not solely responsible  for, the opinions stated therein. The individuals are named for contact purposes  only. A report providing a Fitch rating is neither a prospectus nor a substitute  for the information assembled, verified and presented to investors by the issuer  and its agents in connection with the sale of the securities. Ratings may be  changed or withdrawn at any time for any reason in the sole discretion of Fitch.  Fitch does not provide investment advice of any sort. Ratings are not a  recommendation to buy, sell, or hold any security. Ratings do not comment on the  adequacy of market price, the suitability of any security for a particular  investor, or the tax-exempt nature or taxability of payments made in respect to  any security. Fitch receives fees from issuers, insurers, guarantors, other  obligors, and underwriters for rating securities. Such fees generally vary from  US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In  certain cases, Fitch will rate all or a number of issues issued by a particular  issuer, or insured or guaranteed by a particular insurer or guarantor, for a  single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000  (or the applicable currency equivalent). The assignment, publication, or  dissemination of a rating by Fitch shall not constitute a consent by Fitch to  use its name as an expert in connection with any registration statement filed  under the United States securities laws, the Financial Services and Markets Act  of 2000 of the United Kingdom, or the securities laws of any particular  jurisdiction. Due to the relative efficiency of electronic publishing and  distribution, Fitch research may be available to electronic subscribers up to  three days earlier than to print subscribers.  For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd  holds an Australian financial services license (AFS license no. 337123) which  authorizes it to provide credit ratings to wholesale clients only. Credit  ratings information published by Fitch is not intended to be used by persons who  are retail clients within the meaning of the Corporations Act 2001   ",2016-10-27,MRK,"Thu Oct 27, 2016 | 5:19pm EDT",Correction: Fitch Rates Merck's Euro Notes Offering 'A',http://www.reuters.com//article/idUSFit978493?type=companyNews
578,"  (The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) Fitch Ratings has assigned an 'A' rating to Merck &  Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows  at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent  expiries should support intermediate- to long-term growth.  --Fitch believes that Merck will pursue targeted acquisitions as opposed to  large transformative ones. An improving pipeline and narrowing strategic focus  reduces the need to do big deals.  --Fitch expects Merck will continue favor share repurchases to deleveraging,  with the possibility of further debt-funded stock buybacks. --Fitch forecasts that Merck will generate solid FCF during the forecast period  supported by improving margins and moderate revenue growth. New Products/ Growth Opportunities: Products approved during the last three  years should help to drive intermediate- to long-term, top-line growth for  Merck. Most importantly, Keytruda (skin and lung cancer) is gaining traction in  the market, supported by an ongoing stream of clinical data, but facing  competition from a Bristol-Myers product and potentially similar drugs that may  receive approval during the next few years. Merck is also evaluating Keytruda's  safety and efficacy in other cancers and in combination with other oncolytics.  Bridion (post-surgical recovery), Belsomra (insomnia), Grastek (allergies) and  Rawitek (allergies) are unique-acting therapies, which should provide these two  drugs competitive positions. Zontivitiy (cardiovascular) and Zepatier (hepatitis  C) have entered increasingly crowded segments but should be able to gain some  share from both newer and older treatments. Expanding Late-Stage Pipeline: Fitch expects Merck to continue to build its  late-stage pipeline with new molecular entities (NMEs) to treat cancers,  bacterial and viral infections, diabetes, cardiovascular disorders, central  nervous afflictions, osteoporosis, and other diseases. While the majority of  these projects are internally developed, Merck has partnered with other  innovator firms to take advantage of technological advancements that were  discovered externally. The landscape for drug development is expanding,  particularly as developers learn more about how genetics influence the  development, prevention and treatment of disease. As such, Fitch believes that  it is responsible and strategically advantageous for firms to look externally as  well as internally regarding new drug development. Patent Exposure Manageable: The company has and will continue to face some  significant patent expiries during the next year, but Fitch views the risk as  manageable with roughly 18% of total firm sales are at risk. In addition,  Remicade, which accounts for about 4.2% of total firm sales, is a biologic that  has experienced less rapid sales losses to generic competition compared to  traditional small-molecule pharmaceuticals. Vytorin and Zetia, however, are  small molecules and account for roughly 10% of total revenues. Fitch expects  these two products will lose significant sales shortly after their patents  expire, as is typically the case for small-molecule drugs. Solid Free Cash Flow Expected: Fitch forecasts that Merck will generate $5.7  billion - $5.9 billion in free cash flow (FCF) during 2016. Improving margins  driven by an improving sales mix and strong cost control should more than offset  expected soft near-term, top-line growth. Fitch expects FCF to incrementally  increase during the multi-year forecast period. Targeted Acquisition Most Likely: Fitch looks for Merck to pursue mainly  targeted acquisitions in the intermediate term. The company has improved its  operational and financial prospects through successfully gaining regulatory  approvals on late-stage pipeline projects and has continued to back fill its  pipeline with new and advancing projects. An improved growth and profitability  profile decreases the need for the company to execute large strategic business  combinations. Share Repurchases to Continue: Fitch assumes continued shareholder friendly  actions during the near term, some of which the company may fund with debt.  Merck has occasionally funded its share repurchases with debt. During 2015, the  company purchased a net $3.7 billion of its common stock, compared to $6.1  billion during the prior LTM period. The repurchases were executed under a $15  billion program authorized in May 2013 as well as an additional $10 billion  authorized in March 2015. As of June 30, 2016, the 2013 allotment was fully  utilized, with $6.9 billion remaining on the $10 billion extension. KEY ASSUMPTIONS Fitch's key assumptions within the rating case for Merck's 'A' rating include  the following: --Incrementally increasing revenue during the forecast period, driven by newer  products, largely offset in the near term by foreign exchange headwinds and  select product patent expirations.  --EBITDA operating margin improvement driven by a focus on costs and an  improving sales mix.  --Annual FCF (cash flow from operations minus capital expenditures minus  dividends) of roughly $5.9 billion during 2016. --Targeted acquisitions prioritized over strategic, transformative transactions. --Continued significant share repurchases. --Leverage to range between 1.7x - 1.9x during the next two years. RATING SENSITIVITIES Positive: Future developments that may, individually or collectively, lead to  positive rating action include the following: --Improving operations including new product development that support long-term  positive revenue growth and margin stability/increases; --An operational profile that would consistently generate significantly positive  FCF; --Cash deployment strategy that maintains gross debt leverage below 1.7x,  including managing through operational stress such as patent expiries. Negative: Future developments that may, individually or collectively, lead to  negative rating action include the following: --Material and lasting deterioration in operations and FCF, possibly driven by  patent expiries not being offset by new product development; --Leveraging acquisitions without the prospect of timely debt/leverage  reduction; --Persistent leverage above 2.2x. LIQUIDITY Adequate Liquidity: Fitch looks for Merck to maintain adequate liquidity through  strong FCF generation and ample access to the credit markets. FCF for the LTM  ending June 30, 2016 was $4.7 billion. At the end of the period, Merck had  approximately $11.8 billion in cash/short-term investments (U.S.: 10% - 20% of  total balances/OUS: 80% - 90% of total balances) and full availability on its $6  billion revolver, maturing in August 2019.  Manageable Debt Maturities: As of June 30, 2016, the company had $24.1 billion  in debt outstanding, with $234 million maturing in 2016, $317 million in 2017,  $3 billion in 2018 and $1.3 billion in 2019. Fitch expects near- to mid-term  maturities will be satisfied primarily through refinancing in the public debt  markets. FULL LIST OF RATINGS Fitch has affirmed the following ratings: Merck & Co., Inc. --Long-Term Issuer Default Rating (IDR) at 'A'; --Senior unsecured credit facility at 'A';  --Senior unsecured debt at 'A'; --Short-term IDR at 'F1'; --Commercial paper at 'F1'. The Rating Outlook is Stable. Contact:  Primary Analyst Bob Kirby, CFA Director  +1-312-368-3147  Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602 Secondary Analyst Gregory Dickerson  Director  +1-212-908-0220 Committee Chairperson Megan Neuburger Managing Director +1-212-908-0501 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Summary of Financial Statement Adjustments - Financial statement adjustments  that depart materially from those contained in the published financial  statements of the relevant rated entity or obligor are disclosed below: --Historical and projected EBITDA is adjusted to add back non-cash stock based  compensation. During the LTM period ended March 31, 2016, Fitch added back $304  million in non-cash stock based compensation to its EBITDA calculation and $214  million in restructuring costs to gross profit. Date of Relevant Committee: July 7, 2016 Additional information is available on www.fitchratings.com. Applicable Criteria  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage - Effective from 17 August 2015 to 27 September 2016 (pub. 17  Aug 2015) here Additional Disclosures  Solicitation Status  here Endorsement Policy  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:   here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE,  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF  CONDUCT SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE. Copyright  2016 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its  subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824,  (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or  in part is prohibited except by permission. All rights reserved. In issuing and  maintaining its ratings and in making other reports (including forecast  information), Fitch relies on factual information it receives from issuers and  underwriters and from other sources Fitch believes to be credible. Fitch  conducts a reasonable investigation of the factual information relied upon by it  in accordance with its ratings methodology, and obtains reasonable verification  of that information from independent sources, to the extent such sources are  available for a given security or in a given jurisdiction. The manner of Fitch's  factual investigation and the scope of the third-party verification it obtains  will vary depending on the nature of the rated security and its issuer, the  requirements and practices in the jurisdiction in which the rated security is  offered and sold and/or the issuer is located, the availability and nature of  relevant public information, access to the management of the issuer and its  advisers, the availability of pre-existing third-party verifications such as  audit reports, agreed-upon procedures letters, appraisals, actuarial reports,  engineering reports, legal opinions and other reports provided by third parties,  the availability of independent and competent third- party verification sources  with respect to the particular security or in the particular jurisdiction of the  issuer, and a variety of other factors. Users of Fitch's ratings and reports  should understand that neither an enhanced factual investigation nor any  third-party verification can ensure that all of the information Fitch relies on  in connection with a rating or a report will be accurate and complete.  Ultimately, the issuer and its advisers are responsible for the accuracy of the  information they provide to Fitch and to the market in offering documents and  other reports. In issuing its ratings and its reports, Fitch must rely on the  work of experts, including independent auditors with respect to financial  statements and attorneys with respect to legal and tax matters. Further, ratings  and forecasts of financial and other information are inherently forward-looking  and embody assumptions and predictions about future events that by their nature  cannot be verified as facts. As a result, despite any verification of current  facts, ratings and forecasts can be affected by future events or conditions that  were not anticipated at the time a rating or forecast was issued or affirmed.  The information in this report is provided ""as is"" without any representation or  warranty of any kind, and Fitch does not represent or warrant that the report or  any of its contents will meet any of the requirements of a recipient of the  report. A Fitch rating is an opinion as to the creditworthiness of a security.  This opinion and reports made by Fitch are based on established criteria and  methodologies that Fitch is continuously evaluating and updating. Therefore,  ratings and reports are the collective work product of Fitch and no individual,  or group of individuals, is solely responsible for a rating or   a report. The  rating does not address the risk of loss due to risks other than credit risk,  unless such risk is specifically mentioned. Fitch is not engaged in the offer or  sale of any security. All Fitch reports have shared authorship. Individuals  identified in a Fitch report were involved in, but are not solely responsible  for, the opinions stated therein. The individuals are named for contact purposes  only. A report providing a Fitch rating is neither a prospectus nor a substitute  for the information assembled, verified and presented to investors by the issuer  and its agents in connection with the sale of the securities. Ratings may be  changed or withdrawn at any time for any reason in the sole discretion of Fitch.  Fitch does not provide investment advice of any sort. Ratings are not a  recommendation to buy, sell, or hold any security. Ratings do not comment on the  adequacy of market price, the suitability of any security for a particular  investor, or the tax-exempt nature or taxability of payments made in respect to  any security. Fitch receives fees from issuers, insurers, guarantors, other  obligors, and underwriters for rating securities. Such fees generally vary from  US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In  certain cases, Fitch will rate all or a number of issues issued by a particular  issuer, or insured or guaranteed by a particular insurer or guarantor, for a  single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000  (or the applicable currency equivalent). The assignment, publication, or  dissemination of a rating by Fitch shall not constitute a consent by Fitch to  use its name as an expert in connection with any registration statement filed  under the United States securities laws, the Financial Services and Markets Act  of 2000 of the United Kingdom, or the securities laws of any particular  jurisdiction. Due to the relative efficiency of electronic publishing and  distribution, Fitch research may be available to electronic subscribers up to  three days earlier than to print subscribers.  For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd  holds an Australian financial services license (AFS license no. 337123) which  authorizes it to provide credit ratings to wholesale clients only. Credit  ratings information published by Fitch is not intended to be used by persons who  are retail clients within the meaning of the Corporations Act 2001   ",2016-10-27,MRK,"Thu Oct 27, 2016 | 1:34pm EDT",Fitch Rates Merck's Euro Notes Offering 'A',http://www.reuters.com//article/idUSFit978416?type=companyNews
579,"   By Deena Beasley  Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck & Co Inc and Novo Nordisk A/S colluded to set prices for insulin and other diabetes drugs.The request by U.S. Senator Bernie Sanders and Representative Elijah Cummings follows a similar letter they sent last fall calling for an investigation into 14 drug companies over price increases of generic drugs.U.S. prosecutors could file the first charges by the end of the year in their subsequent criminal investigation of generic drugmakers over suspected price collusion, Bloomberg reported on Thursday. (bloom.bg/2e6cZjF)A Justice Department spokesman declined to comment.In their latest letter to the Justice Department and Federal Trade Commission, Sanders, an independent, and Cummings, a Democrat, raised questions about skyrocketing prices for insulin, and included a chart showing that many of the price spikes appeared to occur in tandem.They noted that the original patent on insulin, a hormone used by diabetics to control blood sugar levels, expired 75 years ago.Sanofi spokeswoman Ashleigh Koss said in an emailed statement that ""Sanofi sets the prices of our treatments independently.""Novo Nordisk also said it sets prices ""independently"" and said it stands by its business practices. A spokeswoman for Merck said the company does not make insulin. Merck makes other products to treat diabetes.Eli Lilly, in an email, said it strongly disagrees with the accusations in the letter. ""The insulin market in the U.S. is highly competitive,"" the pharmaceutical company said.Shares of several generic drugmakers fell on Thursday after the report of pending Justice Department charges. Mylan N.V. closed down 6.9 percent, Allergan Plc fell 4.5 percent and Endo International Plc dropped 19.5 percent. Teva Pharmaceuticals Inc Ltd, which recently acquired Allergan's generics business, fell 9.5 percent.""We do not think the major generic companies have likely participated in significant pricing collusion,"" A/B Bernstein analyst Ronny Gal said in a research note.   Several generic drugmakers, including Mylan, Allergan, Endo and Taro Pharmaceutical Industries Ltd, had previously disclosed that they were subpoenaed in connection with the antitrust investigation by the Justice Department. Bloomberg said the probe spans more than a dozen companies and about two dozen drugs, citing people familiar with the matter. Impax Laboratories Inc said earlier this year that the Justice Department had requested information on four drugs: blood pressure pill digoxin, asthma drug terbutaline sulfate, prilocaine/lidocaine cream and calcipotriene solution, which is used to treat psoriasis.A spokesman from Teva said the company ""is not aware of any facts that would give rise to an exposure to the company with respect to these subpoenas.""Officials at Endo and Lannett Company Inc did not immediately respond to requests for comment.Aggressive drug pricing has come under intense scrutiny after Democratic presidential candidate Hillary Clinton tweeted her intent to tackle high prices last year. An August report from the Government Accountability Office found that more than 300 of 1,441 generic drugs analyzed had at least one price increase of 100 percent or more between the first quarter of 2010 and the first quarter of 2015.In February, Sanders and Cummings asked the U.S. Department of Health and Human Services' enforcement arm to investigate generic drug price increases.Recent price hikes that have drawn fire included Turing Pharmaceuticals' decision in 2015 to raise by 5,000 percent the price of a decades-old treatment for a dangerous parasitic infection.Generic drugmakers, possibly reacting to the political headwinds, reined in price hikes this year. Guggenheim Securities, citing polling of generic drugmakers, last month estimated that overall U.S. generic drug prices would dip by a percentage in the mid-single digits this year.The price erosion has been felt by drug wholesalers like McKesson Corp and Amerisource Bergen Corp, which rely on price fluctuations for part of their profit margins. (Reporting by Deena Beasley in Los Angeles; Additional reporting by Sarah N. Lynch in Washington, D.C., Nikhil Subba and Sweta Singh in Bengaluru; Editing by Bernard Orr and Leslie Adler)",2016-11-04,MRK,"Thu Nov 3, 2016 | 10:56pm EDT",UPDATE 5-Drugmakers under fire for possible U.S. price fixing,http://www.reuters.com//article/usa-drug-pricing-idUSL4N1D44RS?type=companyNews
580,"  Nov 11 Biothera Pharmaceuticals :* Biothera Pharmaceuticals' preclinical data further validate mechanism of its Phase 2 cancer immunotherapy, Imprime PGG * data further elucidate ability of imprime PGG to trigger changes across immune system that enable coordinated, anti-cancer immune response * co,Merck advancing phase 2 clinical research collaboration to evaluate imprime PGG, keytruda in patients with advanced melanoma * Merck, co collaborating with big ten cancer research consortium to commence Imprime PGG plus keytruda phase 1b/2 study in patients with NSCLC  Source text for Eikon:",2016-11-11,MRK,"Fri Nov 11, 2016 | 1:23pm EST",BRIEF-Biothera Pharma's announces new preclinical data on its immunotherapy drug,http://www.reuters.com//article/idUSASC09IBM?type=companyNews
581,"  Nov 14 Merck & Co Inc : * OpGen Inc - entered into research collaboration with Merck to develop rapid diagnostics, it products to help combat threat of antimicrobial resistance  Source text for Eikon:  Further company coverage:  ",2016-11-14,MRK,"Mon Nov 14, 2016 | 7:20am EST",BRIEF-OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance,http://www.reuters.com//article/idUSFWN1DF0RO?type=companyNews
582,  Nov 15 Merck * CEO says price pressure and competition for Erbitux in the EU will continue  Further company coverage:  ,2016-11-15,MRK,"Tue Nov 15, 2016 | 5:01am EST",BRIEF-Merck sees continued price pressure for Erbitux in the EU,http://www.reuters.com//article/idUSF9N1D403X?type=companyNews
583,"   By Brendan Pierson  Gilead Sciences Inc has lost a bid to invalidate two Merck & Co patents on hepatitis C treatments, which Merck claims are infringed by Gilead's blockbuster Harvoni and Sovaldi. U.S. District Judge Leonard Stark in Delaware ruled on Wednesday that Gilead will have to make its argument against the patents' validity at a trial set to start next month, rejecting its argument that they are too indefinite to be put into practice.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2f59B44",2016-11-17,MRK,"Thu Nov 17, 2016 | 5:06pm EST",Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial,http://www.reuters.com//article/health-gilead-idUSL1N1DI2FM?type=companyNews
584,"  Nov 22 Merck :* Merck announces increased quarterly dividend * Sets quarterly dividend of $0.47 per share  * Increased quarterly dividend to $0.47 per share, up $0.01 from $0.46 per outstanding share paid last quarter  Source text for Eikon:  Further company coverage:",2016-11-22,MRK,"Tue Nov 22, 2016 | 1:25pm EST",BRIEF-Merck raises quarterly dividend to $0.47/share from $0.46/share,http://www.reuters.com//article/idUSFWN1DN0RJ?type=companyNews
585,  Nov 28 Merck & Co Inc * FDA grants priority review to Merck's supplemental biologics license application (SBLA) seeking approval for Keytruda(pembrolizumab) for new indication in microsatellite instability-high cancer  Source text for Eikon:  Further company coverage:  ,2016-11-28,MRK,"Mon Nov 28, 2016 | 7:41am EST",BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda,http://www.reuters.com//article/idUSFWN1DT0EG?type=companyNews
586,"   By Brendan Pierson  Early next month, Gilead Sciences Inc will try to convince a federal jury in Delaware that a Merck & Co patent on hepatitis C drugs is invalid. The trial, set to begin on Dec. 5, is the latest development in a long-running dispute between the two companies over patents related to the drugs. Merck claims Gilead's blockbuster hepatitis C drugs Harvoni and Sovaldi infringe its patent.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2gntGnZ",2016-11-28,MRK,"Mon Nov 28, 2016 | 7:19am EST","Gilead, Merck to face off before jury over hepatitis C drug patents",http://www.reuters.com//article/health-idenix-idUSL1N1DT0DD?type=companyNews
587,"  LONDON Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service.Keytruda is already approved as a cost-effective treatment in melanoma but the National Institute for Health and Care Excellence (NICE) had initially blocked its use in lung cancer.""If companies work with us to price drugs reasonably and manage any uncertainties in the evidence base, we can continue to recommend patients have routine access to the treatments they need,"" Carole Longson, director of the NICE centre for health technology evaluation, said in a statement on Friday. Keytruda has proved highly effective in fighting non-small cell lung cancer in patients with high levels of a protein called PD-L1, which makes them more receptive to immunotherapy. The average cost of a course of treatment in Britain is around 29,000 pounds ($36,500) at the full list price but the National Health Service will pay less after getting a confidential discount.  ($1 = 0.7934 pounds)  (Reporting by Ben Hirschler. Editing by Jane Merriman)",2016-12-02,MRK,"Thu Dec 1, 2016 | 7:13pm EST",Merck wins UK okay for Keytruda in lung cancer after price cut,http://www.reuters.com//article/us-merck-britain-cancer-idUSKBN13R009?type=companyNews
